{"id": "civic.eid:238", "description": "The T790M mutation in EGFR has been shown to confer resistance to the tyrosine kinase inhibitor erlotinib, and patients harboring this mutation that are placed on the drug are likely to relapse.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:167", "label": "Denis et al., 2015, Clin. Chim. Acta", "type": "Document", "title": "PubMed: Denis et al., 2015, Clin. Chim. Acta", "pmid": 25668228}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "authoritative evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00001"}, "variant": {"id": "civic.mpid:34", "label": "EGFR T790M", "description": "EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 406.25}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55249071, "stop": 55249071, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "34"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA090928"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16613"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434569"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["THR790MET", "RS121434569"], "members": [{"id": "ga4gh:VA.OvEfBRaS34JkfM0_ZHJVDQEjqtwzyjyp", "label": "NC_000007.13:g.55249071C>T", "digest": "OvEfBRaS34JkfM0_ZHJVDQEjqtwzyjyp", "type": "Allele", "location": {"id": "ga4gh:SL.ZCgOjF-_T0EOBXGc-6yICYui-jgFzJfY", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55181377, "end": 55181378}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.faKID4aj8rP8NKZpWL4mWDToEztTUmbr", "label": "T790M", "digest": "faKID4aj8rP8NKZpWL4mWDToEztTUmbr", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2369C>T"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2369C>T"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Thr790Met"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55249071C>T"}], "location": {"id": "ga4gh:SL.C1y_lDZe8e9pKy3jcj3oJKw_7252Hrxa", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 789, "end": 790}, "state": {"type": "LiteralSequenceExpression", "sequence": "M"}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1409", "description": "Phase 3 randomized clinical trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, metastatic melanoma with the BRAF V600E mutation. At 6 months, overall survival was 84% (95% confidence interval [CI], 78 to 89) in the vemurafenib group and 64% (95% CI, 56 to 73) in the dacarbazine group. A relative reduction of 63% in the risk of death and of 74% in the risk of either death or disease progression was observed with vemurafenib as compared with dacarbazine (P<0.001 for both comparisons).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:954", "label": "Chapman et al., 2011, N. Engl. J. Med.", "type": "Document", "title": "PubMed: Chapman et al., 2011, N. Engl. J. Med.", "pmid": 21639808}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "authoritative evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00001"}, "variant": {"id": "civic.mpid:12", "label": "BRAF V600E", "description": "BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 1353.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453136, "stop": 140453136, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "12"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123643"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13961"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376069"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS113488022", "V640E", "VAL640GLU", "VAL600GLU"], "members": [{"id": "ga4gh:VA.LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "label": "NC_000007.13:g.140453136A>T", "digest": "LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "type": "Allele", "location": {"id": "ga4gh:SL.XutGzMvqbzN-vnxmPt2MJf7ehxmB0opi", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753335, "end": 140753336}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "label": "V600E", "digest": "4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004333.4:c.1799T>A"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Val600Glu"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140453136A>T"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1799T>A"}], "location": {"id": "ga4gh:SL.ZA1XNKhCT_7m2UtmnYb8ZYOVS4eplMEK", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:206", "label": "Skin Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3510"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:8923"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1592", "description": "Osimertinib has been approved for the treatment of EGFR T790M mutant NSCLC.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1053", "label": "Greig, 2016, Drugs", "type": "Document", "title": "PubMed: Greig, 2016, Drugs", "pmid": 26729184}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "authoritative evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00001"}, "variant": {"id": "civic.mpid:34", "label": "EGFR T790M", "description": "EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 406.25}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55249071, "stop": 55249071, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "34"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA090928"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16613"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434569"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["THR790MET", "RS121434569"], "members": [{"id": "ga4gh:VA.OvEfBRaS34JkfM0_ZHJVDQEjqtwzyjyp", "label": "NC_000007.13:g.55249071C>T", "digest": "OvEfBRaS34JkfM0_ZHJVDQEjqtwzyjyp", "type": "Allele", "location": {"id": "ga4gh:SL.ZCgOjF-_T0EOBXGc-6yICYui-jgFzJfY", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55181377, "end": 55181378}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.faKID4aj8rP8NKZpWL4mWDToEztTUmbr", "label": "T790M", "digest": "faKID4aj8rP8NKZpWL4mWDToEztTUmbr", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2369C>T"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2369C>T"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Thr790Met"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55249071C>T"}], "location": {"id": "ga4gh:SL.C1y_lDZe8e9pKy3jcj3oJKw_7252Hrxa", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 789, "end": 790}, "state": {"type": "LiteralSequenceExpression", "sequence": "M"}}}, "therapeutic": {"id": "civic.tid:187", "label": "Osimertinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1721560"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C116377"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-", "AZD-9291", "AZD9291", "Mereletinib", "Tagrisso"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1867", "description": "Randomized, international, open-label, phase 3 trial (NCT02151981) in 419 patients with T790M-positive advanced NSCLC and disease progression after first-line EGFR-TKI therapy. Patients were randomized, in a 2:1 ratio, to oral osimertinib or chemotherapy (pemetrexed plus either carboplatin or cisplatin every 3 weeks for up to six cycles, maintenance pemetrexed was allowed). Primary end point was PFS, which was significantly longer with osimertinib than with chemotherapy (10.1 months vs. 4.4 months; HR 0.30; 95% CI: 0.23 to 0.41; P<0.001). Objective response rate was significantly better with osimertinib (71%; 95% CI, 65 to 76) than with chemotherapy (31%; 95% CI, 24 to 40) (odds ratio for objective response, 5.39; 95% CI, 3.47 to 8.48; P<0.001).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1286", "label": "Mok et al., 2016, N. Engl. J. Med.", "type": "Document", "title": "PubMed: Mok et al., 2016, N. Engl. J. Med.", "pmid": 27959700}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "authoritative evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00001"}, "variant": {"id": "civic.mpid:34", "label": "EGFR T790M", "description": "EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 406.25}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55249071, "stop": 55249071, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "34"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA090928"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16613"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434569"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["THR790MET", "RS121434569"], "members": [{"id": "ga4gh:VA.OvEfBRaS34JkfM0_ZHJVDQEjqtwzyjyp", "label": "NC_000007.13:g.55249071C>T", "digest": "OvEfBRaS34JkfM0_ZHJVDQEjqtwzyjyp", "type": "Allele", "location": {"id": "ga4gh:SL.ZCgOjF-_T0EOBXGc-6yICYui-jgFzJfY", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55181377, "end": 55181378}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.faKID4aj8rP8NKZpWL4mWDToEztTUmbr", "label": "T790M", "digest": "faKID4aj8rP8NKZpWL4mWDToEztTUmbr", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2369C>T"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2369C>T"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Thr790Met"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55249071C>T"}], "location": {"id": "ga4gh:SL.C1y_lDZe8e9pKy3jcj3oJKw_7252Hrxa", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 789, "end": 790}, "state": {"type": "LiteralSequenceExpression", "sequence": "M"}}}, "therapeutic": {"id": "civic.tid:187", "label": "Osimertinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1721560"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C116377"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-", "AZD-9291", "AZD9291", "Mereletinib", "Tagrisso"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2994", "description": "On May 14, 2013, the U.S. Food and Drug Administration approved erlotinib (Tarceva) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1724", "label": "Khozin et al., 2014, Oncologist", "type": "Document", "title": "PubMed: Khozin et al., 2014, Oncologist", "pmid": 24868098}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "authoritative evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00001"}, "variant": {"id": "civic.mpid:33", "label": "EGFR L858R", "description": "EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 379.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "G", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55259515, "stop": 55259515, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "33"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA126713"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16609"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376282"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376280"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434568"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121434568", "LEU858ARG"], "members": [{"id": "ga4gh:VA.TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "label": "NC_000007.13:g.55259515T>G", "digest": "TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "type": "Allele", "location": {"id": "ga4gh:SL.ulUNwZvajob7nzyrlpOd6uUWZIYCsoWb", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55191821, "end": 55191822}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "label": "L858R", "digest": "z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000007.13:g.55259515T>G"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2573T>G"}, {"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2573T>G"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Leu858Arg"}], "location": {"id": "ga4gh:SL.yVGJnwqxV6oCGqC_8nNb58D_wPXJeNJo", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 857, "end": 858}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2997", "description": "Afatinib, an irreversible inhibitor of the ErbB family of tyrosine kinases has been approved in the US for the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) who have tumours with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by a US FDA-approved test", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1725", "label": "Dungo et al., 2013, Drugs", "type": "Document", "title": "PubMed: Dungo et al., 2013, Drugs", "pmid": 23982599}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "authoritative evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00001"}, "variant": {"id": "civic.mpid:33", "label": "EGFR L858R", "description": "EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 379.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "G", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55259515, "stop": 55259515, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "33"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA126713"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16609"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376282"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376280"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434568"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121434568", "LEU858ARG"], "members": [{"id": "ga4gh:VA.TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "label": "NC_000007.13:g.55259515T>G", "digest": "TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "type": "Allele", "location": {"id": "ga4gh:SL.ulUNwZvajob7nzyrlpOd6uUWZIYCsoWb", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55191821, "end": 55191822}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "label": "L858R", "digest": "z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000007.13:g.55259515T>G"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2573T>G"}, {"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2573T>G"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Leu858Arg"}], "location": {"id": "ga4gh:SL.yVGJnwqxV6oCGqC_8nNb58D_wPXJeNJo", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 857, "end": 858}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:146", "label": "Afatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1430438"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:25316", "type": "Disease", "label": "Non-small cell lung cancer squamous"}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C66940"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide", "BIBW 2992", "BIBW2992"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:9431", "description": "The phase II cohort of the CodeBreaK 100 study (NCT03600883) investigated the activity of the KRAS G12C inhibitor sotorasib in previously treated patients with KRAS G12C-mutated non-small cell lung cancer. A total of 124 patients had measurable disease and were evaluated for response by independent central review. Complete response was seen in four patients and partial response in 42 patients, for an objective response rate of 37.1% (95% CI, 28.6 to 46.2). The median progression-free survival and overall survival were 6.8 (95% CI, 5.1 to 8.2) months and 12.5 months (95% CI, 10.0 to could not be evaluated), respectively.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:4080", "label": "Skoulidis et al., 2021, N Engl J Med", "type": "Document", "title": "PubMed: Skoulidis et al., 2021, N Engl J Med", "pmid": 34096690}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "authoritative evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00001"}, "variant": {"id": "civic.mpid:78", "label": "KRAS G12C", "description": "While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 136.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "A", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398285, "stop": 25398285, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "78"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA122528"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12578"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913530"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLY12CYS", "RS121913530"], "members": [{"id": "ga4gh:VA.ONAtlY1naHPhc7I2cFH6POy4zmWKukHw", "label": "NC_000012.11:g.25398285C>A", "digest": "ONAtlY1naHPhc7I2cFH6POy4zmWKukHw", "type": "Allele", "location": {"id": "ga4gh:SL.AiE9G9ocxKfBfR5PRN_ktoggZzig8OcG", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245350, "end": 25245351}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.94GquHCCcRi74uwlI5PGJsf6FsR2M7Ef", "label": "G12C", "digest": "94GquHCCcRi74uwlI5PGJsf6FsR2M7Ef", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004985.4:c.34G>T"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly12Cys"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398285C>A"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.34G>T"}], "location": {"id": "ga4gh:SL.OndkjmujtyUEZSjjCv0C-gpwnVbRgfj8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "civic.tid:654", "label": "Sotorasib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:2550714"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C154287"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["AMG 510", "AMG-510", "AMG510", "Lumakras"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2505", "description": "Patients were treated with a specific RAF inhibitor (dabrafenib), which improved overall survival of patients with BRAF mutations (P<0.003), compared to non-treated patients with BRAF mutations. Patients having BRAF mutations were associated with reduced overall survival (11.1 mo vs. 46.1 mo for wild-type, P=0.006). BRAF mutations were more frequent in tumors with superficially spreading histological sub-type (43%  vs. 19% , P<0.001) compared to BRAF wild-type tumors.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1488", "label": "Long et al., 2011, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Long et al., 2011, J. Clin. Oncol.", "pmid": 21343559}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:559", "label": "BRAF V600K", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 107.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "AC", "variant_bases": "TT", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453136, "stop": 140453137, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "563"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602420"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "375941"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913227"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["VAL600LYS", "RS121913227"], "members": [{"id": "ga4gh:VA.0_wkzhprX1HDwZ86yT7RXkMDNQPco-Uv", "label": "NC_000007.13:g.140453136_140453137delinsTT", "digest": "0_wkzhprX1HDwZ86yT7RXkMDNQPco-Uv", "type": "Allele", "location": {"id": "ga4gh:SL.je4uwNtMCOBUHmd4rSK1ouAb1yszaQqi", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753335, "end": 140753337}, "state": {"type": "LiteralSequenceExpression", "sequence": "TT"}}], "definingContext": {"id": "ga4gh:VA.2E2_MppFwuFLm3OF88kEywJUYc6cVTHC", "label": "V600K", "digest": "2E2_MppFwuFLm3OF88kEywJUYc6cVTHC", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1798_1799delinsAA"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140453136_140453137delinsTT"}, {"syntax": "hgvs.c", "value": "NM_004333.4:c.1798_1799delGTinsAA"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Val600Lys"}], "location": {"id": "ga4gh:SL.ZA1XNKhCT_7m2UtmnYb8ZYOVS4eplMEK", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:22", "label": "Dabrafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1424911"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:675", "type": "Disease", "label": "Thyroid cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7510"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C82386"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["BRAF Inhibitor GSK2118436", "Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-", "GSK-2118436", "GSK-2118436A", "GSK2118436"]}, "tumorType": {"id": "civic.did:7", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3224"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1909"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:3693", "description": "In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with RAS mutations (n=10), including KRAS A146T, KRAS G13D, NRAS G12D and NRAS Q179*, treated with FOLFOX4 plus cetuximab were associated with decreased overall survival (16.3mo vs. 28.5mo, HR:0.43, 95% CI:0.20-0.89, P=0.020) and decreased progression free survival (7.2mo vs. 9.7mo, HR:0.56, 95% CI:0.27-1.16, P=0.11), as compared to patients with wild-type KRAS and NRAS.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1920", "label": "Kaczirek et al., 2015, Clin Colorectal Cancer", "type": "Document", "title": "PubMed: Kaczirek et al., 2015, Clin Colorectal Cancer", "pmid": 25666295}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:36", "label": "NRAS", "description": "Mutations in the RAS family of proteins have frequently been observed across cancer types. The amino acid positions G12, G13 and Q61 account for the overwhelming majority of these mutations. The isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, targeting these RAS mutants has also been very elusive, and has not yet become common practice in the clinic.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:7989"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:4893"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["ALPS4", "CMNS", "KRAS", "N-ras", "NCMS", "NRAS", "NRAS1", "NS6"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:852", "label": "NRAS G12D", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 7.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000369535.4", "chromosome": "1", "start": 115258747, "stop": 115258747, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "878"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA130425"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "39648"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913237"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLY12ASP", "RS121913237"], "members": [{"id": "ga4gh:VA.KRVucDibY-L1AtH-fAZT_9h0EpOPm7Jb", "label": "NC_000001.10:g.115258747C>T", "digest": "KRVucDibY-L1AtH-fAZT_9h0EpOPm7Jb", "type": "Allele", "location": {"id": "ga4gh:SL.mpuf1JTux5X8P-TzGixTFWMPplEESJV3", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Ya6Rs7DHhDeg7YaOSg1EoNi3U_nQ9SvO"}, "start": 114716125, "end": 114716126}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA._cg7s8ZnDlutDHJ_sTnL3ECyJZID8bNH", "label": "G12D", "digest": "_cg7s8ZnDlutDHJ_sTnL3ECyJZID8bNH", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_002524.4:c.35G>A"}, {"syntax": "hgvs.p", "value": "NP_002515.1:p.Gly12Asp"}, {"syntax": "hgvs.g", "value": "NC_000001.10:g.115258747C>T"}, {"syntax": "hgvs.c", "value": "ENST00000369535.4:c.35G>A"}], "location": {"id": "ga4gh:SL.sRu8boSyUbO2MoDfeEWT81oxEYZaEJkC", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.974-EgvIQKi6ptqsI6XUZthCv-Py3S18"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "D"}}}, "therapeutic": {"id": "civic.tid:16", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:318341"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}, {"id": "mesh:D006258", "type": "Disease", "label": "Head and Neck Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C4013"}, "relation": "relatedMatch"}]}, {"id": "mesh:D002294", "type": "Disease", "label": "Carcinoma, Squamous Cell", "mappings": [{"coding": {"system": "ncit", "code": "C2929"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1723"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:3882", "description": "In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with RAS mutations (n=10), including KRAS A146T, KRAS G13D, NRAS G12D and NRAS Q179*, treated with FOLFOX4 plus cetuximab were associated with decreased overall survival (16.3mo vs. 28.5mo, HR:0.43, 95% CI:0.20-0.89, P=0.020) and decreased progression free survival (7.2mo vs. 9.7mo, HR:0.56, 95% CI:0.27-1.16, P=0.11), as compared to patients with wild-type KRAS and NRAS.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1920", "label": "Kaczirek et al., 2015, Clin Colorectal Cancer", "type": "Document", "title": "PubMed: Kaczirek et al., 2015, Clin Colorectal Cancer", "pmid": 25666295}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:81", "label": "KRAS G13D", "description": "While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, results are conflicting with retrospective analyses suggesting a better response to EGFR-Inhibition. A recent prospective phase-II study (12 patients, Schirripa et. al. 2015) could not reproduce this finding and another prospective phase II trial is currently ongoing.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 108.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398281, "stop": 25398281, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "81"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA122534"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12580"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS112445441"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS112445441", "GLY13ASP"], "members": [{"id": "ga4gh:VA.wQro48c_oFxB35UNb2O1Z7Vj6rXnJywl", "label": "NC_000012.11:g.25398281C>T", "digest": "wQro48c_oFxB35UNb2O1Z7Vj6rXnJywl", "type": "Allele", "location": {"id": "ga4gh:SL.rZcsm5bnq3ptyk4298opou7vY9O0etcL", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245346, "end": 25245347}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.h-3tyZSdsQNs9NHrhuwcACnnMnpuT-8Z", "label": "G13D", "digest": "h-3tyZSdsQNs9NHrhuwcACnnMnpuT-8Z", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_033360.3:c.38G>A"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly13Asp"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398281C>T"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.38G>A"}], "location": {"id": "ga4gh:SL.U-3sSsoejW41eQ2Aev0wiG5tEuDiQZTB", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 12, "end": 13}, "state": {"type": "LiteralSequenceExpression", "sequence": "D"}}}, "therapeutic": {"id": "civic.tid:16", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:318341"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}, {"id": "mesh:D006258", "type": "Disease", "label": "Head and Neck Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C4013"}, "relation": "relatedMatch"}]}, {"id": "mesh:D002294", "type": "Disease", "label": "Carcinoma, Squamous Cell", "mappings": [{"coding": {"system": "ncit", "code": "C2929"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1723"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4785", "description": "In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with RAS mutations (n=10), including KRAS A146T, KRAS G13D, NRAS G12D and NRAS Q179*, treated with FOLFOX4 plus cetuximab were associated with decreased overall survival (16.3mo vs. 28.5mo, HR:0.43, 95% CI:0.20-0.89, P=0.020) and decreased progression free survival (7.2mo vs. 9.7mo, HR:0.56, 95% CI:0.27-1.16, P=0.11), as compared to patients with wild-type KRAS and NRAS.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1920", "label": "Kaczirek et al., 2015, Clin Colorectal Cancer", "type": "Document", "title": "PubMed: Kaczirek et al., 2015, Clin Colorectal Cancer", "pmid": 25666295}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:36", "label": "NRAS", "description": "Mutations in the RAS family of proteins have frequently been observed across cancer types. The amino acid positions G12, G13 and Q61 account for the overwhelming majority of these mutations. The isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, targeting these RAS mutants has also been very elusive, and has not yet become common practice in the clinic.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:7989"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:4893"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["ALPS4", "CMNS", "KRAS", "N-ras", "NCMS", "NRAS", "NRAS1", "NS6"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:1562", "label": "NRAS Q179X", "extensions": [{"type": "Extension", "name": "CIViC representative coordinate", "value": {"reference_build": "GRCh37", "type": "coordinates"}}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1654"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.Y_kGVyZGEogz1Fvzo5LGn-Wf1LmsaJhn", "label": "Q179X", "digest": "Y_kGVyZGEogz1Fvzo5LGn-Wf1LmsaJhn", "type": "Allele", "location": {"id": "ga4gh:SL.dFtbnmhJvHQKUBAjWB2Ccgjz2snVexO7", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.974-EgvIQKi6ptqsI6XUZthCv-Py3S18"}, "start": 178, "end": 179}, "state": {"type": "LiteralSequenceExpression", "sequence": "X"}}}, "therapeutic": {"id": "civic.tid:16", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:318341"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}, {"id": "mesh:D006258", "type": "Disease", "label": "Head and Neck Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C4013"}, "relation": "relatedMatch"}]}, {"id": "mesh:D002294", "type": "Disease", "label": "Carcinoma, Squamous Cell", "mappings": [{"coding": {"system": "ncit", "code": "C2929"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1723"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:94", "description": "Patients with other BRAF V600 mutations also respond well to the V600E drug dabrafenib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:104", "label": "Ponti et al., 2013, J. Clin. Pathol.", "type": "Document", "title": "PubMed: Ponti et al., 2013, J. Clin. Pathol.", "pmid": 23463675}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:11", "label": "BRAF V600D", "description": "Patients harboring mutations in valine 600 residue of BRAF have been shown to be sensitive to dabrafenib. For more information on the V600 locus, see the V600E entry.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 47.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "CA", "variant_bases": "AT", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453135, "stop": 140453136, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "11"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602419"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "375939"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913377"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["VAL600ASP", "RS121913377"], "members": [{"id": "ga4gh:VA.nojfgZgtcwQ9Ylm0GuBuGnUT7Ug-_AKX", "label": "NC_000007.13:g.140453135_140453136delinsAT", "digest": "nojfgZgtcwQ9Ylm0GuBuGnUT7Ug-_AKX", "type": "Allele", "location": {"id": "ga4gh:SL.jW40gDuxQ9chCROKZs12FE7cHlX538EU", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753334, "end": 140753336}, "state": {"type": "LiteralSequenceExpression", "sequence": "AT"}}], "definingContext": {"id": "ga4gh:VA.TG8unESalMAFNryF_mfZWfWumrv-uI-U", "label": "V600D", "digest": "TG8unESalMAFNryF_mfZWfWumrv-uI-U", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000007.13:g.140453135_140453136delinsAT"}, {"syntax": "hgvs.c", "value": "NM_004333.4:c.1799_1800delTGinsAT"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Val600Asp"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1799_1800delTGinsAT"}], "location": {"id": "ga4gh:SL.ZA1XNKhCT_7m2UtmnYb8ZYOVS4eplMEK", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "D"}}}, "therapeutic": {"id": "civic.tid:22", "label": "Dabrafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1424911"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:675", "type": "Disease", "label": "Thyroid cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7510"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C82386"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["BRAF Inhibitor GSK2118436", "Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-", "GSK-2118436", "GSK-2118436A", "GSK2118436"]}, "tumorType": {"id": "civic.did:7", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3224"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1909"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1398", "description": "The BRIM-3 Phase III trial NCT01006980 assessed BRAF inhibitor vemurafenib versus dacarbazine in 598 patients with treatment naive metastatic melanoma and confirmed V600E mutation. Significant differences were seen in overall survival (13.3 months with vemurafenib vs. 10.0 months with dacarbazine) and median progression free survival (6.9 months  with vemurafenib vs. 1.6 months with dacarbazine)", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:947", "label": "McArthur et al., 2014, Lancet Oncol.", "type": "Document", "title": "PubMed: McArthur et al., 2014, Lancet Oncol.", "pmid": 24508103}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:12", "label": "BRAF V600E", "description": "BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 1353.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453136, "stop": 140453136, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "12"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123643"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13961"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376069"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS113488022", "V640E", "VAL640GLU", "VAL600GLU"], "members": [{"id": "ga4gh:VA.LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "label": "NC_000007.13:g.140453136A>T", "digest": "LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "type": "Allele", "location": {"id": "ga4gh:SL.XutGzMvqbzN-vnxmPt2MJf7ehxmB0opi", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753335, "end": 140753336}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "label": "V600E", "digest": "4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004333.4:c.1799T>A"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Val600Glu"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140453136A>T"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1799T>A"}], "location": {"id": "ga4gh:SL.ZA1XNKhCT_7m2UtmnYb8ZYOVS4eplMEK", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:7", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3224"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1909"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4860", "description": "The authors pooled patients with exon 19 deletion and L858R EGFR (Exon 21) mutations from both studies (The ARCHER 1009 (NCT01360554) and A7471028 (NCT00769067)) to compare the efficacy of dacomitinib to erlotinib. 121 patients with any EGFR mutation were enrolled, 101 had activating mutations in exon 19 or 21. For those (exon19/21), the median PFS was 14.6 months with dacomitinib and 9.6 months with erlotinib The median survival was 26.6 months with dacomitinib versus 23.2 months with erlotinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2158", "label": "Ramalingam et al., 2016, Ann. Oncol.", "type": "Document", "title": "PubMed: Ramalingam et al., 2016, Ann. Oncol.", "pmid": 26768165}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:33", "label": "EGFR L858R", "description": "EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 379.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "G", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55259515, "stop": 55259515, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "33"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA126713"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16609"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376282"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376280"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434568"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121434568", "LEU858ARG"], "members": [{"id": "ga4gh:VA.TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "label": "NC_000007.13:g.55259515T>G", "digest": "TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "type": "Allele", "location": {"id": "ga4gh:SL.ulUNwZvajob7nzyrlpOd6uUWZIYCsoWb", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55191821, "end": 55191822}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "label": "L858R", "digest": "z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000007.13:g.55259515T>G"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2573T>G"}, {"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2573T>G"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Leu858Arg"}], "location": {"id": "ga4gh:SL.yVGJnwqxV6oCGqC_8nNb58D_wPXJeNJo", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 857, "end": 858}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:44", "label": "Dacomitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:2058848"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C53398"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(2E)-N-(4-((3-Chloro-4-Fluorophenyl)Amino)-7-Methoxyquinazolin-6-yl)-4-Piperidin-1-ylbut-2-Enamide", "EGFR Inhibitor PF-00299804", "PF-00299804", "PF-00299804-03", "PF-299804", "Vizimpro"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:15", "description": "GIST cancer with D842V mutation is resistant to imatinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:61", "label": "Corless et al., 2005, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Corless et al., 2005, J. Clin. Oncol.", "pmid": 15928335}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:38", "label": "PDGFRA", "description": "Commonly mutated in GI tract tumors, PDGFR family genes (mutually exclusive to KIT mutations) are a hallmark of gastrointestinal stromal tumors. Gene fusions involving the PDGFRA kinase domain are highly correlated with eosinophilia, and the WHO classifies myeloid and lymphoid neoplasms with these characteristics as a distinct disorder. Mutations in the 842 region of PDGFRA have been often found to confer resistance to the tyrosine kinase inhibitor, imatinib.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8803"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5156"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD140A", "PDGFR-2", "PDGFR2", "PDGFRA"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:99", "label": "PDGFRA D842V", "description": "PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. Exogenous expression of the A842V mutation resulted in constitutive tyrosine phosphorylation of PDGFRA in the absence of ligand in 293T cells and cytokine-independent proliferation of the IL-3-dependent Ba/F3 cell line, both evidence that this is an activating mutation. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 100.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000257290.5", "chromosome": "4", "start": 55152093, "stop": 55152093, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "99"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123194"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13543"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121908585"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ASP842VAL", "RS121908585"], "members": [{"id": "ga4gh:VA.bDwkJ2filJ3ZGiUFybGFfyaCKdIVK86v", "label": "NC_000004.11:g.55152093A>T", "digest": "bDwkJ2filJ3ZGiUFybGFfyaCKdIVK86v", "type": "Allele", "location": {"id": "ga4gh:SL.LxO2YLfQbI_-TK7GOmSoOpMNiSy_Hgan", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54285925, "end": 54285926}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.vIjnL-aLYl0BSB6JutpdD7yW_qIXtdk8", "label": "D842V", "digest": "vIjnL-aLYl0BSB6JutpdD7yW_qIXtdk8", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006206.4:c.2525A>T"}, {"syntax": "hgvs.p", "value": "NP_006197.1:p.Asp842Val"}, {"syntax": "hgvs.c", "value": "ENST00000257290.5:c.2525A>T"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55152093A>T"}], "location": {"id": "ga4gh:SL.GHXCPrbd_qdPUoHjPwzv5iVFapJ0cn-o", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.XpQn9sZLGv_GU3uiWO7YHq9-_alGjrVX"}, "start": 841, "end": 842}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "civic.tid:5", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:282388"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "Disease", "label": "Systemic mastocytosis", "mappings": [{"coding": {"system": "ncit", "code": "C9235"}, "relation": "relatedMatch"}]}, {"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}, {"id": "hemonc:634", "type": "Disease", "label": "Myelodysplastic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C3247"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:33893", "type": "Disease", "label": "Chronic myelogenous leukemia pediatric"}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}, {"id": "hemonc:616", "type": "Disease", "label": "Hypereosinophilic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C27038"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C62035"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"]}, "tumorType": {"id": "civic.did:2", "label": "Gastrointestinal Stromal Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3868"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9253"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:16", "description": "While cancer with PDGFRA V561D mutation is known to be sensitive to Imatinib, double mutation of V561D and D842V mutants are resistant to imatinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:62", "label": "Heinrich et al., 2006, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Heinrich et al., 2006, J. Clin. Oncol.", "pmid": 16954519}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:38", "label": "PDGFRA", "description": "Commonly mutated in GI tract tumors, PDGFR family genes (mutually exclusive to KIT mutations) are a hallmark of gastrointestinal stromal tumors. Gene fusions involving the PDGFRA kinase domain are highly correlated with eosinophilia, and the WHO classifies myeloid and lymphoid neoplasms with these characteristics as a distinct disorder. Mutations in the 842 region of PDGFRA have been often found to confer resistance to the tyrosine kinase inhibitor, imatinib.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8803"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5156"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD140A", "PDGFR-2", "PDGFR2", "PDGFRA"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:99", "label": "PDGFRA D842V", "description": "PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. Exogenous expression of the A842V mutation resulted in constitutive tyrosine phosphorylation of PDGFRA in the absence of ligand in 293T cells and cytokine-independent proliferation of the IL-3-dependent Ba/F3 cell line, both evidence that this is an activating mutation. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 100.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000257290.5", "chromosome": "4", "start": 55152093, "stop": 55152093, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "99"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123194"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13543"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121908585"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ASP842VAL", "RS121908585"], "members": [{"id": "ga4gh:VA.bDwkJ2filJ3ZGiUFybGFfyaCKdIVK86v", "label": "NC_000004.11:g.55152093A>T", "digest": "bDwkJ2filJ3ZGiUFybGFfyaCKdIVK86v", "type": "Allele", "location": {"id": "ga4gh:SL.LxO2YLfQbI_-TK7GOmSoOpMNiSy_Hgan", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54285925, "end": 54285926}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.vIjnL-aLYl0BSB6JutpdD7yW_qIXtdk8", "label": "D842V", "digest": "vIjnL-aLYl0BSB6JutpdD7yW_qIXtdk8", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006206.4:c.2525A>T"}, {"syntax": "hgvs.p", "value": "NP_006197.1:p.Asp842Val"}, {"syntax": "hgvs.c", "value": "ENST00000257290.5:c.2525A>T"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55152093A>T"}], "location": {"id": "ga4gh:SL.GHXCPrbd_qdPUoHjPwzv5iVFapJ0cn-o", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.XpQn9sZLGv_GU3uiWO7YHq9-_alGjrVX"}, "start": 841, "end": 842}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "civic.tid:5", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:282388"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "Disease", "label": "Systemic mastocytosis", "mappings": [{"coding": {"system": "ncit", "code": "C9235"}, "relation": "relatedMatch"}]}, {"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}, {"id": "hemonc:634", "type": "Disease", "label": "Myelodysplastic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C3247"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:33893", "type": "Disease", "label": "Chronic myelogenous leukemia pediatric"}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}, {"id": "hemonc:616", "type": "Disease", "label": "Hypereosinophilic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C27038"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C62035"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"]}, "tumorType": {"id": "civic.did:2", "label": "Gastrointestinal Stromal Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3868"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9253"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:19", "description": "In patients with JAK2 V617F, the use of pegylated IFN-alpha-2a leads to reduction in the percentage of cells harboring JAK2 V617F.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:64", "label": "Kiladjian et al., 2006, Blood", "type": "Document", "title": "PubMed: Kiladjian et al., 2006, Blood", "pmid": 16709929}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:28", "label": "JAK2", "description": "JAK2 is a kinase that is misregulated or mutated in a number of myeloproliferative diseases and cancers. The mutation V617F is the most clinically relevant variant, and is seen in around half of myeloproliferative disorders. The variant is a known activating mutation, and activated JAK2 is sufficient to drive myeloproliferative disorders in mouse models. V617F, while most recurrent, is not the only mechanism by which JAK2 can be activated in patients. JAK2 is now one of the first diagnostic markers tested upon diagnosis with a myeloproliferative disorder.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6192"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3717"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["JAK2", "JTK10"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:64", "label": "JAK2 V617F", "description": "JAK2 V617F is a highly recurrent mutation in myeloproliferative diseases. It is found in around 98% of patients with polycythemia vera, and just over half of the patients with essential thrombocythemia and primary myelofibrosis. While less associated with cancer, when it is seen, it is more likely to be in myeloid leukemias than lymphoid leukemias. The V617F mutation is an activating mutation, resulting in increased kinase activity. The mutation seems to be restricted to hematologic malignancies. Treatment of JAK mutant diseases with ruxolitinib has seen some clinical success.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 103.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "T", "representative_transcript": "ENST00000381652.3", "chromosome": "9", "start": 5073770, "stop": 5073770, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}, {"label": "gain_of_function_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0002053"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "64"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA124183"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "14662"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS77375493"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["VAL617PHE", "RS77375493"], "members": [{"id": "ga4gh:VA.JqSAq9kDz_jPpo6tO2tUA5O3qI_uGqO6", "label": "NC_000009.11:g.5073770G>T", "digest": "JqSAq9kDz_jPpo6tO2tUA5O3qI_uGqO6", "type": "Allele", "location": {"id": "ga4gh:SL.Q63BDR9AqGifLedv3GSuxkv2BQ4eM4bd", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.KEO-4XBcm1cxeo_DIQ8_ofqGUkp4iZhI"}, "start": 5073769, "end": 5073770}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.hl9CoYsN5bzvyKb-7Nc_sUCs_0oe6Xvp", "label": "V617F", "digest": "hl9CoYsN5bzvyKb-7Nc_sUCs_0oe6Xvp", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000009.11:g.5073770G>T"}, {"syntax": "hgvs.c", "value": "NM_004972.3:c.1849G>T"}, {"syntax": "hgvs.p", "value": "NP_004963.1:p.Val617Phe"}, {"syntax": "hgvs.c", "value": "ENST00000381652.3:c.1849G>T"}], "location": {"id": "ga4gh:SL.vxtxGvjTqkluBrNMEnr2fuAu5Ej1qGtO", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.-OkqBNmqypFmiUe8izaIgIwkeOz5Z__6"}, "start": 616, "end": 617}, "state": {"type": "LiteralSequenceExpression", "sequence": "F"}}}, "therapeutic": {"id": "civic.tid:24385", "label": "Peginterferon Alfa-2b", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:253453"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D008545", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "mesh:D019698", "type": "Disease", "label": "Hepatitis C, Chronic", "mappings": [{"coding": {"system": "mondo", "code": "0005354"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1845"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["PEG Interferon Alpha-2b", "PEG Intron", "PEG-IFN Alfa-2b", "PEG-IFN-a 2b", "PEG-Interferon Alfa-2b", "PEG-Intron", "Pegylated Interferon Alpha-2b", "Polyethylene Glycol IFN-A2b", "Polyethylene Glycol Interferon Alfa-2b", "SCH 54031", "Sylatron"]}, "tumorType": {"id": "civic.did:9", "label": "Polycythemia Vera", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3336"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:8997"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:240", "description": "In Lung Cancer patients with acquired resistance to Dacomitinib (PF00299804), MET amplification and EGFR T790M were found to be the primary drivers of resistance.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:169", "label": "Sequist et al., 2011, Sci Transl Med", "type": "Document", "title": "PubMed: Sequist et al., 2011, Sci Transl Med", "pmid": 21430269}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:34", "label": "EGFR T790M", "description": "EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 406.25}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55249071, "stop": 55249071, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "34"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA090928"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16613"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434569"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["THR790MET", "RS121434569"], "members": [{"id": "ga4gh:VA.OvEfBRaS34JkfM0_ZHJVDQEjqtwzyjyp", "label": "NC_000007.13:g.55249071C>T", "digest": "OvEfBRaS34JkfM0_ZHJVDQEjqtwzyjyp", "type": "Allele", "location": {"id": "ga4gh:SL.ZCgOjF-_T0EOBXGc-6yICYui-jgFzJfY", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55181377, "end": 55181378}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.faKID4aj8rP8NKZpWL4mWDToEztTUmbr", "label": "T790M", "digest": "faKID4aj8rP8NKZpWL4mWDToEztTUmbr", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2369C>T"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2369C>T"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Thr790Met"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55249071C>T"}], "location": {"id": "ga4gh:SL.C1y_lDZe8e9pKy3jcj3oJKw_7252Hrxa", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 789, "end": 790}, "state": {"type": "LiteralSequenceExpression", "sequence": "M"}}}, "therapeutic": {"id": "civic.tid:44", "label": "Dacomitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:2058848"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C53398"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(2E)-N-(4-((3-Chloro-4-Fluorophenyl)Amino)-7-Methoxyquinazolin-6-yl)-4-Piperidin-1-ylbut-2-Enamide", "EGFR Inhibitor PF-00299804", "PF-00299804", "PF-00299804-03", "PF-299804", "Vizimpro"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:306", "description": "KRAS G13D mutation is associated with better response to Cetuximab with longer progression-free and overall survival in colorectal patients compared to other KRAS.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:123", "label": "De Roock et al., 2010, JAMA", "type": "Document", "title": "PubMed: De Roock et al., 2010, JAMA", "pmid": 20978259}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:81", "label": "KRAS G13D", "description": "While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, results are conflicting with retrospective analyses suggesting a better response to EGFR-Inhibition. A recent prospective phase-II study (12 patients, Schirripa et. al. 2015) could not reproduce this finding and another prospective phase II trial is currently ongoing.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 108.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398281, "stop": 25398281, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "81"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA122534"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12580"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS112445441"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS112445441", "GLY13ASP"], "members": [{"id": "ga4gh:VA.wQro48c_oFxB35UNb2O1Z7Vj6rXnJywl", "label": "NC_000012.11:g.25398281C>T", "digest": "wQro48c_oFxB35UNb2O1Z7Vj6rXnJywl", "type": "Allele", "location": {"id": "ga4gh:SL.rZcsm5bnq3ptyk4298opou7vY9O0etcL", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245346, "end": 25245347}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.h-3tyZSdsQNs9NHrhuwcACnnMnpuT-8Z", "label": "G13D", "digest": "h-3tyZSdsQNs9NHrhuwcACnnMnpuT-8Z", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_033360.3:c.38G>A"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly13Asp"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398281C>T"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.38G>A"}], "location": {"id": "ga4gh:SL.U-3sSsoejW41eQ2Aev0wiG5tEuDiQZTB", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 12, "end": 13}, "state": {"type": "LiteralSequenceExpression", "sequence": "D"}}}, "therapeutic": {"id": "civic.tid:16", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:318341"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}, {"id": "mesh:D006258", "type": "Disease", "label": "Head and Neck Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C4013"}, "relation": "relatedMatch"}]}, {"id": "mesh:D002294", "type": "Disease", "label": "Carcinoma, Squamous Cell", "mappings": [{"coding": {"system": "ncit", "code": "C2929"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1723"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:436", "description": "Whole exome sequencing of 6 chronic lymphocytic leukemia patients with acquired resistance to ibrutinib determined 5/6 patients harbored a C481S mutation in BTK.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:259", "label": "Woyach et al., 2014, N. Engl. J. Med.", "type": "Document", "title": "PubMed: Woyach et al., 2014, N. Engl. J. Med.", "pmid": 24869598}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:65", "label": "BTK", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1133"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:695"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["AGMX1", "AT", "ATK", "BPK", "BTK", "IGHD3", "IMD1", "PSCTK1", "XLA"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:168", "label": "BTK C481S", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 40.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000308731.7", "chromosome": "X", "start": 100611165, "stop": 100611165, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "168"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602659"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376204"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS1057519826"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS1057519826", "CYS481SER"], "members": [{"id": "ga4gh:VA.B2r6LyyC_C_jC34mh_GlhgV1lPaemTfB", "label": "NC_000023.10:g.100611165A>T", "digest": "B2r6LyyC_C_jC34mh_GlhgV1lPaemTfB", "type": "Allele", "location": {"id": "ga4gh:SL.IIlx-SzTi6d56dR28MH_yiRY6FFqr-PV", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.w0WZEvgJF0zf_P4yyTzjjv9oW1z61HHP"}, "start": 101356176, "end": 101356177}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.rG6v3SPOgJa1g4G46715Xsu3XBpA3Usx", "label": "C481S", "digest": "rG6v3SPOgJa1g4G46715Xsu3XBpA3Usx", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000308731.7:c.1441T>A"}, {"syntax": "hgvs.g", "value": "NC_000023.10:g.100611165A>T"}, {"syntax": "hgvs.c", "value": "NM_000061.2:c.1441T>A"}, {"syntax": "hgvs.p", "value": "NP_000052.1:p.Cys481Ser"}], "location": {"id": "ga4gh:SL.QjL8LNqOg0Gv2dhr04dFrOtiXnUJrYQI", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.UEFsUeUkTCNvBilBofWdc_UXE0AjL-IA"}, "start": 480, "end": 481}, "state": {"type": "LiteralSequenceExpression", "sequence": "S"}}}, "therapeutic": {"id": "civic.tid:227", "label": "Ibrutinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1442981"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:682", "type": "Disease", "label": "Waldenstroem macroglobulinemia"}, {"id": "hemonc:605", "type": "Disease", "label": "Graft versus host disease", "mappings": [{"coding": {"system": "ncit", "code": "C3063"}, "relation": "relatedMatch"}]}, {"id": "hemonc:581", "type": "Disease", "label": "Chronic lymphocytic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3163"}, "relation": "relatedMatch"}]}, {"id": "hemonc:625", "type": "Disease", "label": "Mantle cell lymphoma", "mappings": [{"coding": {"system": "ncit", "code": "C4337"}, "relation": "relatedMatch"}]}, {"id": "hemonc:626", "type": "Disease", "label": "Marginal zone lymphoma", "mappings": [{"coding": {"system": "ncit", "code": "C4341"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C81934"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["2-Propen-1-one, 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)-", "BTK Inhibitor PCI-32765", "CRA-032765", "Imbruvica", "PCI-32765"]}, "tumorType": {"id": "civic.did:52", "label": "Chronic Lymphocytic Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3163"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1040"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:646", "description": "In a phase1-2 study, patients with the T790M mutation were more sensitive to rocelitinib in comparison to patients with T790M-negative NSCLC.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:408", "label": "Sequist et al., 2015, N. Engl. J. Med.", "type": "Document", "title": "PubMed: Sequist et al., 2015, N. Engl. J. Med.", "pmid": 25923550}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:34", "label": "EGFR T790M", "description": "EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 406.25}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55249071, "stop": 55249071, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "34"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA090928"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16613"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434569"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["THR790MET", "RS121434569"], "members": [{"id": "ga4gh:VA.OvEfBRaS34JkfM0_ZHJVDQEjqtwzyjyp", "label": "NC_000007.13:g.55249071C>T", "digest": "OvEfBRaS34JkfM0_ZHJVDQEjqtwzyjyp", "type": "Allele", "location": {"id": "ga4gh:SL.ZCgOjF-_T0EOBXGc-6yICYui-jgFzJfY", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55181377, "end": 55181378}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.faKID4aj8rP8NKZpWL4mWDToEztTUmbr", "label": "T790M", "digest": "faKID4aj8rP8NKZpWL4mWDToEztTUmbr", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2369C>T"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2369C>T"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Thr790Met"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55249071C>T"}], "location": {"id": "ga4gh:SL.C1y_lDZe8e9pKy3jcj3oJKw_7252Hrxa", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 789, "end": 790}, "state": {"type": "LiteralSequenceExpression", "sequence": "M"}}}, "therapeutic": {"id": "civic.tid:91", "label": "Rociletinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C99905"}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C99905"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["CO-1686", "N-(3-((2-((4-(4-Acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)prop-2-enamide"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:676", "description": "The ERCC2 K751Q variant was significantly correlated with a lower response to cisplatin chemotherapy in osteosarcoma patients and shorter event-free survival. 91 osteosarcoma patients with a median age of 15 years were followed in this study.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:430", "label": "Caronia et al., 2009, Pharmacogenomics J.", "type": "Document", "title": "PubMed: Caronia et al., 2009, Pharmacogenomics J.", "pmid": 19434073}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "germline", "geneContext": {"id": "civic.gid:1736", "label": "ERCC2", "description": "ERCC2 functions as a DNA repair gene involved in separating the double helix via 5\u2019-3\u2019 helicase activity. It forms a part of the transcription factor II Human (TFIIH) complex and is ATP-dependent. The TFIIH complex is known to be involved in the nucleotide excision repair pathway (NER) which can repair DNA damage caused by chemotherapeutic treatment and basal transcription. ERCC2 variants have been observed in a variety of cancers. A number of studies have suggested ERCC2 variants can act as biomarkers to predict response to neoadjuvant treatment, and cancer prognosis. Additionally the Lys751Gln polymorphism has been observed to increase risk in a number of cancer types; however, results have been conflicting.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3434"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2068"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["COFS2", "EM9", "ERCC2", "TFIIH", "TTD", "TTD1", "XPD"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:260", "label": "ERCC2 K751Q", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 35.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "G", "representative_transcript": "ENST00000391945.4", "chromosome": "19", "start": 45854919, "stop": 45854919, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "264"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA158782"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "134105"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["LYS751GLN"], "members": [{"id": "ga4gh:VA.K4tORBJ1TNWRJqG-Qc9BPYRH7IyNpwZJ", "label": "NC_000019.9:g.45854919T>G", "digest": "K4tORBJ1TNWRJqG-Qc9BPYRH7IyNpwZJ", "type": "Allele", "location": {"id": "ga4gh:SL.2dzROI1GsudGgVSQc_MQF2mprA5BmlAp", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.IIB53T8CNeJJdUqzn9V_JnRtQadwWCbl"}, "start": 45351660, "end": 45351661}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.ivyoxuSdhZXBJ4Xqm4y3WGPj3lB6mlEc", "label": "K751Q", "digest": "ivyoxuSdhZXBJ4Xqm4y3WGPj3lB6mlEc", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000019.9:g.45854919T>G"}], "location": {"id": "ga4gh:SL.w-CiS63KhheAS9HRZDe8JVOnEaqQ-lSR", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.uwbPWCW9MnODZ_PbO7YOp0OWsJumOzIF"}, "start": 750, "end": 751}, "state": {"type": "LiteralSequenceExpression", "sequence": "Q"}}}, "therapeutic": {"id": "civic.tid:326", "label": "Cisplatin", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:2555"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:671", "type": "Disease", "label": "Testicular cancer", "mappings": [{"coding": {"system": "ncit", "code": "C5053"}, "relation": "relatedMatch"}]}, {"id": "hemonc:645", "type": "Disease", "label": "Ovarian cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7431"}, "relation": "relatedMatch"}]}, {"id": "hemonc:569", "type": "Disease", "label": "Bladder cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9334"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C376"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(SP-4-2)-Diamminedichloroplatinum", "Abiplatin", "Blastolem", "Briplatin", "CDDP", "Cis-diammine-dichloroplatinum", "Cis-diamminedichloridoplatinum", "Cis-diamminedichloro Platinum (II)", "Cis-diamminedichloroplatinum", "Cis-dichloroammine Platinum (II)", "Cis-platinous Diamine Dichloride", "Cis-platinum", "Cis-platinum II", "Cis-platinum II Diamine Dichloride", "Cismaplat", "Cisplatina", "Cisplatinum", "Cisplatyl", "Citoplatino", "Citosin", "Cysplatyna", "DDP", "Lederplatin", "Metaplatin", "Neoplatin", "Peyrone's Chloride", "Peyrone's Salt", "Placis", "Plastistil", "Platamine", "Platiblastin", "Platiblastin-S", "Platinex", "Platinol", "Platinol- AQ", "Platinol-AQ", "Platinol-AQ VHA Plus", "Platinoxan", "Platinum", "Platinum Diamminodichloride", "Platinum, Diaminedichloro-, Cis- (8CI)", "Platiran", "Platistin", "Platosin"]}, "tumorType": {"id": "civic.did:134", "label": "Osteosarcoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9145"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3347"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:738", "description": "823 patients with GIST under therapy with imatinib were genotyped for this study. 18 patients (2%) with PDGFRA mutations were identified. In D842V-mutant GISTs, PFS (median 3.8 months) and OS (median 25.2 months) were significantly poorer than Non-D842V mutated (PFS median 29.5 months OS median 59.8 months).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:486", "label": "Yoo et al., 2016, Cancer Res Treat", "type": "Document", "title": "PubMed: Yoo et al., 2016, Cancer Res Treat", "pmid": 26130666}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:38", "label": "PDGFRA", "description": "Commonly mutated in GI tract tumors, PDGFR family genes (mutually exclusive to KIT mutations) are a hallmark of gastrointestinal stromal tumors. Gene fusions involving the PDGFRA kinase domain are highly correlated with eosinophilia, and the WHO classifies myeloid and lymphoid neoplasms with these characteristics as a distinct disorder. Mutations in the 842 region of PDGFRA have been often found to confer resistance to the tyrosine kinase inhibitor, imatinib.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8803"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5156"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD140A", "PDGFR-2", "PDGFR2", "PDGFRA"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:99", "label": "PDGFRA D842V", "description": "PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. Exogenous expression of the A842V mutation resulted in constitutive tyrosine phosphorylation of PDGFRA in the absence of ligand in 293T cells and cytokine-independent proliferation of the IL-3-dependent Ba/F3 cell line, both evidence that this is an activating mutation. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 100.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000257290.5", "chromosome": "4", "start": 55152093, "stop": 55152093, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "99"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123194"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13543"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121908585"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ASP842VAL", "RS121908585"], "members": [{"id": "ga4gh:VA.bDwkJ2filJ3ZGiUFybGFfyaCKdIVK86v", "label": "NC_000004.11:g.55152093A>T", "digest": "bDwkJ2filJ3ZGiUFybGFfyaCKdIVK86v", "type": "Allele", "location": {"id": "ga4gh:SL.LxO2YLfQbI_-TK7GOmSoOpMNiSy_Hgan", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54285925, "end": 54285926}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.vIjnL-aLYl0BSB6JutpdD7yW_qIXtdk8", "label": "D842V", "digest": "vIjnL-aLYl0BSB6JutpdD7yW_qIXtdk8", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006206.4:c.2525A>T"}, {"syntax": "hgvs.p", "value": "NP_006197.1:p.Asp842Val"}, {"syntax": "hgvs.c", "value": "ENST00000257290.5:c.2525A>T"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55152093A>T"}], "location": {"id": "ga4gh:SL.GHXCPrbd_qdPUoHjPwzv5iVFapJ0cn-o", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.XpQn9sZLGv_GU3uiWO7YHq9-_alGjrVX"}, "start": 841, "end": 842}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "civic.tid:5", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:282388"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "Disease", "label": "Systemic mastocytosis", "mappings": [{"coding": {"system": "ncit", "code": "C9235"}, "relation": "relatedMatch"}]}, {"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}, {"id": "hemonc:634", "type": "Disease", "label": "Myelodysplastic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C3247"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:33893", "type": "Disease", "label": "Chronic myelogenous leukemia pediatric"}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}, {"id": "hemonc:616", "type": "Disease", "label": "Hypereosinophilic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C27038"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C62035"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"]}, "tumorType": {"id": "civic.did:2", "label": "Gastrointestinal Stromal Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3868"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9253"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:879", "description": "A phase III clinical trial (NCT00949650) found that median progression free survival among patients with exon 19 deletions or L858R EGFR mutations (n = 308) was 13.6 months for afatinib and 6.9 months for chemotherapy (HR, 0.47; 95% CI, 0.34 to 0.65; P = 0.001).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:592", "label": "Sequist et al., 2013, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Sequist et al., 2013, J. Clin. Oncol.", "pmid": 23816960}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:33", "label": "EGFR L858R", "description": "EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 379.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "G", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55259515, "stop": 55259515, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "33"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA126713"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16609"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376282"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376280"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434568"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121434568", "LEU858ARG"], "members": [{"id": "ga4gh:VA.TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "label": "NC_000007.13:g.55259515T>G", "digest": "TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "type": "Allele", "location": {"id": "ga4gh:SL.ulUNwZvajob7nzyrlpOd6uUWZIYCsoWb", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55191821, "end": 55191822}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "label": "L858R", "digest": "z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000007.13:g.55259515T>G"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2573T>G"}, {"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2573T>G"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Leu858Arg"}], "location": {"id": "ga4gh:SL.yVGJnwqxV6oCGqC_8nNb58D_wPXJeNJo", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 857, "end": 858}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:146", "label": "Afatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1430438"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:25316", "type": "Disease", "label": "Non-small cell lung cancer squamous"}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C66940"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide", "BIBW 2992", "BIBW2992"]}, "tumorType": {"id": "civic.did:30", "label": "Lung Adenocarcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3512"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3910"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:965", "description": "This phase I/II trial (NCT01802632) involved 253 non-small cell lung cancer patients with activating EGFR mutations, who had progressed on first generation tyrosine kinase inhibitor treatment, and were subsequently treated with Osimertinib (AZD9291). The overall objective tumor response rate was 51%. Among 127 patients with EGFR T790M who could be evaluated for response, the response rate was 61% (95% CI, 52 to 70). In contrast, among 61 patients without EGFR T790M, the response rate was 21% (95% CI, 12 to 34). The median progression-free survival was 9.6 months in EGFR T790M-positive patients and 2.8 months in EGFR T790M-negative patients.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:667", "label": "J\u00e4nne et al., 2015, N. Engl. J. Med.", "type": "Document", "title": "PubMed: J\u00e4nne et al., 2015, N. Engl. J. Med.", "pmid": 25923549}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:34", "label": "EGFR T790M", "description": "EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 406.25}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55249071, "stop": 55249071, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "34"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA090928"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16613"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434569"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["THR790MET", "RS121434569"], "members": [{"id": "ga4gh:VA.OvEfBRaS34JkfM0_ZHJVDQEjqtwzyjyp", "label": "NC_000007.13:g.55249071C>T", "digest": "OvEfBRaS34JkfM0_ZHJVDQEjqtwzyjyp", "type": "Allele", "location": {"id": "ga4gh:SL.ZCgOjF-_T0EOBXGc-6yICYui-jgFzJfY", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55181377, "end": 55181378}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.faKID4aj8rP8NKZpWL4mWDToEztTUmbr", "label": "T790M", "digest": "faKID4aj8rP8NKZpWL4mWDToEztTUmbr", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2369C>T"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2369C>T"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Thr790Met"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55249071C>T"}], "location": {"id": "ga4gh:SL.C1y_lDZe8e9pKy3jcj3oJKw_7252Hrxa", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 789, "end": 790}, "state": {"type": "LiteralSequenceExpression", "sequence": "M"}}}, "therapeutic": {"id": "civic.tid:187", "label": "Osimertinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1721560"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C116377"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-", "AZD-9291", "AZD9291", "Mereletinib", "Tagrisso"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:982", "description": "Afatinib is an irreversible covalent inhibitor of EGFR (second generation). This Phase III clinical trial (LUX-Lung 6; NCT01121393) was performed in Asian patients with EGFR mutant advanced NSCLC. 364 eligible patients with EGFR mutations were assigned to afatinib (n=242) or gemcitabine and cisplatin (n=122) treatment. The trial observed significantly longer median progression-free survival with afatinib vs. gemcitabine and cisplatin treatment (11.0 vs. 5.6 months). Afatinib/Chemotherapy group compositions: 51.2/50.8 % del 19; 38/37.7 % Leu858Arg; 10.8/11.5 % Uncommon.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:679", "label": "Wu et al., 2014, Lancet Oncol.", "type": "Document", "title": "PubMed: Wu et al., 2014, Lancet Oncol.", "pmid": 24439929}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:33", "label": "EGFR L858R", "description": "EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 379.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "G", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55259515, "stop": 55259515, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "33"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA126713"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16609"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376282"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376280"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434568"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121434568", "LEU858ARG"], "members": [{"id": "ga4gh:VA.TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "label": "NC_000007.13:g.55259515T>G", "digest": "TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "type": "Allele", "location": {"id": "ga4gh:SL.ulUNwZvajob7nzyrlpOd6uUWZIYCsoWb", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55191821, "end": 55191822}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "label": "L858R", "digest": "z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000007.13:g.55259515T>G"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2573T>G"}, {"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2573T>G"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Leu858Arg"}], "location": {"id": "ga4gh:SL.yVGJnwqxV6oCGqC_8nNb58D_wPXJeNJo", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 857, "end": 858}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:146", "label": "Afatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1430438"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:25316", "type": "Disease", "label": "Non-small cell lung cancer squamous"}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C66940"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide", "BIBW 2992", "BIBW2992"]}, "tumorType": {"id": "civic.did:30", "label": "Lung Adenocarcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3512"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3910"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1088", "description": "1325 HER2-positive breast cancer patients treated with trastuzumab and chemotherapy from the N9831 clinical trial were analyzed. There was no statistical difference in disease-free survival between trastuzumab-treated patients who had the FCGR2A 131 H/H high-affinity genotype and patients without that genotype.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:747", "label": "Norton et al., 2014, Cancer Immunol Res", "type": "Document", "title": "PubMed: Norton et al., 2014, Cancer Immunol Res", "pmid": 24989892}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "germline", "geneContext": {"id": "civic.gid:1842", "label": "FCGR2A", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3616"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2212"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD32", "CD32A", "CDw32", "FCG2", "FCGR2", "FCGR2A", "FCGR2A1", "FcGR", "FcgammaRIIa", "IGFR2"]}}, "direction": "refutes", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:452", "label": "FCGR2A H167R", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 35.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "G", "representative_transcript": "ENST00000271450.6", "chromosome": "1", "start": 161479745, "stop": 161479745, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "456"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA124361"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "14823"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS1801274"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["HIS167ARG", "RS1801274", "H131R", "H166R"], "members": [{"id": "ga4gh:VA.wWLhkZ3ryEQUXyybfItMdtIAnQkLZtRN", "label": "NC_000001.10:g.161479745A>G", "digest": "wWLhkZ3ryEQUXyybfItMdtIAnQkLZtRN", "type": "Allele", "location": {"id": "ga4gh:SL.DQc-moWQLR7C4fmCa_3GbHocMOncr0Jh", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Ya6Rs7DHhDeg7YaOSg1EoNi3U_nQ9SvO"}, "start": 161509954, "end": 161509955}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.gjty3dqSVaRQthS2OvtlKHVyiDknbdBX", "label": "H167R", "digest": "gjty3dqSVaRQthS2OvtlKHVyiDknbdBX", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_001136219.1:c.500A>G"}, {"syntax": "hgvs.p", "value": "NP_001129691.1:p.His167Arg"}, {"syntax": "hgvs.c", "value": "ENST00000271450.6:c.500A>G"}, {"syntax": "hgvs.g", "value": "NC_000001.10:g.161479745A>G"}], "location": {"id": "ga4gh:SL.f_YYrAsWGpNkZGi99j6qj1gZUu0WizvD", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HOmnmaaSfcDmxg5mCFOkBdmNkTVj92mc"}, "start": 166, "end": 167}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:84", "label": "Trastuzumab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:2103478"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D001943", "type": "Disease", "label": "Breast Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2910"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1647"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["ABP 980", "ALT02", "Anti-ERB-2", "Anti-HER2/c-erbB2 Monoclonal Antibody", "Anti-c-ERB-2", "Anti-c-erbB2 Monoclonal Antibody", "Anti-erbB-2", "Anti-erbB2 Monoclonal Antibody", "Anti-p185-HER2", "C-erb-2 Monoclonal Antibody", "HER2 Monoclonal Antibody", "Herceptin", "Herceptin Biosimilar PF-05280014", "Herceptin Trastuzumab Biosimilar PF-05280014", "Herzuma", "Immunoglobulin G 1 (Human-Mouse Monoclonal RhuMab HER2gamma1-Chain Antihuman P185(Sup C-erbB2) Receptor), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer", "Kanjinti", "MoAb HER2", "Monoclonal Antibody C-erb-2", "Monoclonal Antibody HER2", "Ogivri", "Ontruzant", "PF-05280014", "RO0452317", "RhuMAb HER2", "SB3", "Trastuzumab Biosimilar ABP 980", "Trastuzumab Biosimilar ALT02", "Trastuzumab Biosimilar EG12014", "Trastuzumab Biosimilar HLX02", "Trastuzumab Biosimilar PF-05280014", "Trastuzumab Biosimilar SB3", "Trastuzumab Biosimilar SIBP-01", "Trastuzumab-anns", "Trastuzumab-dkst", "Trastuzumab-dttb", "Trastuzumab-pkrb", "Trastuzumab-qyyp", "Trazimera"]}, "tumorType": {"id": "civic.did:22", "label": "Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9335"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1612"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1181", "description": "Meta-analysis encompassing eight randomized controlled trials (n = 5967) for assessment of both overall survival (OS) and progression-free survival (PFS) of patients with KRAS mutant metastatic colorectal cancer. For other KRAS MT the hazard ratio for OS benefit with addition of anti-EGFR mAb therapy was 1.06 (95% confidence interval [CI]; 0.96, 1.17), compared to 1.08 (95% CI; 0.73, 1.60) for KRAS G13D [test for interaction p=0.99]. In contrast, the hazard ratio for KRAS wild-type (WT) tumours was 0.85 (95% CI; 0.76, 0.95). Regarding PFS benefit with anti-EGFR mAbs, the hazard ratio was 1.07 (95% CI; 0.92, 1.26) for other KRAS MT, 0.96 (95% CI; 0.73, 1.27) for KRAS G13D, and 0.68 (95% CI; 0.54, 0.85) for KRAS wild-type. Again, the test for interaction (p=0.46) demonstrated no significant difference in PFS benefit for anti-EGFR mAb therapy between KRAS G13D and other KRAS MT.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:814", "label": "Rowland et al., 2016, Eur. J. Cancer", "type": "Document", "title": "PubMed: Rowland et al., 2016, Eur. J. Cancer", "pmid": 26812186}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:81", "label": "KRAS G13D", "description": "While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, results are conflicting with retrospective analyses suggesting a better response to EGFR-Inhibition. A recent prospective phase-II study (12 patients, Schirripa et. al. 2015) could not reproduce this finding and another prospective phase II trial is currently ongoing.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 108.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398281, "stop": 25398281, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "81"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA122534"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12580"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS112445441"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS112445441", "GLY13ASP"], "members": [{"id": "ga4gh:VA.wQro48c_oFxB35UNb2O1Z7Vj6rXnJywl", "label": "NC_000012.11:g.25398281C>T", "digest": "wQro48c_oFxB35UNb2O1Z7Vj6rXnJywl", "type": "Allele", "location": {"id": "ga4gh:SL.rZcsm5bnq3ptyk4298opou7vY9O0etcL", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245346, "end": 25245347}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.h-3tyZSdsQNs9NHrhuwcACnnMnpuT-8Z", "label": "G13D", "digest": "h-3tyZSdsQNs9NHrhuwcACnnMnpuT-8Z", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_033360.3:c.38G>A"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly13Asp"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398281C>T"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.38G>A"}], "location": {"id": "ga4gh:SL.U-3sSsoejW41eQ2Aev0wiG5tEuDiQZTB", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 12, "end": 13}, "state": {"type": "LiteralSequenceExpression", "sequence": "D"}}}, "therapeutic": {"id": "civic.tid:16", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:318341"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}, {"id": "mesh:D006258", "type": "Disease", "label": "Head and Neck Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C4013"}, "relation": "relatedMatch"}]}, {"id": "mesh:D002294", "type": "Disease", "label": "Carcinoma, Squamous Cell", "mappings": [{"coding": {"system": "ncit", "code": "C2929"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1723"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1399", "description": "In the Phase III study of vemurafenib versus dacarbazine BRIM-3 (NCT01006980) in metastatic melanoma, 57 patients were confirmed to have V600K mutation. In this subgroup of treatment-naive patients, significant differences were seen in overall survival (14.5 months with vemurafenib vs. 7.6 months with dacarbazine), as well as median progression free survival (5.9 months with vemurafenib vs. 1.7 months with dacarbazine).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:947", "label": "McArthur et al., 2014, Lancet Oncol.", "type": "Document", "title": "PubMed: McArthur et al., 2014, Lancet Oncol.", "pmid": 24508103}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:559", "label": "BRAF V600K", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 107.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "AC", "variant_bases": "TT", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453136, "stop": 140453137, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "563"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602420"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "375941"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913227"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["VAL600LYS", "RS121913227"], "members": [{"id": "ga4gh:VA.0_wkzhprX1HDwZ86yT7RXkMDNQPco-Uv", "label": "NC_000007.13:g.140453136_140453137delinsTT", "digest": "0_wkzhprX1HDwZ86yT7RXkMDNQPco-Uv", "type": "Allele", "location": {"id": "ga4gh:SL.je4uwNtMCOBUHmd4rSK1ouAb1yszaQqi", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753335, "end": 140753337}, "state": {"type": "LiteralSequenceExpression", "sequence": "TT"}}], "definingContext": {"id": "ga4gh:VA.2E2_MppFwuFLm3OF88kEywJUYc6cVTHC", "label": "V600K", "digest": "2E2_MppFwuFLm3OF88kEywJUYc6cVTHC", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1798_1799delinsAA"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140453136_140453137delinsTT"}, {"syntax": "hgvs.c", "value": "NM_004333.4:c.1798_1799delGTinsAA"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Val600Lys"}], "location": {"id": "ga4gh:SL.ZA1XNKhCT_7m2UtmnYb8ZYOVS4eplMEK", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:7", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3224"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1909"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1405", "description": "In this Phase II pilot study (NCT00405587) of BRAF V600 inhibitor vemurafenib in 21 metastatic colorectal cancer (CRC) patients with BRAF V600E, one patient had a durable 21 week partial response, and seven patients had 8 week stable disease as best response. Median progression free survival was 2.1 months and median overall survival was 7.7 months. The authors conclude that single agent vemurafenib did not show meaningful activity in V600E CRC, in contrast to the significant vemurafenib activity against V600 in melanoma.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:953", "label": "Kopetz et al., 2015, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Kopetz et al., 2015, J. Clin. Oncol.", "pmid": 26460303}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "refutes", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:12", "label": "BRAF V600E", "description": "BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 1353.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453136, "stop": 140453136, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "12"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123643"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13961"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376069"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS113488022", "V640E", "VAL640GLU", "VAL600GLU"], "members": [{"id": "ga4gh:VA.LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "label": "NC_000007.13:g.140453136A>T", "digest": "LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "type": "Allele", "location": {"id": "ga4gh:SL.XutGzMvqbzN-vnxmPt2MJf7ehxmB0opi", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753335, "end": 140753336}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "label": "V600E", "digest": "4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004333.4:c.1799T>A"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Val600Glu"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140453136A>T"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1799T>A"}], "location": {"id": "ga4gh:SL.ZA1XNKhCT_7m2UtmnYb8ZYOVS4eplMEK", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1725", "description": "In a phase II clinical trial, 60% of patients (N=89) with advanced systemic mastocytosis responded to treatment with midostaurin.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1170", "label": "Gotlib et al., 2016, N. Engl. J. Med.", "type": "Document", "title": "PubMed: Gotlib et al., 2016, N. Engl. J. Med.", "pmid": 27355533}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:29", "label": "KIT", "description": "c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3815"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["C-Kit", "CD117", "KIT", "MASTC", "PBT", "SCFR"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:65", "label": "KIT D816V", "description": "KIT D816V is a mutation observed in acute myeloid leukemia (AML). This variant has been linked to poorer prognosis and worse outcome in AML patients.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 67.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000288135.5", "chromosome": "4", "start": 55599321, "stop": 55599321, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "65"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123513"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13852"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913507"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913507", "ASP816VAL"], "members": [{"id": "ga4gh:VA.gdbp5quI5YscqYY01qlHfuJkT7R41cR7", "label": "NC_000004.11:g.55599321A>T", "digest": "gdbp5quI5YscqYY01qlHfuJkT7R41cR7", "type": "Allele", "location": {"id": "ga4gh:SL.K5_kmlkru2gtVBgRFCtI7EVKUJa1E28v", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54733154, "end": 54733155}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.rZDlEZBywJpTMBnXhLjN12Y9HQYHiOiP", "label": "D816V", "digest": "rZDlEZBywJpTMBnXhLjN12Y9HQYHiOiP", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_000222.2:c.2447A>T"}, {"syntax": "hgvs.p", "value": "NP_000213.1:p.Asp816Val"}, {"syntax": "hgvs.c", "value": "ENST00000288135.5:c.2447A>T"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55599321A>T"}], "location": {"id": "ga4gh:SL.EFk3ET7Ws47inqLJnNWEsA-GhUEwihbN", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 815, "end": 816}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "civic.tid:323", "label": "Midostaurin", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1919083"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "Disease", "label": "Systemic mastocytosis", "mappings": [{"coding": {"system": "ncit", "code": "C9235"}, "relation": "relatedMatch"}]}, {"id": "hemonc:552", "type": "Disease", "label": "Acute myeloid leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3171"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1872"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["CGP 41251", "CGP41251", "N-Benzoyl-Staurosporine", "N-Benzoylstaurosporine", "PKC-412", "PKC412", "Rydapt"]}, "tumorType": {"id": "civic.did:2150", "label": "Systemic Mastocytosis", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9235"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:349"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1749", "description": "Multicenter, phase 1, dose-escalation trial of PLX4032 (Vemurafenib). Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients (N=37/48). Patients without the V600E mutation had evidence of tumor regression.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:352", "label": "Flaherty et al., 2010, N. Engl. J. Med.", "type": "Document", "title": "PubMed: Flaherty et al., 2010, N. Engl. J. Med.", "pmid": 20818844}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:12", "label": "BRAF V600E", "description": "BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 1353.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453136, "stop": 140453136, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "12"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123643"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13961"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376069"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS113488022", "V640E", "VAL640GLU", "VAL600GLU"], "members": [{"id": "ga4gh:VA.LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "label": "NC_000007.13:g.140453136A>T", "digest": "LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "type": "Allele", "location": {"id": "ga4gh:SL.XutGzMvqbzN-vnxmPt2MJf7ehxmB0opi", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753335, "end": 140753336}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "label": "V600E", "digest": "4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004333.4:c.1799T>A"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Val600Glu"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140453136A>T"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1799T>A"}], "location": {"id": "ga4gh:SL.ZA1XNKhCT_7m2UtmnYb8ZYOVS4eplMEK", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:7", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3224"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1909"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1757", "description": "Patients with the wild type (C/C) MTHFR gene are 2.91 times (95% CI: [1.23, 6.89]) more likely to have a positive response to neoadjuvant CRT and  3.25 times more likely not to experience relapse (95% CI: [1.37, 7.72]) than patients with the heterozygous  MTHFR [rs1801133 (C>T)] mutation or  the homzygous (T/T).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1221", "label": "Nikas et al., 2015, Am J Cancer Res", "type": "Document", "title": "PubMed: Nikas et al., 2015, Am J Cancer Res", "pmid": 26693073}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "germline", "geneContext": {"id": "civic.gid:3672", "label": "MTHFR", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:7436"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:4524"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["MTHFR"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:254", "label": "MTHFR A222V", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 55.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000376592.1", "chromosome": "1", "start": 11856378, "stop": 11856378, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "258"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA170990"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "3520"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS1801133"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ALA222VAL", "RS1801133", "C677T"], "members": [{"id": "ga4gh:VA.-FDUuNE2cd4eQ6b0J7AB_GVVQfIbhnWh", "label": "NC_000001.10:g.11856378G>A", "digest": "-FDUuNE2cd4eQ6b0J7AB_GVVQfIbhnWh", "type": "Allele", "location": {"id": "ga4gh:SL.YWu4hztxkbnQldZFh7CZroL-C912BkAs", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Ya6Rs7DHhDeg7YaOSg1EoNi3U_nQ9SvO"}, "start": 11796320, "end": 11796321}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.P3yunCZ58gjlGqpAHi5HM4p8HLELggw-", "label": "A222V", "digest": "P3yunCZ58gjlGqpAHi5HM4p8HLELggw-", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_005957.4:c.665C>T"}, {"syntax": "hgvs.p", "value": "NP_005948.3:p.Ala222Val"}, {"syntax": "hgvs.c", "value": "ENST00000376592.1:c.665G>A"}, {"syntax": "hgvs.g", "value": "NC_000001.10:g.11856378G>A"}], "location": {"id": "ga4gh:SL.AHnSF6Rw6xvorKRfezXRB1sI4oAlmuCC", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.4RSETawLfMkNpQBPepa7Uf9ItHAEJUde"}, "start": 221, "end": 222}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "civic.tid:420", "label": "Fluorouracil", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:4492"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C505"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["2,4-Dioxo-5-fluoropyrimidine", "5 FU", "5 Fluorouracil", "5 Fluorouracilum", "5-FU", "5-Fluoro-2,4(1H, 3H)-pyrimidinedione", "5-Fluoro-2,4(1H,3H)-pyrimidinedione", "5-Fluorouracil", "5-Fluracil", "5FU", "AccuSite", "Adrucil", "Carac", "Fluoro Uracil", "Fluouracil", "Flurablastin", "Fluracedyl", "Fluracil", "Fluril", "Fluroblastin", "Ribofluor", "Ro 2-9757", "Ro-2-9757"]}, "tumorType": {"id": "civic.did:579", "label": "Rectum Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C7418"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1993"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1770", "description": "In a trial of 308 patients with chronic lymphocytic leukemia treated with ibrutinib, 31 discontinued treatment due to disease progression (13 CLL progression, 18 Richter\u2019s transformation). 11/13 patients were deep sequenced for BTK and PLCG2. 9 patients were identified with BTK mutations (C481S in 8 patients). In 5 patients, C481S was the sole abnormality.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1237", "label": "Maddocks et al., 2015, JAMA Oncol", "type": "Document", "title": "PubMed: Maddocks et al., 2015, JAMA Oncol", "pmid": 26182309}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:65", "label": "BTK", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1133"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:695"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["AGMX1", "AT", "ATK", "BPK", "BTK", "IGHD3", "IMD1", "PSCTK1", "XLA"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:168", "label": "BTK C481S", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 40.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000308731.7", "chromosome": "X", "start": 100611165, "stop": 100611165, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "168"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602659"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376204"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS1057519826"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS1057519826", "CYS481SER"], "members": [{"id": "ga4gh:VA.B2r6LyyC_C_jC34mh_GlhgV1lPaemTfB", "label": "NC_000023.10:g.100611165A>T", "digest": "B2r6LyyC_C_jC34mh_GlhgV1lPaemTfB", "type": "Allele", "location": {"id": "ga4gh:SL.IIlx-SzTi6d56dR28MH_yiRY6FFqr-PV", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.w0WZEvgJF0zf_P4yyTzjjv9oW1z61HHP"}, "start": 101356176, "end": 101356177}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.rG6v3SPOgJa1g4G46715Xsu3XBpA3Usx", "label": "C481S", "digest": "rG6v3SPOgJa1g4G46715Xsu3XBpA3Usx", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000308731.7:c.1441T>A"}, {"syntax": "hgvs.g", "value": "NC_000023.10:g.100611165A>T"}, {"syntax": "hgvs.c", "value": "NM_000061.2:c.1441T>A"}, {"syntax": "hgvs.p", "value": "NP_000052.1:p.Cys481Ser"}], "location": {"id": "ga4gh:SL.QjL8LNqOg0Gv2dhr04dFrOtiXnUJrYQI", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.UEFsUeUkTCNvBilBofWdc_UXE0AjL-IA"}, "start": 480, "end": 481}, "state": {"type": "LiteralSequenceExpression", "sequence": "S"}}}, "therapeutic": {"id": "civic.tid:227", "label": "Ibrutinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1442981"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:682", "type": "Disease", "label": "Waldenstroem macroglobulinemia"}, {"id": "hemonc:605", "type": "Disease", "label": "Graft versus host disease", "mappings": [{"coding": {"system": "ncit", "code": "C3063"}, "relation": "relatedMatch"}]}, {"id": "hemonc:581", "type": "Disease", "label": "Chronic lymphocytic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3163"}, "relation": "relatedMatch"}]}, {"id": "hemonc:625", "type": "Disease", "label": "Mantle cell lymphoma", "mappings": [{"coding": {"system": "ncit", "code": "C4337"}, "relation": "relatedMatch"}]}, {"id": "hemonc:626", "type": "Disease", "label": "Marginal zone lymphoma", "mappings": [{"coding": {"system": "ncit", "code": "C4341"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C81934"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["2-Propen-1-one, 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)-", "BTK Inhibitor PCI-32765", "CRA-032765", "Imbruvica", "PCI-32765"]}, "tumorType": {"id": "civic.did:52", "label": "Chronic Lymphocytic Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3163"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1040"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1863", "description": "Patients with advanced NSCLC and acquired resistance to EGFR TKI (gefitinib or erlotinib) were analyzed for T790M mutations.  Of the 70 patients analyzed, 36 (51%) had the T790M mutation and 34 (49%) were T790M-negative.  There was no significant difference in the median post-progression or overall survival between patients with T790M mutation and without T790M mutation for initial TKI treatment.  However, subsequent treatment with afatinib showed partial response in six patients where 1/21(5%) were in the T790M-positive group and 5/13 (38%) were in the T790M-negative group (P=0.01).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1282", "label": "Sun et al., 2013, Lung Cancer", "type": "Document", "title": "PubMed: Sun et al., 2013, Lung Cancer", "pmid": 24035188}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:34", "label": "EGFR T790M", "description": "EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 406.25}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55249071, "stop": 55249071, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "34"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA090928"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16613"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434569"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["THR790MET", "RS121434569"], "members": [{"id": "ga4gh:VA.OvEfBRaS34JkfM0_ZHJVDQEjqtwzyjyp", "label": "NC_000007.13:g.55249071C>T", "digest": "OvEfBRaS34JkfM0_ZHJVDQEjqtwzyjyp", "type": "Allele", "location": {"id": "ga4gh:SL.ZCgOjF-_T0EOBXGc-6yICYui-jgFzJfY", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55181377, "end": 55181378}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.faKID4aj8rP8NKZpWL4mWDToEztTUmbr", "label": "T790M", "digest": "faKID4aj8rP8NKZpWL4mWDToEztTUmbr", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2369C>T"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2369C>T"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Thr790Met"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55249071C>T"}], "location": {"id": "ga4gh:SL.C1y_lDZe8e9pKy3jcj3oJKw_7252Hrxa", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 789, "end": 790}, "state": {"type": "LiteralSequenceExpression", "sequence": "M"}}}, "therapeutic": {"id": "civic.tid:146", "label": "Afatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1430438"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:25316", "type": "Disease", "label": "Non-small cell lung cancer squamous"}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C66940"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide", "BIBW 2992", "BIBW2992"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2135", "description": "In a study of 322 advanced melanoma patients with BRAF-V600E (N=281), BRAF-V600K (N=40), or both mutations (N=1), treatment with trametinib was associated with improved progression-free survival (4.8mo vs. 1.5mo; HR: 0.45, 95% CI: 0.33-0.63, P<0.001) compared to chemotherapy control group. Additionally, treatment with trametinib was associated with increased 6-month overall survival (HR: 0.54, 95% CI: 0.32-0.92, P=0.01). The authors note similar outcomes for the primary efficacy population (V600E only) and the intention-to-treat population.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1210", "label": "Flaherty et al., 2012, N. Engl. J. Med.", "type": "Document", "title": "PubMed: Flaherty et al., 2012, N. Engl. J. Med.", "pmid": 22663011}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:12", "label": "BRAF V600E", "description": "BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 1353.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453136, "stop": 140453136, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "12"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123643"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13961"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376069"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS113488022", "V640E", "VAL640GLU", "VAL600GLU"], "members": [{"id": "ga4gh:VA.LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "label": "NC_000007.13:g.140453136A>T", "digest": "LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "type": "Allele", "location": {"id": "ga4gh:SL.XutGzMvqbzN-vnxmPt2MJf7ehxmB0opi", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753335, "end": 140753336}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "label": "V600E", "digest": "4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004333.4:c.1799T>A"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Val600Glu"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140453136A>T"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1799T>A"}], "location": {"id": "ga4gh:SL.ZA1XNKhCT_7m2UtmnYb8ZYOVS4eplMEK", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "civic.tid:19", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1425098"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C77908"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["GSK1120212", "JTP-74057", "MEK Inhibitor GSK1120212", "Mekinist", "N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide"]}, "tumorType": {"id": "civic.did:7", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3224"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1909"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2621", "description": "In a phase 3 clinical trial of non-small cell lung cancer (NSCLC) patients, a subset of patients with EGFR mutations (n=44) treated with gefitinib were associated with improved progression free survival (HR: 0.16, 95% CI: 0.05-0.49, P=0.001), and a higher objective response rate (ORR: 42.1% vs 21.1%, p=0.04) compared to patients treated with docetaxel. Of the 44 patients, 22 had an exon 19 deletion, 16 had an L858R mutation, one patient had an exon 20 T790M mutation, two had an exon G719A mutation and four had other mutations.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1501", "label": "Douillard et al., 2010, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Douillard et al., 2010, J. Clin. Oncol.", "pmid": 20038723}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:33", "label": "EGFR L858R", "description": "EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 379.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "G", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55259515, "stop": 55259515, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "33"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA126713"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16609"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376282"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376280"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434568"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121434568", "LEU858ARG"], "members": [{"id": "ga4gh:VA.TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "label": "NC_000007.13:g.55259515T>G", "digest": "TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "type": "Allele", "location": {"id": "ga4gh:SL.ulUNwZvajob7nzyrlpOd6uUWZIYCsoWb", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55191821, "end": 55191822}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "label": "L858R", "digest": "z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000007.13:g.55259515T>G"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2573T>G"}, {"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2573T>G"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Leu858Arg"}], "location": {"id": "ga4gh:SL.yVGJnwqxV6oCGqC_8nNb58D_wPXJeNJo", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 857, "end": 858}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:14", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:328134"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1855"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:3039", "description": "AKT1 E17K mutations are oncogenic and occur in many cancers at a low prevalence. We performed a multihistology basket study of AZD5363. 58 patients with advanced solid tumors were treated. In patients with AKT1 E17K-mutant tumors (n = 52) and a median of 5 lines of prior therapy, the median PFS was 5.5 months , 6.6 months and 4.2 months in patients with ER+ breast, gynecologic, and other solid tumors, respectively. In an exploratory biomarker analysis, imbalance of the AKT1 E17K-mutant allele, most frequently caused by copy-neutral loss-of-heterozygosity targeting the wild-type allele, was associated with longer PFS as was the presence of coincident PI3K pathway hotspot mutations. Persistent declines in AKT1 E17K in cfDNA were associated with improved PFS and response. Responses were not restricted to patients with detectable AKT1 E17K in pretreatment cfDNA.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1745", "label": "Hyman et al., 2017, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Hyman et al., 2017, J. Clin. Oncol.", "pmid": 28489509}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:2", "label": "AKT1", "description": "AKT1, also referred to as protein kinase B, is a known oncogene. AKT activation relies on the PI3K pathway, and is recognized as a critical node in the pathway. The E17 hotspot is the most characterized of AKT1 mutations, and has been shown to result in activation of the protein. Mutations in AKT1 have also been shown to confer resistance to allosteric kinase inhibitors in vitro.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:391"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:207"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["AKT", "AKT1", "PKB", "PKB-ALPHA", "PRKBA", "RAC", "RAC-ALPHA"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:4", "label": "AKT1 E17K", "description": "AKT1 E17K is a recurrent mutation that has been observed in breast, colorectal, lung, and ovarian cancer. It has been convincingly shown to be an activating mutation resulting in PI3K/AKT/mTOR pathway activity. It has been suggested that this mutation decreases the cell's sensitivity to AKT1 allosteric kinase inhibitors. This, and other AKT1 mutations, are the subject of much research and development for therapeutics.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 33.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000407796.2", "chromosome": "14", "start": 105246551, "stop": 105246551, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "4"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123660"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13983"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS34409589"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLU17LYS", "RS34409589"], "members": [{"id": "ga4gh:VA.swSBQXaa6uybP38HHxbddf9Cvl8JzGEW", "label": "NC_000014.8:g.105246551C>T", "digest": "swSBQXaa6uybP38HHxbddf9Cvl8JzGEW", "type": "Allele", "location": {"id": "ga4gh:SL.q0g2bHXjBdLjnq8rFLJEU3GpNY9o7FeQ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.eK4D2MosgK_ivBkgi6FVPg5UXs1bYESm"}, "start": 104780213, "end": 104780214}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.u-DUjTNvYupRf-vStLK0YPNPV6jEYG1O", "label": "E17K", "digest": "u-DUjTNvYupRf-vStLK0YPNPV6jEYG1O", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000014.8:g.105246551C>T"}, {"syntax": "hgvs.c", "value": "NM_001014432.1:c.49G>A"}, {"syntax": "hgvs.p", "value": "NP_001014432.1:p.Glu17Lys"}, {"syntax": "hgvs.c", "value": "ENST00000407796.2:c.49G>A"}], "location": {"id": "ga4gh:SL._hc6YN89fA0LVGrpJMVLnhhbELQEYuMw", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.GTSPIWYvuDZU59cW1RECFEU1FMiKdEyc"}, "start": 16, "end": 17}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:112", "label": "Capivasertib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C102564"}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C102564"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["AZD5363"]}, "tumorType": {"id": "civic.did:216", "label": "Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9305"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:162"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:3750", "description": "In a phase 2 clinical trial (NCT00949702) of 132 BRAF mutation positive metastatic melanoma patients treated with vemurafenib monotherapy, patients harboring BRAF V600E (n=123) or V600K (n=9) mutations were associated with a favorable objective response rate (53% per RECIST v1.1 criteria, 70/132), with 6% (8/132) and 47% (62/132) of patients achieving complete response and partial response, respectively.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:60", "label": "Trunzer et al., 2013, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Trunzer et al., 2013, J. Clin. Oncol.", "pmid": 23569304}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:12", "label": "BRAF V600E", "description": "BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 1353.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453136, "stop": 140453136, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "12"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123643"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13961"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376069"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS113488022", "V640E", "VAL640GLU", "VAL600GLU"], "members": [{"id": "ga4gh:VA.LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "label": "NC_000007.13:g.140453136A>T", "digest": "LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "type": "Allele", "location": {"id": "ga4gh:SL.XutGzMvqbzN-vnxmPt2MJf7ehxmB0opi", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753335, "end": 140753336}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "label": "V600E", "digest": "4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004333.4:c.1799T>A"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Val600Glu"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140453136A>T"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1799T>A"}], "location": {"id": "ga4gh:SL.ZA1XNKhCT_7m2UtmnYb8ZYOVS4eplMEK", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:7", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3224"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1909"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:5958", "description": "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively.\nWithin the BRAF mutant group, fourteen patients had refractory BRAF V600E-mutated NSCLC (adenocarcinoma, n = 13; sarcomatoid, n = 1). Six patients (43%; 95% CI, 18% to 71%) had objective responses (one CR, five PR), and two additional patients had SD > 120 days. The median DOR was 5 months (range, 4 to 14 months).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2414", "label": "Hainsworth et al., 2018, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Hainsworth et al., 2018, J. Clin. Oncol.", "pmid": 29320312}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:12", "label": "BRAF V600E", "description": "BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 1353.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453136, "stop": 140453136, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "12"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123643"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13961"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376069"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS113488022", "V640E", "VAL640GLU", "VAL600GLU"], "members": [{"id": "ga4gh:VA.LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "label": "NC_000007.13:g.140453136A>T", "digest": "LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "type": "Allele", "location": {"id": "ga4gh:SL.XutGzMvqbzN-vnxmPt2MJf7ehxmB0opi", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753335, "end": 140753336}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "label": "V600E", "digest": "4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004333.4:c.1799T>A"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Val600Glu"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140453136A>T"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1799T>A"}], "location": {"id": "ga4gh:SL.ZA1XNKhCT_7m2UtmnYb8ZYOVS4eplMEK", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:7583", "description": "Off-label use of vemurafenib to treat BRAF V600E mutation-positive, refractory, childhood Langerhans cell histiocytosis (LCH) was evaluated. Fifty-four patients from 12 countries were treated with vemurafenib 20 mg/kg/day. Because LCH is a heterogeneous systemic disease, the quantitative Disease Activity Score (DAS), which reflects overall LCH extension, was used as an evaluation criterion. At 8 weeks, 38 patients had CRs (non-active disease) and 16 had PRs (active disease better). DAS decreased from a median value of 7 to 0 between VMF initiation and day 60 (P < 0.001).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:3012", "label": "Donadieu et al., 2019, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Donadieu et al., 2019, J. Clin. Oncol.", "pmid": 31513482}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:12", "label": "BRAF V600E", "description": "BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 1353.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453136, "stop": 140453136, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "12"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123643"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13961"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376069"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS113488022", "V640E", "VAL640GLU", "VAL600GLU"], "members": [{"id": "ga4gh:VA.LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "label": "NC_000007.13:g.140453136A>T", "digest": "LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "type": "Allele", "location": {"id": "ga4gh:SL.XutGzMvqbzN-vnxmPt2MJf7ehxmB0opi", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753335, "end": 140753336}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "label": "V600E", "digest": "4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004333.4:c.1799T>A"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Val600Glu"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140453136A>T"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1799T>A"}], "location": {"id": "ga4gh:SL.ZA1XNKhCT_7m2UtmnYb8ZYOVS4eplMEK", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:1762", "label": "Langerhans Cell Sarcoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C6921"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:7146"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:7601", "description": "In a phase 2 trial, patients with H3 K27M mutant glioma have been treated with DRD2 antagonist ONC201. Among 29 patients, 1 patient experienced complete clinical regression lasting >14 months, and 3 patients experienced durable partial response by RANO. 10 patients had a best response of stable disease by RANO, with a few of these patients showing substantial tumor regression in some lesions. Author concluded that ONC201 is well tolerated and has clinical activity against K27M-mutated glioma.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:3021", "label": "Isabel Arrillaga, 2019, ASCO Annual Meeting, Abstract 3005", "type": "Document", "title": "ASCO: Isabel Arrillaga, 2019, ASCO Annual Meeting, Abstract 3005"}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:2537", "label": "H3-3A", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:4764"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3020"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["BRYLIB1", "H3-3A", "H3-3B", "H3.3A", "H3F3", "H3F3A"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:2289", "label": "H3-3A K28M", "description": "K28M is a highly recurrent mutation in this gene in multiple cancer types but particularly well known in brain cancers. In amino acid position 27 of H3F3A there is an arginine (R). The medically relevant Lysine (K) is in position 28. Also UNIPROT records the lysine in position 28. However, K27M is common in the literature so is included as a synonym.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 50.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 105, "reference_build": "GRCh38", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000366813.1", "chromosome": "1", "start": 226064434, "stop": 226064434, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "non_conservative_missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001586"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "2416"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602870"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376435"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["K27M"], "definingContext": {"id": "ga4gh:VA.7c2VbQczdeqa9NL0yeddRW3PWH_HwngU", "label": "K28M", "digest": "7c2VbQczdeqa9NL0yeddRW3PWH_HwngU", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000366813.1:c.83A>T"}, {"syntax": "hgvs.p", "value": "ENSP00000355778.1:p.Lys28Met"}], "location": {"id": "ga4gh:SL.gjf8ulZvx_LHzmvLA3b4OW0-Ul1SlMbB", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.2uEiKlgt3rV_axllFiEObLHYBOl2mT38"}, "start": 27, "end": 28}, "state": {"type": "LiteralSequenceExpression", "sequence": "M"}}}, "therapeutic": {"id": "civic.tid:696", "label": "Akt/ERK Inhibitor ONC201", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C113792"}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C113792"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["ONC-201", "ONC201", "TIC10"]}, "tumorType": {"id": "civic.did:2596", "label": "Glioma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3059"}], "type": "Disease"}}
{"id": "civic.eid:7710", "description": "In this retrospective analysis of a phase 3 trial of cabozantinib or placebo in 330 patients. Among those, 51.2% were RET mutation-positive (38.2% with RET M918T), 34.8% were RET mutation-unknown, and 13.9% were RET mutation-negative. Sixteen patients were RAS mutation-positive. Cabozantinib appeared to prolong PFS versus the placebo in the RET mutation-positive subgroup (hazard ratio [HR], 0.23; 95% confidence interval [CI], 0.14-0.38; P\u2009<\u2009.0001). \nPatients in a RET mutation-negative population showed relatively smaller benefits from cabozantinib (HR 0.53).\nThe RET M918T subgroup achieved the greatest observed PFS benefit from cabozantinib versus the placebo (HR 0.15).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:3061", "label": "Sherman et al., 2016, Cancer", "type": "Document", "title": "PubMed: Sherman et al., 2016, Cancer", "pmid": 27525386}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:42", "label": "RET", "description": "RET mutations and the RET fusion RET-PTC lead to activation of this tyrosine kinase receptor and are associated with thyroid cancers. RET point mutations are the most common mutations identified in medullary thyroid cancer (MTC) with germline and somatic mutations in RET associated with hereditary and sporadic forms, respectively. The most common somatic form mutation is M918T (exon 16) and a variety of other mutations effecting exons 10, 11 and 15 have been described. The prognostic significance of these mutations have been hotly debated in the field, however, data suggests that some RET mutation may confer drug resistance. Highly selective and well-tolerated RET inhibitors, selpercatinib (LOXO-292) and pralsetinib (BLU-667), have been FDA approved recently for the treatment of RET fusion-positive non-small-cell lung cancer, RET fusion-positive thyroid cancer and RET-mutant medullary thyroid cancer.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:9967"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5979"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CDHF12", "CDHR16", "HSCR1", "MEN2A", "MEN2B", "MTC1", "PTC", "RET", "RET-ELE1"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:113", "label": "RET M918T", "description": "RET M819T is the most common somatically acquired mutation in medullary thyroid cancer (MTC). While there currently are no RET-specific inhibiting agents, promiscuous kinase inhibitors have seen some success in treating RET overactivity. Data suggests however, that the M918T mutation may lead to drug resistance, especially against the VEGFR-inhibitor motesanib. It has also been suggested that RET M819T leads to more aggressive MTC with a poorer prognosis.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 86.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "C", "representative_transcript": "ENST00000355710.3", "chromosome": "10", "start": 43617416, "stop": 43617416, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "113"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA009082"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13919"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS74799832"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["MET918THR", "RS74799832"], "members": [{"id": "ga4gh:VA.fMYV9MzRrcjzLBqEnsYUV96pUNCnjvyA", "label": "NC_000010.10:g.43617416T>C", "digest": "fMYV9MzRrcjzLBqEnsYUV96pUNCnjvyA", "type": "Allele", "location": {"id": "ga4gh:SL.mSXkkaJ2fQpHLkFwfJEItXTi9eYahAiZ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.ss8r_wB0-b9r44TQTMmVTI92884QvBiB"}, "start": 43121967, "end": 43121968}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.w2q9R8i1OYhtNg-QS5vngW71qwbI40pu", "label": "M918T", "digest": "w2q9R8i1OYhtNg-QS5vngW71qwbI40pu", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_020975.4:c.2753T>C"}, {"syntax": "hgvs.p", "value": "NP_065681.1:p.Met918Thr"}, {"syntax": "hgvs.c", "value": "ENST00000355710.3:c.2753T>C"}, {"syntax": "hgvs.g", "value": "NC_000010.10:g.43617416T>C"}], "location": {"id": "ga4gh:SL.TyVSPbGxZ3uxiWHhkhT0hAi1rEoyMc0-", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.jMu9-ItXSycQsm4hyABeW_UfSNRXRVnl"}, "start": 917, "end": 918}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}}, "therapeutic": {"id": "civic.tid:144", "label": "Cabozantinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1363267"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:65823", "type": "Disease", "label": "Thyroid cancer differentiated"}, {"id": "hemonc:660", "type": "Disease", "label": "Renal cell carcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C9385"}, "relation": "relatedMatch"}]}, {"id": "hemonc:612", "type": "Disease", "label": "Hepatocellular carcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C3099"}, "relation": "relatedMatch"}]}, {"id": "hemonc:68942", "type": "Disease", "label": "Thyroid cancer medullary"}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C52200"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1,1-Cyclopropanedicarboxamide, N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4- Fluorophenyl)-", "N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1- Dicarboxamide"]}, "tumorType": {"id": "civic.did:15", "label": "Thyroid Gland Medullary Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3879"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3973"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:9018", "description": "Open label phase 2 (Clinical Level B) trial including patients from across the globe (USA, Italy, and the Netherlands) investigating sensitivity to Vemurafenib in patients that have BRAF V600E-positive papillary thyroid cancer that have become resistant to radioactive iodine (the standard treatment). There were 116 patients identified for this trial, 51 of which met the conditions to be included. These 51 patients were split into two cohorts: 1) patients that had never been treated with a multikinase inhibitor targeting VEGFR and 2) patients that have previously been treated with a VEGFR multikinase inhibitor. In cohort 1, ten of 26 patients had best overall response. Best overall response was defined as the proportion of patients with a complete or partial response, however these ten patients were all partial response. In the same cohort 1, nine had achieved stable disease control for at least six months; therefore, 19 patients achieved disease control (73% of total cohort 1, 95% CI 52-88). In cohort 2, of 23 eligible patients, six had a partial response as best overall response and six had stable disease control for at least six months; therefore, 12 patients achieved disease control. (55% of total cohort 2, 95% CI 32-76). The authors conclude that vemurafenib is a potential treatment option for late-stage BRAF V600E-positive papillary thyroid cancer for treatment in patients na\u00efve to a multikinase inhibitor (Cohort 1) and to patients that have been previously treated with a multikinase inhibitor (Cohort 2).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1052", "label": "Brose et al., 2016, Lancet Oncol.", "type": "Document", "title": "PubMed: Brose et al., 2016, Lancet Oncol.", "pmid": 27460442}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:12", "label": "BRAF V600E", "description": "BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 1353.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453136, "stop": 140453136, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "12"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123643"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13961"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376069"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS113488022", "V640E", "VAL640GLU", "VAL600GLU"], "members": [{"id": "ga4gh:VA.LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "label": "NC_000007.13:g.140453136A>T", "digest": "LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "type": "Allele", "location": {"id": "ga4gh:SL.XutGzMvqbzN-vnxmPt2MJf7ehxmB0opi", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753335, "end": 140753336}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "label": "V600E", "digest": "4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004333.4:c.1799T>A"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Val600Glu"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140453136A>T"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1799T>A"}], "location": {"id": "ga4gh:SL.ZA1XNKhCT_7m2UtmnYb8ZYOVS4eplMEK", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:156", "label": "Thyroid Gland Papillary Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4035"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3969"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:83", "description": "This was a retrospective analysis of genetic markers in 503 metastatic colorectal cancer patients who participated in the CORRECT phase III trial of regorafenib. PIK3CA mutations were identified in the tumors of 84 patients, including 27 with PIK3CA E542K. Authors found a clinical benefit of regorafenib across PIK3CA mutated and wildtype subgroups (progression free survival with regorafenib vs placebo: mutant HR: 0.54, wildtype HR: 0.50, P=0.85). Authors do not provide direct comparison between patients with wildtype and PIK3CA E542K patients. Note that it's unclear how many PIK3CA wildtype patients harbor KRAS mutations, though authors' suggest that regorafenib induces clinical benefit regardless of KRAS or PIK3CA mutation status.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:4081", "label": "Tabernero et al., 2015, Lancet Oncol", "type": "Document", "title": "PubMed: Tabernero et al., 2015, Lancet Oncol", "pmid": 26184520}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "refutes", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:103", "label": "PIK3CA E542K", "description": "PIK3CA E545K/E542K variants are the second most recurrent PIK3CA mutations in breast cancer and are highly recurrent mutations in many other cancer types. Colorectal cancer patients with the PIK3CA E545K variant, and possibly other variants in the E545 region, may indicate poor prognosis relative to patients with other PIK3CA variants or wild-type PIK3CA. The literature also suggests that E545/E542 variants may confer resistance to EGFR inhibitors (e.g., cetuximab). An FDA approved treatment regimen including a targeted PIK3CA inhibitor is available for specific subtypes of breast cancer. While PIK3CA variants are highly prevalent in many other cancer types, targeted therapies for PIK3CA variants are still in early clinical trial phases in other cancer types.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 75.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000263967.3", "chromosome": "3", "start": 178936082, "stop": 178936082, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "103"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA333572"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "31944"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913273"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLU542LYS", "RS121913273"], "members": [{"id": "ga4gh:VA.52-4tAq0Ya9SeMU4eZSgO0bfqvkd_VE4", "label": "NC_000003.11:g.178936082G>A", "digest": "52-4tAq0Ya9SeMU4eZSgO0bfqvkd_VE4", "type": "Allele", "location": {"id": "ga4gh:SL.65wPuIVC66WPYQqTnuNP-taUZ03NOwmJ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 179218293, "end": 179218294}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.D6daDiDNn1u-e4YtntaYQnxlZ_0T6gtD", "label": "E542K", "digest": "D6daDiDNn1u-e4YtntaYQnxlZ_0T6gtD", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006218.3:c.1624G>A"}, {"syntax": "hgvs.p", "value": "NP_006209.2:p.Glu542Lys"}, {"syntax": "hgvs.c", "value": "ENST00000263967.3:c.1624G>A"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.178936082G>A"}], "location": {"id": "ga4gh:SL.DdVC73cqPrOnzCRvVc8N9tA3ecV5Qunt", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 541, "end": 542}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:27", "label": "Regorafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1312397"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C78204"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide", "BAY 73-4506", "REGORAFENIB ANHYDROUS", "Stivarga"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:126", "description": "This was a retrospective study of 691 cetuximab treated patients with metastatic, chemotherapy refractory colorectal cancer. Of those, 30 patients harbored BRAF V600E, were KRAS, NRAS and PIK3CA wt, and had individual response data. One patient (who harbored BRAF V600E in low copy number) responded, 11 had stable disease, and 18 progressed. Treatments included cetuximab + irinotecan (n=20), cetuximab monotherapy (n=5), cetuximab + FOLFIRI (n=4), and cetuximab + oxaliplatin + 5FU (n=1). Median PFS was 8 weeks (2-32 weeks), median OS was 25 weeks (4-237 weeks), and median number of previous chemotherapy lines was 2 (0-4). Median age was 61 years old (42-78) and there were 16 males and 14 females. Authors concluded that BRAF mutation (23/24 of mutants were BRAF V600E) was strongly associated with poor response to cetuximab and suggested that mutation status of BRAF is more informative than those of NRAS and PIK3CA exon 20 for predicting cetuximab response (second only to KRAS).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:76", "label": "De Roock et al., 2010, Lancet Oncol.", "type": "Document", "title": "PubMed: De Roock et al., 2010, Lancet Oncol.", "pmid": 20619739}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:12", "label": "BRAF V600E", "description": "BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 1353.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453136, "stop": 140453136, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "12"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123643"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13961"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376069"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS113488022", "V640E", "VAL640GLU", "VAL600GLU"], "members": [{"id": "ga4gh:VA.LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "label": "NC_000007.13:g.140453136A>T", "digest": "LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "type": "Allele", "location": {"id": "ga4gh:SL.XutGzMvqbzN-vnxmPt2MJf7ehxmB0opi", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753335, "end": 140753336}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "label": "V600E", "digest": "4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004333.4:c.1799T>A"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Val600Glu"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140453136A>T"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1799T>A"}], "location": {"id": "ga4gh:SL.ZA1XNKhCT_7m2UtmnYb8ZYOVS4eplMEK", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "civic.tid:16", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:318341"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}, {"id": "mesh:D006258", "type": "Disease", "label": "Head and Neck Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C4013"}, "relation": "relatedMatch"}]}, {"id": "mesh:D002294", "type": "Disease", "label": "Carcinoma, Squamous Cell", "mappings": [{"coding": {"system": "ncit", "code": "C2929"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1723"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:239", "description": "In non-small cell lung cancer, the appearance of T790M mutation leads to resistance to gefitinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:168", "label": "Kobayashi et al., 2005, N. Engl. J. Med.", "type": "Document", "title": "PubMed: Kobayashi et al., 2005, N. Engl. J. Med.", "pmid": 15728811}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:34", "label": "EGFR T790M", "description": "EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 406.25}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55249071, "stop": 55249071, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "34"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA090928"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16613"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434569"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["THR790MET", "RS121434569"], "members": [{"id": "ga4gh:VA.OvEfBRaS34JkfM0_ZHJVDQEjqtwzyjyp", "label": "NC_000007.13:g.55249071C>T", "digest": "OvEfBRaS34JkfM0_ZHJVDQEjqtwzyjyp", "type": "Allele", "location": {"id": "ga4gh:SL.ZCgOjF-_T0EOBXGc-6yICYui-jgFzJfY", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55181377, "end": 55181378}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.faKID4aj8rP8NKZpWL4mWDToEztTUmbr", "label": "T790M", "digest": "faKID4aj8rP8NKZpWL4mWDToEztTUmbr", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2369C>T"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2369C>T"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Thr790Met"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55249071C>T"}], "location": {"id": "ga4gh:SL.C1y_lDZe8e9pKy3jcj3oJKw_7252Hrxa", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 789, "end": 790}, "state": {"type": "LiteralSequenceExpression", "sequence": "M"}}}, "therapeutic": {"id": "civic.tid:14", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:328134"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1855"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:304", "description": "In GIST tumor cells and patients harboring KIT V654A mutation, SU11248 is effective for those that are refractory to imatinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:192", "label": "Prenen et al., 2006, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Prenen et al., 2006, Clin. Cancer Res.", "pmid": 16638875}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:29", "label": "KIT", "description": "c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3815"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["C-Kit", "CD117", "KIT", "MASTC", "PBT", "SCFR"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:73", "label": "KIT V654A", "description": "KIT V654A is an exon 13 mutation that lies within the tyrosine kinase 1 domain of the protein. It has been shown to be an activating mutation by in vitro studies. This mutation is associated with imatinib resistance in melanoma patients. However, second generation TKI's such as sunitinib and midostaurin (PKC 412) have seen success in acheiving tumor response.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 18.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "C", "representative_transcript": "ENST00000288135.5", "chromosome": "4", "start": 55594258, "stop": 55594258, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "73"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602402"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "375921"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913523"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913523", "VAL654ALA"], "members": [{"id": "ga4gh:VA.-ZkJiZCgRrCAPN4FwwvYTLTyNSVGxv91", "label": "NC_000004.11:g.55594258T>C", "digest": "-ZkJiZCgRrCAPN4FwwvYTLTyNSVGxv91", "type": "Allele", "location": {"id": "ga4gh:SL.aqVlFVOU1rwA9qOLXQOR_RM3nwtjLODh", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54728091, "end": 54728092}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.9mxRMKbFtCe8j6s8x9imRCuq0xIpXRt6", "label": "V654A", "digest": "9mxRMKbFtCe8j6s8x9imRCuq0xIpXRt6", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_000222.2:c.1961T>C"}, {"syntax": "hgvs.p", "value": "NP_000213.1:p.Val654Ala"}, {"syntax": "hgvs.c", "value": "ENST00000288135.5:c.1961T>C"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55594258T>C"}], "location": {"id": "ga4gh:SL.um97SDid7E4raxzVp8ci7g1w8NKAoJs8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 653, "end": 654}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}}, "therapeutic": {"id": "civic.tid:157", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:357977"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:647", "type": "Disease", "label": "Pancreatic NET", "mappings": [{"coding": {"system": "ncit", "code": "C27720"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:660", "type": "Disease", "label": "Renal cell carcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C9385"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C71622"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"]}, "tumorType": {"id": "civic.did:2", "label": "Gastrointestinal Stromal Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3868"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9253"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:669", "description": "The MTHFR C667T variant was associated with significantly lower relapse-free survival and overall survival in stomach cancer patients treated with 5-Fluorouracil-based therapies. 116 Chinese patients with histologically confirmed gastric cancer were used in this study, and all patients had radical surgery before treatment.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:424", "label": "Huang et al., 2009, Cancer Chemother. Pharmacol.", "type": "Document", "title": "PubMed: Huang et al., 2009, Cancer Chemother. Pharmacol.", "pmid": 18704422}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "germline", "geneContext": {"id": "civic.gid:3672", "label": "MTHFR", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:7436"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:4524"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["MTHFR"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:254", "label": "MTHFR A222V", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 55.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000376592.1", "chromosome": "1", "start": 11856378, "stop": 11856378, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "258"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA170990"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "3520"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS1801133"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ALA222VAL", "RS1801133", "C677T"], "members": [{"id": "ga4gh:VA.-FDUuNE2cd4eQ6b0J7AB_GVVQfIbhnWh", "label": "NC_000001.10:g.11856378G>A", "digest": "-FDUuNE2cd4eQ6b0J7AB_GVVQfIbhnWh", "type": "Allele", "location": {"id": "ga4gh:SL.YWu4hztxkbnQldZFh7CZroL-C912BkAs", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Ya6Rs7DHhDeg7YaOSg1EoNi3U_nQ9SvO"}, "start": 11796320, "end": 11796321}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.P3yunCZ58gjlGqpAHi5HM4p8HLELggw-", "label": "A222V", "digest": "P3yunCZ58gjlGqpAHi5HM4p8HLELggw-", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_005957.4:c.665C>T"}, {"syntax": "hgvs.p", "value": "NP_005948.3:p.Ala222Val"}, {"syntax": "hgvs.c", "value": "ENST00000376592.1:c.665G>A"}, {"syntax": "hgvs.g", "value": "NC_000001.10:g.11856378G>A"}], "location": {"id": "ga4gh:SL.AHnSF6Rw6xvorKRfezXRB1sI4oAlmuCC", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.4RSETawLfMkNpQBPepa7Uf9ItHAEJUde"}, "start": 221, "end": 222}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "civic.tid:420", "label": "Fluorouracil", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:4492"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C505"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["2,4-Dioxo-5-fluoropyrimidine", "5 FU", "5 Fluorouracil", "5 Fluorouracilum", "5-FU", "5-Fluoro-2,4(1H, 3H)-pyrimidinedione", "5-Fluoro-2,4(1H,3H)-pyrimidinedione", "5-Fluorouracil", "5-Fluracil", "5FU", "AccuSite", "Adrucil", "Carac", "Fluoro Uracil", "Fluouracil", "Flurablastin", "Fluracedyl", "Fluracil", "Fluril", "Fluroblastin", "Ribofluor", "Ro 2-9757", "Ro-2-9757"]}, "tumorType": {"id": "civic.did:21", "label": "Stomach Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9331"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:10534"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:674", "description": "The ABCB1 G2677T/A (S893T, rs2032582) homozygous variant was positively correlated with response to paclitaxel treatment in ovarian cancer patients. 51 epithelial and 2 fallopian tube frozen tumors were analyzed for this study.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:428", "label": "Gr\u00e9en et al., 2006, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Gr\u00e9en et al., 2006, Clin. Cancer Res.", "pmid": 16467099}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "germline", "geneContext": {"id": "civic.gid:4244", "label": "ABCB1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:40"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5243"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["ABC20", "ABCB1", "CD243", "CLCS", "GP170", "MDR1", "P-GP", "PGY1", "p-170"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:258", "label": "ABCB1 S893T", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 15.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000265724.3", "chromosome": "7", "start": 87160618, "stop": 87160618, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "262"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA179696"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "166619"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS2032582"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["SER893THR", "A893S", "RS2032582"], "members": [{"id": "ga4gh:VA.QN3zAuApXaH4xyHm-EfRiGoMSU-F6mOS", "label": "NC_000007.13:g.87160618A>T", "digest": "QN3zAuApXaH4xyHm-EfRiGoMSU-F6mOS", "type": "Allele", "location": {"id": "ga4gh:SL.n6sDHRLAjiWS-OZxTN9hJFkLfaBNhSwM", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 87531301, "end": 87531302}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.OCElMC4WZQZgEk8ItlZQ5mrHZVLWfr56", "label": "S893T", "digest": "OCElMC4WZQZgEk8ItlZQ5mrHZVLWfr56", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_000927.4:c.2677T>A"}, {"syntax": "hgvs.p", "value": "NP_000918.2:p.Ser893Thr"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.87160618A>T"}, {"syntax": "hgvs.c", "value": "ENST00000265724.3:c.2677T>A"}], "location": {"id": "ga4gh:SL.GStt_QzgQ-VY3QEBNjz-erTYnX3hDAwH", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.EWhzdULx7zTEbQrXKntDUH24Qp3FZbRa"}, "start": 892, "end": 893}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}}, "therapeutic": {"id": "civic.tid:81", "label": "Paclitaxel", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:56946"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:645", "type": "Disease", "label": "Ovarian cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7431"}, "relation": "relatedMatch"}]}, {"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:54036", "type": "Disease", "label": "Kaposi sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9087"}, "relation": "relatedMatch"}]}, {"id": "hemonc:572", "type": "Disease", "label": "Breast cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9335"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1411"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["5Beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one, 4,10-Diacetate 2-Benzoate 13-Ester With (2R,3S)-N-Benzoyl-3-phenylisoserine", "Anzatax", "Asotax", "Bristaxol", "Praxel", "Taxol", "Taxol Konzentrat", "[2aR-[2a Alpha,4beta,4a Beta,6beta,9alpha(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-(benzoylamino)-alpha-hydroxybenzene-propanoic Acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-1a,33,4,-41,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-41,8,-12,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester"]}, "tumorType": {"id": "civic.did:20", "label": "Ovarian Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C7431"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:2394"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:883", "description": "In a phase 2 study of patients with lung adenocarcinoma (stage IIIb with pleural effusion or stage IV) and EGFR mutations, treated with afatinib were assessed by objective response. 129 patients were treated with afatinib. 66% of the 106 patients with two common activating EGFR mutations (deletion 19 or L858R) had an objective response compared to 39% of 23 patients with less common mutations.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:594", "label": "Yang et al., 2012, Lancet Oncol.", "type": "Document", "title": "PubMed: Yang et al., 2012, Lancet Oncol.", "pmid": 22452895}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:33", "label": "EGFR L858R", "description": "EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 379.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "G", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55259515, "stop": 55259515, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "33"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA126713"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16609"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376282"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376280"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434568"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121434568", "LEU858ARG"], "members": [{"id": "ga4gh:VA.TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "label": "NC_000007.13:g.55259515T>G", "digest": "TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "type": "Allele", "location": {"id": "ga4gh:SL.ulUNwZvajob7nzyrlpOd6uUWZIYCsoWb", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55191821, "end": 55191822}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "label": "L858R", "digest": "z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000007.13:g.55259515T>G"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2573T>G"}, {"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2573T>G"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Leu858Arg"}], "location": {"id": "ga4gh:SL.yVGJnwqxV6oCGqC_8nNb58D_wPXJeNJo", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 857, "end": 858}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:146", "label": "Afatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1430438"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:25316", "type": "Disease", "label": "Non-small cell lung cancer squamous"}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C66940"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide", "BIBW 2992", "BIBW2992"]}, "tumorType": {"id": "civic.did:30", "label": "Lung Adenocarcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3512"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3910"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:885", "description": "A randomized phase 3 trial (NCT00446225) involving 173 NSCLC patients with EGFR mutations (exon 19 deletion or L858R mutation in exon 21) with no history of chemotherapy for metastatic disease. Patients were randomly allocated (1:1) to receive either erlotinib or standard chemotherapy. The primary endpoint was progression-free survival (PFS). Median PFS was 9.7 months in the erlotinib group, compared with 5.2 months in the standard chemotherapy group.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:595", "label": "Rosell et al., 2012, Lancet Oncol.", "type": "Document", "title": "PubMed: Rosell et al., 2012, Lancet Oncol.", "pmid": 22285168}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:33", "label": "EGFR L858R", "description": "EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 379.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "G", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55259515, "stop": 55259515, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "33"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA126713"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16609"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376282"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376280"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434568"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121434568", "LEU858ARG"], "members": [{"id": "ga4gh:VA.TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "label": "NC_000007.13:g.55259515T>G", "digest": "TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "type": "Allele", "location": {"id": "ga4gh:SL.ulUNwZvajob7nzyrlpOd6uUWZIYCsoWb", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55191821, "end": 55191822}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "label": "L858R", "digest": "z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000007.13:g.55259515T>G"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2573T>G"}, {"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2573T>G"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Leu858Arg"}], "location": {"id": "ga4gh:SL.yVGJnwqxV6oCGqC_8nNb58D_wPXJeNJo", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 857, "end": 858}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:964", "description": "An EGFR resistance mutation, C797S, was discovered by deep sequencing of cell-free plasma DNA (cfDNA) from patients with advanced lung cancer whose tumors had developed resistance to osimertinib. Expression of this mutant EGFR construct in a cell line rendered it resistant to osimertinib. ddPCR on serial cfDNA specimens collected from 15 osimertinib-treated subjects (all positive for T790M before treatment) revealed 6 cases with acquired C797S mutation.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:666", "label": "Thress et al., 2015, Nat. Med.", "type": "Document", "title": "PubMed: Thress et al., 2015, Nat. Med.", "pmid": 25939061}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:411", "label": "EGFR C797S", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 17.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "A", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55249091, "stop": 55249091, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "415"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602785"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376342"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS1057519861"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["CYS797SER", "RS1057519861"], "members": [{"id": "ga4gh:VA.1kk6T2qb1Qy4vtWB0ZpWWcCDsmol6TaT", "label": "NC_000007.13:g.55249091T>A", "digest": "1kk6T2qb1Qy4vtWB0ZpWWcCDsmol6TaT", "type": "Allele", "location": {"id": "ga4gh:SL.QutBr2a72ttD2JGX7gsn83DPaLlXLS56", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55181397, "end": 55181398}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.G0JEKgjyKjGHeACGy7ouzmtYjBOUvKQd", "label": "C797S", "digest": "G0JEKgjyKjGHeACGy7ouzmtYjBOUvKQd", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2389T>A"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55249091T>A"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2389T>A"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Cys797Ser"}], "location": {"id": "ga4gh:SL.oirojchlpx4TkwB6RIkiiq69FXRdtka0", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 796, "end": 797}, "state": {"type": "LiteralSequenceExpression", "sequence": "S"}}}, "therapeutic": {"id": "civic.tid:187", "label": "Osimertinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1721560"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C116377"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-", "AZD-9291", "AZD9291", "Mereletinib", "Tagrisso"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:966", "description": "This study summarized 9 EGFR-mutant patients from two clinical trials involving rociletinib (NCT01526928) and subsequent osimertinib (NCT01802632). 8 were T790M-positive prior to treatment with osimertinib. 6 transitioned directly from rociletinib to osimertinib. 3 patients achieved PR and 4 achieved SD. The median PFS was 208 days (95% CI, 41-208 days). Among 6 patients who transitioned directly from rociletinib to osimertinib all derived clinical benefit from osimertinib with either prolonged SD or PR.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:668", "label": "Sequist et al., 2016, JAMA Oncol", "type": "Document", "title": "PubMed: Sequist et al., 2016, JAMA Oncol", "pmid": 26720284}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:34", "label": "EGFR T790M", "description": "EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 406.25}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55249071, "stop": 55249071, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "34"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA090928"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16613"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434569"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["THR790MET", "RS121434569"], "members": [{"id": "ga4gh:VA.OvEfBRaS34JkfM0_ZHJVDQEjqtwzyjyp", "label": "NC_000007.13:g.55249071C>T", "digest": "OvEfBRaS34JkfM0_ZHJVDQEjqtwzyjyp", "type": "Allele", "location": {"id": "ga4gh:SL.ZCgOjF-_T0EOBXGc-6yICYui-jgFzJfY", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55181377, "end": 55181378}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.faKID4aj8rP8NKZpWL4mWDToEztTUmbr", "label": "T790M", "digest": "faKID4aj8rP8NKZpWL4mWDToEztTUmbr", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2369C>T"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2369C>T"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Thr790Met"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55249071C>T"}], "location": {"id": "ga4gh:SL.C1y_lDZe8e9pKy3jcj3oJKw_7252Hrxa", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 789, "end": 790}, "state": {"type": "LiteralSequenceExpression", "sequence": "M"}}}, "therapeutic": {"id": "civic.tid:187", "label": "Osimertinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1721560"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C116377"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-", "AZD-9291", "AZD9291", "Mereletinib", "Tagrisso"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1180", "description": "12 patients with KRAS G13D mutant, metastatic colorectal cancer were treated with single agent cetuximab in a prospective phase II study. The primary endpoint of the trial was 4-month progression-free survival, with a benefit to treatment evaluated to be 50% of patients were progression free at this point. None of 12 patients achieved response by RECIST 1.1 criteria and three patients (25%) were progression-free at 4 months, with disease control rate at 6 months reaching 0%. Median PFS and OS were 1.9 (95% CI 1.7\u20133.8) and 7.2 months (95% CI 5.7\u20139.7).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:813", "label": "Schirripa et al., 2015, Ann. Oncol.", "type": "Document", "title": "PubMed: Schirripa et al., 2015, Ann. Oncol.", "pmid": 26371285}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:81", "label": "KRAS G13D", "description": "While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, results are conflicting with retrospective analyses suggesting a better response to EGFR-Inhibition. A recent prospective phase-II study (12 patients, Schirripa et. al. 2015) could not reproduce this finding and another prospective phase II trial is currently ongoing.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 108.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398281, "stop": 25398281, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "81"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA122534"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12580"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS112445441"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS112445441", "GLY13ASP"], "members": [{"id": "ga4gh:VA.wQro48c_oFxB35UNb2O1Z7Vj6rXnJywl", "label": "NC_000012.11:g.25398281C>T", "digest": "wQro48c_oFxB35UNb2O1Z7Vj6rXnJywl", "type": "Allele", "location": {"id": "ga4gh:SL.rZcsm5bnq3ptyk4298opou7vY9O0etcL", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245346, "end": 25245347}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.h-3tyZSdsQNs9NHrhuwcACnnMnpuT-8Z", "label": "G13D", "digest": "h-3tyZSdsQNs9NHrhuwcACnnMnpuT-8Z", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_033360.3:c.38G>A"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly13Asp"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398281C>T"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.38G>A"}], "location": {"id": "ga4gh:SL.U-3sSsoejW41eQ2Aev0wiG5tEuDiQZTB", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 12, "end": 13}, "state": {"type": "LiteralSequenceExpression", "sequence": "D"}}}, "therapeutic": {"id": "civic.tid:16", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:318341"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}, {"id": "mesh:D006258", "type": "Disease", "label": "Head and Neck Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C4013"}, "relation": "relatedMatch"}]}, {"id": "mesh:D002294", "type": "Disease", "label": "Carcinoma, Squamous Cell", "mappings": [{"coding": {"system": "ncit", "code": "C2929"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1723"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1365", "description": "In a phase 2 clinical trial of sorafenib in patients with hereditary or sporadic advanced medullary thyroid cancer, 10 out of 12 patients genotyped in arm B (sporadic MTC) tested positive for RET mutations. In response to sorafenib, 8 patients with RET M918T mutations had stable disease, 1 RET M918T mutant had partial response, and 1 patient with a RET C634R mutation had stable disease. Prior to study entry, all patients with RET M918T mutations had progressive disease or were newly diagnosed.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:928", "label": "Lam et al., 2010, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Lam et al., 2010, J. Clin. Oncol.", "pmid": 20368568}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:42", "label": "RET", "description": "RET mutations and the RET fusion RET-PTC lead to activation of this tyrosine kinase receptor and are associated with thyroid cancers. RET point mutations are the most common mutations identified in medullary thyroid cancer (MTC) with germline and somatic mutations in RET associated with hereditary and sporadic forms, respectively. The most common somatic form mutation is M918T (exon 16) and a variety of other mutations effecting exons 10, 11 and 15 have been described. The prognostic significance of these mutations have been hotly debated in the field, however, data suggests that some RET mutation may confer drug resistance. Highly selective and well-tolerated RET inhibitors, selpercatinib (LOXO-292) and pralsetinib (BLU-667), have been FDA approved recently for the treatment of RET fusion-positive non-small-cell lung cancer, RET fusion-positive thyroid cancer and RET-mutant medullary thyroid cancer.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:9967"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5979"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CDHF12", "CDHR16", "HSCR1", "MEN2A", "MEN2B", "MTC1", "PTC", "RET", "RET-ELE1"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:113", "label": "RET M918T", "description": "RET M819T is the most common somatically acquired mutation in medullary thyroid cancer (MTC). While there currently are no RET-specific inhibiting agents, promiscuous kinase inhibitors have seen some success in treating RET overactivity. Data suggests however, that the M918T mutation may lead to drug resistance, especially against the VEGFR-inhibitor motesanib. It has also been suggested that RET M819T leads to more aggressive MTC with a poorer prognosis.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 86.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "C", "representative_transcript": "ENST00000355710.3", "chromosome": "10", "start": 43617416, "stop": 43617416, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "113"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA009082"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13919"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS74799832"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["MET918THR", "RS74799832"], "members": [{"id": "ga4gh:VA.fMYV9MzRrcjzLBqEnsYUV96pUNCnjvyA", "label": "NC_000010.10:g.43617416T>C", "digest": "fMYV9MzRrcjzLBqEnsYUV96pUNCnjvyA", "type": "Allele", "location": {"id": "ga4gh:SL.mSXkkaJ2fQpHLkFwfJEItXTi9eYahAiZ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.ss8r_wB0-b9r44TQTMmVTI92884QvBiB"}, "start": 43121967, "end": 43121968}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.w2q9R8i1OYhtNg-QS5vngW71qwbI40pu", "label": "M918T", "digest": "w2q9R8i1OYhtNg-QS5vngW71qwbI40pu", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_020975.4:c.2753T>C"}, {"syntax": "hgvs.p", "value": "NP_065681.1:p.Met918Thr"}, {"syntax": "hgvs.c", "value": "ENST00000355710.3:c.2753T>C"}, {"syntax": "hgvs.g", "value": "NC_000010.10:g.43617416T>C"}], "location": {"id": "ga4gh:SL.TyVSPbGxZ3uxiWHhkhT0hAi1rEoyMc0-", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.jMu9-ItXSycQsm4hyABeW_UfSNRXRVnl"}, "start": 917, "end": 918}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}}, "therapeutic": {"id": "civic.tid:6", "label": "Sorafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:495881"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:65823", "type": "Disease", "label": "Thyroid cancer differentiated"}, {"id": "hemonc:612", "type": "Disease", "label": "Hepatocellular carcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C3099"}, "relation": "relatedMatch"}]}, {"id": "hemonc:660", "type": "Disease", "label": "Renal cell carcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C9385"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C61948"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["BA4 43 9006", "BAY 43-9006", "Bay-439006"]}, "tumorType": {"id": "civic.did:15", "label": "Thyroid Gland Medullary Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3879"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3973"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1406", "description": "In trial NCT00880321, dabrafenib was tested in various solid tumor types harboring mutant BRAF after establishing dosage of 150 mg twice daily. In nine colorectal cancer patients with established V600E mutation, 1 confirmed response, 7 instances of stable disease, and 1 case of progressive disease was seen, which contrasted strongly with a 56% confirmed response rate seen in metastatic V600E melanoma patients similarly treated in the same study.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:345", "label": "Falchook et al., 2012, Lancet", "type": "Document", "title": "PubMed: Falchook et al., 2012, Lancet", "pmid": 22608338}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "refutes", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:12", "label": "BRAF V600E", "description": "BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 1353.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453136, "stop": 140453136, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "12"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123643"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13961"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376069"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS113488022", "V640E", "VAL640GLU", "VAL600GLU"], "members": [{"id": "ga4gh:VA.LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "label": "NC_000007.13:g.140453136A>T", "digest": "LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "type": "Allele", "location": {"id": "ga4gh:SL.XutGzMvqbzN-vnxmPt2MJf7ehxmB0opi", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753335, "end": 140753336}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "label": "V600E", "digest": "4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004333.4:c.1799T>A"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Val600Glu"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140453136A>T"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1799T>A"}], "location": {"id": "ga4gh:SL.ZA1XNKhCT_7m2UtmnYb8ZYOVS4eplMEK", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "civic.tid:22", "label": "Dabrafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1424911"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:675", "type": "Disease", "label": "Thyroid cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7510"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C82386"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["BRAF Inhibitor GSK2118436", "Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-", "GSK-2118436", "GSK-2118436A", "GSK2118436"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1410", "description": "Phase 2 trial in 132 patients with previously treated metastatic melanoma with BRAF V600E mutation. \nConfirmed overall response rate was 53% (95% confidence interval [CI], 44 to 62; 6% with a complete response and 47% with a partial response), median duration of response was 6.7 months (95% CI, 5.6 to 8.6), and median progression-free survival was 6.8 months (95% CI, 5.6 to 8.1). Median overall survival was 15.9 months (95% CI, 11.6 to 18.3).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:354", "label": "Sosman et al., 2012, N. Engl. J. Med.", "type": "Document", "title": "PubMed: Sosman et al., 2012, N. Engl. J. Med.", "pmid": 22356324}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:12", "label": "BRAF V600E", "description": "BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 1353.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453136, "stop": 140453136, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "12"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123643"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13961"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376069"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS113488022", "V640E", "VAL640GLU", "VAL600GLU"], "members": [{"id": "ga4gh:VA.LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "label": "NC_000007.13:g.140453136A>T", "digest": "LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "type": "Allele", "location": {"id": "ga4gh:SL.XutGzMvqbzN-vnxmPt2MJf7ehxmB0opi", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753335, "end": 140753336}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "label": "V600E", "digest": "4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004333.4:c.1799T>A"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Val600Glu"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140453136A>T"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1799T>A"}], "location": {"id": "ga4gh:SL.ZA1XNKhCT_7m2UtmnYb8ZYOVS4eplMEK", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:206", "label": "Skin Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3510"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:8923"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1591", "description": "Open-label non-randomised phase 2 trial in patients with recurrent or metastatic BRAF V600E mutant papillary thyroid cancer refractory to radioactive iodine. Patients had (cohort 2) or had not (cohort 1) previously been treated with VEGFR inhibitors.\n51 patients were enrolled (26 cohort 1, 25 cohort 2). In cohort 1, partial response was achieved in ten (38.5%) patients. Nine patients achieved stable disease for at least 6 months (35%). Median PFS was 18.2 months and median OS not reached after a median follow-up pf 18.8 months.\nIn cohort 2, six patients (27.3%) achieved a partial response and another six patients achieved stable disease for at least six months. Median PFS was 8.9 months and median OS was 14.4. months.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1052", "label": "Brose et al., 2016, Lancet Oncol.", "type": "Document", "title": "PubMed: Brose et al., 2016, Lancet Oncol.", "pmid": 27460442}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:12", "label": "BRAF V600E", "description": "BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 1353.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453136, "stop": 140453136, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "12"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123643"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13961"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376069"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS113488022", "V640E", "VAL640GLU", "VAL600GLU"], "members": [{"id": "ga4gh:VA.LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "label": "NC_000007.13:g.140453136A>T", "digest": "LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "type": "Allele", "location": {"id": "ga4gh:SL.XutGzMvqbzN-vnxmPt2MJf7ehxmB0opi", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753335, "end": 140753336}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "label": "V600E", "digest": "4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004333.4:c.1799T>A"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Val600Glu"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140453136A>T"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1799T>A"}], "location": {"id": "ga4gh:SL.ZA1XNKhCT_7m2UtmnYb8ZYOVS4eplMEK", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:156", "label": "Thyroid Gland Papillary Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4035"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3969"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1665", "description": "90 NSCLC patients with stage IIIB/IV chemotherapy-resistant tumors were treated with gefitinib, and the L858R EGFR mutation was associated with longer time to treatment failure than those with wild-type EGFR (median 9.1 versus 2.1). In multivariate analysis, L858R mutations plus adenocarcinoma was a significant predictive factor for time to treatment failure (HR = 0.1030; P = .0004).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1127", "label": "Yang et al., 2008, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Yang et al., 2008, J. Clin. Oncol.", "pmid": 18509184}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:33", "label": "EGFR L858R", "description": "EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 379.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "G", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55259515, "stop": 55259515, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "33"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA126713"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16609"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376282"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376280"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434568"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121434568", "LEU858ARG"], "members": [{"id": "ga4gh:VA.TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "label": "NC_000007.13:g.55259515T>G", "digest": "TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "type": "Allele", "location": {"id": "ga4gh:SL.ulUNwZvajob7nzyrlpOd6uUWZIYCsoWb", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55191821, "end": 55191822}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "label": "L858R", "digest": "z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000007.13:g.55259515T>G"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2573T>G"}, {"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2573T>G"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Leu858Arg"}], "location": {"id": "ga4gh:SL.yVGJnwqxV6oCGqC_8nNb58D_wPXJeNJo", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 857, "end": 858}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:14", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:328134"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1855"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1669", "description": "In this study, the investigators followed 10 patients treated with vemurafenib, and then they collected biopsies of lesions that progressed. In one of these patients, they identified the L505H mutation.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1130", "label": "Hoogstraat et al., 2015, Pigment Cell Melanoma Res", "type": "Document", "title": "PubMed: Hoogstraat et al., 2015, Pigment Cell Melanoma Res", "pmid": 25515853}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:654", "label": "BRAF L505H", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 19.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140477794, "stop": 140477794, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "658"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA369588358"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["LEU505HIS"], "members": [{"id": "ga4gh:VA.43-Xxx0D3goljjHCEmergHzgd7JyiMu2", "label": "NC_000007.13:g.140477794A>T", "digest": "43-Xxx0D3goljjHCEmergHzgd7JyiMu2", "type": "Allele", "location": {"id": "ga4gh:SL.NdyGTQ_TbJEFwW7RKeAJHmafXTzBWFel", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140777993, "end": 140777994}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.R-CzRnCKUtxncxoPJnYt7vibvUbvdm5l", "label": "L505H", "digest": "R-CzRnCKUtxncxoPJnYt7vibvUbvdm5l", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1514T>A"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140477794A>T"}, {"syntax": "hgvs.c", "value": "NM_004333.4:c.1514T>A"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Leu505His"}], "location": {"id": "ga4gh:SL.RD4uWTa4sWzi0s95cUuCuSMVQ0WvDTjK", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 504, "end": 505}, "state": {"type": "LiteralSequenceExpression", "sequence": "H"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:7", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3224"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1909"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1746", "description": "In this phase II trial, patients with metastatic platinum-refractory urothelial carcinoma (UC) received afatinib (40 mg/day). Among the 21 tumors, five of six patients (83.3%) with ERBB2 (HER2) and/or ERBB3 alterations achieved 3-month progression-free survival (PFS3) versus none of 15 patients without alterations (P < .001). Three of three patients with ERBB3 somatic mutations (G284R, V104M, and R103G) achieved PFS3.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1208", "label": "Choudhury et al., 2016, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Choudhury et al., 2016, J. Clin. Oncol.", "pmid": 27044931}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:1733", "label": "ERBB3", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3431"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2065"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["ERBB3", "ErbB-3", "FERLK", "HER3", "LCCS2", "MDA-BF-1", "VSCN1", "c-erbB-3", "c-erbB3", "erbB3-S", "p180-ErbB3", "p45-sErbB3", "p85-sErbB3"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:682", "label": "ERBB3 V104M", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 15.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000267101.3", "chromosome": "12", "start": 56478854, "stop": 56478854, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "701"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602847"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376410"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["VAL104MET"], "members": [{"id": "ga4gh:VA.z7tojh3NvzxeTqX5seNcHlmCuB-s_-cF", "label": "NC_000012.11:g.56478854G>A", "digest": "z7tojh3NvzxeTqX5seNcHlmCuB-s_-cF", "type": "Allele", "location": {"id": "ga4gh:SL.PDk5PaKxtm88KvzXQxj4vu0GhsWa0qnG", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 56085069, "end": 56085070}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.35Yq2W6kZS6cMbkpwWUoI3ta687CWK5T", "label": "V104M", "digest": "35Yq2W6kZS6cMbkpwWUoI3ta687CWK5T", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000012.11:g.56478854G>A"}], "location": {"id": "ga4gh:SL.aL1SNpGBvMK8MZ39YTRidqeSnwNUBmLF", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.PczR1JRjEKoA7VHZpwjW8_n3hbJL-Lj_"}, "start": 103, "end": 104}, "state": {"type": "LiteralSequenceExpression", "sequence": "M"}}}, "therapeutic": {"id": "civic.tid:146", "label": "Afatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1430438"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:25316", "type": "Disease", "label": "Non-small cell lung cancer squamous"}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C66940"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide", "BIBW 2992", "BIBW2992"]}, "tumorType": {"id": "civic.did:642", "label": "Transitional Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2930"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:2671"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1747", "description": "In this phase II trial, patients with metastatic platinum-refractory urothelial carcinoma (UC) received afatinib (40 mg/day). Among the 21 tumors, five of six patients (83.3%) with ERBB2 (HER2) and/or ERBB3 alterations achieved 3-month progression-free survival (PFS3) versus none of 15 patients without alterations (P < .001). Three of three patients with ERBB3 somatic mutations (G284R, V104M, and R103G) achieved PFS3.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1208", "label": "Choudhury et al., 2016, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Choudhury et al., 2016, J. Clin. Oncol.", "pmid": 27044931}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:1733", "label": "ERBB3", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3431"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2065"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["ERBB3", "ErbB-3", "FERLK", "HER3", "LCCS2", "MDA-BF-1", "VSCN1", "c-erbB-3", "c-erbB3", "erbB3-S", "p180-ErbB3", "p45-sErbB3", "p85-sErbB3"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:683", "label": "ERBB3 R103G", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 15.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "G", "representative_transcript": "ENST00000267101.3", "chromosome": "12", "start": 56478851, "stop": 56478851, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "702"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA385279657"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ARG103GLY"], "members": [{"id": "ga4gh:VA.lfh93KghPlV5tID_IvCdAAErU3BmnwTU", "label": "NC_000012.11:g.56478851C>G", "digest": "lfh93KghPlV5tID_IvCdAAErU3BmnwTU", "type": "Allele", "location": {"id": "ga4gh:SL.4q7Z6rXZWcI-j4xZhm5JhEXeRY1bfDIw", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 56085066, "end": 56085067}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.0SzGYVCtf_ZORpy5MP4inWE8FMZZHX1g", "label": "R103G", "digest": "0SzGYVCtf_ZORpy5MP4inWE8FMZZHX1g", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000012.11:g.56478851C>G"}], "location": {"id": "ga4gh:SL.gzW7Yo6CZA5700hH8hLbo81dkj7MGv4J", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.PczR1JRjEKoA7VHZpwjW8_n3hbJL-Lj_"}, "start": 102, "end": 103}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}}, "therapeutic": {"id": "civic.tid:146", "label": "Afatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1430438"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:25316", "type": "Disease", "label": "Non-small cell lung cancer squamous"}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C66940"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide", "BIBW 2992", "BIBW2992"]}, "tumorType": {"id": "civic.did:642", "label": "Transitional Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2930"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:2671"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1748", "description": "In this phase II trial, patients with metastatic platinum-refractory urothelial carcinoma (UC) received afatinib (40 mg/day). Among the 21 tumors, five of six patients (83.3%) with ERBB2 (HER2) and/or ERBB3 alterations achieved 3-month progression-free survival (PFS3) versus none of 15 patients without alterations (P < .001). Three of three patients with ERBB3 somatic mutations (G284R, V104M, and R103G) achieved PFS3.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1208", "label": "Choudhury et al., 2016, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Choudhury et al., 2016, J. Clin. Oncol.", "pmid": 27044931}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:1733", "label": "ERBB3", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3431"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2065"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["ERBB3", "ErbB-3", "FERLK", "HER3", "LCCS2", "MDA-BF-1", "VSCN1", "c-erbB-3", "c-erbB3", "erbB3-S", "p180-ErbB3", "p45-sErbB3", "p85-sErbB3"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:684", "label": "ERBB3 G284R", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 15.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000267101.3", "chromosome": "12", "start": 56481922, "stop": 56481922, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "703"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602624"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376167"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLY284ARG"], "members": [{"id": "ga4gh:VA.31DO6Aqiz-akY8U2l_aa9oRcOQoU8uWV", "label": "NC_000012.11:g.56481922G>A", "digest": "31DO6Aqiz-akY8U2l_aa9oRcOQoU8uWV", "type": "Allele", "location": {"id": "ga4gh:SL.uMpp_chpb4NmWFMDF0NB-gr8EZILmb_-", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 56088137, "end": 56088138}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.vNd1g0gYLWnjnvHtZc8mVffcnOlZL71c", "label": "G284R", "digest": "vNd1g0gYLWnjnvHtZc8mVffcnOlZL71c", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000012.11:g.56481922G>A"}], "location": {"id": "ga4gh:SL.bG5wU2uHlWt_7rJIn4-pfIV6O6KzPYMj", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.PczR1JRjEKoA7VHZpwjW8_n3hbJL-Lj_"}, "start": 283, "end": 284}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:146", "label": "Afatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1430438"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:25316", "type": "Disease", "label": "Non-small cell lung cancer squamous"}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C66940"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide", "BIBW 2992", "BIBW2992"]}, "tumorType": {"id": "civic.did:642", "label": "Transitional Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2930"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:2671"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2117", "description": "Of 100 metastatic colorectal cancer patients treated with oxaliplatin-based first-line therapy, the 6 patients with either BRAF V600E or D594K had reduced progression-free survival compared to 94 patients with wildtype BRAF (5.0mo vs. 11.7mo, HR:6.4, 95%CI:2.6-15.6, P<0.0001).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1479", "label": "Souglakos et al., 2009, Br. J. Cancer", "type": "Document", "title": "PubMed: Souglakos et al., 2009, Br. J. Cancer", "pmid": 19603024}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:12", "label": "BRAF V600E", "description": "BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 1353.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453136, "stop": 140453136, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "12"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123643"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13961"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376069"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS113488022", "V640E", "VAL640GLU", "VAL600GLU"], "members": [{"id": "ga4gh:VA.LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "label": "NC_000007.13:g.140453136A>T", "digest": "LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "type": "Allele", "location": {"id": "ga4gh:SL.XutGzMvqbzN-vnxmPt2MJf7ehxmB0opi", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753335, "end": 140753336}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "label": "V600E", "digest": "4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004333.4:c.1799T>A"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Val600Glu"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140453136A>T"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1799T>A"}], "location": {"id": "ga4gh:SL.ZA1XNKhCT_7m2UtmnYb8ZYOVS4eplMEK", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "civic.tid:237", "label": "Oxaliplatin", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:32592"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:46096", "type": "Disease", "label": "Colorectal cancer", "mappings": [{"coding": {"system": "ncit", "code": "C4978"}, "relation": "relatedMatch"}]}, {"id": "hemonc:585", "type": "Disease", "label": "Colon cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9242"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1181"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-OHP", "Ai Heng", "Aiheng", "DACPLAT", "Dacotin", "Diaminocyclohexane Oxalatoplatinum", "ELOXATIN", "Eloxatine", "JM-83", "Oxalato (1R,2R-cyclohexanediamine)platinum(II)", "Oxalato (trans-l-1,2-diaminocyclohexane)platinum(II)", "Oxalatoplatin", "Oxalatoplatinum", "RP 54780", "RP-54780", "SR-96669", "Trans-l DACH Oxalatoplatinum", "Trans-l Diaminocyclohexane Oxalatoplatinum", "[(1R,-2R)-1,2-cyclohexanediamine-N,N'][oxalato (2--)-O,O']platinum", "[SP-4-2-(1R-trans)]-(1,2,cyclohexanediamine-N,N')[ethanedioato(2--)-O,O']platinum"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2118", "description": "The presence of BRAF V600E or D594K was associated with reduced progression-free survival in 5 patients with metastatic colorectal cancer treated with irinotecan-based first line therapy (3.5mo vs. 12.8mo, HR:4.1, 95%CI:1.5-11.3, P=0.006) when compared to 39 patients with wildtype BRAF.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1479", "label": "Souglakos et al., 2009, Br. J. Cancer", "type": "Document", "title": "PubMed: Souglakos et al., 2009, Br. J. Cancer", "pmid": 19603024}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:12", "label": "BRAF V600E", "description": "BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 1353.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453136, "stop": 140453136, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "12"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123643"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13961"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376069"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS113488022", "V640E", "VAL640GLU", "VAL600GLU"], "members": [{"id": "ga4gh:VA.LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "label": "NC_000007.13:g.140453136A>T", "digest": "LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "type": "Allele", "location": {"id": "ga4gh:SL.XutGzMvqbzN-vnxmPt2MJf7ehxmB0opi", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753335, "end": 140753336}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "label": "V600E", "digest": "4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004333.4:c.1799T>A"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Val600Glu"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140453136A>T"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1799T>A"}], "location": {"id": "ga4gh:SL.ZA1XNKhCT_7m2UtmnYb8ZYOVS4eplMEK", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "civic.tid:101", "label": "Irinotecan", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:153329"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:46096", "type": "Disease", "label": "Colorectal cancer", "mappings": [{"coding": {"system": "ncit", "code": "C4978"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C62040"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione", "(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate", "7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin", "[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2159", "description": "In a study of 14 patients with progressive non-small cell lung cancer during gefitinib treatment, comparison of DNA sequences from the original diagnostic biopsy specimen and the post-treatment biopsy specimen demonstrated that 7 patients acquired a new EGFR-T790M mutation. In addition, 52 pre-treatment tumours were examined with a sensitive real-time PCR assay and found no evidence of low frequency T790M mutation prior to gefitinib treatment.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1524", "label": "Kosaka et al., 2006, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Kosaka et al., 2006, Clin. Cancer Res.", "pmid": 17020982}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:34", "label": "EGFR T790M", "description": "EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 406.25}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55249071, "stop": 55249071, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "34"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA090928"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16613"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434569"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["THR790MET", "RS121434569"], "members": [{"id": "ga4gh:VA.OvEfBRaS34JkfM0_ZHJVDQEjqtwzyjyp", "label": "NC_000007.13:g.55249071C>T", "digest": "OvEfBRaS34JkfM0_ZHJVDQEjqtwzyjyp", "type": "Allele", "location": {"id": "ga4gh:SL.ZCgOjF-_T0EOBXGc-6yICYui-jgFzJfY", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55181377, "end": 55181378}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.faKID4aj8rP8NKZpWL4mWDToEztTUmbr", "label": "T790M", "digest": "faKID4aj8rP8NKZpWL4mWDToEztTUmbr", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2369C>T"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2369C>T"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Thr790Met"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55249071C>T"}], "location": {"id": "ga4gh:SL.C1y_lDZe8e9pKy3jcj3oJKw_7252Hrxa", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 789, "end": 790}, "state": {"type": "LiteralSequenceExpression", "sequence": "M"}}}, "therapeutic": {"id": "civic.tid:14", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:328134"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1855"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2207", "description": "This was a retrospective study of 691 cetuximab treated patients with metastatic colorectal cancer. Of those, 76 patients harbored KRAS G12D, were BRAF, NRAS and PIK3CA wt, and had individual response data. Five patients had partial response, 34 had stable disease, and 37 progressed. Treatments included cetuximab + irinotecan (n=61), cetuximab + FOLFIRI (n=6), cetuximab monotherapy (n=5), cetuximab + oxaliplatin + 5FU (n=2), cetuximab + 5FU (n=1), cetuximab + oxaliplatin + bevacizumab (n=1). Median PFS was 12 weeks (3-169 weeks), median OS was 31 weeks (6-232 weeks), and median number of previous chemotherapy lines was 2 (0-5). Median age was 62 years old (32-86), and there were 43 males and 33 females. Using these data and data from the larger cohort, authors concluded that KRAS mutation was strongly associated with poor response to cetuximab and suggested that mutation status of KRAS is the most informative compared to BRAF, NRAS, and PIK3CA exon 20 for predicting cetuximab response.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:76", "label": "De Roock et al., 2010, Lancet Oncol.", "type": "Document", "title": "PubMed: De Roock et al., 2010, Lancet Oncol.", "pmid": 20619739}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:79", "label": "KRAS G12D", "description": "While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 162.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398284, "stop": 25398284, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "79"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA122538"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12582"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913529"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913529", "GLY12ASP"], "members": [{"id": "ga4gh:VA.qOYg4yYK-1Je25G30BkV3dWKtKDIAFEJ", "label": "NC_000012.11:g.25398284C>T", "digest": "qOYg4yYK-1Je25G30BkV3dWKtKDIAFEJ", "type": "Allele", "location": {"id": "ga4gh:SL.iF0OXeO-tnumYbGkzaFEQ7cOZI_UCI1s", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245349, "end": 25245350}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.CB571ja_KfZM_Hjn9zjjgV1an3tDWRcl", "label": "G12D", "digest": "CB571ja_KfZM_Hjn9zjjgV1an3tDWRcl", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004985.4:c.35G>A"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly12Asp"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398284C>T"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.35G>A"}], "location": {"id": "ga4gh:SL.OndkjmujtyUEZSjjCv0C-gpwnVbRgfj8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "D"}}}, "therapeutic": {"id": "civic.tid:16", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:318341"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}, {"id": "mesh:D006258", "type": "Disease", "label": "Head and Neck Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C4013"}, "relation": "relatedMatch"}]}, {"id": "mesh:D002294", "type": "Disease", "label": "Carcinoma, Squamous Cell", "mappings": [{"coding": {"system": "ncit", "code": "C2929"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1723"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2219", "description": "This was a retrospective study of 691 cetuximab treated patients with metastatic colorectal cancer. Of those, 39 patients harbored KRAS G12V, were BRAF, NRAS and PIK3CA wt, and had individual response data. Three patients had partial response, 16 had stable disease, and 20 progressed. Treatments included cetuximab + irinotecan (n=30), cetuximab + FOLFIRI (n=2), cetuximab monotherapy (n=2), cetuximab + oxaliplatin + 5FU (n=2), cetuximab + 5FU (n=1), cetuximab + irinotecan + oxaliplatin + 5FU + bevacizumab (n=1), and cetuximab+irinotecan+oxaliplatin+5FU (n=1). Median PFS was 12 weeks (1-37 weeks), median OS was 32 weeks (4-77 weeks), and median number of previous chemotherapy lines was 2 (0-5). Median age was 63 years old (34-76), and there were 21 males and 18 females. Authors concluded that KRAS mutation was strongly associated with poor response to cetuximab and suggested that mutation status of KRAS is the most informative compared to BRAF, NRAS, and PIK3CA exon 20 for predicting cetuximab response.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:76", "label": "De Roock et al., 2010, Lancet Oncol.", "type": "Document", "title": "PubMed: De Roock et al., 2010, Lancet Oncol.", "pmid": 20619739}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:421", "label": "KRAS G12V", "description": "KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 67.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "A", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398284, "stop": 25398284, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "425"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA122540"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12583"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913529"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913529", "GLY12VAL"], "members": [{"id": "ga4gh:VA.-SzXMvMSRoSJgvsIDz-7M7VTFdo4FCtA", "label": "NC_000012.11:g.25398284C>A", "digest": "-SzXMvMSRoSJgvsIDz-7M7VTFdo4FCtA", "type": "Allele", "location": {"id": "ga4gh:SL.iF0OXeO-tnumYbGkzaFEQ7cOZI_UCI1s", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245349, "end": 25245350}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.JTtvYJD7yl02AOq09HjSZDUnfg4gYdUb", "label": "G12V", "digest": "JTtvYJD7yl02AOq09HjSZDUnfg4gYdUb", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004985.4:c.35G>T"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly12Val"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398284C>A"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.35G>T"}], "location": {"id": "ga4gh:SL.OndkjmujtyUEZSjjCv0C-gpwnVbRgfj8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "civic.tid:16", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:318341"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}, {"id": "mesh:D006258", "type": "Disease", "label": "Head and Neck Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C4013"}, "relation": "relatedMatch"}]}, {"id": "mesh:D002294", "type": "Disease", "label": "Carcinoma, Squamous Cell", "mappings": [{"coding": {"system": "ncit", "code": "C2929"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1723"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2634", "description": "In a phase 3 clinical trial of Korean, never-smoker, lung adenocarcinoma patients, a subset of patients with EGFR mutations (n=42) treated with gefitinib were associated with improved overall response rate compared to gemcitabine plus cisplatin treatment (84.6%, 22/26, vs. 37.5%, 6/16, P=0.002). By contrast, in EGFR mutation negative cases, the response rate was much lower (25.9%, 7/27). The frequency of mutation in exon 19 deletion and L858R was 64.3% (27/42) and 36.4% (16/42), respectively. Exon 19 and L858R mutations were mutually exclusive in this cohort.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1513", "label": "Han et al., 2012, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Han et al., 2012, J. Clin. Oncol.", "pmid": 22370314}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:33", "label": "EGFR L858R", "description": "EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 379.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "G", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55259515, "stop": 55259515, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "33"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA126713"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16609"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376282"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376280"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434568"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121434568", "LEU858ARG"], "members": [{"id": "ga4gh:VA.TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "label": "NC_000007.13:g.55259515T>G", "digest": "TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "type": "Allele", "location": {"id": "ga4gh:SL.ulUNwZvajob7nzyrlpOd6uUWZIYCsoWb", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55191821, "end": 55191822}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "label": "L858R", "digest": "z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000007.13:g.55259515T>G"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2573T>G"}, {"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2573T>G"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Leu858Arg"}], "location": {"id": "ga4gh:SL.yVGJnwqxV6oCGqC_8nNb58D_wPXJeNJo", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 857, "end": 858}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:14", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:328134"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1855"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"]}, "tumorType": {"id": "civic.did:30", "label": "Lung Adenocarcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3512"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3910"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:3755", "description": "In a clinical study (NCT01307397) of Polish, stage IIIC/IV, melanoma patients with metastases (n=75) harboring BRAF V600 mutation (as detected by cobas 4800 BRAF V600 Mutation Test), median overall survival was 61.9% (95% CI: 50.1-73.6) and median progression free survival was 7.4 months (95% CI: 5.5-9.2). Median duration of response was 7.4 months (95% CI: 5.7-9.2), with 3% (2/75) and 43% (29/75) of patients achieving a complete and partial response, respectively.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1955", "label": "Rutkowski et al., 2015, Contemp Oncol (Pozn)", "type": "Document", "title": "PubMed: Rutkowski et al., 2015, Contemp Oncol (Pozn)", "pmid": 26557775}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:12", "label": "BRAF V600E", "description": "BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 1353.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453136, "stop": 140453136, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "12"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123643"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13961"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376069"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS113488022", "V640E", "VAL640GLU", "VAL600GLU"], "members": [{"id": "ga4gh:VA.LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "label": "NC_000007.13:g.140453136A>T", "digest": "LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "type": "Allele", "location": {"id": "ga4gh:SL.XutGzMvqbzN-vnxmPt2MJf7ehxmB0opi", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753335, "end": 140753336}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "label": "V600E", "digest": "4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004333.4:c.1799T>A"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Val600Glu"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140453136A>T"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1799T>A"}], "location": {"id": "ga4gh:SL.ZA1XNKhCT_7m2UtmnYb8ZYOVS4eplMEK", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:7", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3224"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1909"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:3757", "description": "In a retrospective study of 300 stage IV melanoma patients, patients with BRAF V600E mutation (n=175) were associated with a 4.8% (8/167) complete response, a 58.1% (97/167) partial response and stable disease in 22.2% (37/167) of cases, while 15% (25/167) of patients harboring BRAF V600E experienced progressive disease.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1957", "label": "Ugurel et al., 2015, Ann. Oncol.", "type": "Document", "title": "PubMed: Ugurel et al., 2015, Ann. Oncol.", "pmid": 25524477}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:12", "label": "BRAF V600E", "description": "BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 1353.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453136, "stop": 140453136, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "12"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123643"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13961"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376069"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS113488022", "V640E", "VAL640GLU", "VAL600GLU"], "members": [{"id": "ga4gh:VA.LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "label": "NC_000007.13:g.140453136A>T", "digest": "LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "type": "Allele", "location": {"id": "ga4gh:SL.XutGzMvqbzN-vnxmPt2MJf7ehxmB0opi", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753335, "end": 140753336}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "label": "V600E", "digest": "4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004333.4:c.1799T>A"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Val600Glu"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140453136A>T"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1799T>A"}], "location": {"id": "ga4gh:SL.ZA1XNKhCT_7m2UtmnYb8ZYOVS4eplMEK", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:7", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3224"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1909"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:3881", "description": "This was a retrospective study of 691 cetuximab treated patients with metastatic colorectal cancer. Of those, 50 patients harbored KRAS G13D, were BRAF, NRAS and PIK3CA wt, and had individual response data. Nine patients had partial response, 19 had stable disease, and 22 progressed. Treatments included cetuximab + irinotecan (n=38), cetuximab + FOLFIRI (n=5), cetuximab monotherapy (n=4), cetuximab + oxaliplatin + 5FU (n=2), and cetuximab + irinotecan + oxaliplatin + 5FU (n=1). Median PFS was 16 weeks (3-101 weeks), median OS was 33 weeks (3-161 weeks), and median number of previous chemotherapy lines was 2 (0-4). Median age was 65 years old (34-78), and there were 29 males and 20 females. Authors concluded that KRAS mutation was strongly associated with poor response to cetuximab and suggested that mutation status of KRAS is the most informative compared to BRAF, NRAS, and PIK3CA exon 20 for predicting cetuximab response.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:76", "label": "De Roock et al., 2010, Lancet Oncol.", "type": "Document", "title": "PubMed: De Roock et al., 2010, Lancet Oncol.", "pmid": 20619739}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:81", "label": "KRAS G13D", "description": "While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, results are conflicting with retrospective analyses suggesting a better response to EGFR-Inhibition. A recent prospective phase-II study (12 patients, Schirripa et. al. 2015) could not reproduce this finding and another prospective phase II trial is currently ongoing.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 108.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398281, "stop": 25398281, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "81"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA122534"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12580"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS112445441"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS112445441", "GLY13ASP"], "members": [{"id": "ga4gh:VA.wQro48c_oFxB35UNb2O1Z7Vj6rXnJywl", "label": "NC_000012.11:g.25398281C>T", "digest": "wQro48c_oFxB35UNb2O1Z7Vj6rXnJywl", "type": "Allele", "location": {"id": "ga4gh:SL.rZcsm5bnq3ptyk4298opou7vY9O0etcL", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245346, "end": 25245347}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.h-3tyZSdsQNs9NHrhuwcACnnMnpuT-8Z", "label": "G13D", "digest": "h-3tyZSdsQNs9NHrhuwcACnnMnpuT-8Z", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_033360.3:c.38G>A"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly13Asp"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398281C>T"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.38G>A"}], "location": {"id": "ga4gh:SL.U-3sSsoejW41eQ2Aev0wiG5tEuDiQZTB", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 12, "end": 13}, "state": {"type": "LiteralSequenceExpression", "sequence": "D"}}}, "therapeutic": {"id": "civic.tid:16", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:318341"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}, {"id": "mesh:D006258", "type": "Disease", "label": "Head and Neck Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C4013"}, "relation": "relatedMatch"}]}, {"id": "mesh:D002294", "type": "Disease", "label": "Carcinoma, Squamous Cell", "mappings": [{"coding": {"system": "ncit", "code": "C2929"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1723"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4006", "description": "This was a retrospective study of 691 cetuximab treated patients with metastatic, chemotherapy refractory colorectal cancer. Of those, 16 patients harbored KRAS G12S, were BRAF, NRAS and PIK3CA wt, and had individual response data. Nine patients had stable disease and seven progressed. Treatments included cetuximab + irinotecan (n=13), cetuximab + FOLFIRI (n=1), cetuximab+5FU (n=1), cetuximab + irinotecan + oxaliplatin + bevacizumab (n=1). Median PFS was 12 weeks (2-50 weeks), median OS was 25 weeks (10-135 weeks), and median number of previous chemotherapy lines was 2 (1-6). Median age was 59 years old (31-69), and there were 9 males and 7 females. Using these data and data from the larger cohort, authors concluded that KRAS mutation was strongly associated with poor response to cetuximab and suggested that mutation status of KRAS is the most informative compared to BRAF, NRAS, and PIK3CA exon 20 for predicting cetuximab response.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:76", "label": "De Roock et al., 2010, Lancet Oncol.", "type": "Document", "title": "PubMed: De Roock et al., 2010, Lancet Oncol.", "pmid": 20619739}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:887", "label": "KRAS G12S", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 38.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398285, "stop": 25398285, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "913"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA135565"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12584"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913530"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLY12SER", "RS121913530"], "members": [{"id": "ga4gh:VA.PnoqUPOSplj2ReUhO0vv3Uwz7urotLNW", "label": "NC_000012.11:g.25398285C>T", "digest": "PnoqUPOSplj2ReUhO0vv3Uwz7urotLNW", "type": "Allele", "location": {"id": "ga4gh:SL.AiE9G9ocxKfBfR5PRN_ktoggZzig8OcG", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245350, "end": 25245351}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.BqLbpvUuI1si3-JoDB-imd4p6DIJVXlO", "label": "G12S", "digest": "BqLbpvUuI1si3-JoDB-imd4p6DIJVXlO", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004985.4:c.34G>A"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly12Ser"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398285C>T"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.34G>A"}], "location": {"id": "ga4gh:SL.OndkjmujtyUEZSjjCv0C-gpwnVbRgfj8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "S"}}}, "therapeutic": {"id": "civic.tid:16", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:318341"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}, {"id": "mesh:D006258", "type": "Disease", "label": "Head and Neck Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C4013"}, "relation": "relatedMatch"}]}, {"id": "mesh:D002294", "type": "Disease", "label": "Carcinoma, Squamous Cell", "mappings": [{"coding": {"system": "ncit", "code": "C2929"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1723"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4180", "description": "In a retrospective study of 300 stage IV melanoma patients, patients with BRAF V600K mutation (n=18) were associated with a 5.6% (1/18) complete response, a 22.2% (4/18) partial response and stable disease in 44.4% (8/18) of cases; however, 27.8% (5/18) of patients harboring BRAF V600K experienced progressive disease and patients with BRAF V600E mutation achieved a more impressive clinical benefit, as compared to patients with BRAF V600K mutation (P=0.016).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1957", "label": "Ugurel et al., 2015, Ann. Oncol.", "type": "Document", "title": "PubMed: Ugurel et al., 2015, Ann. Oncol.", "pmid": 25524477}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:559", "label": "BRAF V600K", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 107.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "AC", "variant_bases": "TT", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453136, "stop": 140453137, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "563"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602420"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "375941"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913227"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["VAL600LYS", "RS121913227"], "members": [{"id": "ga4gh:VA.0_wkzhprX1HDwZ86yT7RXkMDNQPco-Uv", "label": "NC_000007.13:g.140453136_140453137delinsTT", "digest": "0_wkzhprX1HDwZ86yT7RXkMDNQPco-Uv", "type": "Allele", "location": {"id": "ga4gh:SL.je4uwNtMCOBUHmd4rSK1ouAb1yszaQqi", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753335, "end": 140753337}, "state": {"type": "LiteralSequenceExpression", "sequence": "TT"}}], "definingContext": {"id": "ga4gh:VA.2E2_MppFwuFLm3OF88kEywJUYc6cVTHC", "label": "V600K", "digest": "2E2_MppFwuFLm3OF88kEywJUYc6cVTHC", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1798_1799delinsAA"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140453136_140453137delinsTT"}, {"syntax": "hgvs.c", "value": "NM_004333.4:c.1798_1799delGTinsAA"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Val600Lys"}], "location": {"id": "ga4gh:SL.ZA1XNKhCT_7m2UtmnYb8ZYOVS4eplMEK", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:7", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3224"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1909"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4429", "description": "This was a retrospective study of 691 cetuximab treated patients with metastatic colorectal cancer. Of those, 22 patients harbored KRAS G12A, were BRAF, NRAS and PIK3CA wt, and had individual response data. Three patients had partial response, 12 had stable disease, and seven progressed. Treatments included cetuximab + irinotecan (n=18), cetuximab monotherapy (n=1), cetuximab + FOLFIRI (n=2), and cetuximab + oxaliplatin + 5FU (n=1). Median PFS was 18 weeks (1-34 weeks), median OS was 35 weeks (1-143 weeks), and median number of previous chemotherapy lines was 2 (0-5). Median age was 62 years old (22-77) and there were 11 males and 11 females. Using these data and data from the larger cohort, authors concluded that KRAS mutation was strongly associated with poor response to cetuximab and suggested that mutation status of KRAS is the most informative compared to BRAF, NRAS, and PIK3CA exon 20 for predicting cetuximab response.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:76", "label": "De Roock et al., 2010, Lancet Oncol.", "type": "Document", "title": "PubMed: De Roock et al., 2010, Lancet Oncol.", "pmid": 20619739}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:148", "label": "KRAS G12A", "description": "KRAS G12A, like EGFR T790M, has been shown to be capable of driving acquired resistance to tyrosine kinase inhibitors in lung adenocarcinoma.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 63.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "G", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398284, "stop": 25398284, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "148"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA135567"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "45122"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913529"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913529", "GLY12ALA"], "members": [{"id": "ga4gh:VA.7-dFeRWXiDXaQi2ytNFtQt6FAxK65H7Q", "label": "NC_000012.11:g.25398284C>G", "digest": "7-dFeRWXiDXaQi2ytNFtQt6FAxK65H7Q", "type": "Allele", "location": {"id": "ga4gh:SL.iF0OXeO-tnumYbGkzaFEQ7cOZI_UCI1s", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245349, "end": 25245350}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.PtBjoq-ApuaPycxEHH7z31bGtezbAoyU", "label": "G12A", "digest": "PtBjoq-ApuaPycxEHH7z31bGtezbAoyU", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004985.4:c.35G>C"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly12Ala"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398284C>G"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.35G>C"}], "location": {"id": "ga4gh:SL.OndkjmujtyUEZSjjCv0C-gpwnVbRgfj8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}}, "therapeutic": {"id": "civic.tid:16", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:318341"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}, {"id": "mesh:D006258", "type": "Disease", "label": "Head and Neck Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C4013"}, "relation": "relatedMatch"}]}, {"id": "mesh:D002294", "type": "Disease", "label": "Carcinoma, Squamous Cell", "mappings": [{"coding": {"system": "ncit", "code": "C2929"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1723"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:5959", "description": "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively.\nAmong 4 patients with BRAF V600E mutant ovarian cancer, 2 had a partial response and one had stable disease > 120days.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2414", "label": "Hainsworth et al., 2018, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Hainsworth et al., 2018, J. Clin. Oncol.", "pmid": 29320312}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:12", "label": "BRAF V600E", "description": "BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 1353.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453136, "stop": 140453136, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "12"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123643"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13961"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376069"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS113488022", "V640E", "VAL640GLU", "VAL600GLU"], "members": [{"id": "ga4gh:VA.LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "label": "NC_000007.13:g.140453136A>T", "digest": "LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "type": "Allele", "location": {"id": "ga4gh:SL.XutGzMvqbzN-vnxmPt2MJf7ehxmB0opi", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753335, "end": 140753336}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "label": "V600E", "digest": "4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004333.4:c.1799T>A"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Val600Glu"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140453136A>T"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1799T>A"}], "location": {"id": "ga4gh:SL.ZA1XNKhCT_7m2UtmnYb8ZYOVS4eplMEK", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:20", "label": "Ovarian Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C7431"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:2394"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:6045", "description": "In a phase 2 \u201cbasket\u201d study of vemurafenib in BRAF V600-positive non-melanoma cancers, seven patients with anaplastic thyroid cancer were enrolled. All 7 patients had V600E mutations. One complete response and one partial response was observed, for a response rate of 29%.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1040", "label": "Hyman et al., 2015, N. Engl. J. Med.", "type": "Document", "title": "PubMed: Hyman et al., 2015, N. Engl. J. Med.", "pmid": 26287849}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:12", "label": "BRAF V600E", "description": "BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 1353.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453136, "stop": 140453136, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "12"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123643"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13961"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376069"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS113488022", "V640E", "VAL640GLU", "VAL600GLU"], "members": [{"id": "ga4gh:VA.LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "label": "NC_000007.13:g.140453136A>T", "digest": "LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "type": "Allele", "location": {"id": "ga4gh:SL.XutGzMvqbzN-vnxmPt2MJf7ehxmB0opi", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753335, "end": 140753336}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "label": "V600E", "digest": "4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004333.4:c.1799T>A"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Val600Glu"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140453136A>T"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1799T>A"}], "location": {"id": "ga4gh:SL.ZA1XNKhCT_7m2UtmnYb8ZYOVS4eplMEK", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:3040", "label": "Thyroid Gland Anaplastic Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3878"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:0080522"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:6402", "description": "The presence of BRAF V600E or D594K was associated with reduced progression-free survival in 5 patients with metastatic colorectal cancer treated with irinotecan-based first line therapy (3.5mo vs. 12.8mo, HR:4.1, 95%CI:1.5-11.3, P=0.006) when compared to 39 patients with wildtype BRAF.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1479", "label": "Souglakos et al., 2009, Br. J. Cancer", "type": "Document", "title": "PubMed: Souglakos et al., 2009, Br. J. Cancer", "pmid": 19603024}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:2271", "label": "BRAF D594K", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 30.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"type": "coordinates"}}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "2398"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.kBzRAn8hjVNuZzfLgY19ziCy__2OVNoM", "label": "D594K", "digest": "kBzRAn8hjVNuZzfLgY19ziCy__2OVNoM", "type": "Allele", "location": {"id": "ga4gh:SL.WujfpJG33G8kDeus_PN9ykPrKhwkYmfB", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 593, "end": 594}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:101", "label": "Irinotecan", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:153329"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:46096", "type": "Disease", "label": "Colorectal cancer", "mappings": [{"coding": {"system": "ncit", "code": "C4978"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C62040"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione", "(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate", "7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin", "[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:6403", "description": "Of 100 metastatic colorectal cancer patients treated with oxaliplatin-based first-line therapy, the 6 patients with either BRAF V600E or D594K had reduced progression-free survival compared to 94 patients with wildtype BRAF (5.0mo vs. 11.7mo, HR:6.4, 95%CI:2.6-15.6, P<0.0001).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1479", "label": "Souglakos et al., 2009, Br. J. Cancer", "type": "Document", "title": "PubMed: Souglakos et al., 2009, Br. J. Cancer", "pmid": 19603024}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:2271", "label": "BRAF D594K", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 30.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"type": "coordinates"}}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "2398"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.kBzRAn8hjVNuZzfLgY19ziCy__2OVNoM", "label": "D594K", "digest": "kBzRAn8hjVNuZzfLgY19ziCy__2OVNoM", "type": "Allele", "location": {"id": "ga4gh:SL.WujfpJG33G8kDeus_PN9ykPrKhwkYmfB", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 593, "end": 594}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:237", "label": "Oxaliplatin", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:32592"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:46096", "type": "Disease", "label": "Colorectal cancer", "mappings": [{"coding": {"system": "ncit", "code": "C4978"}, "relation": "relatedMatch"}]}, {"id": "hemonc:585", "type": "Disease", "label": "Colon cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9242"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1181"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-OHP", "Ai Heng", "Aiheng", "DACPLAT", "Dacotin", "Diaminocyclohexane Oxalatoplatinum", "ELOXATIN", "Eloxatine", "JM-83", "Oxalato (1R,2R-cyclohexanediamine)platinum(II)", "Oxalato (trans-l-1,2-diaminocyclohexane)platinum(II)", "Oxalatoplatin", "Oxalatoplatinum", "RP 54780", "RP-54780", "SR-96669", "Trans-l DACH Oxalatoplatinum", "Trans-l Diaminocyclohexane Oxalatoplatinum", "[(1R,-2R)-1,2-cyclohexanediamine-N,N'][oxalato (2--)-O,O']platinum", "[SP-4-2-(1R-trans)]-(1,2,cyclohexanediamine-N,N')[ethanedioato(2--)-O,O']platinum"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:806", "description": "This is a retrospective analysis of 98 patients with metastatic colorectal cancer and KRAS mutations. 23 (23.5%) had KRAS p.G13D-mutated tumors. Of the 98 patients, 31 patients received cetuximab, of these, 9 (29.0%) had KRAS p.G13D mutations. Univariate analysis did not show any differences between these groups. Multivariate analysis showed a trend towards better PFS among patients with a G13D mutation (PFS: HR=0.29; 95% CI: 0.08-1.10; P=0.07; OS: HR=0.23; 95% CI: 0.04-1.54; P=0.13).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:540", "label": "Osumi et al., 2015, Mol Clin Oncol", "type": "Document", "title": "PubMed: Osumi et al., 2015, Mol Clin Oncol", "pmid": 26623049}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "refutes", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:81", "label": "KRAS G13D", "description": "While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, results are conflicting with retrospective analyses suggesting a better response to EGFR-Inhibition. A recent prospective phase-II study (12 patients, Schirripa et. al. 2015) could not reproduce this finding and another prospective phase II trial is currently ongoing.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 108.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398281, "stop": 25398281, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "81"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA122534"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12580"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS112445441"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS112445441", "GLY13ASP"], "members": [{"id": "ga4gh:VA.wQro48c_oFxB35UNb2O1Z7Vj6rXnJywl", "label": "NC_000012.11:g.25398281C>T", "digest": "wQro48c_oFxB35UNb2O1Z7Vj6rXnJywl", "type": "Allele", "location": {"id": "ga4gh:SL.rZcsm5bnq3ptyk4298opou7vY9O0etcL", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245346, "end": 25245347}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.h-3tyZSdsQNs9NHrhuwcACnnMnpuT-8Z", "label": "G13D", "digest": "h-3tyZSdsQNs9NHrhuwcACnnMnpuT-8Z", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_033360.3:c.38G>A"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly13Asp"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398281C>T"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.38G>A"}], "location": {"id": "ga4gh:SL.U-3sSsoejW41eQ2Aev0wiG5tEuDiQZTB", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 12, "end": 13}, "state": {"type": "LiteralSequenceExpression", "sequence": "D"}}}, "therapeutic": {"id": "civic.tid:16", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:318341"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}, {"id": "mesh:D006258", "type": "Disease", "label": "Head and Neck Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C4013"}, "relation": "relatedMatch"}]}, {"id": "mesh:D002294", "type": "Disease", "label": "Carcinoma, Squamous Cell", "mappings": [{"coding": {"system": "ncit", "code": "C2929"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1723"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:994", "description": "This was a phase I expansion and pharmacodynamic study of oral MEK inhibitor RO4987655 on advanced cancer. Of 17 patients with BRAF V600E melanoma, 4 achieved partial response, 5 experienced stable disease lasting longer than 16 weeks, and 8 experienced disease progression (including 2 with prior vemurafenib treatment). One of the partial responders had a concomitant EGFR mutation, and two of the stable disease patients had other concomitant mutations (in RET or MET). The median days on treatment was 113 (18-366) for BRAF V600E melanoma patients and 107 (17-323) for BRAF V600 wildtype patients (n=23). Patients with BRAF V600E mutant melanoma experienced similar response rates (24% vs 20%) and rates of metabolic response measured by decrease in FDG uptake assessed by FDG-PET (86% vs 75%) compared to non-BRAF mutant patients. Patients with melanoma, either BRAF wt or V600E, experienced significant decreases in Ki67 expression by day 15 of MEK inhibitor treatment (P<0.02). The authors conclude that RO4987655 has clinical activity in BRAF V600E and BRAF wt melanoma.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:688", "label": "Zimmer et al., 2014, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Zimmer et al., 2014, Clin. Cancer Res.", "pmid": 24947927}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "refutes", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:12", "label": "BRAF V600E", "description": "BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 1353.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453136, "stop": 140453136, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "12"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123643"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13961"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376069"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS113488022", "V640E", "VAL640GLU", "VAL600GLU"], "members": [{"id": "ga4gh:VA.LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "label": "NC_000007.13:g.140453136A>T", "digest": "LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "type": "Allele", "location": {"id": "ga4gh:SL.XutGzMvqbzN-vnxmPt2MJf7ehxmB0opi", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753335, "end": 140753336}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "label": "V600E", "digest": "4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004333.4:c.1799T>A"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Val600Glu"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140453136A>T"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1799T>A"}], "location": {"id": "ga4gh:SL.ZA1XNKhCT_7m2UtmnYb8ZYOVS4eplMEK", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "civic.tid:243", "label": "MEK Inhibitor RO4987655", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C82696"}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C82696"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["RO-4987655", "RO4987655"]}, "tumorType": {"id": "civic.did:7", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3224"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1909"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1579", "description": "Two clinical trials evaluated the effects of vemurafenib in 54 patients with BRAF (V600E) positive hairy-cell leukemia.  The overall response rate was 98% with 19/54 having a complete response and 34/54 having a partial response.  In the Italian study (n=25), the median relapse-free survival was 9 months and in the U.S. study (n=24), rate of progression-free survival was 73% with overall survival rate of 91%.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1043", "label": "Tiacci et al., 2015, N. Engl. J. Med.", "type": "Document", "title": "PubMed: Tiacci et al., 2015, N. Engl. J. Med.", "pmid": 26352686}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:12", "label": "BRAF V600E", "description": "BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 1353.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453136, "stop": 140453136, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "12"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123643"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13961"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376069"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS113488022", "V640E", "VAL640GLU", "VAL600GLU"], "members": [{"id": "ga4gh:VA.LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "label": "NC_000007.13:g.140453136A>T", "digest": "LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "type": "Allele", "location": {"id": "ga4gh:SL.XutGzMvqbzN-vnxmPt2MJf7ehxmB0opi", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753335, "end": 140753336}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "label": "V600E", "digest": "4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004333.4:c.1799T>A"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Val600Glu"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140453136A>T"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1799T>A"}], "location": {"id": "ga4gh:SL.ZA1XNKhCT_7m2UtmnYb8ZYOVS4eplMEK", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:665", "label": "Hairy Cell Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C7402"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:285"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2008", "description": "In recurrent lung cancer patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, patients with KRAS mutations had a lower frequency of partial response (PR) and stable disease (SD) and a higher rate of progressive disease (PD) (PR:0, SD:1, PD:15 vs. PR:24, SD:8, PD:14; P=0.0274) compared to wildtype KRAS patients. Patients with KRAS mutations also had a shorter overall survival compared to wildtype KRAS patients (HR:2.542, 95% CI:1.048-6.168, P=0.0390).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1416", "label": "Endoh et al., 2006, J Thorac Oncol", "type": "Document", "title": "PubMed: Endoh et al., 2006, J Thorac Oncol", "pmid": 17409929}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:148", "label": "KRAS G12A", "description": "KRAS G12A, like EGFR T790M, has been shown to be capable of driving acquired resistance to tyrosine kinase inhibitors in lung adenocarcinoma.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 63.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "G", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398284, "stop": 25398284, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "148"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA135567"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "45122"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913529"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913529", "GLY12ALA"], "members": [{"id": "ga4gh:VA.7-dFeRWXiDXaQi2ytNFtQt6FAxK65H7Q", "label": "NC_000012.11:g.25398284C>G", "digest": "7-dFeRWXiDXaQi2ytNFtQt6FAxK65H7Q", "type": "Allele", "location": {"id": "ga4gh:SL.iF0OXeO-tnumYbGkzaFEQ7cOZI_UCI1s", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245349, "end": 25245350}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.PtBjoq-ApuaPycxEHH7z31bGtezbAoyU", "label": "G12A", "digest": "PtBjoq-ApuaPycxEHH7z31bGtezbAoyU", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004985.4:c.35G>C"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly12Ala"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398284C>G"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.35G>C"}], "location": {"id": "ga4gh:SL.OndkjmujtyUEZSjjCv0C-gpwnVbRgfj8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}}, "therapeutic": {"id": "civic.tid:14", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:328134"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1855"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"]}, "tumorType": {"id": "civic.did:23", "label": "Lung Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C7377"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1324"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2009", "description": "In a study of patients receiving melphalan-based therapy, those with KRAS codon 12 mutations were less likely to have a positive response than those with wildtype KRAS (26.9% vs. 58.3%, P=0.015).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1417", "label": "Greco et al., 2009, J. Exp. Clin. Cancer Res.", "type": "Document", "title": "PubMed: Greco et al., 2009, J. Exp. Clin. Cancer Res.", "pmid": 19284554}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:148", "label": "KRAS G12A", "description": "KRAS G12A, like EGFR T790M, has been shown to be capable of driving acquired resistance to tyrosine kinase inhibitors in lung adenocarcinoma.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 63.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "G", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398284, "stop": 25398284, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "148"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA135567"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "45122"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913529"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913529", "GLY12ALA"], "members": [{"id": "ga4gh:VA.7-dFeRWXiDXaQi2ytNFtQt6FAxK65H7Q", "label": "NC_000012.11:g.25398284C>G", "digest": "7-dFeRWXiDXaQi2ytNFtQt6FAxK65H7Q", "type": "Allele", "location": {"id": "ga4gh:SL.iF0OXeO-tnumYbGkzaFEQ7cOZI_UCI1s", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245349, "end": 25245350}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.PtBjoq-ApuaPycxEHH7z31bGtezbAoyU", "label": "G12A", "digest": "PtBjoq-ApuaPycxEHH7z31bGtezbAoyU", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004985.4:c.35G>C"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly12Ala"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398284C>G"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.35G>C"}], "location": {"id": "ga4gh:SL.OndkjmujtyUEZSjjCv0C-gpwnVbRgfj8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}}, "therapeutic": {"id": "civic.tid:328", "label": "Melphalan", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:6718"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:633", "type": "Disease", "label": "Multiple myeloma", "mappings": [{"coding": {"system": "ncit", "code": "C3242"}, "relation": "relatedMatch"}]}, {"id": "hemonc:645", "type": "Disease", "label": "Ovarian cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7431"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C633"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[bis(2-chloroethyl)amino]-L-phenylalanine", "Alanine Nitrogen Mustard", "CB-3025", "L-PAM", "L-Phenylalanine Mustard", "L-Sarcolysin", "L-Sarcolysin Phenylalanine Mustard", "L-Sarcolysine", "Melphalanum", "P-di(chloroethyl)amino-L-phenylalanine", "Phenylalanine Mustard", "Phenylalanine Nitrogen Mustard", "Sarcoclorin", "Sarkolysin", "WR-19813"]}, "tumorType": {"id": "civic.did:41", "label": "Multiple Myeloma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3242"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9538"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2240", "description": "In recurrent lung cancer patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, patients with KRAS mutations had a lower frequency of partial response (PR) and stable disease (SD) and a higher rate of progressive disease (PD) (PR:0, SD:1, PD:15 vs. PR:24, SD:8, PD:14; P=0.0274) compared to wildtype KRAS patients. Patients with KRAS mutations also had a shorter overall survival compared to wildtype KRAS patients (HR:2.542, 95% CI:1.048-6.168, P=0.0390).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1416", "label": "Endoh et al., 2006, J Thorac Oncol", "type": "Document", "title": "PubMed: Endoh et al., 2006, J Thorac Oncol", "pmid": 17409929}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:79", "label": "KRAS G12D", "description": "While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 162.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398284, "stop": 25398284, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "79"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA122538"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12582"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913529"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913529", "GLY12ASP"], "members": [{"id": "ga4gh:VA.qOYg4yYK-1Je25G30BkV3dWKtKDIAFEJ", "label": "NC_000012.11:g.25398284C>T", "digest": "qOYg4yYK-1Je25G30BkV3dWKtKDIAFEJ", "type": "Allele", "location": {"id": "ga4gh:SL.iF0OXeO-tnumYbGkzaFEQ7cOZI_UCI1s", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245349, "end": 25245350}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.CB571ja_KfZM_Hjn9zjjgV1an3tDWRcl", "label": "G12D", "digest": "CB571ja_KfZM_Hjn9zjjgV1an3tDWRcl", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004985.4:c.35G>A"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly12Asp"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398284C>T"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.35G>A"}], "location": {"id": "ga4gh:SL.OndkjmujtyUEZSjjCv0C-gpwnVbRgfj8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "D"}}}, "therapeutic": {"id": "civic.tid:14", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:328134"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1855"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"]}, "tumorType": {"id": "civic.did:23", "label": "Lung Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C7377"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1324"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2247", "description": "In a study of patients receiving melphalan-based therapy, those with KRAS codon 12 mutations were less likely to have a positive response than those with wildtype KRAS (26.9% vs. 58.3%, P=0.015).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1417", "label": "Greco et al., 2009, J. Exp. Clin. Cancer Res.", "type": "Document", "title": "PubMed: Greco et al., 2009, J. Exp. Clin. Cancer Res.", "pmid": 19284554}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:79", "label": "KRAS G12D", "description": "While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 162.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398284, "stop": 25398284, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "79"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA122538"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12582"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913529"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913529", "GLY12ASP"], "members": [{"id": "ga4gh:VA.qOYg4yYK-1Je25G30BkV3dWKtKDIAFEJ", "label": "NC_000012.11:g.25398284C>T", "digest": "qOYg4yYK-1Je25G30BkV3dWKtKDIAFEJ", "type": "Allele", "location": {"id": "ga4gh:SL.iF0OXeO-tnumYbGkzaFEQ7cOZI_UCI1s", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245349, "end": 25245350}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.CB571ja_KfZM_Hjn9zjjgV1an3tDWRcl", "label": "G12D", "digest": "CB571ja_KfZM_Hjn9zjjgV1an3tDWRcl", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004985.4:c.35G>A"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly12Asp"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398284C>T"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.35G>A"}], "location": {"id": "ga4gh:SL.OndkjmujtyUEZSjjCv0C-gpwnVbRgfj8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "D"}}}, "therapeutic": {"id": "civic.tid:328", "label": "Melphalan", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:6718"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:633", "type": "Disease", "label": "Multiple myeloma", "mappings": [{"coding": {"system": "ncit", "code": "C3242"}, "relation": "relatedMatch"}]}, {"id": "hemonc:645", "type": "Disease", "label": "Ovarian cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7431"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C633"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[bis(2-chloroethyl)amino]-L-phenylalanine", "Alanine Nitrogen Mustard", "CB-3025", "L-PAM", "L-Phenylalanine Mustard", "L-Sarcolysin", "L-Sarcolysin Phenylalanine Mustard", "L-Sarcolysine", "Melphalanum", "P-di(chloroethyl)amino-L-phenylalanine", "Phenylalanine Mustard", "Phenylalanine Nitrogen Mustard", "Sarcoclorin", "Sarkolysin", "WR-19813"]}, "tumorType": {"id": "civic.did:41", "label": "Multiple Myeloma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3242"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9538"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2257", "description": "In recurrent lung cancer patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, patients with KRAS mutations had a lower frequency of partial response (PR) and stable disease (SD) and a higher rate of progressive disease (PD) (PR:0, SD:1, PD:15 vs. PR:24, SD:8, PD:14; P=0.0274) compared to wildtype KRAS patients. Patients with KRAS mutations also had a shorter overall survival compared to wildtype KRAS patients (HR:2.542, 95% CI:1.048-6.168, P=0.0390).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1416", "label": "Endoh et al., 2006, J Thorac Oncol", "type": "Document", "title": "PubMed: Endoh et al., 2006, J Thorac Oncol", "pmid": 17409929}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:78", "label": "KRAS G12C", "description": "While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 136.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "A", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398285, "stop": 25398285, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "78"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA122528"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12578"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913530"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLY12CYS", "RS121913530"], "members": [{"id": "ga4gh:VA.ONAtlY1naHPhc7I2cFH6POy4zmWKukHw", "label": "NC_000012.11:g.25398285C>A", "digest": "ONAtlY1naHPhc7I2cFH6POy4zmWKukHw", "type": "Allele", "location": {"id": "ga4gh:SL.AiE9G9ocxKfBfR5PRN_ktoggZzig8OcG", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245350, "end": 25245351}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.94GquHCCcRi74uwlI5PGJsf6FsR2M7Ef", "label": "G12C", "digest": "94GquHCCcRi74uwlI5PGJsf6FsR2M7Ef", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004985.4:c.34G>T"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly12Cys"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398285C>A"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.34G>T"}], "location": {"id": "ga4gh:SL.OndkjmujtyUEZSjjCv0C-gpwnVbRgfj8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "civic.tid:14", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:328134"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1855"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"]}, "tumorType": {"id": "civic.did:23", "label": "Lung Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C7377"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1324"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2258", "description": "In a study of patients receiving melphalan-based therapy, those with KRAS codon 12 mutations were less likely to have a positive response than those with wildtype KRAS (26.9% vs. 58.3%, P=0.015).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1417", "label": "Greco et al., 2009, J. Exp. Clin. Cancer Res.", "type": "Document", "title": "PubMed: Greco et al., 2009, J. Exp. Clin. Cancer Res.", "pmid": 19284554}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:78", "label": "KRAS G12C", "description": "While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 136.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "A", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398285, "stop": 25398285, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "78"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA122528"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12578"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913530"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLY12CYS", "RS121913530"], "members": [{"id": "ga4gh:VA.ONAtlY1naHPhc7I2cFH6POy4zmWKukHw", "label": "NC_000012.11:g.25398285C>A", "digest": "ONAtlY1naHPhc7I2cFH6POy4zmWKukHw", "type": "Allele", "location": {"id": "ga4gh:SL.AiE9G9ocxKfBfR5PRN_ktoggZzig8OcG", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245350, "end": 25245351}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.94GquHCCcRi74uwlI5PGJsf6FsR2M7Ef", "label": "G12C", "digest": "94GquHCCcRi74uwlI5PGJsf6FsR2M7Ef", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004985.4:c.34G>T"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly12Cys"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398285C>A"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.34G>T"}], "location": {"id": "ga4gh:SL.OndkjmujtyUEZSjjCv0C-gpwnVbRgfj8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "civic.tid:328", "label": "Melphalan", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:6718"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:633", "type": "Disease", "label": "Multiple myeloma", "mappings": [{"coding": {"system": "ncit", "code": "C3242"}, "relation": "relatedMatch"}]}, {"id": "hemonc:645", "type": "Disease", "label": "Ovarian cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7431"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C633"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[bis(2-chloroethyl)amino]-L-phenylalanine", "Alanine Nitrogen Mustard", "CB-3025", "L-PAM", "L-Phenylalanine Mustard", "L-Sarcolysin", "L-Sarcolysin Phenylalanine Mustard", "L-Sarcolysine", "Melphalanum", "P-di(chloroethyl)amino-L-phenylalanine", "Phenylalanine Mustard", "Phenylalanine Nitrogen Mustard", "Sarcoclorin", "Sarkolysin", "WR-19813"]}, "tumorType": {"id": "civic.did:41", "label": "Multiple Myeloma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3242"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9538"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2273", "description": "In recurrent lung cancer patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, patients with KRAS mutations had a lower frequency of partial response (PR) and stable disease (SD) and a higher rate of progressive disease (PD) (PR:0, SD:1, PD:15 vs. PR:24, SD:8, PD:14; P=0.0274) compared to wildtype KRAS patients. Patients with KRAS mutations also had a shorter overall survival compared to wildtype KRAS patients (HR:2.542, 95% CI:1.048-6.168, P=0.0390).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1416", "label": "Endoh et al., 2006, J Thorac Oncol", "type": "Document", "title": "PubMed: Endoh et al., 2006, J Thorac Oncol", "pmid": 17409929}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:887", "label": "KRAS G12S", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 38.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398285, "stop": 25398285, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "913"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA135565"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12584"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913530"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLY12SER", "RS121913530"], "members": [{"id": "ga4gh:VA.PnoqUPOSplj2ReUhO0vv3Uwz7urotLNW", "label": "NC_000012.11:g.25398285C>T", "digest": "PnoqUPOSplj2ReUhO0vv3Uwz7urotLNW", "type": "Allele", "location": {"id": "ga4gh:SL.AiE9G9ocxKfBfR5PRN_ktoggZzig8OcG", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245350, "end": 25245351}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.BqLbpvUuI1si3-JoDB-imd4p6DIJVXlO", "label": "G12S", "digest": "BqLbpvUuI1si3-JoDB-imd4p6DIJVXlO", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004985.4:c.34G>A"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly12Ser"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398285C>T"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.34G>A"}], "location": {"id": "ga4gh:SL.OndkjmujtyUEZSjjCv0C-gpwnVbRgfj8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "S"}}}, "therapeutic": {"id": "civic.tid:14", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:328134"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1855"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"]}, "tumorType": {"id": "civic.did:23", "label": "Lung Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C7377"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1324"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2274", "description": "In a study of patients receiving melphalan-based therapy, those with KRAS codon 12 mutations were less likely to have a positive response than those with wildtype KRAS (26.9% vs. 58.3%, P=0.015).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1417", "label": "Greco et al., 2009, J. Exp. Clin. Cancer Res.", "type": "Document", "title": "PubMed: Greco et al., 2009, J. Exp. Clin. Cancer Res.", "pmid": 19284554}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:887", "label": "KRAS G12S", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 38.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398285, "stop": 25398285, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "913"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA135565"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12584"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913530"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLY12SER", "RS121913530"], "members": [{"id": "ga4gh:VA.PnoqUPOSplj2ReUhO0vv3Uwz7urotLNW", "label": "NC_000012.11:g.25398285C>T", "digest": "PnoqUPOSplj2ReUhO0vv3Uwz7urotLNW", "type": "Allele", "location": {"id": "ga4gh:SL.AiE9G9ocxKfBfR5PRN_ktoggZzig8OcG", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245350, "end": 25245351}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.BqLbpvUuI1si3-JoDB-imd4p6DIJVXlO", "label": "G12S", "digest": "BqLbpvUuI1si3-JoDB-imd4p6DIJVXlO", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004985.4:c.34G>A"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly12Ser"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398285C>T"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.34G>A"}], "location": {"id": "ga4gh:SL.OndkjmujtyUEZSjjCv0C-gpwnVbRgfj8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "S"}}}, "therapeutic": {"id": "civic.tid:328", "label": "Melphalan", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:6718"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:633", "type": "Disease", "label": "Multiple myeloma", "mappings": [{"coding": {"system": "ncit", "code": "C3242"}, "relation": "relatedMatch"}]}, {"id": "hemonc:645", "type": "Disease", "label": "Ovarian cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7431"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C633"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[bis(2-chloroethyl)amino]-L-phenylalanine", "Alanine Nitrogen Mustard", "CB-3025", "L-PAM", "L-Phenylalanine Mustard", "L-Sarcolysin", "L-Sarcolysin Phenylalanine Mustard", "L-Sarcolysine", "Melphalanum", "P-di(chloroethyl)amino-L-phenylalanine", "Phenylalanine Mustard", "Phenylalanine Nitrogen Mustard", "Sarcoclorin", "Sarkolysin", "WR-19813"]}, "tumorType": {"id": "civic.did:41", "label": "Multiple Myeloma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3242"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9538"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2327", "description": "In a study of 189 low-grade gliomas, IDH (IDH1 or IDH2) mutations were found in 132 patients (70%). IDH mutations were associated with improved rate of response to temozolomide as compared to patients with wildtype IDH (61%  vs. 17% , P=0.01).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1425", "label": "Houillier et al., 2010, Neurology", "type": "Document", "title": "PubMed: Houillier et al., 2010, Neurology", "pmid": 20975057}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:26", "label": "IDH1", "description": "IDH1 mutations have been observed in a number of cancer types, including sarcomas, hematologic malignancies, colon cancer and brain cancer. Mutations in the two isocitrate dehydrogenase enzymes involved in cytoplasmic (IDH1) and mitochondrial (IDH2) conversion of alpha-ketoglutarate to D-2-hydroxyglutarate have been described as mutually exclusive in many of these cancer types. The most frequent mutations involve R132 (IDH1) and R172 (IDH2) involve the active site and result in neomorphic enzyme activity. The implications of mutations in this gene vary greatly by cancer type. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 mutations have been associated with worse outcome, shorter overall survival, and normal karyotype. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Unlike the association with cytogenetically normal AML, in glioblastoma, IDH1 mutations have been associated with specific cytogenetic abnormalities, 1p and 19q deletions.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:5382"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3417"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["HEL-216", "HEL-S-26", "IDCD", "IDH", "IDH1", "IDP", "IDPC", "PICD"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:59", "label": "IDH1 R132C", "description": "IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 56.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000415913.1", "chromosome": "2", "start": 209113113, "stop": 209113113, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "59"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602374"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "375891"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913499"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ARG132CYS", "RS121913499"], "members": [{"id": "ga4gh:VA.BSWDYW013eVP-oPsbZ4EbaLXKQ3fbTQe", "label": "NC_000002.11:g.209113113G>A", "digest": "BSWDYW013eVP-oPsbZ4EbaLXKQ3fbTQe", "type": "Allele", "location": {"id": "ga4gh:SL.9sCi1wXjGTNOwjkt3L-5N-rswDF_dNui", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.pnAqCRBrTsUoBghSD1yp_jXWSmlbdh4g"}, "start": 208248388, "end": 208248389}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.348znVA1UKrjwKuq8LLOVrb77xWo5XUO", "label": "R132C", "digest": "348znVA1UKrjwKuq8LLOVrb77xWo5XUO", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_005896.3:c.394C>T"}, {"syntax": "hgvs.p", "value": "NP_005887.2:p.Arg132Cys"}, {"syntax": "hgvs.g", "value": "NC_000002.11:g.209113113G>A"}, {"syntax": "hgvs.c", "value": "ENST00000415913.1:c.394C>T"}], "location": {"id": "ga4gh:SL.6S6Nay-qWJnCSbbpF3hcBRTeoYOc4CJD", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.VZMxTY2iB2G_EuwlpVZ0AnX6R-am08GZ"}, "start": 131, "end": 132}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "civic.tid:11", "label": "Temozolomide", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:37776"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:604", "type": "Disease", "label": "Glioblastoma", "mappings": [{"coding": {"system": "ncit", "code": "C3058"}, "relation": "relatedMatch"}]}, {"id": "hemonc:559", "type": "Disease", "label": "Anaplastic glioma", "mappings": [{"coding": {"system": "ncit", "code": "C127816"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1244"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide", "8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one", "CCRG-81045", "Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-", "M & B 39831", "M And B 39831", "Methazolastone", "RP-46161", "SCH 52365", "TMZ", "Temcad", "Temodal", "Temodar", "Temomedac"]}, "tumorType": {"id": "civic.did:98", "label": "Brain Glioma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "mondo:0005499"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:0060108"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2331", "description": "In a clinical study of 17 relapsed or refractory AML patients harboring IDH1 mutations, these patients were associated with response to AG-120 monotherapy; 4/7 patients who achieved a response experienced complete remission.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1434", "label": "2015, Cancer Discov", "type": "Document", "title": "PubMed: 2015, Cancer Discov", "pmid": 25583779}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:26", "label": "IDH1", "description": "IDH1 mutations have been observed in a number of cancer types, including sarcomas, hematologic malignancies, colon cancer and brain cancer. Mutations in the two isocitrate dehydrogenase enzymes involved in cytoplasmic (IDH1) and mitochondrial (IDH2) conversion of alpha-ketoglutarate to D-2-hydroxyglutarate have been described as mutually exclusive in many of these cancer types. The most frequent mutations involve R132 (IDH1) and R172 (IDH2) involve the active site and result in neomorphic enzyme activity. The implications of mutations in this gene vary greatly by cancer type. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 mutations have been associated with worse outcome, shorter overall survival, and normal karyotype. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Unlike the association with cytogenetically normal AML, in glioblastoma, IDH1 mutations have been associated with specific cytogenetic abnormalities, 1p and 19q deletions.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:5382"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3417"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["HEL-216", "HEL-S-26", "IDCD", "IDH", "IDH1", "IDP", "IDPC", "PICD"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:59", "label": "IDH1 R132C", "description": "IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 56.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000415913.1", "chromosome": "2", "start": 209113113, "stop": 209113113, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "59"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602374"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "375891"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913499"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ARG132CYS", "RS121913499"], "members": [{"id": "ga4gh:VA.BSWDYW013eVP-oPsbZ4EbaLXKQ3fbTQe", "label": "NC_000002.11:g.209113113G>A", "digest": "BSWDYW013eVP-oPsbZ4EbaLXKQ3fbTQe", "type": "Allele", "location": {"id": "ga4gh:SL.9sCi1wXjGTNOwjkt3L-5N-rswDF_dNui", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.pnAqCRBrTsUoBghSD1yp_jXWSmlbdh4g"}, "start": 208248388, "end": 208248389}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.348znVA1UKrjwKuq8LLOVrb77xWo5XUO", "label": "R132C", "digest": "348znVA1UKrjwKuq8LLOVrb77xWo5XUO", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_005896.3:c.394C>T"}, {"syntax": "hgvs.p", "value": "NP_005887.2:p.Arg132Cys"}, {"syntax": "hgvs.g", "value": "NC_000002.11:g.209113113G>A"}, {"syntax": "hgvs.c", "value": "ENST00000415913.1:c.394C>T"}], "location": {"id": "ga4gh:SL.6S6Nay-qWJnCSbbpF3hcBRTeoYOc4CJD", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.VZMxTY2iB2G_EuwlpVZ0AnX6R-am08GZ"}, "start": 131, "end": 132}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "civic.tid:454", "label": "Ivosidenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:2049873"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:580", "type": "Disease", "label": "Cholangiocarcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C4436"}, "relation": "relatedMatch"}]}, {"id": "hemonc:552", "type": "Disease", "label": "Acute myeloid leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3171"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C114383"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["AG-120", "Tibsovo"]}, "tumorType": {"id": "civic.did:3", "label": "Acute Myeloid Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3171"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9119"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2506", "description": "In a study of 322 advanced melanoma patients with BRAF-V600E (N=281), BRAF-V600K (N=40), or both mutations (N=1), treatment with trametinib was associated with improved progression-free survival (4.8mo vs. 1.5mo; HR: 0.45, 95% CI: 0.33-0.63, P<0.001) compared to chemotherapy control group. Additionally, treatment with trametinib was associated with increased 6-month overall survival (HR: 0.54, 95% CI: 0.32-0.92, P=0.01). The authors note similar outcomes for the primary efficacy population (V600E only) and the intention-to-treat population, however, sub-group analysis for patients with V600K did not show significant improvement in PFS (HR: 0.50, 95% CI:0.18-1.35).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1210", "label": "Flaherty et al., 2012, N. Engl. J. Med.", "type": "Document", "title": "PubMed: Flaherty et al., 2012, N. Engl. J. Med.", "pmid": 22663011}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:559", "label": "BRAF V600K", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 107.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "AC", "variant_bases": "TT", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453136, "stop": 140453137, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "563"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602420"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "375941"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913227"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["VAL600LYS", "RS121913227"], "members": [{"id": "ga4gh:VA.0_wkzhprX1HDwZ86yT7RXkMDNQPco-Uv", "label": "NC_000007.13:g.140453136_140453137delinsTT", "digest": "0_wkzhprX1HDwZ86yT7RXkMDNQPco-Uv", "type": "Allele", "location": {"id": "ga4gh:SL.je4uwNtMCOBUHmd4rSK1ouAb1yszaQqi", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753335, "end": 140753337}, "state": {"type": "LiteralSequenceExpression", "sequence": "TT"}}], "definingContext": {"id": "ga4gh:VA.2E2_MppFwuFLm3OF88kEywJUYc6cVTHC", "label": "V600K", "digest": "2E2_MppFwuFLm3OF88kEywJUYc6cVTHC", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1798_1799delinsAA"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140453136_140453137delinsTT"}, {"syntax": "hgvs.c", "value": "NM_004333.4:c.1798_1799delGTinsAA"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Val600Lys"}], "location": {"id": "ga4gh:SL.ZA1XNKhCT_7m2UtmnYb8ZYOVS4eplMEK", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:19", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1425098"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C77908"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["GSK1120212", "JTP-74057", "MEK Inhibitor GSK1120212", "Mekinist", "N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide"]}, "tumorType": {"id": "civic.did:7", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3224"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1909"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4290", "description": "In a prospective study of 46 Caucasian, advanced lung adenocarcinoma patients harboring EGFR mutations, first-line erlotinib treatment was assessed. Average PFS and OS for these 46 patients was 11 months (95% CI: 9.7-12.3 months) and 23 months (95% CI: 21.3-28.6+ months), respectively. A PFS rate of 81% at three months met the primary endpoint of presumed superiority over chemotherapy. Clinical benefit (CR+PR+SD) rate was 81%. Fifteen patients harbored EGFR L858R mutations, which was the only mutation found in exon 21. The authors note similar response profiles for exon 19 (27/46) and exon 21 mutations (15/46) to the overall population.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2067", "label": "De Gr\u00e8ve et al., 2016, PLoS ONE", "type": "Document", "title": "PubMed: De Gr\u00e8ve et al., 2016, PLoS ONE", "pmid": 27032107}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:33", "label": "EGFR L858R", "description": "EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 379.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "G", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55259515, "stop": 55259515, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "33"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA126713"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16609"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376282"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376280"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434568"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121434568", "LEU858ARG"], "members": [{"id": "ga4gh:VA.TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "label": "NC_000007.13:g.55259515T>G", "digest": "TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "type": "Allele", "location": {"id": "ga4gh:SL.ulUNwZvajob7nzyrlpOd6uUWZIYCsoWb", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55191821, "end": 55191822}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "label": "L858R", "digest": "z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000007.13:g.55259515T>G"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2573T>G"}, {"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2573T>G"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Leu858Arg"}], "location": {"id": "ga4gh:SL.yVGJnwqxV6oCGqC_8nNb58D_wPXJeNJo", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 857, "end": 858}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:30", "label": "Lung Adenocarcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3512"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3910"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:6183", "description": "In a Japanese Phase III clinical trial, noninferiority of Gefitinib as compared to Erlotinib was assessed in 561 postoperative recurrent or stage IIIb/VI patients who had undergone prior chemotherapy treatment but no tyrosine kinase inhibitor therapy. In a subset of patients with sole EGFR L858R, there was an insignificant difference between the objective response and disease control rates for patients treated with erlotinib (N=67) and gefitinib (N=78). Progression free survival was also not significantly different and did not meet the noninferiority endpoint with Gefitinib and Erlotinib arms at 8.1 and 8.5 months, respectively (HR, 0.938; 95% CI, 0.675 to 1.304; P = .704).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2478", "label": "Urata et al., 2016, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Urata et al., 2016, J. Clin. Oncol.", "pmid": 27022112}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:33", "label": "EGFR L858R", "description": "EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 379.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "G", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55259515, "stop": 55259515, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "33"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA126713"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16609"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376282"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376280"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434568"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121434568", "LEU858ARG"], "members": [{"id": "ga4gh:VA.TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "label": "NC_000007.13:g.55259515T>G", "digest": "TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "type": "Allele", "location": {"id": "ga4gh:SL.ulUNwZvajob7nzyrlpOd6uUWZIYCsoWb", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55191821, "end": 55191822}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "label": "L858R", "digest": "z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000007.13:g.55259515T>G"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2573T>G"}, {"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2573T>G"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Leu858Arg"}], "location": {"id": "ga4gh:SL.yVGJnwqxV6oCGqC_8nNb58D_wPXJeNJo", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 857, "end": 858}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:14", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:328134"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1855"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"]}, "tumorType": {"id": "civic.did:30", "label": "Lung Adenocarcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3512"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3910"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:11158", "description": "n this open-label phase II study, 20 patients with systemic mastocytosis (SM) were recruited between 2003-2005. 7/20 patients were KIT D816V mutation-negative, among which one patient  achieved objective response and had complete resolution of signs and symptom; with normalization of bone marrow/blood abnormalities and tryptase levels. The patient remains in complete remission after more than 44 months. Moreover, four other patients reported improvement in some of their symptoms but no complete response was recorded. These data support imatinib\u2019s use in SM patients with KIT D816V mutation-negative status.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:4567", "label": "Vega-Ruiz et al., 2009, Leuk Res", "type": "Document", "title": "PubMed: Vega-Ruiz et al., 2009, Leuk Res", "pmid": 19193436}], "predicate": "predictsSensitivityTo", "qualifiers": {"geneContext": {"id": "civic.gid:29", "label": "KIT", "description": "c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3815"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["C-Kit", "CD117", "KIT", "MASTC", "PBT", "SCFR"]}}, "direction": "supports", "strength": {"label": "clinical cohort evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00005"}, "variant": {"id": "civic.mpid:4353", "label": "NOT KIT D816V", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 5.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000288135.5", "chromosome": "4", "start": 55599321, "stop": 55599321, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "65"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123513"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13852"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913507"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ASP816VAL"], "members": [{"id": "ga4gh:VA.gdbp5quI5YscqYY01qlHfuJkT7R41cR7", "label": "NC_000004.11:g.55599321A>T", "digest": "gdbp5quI5YscqYY01qlHfuJkT7R41cR7", "type": "Allele", "location": {"id": "ga4gh:SL.K5_kmlkru2gtVBgRFCtI7EVKUJa1E28v", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54733154, "end": 54733155}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.rZDlEZBywJpTMBnXhLjN12Y9HQYHiOiP", "label": "D816V", "digest": "rZDlEZBywJpTMBnXhLjN12Y9HQYHiOiP", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_000222.2:c.2447A>T"}, {"syntax": "hgvs.p", "value": "NP_000213.1:p.Asp816Val"}, {"syntax": "hgvs.c", "value": "ENST00000288135.5:c.2447A>T"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55599321A>T"}], "location": {"id": "ga4gh:SL.EFk3ET7Ws47inqLJnNWEsA-GhUEwihbN", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 815, "end": 816}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "civic.tid:537", "label": "Imatinib Mesylate", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:282388"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "Disease", "label": "Systemic mastocytosis", "mappings": [{"coding": {"system": "ncit", "code": "C9235"}, "relation": "relatedMatch"}]}, {"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}, {"id": "hemonc:634", "type": "Disease", "label": "Myelodysplastic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C3247"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:33893", "type": "Disease", "label": "Chronic myelogenous leukemia pediatric"}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}, {"id": "hemonc:616", "type": "Disease", "label": "Hypereosinophilic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C27038"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1687"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate", "CGP 57148", "CGP57148B", "Gleevec", "Glivec", "STI 571", "STI-571", "STI571"]}, "tumorType": {"id": "civic.did:2150", "label": "Systemic Mastocytosis", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9235"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:349"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2232", "description": "In a retrospective study of 427 metastatic colorectal patients, KRAS mutations were observed in 43% of the tumor samples. Patients with mutations in codon 12 or 13 of KRAS were associated with reduced response to panitumumab compared to wildtype KRAS (HR:0.99, 95% CI:0.73-1.36 vs. HR:0.45, 95% CI:0.34-0.59; P<0.0001). Additionally, patients with KRAS mutations showed no significant improvement between treatment with panitumumab and best supportive care alone (PFS: 7.4 wk vs 7.3 wk).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1412", "label": "Amado et al., 2008, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Amado et al., 2008, J. Clin. Oncol.", "pmid": 18316791}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:421", "label": "KRAS G12V", "description": "KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 67.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "A", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398284, "stop": 25398284, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "425"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA122540"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12583"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913529"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913529", "GLY12VAL"], "members": [{"id": "ga4gh:VA.-SzXMvMSRoSJgvsIDz-7M7VTFdo4FCtA", "label": "NC_000012.11:g.25398284C>A", "digest": "-SzXMvMSRoSJgvsIDz-7M7VTFdo4FCtA", "type": "Allele", "location": {"id": "ga4gh:SL.iF0OXeO-tnumYbGkzaFEQ7cOZI_UCI1s", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245349, "end": 25245350}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.JTtvYJD7yl02AOq09HjSZDUnfg4gYdUb", "label": "G12V", "digest": "JTtvYJD7yl02AOq09HjSZDUnfg4gYdUb", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004985.4:c.35G>T"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly12Val"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398284C>A"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.35G>T"}], "location": {"id": "ga4gh:SL.OndkjmujtyUEZSjjCv0C-gpwnVbRgfj8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "civic.tid:28", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:263034"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1857"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["ABX-EGF", "ABX-EGF Monoclonal Antibody", "ABX-EGF, Clone E7.6.3", "E7.6.3", "Human IgG2K Monoclonal Antibody", "MoAb ABX-EGF", "MoAb E7.6.3", "Monoclonal Antibody ABX-EGF", "Monoclonal Antibody E7.6.3", "Vectibix"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2236", "description": "In a retrospective study of 427 metastatic colorectal patients, KRAS mutations were observed in 43% of the tumor samples. Patients with mutations in codon 12 or 13 of KRAS were associated with reduced response to panitumumab compared to wildtype KRAS (HR:0.99, 95% CI:0.73-1.36 vs. HR:0.45, 95% CI:0.34-0.59; P<0.0001). Additionally, patients with KRAS mutations showed no significant improvement between treatment with panitumumab and best supportive care alone (PFS: 7.4 wk vs 7.3 wk).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1412", "label": "Amado et al., 2008, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Amado et al., 2008, J. Clin. Oncol.", "pmid": 18316791}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:79", "label": "KRAS G12D", "description": "While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 162.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398284, "stop": 25398284, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "79"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA122538"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12582"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913529"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913529", "GLY12ASP"], "members": [{"id": "ga4gh:VA.qOYg4yYK-1Je25G30BkV3dWKtKDIAFEJ", "label": "NC_000012.11:g.25398284C>T", "digest": "qOYg4yYK-1Je25G30BkV3dWKtKDIAFEJ", "type": "Allele", "location": {"id": "ga4gh:SL.iF0OXeO-tnumYbGkzaFEQ7cOZI_UCI1s", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245349, "end": 25245350}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.CB571ja_KfZM_Hjn9zjjgV1an3tDWRcl", "label": "G12D", "digest": "CB571ja_KfZM_Hjn9zjjgV1an3tDWRcl", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004985.4:c.35G>A"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly12Asp"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398284C>T"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.35G>A"}], "location": {"id": "ga4gh:SL.OndkjmujtyUEZSjjCv0C-gpwnVbRgfj8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "D"}}}, "therapeutic": {"id": "civic.tid:28", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:263034"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1857"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["ABX-EGF", "ABX-EGF Monoclonal Antibody", "ABX-EGF, Clone E7.6.3", "E7.6.3", "Human IgG2K Monoclonal Antibody", "MoAb ABX-EGF", "MoAb E7.6.3", "Monoclonal Antibody ABX-EGF", "Monoclonal Antibody E7.6.3", "Vectibix"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2253", "description": "In a retrospective study of 427 metastatic colorectal patients, KRAS mutations were observed in 43% of the tumor samples. Patients with mutations in codon 12 or 13 of KRAS were associated with reduced response to panitumumab compared to wildtype KRAS (HR:0.99, 95% CI:0.73-1.36 vs. HR:0.45, 95% CI:0.34-0.59; P<0.0001). Additionally, patients with KRAS mutations showed no significant improvement between treatment with panitumumab and best supportive care alone (PFS: 7.4 wk vs 7.3 wk).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1412", "label": "Amado et al., 2008, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Amado et al., 2008, J. Clin. Oncol.", "pmid": 18316791}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:78", "label": "KRAS G12C", "description": "While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 136.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "A", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398285, "stop": 25398285, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "78"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA122528"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12578"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913530"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLY12CYS", "RS121913530"], "members": [{"id": "ga4gh:VA.ONAtlY1naHPhc7I2cFH6POy4zmWKukHw", "label": "NC_000012.11:g.25398285C>A", "digest": "ONAtlY1naHPhc7I2cFH6POy4zmWKukHw", "type": "Allele", "location": {"id": "ga4gh:SL.AiE9G9ocxKfBfR5PRN_ktoggZzig8OcG", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245350, "end": 25245351}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.94GquHCCcRi74uwlI5PGJsf6FsR2M7Ef", "label": "G12C", "digest": "94GquHCCcRi74uwlI5PGJsf6FsR2M7Ef", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004985.4:c.34G>T"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly12Cys"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398285C>A"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.34G>T"}], "location": {"id": "ga4gh:SL.OndkjmujtyUEZSjjCv0C-gpwnVbRgfj8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "civic.tid:28", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:263034"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1857"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["ABX-EGF", "ABX-EGF Monoclonal Antibody", "ABX-EGF, Clone E7.6.3", "E7.6.3", "Human IgG2K Monoclonal Antibody", "MoAb ABX-EGF", "MoAb E7.6.3", "Monoclonal Antibody ABX-EGF", "Monoclonal Antibody E7.6.3", "Vectibix"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2264", "description": "In a retrospective study of 427 metastatic colorectal patients, KRAS mutations were observed in 43% of the tumor samples. Patients with mutations in codon 12 or 13 of KRAS were associated with reduced response to panitumumab compared to wildtype KRAS (HR:0.99, 95% CI:0.73-1.36 vs. HR:0.45, 95% CI:0.34-0.59; P<0.0001). Additionally, patients with KRAS mutations showed no significant improvement between treatment with panitumumab and best supportive care alone (PFS: 7.4 wk vs 7.3 wk).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1412", "label": "Amado et al., 2008, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Amado et al., 2008, J. Clin. Oncol.", "pmid": 18316791}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:526", "label": "KRAS G12R", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 32.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "G", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398285, "stop": 25398285, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "530"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA122531"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12579"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913530"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLY12ARG", "RS121913530"], "members": [{"id": "ga4gh:VA.kEM90GlJNzSYfDBfTs8c2yFQV8uAXPis", "label": "NC_000012.11:g.25398285C>G", "digest": "kEM90GlJNzSYfDBfTs8c2yFQV8uAXPis", "type": "Allele", "location": {"id": "ga4gh:SL.AiE9G9ocxKfBfR5PRN_ktoggZzig8OcG", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245350, "end": 25245351}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.l8Oir2v3p-jxHGny73WMctRV_zRFj8Mg", "label": "G12R", "digest": "l8Oir2v3p-jxHGny73WMctRV_zRFj8Mg", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004985.4:c.34G>C"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly12Arg"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398285C>G"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.34G>C"}], "location": {"id": "ga4gh:SL.OndkjmujtyUEZSjjCv0C-gpwnVbRgfj8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:28", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:263034"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1857"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["ABX-EGF", "ABX-EGF Monoclonal Antibody", "ABX-EGF, Clone E7.6.3", "E7.6.3", "Human IgG2K Monoclonal Antibody", "MoAb ABX-EGF", "MoAb E7.6.3", "Monoclonal Antibody ABX-EGF", "Monoclonal Antibody E7.6.3", "Vectibix"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2269", "description": "In a retrospective study of 427 metastatic colorectal patients, KRAS mutations were observed in 43% of the tumor samples. Patients with mutations in codon 12 or 13 of KRAS were associated with reduced response to panitumumab compared to wildtype KRAS (HR:0.99, 95% CI:0.73-1.36 vs. HR:0.45, 95% CI:0.34-0.59; P<0.0001). Additionally, patients with KRAS mutations showed no significant improvement between treatment with panitumumab and best supportive care alone (PFS: 7.4 wk vs 7.3 wk).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1412", "label": "Amado et al., 2008, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Amado et al., 2008, J. Clin. Oncol.", "pmid": 18316791}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:887", "label": "KRAS G12S", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 38.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398285, "stop": 25398285, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "913"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA135565"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12584"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913530"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLY12SER", "RS121913530"], "members": [{"id": "ga4gh:VA.PnoqUPOSplj2ReUhO0vv3Uwz7urotLNW", "label": "NC_000012.11:g.25398285C>T", "digest": "PnoqUPOSplj2ReUhO0vv3Uwz7urotLNW", "type": "Allele", "location": {"id": "ga4gh:SL.AiE9G9ocxKfBfR5PRN_ktoggZzig8OcG", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245350, "end": 25245351}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.BqLbpvUuI1si3-JoDB-imd4p6DIJVXlO", "label": "G12S", "digest": "BqLbpvUuI1si3-JoDB-imd4p6DIJVXlO", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004985.4:c.34G>A"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly12Ser"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398285C>T"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.34G>A"}], "location": {"id": "ga4gh:SL.OndkjmujtyUEZSjjCv0C-gpwnVbRgfj8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "S"}}}, "therapeutic": {"id": "civic.tid:28", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:263034"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1857"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["ABX-EGF", "ABX-EGF Monoclonal Antibody", "ABX-EGF, Clone E7.6.3", "E7.6.3", "Human IgG2K Monoclonal Antibody", "MoAb ABX-EGF", "MoAb E7.6.3", "Monoclonal Antibody ABX-EGF", "Monoclonal Antibody E7.6.3", "Vectibix"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2508", "description": "In a study of 297 non-small cell lung cancer patients, 15% of the analyzed tumors had  EGFR mutations including deletions in exon 19 (n=22), L858R (n=16) and G719A (n=2). Patients with EGFR mutations treated with gefitinib were associated with improved response rates (42.1% vs. 6.6%, P=0.04) compared to wildtype EGFR patients.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1501", "label": "Douillard et al., 2010, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Douillard et al., 2010, J. Clin. Oncol.", "pmid": 20038723}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:973", "label": "EGFR G719A", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 5.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "C", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55241708, "stop": 55241708, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "999"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA135775"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "45225"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913428"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913428", "GLY719ALA"], "members": [{"id": "ga4gh:VA.pLQEDzZn73HzbyZxHhMEQt-hvSvLBW-z", "label": "NC_000007.13:g.55241708G>C", "digest": "pLQEDzZn73HzbyZxHhMEQt-hvSvLBW-z", "type": "Allele", "location": {"id": "ga4gh:SL.445iMMb4pfz6LS7D6PlkwLjKsPajai3v", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55174014, "end": 55174015}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.SnY-0Sbtmk59BLFKUgyX4ywo8E1SSvXR", "label": "G719A", "digest": "SnY-0Sbtmk59BLFKUgyX4ywo8E1SSvXR", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_005228.4:c.2156G>C"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Gly719Ala"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55241708G>C"}, {"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2156G>C"}], "location": {"id": "ga4gh:SL.UiwCoIGhPuuRY9R_vCfqyuseQTBpzHA3", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 718, "end": 719}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}}, "therapeutic": {"id": "civic.tid:14", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:328134"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1855"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2878", "description": "In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1328", "label": "Swisher et al., 2017, Lancet Oncol.", "type": "Document", "title": "PubMed: Swisher et al., 2017, Lancet Oncol.", "pmid": 27908594}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:6", "label": "BRCA1", "description": "BRCA1 mutations in the germline have become a hallmark for hereditary breast and ovarian cancers. Variants that have been demonstrated to reduce the function of the protein have been shown to increase the risk for these cancers, as well as prostate and pancreatic cancer. These findings have been the impetus for the increased popularity of genetic testing of healthy individuals to assess risk. Recent studies in ovarian cancer have also demonstrated that BRCA mutation status can predict treatment response. A number of trials assessing BRCA mutation status have shown an improved response to platinum agents, and more recently has led to the FDA-approval of PARP inhibitors for BRCA-positive ovarian cancers. These studies have resulted in the Society of Gynecologic Oncology to recommend germline BRCA testing in all patients with a diagnosis of ovarian cancer.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1100"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:672"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["BRCA1", "BRCAI", "BRCC1", "BROVCA1", "FANCS", "IRIS", "PNCA4", "PPP1R53", "PSCP", "RNF53"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:1220", "label": "BRCA1 Q1467*", "extensions": [{"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000357654.3", "chromosome": "17", "start": 41228590, "stop": 41228590, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "stop_gained", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001587"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1246"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA002821"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "55191"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS397509171"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLN1467TER", "RS397509171", "Q1467X"], "members": [{"id": "ga4gh:VA.ztVREfTitwCXaOR5HECEbhEFIMS1U3Ty", "label": "NC_000017.10:g.41228590G>A", "digest": "ztVREfTitwCXaOR5HECEbhEFIMS1U3Ty", "type": "Allele", "location": {"id": "ga4gh:SL.O4_p-HMJyBKNR1XqsmX_eki8SRw_aN07", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dLZ15tNO1Ur0IcGjwc3Sdi_0A6Yf4zm7"}, "start": 43076572, "end": 43076573}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.1A5eUo4W21EWZkIRpHOgnInWj-57r72W", "label": "Q1467*", "digest": "1A5eUo4W21EWZkIRpHOgnInWj-57r72W", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_007294.3:c.4399C>T"}, {"syntax": "hgvs.p", "value": "NP_009225.1:p.Gln1467Ter"}, {"syntax": "hgvs.g", "value": "NC_000017.10:g.41228590G>A"}, {"syntax": "hgvs.c", "value": "ENST00000357654.3:c.4399C>T"}], "location": {"id": "ga4gh:SL.C6KsaNTQifZmGVogRgwCpQS2XYTIQ5rs", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.nUzIPnHMyQV52hzgBbKl5vlbSwx8M8_Y"}, "start": 1466, "end": 1467}, "state": {"type": "LiteralSequenceExpression", "sequence": "*"}}}, "therapeutic": {"id": "civic.tid:431", "label": "Rucaparib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1862579"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C137800"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-Fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-", "8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one"]}, "tumorType": {"id": "civic.did:20", "label": "Ovarian Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C7431"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:2394"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2880", "description": "In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1328", "label": "Swisher et al., 2017, Lancet Oncol.", "type": "Document", "title": "PubMed: Swisher et al., 2017, Lancet Oncol.", "pmid": 27908594}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:7", "label": "BRCA2", "description": "BRCA2 mutations in the germline have become a hallmark for hereditary breast and ovarian cancers. Variants that have been demonstrated to reduce the function of the protein have been shown to increase the risk for these cancers, as well as prostate and pancreatic cancer. These findings have been the impetus for the increased popularity of genetic testing of healthy individuals to assess risk. Recent studies in ovarian cancer have also demonstrated that BRCA mutation status can predict treatment response. A number of trials assessing BRCA mutation status have shown an improved response to platinum agents, and more recently has led to the FDA-approval of PARP inhibitors for BRCA-positive ovarian cancers. These studies have resulted in the Society of Gynecologic Oncology to recommend germline BRCA testing in all patients with a diagnosis of ovarian cancer.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1101"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:675"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["BRCA2", "BRCC2", "BROVCA2", "FACD", "FAD", "FAD1", "FANCD", "FANCD1", "GLM3", "PNCA2", "XRCC11"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:1222", "label": "BRCA2 M1I", "extensions": [{"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "T", "representative_transcript": "ENST00000544455.1", "chromosome": "13", "start": 32890600, "stop": 32890600, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1248"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA019369"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "37871"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS80358650"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS80358650", "MET1ILE"], "members": [{"id": "ga4gh:VA.-uy_PnOSv6tYXO-lruH1PHddd1nXW24M", "label": "NC_000013.10:g.32890600G>T", "digest": "-uy_PnOSv6tYXO-lruH1PHddd1nXW24M", "type": "Allele", "location": {"id": "ga4gh:SL.JUBToxENxCXgHYlSiaOhtpmbhJrroH-N", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ._0wi-qoDrvram155UmcSC-zA5ZK4fpLT"}, "start": 32316462, "end": 32316463}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.8L424PIfgDssRUu1JjqEFrDkd8wpXn8O", "label": "M1I", "digest": "8L424PIfgDssRUu1JjqEFrDkd8wpXn8O", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000013.10:g.32890600G>T"}, {"syntax": "hgvs.c", "value": "NM_000059.3:c.3G>T"}, {"syntax": "hgvs.p", "value": "NP_000050.2:p.Met1Ile"}, {"syntax": "hgvs.c", "value": "ENST00000544455.1:c.3G>T"}], "location": {"id": "ga4gh:SL.RURfIZWas6NmqntuCow3N_HSlhwoBmAp", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.A6rzuv6kdsuIp6gy6fykzgzyJe9NJOC9"}, "start": 0, "end": 1}, "state": {"type": "LiteralSequenceExpression", "sequence": "I"}}}, "therapeutic": {"id": "civic.tid:431", "label": "Rucaparib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1862579"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C137800"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-Fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-", "8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one"]}, "tumorType": {"id": "civic.did:20", "label": "Ovarian Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C7431"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:2394"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2881", "description": "In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1328", "label": "Swisher et al., 2017, Lancet Oncol.", "type": "Document", "title": "PubMed: Swisher et al., 2017, Lancet Oncol.", "pmid": 27908594}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:7", "label": "BRCA2", "description": "BRCA2 mutations in the germline have become a hallmark for hereditary breast and ovarian cancers. Variants that have been demonstrated to reduce the function of the protein have been shown to increase the risk for these cancers, as well as prostate and pancreatic cancer. These findings have been the impetus for the increased popularity of genetic testing of healthy individuals to assess risk. Recent studies in ovarian cancer have also demonstrated that BRCA mutation status can predict treatment response. A number of trials assessing BRCA mutation status have shown an improved response to platinum agents, and more recently has led to the FDA-approval of PARP inhibitors for BRCA-positive ovarian cancers. These studies have resulted in the Society of Gynecologic Oncology to recommend germline BRCA testing in all patients with a diagnosis of ovarian cancer.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1101"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:675"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["BRCA2", "BRCC2", "BROVCA2", "FACD", "FAD", "FAD1", "FANCD", "FANCD1", "GLM3", "PNCA2", "XRCC11"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:1223", "label": "BRCA2 V159M", "extensions": [{"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000544455.1", "chromosome": "13", "start": 32900287, "stop": 32900287, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1249"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA020781"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "51711"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS80358702"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS80358702", "VAL159MET"], "members": [{"id": "ga4gh:VA.X-zVkcb0YpGm4AZtdd_JienfzUtBicWI", "label": "NC_000013.10:g.32900287G>A", "digest": "X-zVkcb0YpGm4AZtdd_JienfzUtBicWI", "type": "Allele", "location": {"id": "ga4gh:SL.YCXm8-d9OLk57I-4Pe6vtmtodL1FTCQm", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ._0wi-qoDrvram155UmcSC-zA5ZK4fpLT"}, "start": 32326149, "end": 32326150}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.7CRyUDQTmLxvy5TkUMhEuiPB2afSCEV2", "label": "V159M", "digest": "7CRyUDQTmLxvy5TkUMhEuiPB2afSCEV2", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000544455.1:c.475G>A"}, {"syntax": "hgvs.c", "value": "NM_000059.3:c.475G>A"}, {"syntax": "hgvs.p", "value": "NP_000050.2:p.Val159Met"}, {"syntax": "hgvs.g", "value": "NC_000013.10:g.32900287G>A"}], "location": {"id": "ga4gh:SL.SM7msAXICAl7Dx1iS4FIiRiTiXXq1icX", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.A6rzuv6kdsuIp6gy6fykzgzyJe9NJOC9"}, "start": 158, "end": 159}, "state": {"type": "LiteralSequenceExpression", "sequence": "M"}}}, "therapeutic": {"id": "civic.tid:431", "label": "Rucaparib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1862579"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C137800"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-Fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-", "8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one"]}, "tumorType": {"id": "civic.did:20", "label": "Ovarian Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C7431"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:2394"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2882", "description": "In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1328", "label": "Swisher et al., 2017, Lancet Oncol.", "type": "Document", "title": "PubMed: Swisher et al., 2017, Lancet Oncol.", "pmid": 27908594}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:7", "label": "BRCA2", "description": "BRCA2 mutations in the germline have become a hallmark for hereditary breast and ovarian cancers. Variants that have been demonstrated to reduce the function of the protein have been shown to increase the risk for these cancers, as well as prostate and pancreatic cancer. These findings have been the impetus for the increased popularity of genetic testing of healthy individuals to assess risk. Recent studies in ovarian cancer have also demonstrated that BRCA mutation status can predict treatment response. A number of trials assessing BRCA mutation status have shown an improved response to platinum agents, and more recently has led to the FDA-approval of PARP inhibitors for BRCA-positive ovarian cancers. These studies have resulted in the Society of Gynecologic Oncology to recommend germline BRCA testing in all patients with a diagnosis of ovarian cancer.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1101"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:675"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["BRCA2", "BRCC2", "BROVCA2", "FACD", "FAD", "FAD1", "FANCD", "FANCD1", "GLM3", "PNCA2", "XRCC11"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:1224", "label": "BRCA2 V211L", "extensions": [{"type": "Extension", "name": "CIViC representative coordinate", "value": {"reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "C", "chromosome": "13", "start": 32900751, "stop": 32900751, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1250"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16619647"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "members": [{"id": "ga4gh:VA.ZrJyG_OO9IPqvYBRU2w3tLjGgT9mjpMT", "label": "NC_000013.10:g.32900751G>C", "digest": "ZrJyG_OO9IPqvYBRU2w3tLjGgT9mjpMT", "type": "Allele", "location": {"id": "ga4gh:SL.2hp5Ir4b4xqTJ5w5-eakcKcHxMPk8Rv_", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ._0wi-qoDrvram155UmcSC-zA5ZK4fpLT"}, "start": 32326613, "end": 32326614}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.rF1e8fb7XqPrU9Offsd-UwAF3PAnQ42V", "label": "V211L", "digest": "rF1e8fb7XqPrU9Offsd-UwAF3PAnQ42V", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000013.10:g.32900751G>C"}], "location": {"id": "ga4gh:SL.qjUyIVNHPUNj5TdCXC52dvGyN0gYjplz", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.A6rzuv6kdsuIp6gy6fykzgzyJe9NJOC9"}, "start": 210, "end": 211}, "state": {"type": "LiteralSequenceExpression", "sequence": "L"}}}, "therapeutic": {"id": "civic.tid:431", "label": "Rucaparib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1862579"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C137800"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-Fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-", "8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one"]}, "tumorType": {"id": "civic.did:20", "label": "Ovarian Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C7431"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:2394"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2883", "description": "In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1328", "label": "Swisher et al., 2017, Lancet Oncol.", "type": "Document", "title": "PubMed: Swisher et al., 2017, Lancet Oncol.", "pmid": 27908594}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:7", "label": "BRCA2", "description": "BRCA2 mutations in the germline have become a hallmark for hereditary breast and ovarian cancers. Variants that have been demonstrated to reduce the function of the protein have been shown to increase the risk for these cancers, as well as prostate and pancreatic cancer. These findings have been the impetus for the increased popularity of genetic testing of healthy individuals to assess risk. Recent studies in ovarian cancer have also demonstrated that BRCA mutation status can predict treatment response. A number of trials assessing BRCA mutation status have shown an improved response to platinum agents, and more recently has led to the FDA-approval of PARP inhibitors for BRCA-positive ovarian cancers. These studies have resulted in the Society of Gynecologic Oncology to recommend germline BRCA testing in all patients with a diagnosis of ovarian cancer.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1101"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:675"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["BRCA2", "BRCC2", "BROVCA2", "FACD", "FAD", "FAD1", "FANCD", "FANCD1", "GLM3", "PNCA2", "XRCC11"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:1225", "label": "BRCA2 V211I", "extensions": [{"type": "Extension", "name": "CIViC representative coordinate", "value": {"reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "chromosome": "13", "start": 32900751, "stop": 32900751, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1251"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA023848"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "members": [{"id": "ga4gh:VA.vFrYs_2PicQS-iSliiyaM4CN_A-abWjW", "label": "NC_000013.10:g.32900751G>A", "digest": "vFrYs_2PicQS-iSliiyaM4CN_A-abWjW", "type": "Allele", "location": {"id": "ga4gh:SL.2hp5Ir4b4xqTJ5w5-eakcKcHxMPk8Rv_", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ._0wi-qoDrvram155UmcSC-zA5ZK4fpLT"}, "start": 32326613, "end": 32326614}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.IPk0GG-6Ulnwquy9gik52x2k2jumsY0Z", "label": "V211I", "digest": "IPk0GG-6Ulnwquy9gik52x2k2jumsY0Z", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000013.10:g.32900751G>A"}], "location": {"id": "ga4gh:SL.qjUyIVNHPUNj5TdCXC52dvGyN0gYjplz", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.A6rzuv6kdsuIp6gy6fykzgzyJe9NJOC9"}, "start": 210, "end": 211}, "state": {"type": "LiteralSequenceExpression", "sequence": "I"}}}, "therapeutic": {"id": "civic.tid:431", "label": "Rucaparib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1862579"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C137800"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-Fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-", "8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one"]}, "tumorType": {"id": "civic.did:20", "label": "Ovarian Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C7431"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:2394"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2884", "description": "In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1328", "label": "Swisher et al., 2017, Lancet Oncol.", "type": "Document", "title": "PubMed: Swisher et al., 2017, Lancet Oncol.", "pmid": 27908594}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:7", "label": "BRCA2", "description": "BRCA2 mutations in the germline have become a hallmark for hereditary breast and ovarian cancers. Variants that have been demonstrated to reduce the function of the protein have been shown to increase the risk for these cancers, as well as prostate and pancreatic cancer. These findings have been the impetus for the increased popularity of genetic testing of healthy individuals to assess risk. Recent studies in ovarian cancer have also demonstrated that BRCA mutation status can predict treatment response. A number of trials assessing BRCA mutation status have shown an improved response to platinum agents, and more recently has led to the FDA-approval of PARP inhibitors for BRCA-positive ovarian cancers. These studies have resulted in the Society of Gynecologic Oncology to recommend germline BRCA testing in all patients with a diagnosis of ovarian cancer.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1101"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:675"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["BRCA2", "BRCC2", "BROVCA2", "FACD", "FAD", "FAD1", "FANCD", "FANCD1", "GLM3", "PNCA2", "XRCC11"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:1226", "label": "BRCA2 R2336P", "extensions": [{"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "C", "representative_transcript": "ENST00000544455.1", "chromosome": "13", "start": 32921033, "stop": 32921033, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1252"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA024716"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "52241"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS28897743"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ARG2336PRO", "RS28897743"], "members": [{"id": "ga4gh:VA.tsht11WOmDoPUnOAY6sNaFfrFnBJtP0r", "label": "NC_000013.10:g.32921033G>C", "digest": "tsht11WOmDoPUnOAY6sNaFfrFnBJtP0r", "type": "Allele", "location": {"id": "ga4gh:SL.qHm23DDNvF2Nq6YKGBARCmaeHqsAOPIi", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ._0wi-qoDrvram155UmcSC-zA5ZK4fpLT"}, "start": 32346895, "end": 32346896}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.SuUoDLPy2qc57nMmUztBN58RSqOVRqV5", "label": "R2336P", "digest": "SuUoDLPy2qc57nMmUztBN58RSqOVRqV5", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_000059.3:c.7007G>C"}, {"syntax": "hgvs.p", "value": "NP_000050.2:p.Arg2336Pro"}, {"syntax": "hgvs.g", "value": "NC_000013.10:g.32921033G>C"}, {"syntax": "hgvs.c", "value": "ENST00000544455.1:c.7007G>C"}], "location": {"id": "ga4gh:SL.AOSn9G8y00DBjm4f0viZ5OwHMRBOasfl", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.A6rzuv6kdsuIp6gy6fykzgzyJe9NJOC9"}, "start": 2335, "end": 2336}, "state": {"type": "LiteralSequenceExpression", "sequence": "P"}}}, "therapeutic": {"id": "civic.tid:431", "label": "Rucaparib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1862579"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C137800"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-Fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-", "8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one"]}, "tumorType": {"id": "civic.did:20", "label": "Ovarian Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C7431"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:2394"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:3851", "description": "In a retrospective study of 23 patients with BRAF V600 mutation (a known vemurafenib sensitizing mutation) that developed cutaneous squamous-cell carcinoma upon treatment with vemurafenib monotherapy, a patient harboring HRAS G13D co-mutation (n=1) was reported to be resistant to vemurafenib treatment.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1924", "label": "Su et al., 2012, N. Engl. J. Med.", "type": "Document", "title": "PubMed: Su et al., 2012, N. Engl. J. Med.", "pmid": 22256804}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:2747", "label": "HRAS", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:5173"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3265"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["C-BAS/HAS", "C-H-RAS", "C-HA-RAS1", "CTLO", "H-RASIDX", "HAMSV", "HRAS", "HRAS1", "RASH1", "p21ras"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:270", "label": "HRAS G13D", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 7.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000451590.1", "chromosome": "11", "start": 534285, "stop": 534285, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "274"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA256488"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12604"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS104894226"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS104894226", "GLY13ASP"], "members": [{"id": "ga4gh:VA.KK4PAcAHPt9-mfcEPHaC04FDYb0S5dda", "label": "NC_000011.9:g.534285C>T", "digest": "KK4PAcAHPt9-mfcEPHaC04FDYb0S5dda", "type": "Allele", "location": {"id": "ga4gh:SL.AFDSMpEdwo7XrLkWFBH7nz1KSjhAyhKd", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.2NkFm8HK88MqeNkCgj78KidCAXgnsfV1"}, "start": 534284, "end": 534285}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.6prtJS5RIQA0aNPe0B9tvAkg-eGZSOkD", "label": "G13D", "digest": "6prtJS5RIQA0aNPe0B9tvAkg-eGZSOkD", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000011.9:g.534285C>T"}, {"syntax": "hgvs.p", "value": "NP_005334.1:p.Gly13Asp"}, {"syntax": "hgvs.c", "value": "NM_005343.3:c.38G>A"}, {"syntax": "hgvs.c", "value": "ENST00000451590.1:c.38G>A"}], "location": {"id": "ga4gh:SL.klLpG5KB05t7h-nfpOQHOQedmddFHEXF", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.WdfMyMhCb_VBdWP9v5VevpsqEsRczr--"}, "start": 12, "end": 13}, "state": {"type": "LiteralSequenceExpression", "sequence": "D"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:130", "label": "Skin Squamous Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4819"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3151"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:3862", "description": "In a colorectal cancer patient with a KRAS Q61H mutation, KRAS Q61H was reported to be refractory to cetuximab treatment. The patient was treated with cetuximab and irinotecan for 18 months, had a partial response to therapy and then experienced progressive disease with a re-biopsy of the tumor identifying a KRAS Q61H mutation.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2008", "label": "Misale et al., 2012, Nature", "type": "Document", "title": "PubMed: Misale et al., 2012, Nature", "pmid": 22722830}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:881", "label": "KRAS Q61H", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 10.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "G", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25380275, "stop": 25380275, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "907"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA180922"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "177881"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS17851045"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS17851045", "GLN61HIS"], "members": [{"id": "ga4gh:VA.KknoDoUKdqdF9eNHyiZmXwsNeW8eSS9a", "label": "NC_000012.11:g.25380275T>G", "digest": "KknoDoUKdqdF9eNHyiZmXwsNeW8eSS9a", "type": "Allele", "location": {"id": "ga4gh:SL.GwbUuOvETJnULllrVw-GakWQVxkoRM41", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25227340, "end": 25227341}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.bNr4TNHNS435xNFuAO9V1z-ArOTcrfs7", "label": "Q61H", "digest": "bNr4TNHNS435xNFuAO9V1z-ArOTcrfs7", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004985.4:c.183A>C"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gln61His"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25380275T>G"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.183A>C"}], "location": {"id": "ga4gh:SL.VDhrtiVqUAZJHGxd84vmD9vaLIXV6c0b", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 60, "end": 61}, "state": {"type": "LiteralSequenceExpression", "sequence": "H"}}}, "therapeutic": {"id": "civic.tid:16", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:318341"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}, {"id": "mesh:D006258", "type": "Disease", "label": "Head and Neck Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C4013"}, "relation": "relatedMatch"}]}, {"id": "mesh:D002294", "type": "Disease", "label": "Carcinoma, Squamous Cell", "mappings": [{"coding": {"system": "ncit", "code": "C2929"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1723"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4022", "description": "In a retrospective study of 15 acute myeloid leukemia patients, the patients with FLT3 D835 mutation (n=2) were associated with improved response to sunitinib treatment (2/2 vs. 2/7) compared to FLT3 wild-type patients. The FLT3 D835 mutation positive patients were treated with sunitinib after failure of standard chemotherapy. After 4wk of sunitinib therapy, one patient showed morphological response and the other patient showed partial response to sunitinib therapy.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2030", "label": "Fiedler et al., 2005, Blood", "type": "Document", "title": "PubMed: Fiedler et al., 2005, Blood", "pmid": 15459012}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:24", "label": "FLT3", "description": "FLT3 is an important cytokine receptor involved in normal hematopoiesis. Mutations in this gene are common in acute myeloid leukemia (AML) and screening for mutations in this gene has been recommended by the World Health Organization in patients with AML, particularly in cases of cytogenetically normal AML (CN-AML). FLT3 mutations commonly co-occur with mutations such as NPM1 that are associated with CN-AML and likely modulate prognostic impact. While FLT3-ITD mutations have been associated with poorer prognosis in AML, the prognostic impact of FLT3-TKD mutations are still up for debate.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3765"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2322"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD135", "FLK-2", "FLK2", "FLT3", "STK1"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:1276", "label": "FLT3 D835V", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 19.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "A", "representative_transcript": "ENST00000241453.7", "chromosome": "13", "start": 28592641, "stop": 28592641, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1302"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA126344"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16272"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121909646"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ASP835VAL", "RS121909646"], "members": [{"id": "ga4gh:VA.d1XMqI0hKulE40Z2rW3jkkLDMVh_2_O1", "label": "NC_000013.10:g.28592641T>A", "digest": "d1XMqI0hKulE40Z2rW3jkkLDMVh_2_O1", "type": "Allele", "location": {"id": "ga4gh:SL.nXY0j3isNbco1FUwE39fcdoIjffTxgkq", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ._0wi-qoDrvram155UmcSC-zA5ZK4fpLT"}, "start": 28018503, "end": 28018504}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.2UJEemVtXP1RM3bMtSQbin9I91Uyiylm", "label": "D835V", "digest": "2UJEemVtXP1RM3bMtSQbin9I91Uyiylm", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000241453.7:c.2504A>T"}, {"syntax": "hgvs.c", "value": "NM_004119.2:c.2504A>T"}, {"syntax": "hgvs.p", "value": "NP_004110.2:p.Asp835Val"}, {"syntax": "hgvs.g", "value": "NC_000013.10:g.28592641T>A"}], "location": {"id": "ga4gh:SL.JUgz5GWLTcSTPLIVCaYEGo7KsH5QpwgJ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.0dtDG7QKyvW7BntvQVpLS83mYRA58LKH"}, "start": 834, "end": 835}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "civic.tid:157", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:357977"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:647", "type": "Disease", "label": "Pancreatic NET", "mappings": [{"coding": {"system": "ncit", "code": "C27720"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:660", "type": "Disease", "label": "Renal cell carcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C9385"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C71622"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"]}, "tumorType": {"id": "civic.did:3", "label": "Acute Myeloid Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3171"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9119"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4147", "description": "In a phase 2 clinical trial of 39 stage 3/4 chemotherapy-naive unresectable melanoma patients, a subungual melanoma patient harboring the KIT K642E mutation was reported to have a partial response to dasatinib monotherapy of 24 weeks with a 56% tumor reduction.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2056", "label": "Kluger et al., 2011, Cancer", "type": "Document", "title": "PubMed: Kluger et al., 2011, Cancer", "pmid": 21523734}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:29", "label": "KIT", "description": "c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3815"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["C-Kit", "CD117", "KIT", "MASTC", "PBT", "SCFR"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:952", "label": "KIT K642E", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 10.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "G", "representative_transcript": "ENST00000288135.5", "chromosome": "4", "start": 55594221, "stop": 55594221, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "978"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123547"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13866"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913512"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["LYS642GLU", "RS121913512"], "members": [{"id": "ga4gh:VA.VzsVyqlcWS87LveLKdzeYwvmm7lz9ie1", "label": "NC_000004.11:g.55594221A>G", "digest": "VzsVyqlcWS87LveLKdzeYwvmm7lz9ie1", "type": "Allele", "location": {"id": "ga4gh:SL.7PW790jMHV75G4i43nyFnA0wBi4smstb", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54728054, "end": 54728055}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.c3eVCAN6jp3r4vtwc3oFyMhn2omrwVB4", "label": "K642E", "digest": "c3eVCAN6jp3r4vtwc3oFyMhn2omrwVB4", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_000222.2:c.1924A>G"}, {"syntax": "hgvs.p", "value": "NP_000213.1:p.Lys642Glu"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55594221A>G"}, {"syntax": "hgvs.c", "value": "ENST00000288135.5:c.1924A>G"}], "location": {"id": "ga4gh:SL.WREnGgCj6j4vnGFA-gtJI9XkOJ5R6-ix", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 641, "end": 642}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "civic.tid:20", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1546019"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C38713"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate", "BMS-354825", "Dasatinib Hydrate", "Dasatinib Monohydrate", "Sprycel"]}, "tumorType": {"id": "civic.did:7", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3224"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1909"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4273", "description": "In stage IV lung adenocarcinoma patients (n=2) harboring EGFR S768I mutation, EGFR S768I was associated with progressive disease after 1 month of erlotinib monotherapy; the patient was previously treated with standard chemotherapy.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2079", "label": "Lund-Iversen et al., 2012, J Thorac Oncol", "type": "Document", "title": "PubMed: Lund-Iversen et al., 2012, J Thorac Oncol", "pmid": 22895145}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:558", "label": "EGFR S768I", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 20.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "T", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55249005, "stop": 55249005, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "562"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA135840"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "45251"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913465"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913465", "SER768ILE"], "members": [{"id": "ga4gh:VA.yr3duXsAtLA9Sd79rm8szW7ILvFJAYWv", "label": "NC_000007.13:g.55249005G>T", "digest": "yr3duXsAtLA9Sd79rm8szW7ILvFJAYWv", "type": "Allele", "location": {"id": "ga4gh:SL.U7UoPZ07_CwylemNLMyLgeGviwbHuvkG", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55181311, "end": 55181312}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.Rxpo23_FYjedhBXFh7SzZci98pLvAm-e", "label": "S768I", "digest": "Rxpo23_FYjedhBXFh7SzZci98pLvAm-e", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2303G>T"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55249005G>T"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2303G>T"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Ser768Ile"}], "location": {"id": "ga4gh:SL.KoPNmE5zRpg7iXpQ7t2eyFUQmxV-H_nU", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 767, "end": 768}, "state": {"type": "LiteralSequenceExpression", "sequence": "I"}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:30", "label": "Lung Adenocarcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3512"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3910"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4643", "description": "In a lung adenocarcinoma patient harboring EGFR D770_N771insGT mutation, EGFR D770_N771insGT was associated with lack of response to treatment with erlotinib monotherapy.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2116", "label": "Arcila et al., 2013, Mol. Cancer Ther.", "type": "Document", "title": "PubMed: Arcila et al., 2013, Mol. Cancer Ther.", "pmid": 23371856}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:1474", "label": "EGFR D770_N771insGT", "extensions": [{"type": "Extension", "name": "CIViC representative coordinate", "value": {"reference_build": "GRCh37", "variant_bases": "GGCACA", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55249012, "stop": 55249013, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "inframe_insertion", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001821"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1566"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA645561586"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ASP770_ASN771INSGLYTHR"], "members": [{"id": "ga4gh:VA.OdkVLBI2BYn4rmrjkqjEh6v_9RKfzswA", "label": "NC_000007.13:g.55249012_55249013insGGCACA", "digest": "OdkVLBI2BYn4rmrjkqjEh6v_9RKfzswA", "type": "Allele", "location": {"id": "ga4gh:SL.EtS4nquqDe57JO3brzp4cAGON3FWOjFX", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55181319, "end": 55181319}, "state": {"type": "LiteralSequenceExpression", "sequence": "GGCACA"}}], "definingContext": {"id": "ga4gh:VA.ipIBocFWPFnoYT5Uwu-P4x8VHVzDufaN", "label": "D770_N771insGT", "digest": "ipIBocFWPFnoYT5Uwu-P4x8VHVzDufaN", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000007.13:g.55249012_55249013insGGCACA"}, {"syntax": "hgvs.c", "value": "NM_005228.3:c.2310_2311insGGCACA"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Cys770_Gly771insGlyThr"}, {"syntax": "hgvs.g", "value": "NC_000007.14:g.55181319_55181320insGGCACA"}, {"syntax": "hgvs.c", "value": "ENST00000275493.7:c.2310_2311insGGCACA"}, {"syntax": "hgvs.p", "value": "ENSP00000275493.2:p.Asp770_Asn771insGlyThr"}], "location": {"id": "ga4gh:SL.ciWb1ylkqUxiviU1djijiuYVZcgsnQnV", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 770, "end": 770}, "state": {"type": "LiteralSequenceExpression", "sequence": "GT"}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:30", "label": "Lung Adenocarcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3512"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3910"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4654", "description": "An Arab basal cell carcinoma patient harboring SMO L412F mutation was associated with response to vismodegib monotherapy. Prior to the identification of the mutation, the patient was treated with acitretin, but did not achieve any response.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2117", "label": "Khamaysi et al., 2016, Br. J. Dermatol.", "type": "Document", "title": "PubMed: Khamaysi et al., 2016, Br. J. Dermatol.", "pmid": 26822128}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5365", "label": "SMO", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:11119"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:6608"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CRJS", "FZD11", "Gx", "PHLS", "SMO", "SMOH"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:1478", "label": "SMO L412F", "extensions": [{"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000249373.3", "chromosome": "7", "start": 128846398, "stop": 128846398, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1570"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA10584652"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "245609"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "members": [{"id": "ga4gh:VA.6kcO_sqNNSHOo6fR6cZJ6_o992202o97", "label": "NC_000007.13:g.128846398C>T", "digest": "6kcO_sqNNSHOo6fR6cZJ6_o992202o97", "type": "Allele", "location": {"id": "ga4gh:SL.xuaPDRPulmJSAqoCc1WSSSBhcVvY0fhY", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 129206556, "end": 129206557}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.R0T5AO-RyfsUgTSJjMtVEJepwCIg3u4G", "label": "L412F", "digest": "R0T5AO-RyfsUgTSJjMtVEJepwCIg3u4G", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_005631.4:c.1234C>T"}, {"syntax": "hgvs.p", "value": "NP_005622.1:p.Leu412Phe"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.128846398C>T"}, {"syntax": "hgvs.c", "value": "ENST00000249373.3:c.1234C>T"}], "location": {"id": "ga4gh:SL.HaUWVAQ8OlnrYBux8-vxkoJ_iekFUNdS", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.WZ7_owJHaml6kJ-2GfPtgYh1GA40K9tc"}, "start": 411, "end": 412}, "state": {"type": "LiteralSequenceExpression", "sequence": "F"}}}, "therapeutic": {"id": "civic.tid:190", "label": "Vismodegib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1242987"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:587", "type": "Disease", "label": "Cutaneous basal cell carcinoma"}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C74038"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide", "Erivedge", "GDC-0449", "Hedgehog Antagonist GDC-0449"]}, "tumorType": {"id": "civic.did:314", "label": "Basal Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2921"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:2513"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4776", "description": "In a retrospective study of 34 non-small cell lung cancer patients, a lung adenocarcinoma patient with POLD1 deleterious (as determined by Polyphen or SIFT) C284Y mutation and a high nonsynonymous mutation burden, treated with pembrolizumab monotherapy, was associated with a durable clinical benefit; POLD1 deleterious mutation was not identified in any patients who did not experience a durable clinical benefit.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2123", "label": "Rizvi et al., 2015, Science", "type": "Document", "title": "PubMed: Rizvi et al., 2015, Science", "pmid": 25765070}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:4384", "label": "POLD1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:9175"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5424"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CDC2", "CRCS10", "MDPL", "POLD", "POLD1"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:1555", "label": "POLD1 C284Y", "extensions": [{"type": "Extension", "name": "CIViC representative coordinate", "value": {"reference_build": "GRCh37", "type": "coordinates"}}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1647"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.k9h3JxOyzXHxNTk5YTrM9kboPqxBvq4p", "label": "C284Y", "digest": "k9h3JxOyzXHxNTk5YTrM9kboPqxBvq4p", "type": "Allele", "location": {"id": "ga4gh:SL.bzzVL6BDZ1_uSHZdb2cttBtJH1ZsbsQV", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Pu0jjZHQYcxoAf0tvg_ITiBtj2cumnsl"}, "start": 283, "end": 284}, "state": {"type": "LiteralSequenceExpression", "sequence": "Y"}}}, "therapeutic": {"id": "civic.tid:138", "label": "Pembrolizumab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1547545"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D008545", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C106432"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide With Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide", "Keytruda", "Lambrolizumab", "MK-3475", "SCH 900475"]}, "tumorType": {"id": "civic.did:30", "label": "Lung Adenocarcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3512"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3910"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4777", "description": "In a retrospective study of 34 non-small cell lung cancer patients, a patient, who never smoked, with POLD1 deleterious E374K mutation (as determined by Polyphen or SIFT) and a high nonsynonymous mutation burden, treated with pembrolizumab monotherapy, was associated with a durable clinical benefit; POLD1 deleterious mutation was not identified in patients who did not experience a durable clinical benefit.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2123", "label": "Rizvi et al., 2015, Science", "type": "Document", "title": "PubMed: Rizvi et al., 2015, Science", "pmid": 25765070}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:4384", "label": "POLD1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:9175"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5424"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CDC2", "CRCS10", "MDPL", "POLD", "POLD1"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:1556", "label": "POLD1 E374K", "extensions": [{"type": "Extension", "name": "CIViC representative coordinate", "value": {"reference_build": "GRCh37", "type": "coordinates"}}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1648"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.kO387KJlXno4YVpHzsYABFOfb_2r4d6D", "label": "E374K", "digest": "kO387KJlXno4YVpHzsYABFOfb_2r4d6D", "type": "Allele", "location": {"id": "ga4gh:SL.DzOH-rVeUCHxJPXK2926cnXFGQtVZzaX", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Pu0jjZHQYcxoAf0tvg_ITiBtj2cumnsl"}, "start": 373, "end": 374}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:138", "label": "Pembrolizumab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1547545"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D008545", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C106432"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide With Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide", "Keytruda", "Lambrolizumab", "MK-3475", "SCH 900475"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:486", "description": "In a patient with thymic carcinoma, the tumor expressing an activating mutation in exon 11 of KIT (V560del) was sensitive to imatinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:296", "label": "Str\u00f6bel et al., 2004, N. Engl. J. Med.", "type": "Document", "title": "PubMed: Str\u00f6bel et al., 2004, N. Engl. J. Med.", "pmid": 15201427}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:29", "label": "KIT", "description": "c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3815"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["C-Kit", "CD117", "KIT", "MASTC", "PBT", "SCFR"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:202", "label": "KIT V560DEL", "description": "V560 Resides within the Juxtamembrane domain on exon 11 of KIT. In melanoma this region is one 4 hotspots and is the 3rd highest recurrently mutated region. Mouse models have shown that mutations in this hotspot lead to  constitutive phosphorylation of KIT which will induce a stronger activation of the PI3K pathway however it is currently unknown if deletions follow the same model. Case studies in Gastrointestinal Stromal Tumors with V560DEL have reported a sensitivity when treated with imatinib and regorafenib.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 12.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "GTT", "representative_transcript": "ENST00000288135.5", "chromosome": "4", "start": 55593612, "stop": 55593614, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "amino_acid_deletion", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001604"}, {"label": "inframe_deletion", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001822"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "202"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123529"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13859"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["V556DEL", "V555DEL", "V559DEL", "VAL560DEL"], "members": [{"id": "ga4gh:VA.zmmhHogAiHozB4_pcU_6L6ISfnTtoIpe", "label": "NC_000004.11:g.55593612_55593614del", "digest": "zmmhHogAiHozB4_pcU_6L6ISfnTtoIpe", "type": "Allele", "location": {"id": "ga4gh:SL.yNSbu64XIVcU0kBCVW3m-rhLWNiogdjT", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54727442, "end": 54727449}, "state": {"type": "ReferenceLengthExpression", "length": 4, "sequence": "GTTG", "repeatSubunitLength": 3}}], "definingContext": {"id": "ga4gh:VA.Wd41lGdl5dYgswrvBAM11u7H5Sd9PO8K", "label": "V560DEL", "digest": "Wd41lGdl5dYgswrvBAM11u7H5Sd9PO8K", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000004.11:g.55593612_55593614del"}, {"syntax": "hgvs.c", "value": "ENST00000288135.5:c.1675_1677delGTT"}, {"syntax": "hgvs.c", "value": "NM_000222.2:c.1675_1677delGTT"}, {"syntax": "hgvs.p", "value": "NP_000213.1:p.Val560del"}], "location": {"id": "ga4gh:SL.yc8LZhzBrig6f-BtJ7a77c4uu6BSgGkO", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 559, "end": 562}, "state": {"type": "LiteralSequenceExpression", "sequence": "DEL"}}}, "therapeutic": {"id": "civic.tid:5", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:282388"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "Disease", "label": "Systemic mastocytosis", "mappings": [{"coding": {"system": "ncit", "code": "C9235"}, "relation": "relatedMatch"}]}, {"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}, {"id": "hemonc:634", "type": "Disease", "label": "Myelodysplastic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C3247"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:33893", "type": "Disease", "label": "Chronic myelogenous leukemia pediatric"}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}, {"id": "hemonc:616", "type": "Disease", "label": "Hypereosinophilic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C27038"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C62035"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"]}, "tumorType": {"id": "civic.did:239", "label": "Thymic Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C7569"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3284"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1108", "description": "The pretreatment tumor contained a somatic nonsense mutation (Q1178*) in the tumor-suppressor gene TSC2 that inactivates the gene, allowing for activation of the mTOR pathway and resulting in sensitivity to mTOR inhibition by everolimus. The patient received a sustained response to everolimus for 18 months.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:372", "label": "Wagle et al., 2014, N. Engl. J. Med.", "type": "Document", "title": "PubMed: Wagle et al., 2014, N. Engl. J. Med.", "pmid": 25295501}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:47", "label": "TSC2", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:12363"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:7249"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["LAM", "PPP1R160", "TSC2", "TSC4"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:465", "label": "TSC2 Q1178*", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 12.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000219476.3", "chromosome": "16", "start": 2130300, "stop": 2130300, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "stop_gained", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001587"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "469"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA019253"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "49263"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS45517297"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLN1178TER", "RS45517297", "Q1178X"], "members": [{"id": "ga4gh:VA.hjQnyraOLn_zcmQLVuNuyQGB644qhspD", "label": "NC_000016.9:g.2130300C>T", "digest": "hjQnyraOLn_zcmQLVuNuyQGB644qhspD", "type": "Allele", "location": {"id": "ga4gh:SL.aijCwa022ZuE0CkC5DtHrtyZIOcOMUcn", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.yC_0RBj3fgBlvgyAuycbzdubtLxq-rE0"}, "start": 2080298, "end": 2080299}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.sGxJmxbzTpw6qqz2Kij3aXSZAPOge_G8", "label": "Q1178*", "digest": "sGxJmxbzTpw6qqz2Kij3aXSZAPOge_G8", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_000548.4:c.3532C>T"}, {"syntax": "hgvs.p", "value": "NP_000539.2:p.Gln1178Ter"}, {"syntax": "hgvs.c", "value": "ENST00000219476.3:c.3532C>T"}, {"syntax": "hgvs.g", "value": "NC_000016.9:g.2130300C>T"}], "location": {"id": "ga4gh:SL.oGuWLVOr5Rdgradq5GJpMXEfcU7JQMDd", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.OBQRUmiVewAVPYXV5ACyxczHF1Q4YGOm"}, "start": 1177, "end": 1178}, "state": {"type": "LiteralSequenceExpression", "sequence": "*"}}}, "therapeutic": {"id": "civic.tid:41", "label": "Everolimus", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:141704"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:641", "type": "Disease", "label": "Neuroendocrine tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3809"}, "relation": "relatedMatch"}]}, {"id": "hemonc:647", "type": "Disease", "label": "Pancreatic NET", "mappings": [{"coding": {"system": "ncit", "code": "C27720"}, "relation": "relatedMatch"}]}, {"id": "hemonc:572", "type": "Disease", "label": "Breast cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9335"}, "relation": "relatedMatch"}]}, {"id": "hemonc:660", "type": "Disease", "label": "Renal cell carcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C9385"}, "relation": "relatedMatch"}]}, {"id": "hemonc:45070", "type": "Disease", "label": "Subependymal giant cell astrocytoma", "mappings": [{"coding": {"system": "ncit", "code": "C3696"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C48387"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone", "42-O-(2-Hydroxy)ethyl Rapamycin", "Afinitor", "Certican", "RAD 001", "RAD001", "Votubia", "Zortress"]}, "tumorType": {"id": "civic.did:155", "label": "Thyroid Gland Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4815"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3963"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1110", "description": "The pretreatment tumor contained a somatic nonsense mutation (Q1178*) in the tumor-suppressor gene TSC2 that inactivates the gene, allowing for activation of the mTOR pathway and resulting in sensitivity to mTOR inhibition by everolimus. The patient received a sustained response to everolimus for 18 months, after which time resistance developed. The resistant tumor had a somatic mutation in MTOR (F2108L), that was not detected in the pretreatment tumor.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:372", "label": "Wagle et al., 2014, N. Engl. J. Med.", "type": "Document", "title": "PubMed: Wagle et al., 2014, N. Engl. J. Med.", "pmid": 25295501}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:2073", "label": "MTOR", "description": "mTOR deregulation has been observed in many cancer types. As a part of the PI3K/Akt pathway, there is a broad interest in mTOR biology across cancer types. mTOR inhibition has been investigated for nearly a decade. Everolimus, temsirolimus and zotarolimus are three of the more commonly used mTOR inhibitors used in clinical treatment today, with modest success.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3942"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2475"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["FRAP", "FRAP1", "FRAP2", "MTOR", "RAFT1", "RAPT1", "SKS"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:466", "label": "MTOR F2108L", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 16.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "T", "representative_transcript": "ENST00000361445.4", "chromosome": "1", "start": 11187094, "stop": 11187094, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "470"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA338391533"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["PHE2108LEU"], "members": [{"id": "ga4gh:VA.YzvPymRhPJHK8FLUDsT0HFqARWO-r49u", "label": "NC_000001.10:g.11187094G>T", "digest": "YzvPymRhPJHK8FLUDsT0HFqARWO-r49u", "type": "Allele", "location": {"id": "ga4gh:SL.zlC7-kDtULKJWt-8NcQ-Uea_444z5iiH", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Ya6Rs7DHhDeg7YaOSg1EoNi3U_nQ9SvO"}, "start": 11127036, "end": 11127037}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.iGp4rv95TedqkgeFdQkddUfWM9rhGQjW", "label": "F2108L", "digest": "iGp4rv95TedqkgeFdQkddUfWM9rhGQjW", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000361445.4:c.6324C>A"}, {"syntax": "hgvs.g", "value": "NC_000001.10:g.11187094G>T"}], "location": {"id": "ga4gh:SL.Md1B3J4jJX8mCK2G31QBGlGeXgERC5VR", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Q9u3Vt0PamiHV4LTrj6mkhp1icb-eMhd"}, "start": 2107, "end": 2108}, "state": {"type": "LiteralSequenceExpression", "sequence": "L"}}}, "therapeutic": {"id": "civic.tid:41", "label": "Everolimus", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:141704"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:641", "type": "Disease", "label": "Neuroendocrine tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3809"}, "relation": "relatedMatch"}]}, {"id": "hemonc:647", "type": "Disease", "label": "Pancreatic NET", "mappings": [{"coding": {"system": "ncit", "code": "C27720"}, "relation": "relatedMatch"}]}, {"id": "hemonc:572", "type": "Disease", "label": "Breast cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9335"}, "relation": "relatedMatch"}]}, {"id": "hemonc:660", "type": "Disease", "label": "Renal cell carcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C9385"}, "relation": "relatedMatch"}]}, {"id": "hemonc:45070", "type": "Disease", "label": "Subependymal giant cell astrocytoma", "mappings": [{"coding": {"system": "ncit", "code": "C3696"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C48387"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone", "42-O-(2-Hydroxy)ethyl Rapamycin", "Afinitor", "Certican", "RAD 001", "RAD001", "Votubia", "Zortress"]}, "tumorType": {"id": "civic.did:155", "label": "Thyroid Gland Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4815"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3963"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:717", "description": "In-vitro studies found this mutation to confer resistance to cetuximab. 2 of 10 patients studied also harbored EGFR S492R and were resistant to cetuximab therapy. Panitumumab was still active in-vitro and in one patient.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:472", "label": "Montagut et al., 2012, Nat. Med.", "type": "Document", "title": "PubMed: Montagut et al., 2012, Nat. Med.", "pmid": 22270724}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:449", "label": "EGFR S492R", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 23.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "A", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55228009, "stop": 55228009, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "453"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602784"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376341"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS1057519860"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS1057519860", "SER492ARG"], "members": [{"id": "ga4gh:VA.QG6TP28zEwR_a3FLB3zjhZRMKqm3Oq9M", "label": "NC_000007.13:g.55228009C>A", "digest": "QG6TP28zEwR_a3FLB3zjhZRMKqm3Oq9M", "type": "Allele", "location": {"id": "ga4gh:SL.6zbdcNSn1HVtMHloyKL-LY9V__Ok18Xr", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55160315, "end": 55160316}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.89xcJTIpW8049gcHbnSmPqYc_wfbunTN", "label": "S492R", "digest": "89xcJTIpW8049gcHbnSmPqYc_wfbunTN", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.1476C>A"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55228009C>A"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Ser492Arg"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.1476C>A"}], "location": {"id": "ga4gh:SL.nTVXt4-Pfk2XJdxFumGxAA71rB4iBqZM", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 491, "end": 492}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:16", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:318341"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}, {"id": "mesh:D006258", "type": "Disease", "label": "Head and Neck Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C4013"}, "relation": "relatedMatch"}]}, {"id": "mesh:D002294", "type": "Disease", "label": "Carcinoma, Squamous Cell", "mappings": [{"coding": {"system": "ncit", "code": "C2929"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1723"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:728", "description": "A case report of a patient with BRAF L597R mutation and clinical response to BRAF-inhibition (Vemurafenib) that correlated to in-vitro models.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:477", "label": "Bahadoran et al., 2013, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Bahadoran et al., 2013, J. Clin. Oncol.", "pmid": 23715574}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:284", "label": "BRAF L597R", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 12.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "C", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453145, "stop": 140453145, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "288"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123649"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13968"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913366"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913366", "LEU597ARG"], "members": [{"id": "ga4gh:VA.POEl_3_26UPoaUTf3nqH0s77PWQJEGPD", "label": "NC_000007.13:g.140453145A>C", "digest": "POEl_3_26UPoaUTf3nqH0s77PWQJEGPD", "type": "Allele", "location": {"id": "ga4gh:SL.cGEXoAH8CN1Vt-bvqUWZ8VkN24o8W6en", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753344, "end": 140753345}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.4-ro_DUvMmS7ZZqCZ7LkbbewqBG5wcs2", "label": "L597R", "digest": "4-ro_DUvMmS7ZZqCZ7LkbbewqBG5wcs2", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004333.4:c.1790T>G"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Leu597Arg"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140453145A>C"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1790T>G"}], "location": {"id": "ga4gh:SL.SfkS-rvyLn3M9HwlYokvq8Bm6IWEWHdt", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 596, "end": 597}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:7", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3224"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1909"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:791", "description": "Case report of a patient with stage IVA HNSCC with near-complete histologic response after 13 days of neoadjuvant erlotinib. Whole-exome sequencing of the pre-treatment tumor revealed a MAPK1 E322K mutation (allelic fraction 0.13). In-vitro studies in two HNSCC cell lines showed enhanced EGFR phosphorylation and erlotinib sensitivity in the mutant line compared with the wild-type line.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:525", "label": "Van Allen et al., 2015, JAMA Oncol", "type": "Document", "title": "PubMed: Van Allen et al., 2015, JAMA Oncol", "pmid": 26181029}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:4532", "label": "MAPK1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6871"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5594"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["ERK", "ERK-2", "ERK2", "ERT1", "MAPK1", "MAPK2", "NS13", "P42MAPK", "PRKM1", "PRKM2", "p38", "p40", "p41", "p41mapk", "p42-MAPK"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:316", "label": "MAPK1 E322K", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 10.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000215832.6", "chromosome": "22", "start": 22127164, "stop": 22127164, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}, {"label": "gain_of_function_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0002053"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "320"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602885"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376450"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLU322LYS"], "members": [{"id": "ga4gh:VA.N4f-289V8Ix_je9iT_MQd_eNgtG6UMp1", "label": "NC_000002.11:g.22127164C>T", "digest": "N4f-289V8Ix_je9iT_MQd_eNgtG6UMp1", "type": "Allele", "location": {"id": "ga4gh:SL.KZVhus0-_lM41JauyxRWLSFFGPtJmGuX", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.pnAqCRBrTsUoBghSD1yp_jXWSmlbdh4g"}, "start": 21904291, "end": 21904292}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.QN2vnsy7Y2a_gr0ZAv4uo-RTxHQdJzz3", "label": "E322K", "digest": "QN2vnsy7Y2a_gr0ZAv4uo-RTxHQdJzz3", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000215832.6:c.964G>A"}, {"syntax": "hgvs.g", "value": "NC_000002.11:g.22127164C>T"}, {"syntax": "hgvs.p", "value": "NP_002736.3:p.Glu322Lys"}, {"syntax": "hgvs.c", "value": "NM_002745.4:c.964G>A"}], "location": {"id": "ga4gh:SL.NbB9n-91BtQParIjKMMtzoemNLkllght", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.N-m1tI22kffhKfdRZK8wCOR3QfI-1lfr"}, "start": 321, "end": 322}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:37", "label": "Head And Neck Squamous Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C34447"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:5520"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1414", "description": "A 73 year old patient with prior history of breast cancer presented with metastatic papillary thyroid carcinoma. After two treatments of I-131 a comprehensive tumor profile revealed BRAF V600E as the only genetic alteration on a near diploid genome with trisomy 1q. Vemurafenib treatment resulted in improvement of symptoms and considerable reductions in tumor mass, and after 23 months the patient remained on therapy with well controlled disease.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:958", "label": "Ali et al., 2014, Case Rep Oncol", "type": "Document", "title": "PubMed: Ali et al., 2014, Case Rep Oncol", "pmid": 24987354}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:12", "label": "BRAF V600E", "description": "BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 1353.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453136, "stop": 140453136, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "12"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123643"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13961"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376069"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS113488022", "V640E", "VAL640GLU", "VAL600GLU"], "members": [{"id": "ga4gh:VA.LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "label": "NC_000007.13:g.140453136A>T", "digest": "LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "type": "Allele", "location": {"id": "ga4gh:SL.XutGzMvqbzN-vnxmPt2MJf7ehxmB0opi", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753335, "end": 140753336}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "label": "V600E", "digest": "4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004333.4:c.1799T>A"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Val600Glu"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140453136A>T"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1799T>A"}], "location": {"id": "ga4gh:SL.ZA1XNKhCT_7m2UtmnYb8ZYOVS4eplMEK", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:156", "label": "Thyroid Gland Papillary Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4035"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3969"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1567", "description": "Paired tumor samples were analyzed from four patients with metastatic melanoma and initial response with a subsequent relapse under pembrolizumab (PD-1 checkpoint inhibitor) therapy. Baseline biopsies were obtained before therapy initiation with pembrolizumab (before prior vemurafenib treatment in patient 1).\nA JAK1 Q503* mutation was observed at the time of relapse in patient 1. This mutation was one of 3 new homozygous mutations in this patient (53 new mutations total) and the tumor was described to be genetically similar to the pre-treatment tumor. CRIPR-Cas9 mediated modelling of the JAK1 mutation in a melanoma cell line led to a loss of response to interferon alpha, beta and gamma.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1036", "label": "Zaretsky et al., 2016, N. Engl. J. Med.", "type": "Document", "title": "PubMed: Zaretsky et al., 2016, N. Engl. J. Med.", "pmid": 27433843}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:3090", "label": "JAK1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6190"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3716"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["AIIDE", "JAK1", "JAK1A", "JAK1B", "JTK3"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:610", "label": "JAK1 Q503*", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 10.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000342505.4", "chromosome": "1", "start": 65321333, "stop": 65321333, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "stop_gained", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001587"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "614"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA340669637"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["Q503X", "GLN503TER"], "members": [{"id": "ga4gh:VA.13aaZMLGDPpd2drFGosNG-3FttlpDkBJ", "label": "NC_000001.10:g.65321333G>A", "digest": "13aaZMLGDPpd2drFGosNG-3FttlpDkBJ", "type": "Allele", "location": {"id": "ga4gh:SL.5Ale4iZLgfwrB363Mm7mJYncc0nClhXS", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Ya6Rs7DHhDeg7YaOSg1EoNi3U_nQ9SvO"}, "start": 64855649, "end": 64855650}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.XloKqR5oS-cm7vFyhTA1XRx2GLb9PrvU", "label": "Q503*", "digest": "XloKqR5oS-cm7vFyhTA1XRx2GLb9PrvU", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000001.10:g.65321333G>A"}, {"syntax": "hgvs.c", "value": "ENST00000342505.4:c.1507C>T"}], "location": {"id": "ga4gh:SL.5aoL4yUjGPZi3-qTWPz_8rq6weClLFOZ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cu-mo9BHF4qdXH41R2iO9Zjkgjg9NZ94"}, "start": 502, "end": 503}, "state": {"type": "LiteralSequenceExpression", "sequence": "*"}}}, "therapeutic": {"id": "civic.tid:138", "label": "Pembrolizumab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1547545"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D008545", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C106432"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide With Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide", "Keytruda", "Lambrolizumab", "MK-3475", "SCH 900475"]}, "tumorType": {"id": "civic.did:206", "label": "Skin Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3510"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:8923"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1602", "description": "A patient with BRAF-mutant melanoma relapsed after treatment with PLX4032 (vemurafenib). The MAP2K1 C121S mutation was identified as a relapse-specific variant and was undetectable in the pre-treatment tumor. In vitro experiments showed that the C121S mutation increased kinase activity and conferred resistance to PLX4032.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1062", "label": "Wagle et al., 2011, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Wagle et al., 2011, J. Clin. Oncol.", "pmid": 21383288}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:31", "label": "MAP2K1", "description": "MAP2K1 is a dual-specificity kinase known for it's involvement in the ERK pathway by activation of ERK1 and ERK2. MAP2K1 activating mutations have been observed in a number of cancers including ovarian,  melanoma and lung. These activating mutations are generally found in the N-terminal negative regulatory region or the ATP-binding region of the N-terminal lobe.  Inhibitors of MEK genes have been shown to inhibit tumor growth in these cases.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6840"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5604"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CFC3", "MAP2K1", "MAPKK1", "MEK1", "MEL", "MKK1", "PRKMK1"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:623", "label": "MAP2K1 C121S", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 10.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "C", "representative_transcript": "ENST00000307102.5", "chromosome": "15", "start": 66729154, "stop": 66729154, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "627"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602455"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "375980"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["CYS121SER"], "members": [{"id": "ga4gh:VA.1V7pPpAkd5ZisPhWuXUgTt3jO0pv5115", "label": "NC_000015.9:g.66729154G>C", "digest": "1V7pPpAkd5ZisPhWuXUgTt3jO0pv5115", "type": "Allele", "location": {"id": "ga4gh:SL.KqyzsCLbBM2P2slru_nl0fncE7dbb1O0", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.AsXvWL1-2i5U_buw6_niVIxD6zTbAuS6"}, "start": 66436815, "end": 66436816}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.I89UeE6dzevspPAXLR2Hf3hLN-jftmLH", "label": "C121S", "digest": "I89UeE6dzevspPAXLR2Hf3hLN-jftmLH", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000307102.5:c.362G>C"}, {"syntax": "hgvs.g", "value": "NC_000015.9:g.66729154G>C"}, {"syntax": "hgvs.c", "value": "NM_002755.3:c.362G>C"}, {"syntax": "hgvs.p", "value": "NP_002746.1:p.Cys121Ser"}], "location": {"id": "ga4gh:SL.a4mB6iLipcfATUVODfEznCDlTYAgUqrt", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.StlJo3M4b8cS253ufe9nPpWqQHBDOSPs"}, "start": 120, "end": 121}, "state": {"type": "LiteralSequenceExpression", "sequence": "S"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:7", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3224"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1909"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1608", "description": "Homozygous VHL R200W mutations result in a rare congenital polycythemia known as Chuvash polycythemia. Treatment of 3 patients with this disease with the JAK1/2 inhibitor ruxolitinib led to symptomatic and hematologic improvements in all patients through 21-78 weeks of treatment.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1065", "label": "Zhou et al., 2016, N. Engl. J. Med.", "type": "Document", "title": "PubMed: Zhou et al., 2016, N. Engl. J. Med.", "pmid": 27518686}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "germline", "geneContext": {"id": "civic.gid:58", "label": "VHL", "description": "Von Hippel-Lindau (VHL) disease is characterized by heterozygous germline mutation in VHL gene on chromosome 3p. Patients are predisposed to developing hemangioblastomas of the brain, spinal cord, and retina; renal cysts and clear cell renal cell carcinoma; pheochromocytoma, pancreatic cysts and neuroendocrine tumors; endolymphatic sac tumors; and epididymal and broad ligament cysts. Cerebellar hemangioblastomas may be associated with headache, vomiting, gait disturbances, or ataxia. Spinal hemangioblastomas and related syrinx usually present with pain. Sensory and motor loss may develop with cord compression. Retinal hemangioblastomas may be the initial manifestation of VHL disease and can cause vision loss. Renal cell carcinoma occurs in about 70% of individuals with VHL and is the leading cause of mortality. Pheochromocytomas can be asymptomatic but may cause sustained or episodic hypertension. Pancreatic lesions often remain asymptomatic and rarely cause endocrine or exocrine insufficiency. Endolymphatic sac tumors can cause hearing loss of varying severity, which can be a presenting symptom. Cystadenomas of the epididymis are relatively common. They rarely cause problems, unless bilateral, in which case they may result in infertility.\n\nThe VHL gene product encodes pVHL, which binds to elongin C, elongin B, cullin-2 and Rbx1. This complex catalyzes the polyubiquitinylation of specific proteins and targets them for degradation by proteosomes. For example, under normoxic conditions, hydroxylated hypoxia-inducble factor alpha subunits (HIF\u03b1) binds pVHL targets HIF\u03b1 for degradation. Under hypoxic conditions, HIF1\u03b1 is not hydroxylated, pVHL does not bind, and HIF1\u03b1 subunits accumulate. HIF1\u03b1 forms heterodimers with HIF1\u03b2 and activates transcription of a variety of hypoxia-inducible genes (i.e., VEGF, EPO, TGF\u03b1, PDGF\u03b2). Likewise, when pVHL is absent or mutated, HIF1\u03b1 subunits accumulate, resulting in cell proliferation and the neovascularization of tumors characteristic of VHL disease.\n\nPathogenic variants in VHL either prevent its expression (i.e., deletions, frameshifts, nonsense mutations, and splice site mutations) or lead to the expression of an abnormal protein (i.e., missense mutations). Missense mutations that destabilize packing of the alpha-helical domains, decrease the stability of the alpha-beta domain interface, interfere with binding of elongin C and HIF1\u03b1, or disrupt hydrophobic core residues result in loss of HIF regulation and are more likely to result in VHL type 1 (no predisposition to pheochromocytoma).  Missense mutations that result in pVHL that is normal with respect to HIF regulation are more likely to be associated with VHL with clinical pheochromocytoma. \n\nAcquired somatic pathogenic variants in VHL may give rise to sporadic VHL-type tumors (i.e., clear cell RCC and hemangioblastoma) without other associated tumors characteristic of the hereditary disease. It should be noted that >90% of the most common form of kidney cancer (clear cell renal cell carcinoma) are associated with bi-allelic somatic mutation in the VHL gene, and is the rationale for the anti-angiogenic therapy for RCC patients.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:12687"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:7428"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["HRCA1", "RCA1", "VHL", "VHL1", "pVHL"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:627", "label": "VHL R200W (c.598C>T)", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 10.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000256474.2", "chromosome": "3", "start": 10191605, "stop": 10191605, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "631"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA020510"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "2232"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS28940298"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ARG200TRP", "C.598C>T", "RS28940298"], "members": [{"id": "ga4gh:VA.MmLPMkVmHptZ0NxNqpLlmen9ldQ2evg5", "label": "NC_000003.11:g.10191605C>T", "digest": "MmLPMkVmHptZ0NxNqpLlmen9ldQ2evg5", "type": "Allele", "location": {"id": "ga4gh:SL.m2wBzMMBe1LanB_40zbqe7xmIK5owFfX", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 10149920, "end": 10149921}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.vnMbab96bI1hu3wUqsYZ0bWfTV8Ycfi4", "label": "R200W (c.598C>T)", "digest": "vnMbab96bI1hu3wUqsYZ0bWfTV8Ycfi4", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_000551.3:c.598C>T"}, {"syntax": "hgvs.p", "value": "NP_000542.1:p.Arg200Trp"}, {"syntax": "hgvs.c", "value": "ENST00000256474.2:c.598C>T"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.10191605C>T"}], "location": {"id": "ga4gh:SL.KCsKbTfhDlYBAlCWIXXC1VO1izLSmquz", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.xBKOKptLLDr-k4hTyCetvARn16pDS_rW"}, "start": 667, "end": 668}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}}, "therapeutic": {"id": "civic.tid:386", "label": "Ruxolitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1193326"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:605", "type": "Disease", "label": "Graft versus host disease", "mappings": [{"coding": {"system": "ncit", "code": "C3063"}, "relation": "relatedMatch"}]}, {"id": "hemonc:655", "type": "Disease", "label": "Polycythemia vera", "mappings": [{"coding": {"system": "ncit", "code": "C3336"}, "relation": "relatedMatch"}]}, {"id": "hemonc:635", "type": "Disease", "label": "Myelofibrosis", "mappings": [{"coding": {"system": "ncit", "code": "C3248"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C77888"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(3R)-3-cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)propanenitrile", "INCB-18424", "INCB18424", "Jakafi", "Oral JAK Inhibitor INCB18424"]}, "tumorType": {"id": "civic.did:2137", "label": "Chuvash Polycythemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "mondo:0009892"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:0060474"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1661", "description": "Case report of a 51-year old patient with recurrent low-grade serous ovarian cancer. Selumetinib treatment in a phase-II trial led to a complete and durable response > 5 years. Sequencing (MSK-IMPACT Panel) was performed on the patients tumor and germline and identified a 15-bp in-frame deletion of MAP2K1 (8.3% of tumor reads but 0% in germline). In-silico modelling suggested loss of negative feedback on kinase activity from this deletion.In-vitro expression of the MEK1 Q56_V60 deletion as well as the previously characterized MEK1 F53L mutation in 293H cells resulted in elevated levels of phosphorylated ERK and phosphorylated ribosomal protein S6 kinase as compared with wild-type MEK1 as well as increased colony formation and tumor growth in-vivo. Selumetinib treatment of MEK1-transfected cells confirmed retained sensitivity to MEK inhibition and inhibition of colony formation.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1124", "label": "Grisham et al., 2015, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Grisham et al., 2015, J. Clin. Oncol.", "pmid": 26324360}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:31", "label": "MAP2K1", "description": "MAP2K1 is a dual-specificity kinase known for it's involvement in the ERK pathway by activation of ERK1 and ERK2. MAP2K1 activating mutations have been observed in a number of cancers including ovarian,  melanoma and lung. These activating mutations are generally found in the N-terminal negative regulatory region or the ATP-binding region of the N-terminal lobe.  Inhibitors of MEK genes have been shown to inhibit tumor growth in these cases.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6840"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5604"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CFC3", "MAP2K1", "MAPKK1", "MEK1", "MEL", "MKK1", "PRKMK1"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:651", "label": "MAP2K1 Q56_V60del", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 10.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "CCAGAAGCAGAAGGT", "representative_transcript": "ENST00000307102.5", "chromosome": "15", "start": 66727449, "stop": 66727463, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "inframe_deletion", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001822"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "655"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA912992484"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "members": [{"id": "ga4gh:VA.lxOXlXM3Rr9HkDmc0TYWCZs30ByoLBPk", "label": "NC_000015.9:g.66727449_66727463del", "digest": "lxOXlXM3Rr9HkDmc0TYWCZs30ByoLBPk", "type": "Allele", "location": {"id": "ga4gh:SL.4RTgRHAZ_-eD541kUwtmMBZ44HN2apxp", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.AsXvWL1-2i5U_buw6_niVIxD6zTbAuS6"}, "start": 66435110, "end": 66435125}, "state": {"type": "ReferenceLengthExpression", "length": 0, "sequence": "", "repeatSubunitLength": 15}}], "definingContext": {"id": "ga4gh:VA.qN9P4y9Q2ciQjz3n_26beUEXdhmhEtaN", "label": "Q56_V60del", "digest": "qN9P4y9Q2ciQjz3n_26beUEXdhmhEtaN", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000307102.5:c.165_179del"}, {"syntax": "hgvs.g", "value": "NC_000015.9:g.66727449_66727463del"}], "location": {"id": "ga4gh:SL.XUpfbCJCIufBGckM4miCb9ac-jfcU9Nx", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.StlJo3M4b8cS253ufe9nPpWqQHBDOSPs"}, "start": 55, "end": 60}, "state": {"type": "ReferenceLengthExpression", "length": 0, "sequence": "", "repeatSubunitLength": 5}}}, "therapeutic": {"id": "civic.tid:63", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:2289380"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C66939"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["ARRY-142886", "AZD6244", "MEK Inhibitor AZD6244"]}, "tumorType": {"id": "civic.did:87", "label": "Ovarian Serous Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C7550"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:0050933"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1864", "description": "Case report of a patient with lung adenocarcinoma harboring both a mutation in EGFR and an amplification of MET. After progression on erlotinib the patient was treated with combined type I MET (savolitinib) and EGFR (osimertinib) inhibition and responded. When resistance developed, a new MET kinase domain mutation, D1228V, was detected. Drug binding predictions and in vitro studies demonstrated that the D1228V mutation induces resistance to type I but not type II MET TKIs. The patient was treated with erlotinib (EGFR TKI) combined with cabozantinib, a type II MET inhibitor, and had a response which continued at the time of report (5 months).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1283", "label": "Bahcall et al., 2016, Cancer Discov", "type": "Document", "title": "PubMed: Bahcall et al., 2016, Cancer Discov", "pmid": 27694386}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:52", "label": "MET", "description": "Mesenchymal Epithelial Transition MET is a prototypical receptor tyrosine kinase. Its ligand is Hepatocyte Growth Factor (HGF). MET alterations are drivers of human cancer. Amplification and resulting overexpression has been reported in several cancers, and make the receptor's activity independent of HGF. Gene fusions also decouple kinase activity from the cell membrane and render it constitutively active. Finally, exclusion of the juxtamembrane (JM) domain of the kinase by \"skipping\" of exon 14 activates the kinase. FDA-approved selective MET inhibitors, including tepotinib and capmatinib, have shown efficacy in cancers with exon 14 skipping mutations or MET amplification.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:7029"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:4233"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["AUTS9", "DA11", "DFNB97", "HGFR", "MET", "RCCP2", "c-Met"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:776", "label": "MET D1228V", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 20.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000397752.3", "chromosome": "7", "start": 116423408, "stop": 116423408, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "798"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA368991571"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ASP1228VAL", "D1246V", "ASP1246VAL"], "definingContext": {"id": "ga4gh:VA.U0RxcDDM8Jxf39mIXg2lLd6qVofmcpvW", "label": "D1228V", "digest": "U0RxcDDM8Jxf39mIXg2lLd6qVofmcpvW", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000318493.11:c.3737A>T"}, {"syntax": "hgvs.p", "value": "ENSP00000317272.6:p.Asp1246Val"}, {"syntax": "hgvs.c", "value": "NM_001127500.3:c.3737A>T"}, {"syntax": "hgvs.p", "value": "NP_001120972.1:p.Asp1246Val"}], "location": {"id": "ga4gh:SL.Bupc48G2kXRjnN7z5wflGzXSKJ-uhzkZ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.QITcgkaDXSK1bJllcGyJVlXeD_SiQdfo"}, "start": 1227, "end": 1228}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "civic.tid:144", "label": "Cabozantinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1363267"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:65823", "type": "Disease", "label": "Thyroid cancer differentiated"}, {"id": "hemonc:660", "type": "Disease", "label": "Renal cell carcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C9385"}, "relation": "relatedMatch"}]}, {"id": "hemonc:612", "type": "Disease", "label": "Hepatocellular carcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C3099"}, "relation": "relatedMatch"}]}, {"id": "hemonc:68942", "type": "Disease", "label": "Thyroid cancer medullary"}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C52200"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1,1-Cyclopropanedicarboxamide, N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4- Fluorophenyl)-", "N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1- Dicarboxamide"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1865", "description": "Case report of a patient with lung adenocarcinoma harboring both a mutation in EGFR and an amplification of MET. After progression on erlotinib the patient was treated with combined type I MET (savolitinib) and EGFR (osimertinib) inhibition and responded. When resistance developed, a new MET kinase domain mutation, D1228V, was detected. Drug binding predictions and in vitro studies demonstrated that the D1228V mutation induces resistance to type I but not type II MET TKIs. The patient was treated with erlotinib (EGFR TKI) combined with cabozantinib, a type II MET inhibitor, and had a response which continued at the time of report (5 months).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1283", "label": "Bahcall et al., 2016, Cancer Discov", "type": "Document", "title": "PubMed: Bahcall et al., 2016, Cancer Discov", "pmid": 27694386}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:52", "label": "MET", "description": "Mesenchymal Epithelial Transition MET is a prototypical receptor tyrosine kinase. Its ligand is Hepatocyte Growth Factor (HGF). MET alterations are drivers of human cancer. Amplification and resulting overexpression has been reported in several cancers, and make the receptor's activity independent of HGF. Gene fusions also decouple kinase activity from the cell membrane and render it constitutively active. Finally, exclusion of the juxtamembrane (JM) domain of the kinase by \"skipping\" of exon 14 activates the kinase. FDA-approved selective MET inhibitors, including tepotinib and capmatinib, have shown efficacy in cancers with exon 14 skipping mutations or MET amplification.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:7029"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:4233"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["AUTS9", "DA11", "DFNB97", "HGFR", "MET", "RCCP2", "c-Met"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:776", "label": "MET D1228V", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 20.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000397752.3", "chromosome": "7", "start": 116423408, "stop": 116423408, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "798"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA368991571"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ASP1228VAL", "D1246V", "ASP1246VAL"], "definingContext": {"id": "ga4gh:VA.U0RxcDDM8Jxf39mIXg2lLd6qVofmcpvW", "label": "D1228V", "digest": "U0RxcDDM8Jxf39mIXg2lLd6qVofmcpvW", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000318493.11:c.3737A>T"}, {"syntax": "hgvs.p", "value": "ENSP00000317272.6:p.Asp1246Val"}, {"syntax": "hgvs.c", "value": "NM_001127500.3:c.3737A>T"}, {"syntax": "hgvs.p", "value": "NP_001120972.1:p.Asp1246Val"}], "location": {"id": "ga4gh:SL.Bupc48G2kXRjnN7z5wflGzXSKJ-uhzkZ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.QITcgkaDXSK1bJllcGyJVlXeD_SiQdfo"}, "start": 1227, "end": 1228}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "civic.tid:425", "label": "Savolitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C104732"}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C104732"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["AZD 6094", "AZD6094", "HMPL-504", "Volitinib"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1985", "description": "Case report of a patient with CLL and Richter-transformed relapse under ibrutinib (after an initial partial response for 10 months). Sequencing of sequential samples of this patient revealed a novel BTK T316 mutation at relapse (allele frequency of 75%). Characterization of this mutation showed that is was located on the SH2 domain, not associated with Ibrutinib binding. Introduction of this mutation in an Ibrutinib-sensitive lymphoma cell line showed resistance comparable to the known C481 resistance mutations, which was also confirmed by absence of downstream signaling.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1395", "label": "Sharma et al., 2016, Oncotarget", "type": "Document", "title": "PubMed: Sharma et al., 2016, Oncotarget", "pmid": 27626698}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:65", "label": "BTK", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1133"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:695"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["AGMX1", "AT", "ATK", "BPK", "BTK", "IGHD3", "IMD1", "PSCTK1", "XLA"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:844", "label": "BTK T316A", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 10.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "C", "representative_transcript": "ENST00000308731.7", "chromosome": "X", "start": 100613633, "stop": 100613633, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "870"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA413928923"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["THR316ALA"], "members": [{"id": "ga4gh:VA.Q9Jk9-Uq0sRKcYrnnwmUw6tSYHZ89Pu7", "label": "NC_000023.10:g.100613633T>C", "digest": "Q9Jk9-Uq0sRKcYrnnwmUw6tSYHZ89Pu7", "type": "Allele", "location": {"id": "ga4gh:SL.ku54LVmkAgaEkQfmShY_gYJJrHdxmlHn", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.w0WZEvgJF0zf_P4yyTzjjv9oW1z61HHP"}, "start": 101358644, "end": 101358645}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.emU0tRvVVdVUytDAY6RY87oFXCsQRDbr", "label": "T316A", "digest": "emU0tRvVVdVUytDAY6RY87oFXCsQRDbr", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000308731.7:c.946T>C"}, {"syntax": "hgvs.c", "value": "NM_000061.2:c.946T>C"}, {"syntax": "hgvs.g", "value": "NC_000023.10:g.100613633T>C"}], "location": {"id": "ga4gh:SL.AhuQyY2VVAnO9i8wJS3GpImfr7KnPmnB", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.UEFsUeUkTCNvBilBofWdc_UXE0AjL-IA"}, "start": 315, "end": 316}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}}, "therapeutic": {"id": "civic.tid:227", "label": "Ibrutinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1442981"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:682", "type": "Disease", "label": "Waldenstroem macroglobulinemia"}, {"id": "hemonc:605", "type": "Disease", "label": "Graft versus host disease", "mappings": [{"coding": {"system": "ncit", "code": "C3063"}, "relation": "relatedMatch"}]}, {"id": "hemonc:581", "type": "Disease", "label": "Chronic lymphocytic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3163"}, "relation": "relatedMatch"}]}, {"id": "hemonc:625", "type": "Disease", "label": "Mantle cell lymphoma", "mappings": [{"coding": {"system": "ncit", "code": "C4337"}, "relation": "relatedMatch"}]}, {"id": "hemonc:626", "type": "Disease", "label": "Marginal zone lymphoma", "mappings": [{"coding": {"system": "ncit", "code": "C4341"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C81934"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["2-Propen-1-one, 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)-", "BTK Inhibitor PCI-32765", "CRA-032765", "Imbruvica", "PCI-32765"]}, "tumorType": {"id": "civic.did:52", "label": "Chronic Lymphocytic Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3163"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1040"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4198", "description": "Mutational profiling was performed on EGFR exons 18-24 from a group of 10 retrospectively chosen patients who had shown partial response or clinical improvement in response to gefitinib. Of 7 tumors with EGFR mutations, 4 were del E746-A750. 3 had adenocarcinoma with bronchioloalveolar carcinoma (BAC) features, with response duration and overall survival of 8 and 15 months, 5+ and 5+ months (treatment ongoing at study end) and 28 and 30+ months (alive at study end), and one former smoker with adenocarcinoma with BAC features, who had response duration of 5+ months with treatment ongoing at study end.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1509", "label": "Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A.", "type": "Document", "title": "PubMed: Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A.", "pmid": 15329413}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:976", "label": "EGFR E746_A750del", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 19.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "GGAATTAAGAGAAGC", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55242465, "stop": 55242479, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "inframe_deletion", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001822"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1002"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA175996"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "163343"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913421"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913421", "E746_A750DELELREA"], "definingContext": {"id": "ga4gh:VA.Ey1-CesK8oo-eXa_cmB-4HfLUcltVDYL", "label": "E746_A750del", "digest": "Ey1-CesK8oo-eXa_cmB-4HfLUcltVDYL", "type": "Allele", "location": {"id": "ga4gh:SL.HiZy3E33xYU7hmo3ATl-_NSUCbexpZRq", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 745, "end": 750}, "state": {"type": "ReferenceLengthExpression", "length": 0, "sequence": "", "repeatSubunitLength": 5}}}, "therapeutic": {"id": "civic.tid:14", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:328134"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1855"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4494", "description": "2 patients with EGFR D770_N771insGL mutant lung adenocarcinoma were treated with first line erlotinib.\n\nA 45 year old male never smoker had progressive disease as best response with +24% change to target lesions, progression free survival of 3.8 months, and still alive at study end after 39.3 months. \n\nA 79 year old female never smoker had progressive disease as best response with +13% change to target lesions, progression free survival of 6 months and overall survival of 14 months.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1230", "label": "Yasuda et al., 2013, Sci Transl Med", "type": "Document", "title": "PubMed: Yasuda et al., 2013, Sci Transl Med", "pmid": 24353160}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:1422", "label": "EGFR D770_N771insGL", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 10.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"reference_build": "GRCh37", "variant_bases": "GGGTTA", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55249012, "stop": 55249013, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "inframe_insertion", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001821"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1514"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA645561585"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "45257"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS397517111"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS397517111"], "members": [{"id": "ga4gh:VA.8a_YvFQqGMSa3IHRnvUcwwRL46J5hlJq", "label": "NC_000007.13:g.55249012_55249013insGGGTTA", "digest": "8a_YvFQqGMSa3IHRnvUcwwRL46J5hlJq", "type": "Allele", "location": {"id": "ga4gh:SL.EtS4nquqDe57JO3brzp4cAGON3FWOjFX", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55181319, "end": 55181319}, "state": {"type": "LiteralSequenceExpression", "sequence": "GGGTTA"}}], "definingContext": {"id": "ga4gh:VA.AOCCh_BU5wKkdgoDNqkORF_x4GQwWh1T", "label": "D770_N771insGL", "digest": "AOCCh_BU5wKkdgoDNqkORF_x4GQwWh1T", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000007.13:g.55249012_55249013insGGGTTA"}, {"syntax": "hgvs.c", "value": "NM_005228.3:c.2310_2311insGGGTTA"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Asp770_Asn771insGlyLeu"}], "location": {"id": "ga4gh:SL.ciWb1ylkqUxiviU1djijiuYVZcgsnQnV", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 770, "end": 770}, "state": {"type": "LiteralSequenceExpression", "sequence": "GL"}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:30", "label": "Lung Adenocarcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3512"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3910"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4801", "description": "In a study of 19 non-small cell lung carcinoma patients with EGFR exon 20 insertion mutation and treated with erlotinib monotherapy, patients with EGFR D770delinsGY mutation (n=2) experienced progressive disease. Both patients were white females, had adenocarcinoma, and were treated with erlotinib as first line therapy. One was 76 years old with 6 former pack years, 38.1% increase in target lesion, 1 month PFS and 12 month OS. The other was 67 years old with 2 former pack years, 6.0% increase in target lesion, 1 month PFS and 1.5 month OS.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1230", "label": "Yasuda et al., 2013, Sci Transl Med", "type": "Document", "title": "PubMed: Yasuda et al., 2013, Sci Transl Med", "pmid": 24353160}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:2090", "label": "EGFR D770delinsGY", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 10.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "representative_transcript": "ENST00000275493.2", "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "inframe_insertion", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001821"}, {"label": "delins", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:1000032"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "2214"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.TTzh-rK0inUFWqz7CDWIOBTXhezfVplz", "label": "D770delinsGY", "digest": "TTzh-rK0inUFWqz7CDWIOBTXhezfVplz", "type": "Allele", "location": {"id": "ga4gh:SL.MJqWZl5MzFzO75Hlqnsp_bjsnzh5LHSW", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 769, "end": 770}, "state": {"type": "LiteralSequenceExpression", "sequence": "GY"}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:30", "label": "Lung Adenocarcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3512"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3910"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:6260", "description": "In a retrospective study of 44 relapsed melanoma patients with BRAF V600E/K (known BRAF inhibitor sensitizing mutations), AKT1 Q79K was associated with acquired resistance to BRAF inhibitor (dabrafenib) monotherapy in one patient. This patient was a 38 year old female with stage IV M1a melanoma who took dabrafenib (35 mg twice daily to 100 mg three times a day). The best overall response was a 100% reduction in the sum of target lesions, and progression free survival lasted 119 days. Prior to dabrafenib monotherapy, this patient's baseline tumor harbored BRAF V600K\u2014no other somatic alterations were noted. Following relapse, the patient gained AKT1 Q79K in one of two disease progressive tumors. Whole exome sequencing and Sanger re-sequencing were used for all tumors. The authors hypothesized that disruptions in the PI3K-PTEN-AKT pathway represent a core mechanism of acquired resistance to BRAF inhibitor therapy.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1941", "label": "Shi et al., 2014, Cancer Discov", "type": "Document", "title": "PubMed: Shi et al., 2014, Cancer Discov", "pmid": 24265155}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:2", "label": "AKT1", "description": "AKT1, also referred to as protein kinase B, is a known oncogene. AKT activation relies on the PI3K pathway, and is recognized as a critical node in the pathway. The E17 hotspot is the most characterized of AKT1 mutations, and has been shown to result in activation of the protein. Mutations in AKT1 have also been shown to confer resistance to allosteric kinase inhibitors in vitro.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:391"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:207"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["AKT", "AKT1", "PKB", "PKB-ALPHA", "PRKBA", "RAC", "RAC-ALPHA"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:169", "label": "AKT1 Q79K", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 16.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "T", "representative_transcript": "ENST00000407796.2", "chromosome": "14", "start": 105243048, "stop": 105243048, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "169"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602625"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376168"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS1057519804"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS1057519804", "GLN79LYS", "Q17K"], "members": [{"id": "ga4gh:VA._FsX8vVR1C-jMiRgJX02CDSaclfGir3N", "label": "NC_000014.8:g.105243048G>T", "digest": "_FsX8vVR1C-jMiRgJX02CDSaclfGir3N", "type": "Allele", "location": {"id": "ga4gh:SL.3aaJAnaiyOBfpjFMV7GuwwO23IHjh4zQ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.eK4D2MosgK_ivBkgi6FVPg5UXs1bYESm"}, "start": 104776710, "end": 104776711}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.Wpny1uCajSwqyosBpgHrpj66_am_42P3", "label": "Q79K", "digest": "Wpny1uCajSwqyosBpgHrpj66_am_42P3", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000014.8:g.105243048G>T"}, {"syntax": "hgvs.c", "value": "NM_001014432.1:c.235C>A"}, {"syntax": "hgvs.p", "value": "NP_001014432.1:p.Gln79Lys"}, {"syntax": "hgvs.c", "value": "ENST00000407796.2:c.235C>A"}], "location": {"id": "ga4gh:SL.yCJndQuCYYFMkmq_34dv0sqS_zpJ8wMk", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.GTSPIWYvuDZU59cW1RECFEU1FMiKdEyc"}, "start": 78, "end": 79}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:22", "label": "Dabrafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1424911"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:675", "type": "Disease", "label": "Thyroid cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7510"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C82386"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["BRAF Inhibitor GSK2118436", "Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-", "GSK-2118436", "GSK-2118436A", "GSK2118436"]}, "tumorType": {"id": "civic.did:7", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3224"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1909"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:6268", "description": "In a retrospective study of 44 relapsed melanoma patients harboring BRAF V600E/K (known BRAF inhibitor sensitizing mutations), PREX2 R172I was associated with a case of acquired resistance to BRAF inhibitor (vemurafenib) monotherapy in one patient. This patient was an 83 year old male with stage IV M1c melanoma who took vemurafenib (960mg twice daily). The best overall response was a 5% increase in sum of target lesions, and progression free survival lasted 132 days. Prior to vemurafenib monotherapy, this patient harbored BRAF V600K and no other somatic genetic alterations noted in the baseline tumor. Following relapse, the patient gained PREX2 R172I in one of two disease progressive tumors. Whole exome sequencing and Sanger re-sequencing were used for all tumors. The authors indicated that the biology behind this potential resistance mutation was unknown.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1941", "label": "Shi et al., 2014, Cancer Discov", "type": "Document", "title": "PubMed: Shi et al., 2014, Cancer Discov", "pmid": 24265155}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:15344", "label": "PREX2", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:22950"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:80243"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["DEP.2", "DEPDC2", "P-REX2", "PPP1R129", "PREX2"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:2237", "label": "PREX2 R172I", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 10.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "T", "representative_transcript": "ENST00000288368.4", "chromosome": "8", "start": 68939530, "stop": 68939530, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "2364"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA371196220"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ARG172ILE"], "definingContext": {"id": "ga4gh:VA.AcZzNBF2UJce9wBvjxs9zhj8YHX5zCFe", "label": "R172I", "digest": "AcZzNBF2UJce9wBvjxs9zhj8YHX5zCFe", "type": "Allele", "location": {"id": "ga4gh:SL.-HNmhaqo1xI4ENrFNPaqKAMpzMmmu95m", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Aq6T7QxlwC3KHbT1V07CcKAoaGWh8Ay5"}, "start": 171, "end": 172}, "state": {"type": "LiteralSequenceExpression", "sequence": "I"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:7", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3224"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1909"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:6381", "description": "Case report of a patient treated with ruxolitinib, an FDA-approved JAK1/2 inhibitor, which resulted in dramatic improvement of his blood counts. He also had significant reduction of spleen volume and constitutional symptoms.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2522", "label": "Dao et al., 2014, Leuk Res Rep", "type": "Document", "title": "PubMed: Dao et al., 2014, Leuk Res Rep", "pmid": 25180155}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:1239", "label": "CSF3R", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:2439"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1441"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD114", "CSF3R", "GCSFR", "SCN7"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:2260", "label": "CSF3R T618I", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 14.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000373103.1", "chromosome": "1", "start": 36933434, "stop": 36933434, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "2387"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA204418"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "208339"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["THR618ILE"], "members": [{"id": "ga4gh:VA.PqIGMb_ZLJSkL_CUXQwwU2JVvWFC3gsQ", "label": "NC_000001.10:g.36933434G>A", "digest": "PqIGMb_ZLJSkL_CUXQwwU2JVvWFC3gsQ", "type": "Allele", "location": {"id": "ga4gh:SL.61Arkbj-enko68XltIfqq23i3ZfS1FLC", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Ya6Rs7DHhDeg7YaOSg1EoNi3U_nQ9SvO"}, "start": 36467832, "end": 36467833}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.TzXHm8W6Y2yQ-vVTzhhsaeCmd7dG53MQ", "label": "T618I", "digest": "TzXHm8W6Y2yQ-vVTzhhsaeCmd7dG53MQ", "type": "Allele", "expressions": [{"syntax": "hgvs.p", "value": "NP_724781.1:p.Thr618Ile"}, {"syntax": "hgvs.c", "value": "NM_156039.3:c.1853C>T"}, {"syntax": "hgvs.c", "value": "ENST00000373103.1:c.1853G>A"}, {"syntax": "hgvs.g", "value": "NC_000001.10:g.36933434G>A"}, {"syntax": "hgvs.g", "value": "NC_000001.11:g.36467833G>A"}], "location": {"id": "ga4gh:SL.Rvinur1IdQxw7SP8IkgCBzsFrU4BMNo6", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.DED83_tWyJUC7C4oX5dwag6RxdJZ20RL"}, "start": 617, "end": 618}, "state": {"type": "LiteralSequenceExpression", "sequence": "I"}}}, "therapeutic": {"id": "civic.tid:386", "label": "Ruxolitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1193326"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:605", "type": "Disease", "label": "Graft versus host disease", "mappings": [{"coding": {"system": "ncit", "code": "C3063"}, "relation": "relatedMatch"}]}, {"id": "hemonc:655", "type": "Disease", "label": "Polycythemia vera", "mappings": [{"coding": {"system": "ncit", "code": "C3336"}, "relation": "relatedMatch"}]}, {"id": "hemonc:635", "type": "Disease", "label": "Myelofibrosis", "mappings": [{"coding": {"system": "ncit", "code": "C3248"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C77888"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(3R)-3-cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)propanenitrile", "INCB-18424", "INCB18424", "Jakafi", "Oral JAK Inhibitor INCB18424"]}, "tumorType": {"id": "civic.did:2127", "label": "Chronic Neutrophilic Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3179"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:0080187"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:8063", "description": "Among 32 colorectal cancer patients with acquired resistance (PFS > 12 weeks) to cetuximab, one was determined to have V955I mutation. V995I allelic fractions low at start of treatment but increased in frequency during treatment. PolyPhen-2 and SIFT functional predict folding changes to activation-loop domain. DiFi cells transfected with PIK3CA V955I plasmid assayed with western blot for pAKT (phosphorylated AKT) and pERK showed increased phosphorylation, which was not affected by the addition of cetuximab. PIK3CA V955I transfected cells also promoted cell viability in the presence of cetuximab.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2196", "label": "Xu et al., 2017, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Xu et al., 2017, Clin. Cancer Res.", "pmid": 28424201}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:2870", "label": "PIK3CA V955I", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 10.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000263967.3", "chromosome": "3", "start": 178948091, "stop": 178948091, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "3001"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA355281422"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["VAL955ILE"], "members": [{"id": "ga4gh:VA.0bhVcYgw3X-GDb8igX8SyW2_RTEHGKGf", "label": "NC_000003.11:g.178948091G>A", "digest": "0bhVcYgw3X-GDb8igX8SyW2_RTEHGKGf", "type": "Allele", "location": {"id": "ga4gh:SL.3FEk6Q34xARPikPdqxA4NnSdMG_-xdNf", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 179230302, "end": 179230303}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.PZKqfSEiMcrAbTqN0gN1-FESEw1UWO3t", "label": "V955I", "digest": "PZKqfSEiMcrAbTqN0gN1-FESEw1UWO3t", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000003.11:g.178948091G>A"}, {"syntax": "hgvs.c", "value": "NM_006218.2:c.2863G>A"}, {"syntax": "hgvs.c", "value": "ENST00000263967.3:c.2863G>A"}, {"syntax": "hgvs.p", "value": "NP_006209.2:p.Val955Ile"}], "location": {"id": "ga4gh:SL.NM-zezP6Rf9bLI3P__C97zrwuAlvr06z", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 954, "end": 955}, "state": {"type": "LiteralSequenceExpression", "sequence": "I"}}}, "therapeutic": {"id": "civic.tid:16", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:318341"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}, {"id": "mesh:D006258", "type": "Disease", "label": "Head and Neck Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C4013"}, "relation": "relatedMatch"}]}, {"id": "mesh:D002294", "type": "Disease", "label": "Carcinoma, Squamous Cell", "mappings": [{"coding": {"system": "ncit", "code": "C2929"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1723"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:9404", "description": "This case reports a 16-mo-old boy with metastatic neuroblastoma (stage M). Genomic analysis of a diagnostic biopsy of the tumor and matched normal identified two germline mutations in FANCA and somatic ALK-I1171T mutation. Functional investigation of this mutation including PC12 cell neurite outgrowth, NIH3T3 transformation and phosophoproteomics showing increased ALK signaling all suggested that it was a gain function. The patient was treated with Ceritinib as a monotherapy for 7.5 months. The residual primary decreased in size (44% volume reduction at 6 months of treatment) and was surgically removed. At 21 months of followup a complete remission was observed (including all metastatic sites).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:4032", "label": "Guan et al., 2018, Cold Spring Harb Mol Case Stud", "type": "Document", "title": "PubMed: Guan et al., 2018, Cold Spring Harb Mol Case Stud", "pmid": 29907598}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:1", "label": "ALK", "description": "ALK amplifications, fusions and mutations have been shown to be driving events in non-small cell lung cancer. While crizontinib has demonstrated efficacy in treating the amplification, mutations in ALK have been shown to confer resistance to current tyrosine kinase inhibitors. Second-generation TKI's have seen varied success in treating these resistant cases, and the HSP90 inhibitor 17-AAG has been shown to be cytostatic in ALK-altered cell lines.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:427"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:238"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["ALK", "ALK1", "CD246", "NBLST3"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:3239", "label": "ALK I1171T", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 10.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"type": "coordinates"}}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "3371"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.LG2Y62nu5O-kFxX_vKm4SdEeC5fcbs-1", "label": "I1171T", "digest": "LG2Y62nu5O-kFxX_vKm4SdEeC5fcbs-1", "type": "Allele", "location": {"id": "ga4gh:SL._dX7tpaMcINaYeX0u-tSJ6G_wPvJIjLS", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.q9CnK-HKWh9eqhOi8FlzR7M0pCmUrWPs"}, "start": 1170, "end": 1171}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}}, "therapeutic": {"id": "civic.tid:159", "label": "Ceritinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1535457"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C115112"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["2,4-Pyrimidinediamine, 5-chloro-N4-(2-((1-methylethyl)sulfonyl)phenyl)-N2-(5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl)-", "LDK 378", "LDK378", "Zykadia"]}, "tumorType": {"id": "civic.did:13", "label": "Neuroblastoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3270"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:769"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:10031", "description": "A cohort of 32 colorectal cancer patients with acquired resistance to cetuximab (PFS > 12 weeks) was analyzed for resistance mutations using targeted deep sequencing of ctDNA. Three patients had the PIK3CA p.K944N mutation. Cell viability studies of DiFi cells transfected with this PIK3CA variant confirmed resistance.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2196", "label": "Xu et al., 2017, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Xu et al., 2017, Clin. Cancer Res.", "pmid": 28424201}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:3534", "label": "PIK3CA K944N", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 10.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"type": "coordinates"}}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "3666"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.wTIomnpbgPJAiDG4jTj1k4W5nhX6Amrc", "label": "K944N", "digest": "wTIomnpbgPJAiDG4jTj1k4W5nhX6Amrc", "type": "Allele", "location": {"id": "ga4gh:SL.Wn-NpFOF27cmBynrMgNyrRs_sAInId5b", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 943, "end": 944}, "state": {"type": "LiteralSequenceExpression", "sequence": "N"}}}, "therapeutic": {"id": "civic.tid:16", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:318341"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}, {"id": "mesh:D006258", "type": "Disease", "label": "Head and Neck Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C4013"}, "relation": "relatedMatch"}]}, {"id": "mesh:D002294", "type": "Disease", "label": "Carcinoma, Squamous Cell", "mappings": [{"coding": {"system": "ncit", "code": "C2929"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1723"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:10032", "description": "A cohort of 32 colorectal cancer patients with acquired resistance to cetuximab (PFS > 12 weeks) was analyzed for resistance mutations using targeted deep sequencing of ctDNA. One patient had the PIK3CA F930S mutation. Cell viability studies of DiFi cells transfected with this PIK3CA variant confirmed resistance.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2196", "label": "Xu et al., 2017, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Xu et al., 2017, Clin. Cancer Res.", "pmid": 28424201}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:3535", "label": "PIK3CA F930S", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 10.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"type": "coordinates"}}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "3667"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.ys4CdMZlJpfjwuXjFSIpWVrNGH0tvnJ2", "label": "F930S", "digest": "ys4CdMZlJpfjwuXjFSIpWVrNGH0tvnJ2", "type": "Allele", "location": {"id": "ga4gh:SL.wfy5SrWPtY38Fz05VUtYAoUmL-J2YDQj", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 929, "end": 930}, "state": {"type": "LiteralSequenceExpression", "sequence": "S"}}}, "therapeutic": {"id": "civic.tid:16", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:318341"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}, {"id": "mesh:D006258", "type": "Disease", "label": "Head and Neck Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C4013"}, "relation": "relatedMatch"}]}, {"id": "mesh:D002294", "type": "Disease", "label": "Carcinoma, Squamous Cell", "mappings": [{"coding": {"system": "ncit", "code": "C2929"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1723"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:10033", "description": "A cohort of 32 colorectal cancer patients with acquired resistance to cetuximab (PFS > 12 weeks) was analyzed for resistance mutations using targeted deep sequencing of ctDNA. One patient had the PIK3CA p.V955G mutation. Cell viability studies of DiFi cells transfected with this PIK3CA variant confirmed resistance.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2196", "label": "Xu et al., 2017, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Xu et al., 2017, Clin. Cancer Res.", "pmid": 28424201}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:3536", "label": "PIK3CA V955G", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 10.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"type": "coordinates"}}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "3668"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.rJyzdEu_aZy9Ssq7-5CjYAqJyjpIRjkT", "label": "V955G", "digest": "rJyzdEu_aZy9Ssq7-5CjYAqJyjpIRjkT", "type": "Allele", "location": {"id": "ga4gh:SL.NM-zezP6Rf9bLI3P__C97zrwuAlvr06z", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 954, "end": 955}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}}, "therapeutic": {"id": "civic.tid:16", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:318341"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}, {"id": "mesh:D006258", "type": "Disease", "label": "Head and Neck Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C4013"}, "relation": "relatedMatch"}]}, {"id": "mesh:D002294", "type": "Disease", "label": "Carcinoma, Squamous Cell", "mappings": [{"coding": {"system": "ncit", "code": "C2929"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1723"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:10034", "description": "A cohort of 32 colorectal cancer patients with acquired resistance to cetuximab (PFS > 12 weeks) was analyzed for resistance mutations using targeted deep sequencing of ctDNA. One patient had the PIK3CA p.K966E mutation. Cell viability studies of DiFi cells transfected with this PIK3CA variant confirmed resistance.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2196", "label": "Xu et al., 2017, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Xu et al., 2017, Clin. Cancer Res.", "pmid": 28424201}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:3537", "label": "PIK3CA K966E", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 10.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"type": "coordinates"}}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "3669"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.yb7yfGRtujBlTL3LGtJH6ZE1w3sdHXBK", "label": "K966E", "digest": "yb7yfGRtujBlTL3LGtJH6ZE1w3sdHXBK", "type": "Allele", "location": {"id": "ga4gh:SL.2zzSgm3dtLpedQRbKk3haNZUwhN0KpWy", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 965, "end": 966}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "civic.tid:16", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:318341"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}, {"id": "mesh:D006258", "type": "Disease", "label": "Head and Neck Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C4013"}, "relation": "relatedMatch"}]}, {"id": "mesh:D002294", "type": "Disease", "label": "Carcinoma, Squamous Cell", "mappings": [{"coding": {"system": "ncit", "code": "C2929"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1723"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:647", "description": "Treatment with the PARP inhibitor olaparib in patients whose prostate cancers were no longer responding to standard treatments and who had defects in DNA-repair genes led to a high response rate. Overall, 4/6 patients (3/5 with no other identified aberrations in DNA repair genes) with several germline and somatic aberrations of ATM had a response. Responders included a single patient with a somatic frameshift mutation (ATM V2288fs*1) predicted to result in truncation prior to the PI3K catalytic domain and other domains for p53 recognition and response to DNA damage. No other alterations in ATM were observed; however, this patient also had frameshift mutations in MLH3, MRE11 and NBN.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:409", "label": "Mateo et al., 2015, N. Engl. J. Med.", "type": "Document", "title": "PubMed: Mateo et al., 2015, N. Engl. J. Med.", "pmid": 26510020}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:69", "label": "ATM", "description": "Ataxia-telangiectasia (A-T) is a recessive disorder resulting from germline mutation of the A-T mutated (ATM) gene on chromosome 11q. Upon sensing double-stranded breaks (DSB), the wild-type kinase encoded by ATM initiates the DNA-damage response by phosphorylating histone H2AX and, subsequently, various other proteins, such as BRCA1 and the MRE11\u2013RAD50\u2013NBS1 (MRN) complex, which are recruited to the damaged site. Additionally, ATM phosphorylates p53, resulting in expression of the cyclin-dependent kinase inhibitor p21 and leading to senescence or apoptosis. Somatic variants can result in inhibition or loss of these functions and can cause resistance to therapies that rely on inducing apoptosis via DSBs. Germline variants in A-T patients result in a predisposition to cancer, most frequently hematologic or breast. PARP inhibition has been studied for its potential in treating ATM mutated breast cancer patients.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:795"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:472"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["AT1", "ATA", "ATC", "ATD", "ATDC", "ATE", "ATM", "TEL1", "TELO1"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:239", "label": "ATM S2289*", "description": "A frameshift mutation at the DNA level predicted to cause truncation before the C-terminal phosphoinositide 3-kinase (PI3K) catalytic domain at amino acid 2289.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 7.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "TC", "representative_transcript": "ENST00000278616.4", "chromosome": "11", "start": 108196840, "stop": 108196841, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "frameshift_truncation", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001910"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "243"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA10588507"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["V2288FS*1"], "definingContext": {"id": "ga4gh:VA.M_yGNe1n8-tDa1Ig1WfBRZNySg63RmsC", "label": "S2289*", "digest": "M_yGNe1n8-tDa1Ig1WfBRZNySg63RmsC", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000278616.4:c.6863_6864delTC"}], "location": {"id": "ga4gh:SL.slLXnwVcKUnMe8Nteg396N1iKsUu1pk9", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6k1y4bTo7pEJ-a1GaniRBaCJXXGkBGFO"}, "start": 2288, "end": 2289}, "state": {"type": "LiteralSequenceExpression", "sequence": "*"}}}, "therapeutic": {"id": "civic.tid:42", "label": "Olaparib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1597582"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:645", "type": "Disease", "label": "Ovarian cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7431"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}, {"id": "hemonc:658", "type": "Disease", "label": "Prostate cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7378"}, "relation": "relatedMatch"}]}, {"id": "hemonc:572", "type": "Disease", "label": "Breast cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9335"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C71721"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["AZD 2281", "AZD-2281", "AZD2281", "KU-0059436", "Lynparza", "PARP Inhibitor AZD2281"]}, "tumorType": {"id": "civic.did:46", "label": "Prostate Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C7378"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:10283"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:648", "description": "Treatment with the PARP inhibitor olaparib in patients whose prostate cancers were no longer responding to standard treatments and who had defects in DNA-repair genes led to a high response rate. Overall, 4/6 patients (3/5 with no other identified aberrations in DNA repair genes) with several germline and somatic aberrations of ATM had a response. Responders included a single patient with a somatic missense mutation (ATM N2875H) and no other alterations in ATM or other DNA repair genes.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:409", "label": "Mateo et al., 2015, N. Engl. J. Med.", "type": "Document", "title": "PubMed: Mateo et al., 2015, N. Engl. J. Med.", "pmid": 26510020}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:69", "label": "ATM", "description": "Ataxia-telangiectasia (A-T) is a recessive disorder resulting from germline mutation of the A-T mutated (ATM) gene on chromosome 11q. Upon sensing double-stranded breaks (DSB), the wild-type kinase encoded by ATM initiates the DNA-damage response by phosphorylating histone H2AX and, subsequently, various other proteins, such as BRCA1 and the MRE11\u2013RAD50\u2013NBS1 (MRN) complex, which are recruited to the damaged site. Additionally, ATM phosphorylates p53, resulting in expression of the cyclin-dependent kinase inhibitor p21 and leading to senescence or apoptosis. Somatic variants can result in inhibition or loss of these functions and can cause resistance to therapies that rely on inducing apoptosis via DSBs. Germline variants in A-T patients result in a predisposition to cancer, most frequently hematologic or breast. PARP inhibition has been studied for its potential in treating ATM mutated breast cancer patients.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:795"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:472"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["AT1", "ATA", "ATC", "ATD", "ATDC", "ATE", "ATM", "TEL1", "TELO1"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:240", "label": "ATM N2875H", "description": "A missense mutation within the C-terminal phosphoinositide 3-kinase (PI3K) catalytic domain", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 7.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "C", "representative_transcript": "ENST00000278616.4", "chromosome": "11", "start": 108218044, "stop": 108218044, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "244"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602795"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376353"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS1057519869"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ASN2875HIS", "RS1057519869"], "members": [{"id": "ga4gh:VA.jaf6t1e6ODQHA-3VnsXihZOdgqb7Xy8P", "label": "NC_000011.9:g.108218044A>C", "digest": "jaf6t1e6ODQHA-3VnsXihZOdgqb7Xy8P", "type": "Allele", "location": {"id": "ga4gh:SL.nUPkVdcMYtm4BhLdAMpWMvejOtEjQsDA", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.2NkFm8HK88MqeNkCgj78KidCAXgnsfV1"}, "start": 108347316, "end": 108347317}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.wIZA5G-tTPJpuyL9TQLHNEu8v0N2oEu9", "label": "N2875H", "digest": "wIZA5G-tTPJpuyL9TQLHNEu8v0N2oEu9", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000278616.4:c.8623A>C"}, {"syntax": "hgvs.g", "value": "NC_000011.9:g.108218044A>C"}, {"syntax": "hgvs.c", "value": "NM_000051.3:c.8623A>C"}, {"syntax": "hgvs.p", "value": "NP_000042.3:p.Asn2875His"}], "location": {"id": "ga4gh:SL.S5GHP7WwI86FqtXEy3oj6PDVg1C9tG9R", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6k1y4bTo7pEJ-a1GaniRBaCJXXGkBGFO"}, "start": 2874, "end": 2875}, "state": {"type": "LiteralSequenceExpression", "sequence": "H"}}}, "therapeutic": {"id": "civic.tid:42", "label": "Olaparib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1597582"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:645", "type": "Disease", "label": "Ovarian cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7431"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}, {"id": "hemonc:658", "type": "Disease", "label": "Prostate cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7378"}, "relation": "relatedMatch"}]}, {"id": "hemonc:572", "type": "Disease", "label": "Breast cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9335"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C71721"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["AZD 2281", "AZD-2281", "AZD2281", "KU-0059436", "Lynparza", "PARP Inhibitor AZD2281"]}, "tumorType": {"id": "civic.did:46", "label": "Prostate Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C7378"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:10283"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:699", "description": "Case report of a patient with metastatic colorectal carcinoma and a novel HRAS G13D mutation showed resistance to treatment with panitumumab. In vitro models of HRAS G13D confirmed resistance mechanism in the same study.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:457", "label": "Boidot et al., 2016, Int J Colorectal Dis", "type": "Document", "title": "PubMed: Boidot et al., 2016, Int J Colorectal Dis", "pmid": 26561417}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:2747", "label": "HRAS", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:5173"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3265"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["C-BAS/HAS", "C-H-RAS", "C-HA-RAS1", "CTLO", "H-RASIDX", "HAMSV", "HRAS", "HRAS1", "RASH1", "p21ras"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:270", "label": "HRAS G13D", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 7.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000451590.1", "chromosome": "11", "start": 534285, "stop": 534285, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "274"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA256488"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12604"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS104894226"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS104894226", "GLY13ASP"], "members": [{"id": "ga4gh:VA.KK4PAcAHPt9-mfcEPHaC04FDYb0S5dda", "label": "NC_000011.9:g.534285C>T", "digest": "KK4PAcAHPt9-mfcEPHaC04FDYb0S5dda", "type": "Allele", "location": {"id": "ga4gh:SL.AFDSMpEdwo7XrLkWFBH7nz1KSjhAyhKd", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.2NkFm8HK88MqeNkCgj78KidCAXgnsfV1"}, "start": 534284, "end": 534285}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.6prtJS5RIQA0aNPe0B9tvAkg-eGZSOkD", "label": "G13D", "digest": "6prtJS5RIQA0aNPe0B9tvAkg-eGZSOkD", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000011.9:g.534285C>T"}, {"syntax": "hgvs.p", "value": "NP_005334.1:p.Gly13Asp"}, {"syntax": "hgvs.c", "value": "NM_005343.3:c.38G>A"}, {"syntax": "hgvs.c", "value": "ENST00000451590.1:c.38G>A"}], "location": {"id": "ga4gh:SL.klLpG5KB05t7h-nfpOQHOQedmddFHEXF", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.WdfMyMhCb_VBdWP9v5VevpsqEsRczr--"}, "start": 12, "end": 13}, "state": {"type": "LiteralSequenceExpression", "sequence": "D"}}}, "therapeutic": {"id": "civic.tid:145", "label": "Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C2167"}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C2167"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:709", "description": "In a phase-I study of AZD5363, partial response was observed in 2 patients with breast and ovarian carcinoma, respectively, and AKT1 E17K mutations. While full study results have not yet been published, this paper highlights in vitro results that further confirm the role of AKT E17K mutation.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:466", "label": "Davies et al., 2015, Mol. Cancer Ther.", "type": "Document", "title": "PubMed: Davies et al., 2015, Mol. Cancer Ther.", "pmid": 26351323}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:2", "label": "AKT1", "description": "AKT1, also referred to as protein kinase B, is a known oncogene. AKT activation relies on the PI3K pathway, and is recognized as a critical node in the pathway. The E17 hotspot is the most characterized of AKT1 mutations, and has been shown to result in activation of the protein. Mutations in AKT1 have also been shown to confer resistance to allosteric kinase inhibitors in vitro.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:391"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:207"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["AKT", "AKT1", "PKB", "PKB-ALPHA", "PRKBA", "RAC", "RAC-ALPHA"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:4", "label": "AKT1 E17K", "description": "AKT1 E17K is a recurrent mutation that has been observed in breast, colorectal, lung, and ovarian cancer. It has been convincingly shown to be an activating mutation resulting in PI3K/AKT/mTOR pathway activity. It has been suggested that this mutation decreases the cell's sensitivity to AKT1 allosteric kinase inhibitors. This, and other AKT1 mutations, are the subject of much research and development for therapeutics.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 33.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000407796.2", "chromosome": "14", "start": 105246551, "stop": 105246551, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "4"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123660"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13983"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS34409589"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLU17LYS", "RS34409589"], "members": [{"id": "ga4gh:VA.swSBQXaa6uybP38HHxbddf9Cvl8JzGEW", "label": "NC_000014.8:g.105246551C>T", "digest": "swSBQXaa6uybP38HHxbddf9Cvl8JzGEW", "type": "Allele", "location": {"id": "ga4gh:SL.q0g2bHXjBdLjnq8rFLJEU3GpNY9o7FeQ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.eK4D2MosgK_ivBkgi6FVPg5UXs1bYESm"}, "start": 104780213, "end": 104780214}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.u-DUjTNvYupRf-vStLK0YPNPV6jEYG1O", "label": "E17K", "digest": "u-DUjTNvYupRf-vStLK0YPNPV6jEYG1O", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000014.8:g.105246551C>T"}, {"syntax": "hgvs.c", "value": "NM_001014432.1:c.49G>A"}, {"syntax": "hgvs.p", "value": "NP_001014432.1:p.Glu17Lys"}, {"syntax": "hgvs.c", "value": "ENST00000407796.2:c.49G>A"}], "location": {"id": "ga4gh:SL._hc6YN89fA0LVGrpJMVLnhhbELQEYuMw", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.GTSPIWYvuDZU59cW1RECFEU1FMiKdEyc"}, "start": 16, "end": 17}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:112", "label": "Capivasertib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C102564"}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C102564"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["AZD5363"]}, "tumorType": {"id": "civic.did:22", "label": "Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9335"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1612"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:739", "description": "A case report of an 86-year old patient with metastasized Merkel cell carcinoma who achieved a complete clinical response under therapy with the PI3K-inhibitor Idelalisib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:487", "label": "Shiver et al., 2015, N. Engl. J. Med.", "type": "Document", "title": "PubMed: Shiver et al., 2015, N. Engl. J. Med.", "pmid": 26466009}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:290", "label": "PIK3CA P471L", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 7.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000263967.3", "chromosome": "3", "start": 178928226, "stop": 178928226, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "294"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602799"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376359"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS1057519872"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["PRO471LEU", "RS1057519872"], "members": [{"id": "ga4gh:VA.q6-UeKBFA7FGkT9Dd6d6FsTcyHSxKxdt", "label": "NC_000003.11:g.178928226C>T", "digest": "q6-UeKBFA7FGkT9Dd6d6FsTcyHSxKxdt", "type": "Allele", "location": {"id": "ga4gh:SL.l7ic6P6Ifu7tWz-t23R9JxkxhkPfeq7Q", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 179210437, "end": 179210438}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.uxE4nsBysHRje75BCftVkJfZH5EtLAHw", "label": "P471L", "digest": "uxE4nsBysHRje75BCftVkJfZH5EtLAHw", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000263967.3:c.1412C>T"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.178928226C>T"}, {"syntax": "hgvs.c", "value": "NM_006218.3:c.1412C>T"}, {"syntax": "hgvs.p", "value": "NP_006209.2:p.Pro471Leu"}], "location": {"id": "ga4gh:SL.UwzoquKkLLTaXQckuPeFJGkbsn2zOS6D", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 470, "end": 471}, "state": {"type": "LiteralSequenceExpression", "sequence": "L"}}}, "therapeutic": {"id": "civic.tid:120", "label": "Idelalisib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1544460"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:599", "type": "Disease", "label": "Follicular lymphoma", "mappings": [{"coding": {"system": "ncit", "code": "C3209"}, "relation": "relatedMatch"}]}, {"id": "hemonc:581", "type": "Disease", "label": "Chronic lymphocytic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3163"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C78825"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["5-Fluoro-3-phenyl-2-((S)-1-(9H-purin-6-ylamino)-propyl)-3H- Quinazolin-4-one", "CAL-101", "GS 1101", "GS-1101", "Phosphoinositide-3 Kinase Delta Inhibitor CAL-101", "Zydelig"]}, "tumorType": {"id": "civic.did:311", "label": "Merkel Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4068"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3965"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:745", "description": "In this case report, the D473H mutation was reported as an acquired mechanism of resistance to the hedgehog pathway inhibitor GDC-0449 (vismodegib).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:492", "label": "Yauch et al., 2009, Science", "type": "Document", "title": "PubMed: Yauch et al., 2009, Science", "pmid": 19726788}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5365", "label": "SMO", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:11119"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:6608"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CRJS", "FZD11", "Gx", "PHLS", "SMO", "SMOH"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:295", "label": "SMO D473H", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 13.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "C", "representative_transcript": "ENST00000249373.3", "chromosome": "7", "start": 128849189, "stop": 128849189, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "299"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602418"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "375938"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ASP473HIS"], "members": [{"id": "ga4gh:VA.ZVCK9HOdFlJ6l05ZamMYMa40CxbnW_68", "label": "NC_000007.13:g.128849189G>C", "digest": "ZVCK9HOdFlJ6l05ZamMYMa40CxbnW_68", "type": "Allele", "location": {"id": "ga4gh:SL.9oTXJyrlvxQPTIZcX1gLo-h1CCliO1La", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 129209347, "end": 129209348}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.bmjdTLZ7ZUlYK_if1ufZE9kODAOrc9bv", "label": "D473H", "digest": "bmjdTLZ7ZUlYK_if1ufZE9kODAOrc9bv", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_005631.4:c.1417G>A"}, {"syntax": "hgvs.p", "value": "NP_005622.1:p.Asp473His"}, {"syntax": "hgvs.c", "value": "ENST00000249373.3:c.1417G>A"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.128849189G>C"}], "location": {"id": "ga4gh:SL.RZjuMMfOUQOz28W5DoaOxGhNAgw91ydS", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.WZ7_owJHaml6kJ-2GfPtgYh1GA40K9tc"}, "start": 472, "end": 473}, "state": {"type": "LiteralSequenceExpression", "sequence": "H"}}}, "therapeutic": {"id": "civic.tid:190", "label": "Vismodegib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1242987"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:587", "type": "Disease", "label": "Cutaneous basal cell carcinoma"}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C74038"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide", "Erivedge", "GDC-0449", "Hedgehog Antagonist GDC-0449"]}, "tumorType": {"id": "civic.did:361", "label": "Medulloblastoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3222"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:0050902"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1048", "description": "In this phase II study (NCT00818441) of dacomitinib in HER2 amplified or mutant NSCLC tumors, three of 26 patients with HER2 p.P780_Y781insGSP or p.M774delinsWLV showed partial responses of duration between 3 and 14 months, while 13 patients with the more common HER2 p. A775_G776insYVMA showed no partial responses.  The authors conclude that in the set of activating HER2 mutations, benefits of an individual agent may be specific to certain mutations, and that \"HER2-positive lung cancers\" is not an adequate term to describe this group of distinguishable illnesses.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:729", "label": "Kris et al., 2015, Ann. Oncol.", "type": "Document", "title": "PubMed: Kris et al., 2015, Ann. Oncol.", "pmid": 25899785}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:20", "label": "ERBB2", "description": "ERBB2, commonly referred to as HER2, is amplified and/or overexpressed in 20-30% of invasive breast carcinomas. HER2-positive breast cancer is treated in a separate manner from other subtypes of breast cancer and commonly presents as more aggressive disease. Metastatic HER2-positive breast cancer is now commonly treated with HER2-targeted therapy. Apart from being amplified/overexpressed, ERBB2 activating mutations have been shown to have clinical importance in HER2-negative breast cancer. These mutations have shown sensitivity to the tyrosine kinase inhibitor neratinib, and highlight the importance of clinical sequencing efforts in treating breast cancer.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3430"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2064"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD340", "ERBB2", "HER-2", "HER-2/neu", "HER2", "MLN 19", "MLN-19", "NEU", "NGL", "TKR1", "VSCN2", "c-ERB-2", "c-ERB2", "p185(erbB2)"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:41", "label": "ERBB2 P780INS", "description": "ERBB2 P780 insertion was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 activating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 12.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "variant_bases": "GGCTCCCCA", "representative_transcript": "ENST00000269571.5", "chromosome": "17", "start": 37881011, "stop": 37881012, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "inframe_insertion", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001821"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "41"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA135401"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["PRO780INS"], "members": [{"id": "ga4gh:VA.Rm70dGCbAO_X7QjFjqL_xO-RSe4Pqc4D", "label": "NC_000017.10:g.37881011_37881012insGGCTCCCCA", "digest": "Rm70dGCbAO_X7QjFjqL_xO-RSe4Pqc4D", "type": "Allele", "location": {"id": "ga4gh:SL.a2qHNw71BGPT8WBkidMfSE5Jv8QgsBoj", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dLZ15tNO1Ur0IcGjwc3Sdi_0A6Yf4zm7"}, "start": 39724749, "end": 39724758}, "state": {"type": "ReferenceLengthExpression", "length": 18, "sequence": "GGCTCCCCAGGCTCCCCA", "repeatSubunitLength": 9}}], "definingContext": {"id": "ga4gh:VA.3_K2bUPsnVGTVB9lwXogZ0hyDBSYHbcr", "label": "P780INS", "digest": "3_K2bUPsnVGTVB9lwXogZ0hyDBSYHbcr", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000269571.5:c.2340_2341insGGCTCCCCA"}, {"syntax": "hgvs.g", "value": "NC_000017.10:g.37881011_37881012insGGCTCCCCA"}], "location": {"id": "ga4gh:SL.2pCi07aKnN42HAGWlaQ58MA1ofT6A0x6", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.AF1UFydIo02-bMplonKSfxlWY2q6ze3m"}, "start": 779, "end": 782}, "state": {"type": "LiteralSequenceExpression", "sequence": "INS"}}}, "therapeutic": {"id": "civic.tid:44", "label": "Dacomitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:2058848"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C53398"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(2E)-N-(4-((3-Chloro-4-Fluorophenyl)Amino)-7-Methoxyquinazolin-6-yl)-4-Piperidin-1-ylbut-2-Enamide", "EGFR Inhibitor PF-00299804", "PF-00299804", "PF-00299804-03", "PF-299804", "Vizimpro"]}, "tumorType": {"id": "civic.did:30", "label": "Lung Adenocarcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3512"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3910"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1271", "description": "In a Phase I trial (NCT00939770) of the drug crizotinib in pediatric patients, a subset of 11 neuroblastoma patients were characterized for mutations in ALK. Of these 11 patients, 4 had the F1174L mutation. Among these 4 patients, stable disease (SD) was observed in one, and progressive disease (PD) was observed in 3 others after administration of crizotinib. In contrast, in the remaining 7 patients with mutations different than F1174L, 4 had PD, 2 had SD and one had complete response as best response after initiation of crizotinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:859", "label": "Moss\u00e9 et al., 2013, Lancet Oncol.", "type": "Document", "title": "PubMed: Moss\u00e9 et al., 2013, Lancet Oncol.", "pmid": 23598171}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:1", "label": "ALK", "description": "ALK amplifications, fusions and mutations have been shown to be driving events in non-small cell lung cancer. While crizontinib has demonstrated efficacy in treating the amplification, mutations in ALK have been shown to confer resistance to current tyrosine kinase inhibitors. Second-generation TKI's have seen varied success in treating these resistant cases, and the HSP90 inhibitor 17-AAG has been shown to be cytostatic in ALK-altered cell lines.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:427"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:238"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["ALK", "ALK1", "CD246", "NBLST3"]}}, "direction": "refutes", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:8", "label": "ALK F1174L", "description": "ALK F1174L has been observed as recurrent in neuroblastoma, non-small cell lung cancer (NSCLC), and other cancer types. Neuroblastoma cells containing this mutation have shown resistance to low doses of criztonib. However, increased dosage can overcome this resistance in cell lines studies. TAE684 has also proven effective in both NSCLC and neuroblastoma F1174L containing cells.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 33.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "T", "representative_transcript": "ENST00000389048.3", "chromosome": "2", "start": 29443695, "stop": 29443695, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "8"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA279586"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "217851"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS863225281"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["PHE1174LEU", "RS863225281"], "members": [{"id": "ga4gh:VA.ivl5YUYPCfDa2igYKGlCTZec5eKC7oYY", "label": "NC_000002.11:g.29443695G>T", "digest": "ivl5YUYPCfDa2igYKGlCTZec5eKC7oYY", "type": "Allele", "location": {"id": "ga4gh:SL.Nn_joIP_IBbU0SOamVk3VuamNXOVBxPt", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.pnAqCRBrTsUoBghSD1yp_jXWSmlbdh4g"}, "start": 29220828, "end": 29220829}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.nTPnpFtWudqItR2YaGBsaJwRgGobSWAr", "label": "F1174L", "digest": "nTPnpFtWudqItR2YaGBsaJwRgGobSWAr", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004304.4:c.3522C>A"}, {"syntax": "hgvs.p", "value": "NP_004295.2:p.Phe1174Leu"}, {"syntax": "hgvs.g", "value": "NC_000002.11:g.29443695G>T"}, {"syntax": "hgvs.c", "value": "ENST00000389048.3:c.3522C>A"}], "location": {"id": "ga4gh:SL.n1vbI2DGWZjLWoNdaUdc1ISSHenlCMar", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.q9CnK-HKWh9eqhOi8FlzR7M0pCmUrWPs"}, "start": 1173, "end": 1174}, "state": {"type": "LiteralSequenceExpression", "sequence": "L"}}}, "therapeutic": {"id": "civic.tid:12", "label": "Crizotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1148495"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:25958", "type": "Disease", "label": "Anaplastic large cell lymphoma pediatric"}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C74061"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine", "2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-", "MET Tyrosine Kinase Inhibitor PF-02341066", "PF-02341066", "PF-2341066", "Xalkori"]}, "tumorType": {"id": "civic.did:13", "label": "Neuroblastoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3270"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:769"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1333", "description": "A participant in Children's Oncology Group (COG) study AVDL0912 with measurable neuroblastoma mutated at ALK F1245C was administered crizotinib at 100mg twice daily.  The patient showed progressive disease as best response after two 28-day cycles on crizotinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:859", "label": "Moss\u00e9 et al., 2013, Lancet Oncol.", "type": "Document", "title": "PubMed: Moss\u00e9 et al., 2013, Lancet Oncol.", "pmid": 23598171}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:1", "label": "ALK", "description": "ALK amplifications, fusions and mutations have been shown to be driving events in non-small cell lung cancer. While crizontinib has demonstrated efficacy in treating the amplification, mutations in ALK have been shown to confer resistance to current tyrosine kinase inhibitors. Second-generation TKI's have seen varied success in treating these resistant cases, and the HSP90 inhibitor 17-AAG has been shown to be cytostatic in ALK-altered cell lines.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:427"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:238"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["ALK", "ALK1", "CD246", "NBLST3"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:545", "label": "ALK F1245C", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 10.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "C", "representative_transcript": "ENST00000389048.3", "chromosome": "2", "start": 29436859, "stop": 29436859, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "549"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA279597"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "217856"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS863225283"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["PHE1245CYS", "RS863225283"], "members": [{"id": "ga4gh:VA.BPCPJboEVkn3wbp34En6MYWPWHdU1Lhl", "label": "NC_000002.11:g.29436859A>C", "digest": "BPCPJboEVkn3wbp34En6MYWPWHdU1Lhl", "type": "Allele", "location": {"id": "ga4gh:SL.4KybjY8kLxVLTSwIFNz4yL-DGyUbpHby", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.pnAqCRBrTsUoBghSD1yp_jXWSmlbdh4g"}, "start": 29213992, "end": 29213993}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.La7Bq3laHrg2hFa_24-oJyLcI-qe2bR9", "label": "F1245C", "digest": "La7Bq3laHrg2hFa_24-oJyLcI-qe2bR9", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004304.4:c.3734T>G"}, {"syntax": "hgvs.p", "value": "NP_004295.2:p.Phe1245Cys"}, {"syntax": "hgvs.g", "value": "NC_000002.11:g.29436859A>C"}, {"syntax": "hgvs.c", "value": "ENST00000389048.3:c.3734T>G"}], "location": {"id": "ga4gh:SL.PjeevFCGEbzNOcnHnO4yLte9_QUI2Ig2", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.q9CnK-HKWh9eqhOi8FlzR7M0pCmUrWPs"}, "start": 1244, "end": 1245}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "civic.tid:12", "label": "Crizotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1148495"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:25958", "type": "Disease", "label": "Anaplastic large cell lymphoma pediatric"}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C74061"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine", "2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-", "MET Tyrosine Kinase Inhibitor PF-02341066", "PF-02341066", "PF-2341066", "Xalkori"]}, "tumorType": {"id": "civic.did:13", "label": "Neuroblastoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3270"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:769"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1394", "description": "A patient with metastatic lung adenocarcinoma was found to harbor EGFR T790M and S768I mutations when acquired resistance developed after 8 years of erlotinib treatment. Analysis of original tumor samples from 2001 and 2003 were found to also harbor the S768I (but not T790M) mutation. Three-dimensional visualization showed the 768 position to be outside of the erlotinib binding position.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:944", "label": "Hellmann et al., 2014, J Thorac Oncol", "type": "Document", "title": "PubMed: Hellmann et al., 2014, J Thorac Oncol", "pmid": 25521405}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:558", "label": "EGFR S768I", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 20.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "T", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55249005, "stop": 55249005, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "562"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA135840"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "45251"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913465"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913465", "SER768ILE"], "members": [{"id": "ga4gh:VA.yr3duXsAtLA9Sd79rm8szW7ILvFJAYWv", "label": "NC_000007.13:g.55249005G>T", "digest": "yr3duXsAtLA9Sd79rm8szW7ILvFJAYWv", "type": "Allele", "location": {"id": "ga4gh:SL.U7UoPZ07_CwylemNLMyLgeGviwbHuvkG", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55181311, "end": 55181312}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.Rxpo23_FYjedhBXFh7SzZci98pLvAm-e", "label": "S768I", "digest": "Rxpo23_FYjedhBXFh7SzZci98pLvAm-e", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2303G>T"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55249005G>T"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2303G>T"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Ser768Ile"}], "location": {"id": "ga4gh:SL.KoPNmE5zRpg7iXpQ7t2eyFUQmxV-H_nU", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 767, "end": 768}, "state": {"type": "LiteralSequenceExpression", "sequence": "I"}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:30", "label": "Lung Adenocarcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3512"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3910"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1400", "description": "A 53 year old male presented with a scalp lesion which was incompletely excised. Metastases were seen in lymph node biopsy and subsequently in CT. BRAF inhibitor vemurafenib was then administered at 960 mg twice daily and later at 720 mg twice daily and reduction in metastases was observed. After 2 years complete radiological response was seen, while treatment was discontinued due to cardiomyopathy. 12 months after stopping vemurafenib patient did not show evidence of metastatic melanoma.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:948", "label": "Sahadudheen et al., 2016, Case Rep Oncol Med", "type": "Document", "title": "PubMed: Sahadudheen et al., 2016, Case Rep Oncol Med", "pmid": 26989536}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:559", "label": "BRAF V600K", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 107.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "AC", "variant_bases": "TT", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453136, "stop": 140453137, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "563"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602420"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "375941"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913227"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["VAL600LYS", "RS121913227"], "members": [{"id": "ga4gh:VA.0_wkzhprX1HDwZ86yT7RXkMDNQPco-Uv", "label": "NC_000007.13:g.140453136_140453137delinsTT", "digest": "0_wkzhprX1HDwZ86yT7RXkMDNQPco-Uv", "type": "Allele", "location": {"id": "ga4gh:SL.je4uwNtMCOBUHmd4rSK1ouAb1yszaQqi", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753335, "end": 140753337}, "state": {"type": "LiteralSequenceExpression", "sequence": "TT"}}], "definingContext": {"id": "ga4gh:VA.2E2_MppFwuFLm3OF88kEywJUYc6cVTHC", "label": "V600K", "digest": "2E2_MppFwuFLm3OF88kEywJUYc6cVTHC", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1798_1799delinsAA"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140453136_140453137delinsTT"}, {"syntax": "hgvs.c", "value": "NM_004333.4:c.1798_1799delGTinsAA"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Val600Lys"}], "location": {"id": "ga4gh:SL.ZA1XNKhCT_7m2UtmnYb8ZYOVS4eplMEK", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:7", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3224"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1909"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1460", "description": "Case report of a 69 year old patient with metastatic melanoma treated with MEK inhibitor TAK-733 in a clinical trial. A partial radiographic response with a decrease of 31% in the sum of maximum diameters of target metastatic lesions in the liver and spleen was noted after 2 cycles of therapy and remained progression free at more than 24 weeks. Follow-up sequencing analysis of DNA from the patient's tumor revealed a somatic BRAF L597S mutation.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:338", "label": "Dahlman et al., 2012, Cancer Discov", "type": "Document", "title": "PubMed: Dahlman et al., 2012, Cancer Discov", "pmid": 22798288}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:578", "label": "BRAF L597S", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 9.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "AG", "variant_bases": "GA", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453145, "stop": 140453146, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "582"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602421"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "375942"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["LEU597SER"], "members": [{"id": "ga4gh:VA.rUz4rYx_rneGPOX1aAGU5etxHoDlH6aK", "label": "NC_000007.13:g.140453145_140453146delinsGA", "digest": "rUz4rYx_rneGPOX1aAGU5etxHoDlH6aK", "type": "Allele", "location": {"id": "ga4gh:SL.hWyrwvXjSFOO0Owk9CD2XBwGm7jWPVSv", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753344, "end": 140753346}, "state": {"type": "LiteralSequenceExpression", "sequence": "GA"}}], "definingContext": {"id": "ga4gh:VA.8TO1l1AxfN9jTe03H0UD7xjnAyIZ-rsw", "label": "L597S", "digest": "8TO1l1AxfN9jTe03H0UD7xjnAyIZ-rsw", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000007.13:g.140453145_140453146delinsGA"}, {"syntax": "hgvs.c", "value": "NM_004333.4:c.1789_1790delCTinsTC"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Leu597Ser"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1789_1790delCTinsTC"}], "location": {"id": "ga4gh:SL.SfkS-rvyLn3M9HwlYokvq8Bm6IWEWHdt", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 596, "end": 597}, "state": {"type": "LiteralSequenceExpression", "sequence": "S"}}}, "therapeutic": {"id": "civic.tid:350", "label": "MEK Inhibitor TAK-733", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C84858"}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C84858"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["TAK-733"]}, "tumorType": {"id": "civic.did:206", "label": "Skin Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3510"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:8923"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1463", "description": "Case report of a phase 1 study in advanced melanoma patients. 97 patients with melanoma were enrolled and treated with trametinib. One patient with a BRAF Leu597Val had a confirmed partial response with 60% tumour reduction and received study treatment for more than 2 years.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:850", "label": "Falchook et al., 2012, Lancet Oncol.", "type": "Document", "title": "PubMed: Falchook et al., 2012, Lancet Oncol.", "pmid": 22805292}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:581", "label": "BRAF L597V", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 7.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "C", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453146, "stop": 140453146, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "585"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123651"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13969"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913369"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["LEU597VAL", "RS121913369"], "members": [{"id": "ga4gh:VA.dL5HxLMTP3nmYeKPHsxRBYZjLNIgHye3", "label": "NC_000007.13:g.140453146G>C", "digest": "dL5HxLMTP3nmYeKPHsxRBYZjLNIgHye3", "type": "Allele", "location": {"id": "ga4gh:SL.HO74NB0TEHLvCKQH1ai4VzFzTL_vprQ_", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753345, "end": 140753346}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.sf14aq4AIimHLDpyTbJZBsAyMqpmUPga", "label": "L597V", "digest": "sf14aq4AIimHLDpyTbJZBsAyMqpmUPga", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004333.4:c.1789C>G"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Leu597Val"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140453146G>C"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1789C>G"}], "location": {"id": "ga4gh:SL.SfkS-rvyLn3M9HwlYokvq8Bm6IWEWHdt", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 596, "end": 597}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "civic.tid:19", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1425098"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C77908"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["GSK1120212", "JTP-74057", "MEK Inhibitor GSK1120212", "Mekinist", "N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide"]}, "tumorType": {"id": "civic.did:206", "label": "Skin Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3510"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:8923"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1556", "description": "Three children with relapsed or refractory FLT3-ITD-positive AML were treated with sorafenib. FLT3 mutations were assessed before treatment and at the time of resistance. During the initiation of the treatment, all three patients had undetectable levels of FLT3 (D835H) mutations, however, after resistance developed, the mutation frequency rose to 33.1%, 35.7%, and 11.0% in the three patients. Ba/F3 cells expressing FLT3 mutants were resistant to sorafenib-dependent inhibition of cell viability", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1028", "label": "Baker et al., 2013, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Baker et al., 2013, Clin. Cancer Res.", "pmid": 23969938}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:24", "label": "FLT3", "description": "FLT3 is an important cytokine receptor involved in normal hematopoiesis. Mutations in this gene are common in acute myeloid leukemia (AML) and screening for mutations in this gene has been recommended by the World Health Organization in patients with AML, particularly in cases of cytogenetically normal AML (CN-AML). FLT3 mutations commonly co-occur with mutations such as NPM1 that are associated with CN-AML and likely modulate prognostic impact. While FLT3-ITD mutations have been associated with poorer prognosis in AML, the prognostic impact of FLT3-TKD mutations are still up for debate.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3765"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2322"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD135", "FLK-2", "FLK2", "FLT3", "STK1"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:608", "label": "FLT3 D835H", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 9.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "G", "representative_transcript": "ENST00000241453.7", "chromosome": "13", "start": 28592642, "stop": 28592642, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "612"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA280208"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16273"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913488"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ASP835HIS", "RS121913488"], "members": [{"id": "ga4gh:VA.wV0gjNrVs2cIsNLtqJZUSkKM4zqcSp7e", "label": "NC_000013.10:g.28592642C>G", "digest": "wV0gjNrVs2cIsNLtqJZUSkKM4zqcSp7e", "type": "Allele", "location": {"id": "ga4gh:SL.h349NKXyd2oh8TNpC8OtaAz9DTlScEHk", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ._0wi-qoDrvram155UmcSC-zA5ZK4fpLT"}, "start": 28018504, "end": 28018505}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.u64XI1wlyPeueS_XwPKmPT_-ihpbM0tY", "label": "D835H", "digest": "u64XI1wlyPeueS_XwPKmPT_-ihpbM0tY", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004119.2:c.2503G>C"}, {"syntax": "hgvs.p", "value": "NP_004110.2:p.Asp835His"}, {"syntax": "hgvs.c", "value": "ENST00000241453.7:c.2503G>C"}, {"syntax": "hgvs.g", "value": "NC_000013.10:g.28592642C>G"}], "location": {"id": "ga4gh:SL.JUgz5GWLTcSTPLIVCaYEGo7KsH5QpwgJ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.0dtDG7QKyvW7BntvQVpLS83mYRA58LKH"}, "start": 834, "end": 835}, "state": {"type": "LiteralSequenceExpression", "sequence": "H"}}}, "therapeutic": {"id": "civic.tid:6", "label": "Sorafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:495881"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:65823", "type": "Disease", "label": "Thyroid cancer differentiated"}, {"id": "hemonc:612", "type": "Disease", "label": "Hepatocellular carcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C3099"}, "relation": "relatedMatch"}]}, {"id": "hemonc:660", "type": "Disease", "label": "Renal cell carcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C9385"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C61948"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["BA4 43 9006", "BAY 43-9006", "Bay-439006"]}, "tumorType": {"id": "civic.did:3", "label": "Acute Myeloid Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3171"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9119"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1698", "description": "A 65-year-old man presented with stage II myeloma.  He was initially treated with chemotherapy and he received an autologous stem cell transplant. Sequencing of the recurrent tumor harbored BRAF V600E mutation and he was treated with vemurafenib.  After 7 weeks of treatment, the patient relapsed and died.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1147", "label": "Sharman et al., 2014, Clin Lymphoma Myeloma Leuk", "type": "Document", "title": "PubMed: Sharman et al., 2014, Clin Lymphoma Myeloma Leuk", "pmid": 24997557}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:12", "label": "BRAF V600E", "description": "BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 1353.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453136, "stop": 140453136, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "12"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123643"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13961"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376069"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS113488022", "V640E", "VAL640GLU", "VAL600GLU"], "members": [{"id": "ga4gh:VA.LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "label": "NC_000007.13:g.140453136A>T", "digest": "LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "type": "Allele", "location": {"id": "ga4gh:SL.XutGzMvqbzN-vnxmPt2MJf7ehxmB0opi", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753335, "end": 140753336}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "label": "V600E", "digest": "4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004333.4:c.1799T>A"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Val600Glu"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140453136A>T"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1799T>A"}], "location": {"id": "ga4gh:SL.ZA1XNKhCT_7m2UtmnYb8ZYOVS4eplMEK", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:41", "label": "Multiple Myeloma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3242"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9538"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1786", "description": "In a meta-analysis of 7 clinical trials evaluating the efficacy of erlotinib, one patient was described with the exon 19 mutation K757R from the MERIT study. Progression-free (250 days) and overall (435 days) survival suggested sensitivity in this patient. Literature analysis did not identify additional reports of patients harboring this mutation.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1244", "label": "Klughammer et al., 2016, J Thorac Oncol", "type": "Document", "title": "PubMed: Klughammer et al., 2016, J Thorac Oncol", "pmid": 26773740}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:704", "label": "EGFR K757R", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 7.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "G", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55242500, "stop": 55242500, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "723"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA4266023"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "560009"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS397517102"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS397517102", "LYS757ARG"], "members": [{"id": "ga4gh:VA.2wfmula210OV1Z-yD6y69oyiaxB7Yu7e", "label": "NC_000007.13:g.55242500A>G", "digest": "2wfmula210OV1Z-yD6y69oyiaxB7Yu7e", "type": "Allele", "location": {"id": "ga4gh:SL.6SfZjEyceFuWh1ZHUZKAeuHrqnM-m-XP", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55174806, "end": 55174807}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.wEi94EXPOq9BhQT-M4poT4Dj7ocKlnKx", "label": "K757R", "digest": "wEi94EXPOq9BhQT-M4poT4Dj7ocKlnKx", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2270A>G"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55242500A>G"}, {"syntax": "hgvs.c", "value": "NM_005228.3:c.2270A>G"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Lys757Arg"}, {"syntax": "hgvs.c", "value": "NM_005228.5:c.2270A>G"}, {"syntax": "hgvs.g", "value": "NC_000007.14:g.55174807A>G"}], "location": {"id": "ga4gh:SL.wkEYHtSjHh9RhH2oVxObVMnM5muKGjSD", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 756, "end": 757}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:30", "label": "Lung Adenocarcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3512"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3910"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1799", "description": "In this meta-analysis of 7 clinical trials evaluating the efficacy of erlotinib, 1 patient with V769_770insASV had overall and progression-free survival of 642 days. From this and literature review it was concluded that although EGFR exon 20 insertions may confer reduced sensitivity to erlotinib, patients with this particular mutation appeared to benefit from therapy.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1244", "label": "Klughammer et al., 2016, J Thorac Oncol", "type": "Document", "title": "PubMed: Klughammer et al., 2016, J Thorac Oncol", "pmid": 26773740}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:717", "label": "EGFR V769_D770insASV", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 7.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "variant_bases": "GCCAGCGTG", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55249009, "stop": 55249010, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "direct_tandem_duplication", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:1000039"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "736"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA180588"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "177678"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["VAL769_ASP770INSALASERVAL, V769_770INSASV"], "definingContext": {"id": "ga4gh:VA.AsbEsJdOsrzZo1MIu7Q0xJcnHsa4XEV9", "label": "V769_D770insASV", "digest": "AsbEsJdOsrzZo1MIu7Q0xJcnHsa4XEV9", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_005228.4:c.2300_2308dupCCAGCGTGG"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Val769_Asp770insAlaSerVal"}, {"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2300_2308dupCCAGCGTGG"}], "location": {"id": "ga4gh:SL.xdFHLf7Q45VKT57U4kwcDd7MUOtV2Bdz", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 766, "end": 769}, "state": {"type": "ReferenceLengthExpression", "length": 6, "sequence": "ASVASV", "repeatSubunitLength": 3}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:30", "label": "Lung Adenocarcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3512"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3910"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1889", "description": "A Phase II study for use of Afatinib in non- or light smokers with lung adenocarcinoma. Three patients with metastatic lung adenocarcinomas bearing mutations in the kinase domain of HER2 gene were identified (Y772_A775dup, G776L, and G778_P780dup). Objective response was observed in all three of these patients. The patient with G776L (Case 2 in the paper) achieved a partial response after two months of afatinib (50 mg/day). The time to progression of this single agent was four months. The patient was also noted to have a EGFR kinase domain (exon 21: p.Ala859Thr) mutation.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:661", "label": "De Gr\u00e8ve et al., 2012, Lung Cancer", "type": "Document", "title": "PubMed: De Gr\u00e8ve et al., 2012, Lung Cancer", "pmid": 22325357}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:20", "label": "ERBB2", "description": "ERBB2, commonly referred to as HER2, is amplified and/or overexpressed in 20-30% of invasive breast carcinomas. HER2-positive breast cancer is treated in a separate manner from other subtypes of breast cancer and commonly presents as more aggressive disease. Metastatic HER2-positive breast cancer is now commonly treated with HER2-targeted therapy. Apart from being amplified/overexpressed, ERBB2 activating mutations have been shown to have clinical importance in HER2-negative breast cancer. These mutations have shown sensitivity to the tyrosine kinase inhibitor neratinib, and highlight the importance of clinical sequencing efforts in treating breast cancer.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3430"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2064"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD340", "ERBB2", "HER-2", "HER-2/neu", "HER2", "MLN 19", "MLN-19", "NEU", "NGL", "TKR1", "VSCN2", "c-ERB-2", "c-ERB2", "p185(erbB2)"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:794", "label": "ERBB2 G776L", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 7.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "GG", "variant_bases": "CT", "representative_transcript": "ENST00000269571.5", "chromosome": "17", "start": 37880997, "stop": 37880998, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "816"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA913189238"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLY776LEU"], "members": [{"id": "ga4gh:VA.HPDytz9IO_NtINMCw7PR3W-kRLQrxX3I", "label": "NC_000017.10:g.37880997_37880998delinsCT", "digest": "HPDytz9IO_NtINMCw7PR3W-kRLQrxX3I", "type": "Allele", "location": {"id": "ga4gh:SL.l_SESzRvV9YZc77fT8MDGLuo3Lwwn1U1", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dLZ15tNO1Ur0IcGjwc3Sdi_0A6Yf4zm7"}, "start": 39724743, "end": 39724745}, "state": {"type": "LiteralSequenceExpression", "sequence": "CT"}}], "definingContext": {"id": "ga4gh:VA.mmTrkvxQIeIZmp-tmWNKDkWGmgKnpKjP", "label": "G776L", "digest": "mmTrkvxQIeIZmp-tmWNKDkWGmgKnpKjP", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000269571.5:c.2326_2327delinsCT"}, {"syntax": "hgvs.g", "value": "NC_000017.10:g.37880997_37880998delinsCT"}, {"syntax": "hgvs.p", "value": "NP_001276866.1:p.Gly776Leu"}, {"syntax": "hgvs.c", "value": "NM_001289937.1:c.2326_2327delinsCT"}], "location": {"id": "ga4gh:SL.tQGMp_RLZJAzG7vHXSlzAe3PdWin8z6Y", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.AF1UFydIo02-bMplonKSfxlWY2q6ze3m"}, "start": 775, "end": 776}, "state": {"type": "LiteralSequenceExpression", "sequence": "L"}}}, "therapeutic": {"id": "civic.tid:146", "label": "Afatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1430438"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:25316", "type": "Disease", "label": "Non-small cell lung cancer squamous"}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C66940"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide", "BIBW 2992", "BIBW2992"]}, "tumorType": {"id": "civic.did:30", "label": "Lung Adenocarcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3512"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3910"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1894", "description": "Phase 2 trial of ERBB-inhibitor dacomitinib in stage IIIB/IV lung cancers with HER2 mutations or amplification (N=30). One patient was found to harbor a unique Exon 20 indel (p. M774delinsWLV, c.2320A>TGGCT GG; p. M774delinsWLV, c.2320delins TGGCTGG) and was among the three patients that had a partial response.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:729", "label": "Kris et al., 2015, Ann. Oncol.", "type": "Document", "title": "PubMed: Kris et al., 2015, Ann. Oncol.", "pmid": 25899785}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:20", "label": "ERBB2", "description": "ERBB2, commonly referred to as HER2, is amplified and/or overexpressed in 20-30% of invasive breast carcinomas. HER2-positive breast cancer is treated in a separate manner from other subtypes of breast cancer and commonly presents as more aggressive disease. Metastatic HER2-positive breast cancer is now commonly treated with HER2-targeted therapy. Apart from being amplified/overexpressed, ERBB2 activating mutations have been shown to have clinical importance in HER2-negative breast cancer. These mutations have shown sensitivity to the tyrosine kinase inhibitor neratinib, and highlight the importance of clinical sequencing efforts in treating breast cancer.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3430"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2064"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD340", "ERBB2", "HER-2", "HER-2/neu", "HER2", "MLN 19", "MLN-19", "NEU", "NGL", "TKR1", "VSCN2", "c-ERB-2", "c-ERB2", "p185(erbB2)"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:796", "label": "ERBB2 M774DELINSWLV", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 7.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "TGGCTGG", "representative_transcript": "ENST00000269571.5", "chromosome": "17", "start": 37880991, "stop": 37880991, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "inframe_indel", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001820"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "818"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "unregistered"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.B8Fry1P9JTS2zrPx7U6xJB_vQp0RejVn", "label": "M774DELINSWLV", "digest": "B8Fry1P9JTS2zrPx7U6xJB_vQp0RejVn", "type": "Allele", "location": {"id": "ga4gh:SL.GzdelJdsLWSYzH8I90e60FvlTrwQATVY", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.AF1UFydIo02-bMplonKSfxlWY2q6ze3m"}, "start": 773, "end": 781}, "state": {"type": "LiteralSequenceExpression", "sequence": "DELINSWL"}}}, "therapeutic": {"id": "civic.tid:44", "label": "Dacomitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:2058848"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C53398"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(2E)-N-(4-((3-Chloro-4-Fluorophenyl)Amino)-7-Methoxyquinazolin-6-yl)-4-Piperidin-1-ylbut-2-Enamide", "EGFR Inhibitor PF-00299804", "PF-00299804", "PF-00299804-03", "PF-299804", "Vizimpro"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1898", "description": "A patient with metastatic colorectal cancer was enrolled in a phase 2 clinical trial (NCT01174121). 24 cultures of tumor-infiltrating lymphocytes were expanded from 3 lung metastasis resections. After cultures were tested for reactivity, the patient was infused with 1.48 x 10^11 tumor-infiltrating lymphocytes (75% CD8+ T cells) that were specifically reactive to KRAS G12D. All 7 metastatic lung lesions regressed 40 days after therapy, and the patient had a 9-month partial response.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1330", "label": "Tran et al., 2016, N. Engl. J. Med.", "type": "Document", "title": "PubMed: Tran et al., 2016, N. Engl. J. Med.", "pmid": 27959684}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:79", "label": "KRAS G12D", "description": "While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 162.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398284, "stop": 25398284, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "79"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA122538"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12582"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913529"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913529", "GLY12ASP"], "members": [{"id": "ga4gh:VA.qOYg4yYK-1Je25G30BkV3dWKtKDIAFEJ", "label": "NC_000012.11:g.25398284C>T", "digest": "qOYg4yYK-1Je25G30BkV3dWKtKDIAFEJ", "type": "Allele", "location": {"id": "ga4gh:SL.iF0OXeO-tnumYbGkzaFEQ7cOZI_UCI1s", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245349, "end": 25245350}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.CB571ja_KfZM_Hjn9zjjgV1an3tDWRcl", "label": "G12D", "digest": "CB571ja_KfZM_Hjn9zjjgV1an3tDWRcl", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004985.4:c.35G>A"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly12Asp"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398284C>T"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.35G>A"}], "location": {"id": "ga4gh:SL.OndkjmujtyUEZSjjCv0C-gpwnVbRgfj8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "D"}}}, "therapeutic": {"id": "civic.tid:685", "label": "Therapeutic Tumor Infiltrating Lymphocytes", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C28699"}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C28699"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["Tumor Infiltrating Lymphocyte Therapy", "Tumor Infiltrating Lymphocytes"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1999", "description": "One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored PIK3CA C420R and was wildtype for KRAS, BRAF and NRAS. This patient was was a 60 year old female treated with cetuximab monotherapy as 5th line therapy who experienced partial response and had PFS of 31 weeks and OS of 59 weeks.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:76", "label": "De Roock et al., 2010, Lancet Oncol.", "type": "Document", "title": "PubMed: De Roock et al., 2010, Lancet Oncol.", "pmid": 20619739}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "refutes", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:905", "label": "PIK3CA C420R", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 15.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "C", "representative_transcript": "ENST00000263967.3", "chromosome": "3", "start": 178927980, "stop": 178927980, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "931"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA180900"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "31945"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913272"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913272", "CYS420ARG"], "members": [{"id": "ga4gh:VA.FlWk9g7sLbC8jhlkETg-iAbLifrcCblI", "label": "NC_000003.11:g.178927980T>C", "digest": "FlWk9g7sLbC8jhlkETg-iAbLifrcCblI", "type": "Allele", "location": {"id": "ga4gh:SL.bS8dt3-rIEVr55ZRfkP8_zkpelSgcLlN", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 179210191, "end": 179210192}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.sW9clODd77-lRPaz7mtJ9uDSRsUl9X95", "label": "C420R", "digest": "sW9clODd77-lRPaz7mtJ9uDSRsUl9X95", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006218.3:c.1258T>C"}, {"syntax": "hgvs.p", "value": "NP_006209.2:p.Cys420Arg"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.178927980T>C"}, {"syntax": "hgvs.c", "value": "ENST00000263967.3:c.1258T>C"}], "location": {"id": "ga4gh:SL.8wBa2QJy6PBZLWfYP-48VOsHavtiOe3x", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 419, "end": 420}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:16", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:318341"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}, {"id": "mesh:D006258", "type": "Disease", "label": "Head and Neck Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C4013"}, "relation": "relatedMatch"}]}, {"id": "mesh:D002294", "type": "Disease", "label": "Carcinoma, Squamous Cell", "mappings": [{"coding": {"system": "ncit", "code": "C2929"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1723"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2178", "description": "Three patients participating in a large retrospective study of EGFR monoclonal antibodies in metastatic, treatment refractory colorectal cancer had tumors which harbored KRAS G13D, were wildtype for NRAS, BRAF and PIK3CA, and had individual response data. All three patients were males treated with panitumumab monotherapy. Their characteristics are as follows: 51 year old who experienced progressive disease (PFS: 8 weeks; OS: 24 weeks) and had three prior lines of chemotherapy; 54 year old who experienced progressive disease (PFS: 8 weeks; OS: 17 weeks) and had two prior lines of chemotherapy; 52 year old who experienced stable disease (PFS: 12 weeks; OS: 46 weeks) and had two prior lines of chemotherapy. Per the authors criteria, the clinical benefit rate is 1/3 and the response rate is 0/3.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:76", "label": "De Roock et al., 2010, Lancet Oncol.", "type": "Document", "title": "PubMed: De Roock et al., 2010, Lancet Oncol.", "pmid": 20619739}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:81", "label": "KRAS G13D", "description": "While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, results are conflicting with retrospective analyses suggesting a better response to EGFR-Inhibition. A recent prospective phase-II study (12 patients, Schirripa et. al. 2015) could not reproduce this finding and another prospective phase II trial is currently ongoing.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 108.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398281, "stop": 25398281, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "81"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA122534"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12580"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS112445441"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS112445441", "GLY13ASP"], "members": [{"id": "ga4gh:VA.wQro48c_oFxB35UNb2O1Z7Vj6rXnJywl", "label": "NC_000012.11:g.25398281C>T", "digest": "wQro48c_oFxB35UNb2O1Z7Vj6rXnJywl", "type": "Allele", "location": {"id": "ga4gh:SL.rZcsm5bnq3ptyk4298opou7vY9O0etcL", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245346, "end": 25245347}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.h-3tyZSdsQNs9NHrhuwcACnnMnpuT-8Z", "label": "G13D", "digest": "h-3tyZSdsQNs9NHrhuwcACnnMnpuT-8Z", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_033360.3:c.38G>A"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly13Asp"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398281C>T"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.38G>A"}], "location": {"id": "ga4gh:SL.U-3sSsoejW41eQ2Aev0wiG5tEuDiQZTB", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 12, "end": 13}, "state": {"type": "LiteralSequenceExpression", "sequence": "D"}}}, "therapeutic": {"id": "civic.tid:28", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:263034"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1857"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["ABX-EGF", "ABX-EGF Monoclonal Antibody", "ABX-EGF, Clone E7.6.3", "E7.6.3", "Human IgG2K Monoclonal Antibody", "MoAb ABX-EGF", "MoAb E7.6.3", "Monoclonal Antibody ABX-EGF", "Monoclonal Antibody E7.6.3", "Vectibix"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2193", "description": "One patient participating in a large retrospective study of EGFR monoclonal antibodies in metastatic, treatment refractory colorectal cancer had a tumor which harbored KRAS G12D, was wildtype for NRAS, BRAF and PIK3CA, and had individual response data. This patient was was a 55 year old female treated with panitumumab monotherapy as 3rd line therapy who experienced progressive disease (PFS: 8 weeks; OS: 9 weeks).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:76", "label": "De Roock et al., 2010, Lancet Oncol.", "type": "Document", "title": "PubMed: De Roock et al., 2010, Lancet Oncol.", "pmid": 20619739}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:79", "label": "KRAS G12D", "description": "While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 162.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398284, "stop": 25398284, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "79"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA122538"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12582"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913529"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913529", "GLY12ASP"], "members": [{"id": "ga4gh:VA.qOYg4yYK-1Je25G30BkV3dWKtKDIAFEJ", "label": "NC_000012.11:g.25398284C>T", "digest": "qOYg4yYK-1Je25G30BkV3dWKtKDIAFEJ", "type": "Allele", "location": {"id": "ga4gh:SL.iF0OXeO-tnumYbGkzaFEQ7cOZI_UCI1s", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245349, "end": 25245350}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.CB571ja_KfZM_Hjn9zjjgV1an3tDWRcl", "label": "G12D", "digest": "CB571ja_KfZM_Hjn9zjjgV1an3tDWRcl", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004985.4:c.35G>A"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly12Asp"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398284C>T"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.35G>A"}], "location": {"id": "ga4gh:SL.OndkjmujtyUEZSjjCv0C-gpwnVbRgfj8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "D"}}}, "therapeutic": {"id": "civic.tid:28", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:263034"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1857"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["ABX-EGF", "ABX-EGF Monoclonal Antibody", "ABX-EGF, Clone E7.6.3", "E7.6.3", "Human IgG2K Monoclonal Antibody", "MoAb ABX-EGF", "MoAb E7.6.3", "Monoclonal Antibody ABX-EGF", "Monoclonal Antibody E7.6.3", "Vectibix"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2217", "description": "This was a retrospective study of 691 cetuximab treated patients with metastatic, chemotherapy refractory colorectal cancer. Of those, 16 patients harbored PIK3CA E545K (exon 10), were wt for BRAF, NRAS and PIK3CA, and had individual response data. Five patients had partial response, six had stable disease, and five progressed, resulting in a response rate of 5/16 and a clinical benefit rate of 11/16 according to author criteria. Treatments included cetuximab + irinotecan (n=13), cetuximab monotherapy (n=1), cetuximab + bevacizumab (n=1), and cetuximab + oxaliplatin + 5FU (n=1). Median PFS was 24 weeks (2-60 weeks), median OS was 43 weeks (9-107 weeks), and median number of previous chemotherapy lines was 2 (1-5). Median age was 58 years old (43-79), and there were 10 males and 6 females. Using these and data from the larger cohort, authors concluded that PIK3CA exon 10 (listed as exon 9 in source) mutations are associated with weak or no resistance to cetuximab.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:76", "label": "De Roock et al., 2010, Lancet Oncol.", "type": "Document", "title": "PubMed: De Roock et al., 2010, Lancet Oncol.", "pmid": 20619739}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "refutes", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:104", "label": "PIK3CA E545K", "description": "PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 77.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000263967.3", "chromosome": "3", "start": 178936091, "stop": 178936091, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "104"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123334"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13655"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS104886003"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLU545LYS", "RS104886003"], "members": [{"id": "ga4gh:VA.uqD1zF6cMOYhBp8ur5oLTMqV0jxiC2a7", "label": "NC_000003.11:g.178936091G>A", "digest": "uqD1zF6cMOYhBp8ur5oLTMqV0jxiC2a7", "type": "Allele", "location": {"id": "ga4gh:SL.5l5tuxgJGb8y7CQzkKLPUvS-Cx4kr2ju", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 179218302, "end": 179218303}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.uw7DyLM7r98pn66LOXU3tAknmkV7jiJ0", "label": "E545K", "digest": "uw7DyLM7r98pn66LOXU3tAknmkV7jiJ0", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006218.3:c.1633G>A"}, {"syntax": "hgvs.p", "value": "NP_006209.2:p.Glu545Lys"}, {"syntax": "hgvs.c", "value": "ENST00000263967.3:c.1633G>A"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.178936091G>A"}], "location": {"id": "ga4gh:SL.SrEa0lPyesLrOX0M_aW51d-JdJhU-D3p", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 544, "end": 545}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:16", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:318341"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}, {"id": "mesh:D006258", "type": "Disease", "label": "Head and Neck Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C4013"}, "relation": "relatedMatch"}]}, {"id": "mesh:D002294", "type": "Disease", "label": "Carcinoma, Squamous Cell", "mappings": [{"coding": {"system": "ncit", "code": "C2929"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1723"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2513", "description": "EGFR exons 18-24 were analyzed in 7 patients who had shown a partial response to erlotinib in a phase II trial for bronchioloalveolar carcinoma (BAC, or in situ pulmonary adenocarcinoma). One patient (Patient E2) had the E746_A750del mutation. The patient was a male never smoker, and demonstrated response for 8.5 months. Overall survival was 21+ months as the patient was alive at study end.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1509", "label": "Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A.", "type": "Document", "title": "PubMed: Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A.", "pmid": 15329413}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:976", "label": "EGFR E746_A750del", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 19.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "GGAATTAAGAGAAGC", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55242465, "stop": 55242479, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "inframe_deletion", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001822"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1002"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA175996"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "163343"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913421"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913421", "E746_A750DELELREA"], "definingContext": {"id": "ga4gh:VA.Ey1-CesK8oo-eXa_cmB-4HfLUcltVDYL", "label": "E746_A750del", "digest": "Ey1-CesK8oo-eXa_cmB-4HfLUcltVDYL", "type": "Allele", "location": {"id": "ga4gh:SL.HiZy3E33xYU7hmo3ATl-_NSUCbexpZRq", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 745, "end": 750}, "state": {"type": "ReferenceLengthExpression", "length": 0, "sequence": "", "repeatSubunitLength": 5}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:1163", "label": "Bronchiolo-alveolar Adenocarcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2923"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:4926"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2886", "description": "FFPE tumor specimens from 295 melanoma patients were screened for KIT amplification and mutation. Of these, 51 patients had variants in KIT and 28 of these were treated with imatinib mesylate at 400 mg orally, twice daily with 25 patients eligible for response evaluation. None of the patients had mutations in BRAF, NRAS, or GNAQ. Two patients achieved a durable complete response, two achieved a durable partial response, and 5 achieved stable disease >12 weeks with a median survival of 46.3 weeks. One patient harboring a somatic D820Y mutation at roughly 50% variant allele frequency (1:1 with wild type) displayed Imatinib mesylate\u2013resistance and disease progression, which is consistent with resistant mechanisms described in Gastro-Intestinal Stromal Tumors.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1593", "label": "Carvajal et al., 2011, JAMA", "type": "Document", "title": "PubMed: Carvajal et al., 2011, JAMA", "pmid": 21642685}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:29", "label": "KIT", "description": "c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3815"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["C-Kit", "CD117", "KIT", "MASTC", "PBT", "SCFR"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:960", "label": "KIT D820Y", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 14.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "T", "representative_transcript": "ENST00000288135.5", "chromosome": "4", "start": 55599332, "stop": 55599332, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "986"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602408"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "375928"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS1057519710"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS1057519710", "ASP820TYR"], "members": [{"id": "ga4gh:VA.5r-C3LlZD9ZUxpzHonsY_73ObMcsnLfe", "label": "NC_000004.11:g.55599332G>T", "digest": "5r-C3LlZD9ZUxpzHonsY_73ObMcsnLfe", "type": "Allele", "location": {"id": "ga4gh:SL.U-4Q2T2UMOZypgIGPT5ywR4z_1iS_0S2", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54733165, "end": 54733166}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.eRIxjMxh82kLJLDQDT9QFEkAStdnxgEA", "label": "D820Y", "digest": "eRIxjMxh82kLJLDQDT9QFEkAStdnxgEA", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_000222.2:c.2458G>T"}, {"syntax": "hgvs.p", "value": "NP_000213.1:p.Asp820Tyr"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55599332G>T"}, {"syntax": "hgvs.c", "value": "ENST00000288135.5:c.2458G>T"}], "location": {"id": "ga4gh:SL.IP0kMJA-uoNQiQegymLJcTzqq32pKPm2", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 819, "end": 820}, "state": {"type": "LiteralSequenceExpression", "sequence": "Y"}}}, "therapeutic": {"id": "civic.tid:5", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:282388"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "Disease", "label": "Systemic mastocytosis", "mappings": [{"coding": {"system": "ncit", "code": "C9235"}, "relation": "relatedMatch"}]}, {"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}, {"id": "hemonc:634", "type": "Disease", "label": "Myelodysplastic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C3247"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:33893", "type": "Disease", "label": "Chronic myelogenous leukemia pediatric"}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}, {"id": "hemonc:616", "type": "Disease", "label": "Hypereosinophilic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C27038"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C62035"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"]}, "tumorType": {"id": "civic.did:7", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3224"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1909"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2918", "description": "147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors were analyzed to identify molecular correlates of imatinib resistance. N822K was observed as a secondary KIT mutation in two patients with secondary imatinib resistance and one patient with primary resistance, and also as a primary mutation in a patient with primary resistance. The mutation was shown to occur at a hotspot (N822) of previously reported secondary KIT mutations in imatinib resistant GISTs. When co-expressed with V560D (imatinib sensitive) in vitro N822K showed moderate imatinib resistance.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:62", "label": "Heinrich et al., 2006, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Heinrich et al., 2006, J. Clin. Oncol.", "pmid": 16954519}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:29", "label": "KIT", "description": "c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3815"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["C-Kit", "CD117", "KIT", "MASTC", "PBT", "SCFR"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:1237", "label": "KIT N822K", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 29.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "A", "representative_transcript": "ENST00000288135.5", "chromosome": "4", "start": 55599340, "stop": 55599340, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1263"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602411"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "375931"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913514"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ASN822LYS", "RS121913514"], "members": [{"id": "ga4gh:VA.3i1HI4wqippKn-gtuyM4kiLBVQD0N763", "label": "NC_000004.11:g.55599340T>A", "digest": "3i1HI4wqippKn-gtuyM4kiLBVQD0N763", "type": "Allele", "location": {"id": "ga4gh:SL.hQJlf-hzQ4szaLAhFocudRE99wMKEJfi", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54733173, "end": 54733174}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.z_WJsSByobbgzhHAaWw4kVBhNnyADN57", "label": "N822K", "digest": "z_WJsSByobbgzhHAaWw4kVBhNnyADN57", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_000222.2:c.2466T>A"}, {"syntax": "hgvs.p", "value": "NP_000213.1:p.Asn822Lys"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55599340T>A"}, {"syntax": "hgvs.c", "value": "ENST00000288135.5:c.2466T>A"}], "location": {"id": "ga4gh:SL.B6627_40nR9hpf23ICFLQ0TZsfFxpBNq", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 821, "end": 822}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:5", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:282388"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "Disease", "label": "Systemic mastocytosis", "mappings": [{"coding": {"system": "ncit", "code": "C9235"}, "relation": "relatedMatch"}]}, {"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}, {"id": "hemonc:634", "type": "Disease", "label": "Myelodysplastic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C3247"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:33893", "type": "Disease", "label": "Chronic myelogenous leukemia pediatric"}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}, {"id": "hemonc:616", "type": "Disease", "label": "Hypereosinophilic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C27038"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C62035"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"]}, "tumorType": {"id": "civic.did:2", "label": "Gastrointestinal Stromal Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3868"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9253"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2919", "description": "147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors were analyzed to identify molecular correlates of imatinib resistance. Y823D was observed as a secondary KIT mutation in five patients with secondary imatinib resistance. The mutation was shown to occur at a hotspot (Y823) of previously reported secondary KIT mutations in imatinib resistant GISTs. When co-expressed with V560D (imatinib sensitive) in vitro Y823D showed \"extreme\" imatinib resistance.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:62", "label": "Heinrich et al., 2006, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Heinrich et al., 2006, J. Clin. Oncol.", "pmid": 16954519}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:29", "label": "KIT", "description": "c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3815"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["C-Kit", "CD117", "KIT", "MASTC", "PBT", "SCFR"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:963", "label": "KIT Y823D", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 7.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "G", "representative_transcript": "ENST00000288135.5", "chromosome": "4", "start": 55599341, "stop": 55599341, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "989"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602561"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376101"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS1057519761"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["TYR823ASP", "RS1057519761"], "members": [{"id": "ga4gh:VA.ZUhD1lZy890tSa7X92v3GS97PYZAT0-1", "label": "NC_000004.11:g.55599341T>G", "digest": "ZUhD1lZy890tSa7X92v3GS97PYZAT0-1", "type": "Allele", "location": {"id": "ga4gh:SL.RgBCEvePdd7fyzyVtOPkV1_YpKC7Gl2H", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54733174, "end": 54733175}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.V8wakshv5-TNpqJhl_hEpODVHJqyFr7O", "label": "Y823D", "digest": "V8wakshv5-TNpqJhl_hEpODVHJqyFr7O", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_000222.2:c.2467T>G"}, {"syntax": "hgvs.p", "value": "NP_000213.1:p.Tyr823Asp"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55599341T>G"}, {"syntax": "hgvs.c", "value": "ENST00000288135.5:c.2467T>G"}], "location": {"id": "ga4gh:SL.GR_qpaSZ4tDH1XMXj5pKqYNFVQCVbFLB", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 822, "end": 823}, "state": {"type": "LiteralSequenceExpression", "sequence": "D"}}}, "therapeutic": {"id": "civic.tid:5", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:282388"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "Disease", "label": "Systemic mastocytosis", "mappings": [{"coding": {"system": "ncit", "code": "C9235"}, "relation": "relatedMatch"}]}, {"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}, {"id": "hemonc:634", "type": "Disease", "label": "Myelodysplastic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C3247"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:33893", "type": "Disease", "label": "Chronic myelogenous leukemia pediatric"}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}, {"id": "hemonc:616", "type": "Disease", "label": "Hypereosinophilic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C27038"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C62035"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"]}, "tumorType": {"id": "civic.did:2", "label": "Gastrointestinal Stromal Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3868"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9253"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2920", "description": "147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors were analyzed to identify molecular correlates of imatinib resistance. C809G was observed as a secondary KIT mutation in one patient with secondary imatinib resistance. In vitro, C809G showed imatinib resistance both in isolation and when coexpressed with K642E + N822H (the primary KIT mutations, found on the same allele, for this patient).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:62", "label": "Heinrich et al., 2006, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Heinrich et al., 2006, J. Clin. Oncol.", "pmid": 16954519}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:29", "label": "KIT", "description": "c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3815"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["C-Kit", "CD117", "KIT", "MASTC", "PBT", "SCFR"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:1238", "label": "KIT C809G", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 7.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "G", "representative_transcript": "ENST00000288135.5", "chromosome": "4", "start": 55599299, "stop": 55599299, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1264"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA356911727"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["CYS809GLY"], "members": [{"id": "ga4gh:VA.L9HeJ2WRLdzUZd_7FN6vajelX5srWWb9", "label": "NC_000004.11:g.55599299T>G", "digest": "L9HeJ2WRLdzUZd_7FN6vajelX5srWWb9", "type": "Allele", "location": {"id": "ga4gh:SL.TVAhVenEkgyEIkJP8baGDeBh6MU6BOIR", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54733132, "end": 54733133}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.Tv7v_BPvI2TQYKnZohytxE6D_6RWWWhi", "label": "C809G", "digest": "Tv7v_BPvI2TQYKnZohytxE6D_6RWWWhi", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000288135.5:c.2425T>G"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55599299T>G"}, {"syntax": "hgvs.c", "value": "NM_000222.2:c.2425T>G"}, {"syntax": "hgvs.p", "value": "NP_000213.1:p.Cys809Gly"}], "location": {"id": "ga4gh:SL.EoT969X_e7GfV0FyeuChRTYU79Yeo-TW", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 808, "end": 809}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}}, "therapeutic": {"id": "civic.tid:5", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:282388"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "Disease", "label": "Systemic mastocytosis", "mappings": [{"coding": {"system": "ncit", "code": "C9235"}, "relation": "relatedMatch"}]}, {"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}, {"id": "hemonc:634", "type": "Disease", "label": "Myelodysplastic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C3247"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:33893", "type": "Disease", "label": "Chronic myelogenous leukemia pediatric"}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}, {"id": "hemonc:616", "type": "Disease", "label": "Hypereosinophilic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C27038"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C62035"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"]}, "tumorType": {"id": "civic.did:2", "label": "Gastrointestinal Stromal Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3868"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9253"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2921", "description": "147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors were analyzed to identify molecular correlates of imatinib resistance. D820A was observed as a secondary KIT mutation in one patient with secondary imatinib resistance. The mutation was shown to occur at a hotspot (D820) of previously reported secondary KIT mutations in imatinib resistant GISTs. A cell line derived from a separate patient with the same primary (V560D) and secondary (D820A) mutations showed moderately increased resistance to imatinib compared to reports for GIST lines with primary exon 11 KIT mutations alone.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:62", "label": "Heinrich et al., 2006, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Heinrich et al., 2006, J. Clin. Oncol.", "pmid": 16954519}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:29", "label": "KIT", "description": "c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3815"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["C-Kit", "CD117", "KIT", "MASTC", "PBT", "SCFR"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:1239", "label": "KIT D820A", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 7.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "C", "representative_transcript": "ENST00000288135.5", "chromosome": "4", "start": 55599333, "stop": 55599333, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1265"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA356911952"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ASP820ALA"], "members": [{"id": "ga4gh:VA.u8O0LC07v1S3Lq1TsRNBQV8vFuDJVWuj", "label": "NC_000004.11:g.55599333A>C", "digest": "u8O0LC07v1S3Lq1TsRNBQV8vFuDJVWuj", "type": "Allele", "location": {"id": "ga4gh:SL.X5vfC1ObfeFcLPzLuFrgcBfmgDvQWzDD", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54733166, "end": 54733167}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.mFLVhfgHPtAPBuSYTVOUzFEbLJ8i-pY4", "label": "D820A", "digest": "mFLVhfgHPtAPBuSYTVOUzFEbLJ8i-pY4", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000288135.5:c.2459A>C"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55599333A>C"}, {"syntax": "hgvs.c", "value": "NM_000222.2:c.2459A>C"}, {"syntax": "hgvs.p", "value": "NP_000213.1:p.Asp820Ala"}], "location": {"id": "ga4gh:SL.IP0kMJA-uoNQiQegymLJcTzqq32pKPm2", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 819, "end": 820}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}}, "therapeutic": {"id": "civic.tid:5", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:282388"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "Disease", "label": "Systemic mastocytosis", "mappings": [{"coding": {"system": "ncit", "code": "C9235"}, "relation": "relatedMatch"}]}, {"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}, {"id": "hemonc:634", "type": "Disease", "label": "Myelodysplastic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C3247"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:33893", "type": "Disease", "label": "Chronic myelogenous leukemia pediatric"}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}, {"id": "hemonc:616", "type": "Disease", "label": "Hypereosinophilic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C27038"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C62035"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"]}, "tumorType": {"id": "civic.did:2", "label": "Gastrointestinal Stromal Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3868"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9253"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2922", "description": "147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors were analyzed to identify molecular correlates of imatinib resistance. D820G was observed as a secondary KIT mutation in two patients with secondary imatinib resistance. The mutation was shown to occur at a hotspot (D820) of previously reported secondary KIT mutations in imatinib resistant GISTs. When co-expressed with V560D (imatinib sensitive) in vitro D820G showed \"extreme\" imatinib resistance.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:62", "label": "Heinrich et al., 2006, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Heinrich et al., 2006, J. Clin. Oncol.", "pmid": 16954519}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:29", "label": "KIT", "description": "c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3815"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["C-Kit", "CD117", "KIT", "MASTC", "PBT", "SCFR"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:1240", "label": "KIT D820G", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 7.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "G", "representative_transcript": "ENST00000288135.5", "chromosome": "4", "start": 55599333, "stop": 55599333, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1266"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123516"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13853"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913682"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913682", "ASP820GLY"], "members": [{"id": "ga4gh:VA.vYd5YGENoBuUWSoXOvNZtH6TIs_oP-TN", "label": "NC_000004.11:g.55599333A>G", "digest": "vYd5YGENoBuUWSoXOvNZtH6TIs_oP-TN", "type": "Allele", "location": {"id": "ga4gh:SL.X5vfC1ObfeFcLPzLuFrgcBfmgDvQWzDD", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54733166, "end": 54733167}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.AUeYCAmLsFHvJIp_x6G37bXpIww1A-9X", "label": "D820G", "digest": "AUeYCAmLsFHvJIp_x6G37bXpIww1A-9X", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_000222.2:c.2459A>G"}, {"syntax": "hgvs.p", "value": "NP_000213.1:p.Asp820Gly"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55599333A>G"}, {"syntax": "hgvs.c", "value": "ENST00000288135.5:c.2459A>G"}], "location": {"id": "ga4gh:SL.IP0kMJA-uoNQiQegymLJcTzqq32pKPm2", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 819, "end": 820}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}}, "therapeutic": {"id": "civic.tid:5", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:282388"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "Disease", "label": "Systemic mastocytosis", "mappings": [{"coding": {"system": "ncit", "code": "C9235"}, "relation": "relatedMatch"}]}, {"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}, {"id": "hemonc:634", "type": "Disease", "label": "Myelodysplastic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C3247"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:33893", "type": "Disease", "label": "Chronic myelogenous leukemia pediatric"}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}, {"id": "hemonc:616", "type": "Disease", "label": "Hypereosinophilic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C27038"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C62035"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"]}, "tumorType": {"id": "civic.did:2", "label": "Gastrointestinal Stromal Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3868"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9253"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2923", "description": "147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors were analyzed to identify molecular correlates of imatinib resistance. D816H was observed as a secondary KIT mutation in two patients with secondary imatinib resistance. The mutation was shown to occur at a hotspot (D816) of previously reported secondary KIT mutations in imatinib resistant GISTs. When co-expressed with V560D (imatinib sensitive) in vitro D816H showed \"extreme\" imatinib resistance. It was also highly resistant in isolation.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:62", "label": "Heinrich et al., 2006, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Heinrich et al., 2006, J. Clin. Oncol.", "pmid": 16954519}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:29", "label": "KIT", "description": "c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3815"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["C-Kit", "CD117", "KIT", "MASTC", "PBT", "SCFR"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:957", "label": "KIT D816H", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 7.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "C", "representative_transcript": "ENST00000288135.5", "chromosome": "4", "start": 55599320, "stop": 55599320, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "983"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123540"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13863"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913506"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913506", "ASP816HIS"], "members": [{"id": "ga4gh:VA.mqXxH2ah2F3LZAlTanVXvirHi23xzLfj", "label": "NC_000004.11:g.55599320G>C", "digest": "mqXxH2ah2F3LZAlTanVXvirHi23xzLfj", "type": "Allele", "location": {"id": "ga4gh:SL.2wzwaz5SoffZrn-8KSc-Dl_dCBNoxtzy", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54733153, "end": 54733154}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.D1eLtjcFQ0eDwFioywcx3Zjp1Fz6OYJ4", "label": "D816H", "digest": "D1eLtjcFQ0eDwFioywcx3Zjp1Fz6OYJ4", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_000222.2:c.2446G>C"}, {"syntax": "hgvs.p", "value": "NP_000213.1:p.Asp816His"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55599320G>C"}, {"syntax": "hgvs.c", "value": "ENST00000288135.5:c.2446G>C"}], "location": {"id": "ga4gh:SL.EFk3ET7Ws47inqLJnNWEsA-GhUEwihbN", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 815, "end": 816}, "state": {"type": "LiteralSequenceExpression", "sequence": "H"}}}, "therapeutic": {"id": "civic.tid:5", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:282388"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "Disease", "label": "Systemic mastocytosis", "mappings": [{"coding": {"system": "ncit", "code": "C9235"}, "relation": "relatedMatch"}]}, {"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}, {"id": "hemonc:634", "type": "Disease", "label": "Myelodysplastic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C3247"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:33893", "type": "Disease", "label": "Chronic myelogenous leukemia pediatric"}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}, {"id": "hemonc:616", "type": "Disease", "label": "Hypereosinophilic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C27038"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C62035"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"]}, "tumorType": {"id": "civic.did:2", "label": "Gastrointestinal Stromal Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3868"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9253"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2924", "description": "147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors were analyzed to identify molecular correlates of imatinib resistance. T670I was observed as a secondary KIT mutation in one patient with secondary imatinib resistance. The mutation was shown to occur at a hotspot (T670) of previously reported secondary KIT mutations in imatinib resistant GISTs. When co-expressed with V560D (imatinib sensitive) in vitro T670I showed \"extreme\" imatinib resistance. It also showed resistance in isolation.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:62", "label": "Heinrich et al., 2006, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Heinrich et al., 2006, J. Clin. Oncol.", "pmid": 16954519}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:29", "label": "KIT", "description": "c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3815"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["C-Kit", "CD117", "KIT", "MASTC", "PBT", "SCFR"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:1241", "label": "KIT T670I", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 21.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000288135.5", "chromosome": "4", "start": 55595519, "stop": 55595519, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1267"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602525"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376058"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913516"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["THR670ILE", "RS121913516"], "members": [{"id": "ga4gh:VA.dTZgbPkwISVGYwXmm_4WCyPX9W-LSOOh", "label": "NC_000004.11:g.55595519C>T", "digest": "dTZgbPkwISVGYwXmm_4WCyPX9W-LSOOh", "type": "Allele", "location": {"id": "ga4gh:SL.reFRinn6ZsNtpwqaKz6HHHpO34YKczpW", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54729352, "end": 54729353}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.f55Nm2_RKZg7Hnpo-JVhQVAliadbUqMJ", "label": "T670I", "digest": "f55Nm2_RKZg7Hnpo-JVhQVAliadbUqMJ", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_000222.2:c.2009C>T"}, {"syntax": "hgvs.p", "value": "NP_000213.1:p.Thr670Ile"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55595519C>T"}, {"syntax": "hgvs.c", "value": "ENST00000288135.5:c.2009C>T"}], "location": {"id": "ga4gh:SL.jq2-jclk1pqHSIl0gTtHsMPBMD7VcMmN", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 669, "end": 670}, "state": {"type": "LiteralSequenceExpression", "sequence": "I"}}}, "therapeutic": {"id": "civic.tid:5", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:282388"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "Disease", "label": "Systemic mastocytosis", "mappings": [{"coding": {"system": "ncit", "code": "C9235"}, "relation": "relatedMatch"}]}, {"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}, {"id": "hemonc:634", "type": "Disease", "label": "Myelodysplastic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C3247"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:33893", "type": "Disease", "label": "Chronic myelogenous leukemia pediatric"}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}, {"id": "hemonc:616", "type": "Disease", "label": "Hypereosinophilic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C27038"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C62035"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"]}, "tumorType": {"id": "civic.did:2", "label": "Gastrointestinal Stromal Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3868"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9253"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2987", "description": "Clinical trial of entrectinib in patients with ALK/ROS/TRK altered tumors. One patient with an ALK F1245V-mutant neuroblastoma achieved a durable, confirmed partial response (PR) lasting 8.3 months. The patient remained on study treatment for more than 3.5 years because of clinical benefit.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1689", "label": "Drilon et al., 2017, Cancer Discov", "type": "Document", "title": "PubMed: Drilon et al., 2017, Cancer Discov", "pmid": 28183697}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:1", "label": "ALK", "description": "ALK amplifications, fusions and mutations have been shown to be driving events in non-small cell lung cancer. While crizontinib has demonstrated efficacy in treating the amplification, mutations in ALK have been shown to confer resistance to current tyrosine kinase inhibitors. Second-generation TKI's have seen varied success in treating these resistant cases, and the HSP90 inhibitor 17-AAG has been shown to be cytostatic in ALK-altered cell lines.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:427"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:238"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["ALK", "ALK1", "CD246", "NBLST3"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:1269", "label": "ALK F1245V", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 7.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "C", "representative_transcript": "ENST00000389048.3", "chromosome": "2", "start": 29436860, "stop": 29436860, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1295"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA345003"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "65671"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS281864720"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS281864720", "PHE1245VAL"], "members": [{"id": "ga4gh:VA.WW9f23zQlaiC67uTwGcNe54oRYBV4uZl", "label": "NC_000002.11:g.29436860A>C", "digest": "WW9f23zQlaiC67uTwGcNe54oRYBV4uZl", "type": "Allele", "location": {"id": "ga4gh:SL.p3z8O5slseS4K5Gr8Uv1Io4dNk3g8NLM", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.pnAqCRBrTsUoBghSD1yp_jXWSmlbdh4g"}, "start": 29213993, "end": 29213994}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.w-yxe38AIWqpE7i5_Z0q0CCapZ8IXQ9W", "label": "F1245V", "digest": "w-yxe38AIWqpE7i5_Z0q0CCapZ8IXQ9W", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004304.4:c.3733T>G"}, {"syntax": "hgvs.p", "value": "NP_004295.2:p.Phe1245Val"}, {"syntax": "hgvs.g", "value": "NC_000002.11:g.29436860A>C"}, {"syntax": "hgvs.c", "value": "ENST00000389048.3:c.3733T>G"}], "location": {"id": "ga4gh:SL.PjeevFCGEbzNOcnHnO4yLte9_QUI2Ig2", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.q9CnK-HKWh9eqhOi8FlzR7M0pCmUrWPs"}, "start": 1244, "end": 1245}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "civic.tid:426", "label": "Entrectinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:2197862"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C114984"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["N-(5-(3,5-Difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide", "RXDX 101", "RXDX-101", "RXDX101", "Rozlytrek"]}, "tumorType": {"id": "civic.did:13", "label": "Neuroblastoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3270"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:769"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:3028", "description": "A patient with an uncontrolled relapse of c-kit-positive mesenchymal tumor in descending part of the duodenum had received 400mg Imatinib daily for more than 10 years at the time of publication. He responded well to therapy (Karnofsky index 90%). KIT V559D (Exon 11) was identified in the diagnostic biopsy and indicated as a positive predictor of imatinib response with long term usage.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1734", "label": "Cameron et al., 2011, Case Rep Oncol", "type": "Document", "title": "PubMed: Cameron et al., 2011, Case Rep Oncol", "pmid": 22114577}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:29", "label": "KIT", "description": "c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3815"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["C-Kit", "CD117", "KIT", "MASTC", "PBT", "SCFR"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:942", "label": "KIT V559D", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 11.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "A", "representative_transcript": "ENST00000288135.5", "chromosome": "4", "start": 55593610, "stop": 55593610, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "968"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123522"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13856"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913517"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913517", "VAL559ASP"], "members": [{"id": "ga4gh:VA.UDvVDM1zzwMqLhvDq2SS8X9Po77Q72cY", "label": "NC_000004.11:g.55593610T>A", "digest": "UDvVDM1zzwMqLhvDq2SS8X9Po77Q72cY", "type": "Allele", "location": {"id": "ga4gh:SL.Hv0pou2DVMK5PL7qj6ILdFnCjvevrPgx", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54727443, "end": 54727444}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.rCrXvqjAiKVUyQaGUAjJ98sQooXpRwxC", "label": "V559D", "digest": "rCrXvqjAiKVUyQaGUAjJ98sQooXpRwxC", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_000222.2:c.1676T>A"}, {"syntax": "hgvs.p", "value": "NP_000213.1:p.Val559Asp"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55593610T>A"}, {"syntax": "hgvs.c", "value": "ENST00000288135.5:c.1676T>A"}], "location": {"id": "ga4gh:SL.x7Hcqa-bjYl3poWQxSaNrgoq0t-TIzug", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 558, "end": 559}, "state": {"type": "LiteralSequenceExpression", "sequence": "D"}}}, "therapeutic": {"id": "civic.tid:5", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:282388"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "Disease", "label": "Systemic mastocytosis", "mappings": [{"coding": {"system": "ncit", "code": "C9235"}, "relation": "relatedMatch"}]}, {"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}, {"id": "hemonc:634", "type": "Disease", "label": "Myelodysplastic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C3247"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:33893", "type": "Disease", "label": "Chronic myelogenous leukemia pediatric"}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}, {"id": "hemonc:616", "type": "Disease", "label": "Hypereosinophilic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C27038"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C62035"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"]}, "tumorType": {"id": "civic.did:2", "label": "Gastrointestinal Stromal Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3868"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9253"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:3777", "description": "In a case report, a 28 month old patient with a cervicomedullary low grade glioma compatible with pilocytic astrocytoma which was resected had a second lesion consistent with a ganglioglioma 3 years later. This mass progressed under treatment at which point PCR amplification of BRAF exon 15 and subsequent Sanger sequencing the initial biopsy revealed the tumor harbored a BRAF V600E mutation. Based on these results, vemurafenib monotherapy was started and radiological and clinical response was noted after 3 months of treatment, which was sustained after 6 months of therapy. Prior to vemurafenib treatment, the patient had undergone tracheotomy, was treated with standard chemotherapy and underwent another surgery, but had developed progressive disease.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1974", "label": "del Bufalo et al., 2014, J Transl Med", "type": "Document", "title": "PubMed: del Bufalo et al., 2014, J Transl Med", "pmid": 25524464}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:12", "label": "BRAF V600E", "description": "BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 1353.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453136, "stop": 140453136, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "12"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123643"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13961"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376069"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS113488022", "V640E", "VAL640GLU", "VAL600GLU"], "members": [{"id": "ga4gh:VA.LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "label": "NC_000007.13:g.140453136A>T", "digest": "LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "type": "Allele", "location": {"id": "ga4gh:SL.XutGzMvqbzN-vnxmPt2MJf7ehxmB0opi", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753335, "end": 140753336}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "label": "V600E", "digest": "4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004333.4:c.1799T>A"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Val600Glu"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140453136A>T"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1799T>A"}], "location": {"id": "ga4gh:SL.ZA1XNKhCT_7m2UtmnYb8ZYOVS4eplMEK", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:1673", "label": "Childhood Pilocytic Astrocytoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4048"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:6812"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:3787", "description": "A stage 4B, low-grade papillary serous ovarian adenocarcinoma patient, harboring a BRAF V600E mutation was associated with response to vemurafenib monotherapy. The patient was treated with standard chemotherapy, hormone therapy and bevacizumab prior to the identification of the BRAF V600E mutation; next, the patient was treated with paclitaxel and an anti-HER3 antibody and finally with vemurafenib, obtaining a partial response of greater than 1 year.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1984", "label": "Combe et al., 2015, Invest New Drugs", "type": "Document", "title": "PubMed: Combe et al., 2015, Invest New Drugs", "pmid": 26490654}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:12", "label": "BRAF V600E", "description": "BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 1353.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453136, "stop": 140453136, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "12"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123643"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13961"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376069"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS113488022", "V640E", "VAL640GLU", "VAL600GLU"], "members": [{"id": "ga4gh:VA.LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "label": "NC_000007.13:g.140453136A>T", "digest": "LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "type": "Allele", "location": {"id": "ga4gh:SL.XutGzMvqbzN-vnxmPt2MJf7ehxmB0opi", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753335, "end": 140753336}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "label": "V600E", "digest": "4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004333.4:c.1799T>A"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Val600Glu"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140453136A>T"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1799T>A"}], "location": {"id": "ga4gh:SL.ZA1XNKhCT_7m2UtmnYb8ZYOVS4eplMEK", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:87", "label": "Ovarian Serous Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C7550"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:0050933"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:3802", "description": "In a study, a group of 6 participants, 5 with stage IV and one with stage IIIB lung adenocarcinoma, were sequenced at EGFR exons 18 to 21. All patients had L861Q mutation and were treated with the 1st generation TKI gefitinib. 4 patients had partial response with progression free survival (PFS) of 4.3, 19.3, 10.0, 8.7 months; overall survival (OS) of 4.3, 34.9, 15.7, 15.7 months; and all 4 were alive at study end. One patient had stable disease, PFS 6.5 months, OS 15.2 months, and was not alive at study end. One patient had progressive disease as response, with PFS of 2.8 months, OS of 10.7 months, and was not alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1503", "label": "Wu et al., 2011, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Wu et al., 2011, Clin. Cancer Res.", "pmid": 21531810}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:994", "label": "EGFR L861Q", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 10.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "A", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55259524, "stop": 55259524, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1020"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA176021"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "163380"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913444"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913444"], "members": [{"id": "ga4gh:VA.gosyXp1_96gY3LXwM9FTcZ77whCb9je0", "label": "NC_000007.13:g.55259524T>A", "digest": "gosyXp1_96gY3LXwM9FTcZ77whCb9je0", "type": "Allele", "location": {"id": "ga4gh:SL.TVFNAFf4th9p_qt2bsc8B9wqdctqBx4P", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55191830, "end": 55191831}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.dHgO6rd84GcjW82xzZ4P0NIE9yfgcYr_", "label": "L861Q", "digest": "dHgO6rd84GcjW82xzZ4P0NIE9yfgcYr_", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_005228.4:c.2582T>A"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Leu861Gln"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55259524T>A"}, {"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2582T>A"}], "location": {"id": "ga4gh:SL.wYr958J0kHH8yi78nvyE2QQukosbaxSX", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 860, "end": 861}, "state": {"type": "LiteralSequenceExpression", "sequence": "Q"}}}, "therapeutic": {"id": "civic.tid:14", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:328134"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1855"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:3824", "description": "One patient participating in a large retrospective study of EGFR monoclonal antibodies in metastatic, treatment refractory colorectal cancer had a tumor which harbored KRAS G12V, was wildtype for NRAS, BRAF and PIK3CA, and had individual response data. This patient was was a 78 year old female treated with panitumumab monotherapy as 2nd line therapy who experienced progressive disease (PFS: 5 weeks).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:76", "label": "De Roock et al., 2010, Lancet Oncol.", "type": "Document", "title": "PubMed: De Roock et al., 2010, Lancet Oncol.", "pmid": 20619739}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:421", "label": "KRAS G12V", "description": "KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 67.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "A", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398284, "stop": 25398284, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "425"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA122540"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12583"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913529"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913529", "GLY12VAL"], "members": [{"id": "ga4gh:VA.-SzXMvMSRoSJgvsIDz-7M7VTFdo4FCtA", "label": "NC_000012.11:g.25398284C>A", "digest": "-SzXMvMSRoSJgvsIDz-7M7VTFdo4FCtA", "type": "Allele", "location": {"id": "ga4gh:SL.iF0OXeO-tnumYbGkzaFEQ7cOZI_UCI1s", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245349, "end": 25245350}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.JTtvYJD7yl02AOq09HjSZDUnfg4gYdUb", "label": "G12V", "digest": "JTtvYJD7yl02AOq09HjSZDUnfg4gYdUb", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004985.4:c.35G>T"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly12Val"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398284C>A"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.35G>T"}], "location": {"id": "ga4gh:SL.OndkjmujtyUEZSjjCv0C-gpwnVbRgfj8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "civic.tid:28", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:263034"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1857"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["ABX-EGF", "ABX-EGF Monoclonal Antibody", "ABX-EGF, Clone E7.6.3", "E7.6.3", "Human IgG2K Monoclonal Antibody", "MoAb ABX-EGF", "MoAb E7.6.3", "Monoclonal Antibody ABX-EGF", "Monoclonal Antibody E7.6.3", "Vectibix"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:3827", "description": "One patient participating in a large retrospective study of EGFR monoclonal antibodies in metastatic colorectal cancer had a tumor which harbored BRAF V600E, was wildtype for NRAS, KRAS and PIK3CA, and had individual response data. This patient was was a male treated with panitumumab monotherapy as 1st line therapy who experienced progressive disease (PFS: 7 weeks; OS: 10 weeks).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:76", "label": "De Roock et al., 2010, Lancet Oncol.", "type": "Document", "title": "PubMed: De Roock et al., 2010, Lancet Oncol.", "pmid": 20619739}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:12", "label": "BRAF V600E", "description": "BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 1353.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453136, "stop": 140453136, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "12"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123643"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13961"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376069"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS113488022", "V640E", "VAL640GLU", "VAL600GLU"], "members": [{"id": "ga4gh:VA.LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "label": "NC_000007.13:g.140453136A>T", "digest": "LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "type": "Allele", "location": {"id": "ga4gh:SL.XutGzMvqbzN-vnxmPt2MJf7ehxmB0opi", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753335, "end": 140753336}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "label": "V600E", "digest": "4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004333.4:c.1799T>A"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Val600Glu"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140453136A>T"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1799T>A"}], "location": {"id": "ga4gh:SL.ZA1XNKhCT_7m2UtmnYb8ZYOVS4eplMEK", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "civic.tid:28", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:263034"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1857"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["ABX-EGF", "ABX-EGF Monoclonal Antibody", "ABX-EGF, Clone E7.6.3", "E7.6.3", "Human IgG2K Monoclonal Antibody", "MoAb ABX-EGF", "MoAb E7.6.3", "Monoclonal Antibody ABX-EGF", "Monoclonal Antibody E7.6.3", "Vectibix"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:3847", "description": "One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored PIK3CA G1049R (exon 20), was wildtype for KRAS, BRAF and NRAS, and had individual response data. This patient was was a 69 year old male treated with cetuximab + FOLFIRI as 3rd line therapy who experienced progressive disease and had PFS of 13 weeks and OS of 36 weeks. Using this information and data from the larger cohort, authors concluded that PIK3CA exon 21 (listed as exon 20 in source) mutations predict poor response to cetuximab.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:76", "label": "De Roock et al., 2010, Lancet Oncol.", "type": "Document", "title": "PubMed: De Roock et al., 2010, Lancet Oncol.", "pmid": 20619739}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:914", "label": "PIK3CA G1049R", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 7.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "C", "representative_transcript": "ENST00000263967.3", "chromosome": "3", "start": 178952090, "stop": 178952090, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "940"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602520"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376053"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913277"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLY1049ARG", "RS121913277"], "members": [{"id": "ga4gh:VA.QR1FtnKj1yO9gXWGtt_9Zlt2g0CZDgC3", "label": "NC_000003.11:g.178952090G>C", "digest": "QR1FtnKj1yO9gXWGtt_9Zlt2g0CZDgC3", "type": "Allele", "location": {"id": "ga4gh:SL.vEQpXu2hh_CYX3Je5Tzwzb1I3C551OCw", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 179234301, "end": 179234302}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.eWCosAQLvB-bdf-vEDT0nIOkDUn_ZJ0s", "label": "G1049R", "digest": "eWCosAQLvB-bdf-vEDT0nIOkDUn_ZJ0s", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006218.3:c.3145G>C"}, {"syntax": "hgvs.p", "value": "NP_006209.2:p.Gly1049Arg"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.178952090G>C"}, {"syntax": "hgvs.c", "value": "ENST00000263967.3:c.3145G>C"}], "location": {"id": "ga4gh:SL.QTbJMRl4fm9kBTuo8M6Zza7CMxC6fOFT", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 1048, "end": 1049}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:16", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:318341"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}, {"id": "mesh:D006258", "type": "Disease", "label": "Head and Neck Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C4013"}, "relation": "relatedMatch"}]}, {"id": "mesh:D002294", "type": "Disease", "label": "Carcinoma, Squamous Cell", "mappings": [{"coding": {"system": "ncit", "code": "C2929"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1723"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4082", "description": "Patients 11, 69, and 73 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) KIT W557_K558 deletion. Following failure of imatinib, the GIST was again genotyped, but no secondary mutations were found. Patient 11 started on 25 mg sunitinib daily, for a two week on/two week off schedule. Patients 69 and 73 were on a 50 mg sunitib per day for four weeks on/ two weeks off. All three patients experienced stable disease for less than 6 months. Time to progression for patients 11, 69, and 73: 8, 22, and 10 weeks. Overall survival for patients 11, 69, and 73: 10, 38, and 19 weeks (Table A1).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:965", "label": "Heinrich et al., 2008, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Heinrich et al., 2008, J. Clin. Oncol.", "pmid": 18955458}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:29", "label": "KIT", "description": "c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3815"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["C-Kit", "CD117", "KIT", "MASTC", "PBT", "SCFR"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:935", "label": "KIT W557_K558del", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 14.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "TGGAAG", "representative_transcript": "ENST00000288135.5", "chromosome": "4", "start": 55593603, "stop": 55593608, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "conservative_inframe_deletion", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001825"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "961"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA356974"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "222957"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.-0OOWY5vOXkNYm5Z0RXu2KkfAlKQP2uY", "label": "W557_K558del", "digest": "-0OOWY5vOXkNYm5Z0RXu2KkfAlKQP2uY", "type": "Allele", "location": {"id": "ga4gh:SL.Qlyg5JEGgGMGca_5rxiWtYk7c8GWZc0P", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 556, "end": 558}, "state": {"type": "ReferenceLengthExpression", "length": 0, "sequence": "", "repeatSubunitLength": 2}}}, "therapeutic": {"id": "civic.tid:157", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:357977"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:647", "type": "Disease", "label": "Pancreatic NET", "mappings": [{"coding": {"system": "ncit", "code": "C27720"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:660", "type": "Disease", "label": "Renal cell carcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C9385"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C71622"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"]}, "tumorType": {"id": "civic.did:2", "label": "Gastrointestinal Stromal Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3868"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9253"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4122", "description": "Patient 72 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) KIT V560D mutation. Following failure of imatinib, the GIST was again genotyped, but no secondary mutations were found. The patient took 50 mg sunitinib per day on a treatment schedule of four weeks on/two weeks off. The patient experienced progressive disease. Time to progression and overall survival were 9 and 33 weeks.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:965", "label": "Heinrich et al., 2008, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Heinrich et al., 2008, J. Clin. Oncol.", "pmid": 18955458}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:29", "label": "KIT", "description": "c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3815"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["C-Kit", "CD117", "KIT", "MASTC", "PBT", "SCFR"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:945", "label": "KIT V560D", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 14.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "A", "representative_transcript": "ENST00000288135.5", "chromosome": "4", "start": 55593613, "stop": 55593613, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "971"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602396"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "375914"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913521"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["VAL560ASP", "RS121913521"], "members": [{"id": "ga4gh:VA.DEtz2mJjlbwY6JoXYkr8EqhQY7XknzpB", "label": "NC_000004.11:g.55593613T>A", "digest": "DEtz2mJjlbwY6JoXYkr8EqhQY7XknzpB", "type": "Allele", "location": {"id": "ga4gh:SL.dSrWFS7PMfm4pI1lOMkuEOGD6Gh2p72S", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54727446, "end": 54727447}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.6kMa53-8b1JK_9Ul0KIKRsixzhy2VhdG", "label": "V560D", "digest": "6kMa53-8b1JK_9Ul0KIKRsixzhy2VhdG", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000288135.5:c.1679T>A"}, {"syntax": "hgvs.c", "value": "NM_000222.2:c.1679T>A"}, {"syntax": "hgvs.p", "value": "NP_000213.1:p.Val560Asp"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55593613T>A"}], "location": {"id": "ga4gh:SL.xjCeL58wMAH2q4KMEcgogvUiNRC5EJ4X", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 559, "end": 560}, "state": {"type": "LiteralSequenceExpression", "sequence": "D"}}}, "therapeutic": {"id": "civic.tid:157", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:357977"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:647", "type": "Disease", "label": "Pancreatic NET", "mappings": [{"coding": {"system": "ncit", "code": "C27720"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:660", "type": "Disease", "label": "Renal cell carcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C9385"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C71622"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"]}, "tumorType": {"id": "civic.did:2", "label": "Gastrointestinal Stromal Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3868"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9253"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4226", "description": "In a study, 1 participant with stage IV adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have V774A mutation, and was treated with the 1st generation TKI gefitinib. The patient (F, 51, nonsmoker) had a partial response, progression free survival (PFS) of 6.9 months, overall survival (OS) of 29.7 months and was alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1503", "label": "Wu et al., 2011, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Wu et al., 2011, Clin. Cancer Res.", "pmid": 21531810}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:1768", "label": "EGFR V774A", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 7.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "C", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55249023, "stop": 55249023, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1892"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA367578723"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["VAL774ALA"], "definingContext": {"id": "ga4gh:VA.B5fRq39Ab9hRZib0opWbdMaXgVPCIOay", "label": "V774A", "digest": "B5fRq39Ab9hRZib0opWbdMaXgVPCIOay", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2321T>C"}], "location": {"id": "ga4gh:SL.cgV6PLNk8QmTSLVtfsY2d8jl3wxonI2M", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 773, "end": 774}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}}, "therapeutic": {"id": "civic.tid:14", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:328134"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1855"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4248", "description": "In a study, 1 participant with stage IIIB lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have V834I mutation, and was treated with the 1st generation TKI gefitinib. The patient (F, 79, nonsmoker) had a partial response, progression free survival (PFS) of 5.0 months, overall survival (OS) of 15.0 months and was not alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1503", "label": "Wu et al., 2011, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Wu et al., 2011, Clin. Cancer Res.", "pmid": 21531810}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:1773", "label": "EGFR V834I", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 7.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"type": "coordinates"}}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1897"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.BocEsI2BLOs85DplUGmzBlsxGuELbXvT", "label": "V834I", "digest": "BocEsI2BLOs85DplUGmzBlsxGuELbXvT", "type": "Allele", "location": {"id": "ga4gh:SL.Dhv9JF8agt0qB8oifPZdKtJzRMpqb9wU", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 833, "end": 834}, "state": {"type": "LiteralSequenceExpression", "sequence": "I"}}}, "therapeutic": {"id": "civic.tid:14", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:328134"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1855"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4252", "description": "In a study, 1 participant with stage IV lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have L838P mutation, and was treated with the 1st generation TKI gefitinib. The patient (F, 66, nonsmoker) had a partial response, progression free survival (PFS) of 15.2 months, overall survival (OS) of 29.3 months and was not alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1503", "label": "Wu et al., 2011, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Wu et al., 2011, Clin. Cancer Res.", "pmid": 21531810}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:1365", "label": "EGFR L838P", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 7.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "C", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55259455, "stop": 55259455, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1457"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA367580150"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["LEU838PRO"], "members": [{"id": "ga4gh:VA._zRYmNGPR_1kK5IAGtOIIZkVKw5u32QY", "label": "NC_000007.14:g.55191762T>C", "digest": "_zRYmNGPR_1kK5IAGtOIIZkVKw5u32QY", "type": "Allele", "location": {"id": "ga4gh:SL.OLenKmGw76odx0N4V3yxEdi8KQjNXzOi", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55191761, "end": 55191762}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.uHuNjSpRVu3ymcCadSeXa9JBY9rN9P3V", "label": "L838P", "digest": "uHuNjSpRVu3ymcCadSeXa9JBY9rN9P3V", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000007.14:g.55191762T>C"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55259455T>C"}, {"syntax": "hgvs.c", "value": "ENST00000275493.7:c.2513T>C"}, {"syntax": "hgvs.p", "value": "ENSP00000275493.2:p.Leu838Pro"}, {"syntax": "hgvs.c", "value": "NM_005228.5:c.2513T>C"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Leu838Pro"}], "location": {"id": "ga4gh:SL.fW8LofQe7slaMyyvubd1NNghqvCD5BV-", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 837, "end": 838}, "state": {"type": "LiteralSequenceExpression", "sequence": "P"}}}, "therapeutic": {"id": "civic.tid:14", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:328134"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1855"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4288", "description": "This study analyzed patients with non small cell lung cancer (NSCLC) who were positive for EML4-ALK fusions (ALK+) and progressed on crizotinib monotherapy. One patient was biopsied twice following crizotinib progression and once pre-treatment. This patient was a 27 year old female with one pack year who experienced partial response on crizotinib as 4th line therapy. The patient's pre-crizotinib biopsy was ALK+ and lacked the EGFR mutation. A biopsy taken after 63 days on crizotinib showed EGFR L858R mutation and lacked ALK gene rearrangement by FISH (ALK Loss). Of note, a second post-treatment biopsy (after 113 on crizotinib) showed ALK rearrangement but lacked EGFR mutation. The authors interpreted the emergence of an ALK negative tumor (first post-critozitinib biopsy) as evidence of a separate oncogenic driver (EGFR L858R).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:507", "label": "Doebele et al., 2012, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Doebele et al., 2012, Clin. Cancer Res.", "pmid": 22235099}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:33", "label": "EGFR L858R", "description": "EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 379.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "G", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55259515, "stop": 55259515, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "33"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA126713"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16609"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376282"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376280"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434568"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121434568", "LEU858ARG"], "members": [{"id": "ga4gh:VA.TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "label": "NC_000007.13:g.55259515T>G", "digest": "TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "type": "Allele", "location": {"id": "ga4gh:SL.ulUNwZvajob7nzyrlpOd6uUWZIYCsoWb", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55191821, "end": 55191822}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "label": "L858R", "digest": "z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000007.13:g.55259515T>G"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2573T>G"}, {"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2573T>G"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Leu858Arg"}], "location": {"id": "ga4gh:SL.yVGJnwqxV6oCGqC_8nNb58D_wPXJeNJo", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 857, "end": 858}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:12", "label": "Crizotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1148495"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:25958", "type": "Disease", "label": "Anaplastic large cell lymphoma pediatric"}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C74061"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine", "2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-", "MET Tyrosine Kinase Inhibitor PF-02341066", "PF-02341066", "PF-2341066", "Xalkori"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4424", "description": "This was a retrospective study of 691 cetuximab treated patients with metastatic colorectal cancer. Of those, 7 patients harbored PIK3CA E542K (exon 10), were wt for BRAF, NRAS and PIK3CA, and had individual response data. Two patients had partial response, three had stable disease, and two progressed, resulting in a response rate of 2/7 and a clinical benefit rate of 5/7 according to author criteria. Treatments included cetuximab + irinotecan (n=5), cetuximab + FOLFIRI (n=1), and cetuximab monotherapy (n=1). Median PFS was 34 weeks (17-48 weeks), median OS was 46 weeks (27-91 weeks), and median number of previous chemotherapy lines was 2 (0-4). Median age was 59 years old (53-74), and there were 6 females and one male. Using these and data from the larger cohort, authors concluded that PIK3CA exon 10 (listed as exon 9 in source) mutations are associated with weak or no resistance to cetuximab.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:76", "label": "De Roock et al., 2010, Lancet Oncol.", "type": "Document", "title": "PubMed: De Roock et al., 2010, Lancet Oncol.", "pmid": 20619739}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "refutes", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:103", "label": "PIK3CA E542K", "description": "PIK3CA E545K/E542K variants are the second most recurrent PIK3CA mutations in breast cancer and are highly recurrent mutations in many other cancer types. Colorectal cancer patients with the PIK3CA E545K variant, and possibly other variants in the E545 region, may indicate poor prognosis relative to patients with other PIK3CA variants or wild-type PIK3CA. The literature also suggests that E545/E542 variants may confer resistance to EGFR inhibitors (e.g., cetuximab). An FDA approved treatment regimen including a targeted PIK3CA inhibitor is available for specific subtypes of breast cancer. While PIK3CA variants are highly prevalent in many other cancer types, targeted therapies for PIK3CA variants are still in early clinical trial phases in other cancer types.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 75.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000263967.3", "chromosome": "3", "start": 178936082, "stop": 178936082, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "103"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA333572"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "31944"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913273"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLU542LYS", "RS121913273"], "members": [{"id": "ga4gh:VA.52-4tAq0Ya9SeMU4eZSgO0bfqvkd_VE4", "label": "NC_000003.11:g.178936082G>A", "digest": "52-4tAq0Ya9SeMU4eZSgO0bfqvkd_VE4", "type": "Allele", "location": {"id": "ga4gh:SL.65wPuIVC66WPYQqTnuNP-taUZ03NOwmJ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 179218293, "end": 179218294}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.D6daDiDNn1u-e4YtntaYQnxlZ_0T6gtD", "label": "E542K", "digest": "D6daDiDNn1u-e4YtntaYQnxlZ_0T6gtD", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006218.3:c.1624G>A"}, {"syntax": "hgvs.p", "value": "NP_006209.2:p.Glu542Lys"}, {"syntax": "hgvs.c", "value": "ENST00000263967.3:c.1624G>A"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.178936082G>A"}], "location": {"id": "ga4gh:SL.DdVC73cqPrOnzCRvVc8N9tA3ecV5Qunt", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 541, "end": 542}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:16", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:318341"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}, {"id": "mesh:D006258", "type": "Disease", "label": "Head and Neck Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C4013"}, "relation": "relatedMatch"}]}, {"id": "mesh:D002294", "type": "Disease", "label": "Carcinoma, Squamous Cell", "mappings": [{"coding": {"system": "ncit", "code": "C2929"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1723"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4493", "description": "A 61 year old male never smoker with EGFR H773_V774insNPH mutant lung adenocarcinoma was treated with fourth line erlotinib and had progressive disease as best response, progression free survival of 1.6 months, and overall survival of 4.4 months.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1230", "label": "Yasuda et al., 2013, Sci Transl Med", "type": "Document", "title": "PubMed: Yasuda et al., 2013, Sci Transl Med", "pmid": 24353160}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:1421", "label": "EGFR H773_V774insNPH", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 7.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"reference_build": "GRCh37", "variant_bases": "AACCCCCAC", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55249012, "stop": 55249013, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "inframe_insertion", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001821"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1513"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA180983"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "177911"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.z6IZsNMoRmsfAyfDXpBeEOL_DVUtBThl", "label": "H773_V774insNPH", "digest": "z6IZsNMoRmsfAyfDXpBeEOL_DVUtBThl", "type": "Allele", "location": {"id": "ga4gh:SL.9tCLrFlpEZycPzMHJadh5DBcqLA2ubNH", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 770, "end": 773}, "state": {"type": "ReferenceLengthExpression", "length": 6, "sequence": "NPHNPH", "repeatSubunitLength": 3}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:30", "label": "Lung Adenocarcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3512"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3910"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4597", "description": "Patients 29 and 66 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) PDGFRA D842V mutation. Following failure of imatinib, the GIST was again genotyped, but no secondary mutations were found. Patients took 50 mg sunitib per day. Patient 29 was on a treatment schedule of two weeks on/two weeks off, and patient 66 was scheduled for four weeks on/two weeks off.  Patient 29 experienced stable disease for less than 6 months and patient 66 experienced disease progression. Time to progression was censored at 0.1 weeks for patient 29 and was 10 weeks for patient 66. Overall survival was 99 and censored at 129 weeks for patients 29 and 66.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:965", "label": "Heinrich et al., 2008, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Heinrich et al., 2008, J. Clin. Oncol.", "pmid": 18955458}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:38", "label": "PDGFRA", "description": "Commonly mutated in GI tract tumors, PDGFR family genes (mutually exclusive to KIT mutations) are a hallmark of gastrointestinal stromal tumors. Gene fusions involving the PDGFRA kinase domain are highly correlated with eosinophilia, and the WHO classifies myeloid and lymphoid neoplasms with these characteristics as a distinct disorder. Mutations in the 842 region of PDGFRA have been often found to confer resistance to the tyrosine kinase inhibitor, imatinib.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8803"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5156"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD140A", "PDGFR-2", "PDGFR2", "PDGFRA"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:99", "label": "PDGFRA D842V", "description": "PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. Exogenous expression of the A842V mutation resulted in constitutive tyrosine phosphorylation of PDGFRA in the absence of ligand in 293T cells and cytokine-independent proliferation of the IL-3-dependent Ba/F3 cell line, both evidence that this is an activating mutation. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 100.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000257290.5", "chromosome": "4", "start": 55152093, "stop": 55152093, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "99"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123194"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13543"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121908585"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ASP842VAL", "RS121908585"], "members": [{"id": "ga4gh:VA.bDwkJ2filJ3ZGiUFybGFfyaCKdIVK86v", "label": "NC_000004.11:g.55152093A>T", "digest": "bDwkJ2filJ3ZGiUFybGFfyaCKdIVK86v", "type": "Allele", "location": {"id": "ga4gh:SL.LxO2YLfQbI_-TK7GOmSoOpMNiSy_Hgan", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54285925, "end": 54285926}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.vIjnL-aLYl0BSB6JutpdD7yW_qIXtdk8", "label": "D842V", "digest": "vIjnL-aLYl0BSB6JutpdD7yW_qIXtdk8", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006206.4:c.2525A>T"}, {"syntax": "hgvs.p", "value": "NP_006197.1:p.Asp842Val"}, {"syntax": "hgvs.c", "value": "ENST00000257290.5:c.2525A>T"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55152093A>T"}], "location": {"id": "ga4gh:SL.GHXCPrbd_qdPUoHjPwzv5iVFapJ0cn-o", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.XpQn9sZLGv_GU3uiWO7YHq9-_alGjrVX"}, "start": 841, "end": 842}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "civic.tid:157", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:357977"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:647", "type": "Disease", "label": "Pancreatic NET", "mappings": [{"coding": {"system": "ncit", "code": "C27720"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:660", "type": "Disease", "label": "Renal cell carcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C9385"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C71622"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"]}, "tumorType": {"id": "civic.did:2", "label": "Gastrointestinal Stromal Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3868"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9253"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4667", "description": "EGFR exons 18-24 were analyzed in 7 patients who had shown a partial response to erlotinib in a phase II trial for bronchioloalveolar carcinoma (BAC, or in situ pulmonary adenocarcinoma). One patient (Patient E1) had the del L747-S752 insQ mutation. The patient was a male never smoker and demonstrated response for 8 months. He continued to show response and remain on the drug when the manuscript was written.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1509", "label": "Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A.", "type": "Document", "title": "PubMed: Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A.", "pmid": 15329413}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:1488", "label": "EGFR L747_S752delinsQ", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 7.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"reference_build": "GRCh37", "reference_bases": "TTAAGAGAAGCAACATCT", "variant_bases": "CAA", "chromosome": "7", "start": 55242469, "stop": 55242486, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "inframe_insertion", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001821"}, {"label": "inframe_deletion", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001822"}, {"label": "delins", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:1000032"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1580"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA645561524"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["DEL L747-S752INSQ", "LEU747_SER752DELINSGLN"], "members": [{"id": "ga4gh:VA.Wa4s76Lir22aqau6w98vQe7oWrVR5pOJ", "label": "NC_000007.14:g.55174776_55174793delinsCAA", "digest": "Wa4s76Lir22aqau6w98vQe7oWrVR5pOJ", "type": "Allele", "location": {"id": "ga4gh:SL.lSrl3-agtNaGax3YJK__oTn-1ap7hRSZ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55174775, "end": 55174793}, "state": {"type": "LiteralSequenceExpression", "sequence": "CAA"}}], "definingContext": {"id": "ga4gh:VA.vBQ2TCfRHiG3ud_vqE88BNZEK7Qw28kg", "label": "L747_S752delinsQ", "digest": "vBQ2TCfRHiG3ud_vqE88BNZEK7Qw28kg", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000007.14:g.55174776_55174793delinsCAA"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55242469_55242486delinsCAA"}, {"syntax": "hgvs.c", "value": "ENST00000275493.7:c.2239_2256delinsCAA"}, {"syntax": "hgvs.p", "value": "ENSP00000275493.2:p.Leu747_Ser752delinsGln"}, {"syntax": "hgvs.c", "value": "NM_005228.5:c.2239_2256delinsCAA"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Leu747_Ser752delinsGln"}], "location": {"id": "ga4gh:SL.1btwhKRj0zZQwo-_CalR-WavTB019t-V", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 746, "end": 752}, "state": {"type": "LiteralSequenceExpression", "sequence": "Q"}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:30", "label": "Lung Adenocarcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3512"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3910"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4669", "description": "In a study, 1 participant with stage IV lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have L861R mutation, and was treated with the 1st generation TKI gefitinib. The patient (M, 83, nonsmoker) had a partial response, progression free survival (PFS) of 37.5 months, overall survival (OS) of 53.3 months and was alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1503", "label": "Wu et al., 2011, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Wu et al., 2011, Clin. Cancer Res.", "pmid": 21531810}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:1385", "label": "EGFR L861R", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 7.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "G", "representative_transcript": "ENST00000", "chromosome": "7", "start": 55259524, "stop": 55259524, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1477"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA135940"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "45287"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913444"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913444"], "members": [{"id": "ga4gh:VA.ctJ2V9gLJzR_Tl9xjKTbXI5FCTMQdEUH", "label": "NC_000007.13:g.55259524T>G", "digest": "ctJ2V9gLJzR_Tl9xjKTbXI5FCTMQdEUH", "type": "Allele", "location": {"id": "ga4gh:SL.TVFNAFf4th9p_qt2bsc8B9wqdctqBx4P", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55191830, "end": 55191831}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.FdoJYoITgbjmsARxqtw4nE3k8PZHNtdn", "label": "L861R", "digest": "FdoJYoITgbjmsARxqtw4nE3k8PZHNtdn", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_005228.4:c.2582T>G"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Leu861Arg"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55259524T>G"}, {"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2582T>G"}], "location": {"id": "ga4gh:SL.wYr958J0kHH8yi78nvyE2QQukosbaxSX", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 860, "end": 861}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:14", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:328134"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1855"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4802", "description": "A 79 year old Asian male never smoker with not otherwise specified NSCLC harboring EGFR P772_H773insYNP mutation was given erlotinib as first line treatment, and had progressive disease as best response with +2.3% change to target lesions, progression free survival of 2.1 months and overall survival of 16.5 months.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1230", "label": "Yasuda et al., 2013, Sci Transl Med", "type": "Document", "title": "PubMed: Yasuda et al., 2013, Sci Transl Med", "pmid": 24353160}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:1575", "label": "EGFR P772_H773insYNP", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 7.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"reference_build": "GRCh37", "variant_bases": "TATAATCCC", "chromosome": "7", "start": 55249018, "stop": 55249019, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "inframe_insertion", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001821"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1667"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA2573051294"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.iVCEpv7T5cWktCTe0hcWHVg9zb7L_enJ", "label": "P772_H773insYNP", "digest": "iVCEpv7T5cWktCTe0hcWHVg9zb7L_enJ", "type": "Allele", "location": {"id": "ga4gh:SL.DZ0qQAkUWbPRbDVeL1B2-_SYyayHSXIR", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 770, "end": 772}, "state": {"type": "ReferenceLengthExpression", "length": 5, "sequence": "NPYNP", "repeatSubunitLength": 3}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4803", "description": "A 57 year old male 10 packyear former smoker with lung adenocarcinoma with EGFR P772_V774insPHV mutation was given erlotinib as first line treatment, and had progressive disease as best response with progression free survival of 2 months and overall survival of 16 months.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1230", "label": "Yasuda et al., 2013, Sci Transl Med", "type": "Document", "title": "PubMed: Yasuda et al., 2013, Sci Transl Med", "pmid": 24353160}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "refutes", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:1576", "label": "EGFR P772_V774insPHV", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 7.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"reference_build": "GRCh37", "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "inframe_insertion", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001821"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1668"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.agK6N4kJJbyNfz_Er2_ox0Vbo0egJ2R3", "label": "P772_V774insPHV", "digest": "agK6N4kJJbyNfz_Er2_ox0Vbo0egJ2R3", "type": "Allele", "location": {"id": "ga4gh:SL.Ac3k3VmJUUgSaSHM8x1zAHrQdcaqZvqF", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 772, "end": 772}, "state": {"type": "LiteralSequenceExpression", "sequence": "PHV"}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:30", "label": "Lung Adenocarcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3512"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3910"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4905", "description": "Case study report including one patient with L597Q mutation-positive metastatic melanoma (M1b disease) treated with the MEK inhibitor trametinib. The L597Q patient achieved a RECIST partial response and showed maximum tumor shrinkage of 33% with trametinib as the first-line treatment and had a partial response for 6.2 months.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2178", "label": "Bowyer et al., 2014, Melanoma Res.", "type": "Document", "title": "PubMed: Bowyer et al., 2014, Melanoma Res.", "pmid": 24933606}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:579", "label": "BRAF L597Q", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 14.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453145, "stop": 140453145, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "583"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602257"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "76687"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913366"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913366", "LEU597GLN"], "members": [{"id": "ga4gh:VA.zATpR7iDy-_AbeeQ93IgDZwYYZwApall", "label": "NC_000007.13:g.140453145A>T", "digest": "zATpR7iDy-_AbeeQ93IgDZwYYZwApall", "type": "Allele", "location": {"id": "ga4gh:SL.cGEXoAH8CN1Vt-bvqUWZ8VkN24o8W6en", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753344, "end": 140753345}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.ACflef8GdM92PuUEXZWrBIw7zckEaek7", "label": "L597Q", "digest": "ACflef8GdM92PuUEXZWrBIw7zckEaek7", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004333.4:c.1790T>A"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Leu597Gln"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140453145A>T"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1790T>A"}], "location": {"id": "ga4gh:SL.SfkS-rvyLn3M9HwlYokvq8Bm6IWEWHdt", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 596, "end": 597}, "state": {"type": "LiteralSequenceExpression", "sequence": "Q"}}}, "therapeutic": {"id": "civic.tid:19", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1425098"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C77908"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["GSK1120212", "JTP-74057", "MEK Inhibitor GSK1120212", "Mekinist", "N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide"]}, "tumorType": {"id": "civic.did:206", "label": "Skin Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3510"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:8923"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:5938", "description": "A 43 year old female neversmoker lung adenocarcinoma patient with EGFR M766_A767insASV mutation was given erlotinib as first line treatment, and had progressive disease as best response with -3.9% change to target lesions, progression free survival of 1 month.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1230", "label": "Yasuda et al., 2013, Sci Transl Med", "type": "Document", "title": "PubMed: Yasuda et al., 2013, Sci Transl Med", "pmid": 24353160}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "refutes", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:2089", "label": "EGFR M766_A767insASV", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 7.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"type": "coordinates"}}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "2213"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.AsbEsJdOsrzZo1MIu7Q0xJcnHsa4XEV9", "label": "M766_A767insASV", "digest": "AsbEsJdOsrzZo1MIu7Q0xJcnHsa4XEV9", "type": "Allele", "location": {"id": "ga4gh:SL.xdFHLf7Q45VKT57U4kwcDd7MUOtV2Bdz", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 766, "end": 769}, "state": {"type": "ReferenceLengthExpression", "length": 6, "sequence": "ASVASV", "repeatSubunitLength": 3}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:5962", "description": "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. One patient with BRAF V600E mutant laryngeal cancer had a partial response with vemurafenib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2414", "label": "Hainsworth et al., 2018, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Hainsworth et al., 2018, J. Clin. Oncol.", "pmid": 29320312}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:12", "label": "BRAF V600E", "description": "BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 1353.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453136, "stop": 140453136, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "12"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123643"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13961"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376069"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS113488022", "V640E", "VAL640GLU", "VAL600GLU"], "members": [{"id": "ga4gh:VA.LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "label": "NC_000007.13:g.140453136A>T", "digest": "LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "type": "Allele", "location": {"id": "ga4gh:SL.XutGzMvqbzN-vnxmPt2MJf7ehxmB0opi", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753335, "end": 140753336}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "label": "V600E", "digest": "4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004333.4:c.1799T>A"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Val600Glu"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140453136A>T"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1799T>A"}], "location": {"id": "ga4gh:SL.ZA1XNKhCT_7m2UtmnYb8ZYOVS4eplMEK", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:124", "label": "Laryngeal Squamous Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4044"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:2876"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:6005", "description": "Patients with recurrent pancreatic adenocarcinoma was treated with gemcitabine + nab-paclitaxel, FOLFIRINOX and docetaxel + irinotecan. After failure of these treatment, a tumor specimen from the pancreaticoduodenectomy was analyzed, which revealed an activating mutation in exon 19 (L747_P753>S) of EGFR. Mutations were also detected in CDKN2A, TP53, and amplifications of PRKCI and TERC. He began erlotinib at 150mg daily. CT imaging revealed a partial response by RECIST at 8, 24 and 32 weeks after starting erlotinib. At 40 weeks CT imaging revealed unequivocal disease progression. After disease progression to erlotinib, a repeat liver biopsy revealed an EGFR T790M mutation. He began treatment with osimertinib at 80mg daily. After 8 weeks of this treatment CT imaging revealed unequivocal disease progression.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2359", "label": "Cecchini et al., 2017, J Natl Compr Canc Netw", "type": "Document", "title": "PubMed: Cecchini et al., 2017, J Natl Compr Canc Netw", "pmid": 28874593}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:986", "label": "EGFR L747_P753delinsS", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 7.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "TAAGAGAAGCAACATCTC", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55242470, "stop": 55242487, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "inframe_deletion", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001822"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1012"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA126710"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16608"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913438"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913438"], "definingContext": {"id": "ga4gh:VA.-c6XnKqvtA5dL94gYBHlQhqCq5rHn11h", "label": "L747_P753delinsS", "digest": "-c6XnKqvtA5dL94gYBHlQhqCq5rHn11h", "type": "Allele", "location": {"id": "ga4gh:SL.w39a-eLibeKXZnSrcZ4FTN09Mwklmg4L", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 746, "end": 753}, "state": {"type": "LiteralSequenceExpression", "sequence": "S"}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:158", "label": "Pancreatic Adenocarcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C8294"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:4074"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:7068", "description": "In this phase 1 trial, 57 patients were treated with the selective RET Inhibitor selpercatinib (LOXO-292). A 57-year-old male with a hereditary RET V804M gatekeeper mutation treated with 3 prior multi-kinase inhibitors had a complete response that remained in effect at 6 months.  Significant decreases in calcitonin and CEA were noted.  Drug dosing was initiated at 80 mg BID and escalated to 120 mg BID by the time of the CR confirmation and then further increased to 160 mg BID.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2745", "label": "Alexander E. Drilon, 2018, ASCO Annual Meeting, Abstract 102", "type": "Document", "title": "ASCO: Alexander E. Drilon, 2018, ASCO Annual Meeting, Abstract 102"}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "germline", "geneContext": {"id": "civic.gid:42", "label": "RET", "description": "RET mutations and the RET fusion RET-PTC lead to activation of this tyrosine kinase receptor and are associated with thyroid cancers. RET point mutations are the most common mutations identified in medullary thyroid cancer (MTC) with germline and somatic mutations in RET associated with hereditary and sporadic forms, respectively. The most common somatic form mutation is M918T (exon 16) and a variety of other mutations effecting exons 10, 11 and 15 have been described. The prognostic significance of these mutations have been hotly debated in the field, however, data suggests that some RET mutation may confer drug resistance. Highly selective and well-tolerated RET inhibitors, selpercatinib (LOXO-292) and pralsetinib (BLU-667), have been FDA approved recently for the treatment of RET fusion-positive non-small-cell lung cancer, RET fusion-positive thyroid cancer and RET-mutant medullary thyroid cancer.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:9967"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5979"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CDHF12", "CDHR16", "HSCR1", "MEN2A", "MEN2B", "MTC1", "PTC", "RET", "RET-ELE1"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:2441", "label": "RET V804M", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 7.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"type": "coordinates"}}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "2568"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.KtD83NGg8pHKnWVE704OtmzcImuG91vL", "label": "V804M", "digest": "KtD83NGg8pHKnWVE704OtmzcImuG91vL", "type": "Allele", "location": {"id": "ga4gh:SL.9z_Iysbjbr6OLphzHBq3j4HLywGtrJnl", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.jMu9-ItXSycQsm4hyABeW_UfSNRXRVnl"}, "start": 803, "end": 804}, "state": {"type": "LiteralSequenceExpression", "sequence": "M"}}}, "therapeutic": {"id": "civic.tid:601", "label": "Selpercatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:2370147"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:675", "type": "Disease", "label": "Thyroid cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7510"}, "relation": "relatedMatch"}]}, {"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C134987"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["6-(2-Hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo(3.1.1)heptan-3-yl)pyridin-3-yl)pyrazolo(1,5-a)pyridine-3-carbonitril", "LOXO-292", "RET Inhibitor LOXO-292", "RET Kinase Inhibitor LOXO-292", "Retevmo", "WHO 10967"]}, "tumorType": {"id": "civic.did:15", "label": "Thyroid Gland Medullary Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3879"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3973"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:7463", "description": "A melanoma patient harboring the KIT S628N activating mutation underwent second-line imatinib therapy following lung metastatic progression that appeared after an eighth cycle of chemotherapy. The S628N mutation was not present in the blood, which confirmed that it was a somatic mutation. After 3 months of imatinib treatment (300 mg/d for first three weeks, then 400 mg/d), the patient exhibited disease progression and increased tumor size, and after an additional three months of imatinib treatment (400 mg/d), the patient developed multiple supratentorial brain metastases in addition to increased lung metastases and died 5 days later. The authors reported preclinical data which indicated variant sensitivity to imatinib. although this outcome did not coroberate the preclinical result, the authors still concluded the variant may be sensitive.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2054", "label": "Vita et al., 2014, JAMA Dermatol", "type": "Document", "title": "PubMed: Vita et al., 2014, JAMA Dermatol", "pmid": 25317746}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:29", "label": "KIT", "description": "c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3815"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["C-Kit", "CD117", "KIT", "MASTC", "PBT", "SCFR"]}}, "direction": "refutes", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:1567", "label": "KIT S628N", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 9.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "chromosome": "4", "start": 55594180, "stop": 55594180, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1659"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA356908374"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["S624N"], "definingContext": {"id": "ga4gh:VA.mVaFld0e_pNp2GqyGyN2yE9aaVwS2g0g", "label": "S628N", "digest": "mVaFld0e_pNp2GqyGyN2yE9aaVwS2g0g", "type": "Allele", "location": {"id": "ga4gh:SL.K5ZVJLkoFH2Zih-ddYvFNkhgGqwQdWOC", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 627, "end": 628}, "state": {"type": "LiteralSequenceExpression", "sequence": "N"}}}, "therapeutic": {"id": "civic.tid:5", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:282388"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "Disease", "label": "Systemic mastocytosis", "mappings": [{"coding": {"system": "ncit", "code": "C9235"}, "relation": "relatedMatch"}]}, {"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}, {"id": "hemonc:634", "type": "Disease", "label": "Myelodysplastic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C3247"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:33893", "type": "Disease", "label": "Chronic myelogenous leukemia pediatric"}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}, {"id": "hemonc:616", "type": "Disease", "label": "Hypereosinophilic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C27038"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C62035"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"]}, "tumorType": {"id": "civic.did:7", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3224"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1909"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:7498", "description": "A patient with platinum-refractory oral cavity head and neck squamous carcinoma underwent comprehensive genomic profiling that identified an activating MET R1004G mutation. The patient showed a rapid response to the treatment of crizotinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2980", "label": "Chu et al., 2019, Oncologist", "type": "Document", "title": "PubMed: Chu et al., 2019, Oncologist", "pmid": 31391294}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:52", "label": "MET", "description": "Mesenchymal Epithelial Transition MET is a prototypical receptor tyrosine kinase. Its ligand is Hepatocyte Growth Factor (HGF). MET alterations are drivers of human cancer. Amplification and resulting overexpression has been reported in several cancers, and make the receptor's activity independent of HGF. Gene fusions also decouple kinase activity from the cell membrane and render it constitutively active. Finally, exclusion of the juxtamembrane (JM) domain of the kinase by \"skipping\" of exon 14 activates the kinase. FDA-approved selective MET inhibitors, including tepotinib and capmatinib, have shown efficacy in cancers with exon 14 skipping mutations or MET amplification.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:7029"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:4233"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["AUTS9", "DA11", "DFNB97", "HGFR", "MET", "RCCP2", "c-Met"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:2643", "label": "MET R1004G", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 7.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "G", "representative_transcript": "ENST00000397752.8", "chromosome": "7", "start": 116412025, "stop": 116412025, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "2774"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA368987455"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ARG1004GLY"], "members": [{"id": "ga4gh:VA.e1Vdg0jnC0G8all3IK7iO09d_8iL7Xcw", "label": "NC_000007.14:g.116771971C>G", "digest": "e1Vdg0jnC0G8all3IK7iO09d_8iL7Xcw", "type": "Allele", "location": {"id": "ga4gh:SL.zRGs5szjeu8abt38IrlrHq8BFg2Ap8XM", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 116771970, "end": 116771971}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.uGd0OJJJco00LP9n1uJFZNrABdhFxU_0", "label": "R1004G", "digest": "uGd0OJJJco00LP9n1uJFZNrABdhFxU_0", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000007.14:g.116771971C>G"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.116412025C>G"}, {"syntax": "hgvs.c", "value": "ENST00000397752.8:c.3010C>G"}, {"syntax": "hgvs.p", "value": "ENSP00000380860.3:p.Arg1004Gly"}, {"syntax": "hgvs.c", "value": "NM_000245.4:c.3010C>G"}, {"syntax": "hgvs.p", "value": "NP_000236.2:p.Arg1004Gly"}], "location": {"id": "ga4gh:SL._-o9tCBk9jb6xCrWF_A-aNwKpyTosdwd", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.QITcgkaDXSK1bJllcGyJVlXeD_SiQdfo"}, "start": 1003, "end": 1004}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}}, "therapeutic": {"id": "civic.tid:12", "label": "Crizotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1148495"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:25958", "type": "Disease", "label": "Anaplastic large cell lymphoma pediatric"}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C74061"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine", "2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-", "MET Tyrosine Kinase Inhibitor PF-02341066", "PF-02341066", "PF-2341066", "Xalkori"]}, "tumorType": {"id": "civic.did:453", "label": "Head And Neck Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4013"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:11934"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:7730", "description": "In a case report, a patient with pancreatic cancer harboring BRAF N486-P490del was treated with trametinib.\nWithin 4 weeks of initiating therapy, her serum\nCA19-9 had fallen from 36,000 to 8,100 U/mL, and the radiographic partial response was revealed by CT at 8 weeks after initiation of trametinib. cfDNA measurements for BRAF and TP53 alleles revealed a dramatic decline in response to trametinib. \nAfter 6 months of therapy, radiographic progression was identified.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:3083", "label": "Aguirre et al., 2018, Cancer Discov", "type": "Document", "title": "PubMed: Aguirre et al., 2018, Cancer Discov", "pmid": 29903880}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:2663", "label": "BRAF N486_P490del", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 7.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"type": "coordinates"}}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "2794"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.qiBmeiaWQpVa-NQbBk-tRb29arFXHlII", "label": "N486_P490del", "digest": "qiBmeiaWQpVa-NQbBk-tRb29arFXHlII", "type": "Allele", "location": {"id": "ga4gh:SL.pRIuuJl4QmSYtF_miIVEy5rk_K1QhxWZ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 485, "end": 490}, "state": {"type": "ReferenceLengthExpression", "length": 0, "sequence": "", "repeatSubunitLength": 5}}}, "therapeutic": {"id": "civic.tid:19", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1425098"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C77908"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["GSK1120212", "JTP-74057", "MEK Inhibitor GSK1120212", "Mekinist", "N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide"]}, "tumorType": {"id": "civic.did:556", "label": "Pancreatic Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9005"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1793"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:7833", "description": "FGFR2 p.P253R mutation detected in patient with head and neck SCC.  Mutation initially detected by RNA-Seq and confirmed by Sanger sequencing.  Patient is 52 y/o male with initial diagnosis of SCC of right tongue in 2008.  Recurrences treated with surgery, radiotherapy and chemotherapy including carboplatin, paclitaxel, cisplatin, and cetuximab.  In 2012, progression was detected in right neck and left axilla.  Patient was treated with 800 mg of pazopanib daily.  At 12 day follow up patient had marked reduction in tumor size.  Patient continued treatment for 2 months until he presented with right carotid hemorrhage.  Last follow up shows patient is alive 11 months after beginning pazopanib treatment.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:3136", "label": "Liao et al., 2013, Cancer Res.", "type": "Document", "title": "PubMed: Liao et al., 2013, Cancer Res.", "pmid": 23786770}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:22", "label": "FGFR2", "description": "The FGFR proteins are involved in a wide array of pathways known to play a signficant role in cancer. Activation of these receptors can lead to activation of the RAS-MAPK pathway and the PI3K-AKT pathway, among others. The mechanisms by which FGFR can be misregulated vary between cancers. Amplification of the receptors has been observed in lung and breast cancers, coding mutations and deletions have been seen in many cancers, and more recently, FGFR fusions that lead to pathway actiation have been demonstrated to have oncogenic potential across multiple cancer types. The targeted therapeutics ponatinib, dovitinib and pazopanib have seen success in treating over-active FGFR signalling, prompting use of diagnostic sequencing targeting the FGFR genes, especially in lung cancer patients.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3689"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2263"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["BBDS", "BEK", "BFR-1", "CD332", "CEK3", "CFD1", "ECT1", "FGFR2", "JWS", "K-SAM", "KGFR", "TK14", "TK25"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:2774", "label": "FGFR2 P253R", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 7.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"type": "coordinates"}}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "2905"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.Xp3fbJX5393wp0YXbmwTNeoxcZhfO8uN", "label": "P253R", "digest": "Xp3fbJX5393wp0YXbmwTNeoxcZhfO8uN", "type": "Allele", "location": {"id": "ga4gh:SL.KzR9KnZV6jWG2UqL83xPxaPgLCHntkqG", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.hAWsXlUEul8pcUbRmOHRQ6osiUdGIiWs"}, "start": 252, "end": 253}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:56", "label": "Pazopanib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:714438"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C74547"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["Benzenesulfonamide, 5-((4-((2,3-dimethyl-2H-indazol-6-yl)methylamino)-2-pyrimidinyl)amino)-2-methyl-", "GW786034"]}, "tumorType": {"id": "civic.did:37", "label": "Head And Neck Squamous Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C34447"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:5520"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:9223", "description": "In a retrospective study of 2316 Chinese patients with stage IV non-small cell lung carcinoma, a 63 year old female with the EGFR exon 20 insertion D770_N771insG received osimertinib as second-line treatment. The patient had clinical improvement and achieved partial response with nearly 50% reduction in tumour size. Progression-free survival was 6.4 months.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:3023", "label": "Fang et al., 2019, BMC Cancer", "type": "Document", "title": "PubMed: Fang et al., 2019, BMC Cancer", "pmid": 31208370}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:1420", "label": "EGFR D770_N771insG", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 7.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"reference_build": "GRCh37", "variant_bases": "GGT", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55249012, "stop": 55249013, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "inframe_insertion", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001821"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1512"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA645561591"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ASP770_ASN771INSGLY"], "members": [{"id": "ga4gh:VA.4FFi5vRWMhlFZT9LxcRzyZNTx-FnGZhE", "label": "NC_000007.14:g.55181319_55181320insGGT", "digest": "4FFi5vRWMhlFZT9LxcRzyZNTx-FnGZhE", "type": "Allele", "location": {"id": "ga4gh:SL.EtS4nquqDe57JO3brzp4cAGON3FWOjFX", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55181319, "end": 55181319}, "state": {"type": "LiteralSequenceExpression", "sequence": "GGT"}}], "definingContext": {"id": "ga4gh:VA.kB1mjQ7tqP6BcRU6WmYzo-Zwn9dHQ8zE", "label": "D770_N771insG", "digest": "kB1mjQ7tqP6BcRU6WmYzo-Zwn9dHQ8zE", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000007.14:g.55181319_55181320insGGT"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55249012_55249013insGGT"}, {"syntax": "hgvs.c", "value": "ENST00000275493.7:c.2310_2311insGGT"}, {"syntax": "hgvs.p", "value": "ENSP00000275493.2:p.Asp770_Asn771insGly"}, {"syntax": "hgvs.c", "value": "NM_005228.5:c.2310_2311insGGT"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Asp770_Asn771insGly"}], "location": {"id": "ga4gh:SL.ciWb1ylkqUxiviU1djijiuYVZcgsnQnV", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 770, "end": 770}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}}, "therapeutic": {"id": "civic.tid:187", "label": "Osimertinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1721560"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C116377"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-", "AZD-9291", "AZD9291", "Mereletinib", "Tagrisso"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:10035", "description": "A cohort of 32 colorectal cancer patients with acquired resistance to cetuximab (PFS > 12 weeks) was analyzed. 1 patient had the PIK3CA p.L938* mutation. Cell viability studies of DiFi cells transfected with this PIK3CA variant did not exhibit resistance.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2196", "label": "Xu et al., 2017, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Xu et al., 2017, Clin. Cancer Res.", "pmid": 28424201}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "refutes", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:3538", "label": "PIK3CA L938*", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 7.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"type": "coordinates"}}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "3670"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.wbe4omIJmBxpsZlHpkPLKFrzixJG1mmW", "label": "L938*", "digest": "wbe4omIJmBxpsZlHpkPLKFrzixJG1mmW", "type": "Allele", "location": {"id": "ga4gh:SL.WTLNELJRpUOhEkN0t3RVuXc9YMbrut_u", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 937, "end": 938}, "state": {"type": "LiteralSequenceExpression", "sequence": "*"}}}, "therapeutic": {"id": "civic.tid:16", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:318341"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}, {"id": "mesh:D006258", "type": "Disease", "label": "Head and Neck Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C4013"}, "relation": "relatedMatch"}]}, {"id": "mesh:D002294", "type": "Disease", "label": "Carcinoma, Squamous Cell", "mappings": [{"coding": {"system": "ncit", "code": "C2929"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1723"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:10325", "description": "Case report of a 32-year old male patient with pilocytic astrocytoma. Genomic profiling (FoundationOne) revealed a FGFR1 N546K mutation. The patient was enrolled in a phase I/II trial of pemigatinib and achieved a partial response lasting 18 months.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:4291", "label": "Capone et al., 2022, JCO Precis Oncol", "type": "Document", "title": "PubMed: Capone et al., 2022, JCO Precis Oncol", "pmid": 35507888}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:1885", "label": "FGFR1", "description": "FGFR1 is a member of the Fibroblast Growth Factor family, comprising of 4 receptors and 18 Ligands. \nFGFR1 signalling downstream functions mainly via PI3K and MAPK pathways (Turner et. al.).\nSeveral ways of involvement of FGFR1 in cancer have been proposed: auto- and paracrine activation, amplification and overexpression (Marshall et. al,  Weiss et. al.,  Cheng et. al.).\nEspecially amplification of FGFR1 in lung cancer is an emerging treatment target with clinical studies currently ongoing (e.g. NCT01004224). However, FGFR1 amplification does not always correlate with protein expression and predictive biomarkers still remain to be defined in clinic (von M\u00e4ssenhausen et. al.).\nMutation of FGFR1 seems to be less common, but has been described in glioblastoma, pilocytic astrocytomas and Ewing's sarcoma (Rand et. al., Jones et. al., Agelopoulos et. al.).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3688"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2260"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["BFGFR", "CD331", "CEK", "ECCL", "FGFBR", "FGFR-1", "FGFR1", "FLG", "FLT-2", "FLT2", "HBGFR", "HH2", "HRTFDS", "KAL2", "N-SAM", "OGD", "bFGF-R-1"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:511", "label": "FGFR1 N546K", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 8.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "T", "representative_transcript": "ENST00000341462.5", "chromosome": "8", "start": 38274849, "stop": 38274849, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "515"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA357830"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "224896"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS779707422"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ASN546LYS", "RS779707422"], "members": [{"id": "ga4gh:VA.u2sHe5gOQvbCZRZZMFEQ2Sl0hYbNwygf", "label": "NC_000008.10:g.38274849G>T", "digest": "u2sHe5gOQvbCZRZZMFEQ2Sl0hYbNwygf", "type": "Allele", "location": {"id": "ga4gh:SL.dtmGDyMMVpjnu5xGAzt9ruAc-BpIOZEj", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.209Z7zJ-mFypBEWLk4rNC6S_OxY5p7bs"}, "start": 38417330, "end": 38417331}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.wbJ2omrem_S6nPCgzoFBWVeH4GF1jF5e", "label": "N546K", "digest": "wbJ2omrem_S6nPCgzoFBWVeH4GF1jF5e", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_023110.2:c.1638C>A"}, {"syntax": "hgvs.p", "value": "NP_075598.2:p.Asn546Lys"}, {"syntax": "hgvs.c", "value": "ENST00000341462.5:c.1638C>A"}, {"syntax": "hgvs.g", "value": "NC_000008.10:g.38274849G>T"}], "location": {"id": "ga4gh:SL.Iya4HK_WAy421mVW8A9mDcO9HsIJjQkm", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fgaUDXKfU18Tt8FUC5-BeWqLIEhEdMZ-"}, "start": 545, "end": 546}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:1975", "label": "Pemigatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:2359268"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:580", "type": "Disease", "label": "Cholangiocarcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C4436"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C121553"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["2H-Pyrrolo(3',2':5,6)pyrido(4,3-d)pyrimidin-2-one, 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-1,3,4,7-tetrahydro-8-(4-morpholinylmethyl)-", "INCB054828", "Pemazyre"]}, "tumorType": {"id": "civic.did:166", "label": "Pilocytic Astrocytoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4047"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:4851"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:17", "description": "In one patient with S214C mutation, the use of sorafenib has led to more than 5 years of survival and near remission.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:6", "label": "Imielinski et al., 2014, J. Clin. Invest.", "type": "Document", "title": "PubMed: Imielinski et al., 2014, J. Clin. Invest.", "pmid": 24569458}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:3", "label": "ARAF", "description": "ARAF has recently become increasingly considered for its oncogenic potential. Its potential as a target for informing clinical action was demonstrated by a single case of advanced lung adenocarcinoma harboring an S214C mutation that, when treated with sorafenib, acheived near-complete clinical remission. This finding has brought new focus on ARAF as a marker that should be assayed for in cancer treatment.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:646"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:369"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["A-RAF", "ARAF", "ARAF1", "PKS2", "RAFA1"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:10", "label": "ARAF S214C", "description": "ARAF S214C has been found to be a recurrent oncogenic mutation in non-small cell lung cancer. It has been shown to confer sensitivity to sorafenib and trametenib in cell lines. In a case study of advanced stage lung adenocarcinoma harboring this mutation, sorafenib also acheived near-complete clinical remission. This case has brought more interest to the variant from a research and clinical perspective.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 14.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "G", "representative_transcript": "ENST00000377045.4", "chromosome": "X", "start": 47426121, "stop": 47426121, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "10"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602595"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376137"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS1057519786"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["SER214CYS", "RS1057519786"], "members": [{"id": "ga4gh:VA.iS-EX0f5LOqsa0vLfz5koLPOY2J8iimH", "label": "NC_000023.10:g.47426121C>G", "digest": "iS-EX0f5LOqsa0vLfz5koLPOY2J8iimH", "type": "Allele", "location": {"id": "ga4gh:SL.I48cKOrIIUt0O4UbzkNapyx8qDxIvS-k", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.w0WZEvgJF0zf_P4yyTzjjv9oW1z61HHP"}, "start": 47566721, "end": 47566722}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.0XRP9ec08nseaod7LSuyfLDce-hpvEfm", "label": "S214C", "digest": "0XRP9ec08nseaod7LSuyfLDce-hpvEfm", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000023.10:g.47426121C>G"}, {"syntax": "hgvs.c", "value": "NM_001654.4:c.641C>G"}, {"syntax": "hgvs.p", "value": "NP_001645.1:p.Ser214Cys"}, {"syntax": "hgvs.c", "value": "ENST00000377045.4:c.641C>G"}], "location": {"id": "ga4gh:SL.aLNS5vmoCkYAlgAlZOUGVDsai7ucgVL1", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.zWUEijoFMvm7vDgj6af1ZwwBERSNnm4a"}, "start": 213, "end": 214}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "civic.tid:6", "label": "Sorafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:495881"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:65823", "type": "Disease", "label": "Thyroid cancer differentiated"}, {"id": "hemonc:612", "type": "Disease", "label": "Hepatocellular carcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C3099"}, "relation": "relatedMatch"}]}, {"id": "hemonc:660", "type": "Disease", "label": "Renal cell carcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C9385"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C61948"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["BA4 43 9006", "BAY 43-9006", "Bay-439006"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:21", "description": "Likely due to increased reliance of mutant NRAS on HSP90 for stabilization, inhibition of HSP90 by 17-AAG was shown to be effective in a patient with metastatic malignant melanoma with an NRAS G13D mutation.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:66", "label": "Banerji et al., 2008, Mol. Cancer Ther.", "type": "Document", "title": "PubMed: Banerji et al., 2008, Mol. Cancer Ther.", "pmid": 18375819}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:36", "label": "NRAS", "description": "Mutations in the RAS family of proteins have frequently been observed across cancer types. The amino acid positions G12, G13 and Q61 account for the overwhelming majority of these mutations. The isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, targeting these RAS mutants has also been very elusive, and has not yet become common practice in the clinic.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:7989"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:4893"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["ALPS4", "CMNS", "KRAS", "N-ras", "NCMS", "NRAS", "NRAS1", "NS6"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:93", "label": "NRAS G13D", "description": "While the NRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 5.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000369535.4", "chromosome": "1", "start": 115258744, "stop": 115258744, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "93"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123620"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13901"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434596"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121434596", "GLY13ASP"], "members": [{"id": "ga4gh:VA.ZCygFrh9x7Pep_Lod5s3v7-6VWyTL8WJ", "label": "NC_000001.10:g.115258744C>T", "digest": "ZCygFrh9x7Pep_Lod5s3v7-6VWyTL8WJ", "type": "Allele", "location": {"id": "ga4gh:SL.nmACO-Xumvq90HUwUzCGbqk5T84VcEZd", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Ya6Rs7DHhDeg7YaOSg1EoNi3U_nQ9SvO"}, "start": 114716122, "end": 114716123}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.eAAtCyXPBt2Xx3lWF9HbFuaOSpV8rsbL", "label": "G13D", "digest": "eAAtCyXPBt2Xx3lWF9HbFuaOSpV8rsbL", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_002524.4:c.38G>A"}, {"syntax": "hgvs.p", "value": "NP_002515.1:p.Gly13Asp"}, {"syntax": "hgvs.g", "value": "NC_000001.10:g.115258744C>T"}, {"syntax": "hgvs.c", "value": "ENST00000369535.4:c.38G>A"}], "location": {"id": "ga4gh:SL.t-hocVsezBIy119fFcy8ti1HtURU7Brr", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.974-EgvIQKi6ptqsI6XUZthCv-Py3S18"}, "start": 12, "end": 13}, "state": {"type": "LiteralSequenceExpression", "sequence": "D"}}}, "therapeutic": {"id": "civic.tid:10", "label": "Tanespimycin", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C37899"}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C37899"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["17-(Allylamino)-17-demethoxygeldanamycin", "17-AAG", "17-Allylamino-17-demethoxygeldanamycin", "17-Demethoxy-17-(2-propenylamino)geldanamycin", "17-N-allylamino-17-demethoxy Geldanamycin", "17-N-allylamino-17-demethoxygeldanamycin", "Geldanamycin, 17-allylamino-17-demethoxy-", "KOS-953"]}, "tumorType": {"id": "civic.did:7", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3224"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1909"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:22", "description": "In a melanoma patient with NRAS Q61L mutation, treatment with temozolomide resulted in disease free survival of 14 months.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:67", "label": "Soon et al., 2011, Arch Dermatol", "type": "Document", "title": "PubMed: Soon et al., 2011, Arch Dermatol", "pmid": 21576590}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:36", "label": "NRAS", "description": "Mutations in the RAS family of proteins have frequently been observed across cancer types. The amino acid positions G12, G13 and Q61 account for the overwhelming majority of these mutations. The isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, targeting these RAS mutants has also been very elusive, and has not yet become common practice in the clinic.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:7989"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:4893"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["ALPS4", "CMNS", "KRAS", "N-ras", "NCMS", "NRAS", "NRAS1", "NS6"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:95", "label": "NRAS Q61L", "description": "NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 12.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "A", "representative_transcript": "ENST00000369535.4", "chromosome": "1", "start": 115256529, "stop": 115256529, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "95"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602361"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "375874"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS11554290"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLN61LEU", "RS11554290"], "members": [{"id": "ga4gh:VA.KREc9LF3yKiPBABBnozb98MUqhfUhD6M", "label": "NC_000001.10:g.115256529T>A", "digest": "KREc9LF3yKiPBABBnozb98MUqhfUhD6M", "type": "Allele", "location": {"id": "ga4gh:SL.ICQvBKJrea6CbnZOrJ1JkwYCj5KH0SKc", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Ya6Rs7DHhDeg7YaOSg1EoNi3U_nQ9SvO"}, "start": 114713907, "end": 114713908}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.xe-_mdqshkZ6KPFrn549cCE8Xh1_lT8R", "label": "Q61L", "digest": "xe-_mdqshkZ6KPFrn549cCE8Xh1_lT8R", "type": "Allele", "expressions": [{"syntax": "hgvs.p", "value": "NP_002515.1:p.Gln61Leu"}, {"syntax": "hgvs.g", "value": "NC_000001.10:g.115256529T>A"}, {"syntax": "hgvs.c", "value": "NM_002524.4:c.182A>T"}, {"syntax": "hgvs.c", "value": "ENST00000369535.4:c.182A>T"}], "location": {"id": "ga4gh:SL.M2SLz3Ru3LNVsb6q5XgLmSlH8XXS68v2", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.974-EgvIQKi6ptqsI6XUZthCv-Py3S18"}, "start": 60, "end": 61}, "state": {"type": "LiteralSequenceExpression", "sequence": "L"}}}, "therapeutic": {"id": "civic.tid:11", "label": "Temozolomide", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:37776"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:604", "type": "Disease", "label": "Glioblastoma", "mappings": [{"coding": {"system": "ncit", "code": "C3058"}, "relation": "relatedMatch"}]}, {"id": "hemonc:559", "type": "Disease", "label": "Anaplastic glioma", "mappings": [{"coding": {"system": "ncit", "code": "C127816"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1244"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide", "8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one", "CCRG-81045", "Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-", "M & B 39831", "M And B 39831", "Methazolastone", "RP-46161", "SCH 52365", "TMZ", "Temcad", "Temodal", "Temodar", "Temomedac"]}, "tumorType": {"id": "civic.did:7", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3224"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1909"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:23", "description": "In a melanoma patient with Q61R mutation, treatment with temozolomide resulted in overall survival of 16 months.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:67", "label": "Soon et al., 2011, Arch Dermatol", "type": "Document", "title": "PubMed: Soon et al., 2011, Arch Dermatol", "pmid": 21576590}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:36", "label": "NRAS", "description": "Mutations in the RAS family of proteins have frequently been observed across cancer types. The amino acid positions G12, G13 and Q61 account for the overwhelming majority of these mutations. The isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, targeting these RAS mutants has also been very elusive, and has not yet become common practice in the clinic.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:7989"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:4893"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["ALPS4", "CMNS", "KRAS", "N-ras", "NCMS", "NRAS", "NRAS1", "NS6"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:96", "label": "NRAS Q61R", "description": "NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 10.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "C", "representative_transcript": "ENST00000369535.4", "chromosome": "1", "start": 115256529, "stop": 115256529, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "96"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123618"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13900"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS11554290"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS11554290", "GLN61ARG"], "members": [{"id": "ga4gh:VA.EJ6pXo1K5IP_VXzrTgKNp8y2V2hZegka", "label": "NC_000001.10:g.115256529T>C", "digest": "EJ6pXo1K5IP_VXzrTgKNp8y2V2hZegka", "type": "Allele", "location": {"id": "ga4gh:SL.ICQvBKJrea6CbnZOrJ1JkwYCj5KH0SKc", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Ya6Rs7DHhDeg7YaOSg1EoNi3U_nQ9SvO"}, "start": 114713907, "end": 114713908}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.USG7HMsbsCL-HLp7z50IVOkVLuPLyFl-", "label": "Q61R", "digest": "USG7HMsbsCL-HLp7z50IVOkVLuPLyFl-", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_002524.4:c.182A>G"}, {"syntax": "hgvs.p", "value": "NP_002515.1:p.Gln61Arg"}, {"syntax": "hgvs.g", "value": "NC_000001.10:g.115256529T>C"}, {"syntax": "hgvs.c", "value": "ENST00000369535.4:c.182A>G"}], "location": {"id": "ga4gh:SL.M2SLz3Ru3LNVsb6q5XgLmSlH8XXS68v2", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.974-EgvIQKi6ptqsI6XUZthCv-Py3S18"}, "start": 60, "end": 61}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:11", "label": "Temozolomide", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:37776"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:604", "type": "Disease", "label": "Glioblastoma", "mappings": [{"coding": {"system": "ncit", "code": "C3058"}, "relation": "relatedMatch"}]}, {"id": "hemonc:559", "type": "Disease", "label": "Anaplastic glioma", "mappings": [{"coding": {"system": "ncit", "code": "C127816"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1244"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide", "8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one", "CCRG-81045", "Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-", "M & B 39831", "M And B 39831", "Methazolastone", "RP-46161", "SCH 52365", "TMZ", "Temcad", "Temodal", "Temodar", "Temomedac"]}, "tumorType": {"id": "civic.did:7", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3224"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1909"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:91", "description": "In a patient with V600E-positive NSCLC, KRAS G12D seemed to confer resistance to dabrafenib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:101", "label": "Rudin et al., 2013, J Thorac Oncol", "type": "Document", "title": "PubMed: Rudin et al., 2013, J Thorac Oncol", "pmid": 23524406}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:12", "label": "BRAF V600E", "description": "BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 1353.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453136, "stop": 140453136, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "12"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123643"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13961"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376069"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS113488022", "V640E", "VAL640GLU", "VAL600GLU"], "members": [{"id": "ga4gh:VA.LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "label": "NC_000007.13:g.140453136A>T", "digest": "LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "type": "Allele", "location": {"id": "ga4gh:SL.XutGzMvqbzN-vnxmPt2MJf7ehxmB0opi", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753335, "end": 140753336}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "label": "V600E", "digest": "4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004333.4:c.1799T>A"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Val600Glu"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140453136A>T"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1799T>A"}], "location": {"id": "ga4gh:SL.ZA1XNKhCT_7m2UtmnYb8ZYOVS4eplMEK", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "civic.tid:22", "label": "Dabrafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1424911"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:675", "type": "Disease", "label": "Thyroid cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7510"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C82386"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["BRAF Inhibitor GSK2118436", "Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-", "GSK-2118436", "GSK-2118436A", "GSK2118436"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:757", "description": "One patient with BRAF V600E mutated melanoma (with no detected PI3K pathway deregulation) had a partial response on treatment with pictilisib, a PI3K inhibitor, for 9.5 months. Study was a phase-1 with 60 patients enrolled.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:500", "label": "Sarker et al., 2015, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Sarker et al., 2015, Clin. Cancer Res.", "pmid": 25370471}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:12", "label": "BRAF V600E", "description": "BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 1353.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453136, "stop": 140453136, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "12"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123643"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13961"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376069"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS113488022", "V640E", "VAL640GLU", "VAL600GLU"], "members": [{"id": "ga4gh:VA.LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "label": "NC_000007.13:g.140453136A>T", "digest": "LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "type": "Allele", "location": {"id": "ga4gh:SL.XutGzMvqbzN-vnxmPt2MJf7ehxmB0opi", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753335, "end": 140753336}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "label": "V600E", "digest": "4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004333.4:c.1799T>A"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Val600Glu"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140453136A>T"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1799T>A"}], "location": {"id": "ga4gh:SL.ZA1XNKhCT_7m2UtmnYb8ZYOVS4eplMEK", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "civic.tid:141", "label": "Pictilisib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C165479"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:7", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3224"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1909"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:794", "description": "Case report of a patient with metastatic lung adenocarcinoma. Whole exome sequencing of the metastatic tumor revealed KRAS A146V, STK11 frameshift deletion and ATM alteration. Preclinical evidence led to administration of CDK4 inhibitor LY2835219. Specifically, the PHIAL algorithm nominated this variant as actionable on the basis of a predicted synthetic lethal relationship between activated KRAS and CDK4. The patient achieved stable disease and was on treatment for 16 weeks which was the patients best and only clinical response to any cancer-directed therapy.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:528", "label": "Van Allen et al., 2014, Nat. Med.", "type": "Document", "title": "PubMed: Van Allen et al., 2014, Nat. Med.", "pmid": 24836576}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:318", "label": "KRAS A146V", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 8.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25378561, "stop": 25378561, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "322"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602440"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "375962"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS1057519725"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ALA146VAL", "RS1057519725"], "members": [{"id": "ga4gh:VA._W1MuYZswoila3Z7NG0In5P8c6vVP622", "label": "NC_000012.11:g.25378561G>A", "digest": "_W1MuYZswoila3Z7NG0In5P8c6vVP622", "type": "Allele", "location": {"id": "ga4gh:SL.9PfS1IgCQYOhM6qXMr7QN0FQCLtR_TCE", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25225626, "end": 25225627}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.K4n2i9QJMSHxusuDLbrm3oHyZE60cwbT", "label": "A146V", "digest": "K4n2i9QJMSHxusuDLbrm3oHyZE60cwbT", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000256078.4:c.437C>T"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25378561G>A"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Ala146Val"}, {"syntax": "hgvs.c", "value": "NM_004985.4:c.437C>T"}], "location": {"id": "ga4gh:SL._CquPzCaBRsKIPLk44LfCpdfLFit4ep6", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 145, "end": 146}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "civic.tid:148", "label": "Abemaciclib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1946825"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:572", "type": "Disease", "label": "Breast cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9335"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C97660"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["2-Pyrimidinamine, N-(5-((4-ethyl-1-piperazinyl)methyl)-2-pyridinyl)-5-fluoro-4-(4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl)", "LY-2835219", "LY2835219", "Verzenio"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:937", "description": "Among 33 patients treated with pan-AKT inhibitor MK-2206 in this phase 1 study, one patient with pancreatic adenocarcinoma and PTEN loss and a KRAS G12D mutation experienced a decrease of approximately 60% in cancer antigen 19-9 levels and 23% shrinkage in tumor measurements.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:641", "label": "Yap et al., 2011, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Yap et al., 2011, J. Clin. Oncol.", "pmid": 22025163}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:79", "label": "KRAS G12D", "description": "While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 162.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398284, "stop": 25398284, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "79"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA122538"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12582"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913529"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913529", "GLY12ASP"], "members": [{"id": "ga4gh:VA.qOYg4yYK-1Je25G30BkV3dWKtKDIAFEJ", "label": "NC_000012.11:g.25398284C>T", "digest": "qOYg4yYK-1Je25G30BkV3dWKtKDIAFEJ", "type": "Allele", "location": {"id": "ga4gh:SL.iF0OXeO-tnumYbGkzaFEQ7cOZI_UCI1s", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245349, "end": 25245350}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.CB571ja_KfZM_Hjn9zjjgV1an3tDWRcl", "label": "G12D", "digest": "CB571ja_KfZM_Hjn9zjjgV1an3tDWRcl", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004985.4:c.35G>A"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly12Asp"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398284C>T"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.35G>A"}], "location": {"id": "ga4gh:SL.OndkjmujtyUEZSjjCv0C-gpwnVbRgfj8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "D"}}}, "therapeutic": {"id": "civic.tid:43", "label": "Akt Inhibitor MK2206", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C90581"}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C90581"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1,2,4-Triazolo(3,4-f)(1,6)naphthyridin-3(2H)-one, 8-(4-(1-aminocyclobutyl)phenyl)-9-phenyl-", "MK 2206", "MK-2206", "MK-2206 FREE BASE", "MK2206"]}, "tumorType": {"id": "civic.did:169", "label": "Pancreatic Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3850"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:4905"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1078", "description": "Tumor sequencing in pre- and post-therapy specimens from ten individuals with mCRC who experienced disease progression after a prior response to cetuximab with chemotherapy was performed. The S492R mutation was identified in two persons. One of them had already died, the other received treatment with panitumumab and had a partial response (50% tumor reduction in all liver lesions) for 5 months.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:472", "label": "Montagut et al., 2012, Nat. Med.", "type": "Document", "title": "PubMed: Montagut et al., 2012, Nat. Med.", "pmid": 22270724}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:449", "label": "EGFR S492R", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 23.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "A", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55228009, "stop": 55228009, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "453"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602784"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376341"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS1057519860"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS1057519860", "SER492ARG"], "members": [{"id": "ga4gh:VA.QG6TP28zEwR_a3FLB3zjhZRMKqm3Oq9M", "label": "NC_000007.13:g.55228009C>A", "digest": "QG6TP28zEwR_a3FLB3zjhZRMKqm3Oq9M", "type": "Allele", "location": {"id": "ga4gh:SL.6zbdcNSn1HVtMHloyKL-LY9V__Ok18Xr", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55160315, "end": 55160316}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.89xcJTIpW8049gcHbnSmPqYc_wfbunTN", "label": "S492R", "digest": "89xcJTIpW8049gcHbnSmPqYc_wfbunTN", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.1476C>A"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55228009C>A"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Ser492Arg"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.1476C>A"}], "location": {"id": "ga4gh:SL.nTVXt4-Pfk2XJdxFumGxAA71rB4iBqZM", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 491, "end": 492}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:28", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:263034"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1857"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["ABX-EGF", "ABX-EGF Monoclonal Antibody", "ABX-EGF, Clone E7.6.3", "E7.6.3", "Human IgG2K Monoclonal Antibody", "MoAb ABX-EGF", "MoAb E7.6.3", "Monoclonal Antibody ABX-EGF", "Monoclonal Antibody E7.6.3", "Vectibix"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1131", "description": "A 43-year-old female was diagnosed with an adenocarcinoma of the ascending colon and received 6-months of adjuvant chemotherapy. After 5 years of completion of adjuvant chemotherapy, the disease relapsed. EGFR was assessed by immunohistochemistry, and the patient was subsequently treated with the anti-EGFR monoclonal antibody panitumumab. However, there was a rapid clinical worsening, which may possibly be attributed to a somatic mutation in KRAS (Q22*).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:782", "label": "Palmirotta et al., 2009, Anticancer Res.", "type": "Document", "title": "PubMed: Palmirotta et al., 2009, Anticancer Res.", "pmid": 19661358}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:475", "label": "KRAS Q22*", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 5.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398255, "stop": 25398255, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "stop_gained", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001587"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "479"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA384157370"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLN22TER", "Q22X"], "members": [{"id": "ga4gh:VA.D3p9YXBo6xbefqWNWnhDSJw31UBA1S7_", "label": "NC_000012.11:g.25398255G>A", "digest": "D3p9YXBo6xbefqWNWnhDSJw31UBA1S7_", "type": "Allele", "location": {"id": "ga4gh:SL.WaltAeIGYD3k8DLvII3AexSP-Z7ra0LU", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245320, "end": 25245321}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.KC2QNgW2MtB6PSGtZDoYWsgmTfibUfHc", "label": "Q22*", "digest": "KC2QNgW2MtB6PSGtZDoYWsgmTfibUfHc", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000256078.4:c.64C>T"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398255G>A"}, {"syntax": "hgvs.c", "value": "NM_004985.4:c.64C>T"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gln22Ter"}], "location": {"id": "ga4gh:SL.dxOQmNrU0YclZ4GJhc-9tzzReRO13_d8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 21, "end": 22}, "state": {"type": "LiteralSequenceExpression", "sequence": "*"}}}, "therapeutic": {"id": "civic.tid:28", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:263034"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1857"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["ABX-EGF", "ABX-EGF Monoclonal Antibody", "ABX-EGF, Clone E7.6.3", "E7.6.3", "Human IgG2K Monoclonal Antibody", "MoAb ABX-EGF", "MoAb E7.6.3", "Monoclonal Antibody ABX-EGF", "Monoclonal Antibody E7.6.3", "Vectibix"]}, "tumorType": {"id": "civic.did:691", "label": "Colon Mucinous Adenocarcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C7966"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3029"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1269", "description": "This Phase I study of crizotinib involved a cohort of pediatric neuroblastoma patients between ages 12 months and 22 years. In 11 patients with characterized ALK mutations, 4 had R1275Q mutations, and two of these were germline mutations.  Of these 2 germline patients, 1 showed stable disease (SD) and 1 complete response (CR). In contrast, in the 7 characterized patients with ALK mutations that were not R1275Q, 6 showed PD and 1 SD. The authors conclude this finding is promising and merits further study.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:859", "label": "Moss\u00e9 et al., 2013, Lancet Oncol.", "type": "Document", "title": "PubMed: Moss\u00e9 et al., 2013, Lancet Oncol.", "pmid": 23598171}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "germline", "geneContext": {"id": "civic.gid:1", "label": "ALK", "description": "ALK amplifications, fusions and mutations have been shown to be driving events in non-small cell lung cancer. While crizontinib has demonstrated efficacy in treating the amplification, mutations in ALK have been shown to confer resistance to current tyrosine kinase inhibitors. Second-generation TKI's have seen varied success in treating these resistant cases, and the HSP90 inhibitor 17-AAG has been shown to be cytostatic in ALK-altered cell lines.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:427"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:238"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["ALK", "ALK1", "CD246", "NBLST3"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:9", "label": "ALK R1275Q", "description": "ALK R1275Q has been observed as a recurrent mutation in  neuroblastoma, non-small cell lung cancer (NSCLC), as well as other cancer types. Neuroblastoma cells with this mutation have shown sensitivity to the ALK-inhibitor TAE684. This and the geldanamycin deriviative 17-DMAG have been shown to be effective in NSCLC cell lines.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 23.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000389048.3", "chromosome": "2", "start": 29432664, "stop": 29432664, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "9"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA341482"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "18083"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS113994087"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS113994087", "ARG1275GLN"], "members": [{"id": "ga4gh:VA.t3vU-1OKU2n8Hp6J5zIgf-fdOngWPcJI", "label": "NC_000002.11:g.29432664C>T", "digest": "t3vU-1OKU2n8Hp6J5zIgf-fdOngWPcJI", "type": "Allele", "location": {"id": "ga4gh:SL.-qNrY8pBD7rUqlnqrgBF-ZRDSEJspR0m", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.pnAqCRBrTsUoBghSD1yp_jXWSmlbdh4g"}, "start": 29209797, "end": 29209798}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.gX5hniEm7ni0BSgk4ACRN6yU5ARPwd1n", "label": "R1275Q", "digest": "gX5hniEm7ni0BSgk4ACRN6yU5ARPwd1n", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004304.4:c.3824G>A"}, {"syntax": "hgvs.p", "value": "NP_004295.2:p.Arg1275Gln"}, {"syntax": "hgvs.g", "value": "NC_000002.11:g.29432664C>T"}, {"syntax": "hgvs.c", "value": "ENST00000389048.3:c.3824G>A"}], "location": {"id": "ga4gh:SL.zbNZWCvHj679lMb2bPXhsYkuglQbHXmT", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.q9CnK-HKWh9eqhOi8FlzR7M0pCmUrWPs"}, "start": 1274, "end": 1275}, "state": {"type": "LiteralSequenceExpression", "sequence": "Q"}}}, "therapeutic": {"id": "civic.tid:12", "label": "Crizotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1148495"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:25958", "type": "Disease", "label": "Anaplastic large cell lymphoma pediatric"}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C74061"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine", "2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-", "MET Tyrosine Kinase Inhibitor PF-02341066", "PF-02341066", "PF-2341066", "Xalkori"]}, "tumorType": {"id": "civic.did:13", "label": "Neuroblastoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3270"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:769"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1270", "description": "A cohort of pediatric neuroblastoma patients ages 12 months to 22 years were assessed for response to crizotinib in a Phase I study.  11 patients in this cohort had characterized ALK mutations, 4 of which were R1275Q mutation. Two of these R1275Q mutations were germline and two were somatic. Of these 2 somatic R1275Q patients, 1 showed progressive disease (PD) and 1 showed stable disease (SD). In contrast, of the 7 characterized patients with ALK mutations that were not R1275Q, 6 showed PD and 1 SD. The stable disease patient had an R1275L mutation in ALK. In general, patients with germline or somatic R1275Q mutations or R1275L mutations had 1 complete response, 3 SD and one PD, while patients with other ALK mutations had 6 PD.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:859", "label": "Moss\u00e9 et al., 2013, Lancet Oncol.", "type": "Document", "title": "PubMed: Moss\u00e9 et al., 2013, Lancet Oncol.", "pmid": 23598171}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:1", "label": "ALK", "description": "ALK amplifications, fusions and mutations have been shown to be driving events in non-small cell lung cancer. While crizontinib has demonstrated efficacy in treating the amplification, mutations in ALK have been shown to confer resistance to current tyrosine kinase inhibitors. Second-generation TKI's have seen varied success in treating these resistant cases, and the HSP90 inhibitor 17-AAG has been shown to be cytostatic in ALK-altered cell lines.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:427"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:238"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["ALK", "ALK1", "CD246", "NBLST3"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:9", "label": "ALK R1275Q", "description": "ALK R1275Q has been observed as a recurrent mutation in  neuroblastoma, non-small cell lung cancer (NSCLC), as well as other cancer types. Neuroblastoma cells with this mutation have shown sensitivity to the ALK-inhibitor TAE684. This and the geldanamycin deriviative 17-DMAG have been shown to be effective in NSCLC cell lines.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 23.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000389048.3", "chromosome": "2", "start": 29432664, "stop": 29432664, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "9"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA341482"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "18083"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS113994087"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS113994087", "ARG1275GLN"], "members": [{"id": "ga4gh:VA.t3vU-1OKU2n8Hp6J5zIgf-fdOngWPcJI", "label": "NC_000002.11:g.29432664C>T", "digest": "t3vU-1OKU2n8Hp6J5zIgf-fdOngWPcJI", "type": "Allele", "location": {"id": "ga4gh:SL.-qNrY8pBD7rUqlnqrgBF-ZRDSEJspR0m", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.pnAqCRBrTsUoBghSD1yp_jXWSmlbdh4g"}, "start": 29209797, "end": 29209798}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.gX5hniEm7ni0BSgk4ACRN6yU5ARPwd1n", "label": "R1275Q", "digest": "gX5hniEm7ni0BSgk4ACRN6yU5ARPwd1n", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004304.4:c.3824G>A"}, {"syntax": "hgvs.p", "value": "NP_004295.2:p.Arg1275Gln"}, {"syntax": "hgvs.g", "value": "NC_000002.11:g.29432664C>T"}, {"syntax": "hgvs.c", "value": "ENST00000389048.3:c.3824G>A"}], "location": {"id": "ga4gh:SL.zbNZWCvHj679lMb2bPXhsYkuglQbHXmT", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.q9CnK-HKWh9eqhOi8FlzR7M0pCmUrWPs"}, "start": 1274, "end": 1275}, "state": {"type": "LiteralSequenceExpression", "sequence": "Q"}}}, "therapeutic": {"id": "civic.tid:12", "label": "Crizotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1148495"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:25958", "type": "Disease", "label": "Anaplastic large cell lymphoma pediatric"}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C74061"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine", "2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-", "MET Tyrosine Kinase Inhibitor PF-02341066", "PF-02341066", "PF-2341066", "Xalkori"]}, "tumorType": {"id": "civic.did:13", "label": "Neuroblastoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3270"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:769"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1395", "description": "Case report of an 81-year old man with lung adenocarcinoma and EGFR S768I mutation. The patient then received chemotheraoy (vinorelbine) and showed stable disease. Gefitinib was administered when disease progression was noted 4 months later and the patient was followed-up without signs of disease progression for 461 days.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:945", "label": "Masago et al., 2010, Jpn. J. Clin. Oncol.", "type": "Document", "title": "PubMed: Masago et al., 2010, Jpn. J. Clin. Oncol.", "pmid": 20522446}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:558", "label": "EGFR S768I", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 20.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "T", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55249005, "stop": 55249005, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "562"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA135840"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "45251"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913465"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913465", "SER768ILE"], "members": [{"id": "ga4gh:VA.yr3duXsAtLA9Sd79rm8szW7ILvFJAYWv", "label": "NC_000007.13:g.55249005G>T", "digest": "yr3duXsAtLA9Sd79rm8szW7ILvFJAYWv", "type": "Allele", "location": {"id": "ga4gh:SL.U7UoPZ07_CwylemNLMyLgeGviwbHuvkG", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55181311, "end": 55181312}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.Rxpo23_FYjedhBXFh7SzZci98pLvAm-e", "label": "S768I", "digest": "Rxpo23_FYjedhBXFh7SzZci98pLvAm-e", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2303G>T"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55249005G>T"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2303G>T"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Ser768Ile"}], "location": {"id": "ga4gh:SL.KoPNmE5zRpg7iXpQ7t2eyFUQmxV-H_nU", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 767, "end": 768}, "state": {"type": "LiteralSequenceExpression", "sequence": "I"}}}, "therapeutic": {"id": "civic.tid:14", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:328134"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1855"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"]}, "tumorType": {"id": "civic.did:30", "label": "Lung Adenocarcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3512"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3910"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1423", "description": "In 5 patients with KIT M541L mutation-positive chronic eosinophilic leukemia (4 somatic and 1 germline mutation), treatment with low dose imatinib resulted in complete and lasting remission with a median follow up of 74 months and 1 patient relapse at 50 months.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:964", "label": "Iurlo et al., 2014, Oncotarget", "type": "Document", "title": "PubMed: Iurlo et al., 2014, Oncotarget", "pmid": 25015329}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:29", "label": "KIT", "description": "c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3815"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["C-Kit", "CD117", "KIT", "MASTC", "PBT", "SCFR"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:201", "label": "KIT M541L", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 25.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "C", "representative_transcript": "ENST00000288135.5", "chromosome": "4", "start": 55593464, "stop": 55593464, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "201"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA160347"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "41599"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS3822214"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["MET541LEU", "RS3822214"], "members": [{"id": "ga4gh:VA.sOzRU-tQ3ZFWYJSe26eag0maq4n_2mzQ", "label": "NC_000004.11:g.55593464A>C", "digest": "sOzRU-tQ3ZFWYJSe26eag0maq4n_2mzQ", "type": "Allele", "location": {"id": "ga4gh:SL._t35QHShDtUJMkzHF_9sYcngMDSYuLzK", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54727297, "end": 54727298}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.OTXZTBfjx_gan23fxTFZ1oJeHJkC_U97", "label": "M541L", "digest": "OTXZTBfjx_gan23fxTFZ1oJeHJkC_U97", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_000222.2:c.1621A>C"}, {"syntax": "hgvs.p", "value": "NP_000213.1:p.Met541Leu"}, {"syntax": "hgvs.c", "value": "ENST00000288135.5:c.1621A>C"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55593464A>C"}], "location": {"id": "ga4gh:SL.mfny7Z9JwD1X3YJwNf9FoUNPbzteEbpP", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 540, "end": 541}, "state": {"type": "LiteralSequenceExpression", "sequence": "L"}}}, "therapeutic": {"id": "civic.tid:5", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:282388"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "Disease", "label": "Systemic mastocytosis", "mappings": [{"coding": {"system": "ncit", "code": "C9235"}, "relation": "relatedMatch"}]}, {"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}, {"id": "hemonc:634", "type": "Disease", "label": "Myelodysplastic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C3247"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:33893", "type": "Disease", "label": "Chronic myelogenous leukemia pediatric"}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}, {"id": "hemonc:616", "type": "Disease", "label": "Hypereosinophilic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C27038"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C62035"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"]}, "tumorType": {"id": "civic.did:251", "label": "Chronic Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3483"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1036"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1533", "description": "A 26-year old patient presented with vemurafenib resistant BRAF-mutated (V600E) cutaneous melanoma. Five of his metastases were evaluated using whole genome sequencing. A GNAQ (Q209P) mutation was identified as unanimously present in all five tumors.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1021", "label": "Turajlic et al., 2014, Ann. Oncol.", "type": "Document", "title": "PubMed: Turajlic et al., 2014, Ann. Oncol.", "pmid": 24504448}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:2317", "label": "GNAQ", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:4390"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2776"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CMAL", "CMC1", "G-ALPHA-q", "GAQ", "GNAQ", "SWS"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:600", "label": "GNAQ Q209P", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 8.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "G", "representative_transcript": "ENST00000286548.4", "chromosome": "9", "start": 80409488, "stop": 80409488, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "604"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602436"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "375957"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913492"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLN209PRO", "RS121913492"], "members": [{"id": "ga4gh:VA.EPdRwsN7yg5aPaPPN2nluuwTe1i6SRBV", "label": "NC_000009.11:g.80409488T>G", "digest": "EPdRwsN7yg5aPaPPN2nluuwTe1i6SRBV", "type": "Allele", "location": {"id": "ga4gh:SL.XP6bNaRMIVbqhVX480hxi08JFegiXDnV", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.KEO-4XBcm1cxeo_DIQ8_ofqGUkp4iZhI"}, "start": 77794571, "end": 77794572}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.g1Biz7O3dGH6mgD4S-SLGy94fL8cns9W", "label": "Q209P", "digest": "g1Biz7O3dGH6mgD4S-SLGy94fL8cns9W", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000009.11:g.80409488T>G"}, {"syntax": "hgvs.c", "value": "NM_002072.4:c.626A>C"}, {"syntax": "hgvs.p", "value": "NP_002063.2:p.Gln209Pro"}, {"syntax": "hgvs.c", "value": "ENST00000286548.4:c.626A>C"}], "location": {"id": "ga4gh:SL.duMUDbKDrF84xb5ocya-iRXvi4h90Ra3", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.EpurV-J9bhHIbKgOgfj7FaQhcbl9tAbN"}, "start": 208, "end": 209}, "state": {"type": "LiteralSequenceExpression", "sequence": "P"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:206", "label": "Skin Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3510"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:8923"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1549", "description": "Phase 1 study with the dual PI3K/mTOR inhibitor apitolisib. 120 patients were treated at doses between 2 and 70mg. Of the 14 evaluable patients with PIK3CA mutations total, there were 3 PRs (1 confirmed), 8 SD, and 3 PD as best radiological responses. One of the partial responses harbored a PIK3CA E542K mutation.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1026", "label": "Dolly et al., 2016, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Dolly et al., 2016, Clin. Cancer Res.", "pmid": 26787751}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:103", "label": "PIK3CA E542K", "description": "PIK3CA E545K/E542K variants are the second most recurrent PIK3CA mutations in breast cancer and are highly recurrent mutations in many other cancer types. Colorectal cancer patients with the PIK3CA E545K variant, and possibly other variants in the E545 region, may indicate poor prognosis relative to patients with other PIK3CA variants or wild-type PIK3CA. The literature also suggests that E545/E542 variants may confer resistance to EGFR inhibitors (e.g., cetuximab). An FDA approved treatment regimen including a targeted PIK3CA inhibitor is available for specific subtypes of breast cancer. While PIK3CA variants are highly prevalent in many other cancer types, targeted therapies for PIK3CA variants are still in early clinical trial phases in other cancer types.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 75.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000263967.3", "chromosome": "3", "start": 178936082, "stop": 178936082, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "103"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA333572"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "31944"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913273"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLU542LYS", "RS121913273"], "members": [{"id": "ga4gh:VA.52-4tAq0Ya9SeMU4eZSgO0bfqvkd_VE4", "label": "NC_000003.11:g.178936082G>A", "digest": "52-4tAq0Ya9SeMU4eZSgO0bfqvkd_VE4", "type": "Allele", "location": {"id": "ga4gh:SL.65wPuIVC66WPYQqTnuNP-taUZ03NOwmJ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 179218293, "end": 179218294}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.D6daDiDNn1u-e4YtntaYQnxlZ_0T6gtD", "label": "E542K", "digest": "D6daDiDNn1u-e4YtntaYQnxlZ_0T6gtD", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006218.3:c.1624G>A"}, {"syntax": "hgvs.p", "value": "NP_006209.2:p.Glu542Lys"}, {"syntax": "hgvs.c", "value": "ENST00000263967.3:c.1624G>A"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.178936082G>A"}], "location": {"id": "ga4gh:SL.DdVC73cqPrOnzCRvVc8N9tA3ecV5Qunt", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 541, "end": 542}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:377", "label": "Apitolisib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C91731"}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C91731"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["GDC 0980", "GDC-0980", "GNE 390", "RG 7422"]}, "tumorType": {"id": "civic.did:37", "label": "Head And Neck Squamous Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C34447"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:5520"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1580", "description": "One patient enrolled in a clinical study to evaluate vemurafenib treatment of BRAF V600E mutant hairy-cell leukemia developed resistance to vemurafenib retreatment. 300-gene targeted sequencing of the patient\u2019s genome revealed activating subclonal KRAS mutations (KRAS G12D, 15.2% allele frequency; KRAS K117N, 1.2%), as well as a RUNX1 A55E mutation (5.9%) that had not been seen prior to vemurafenib treatment or at remission. BRAF V600E allele frequency was detectable (2.4%) at the time of remission but dramatically increased at relapse (64.9%).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1043", "label": "Tiacci et al., 2015, N. Engl. J. Med.", "type": "Document", "title": "PubMed: Tiacci et al., 2015, N. Engl. J. Med.", "pmid": 26352686}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:79", "label": "KRAS G12D", "description": "While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 162.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398284, "stop": 25398284, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "79"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA122538"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12582"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913529"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913529", "GLY12ASP"], "members": [{"id": "ga4gh:VA.qOYg4yYK-1Je25G30BkV3dWKtKDIAFEJ", "label": "NC_000012.11:g.25398284C>T", "digest": "qOYg4yYK-1Je25G30BkV3dWKtKDIAFEJ", "type": "Allele", "location": {"id": "ga4gh:SL.iF0OXeO-tnumYbGkzaFEQ7cOZI_UCI1s", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245349, "end": 25245350}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.CB571ja_KfZM_Hjn9zjjgV1an3tDWRcl", "label": "G12D", "digest": "CB571ja_KfZM_Hjn9zjjgV1an3tDWRcl", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004985.4:c.35G>A"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly12Asp"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398284C>T"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.35G>A"}], "location": {"id": "ga4gh:SL.OndkjmujtyUEZSjjCv0C-gpwnVbRgfj8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "D"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:665", "label": "Hairy Cell Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C7402"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:285"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1603", "description": "Case report of a 67 year old woman with high-grade papillary urothelial carcinoma. The patient underwent chemotherapy and palliative cystectomy followed by tumor progression and pulmonary lesion enlargement. Genomic profiling of the cystectomy specimen identified FGFR3, CCND1 and FGF19 amplification as well as an FGFR3 S249C mutation (allele frequency 58%). Pazopanib was initiated on the basis of these findings and a partial response was achieved for >6 months.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1063", "label": "Palma et al., 2015, Eur. Urol.", "type": "Document", "title": "PubMed: Palma et al., 2015, Eur. Urol.", "pmid": 25766722}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:23", "label": "FGFR3", "description": "The FGFR proteins are involved in a wide array of pathways known to play a signficant role in cancer. Activation of these receptors can lead to activation of the RAS-MAPK pathway and the PI3K-AKT pathway, among others. The mechanisms by which FGFR can be misregulated vary between cancers. Amplification of the receptors has been observed in lung and breast cancers, coding mutations and deletions have been seen in many cancers, and more recently, FGFR fusions that lead to pathway actiation have been demonstrated to have oncogenic potential across multiple cancer types. The targeted therapeutics ponatinib, dovitinib and pazopanib have seen success in treating over-active FGFR signalling, prompting use of diagnostic sequencing targeting the FGFR genes, especially in lung cancer patients.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3690"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2261"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["ACH", "CD333", "CEK2", "FGFR3", "HSFGFR3EX", "JTK4"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:624", "label": "FGFR3 S249C", "description": "This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 18.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "G", "representative_transcript": "ENST00000340107.4", "chromosome": "4", "start": 1803568, "stop": 1803568, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "628"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA126380"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16339"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913483"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913483", "SER249CYS"], "members": [{"id": "ga4gh:VA.Kq6y5fv8Y64R1JLVlTDN91_aJtXLk4z6", "label": "NC_000004.11:g.1803568C>G", "digest": "Kq6y5fv8Y64R1JLVlTDN91_aJtXLk4z6", "type": "Allele", "location": {"id": "ga4gh:SL.t_cbFhXGQQNSKZ8qMpd3pd4LvHKELIgd", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 1801840, "end": 1801841}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.ScwqpwMfwX2Vt2TkAnlqTatmdC2UwnMi", "label": "S249C", "digest": "ScwqpwMfwX2Vt2TkAnlqTatmdC2UwnMi", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000004.11:g.1803568C>G"}, {"syntax": "hgvs.c", "value": "NM_000142.4:c.746C>G"}, {"syntax": "hgvs.p", "value": "NP_000133.1:p.Ser249Cys"}, {"syntax": "hgvs.p", "value": "ENST00000340107.4c.746C>G"}], "location": {"id": "ga4gh:SL.Q9zQuJzbEtQG2B7hyCuLmZovGiNuWxiY", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.xO86teDIIalLkqprCQaXyuvdPqvBxBG3"}, "start": 248, "end": 249}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "civic.tid:56", "label": "Pazopanib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:714438"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C74547"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["Benzenesulfonamide, 5-((4-((2,3-dimethyl-2H-indazol-6-yl)methylamino)-2-pyrimidinyl)amino)-2-methyl-", "GW786034"]}, "tumorType": {"id": "civic.did:642", "label": "Transitional Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2930"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:2671"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1617", "description": "Case study of a 46-year old male patient with Peutz-Jeghers Syndrome and pancreatic cancer. A germline STK11 D194E mutation was identified with LOH in the tumor sample. phospho-S6 ribosomal protein staining was observed in the tumor indicating mTOR pathway activation. Everolimus treatement led to partial response (but no change in phospho-S6 ribosomal protein staining) for 9 months.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1069", "label": "Kl\u00fcmpen et al., 2011, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Kl\u00fcmpen et al., 2011, J. Clin. Oncol.", "pmid": 21189378}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "germline", "geneContext": {"id": "civic.gid:5534", "label": "STK11", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:11389"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:6794"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["LKB1", "PJS", "STK11", "hLKB1"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:630", "label": "STK11 D194E", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 5.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "A", "representative_transcript": "ENST00000326873.7", "chromosome": "19", "start": 1220489, "stop": 1220489, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}, {"label": "loss_of_heterozygosity", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001786"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "634"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA023096"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "185384"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS786202134"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ASP194GLU", "RS786202134"], "members": [{"id": "ga4gh:VA.ZL4YwDGkWJWLWHfpLBNn-h7Hp9jiss7A", "label": "NC_000019.9:g.1220489C>A", "digest": "ZL4YwDGkWJWLWHfpLBNn-h7Hp9jiss7A", "type": "Allele", "location": {"id": "ga4gh:SL.xzjDprmpybLIbQWt84hr_2MVqiR8yctg", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.IIB53T8CNeJJdUqzn9V_JnRtQadwWCbl"}, "start": 1220489, "end": 1220490}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.7cRa8L-oGIBYJHZuIjf6wAxWyZJc3Tv5", "label": "D194E", "digest": "7cRa8L-oGIBYJHZuIjf6wAxWyZJc3Tv5", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_000455.4:c.582C>A"}, {"syntax": "hgvs.p", "value": "NP_000446.1:p.Asp194Glu"}, {"syntax": "hgvs.c", "value": "ENST00000326873.7:c.582C>A"}, {"syntax": "hgvs.g", "value": "NC_000019.9:g.1220489C>A"}], "location": {"id": "ga4gh:SL.em7ivimaJEX3-wE0PI0Vo1sLCbmWMUmn", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.gMBRavVxWyTadnQQ5wLw7tWre4re5DKY"}, "start": 193, "end": 194}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "civic.tid:41", "label": "Everolimus", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:141704"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:641", "type": "Disease", "label": "Neuroendocrine tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3809"}, "relation": "relatedMatch"}]}, {"id": "hemonc:647", "type": "Disease", "label": "Pancreatic NET", "mappings": [{"coding": {"system": "ncit", "code": "C27720"}, "relation": "relatedMatch"}]}, {"id": "hemonc:572", "type": "Disease", "label": "Breast cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9335"}, "relation": "relatedMatch"}]}, {"id": "hemonc:660", "type": "Disease", "label": "Renal cell carcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C9385"}, "relation": "relatedMatch"}]}, {"id": "hemonc:45070", "type": "Disease", "label": "Subependymal giant cell astrocytoma", "mappings": [{"coding": {"system": "ncit", "code": "C3696"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C48387"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone", "42-O-(2-Hydroxy)ethyl Rapamycin", "Afinitor", "Certican", "RAD 001", "RAD001", "Votubia", "Zortress"]}, "tumorType": {"id": "civic.did:556", "label": "Pancreatic Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9005"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1793"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1652", "description": "Case report of a patient with NSCLC harboring a MET exon 14 skipping mutation and initial response to crizotinib. A second biopsy at the time of progression revealed an acquired MET D1228N mutation.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1116", "label": "Heist et al., 2016, J Thorac Oncol", "type": "Document", "title": "PubMed: Heist et al., 2016, J Thorac Oncol", "pmid": 27343442}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:52", "label": "MET", "description": "Mesenchymal Epithelial Transition MET is a prototypical receptor tyrosine kinase. Its ligand is Hepatocyte Growth Factor (HGF). MET alterations are drivers of human cancer. Amplification and resulting overexpression has been reported in several cancers, and make the receptor's activity independent of HGF. Gene fusions also decouple kinase activity from the cell membrane and render it constitutively active. Finally, exclusion of the juxtamembrane (JM) domain of the kinase by \"skipping\" of exon 14 activates the kinase. FDA-approved selective MET inhibitors, including tepotinib and capmatinib, have shown efficacy in cancers with exon 14 skipping mutations or MET amplification.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:7029"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:4233"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["AUTS9", "DA11", "DFNB97", "HGFR", "MET", "RCCP2", "c-Met"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:645", "label": "MET D1228N", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 5.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000397752.3", "chromosome": "7", "start": 116423407, "stop": 116423407, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "649"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA257000"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13884"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["D1246N", "ASP1228ASN", "ASP1246ASN"], "members": [{"id": "ga4gh:VA.zvOLR_KJgwNfZVpYbUA6IPmR86rWKp-5", "label": "NC_000007.13:g.116423407G>A", "digest": "zvOLR_KJgwNfZVpYbUA6IPmR86rWKp-5", "type": "Allele", "location": {"id": "ga4gh:SL.tG-owIi8Vf0cjyh17mBLRvA7hwNmrsef", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 116783352, "end": 116783353}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.bVM58R2x4zK1VVZUZFDxFOcnPVIB5gcM", "label": "D1228N", "digest": "bVM58R2x4zK1VVZUZFDxFOcnPVIB5gcM", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000007.13:g.116423407G>A"}, {"syntax": "hgvs.g", "value": "NC_000007.14:g.116783353G>A"}, {"syntax": "hgvs.c", "value": "ENST00000397752.8:c.3682G>A"}, {"syntax": "hgvs.p", "value": "ENSP00000380860.3:p.Asp1228Asn"}, {"syntax": "hgvs.p", "value": "ENSP00000380860.3:p.Asp1228Asn"}, {"syntax": "hgvs.c", "value": "ENST00000397752.7:c.3682G>A"}, {"syntax": "hgvs.c", "value": "NM_000245.4:c.3682G>A"}, {"syntax": "hgvs.p", "value": "NP_000236.2:p.Asp1228Asn"}, {"syntax": "hgvs.p", "value": "NP_000236.2:p.Asp1228Asn"}, {"syntax": "hgvs.c", "value": "NM_000245.3:c.3682G>A"}], "location": {"id": "ga4gh:SL.Bupc48G2kXRjnN7z5wflGzXSKJ-uhzkZ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.QITcgkaDXSK1bJllcGyJVlXeD_SiQdfo"}, "start": 1227, "end": 1228}, "state": {"type": "LiteralSequenceExpression", "sequence": "N"}}}, "therapeutic": {"id": "civic.tid:12", "label": "Crizotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1148495"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:25958", "type": "Disease", "label": "Anaplastic large cell lymphoma pediatric"}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C74061"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine", "2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-", "MET Tyrosine Kinase Inhibitor PF-02341066", "PF-02341066", "PF-2341066", "Xalkori"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1699", "description": "A 54-year-old man presented with stage II myeloma.  He was initially treated with chemotherapy and received an autologous stem cell transplant.  Genomic profiling of the bone biopsy revealed BRAF V600E activating mutation and the patient was treated with vemurafenib.  At 4-months post treatment (time of case study report) the patient maintains near-resolution of hypermetabolic lesions.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1147", "label": "Sharman et al., 2014, Clin Lymphoma Myeloma Leuk", "type": "Document", "title": "PubMed: Sharman et al., 2014, Clin Lymphoma Myeloma Leuk", "pmid": 24997557}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:12", "label": "BRAF V600E", "description": "BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 1353.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453136, "stop": 140453136, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "12"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123643"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13961"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376069"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS113488022", "V640E", "VAL640GLU", "VAL600GLU"], "members": [{"id": "ga4gh:VA.LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "label": "NC_000007.13:g.140453136A>T", "digest": "LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "type": "Allele", "location": {"id": "ga4gh:SL.XutGzMvqbzN-vnxmPt2MJf7ehxmB0opi", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753335, "end": 140753336}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "label": "V600E", "digest": "4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004333.4:c.1799T>A"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Val600Glu"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140453136A>T"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1799T>A"}], "location": {"id": "ga4gh:SL.ZA1XNKhCT_7m2UtmnYb8ZYOVS4eplMEK", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:41", "label": "Multiple Myeloma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3242"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9538"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1715", "description": "Case report of a 59-year-old white female patient (60 pack-years) with a CUP-syndrome. Molecular profiling identified both MET amplification (16 copies) and a KRAS G12V mutation. The patient was treated with crizotinib and experienced a complete normalization of tumor metabolic activity for more than 19 months. Other identified aberrations include CCND1 amplification (8 copies), MYC amplification (9 copies) as well as KRAS G12V, TP53 R273L and CARD11 N184S.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1158", "label": "Palma et al., 2014, Case Rep Oncol", "type": "Document", "title": "PubMed: Palma et al., 2014, Case Rep Oncol", "pmid": 25232318}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "refutes", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:421", "label": "KRAS G12V", "description": "KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 67.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "A", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398284, "stop": 25398284, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "425"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA122540"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12583"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913529"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913529", "GLY12VAL"], "members": [{"id": "ga4gh:VA.-SzXMvMSRoSJgvsIDz-7M7VTFdo4FCtA", "label": "NC_000012.11:g.25398284C>A", "digest": "-SzXMvMSRoSJgvsIDz-7M7VTFdo4FCtA", "type": "Allele", "location": {"id": "ga4gh:SL.iF0OXeO-tnumYbGkzaFEQ7cOZI_UCI1s", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245349, "end": 25245350}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.JTtvYJD7yl02AOq09HjSZDUnfg4gYdUb", "label": "G12V", "digest": "JTtvYJD7yl02AOq09HjSZDUnfg4gYdUb", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004985.4:c.35G>T"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly12Val"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398284C>A"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.35G>T"}], "location": {"id": "ga4gh:SL.OndkjmujtyUEZSjjCv0C-gpwnVbRgfj8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "civic.tid:12", "label": "Crizotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1148495"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:25958", "type": "Disease", "label": "Anaplastic large cell lymphoma pediatric"}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C74061"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine", "2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-", "MET Tyrosine Kinase Inhibitor PF-02341066", "PF-02341066", "PF-2341066", "Xalkori"]}, "tumorType": {"id": "civic.did:216", "label": "Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9305"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:162"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1724", "description": "An ERRFI1 (E384X) was detected in a patient with metastatic, recurrent/refractory cholangiocarcinoma (allelic fraction 11%) without any mutations or amplifications in other EGFR signaling members such as EGFR and BRAF. The patient was treated with erlotinib 150 mg orally/daily. After 3 months, RECIST v1.1 partial response evidenced by a decrease of 58% in the sum of largest diameters was observed.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:186", "label": "Borad et al., 2014, PLoS Genet.", "type": "Document", "title": "PubMed: Borad et al., 2014, PLoS Genet.", "pmid": 24550739}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:12271", "label": "ERRFI1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:18185"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:54206"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["ERRFI1", "GENE-33", "MIG-6", "MIG6", "RALT"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:672", "label": "ERRFI1 E384*", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 5.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "A", "representative_transcript": "ENST00000377482.5", "chromosome": "1", "start": 8073509, "stop": 8073509, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "stop_gained", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001587"}, {"label": "loss_of_function_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0002054"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "691"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA338219584"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["E384X", "GLU384TER"], "members": [{"id": "ga4gh:VA.JX_FH6W6rts4VAX6GWlurlqheqrgHGoT", "label": "NC_000001.10:g.8073509C>A", "digest": "JX_FH6W6rts4VAX6GWlurlqheqrgHGoT", "type": "Allele", "location": {"id": "ga4gh:SL.7OgD2CdGqpAFD4QIHPSpkstThWzu4fCy", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Ya6Rs7DHhDeg7YaOSg1EoNi3U_nQ9SvO"}, "start": 8013448, "end": 8013449}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.kWW7c-ipidvW6wjftZ21AGcUIcXkn_2F", "label": "E384*", "digest": "kWW7c-ipidvW6wjftZ21AGcUIcXkn_2F", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000001.10:g.8073509C>A"}], "location": {"id": "ga4gh:SL.ywU3EnaEVGev-HAzMQceWPLbR2EEEMEW", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.C49OdjhPGBXjeiBVRZb2HYBbiYuYPtK_"}, "start": 383, "end": 384}, "state": {"type": "LiteralSequenceExpression", "sequence": "*"}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:29", "label": "Cholangiocarcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4436"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:4947"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2157", "description": "In a lung adenocarcinoma patient harboring an EGFR E746_A750 mutation and an acquired EGFR T790M co-mutation, EGFR T790M was associated with sensitivity to osimertinib monotherapy. Prior to the development of the EGFR T790M mutation, the patient was treated with gefitinib and achieved a partial response, but subsequently tumor progression occurred; however, osimertinib treatment resulted a favorable tumor response with the extinguishment of the EGFR T790M mutation. In a stage IV lung adenocarcinoma patient harboring an EGFR L858R mutation and an acquired EGFR T790M co-mutation, EGFR T790M was associated with sensitivity to osimertinib monotherapy. Prior to the development of the EGFR T790M mutation, the patient was treated with erlotinib, followed by gefitinib for 12 months and achieved stable disease, but subsequently metastasis occurred; the EGFR T790M was then identified and subsequent 10 month treatment with osimertinib monotherapy resulted in a 45% disease regression.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1516", "label": "Planchard et al., 2015, Ann. Oncol.", "type": "Document", "title": "PubMed: Planchard et al., 2015, Ann. Oncol.", "pmid": 26269204}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:34", "label": "EGFR T790M", "description": "EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 406.25}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55249071, "stop": 55249071, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "34"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA090928"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16613"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434569"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["THR790MET", "RS121434569"], "members": [{"id": "ga4gh:VA.OvEfBRaS34JkfM0_ZHJVDQEjqtwzyjyp", "label": "NC_000007.13:g.55249071C>T", "digest": "OvEfBRaS34JkfM0_ZHJVDQEjqtwzyjyp", "type": "Allele", "location": {"id": "ga4gh:SL.ZCgOjF-_T0EOBXGc-6yICYui-jgFzJfY", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55181377, "end": 55181378}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.faKID4aj8rP8NKZpWL4mWDToEztTUmbr", "label": "T790M", "digest": "faKID4aj8rP8NKZpWL4mWDToEztTUmbr", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2369C>T"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2369C>T"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Thr790Met"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55249071C>T"}], "location": {"id": "ga4gh:SL.C1y_lDZe8e9pKy3jcj3oJKw_7252Hrxa", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 789, "end": 790}, "state": {"type": "LiteralSequenceExpression", "sequence": "M"}}}, "therapeutic": {"id": "civic.tid:187", "label": "Osimertinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1721560"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C116377"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-", "AZD-9291", "AZD9291", "Mereletinib", "Tagrisso"]}, "tumorType": {"id": "civic.did:30", "label": "Lung Adenocarcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3512"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3910"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2184", "description": "Five patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored NRAS Q61R and were wildtype for KRAS, BRAF and PIK3CA. Overall, one patient experienced stable disease, and the other four experienced progressive disease.The five patients whose tumors harbored NRAS Q61R included a 65 year old male treated with cetuximab monotherapy as a 3rd line treatment who experienced progressive disease and had PFS of 6 weeks and OS of 41 weeks; a 47 year old female treated with cetuximab and ironotecan as a 5th line therapy who experienced progressive disease and had PFS of 4 weeks and OS of 10 weeks; a 60 year old female treated with cetuximab and ironotecan as a 3rd line therapy who experienced stable disease and had PFS of 24 weeks and OS of 38 weeks; a 47 year old female treated with cetuximab and ironotecan as a 3rd line therapy who experienced progressive disease and had PFS of 14 weeks and OS of 18 weeks; and a 77 year old male treated with cetuximab monotherapy as a 1st line therapy who experienced progressive disease and had PFS of 7 weeks and OS of 67 weeks.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:76", "label": "De Roock et al., 2010, Lancet Oncol.", "type": "Document", "title": "PubMed: De Roock et al., 2010, Lancet Oncol.", "pmid": 20619739}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:36", "label": "NRAS", "description": "Mutations in the RAS family of proteins have frequently been observed across cancer types. The amino acid positions G12, G13 and Q61 account for the overwhelming majority of these mutations. The isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, targeting these RAS mutants has also been very elusive, and has not yet become common practice in the clinic.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:7989"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:4893"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["ALPS4", "CMNS", "KRAS", "N-ras", "NCMS", "NRAS", "NRAS1", "NS6"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:96", "label": "NRAS Q61R", "description": "NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 10.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "C", "representative_transcript": "ENST00000369535.4", "chromosome": "1", "start": 115256529, "stop": 115256529, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "96"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123618"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13900"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS11554290"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS11554290", "GLN61ARG"], "members": [{"id": "ga4gh:VA.EJ6pXo1K5IP_VXzrTgKNp8y2V2hZegka", "label": "NC_000001.10:g.115256529T>C", "digest": "EJ6pXo1K5IP_VXzrTgKNp8y2V2hZegka", "type": "Allele", "location": {"id": "ga4gh:SL.ICQvBKJrea6CbnZOrJ1JkwYCj5KH0SKc", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Ya6Rs7DHhDeg7YaOSg1EoNi3U_nQ9SvO"}, "start": 114713907, "end": 114713908}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.USG7HMsbsCL-HLp7z50IVOkVLuPLyFl-", "label": "Q61R", "digest": "USG7HMsbsCL-HLp7z50IVOkVLuPLyFl-", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_002524.4:c.182A>G"}, {"syntax": "hgvs.p", "value": "NP_002515.1:p.Gln61Arg"}, {"syntax": "hgvs.g", "value": "NC_000001.10:g.115256529T>C"}, {"syntax": "hgvs.c", "value": "ENST00000369535.4:c.182A>G"}], "location": {"id": "ga4gh:SL.M2SLz3Ru3LNVsb6q5XgLmSlH8XXS68v2", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.974-EgvIQKi6ptqsI6XUZthCv-Py3S18"}, "start": 60, "end": 61}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:16", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:318341"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}, {"id": "mesh:D006258", "type": "Disease", "label": "Head and Neck Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C4013"}, "relation": "relatedMatch"}]}, {"id": "mesh:D002294", "type": "Disease", "label": "Carcinoma, Squamous Cell", "mappings": [{"coding": {"system": "ncit", "code": "C2929"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1723"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2268", "description": "In recurrent lung cancer patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, patients with KRAS mutations had a lower frequency of partial response (PR) and stable disease (SD) and a higher rate of progressive disease (PD) (PR:0, SD:1, PD:15 vs. PR:24, SD:8, PD:14; P=0.0274) compared to wildtype KRAS patients. Patients with KRAS mutations also had a shorter overall survival compared to wildtype KRAS patients (HR:2.542, 95% CI:1.048-6.168, P=0.0390).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1416", "label": "Endoh et al., 2006, J Thorac Oncol", "type": "Document", "title": "PubMed: Endoh et al., 2006, J Thorac Oncol", "pmid": 17409929}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:421", "label": "KRAS G12V", "description": "KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 67.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "A", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398284, "stop": 25398284, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "425"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA122540"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12583"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913529"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913529", "GLY12VAL"], "members": [{"id": "ga4gh:VA.-SzXMvMSRoSJgvsIDz-7M7VTFdo4FCtA", "label": "NC_000012.11:g.25398284C>A", "digest": "-SzXMvMSRoSJgvsIDz-7M7VTFdo4FCtA", "type": "Allele", "location": {"id": "ga4gh:SL.iF0OXeO-tnumYbGkzaFEQ7cOZI_UCI1s", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245349, "end": 25245350}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.JTtvYJD7yl02AOq09HjSZDUnfg4gYdUb", "label": "G12V", "digest": "JTtvYJD7yl02AOq09HjSZDUnfg4gYdUb", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004985.4:c.35G>T"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly12Val"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398284C>A"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.35G>T"}], "location": {"id": "ga4gh:SL.OndkjmujtyUEZSjjCv0C-gpwnVbRgfj8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "civic.tid:14", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:328134"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1855"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"]}, "tumorType": {"id": "civic.did:23", "label": "Lung Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C7377"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1324"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2417", "description": "This patient was part of a larger cohort of 397 patients with incurable (i.e. metastatic or unresectable) CD117-positive Gastrointestinal stromal tumors (GISTs) enrolled in the North American phase III study SWOG S0033/CALGB 150105 who were treated with either 400mg or 800mg of imatinib per day. This patient's GIST had a KIT exon 8 deletion/insertion TYD417-419Y. This patient represents the first reported sporadic GIST with a KIT exon 8 mutation as germline DNA from surrounding normal tissue was was KIT wildtype. The patient had an unconfirmed partial response to 400mg daily imatinib (TTP 8.1 months) and a censored OS of 59.3 months.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1586", "label": "Heinrich et al., 2008, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Heinrich et al., 2008, J. Clin. Oncol.", "pmid": 18955451}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:29", "label": "KIT", "description": "c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3815"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["C-Kit", "CD117", "KIT", "MASTC", "PBT", "SCFR"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:2493", "label": "KIT T417_D419delinsY", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 5.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"type": "coordinates"}}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "2620"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.AMl3d6vZEkCU_QyStsYKeai_q8kIxEWN", "label": "T417_D419delinsY", "digest": "AMl3d6vZEkCU_QyStsYKeai_q8kIxEWN", "type": "Allele", "location": {"id": "ga4gh:SL.GYtP1TsI3YvEkslW9Q3ZYGJu8yYgQLez", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 416, "end": 419}, "state": {"type": "LiteralSequenceExpression", "sequence": "Y"}}}, "therapeutic": {"id": "civic.tid:5", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:282388"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "Disease", "label": "Systemic mastocytosis", "mappings": [{"coding": {"system": "ncit", "code": "C9235"}, "relation": "relatedMatch"}]}, {"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}, {"id": "hemonc:634", "type": "Disease", "label": "Myelodysplastic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C3247"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:33893", "type": "Disease", "label": "Chronic myelogenous leukemia pediatric"}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}, {"id": "hemonc:616", "type": "Disease", "label": "Hypereosinophilic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C27038"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C62035"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"]}, "tumorType": {"id": "civic.did:2", "label": "Gastrointestinal Stromal Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3868"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9253"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2478", "description": "This prospective study of 127 patients with metastatic gastrointestinal stromal tumors (GISTs) examined the relationship between kinase (KIT and PDGFRA) genotype and treatment outcome for patients enrolled in a randomized phase II trial of imatinib (CSTI571B 2222). Three patients' GISTs harbored PDGFRA D842V. Two of these patients experienced progressive disease and one was unassessable. The authors conclude that this finding is consistent with the work of others suggesting that PDGFRA D842V is an imatinib resistant variant in GIST.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:412", "label": "Heinrich et al., 2003, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Heinrich et al., 2003, J. Clin. Oncol.", "pmid": 14645423}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:38", "label": "PDGFRA", "description": "Commonly mutated in GI tract tumors, PDGFR family genes (mutually exclusive to KIT mutations) are a hallmark of gastrointestinal stromal tumors. Gene fusions involving the PDGFRA kinase domain are highly correlated with eosinophilia, and the WHO classifies myeloid and lymphoid neoplasms with these characteristics as a distinct disorder. Mutations in the 842 region of PDGFRA have been often found to confer resistance to the tyrosine kinase inhibitor, imatinib.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8803"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5156"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD140A", "PDGFR-2", "PDGFR2", "PDGFRA"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:99", "label": "PDGFRA D842V", "description": "PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. Exogenous expression of the A842V mutation resulted in constitutive tyrosine phosphorylation of PDGFRA in the absence of ligand in 293T cells and cytokine-independent proliferation of the IL-3-dependent Ba/F3 cell line, both evidence that this is an activating mutation. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 100.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000257290.5", "chromosome": "4", "start": 55152093, "stop": 55152093, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "99"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123194"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13543"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121908585"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ASP842VAL", "RS121908585"], "members": [{"id": "ga4gh:VA.bDwkJ2filJ3ZGiUFybGFfyaCKdIVK86v", "label": "NC_000004.11:g.55152093A>T", "digest": "bDwkJ2filJ3ZGiUFybGFfyaCKdIVK86v", "type": "Allele", "location": {"id": "ga4gh:SL.LxO2YLfQbI_-TK7GOmSoOpMNiSy_Hgan", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54285925, "end": 54285926}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.vIjnL-aLYl0BSB6JutpdD7yW_qIXtdk8", "label": "D842V", "digest": "vIjnL-aLYl0BSB6JutpdD7yW_qIXtdk8", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006206.4:c.2525A>T"}, {"syntax": "hgvs.p", "value": "NP_006197.1:p.Asp842Val"}, {"syntax": "hgvs.c", "value": "ENST00000257290.5:c.2525A>T"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55152093A>T"}], "location": {"id": "ga4gh:SL.GHXCPrbd_qdPUoHjPwzv5iVFapJ0cn-o", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.XpQn9sZLGv_GU3uiWO7YHq9-_alGjrVX"}, "start": 841, "end": 842}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "civic.tid:5", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:282388"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "Disease", "label": "Systemic mastocytosis", "mappings": [{"coding": {"system": "ncit", "code": "C9235"}, "relation": "relatedMatch"}]}, {"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}, {"id": "hemonc:634", "type": "Disease", "label": "Myelodysplastic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C3247"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:33893", "type": "Disease", "label": "Chronic myelogenous leukemia pediatric"}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}, {"id": "hemonc:616", "type": "Disease", "label": "Hypereosinophilic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C27038"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C62035"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"]}, "tumorType": {"id": "civic.did:2", "label": "Gastrointestinal Stromal Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3868"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9253"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2632", "description": "In a phase II trial for bronchioloalveolar carcinoma (BAC, or in situ pulmonary adenocarcinoma), EGFR exons 18-24 were analyzed in 7 patients who had shown a partial response to erlotinib. Two patients had the del L858R mutation. One patient was a male former smoker who demonstrated response for 3 months with overall survival of 3.5 months, and the other patient was a female never smoker who had response for 6 months and overall survival of 17+ months as the patient was alive at study end.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1509", "label": "Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A.", "type": "Document", "title": "PubMed: Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A.", "pmid": 15329413}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:33", "label": "EGFR L858R", "description": "EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 379.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "G", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55259515, "stop": 55259515, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "33"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA126713"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16609"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376282"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376280"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434568"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121434568", "LEU858ARG"], "members": [{"id": "ga4gh:VA.TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "label": "NC_000007.13:g.55259515T>G", "digest": "TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "type": "Allele", "location": {"id": "ga4gh:SL.ulUNwZvajob7nzyrlpOd6uUWZIYCsoWb", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55191821, "end": 55191822}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "label": "L858R", "digest": "z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000007.13:g.55259515T>G"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2573T>G"}, {"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2573T>G"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Leu858Arg"}], "location": {"id": "ga4gh:SL.yVGJnwqxV6oCGqC_8nNb58D_wPXJeNJo", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 857, "end": 858}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2889", "description": "A 69 y.o. woman presented with metastatic mucosal melanoma of the anus. KIT was amplified in the tumor and harbored the K642E mutation. Post surgery with extensive margins, she was given a dose of anti-CTLA-4 antibody and adjuvant radiation therapy for 2.5 weeks.  Two weeks post radiation she developed nodules in the same region and testing indicated they were malignant melanoma with high KIT expression. She enrolled in a clinical trial with a dose of 400mg imatinib per day (Nov 2006). Less than 4 weeks later, all nodules had disappeared. Upon a lowered dosage to 200mg of imatinib, the nodules returned and subsequently the dosage was increased to 600mg/day. The patient remained melanoma-free on 600mg imatinib until a follow up in Jan 2008. The authors do not provide further details on patient outcome.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1649", "label": "Lutzky et al., 2008, Pigment Cell Melanoma Res", "type": "Document", "title": "PubMed: Lutzky et al., 2008, Pigment Cell Melanoma Res", "pmid": 18510589}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:29", "label": "KIT", "description": "c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3815"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["C-Kit", "CD117", "KIT", "MASTC", "PBT", "SCFR"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:952", "label": "KIT K642E", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 10.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "G", "representative_transcript": "ENST00000288135.5", "chromosome": "4", "start": 55594221, "stop": 55594221, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "978"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123547"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13866"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913512"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["LYS642GLU", "RS121913512"], "members": [{"id": "ga4gh:VA.VzsVyqlcWS87LveLKdzeYwvmm7lz9ie1", "label": "NC_000004.11:g.55594221A>G", "digest": "VzsVyqlcWS87LveLKdzeYwvmm7lz9ie1", "type": "Allele", "location": {"id": "ga4gh:SL.7PW790jMHV75G4i43nyFnA0wBi4smstb", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54728054, "end": 54728055}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.c3eVCAN6jp3r4vtwc3oFyMhn2omrwVB4", "label": "K642E", "digest": "c3eVCAN6jp3r4vtwc3oFyMhn2omrwVB4", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_000222.2:c.1924A>G"}, {"syntax": "hgvs.p", "value": "NP_000213.1:p.Lys642Glu"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55594221A>G"}, {"syntax": "hgvs.c", "value": "ENST00000288135.5:c.1924A>G"}], "location": {"id": "ga4gh:SL.WREnGgCj6j4vnGFA-gtJI9XkOJ5R6-ix", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 641, "end": 642}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "civic.tid:5", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:282388"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "Disease", "label": "Systemic mastocytosis", "mappings": [{"coding": {"system": "ncit", "code": "C9235"}, "relation": "relatedMatch"}]}, {"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}, {"id": "hemonc:634", "type": "Disease", "label": "Myelodysplastic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C3247"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:33893", "type": "Disease", "label": "Chronic myelogenous leukemia pediatric"}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}, {"id": "hemonc:616", "type": "Disease", "label": "Hypereosinophilic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C27038"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C62035"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"]}, "tumorType": {"id": "civic.did:83", "label": "Mucosal Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C114828"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:0050929"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2906", "description": "S768I mutations in exon 20 of the EGFR gene are rare and are typically seen in conjunction with sensitizing EGFR mutations. Because of this mutation's rarity and the variability of responses of treated cases, its exact prognostic and predictive role is not fully understood. In our experience, S768I mutations in isolation do not necessarily confer sensitivity to erlotinib, but in conjunction with sensitizing EGFR mutations, S768I mutations do not restrict efficacy.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1669", "label": "Leventakos et al., 2016, J Thorac Oncol", "type": "Document", "title": "PubMed: Leventakos et al., 2016, J Thorac Oncol", "pmid": 27211795}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "refutes", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:558", "label": "EGFR S768I", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 20.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "T", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55249005, "stop": 55249005, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "562"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA135840"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "45251"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913465"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913465", "SER768ILE"], "members": [{"id": "ga4gh:VA.yr3duXsAtLA9Sd79rm8szW7ILvFJAYWv", "label": "NC_000007.13:g.55249005G>T", "digest": "yr3duXsAtLA9Sd79rm8szW7ILvFJAYWv", "type": "Allele", "location": {"id": "ga4gh:SL.U7UoPZ07_CwylemNLMyLgeGviwbHuvkG", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55181311, "end": 55181312}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.Rxpo23_FYjedhBXFh7SzZci98pLvAm-e", "label": "S768I", "digest": "Rxpo23_FYjedhBXFh7SzZci98pLvAm-e", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2303G>T"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55249005G>T"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2303G>T"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Ser768Ile"}], "location": {"id": "ga4gh:SL.KoPNmE5zRpg7iXpQ7t2eyFUQmxV-H_nU", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 767, "end": 768}, "state": {"type": "LiteralSequenceExpression", "sequence": "I"}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4062", "description": "Patient 3 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) KIT K550_K558 deletion. Following failure of imatinib, the GIST was again genotyped, but no secondary mutations were found. The patient started on 50mg sunitinib on a schedule of two weeks on/two weeks off. This patient experienced stable disease less than 6 months; time to progresssion of 14 weeks and overall survival of 17 weeks (Table A1).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:965", "label": "Heinrich et al., 2008, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Heinrich et al., 2008, J. Clin. Oncol.", "pmid": 18955458}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:29", "label": "KIT", "description": "c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3815"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["C-Kit", "CD117", "KIT", "MASTC", "PBT", "SCFR"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:923", "label": "KIT K550_K558del", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 5.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "AAACCCATGTATGAAGTACAGTGGAAG", "representative_transcript": "ENST00000288135.5", "chromosome": "4", "start": 55593582, "stop": 55593608, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "inframe_deletion", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001822"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "949"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123524"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13857"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913234"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["KPMYEVQWK550-558DEL", "RS121913234"], "definingContext": {"id": "ga4gh:VA.KskdFsJad0DhtpbBJR81XOo60lakEvZH", "label": "K550_K558del", "digest": "KskdFsJad0DhtpbBJR81XOo60lakEvZH", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_000222.2:c.1648_1674del27"}, {"syntax": "hgvs.p", "value": "NP_000213.1:p.Lys550_Lys558del"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55593582_55593608del27"}, {"syntax": "hgvs.c", "value": "ENST00000288135.5:c.1648_1674del27"}], "location": {"id": "ga4gh:SL.VZsNtPUDOBWnmwrsDUV00bbKAP9jT4lE", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Q9MPzyLwkv3LGwhdCmLQk97t4C4Szmp3"}, "start": 549, "end": 558}, "state": {"type": "ReferenceLengthExpression", "length": 0, "sequence": "", "repeatSubunitLength": 9}}}, "therapeutic": {"id": "civic.tid:157", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:357977"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:647", "type": "Disease", "label": "Pancreatic NET", "mappings": [{"coding": {"system": "ncit", "code": "C27720"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:660", "type": "Disease", "label": "Renal cell carcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C9385"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C71622"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"]}, "tumorType": {"id": "civic.did:2", "label": "Gastrointestinal Stromal Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3868"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9253"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4095", "description": "Patient 47 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) KIT K558_V559 deletion. Following failure of imatinib, the GIST was again genotyped, but no secondary mutations were found. The patient took 50 mg sunitinib per day on a treatment schedule of two weeks on/one week off.  The patient experienced progressive disease. Time to progression was censored at 5 weeks, and overall survival was 60 weeks.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:965", "label": "Heinrich et al., 2008, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Heinrich et al., 2008, J. Clin. Oncol.", "pmid": 18955458}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:29", "label": "KIT", "description": "c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3815"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["C-Kit", "CD117", "KIT", "MASTC", "PBT", "SCFR"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:938", "label": "KIT K558_V559del", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 5.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "AAGGTT", "representative_transcript": "ENST00000288135.5", "chromosome": "4", "start": 55593606, "stop": 55593611, "type": "coordinates"}}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "964"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA645516838"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.BZMXLl2o634ib3c2wu0wRg5F_Wrun8fq", "label": "K558_V559del", "digest": "BZMXLl2o634ib3c2wu0wRg5F_Wrun8fq", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000288135.5:c.1672_1677delAAGGTT"}], "location": {"id": "ga4gh:SL.YafCK9WFTb38wmhGmtPReaMTWrWN_75y", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 557, "end": 559}, "state": {"type": "ReferenceLengthExpression", "length": 0, "sequence": "", "repeatSubunitLength": 2}}}, "therapeutic": {"id": "civic.tid:157", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:357977"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:647", "type": "Disease", "label": "Pancreatic NET", "mappings": [{"coding": {"system": "ncit", "code": "C27720"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:660", "type": "Disease", "label": "Renal cell carcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C9385"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C71622"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"]}, "tumorType": {"id": "civic.did:2", "label": "Gastrointestinal Stromal Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3868"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9253"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4136", "description": "Patient 29 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) KIT L576P mutation. Following failure of imatinib, the GIST was again genotyped, but no secondary mutations were found. The patient took 50 mg sunitinib per day on a treatment schedule of two weeks on/two weeks off.  The patient experienced stable disease for less than 6 months. Time to progression and overall survival were 31 and 29 weeks.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:965", "label": "Heinrich et al., 2008, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Heinrich et al., 2008, J. Clin. Oncol.", "pmid": 18955458}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:29", "label": "KIT", "description": "c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3815"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["C-Kit", "CD117", "KIT", "MASTC", "PBT", "SCFR"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:72", "label": "KIT L576P", "description": "KIT L576P is an exon 11 mutation that lies within the juxtamembrane domain. It is one of the most recurrent KIT mutations in melanoma, and both in vitro and in vivo studies have shown sensitivity to imatinib.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 16.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "C", "representative_transcript": "ENST00000288135.5", "chromosome": "4", "start": 55593661, "stop": 55593661, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "72"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602401"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "375919"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913513"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913513", "LEU576PRO"], "members": [{"id": "ga4gh:VA.cDfuVZGVVrXoZw4OCMvPzRoE-wmxPCe7", "label": "NC_000004.11:g.55593661T>C", "digest": "cDfuVZGVVrXoZw4OCMvPzRoE-wmxPCe7", "type": "Allele", "location": {"id": "ga4gh:SL.L4ctgq33nZK-3qpkyZ3AGmnjLX5oDTT3", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54727494, "end": 54727495}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.HWknWoV4xcSvDuWAAwCjl8LfzvkYKaur", "label": "L576P", "digest": "HWknWoV4xcSvDuWAAwCjl8LfzvkYKaur", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_000222.2:c.1727T>C"}, {"syntax": "hgvs.p", "value": "NP_000213.1:p.Leu576Pro"}, {"syntax": "hgvs.c", "value": "ENST00000288135.5:c.1727T>C"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55593661T>C"}], "location": {"id": "ga4gh:SL.CsgoOC4XNjQhj2UDGEcredbnxi0kTV5V", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 575, "end": 576}, "state": {"type": "LiteralSequenceExpression", "sequence": "P"}}}, "therapeutic": {"id": "civic.tid:157", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:357977"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:647", "type": "Disease", "label": "Pancreatic NET", "mappings": [{"coding": {"system": "ncit", "code": "C27720"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:660", "type": "Disease", "label": "Renal cell carcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C9385"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C71622"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"]}, "tumorType": {"id": "civic.did:2", "label": "Gastrointestinal Stromal Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3868"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9253"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4142", "description": "Patient 74 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) KIT D579 deletion. Following failure of imatinib, the GIST was again genotyped, but no secondary mutations were found. The patient took 50 mg sunitinib per day on a treatment schedule of four weeks on/two weeks off. The patient experienced stable disease for less than six months. Time to progression was censored at 10 weeks and overall survival was 85 weeks.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:965", "label": "Heinrich et al., 2008, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Heinrich et al., 2008, J. Clin. Oncol.", "pmid": 18955458}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:29", "label": "KIT", "description": "c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3815"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["C-Kit", "CD117", "KIT", "MASTC", "PBT", "SCFR"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:951", "label": "KIT D579del", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 5.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "GAT", "representative_transcript": "ENST00000288135.5", "chromosome": "4", "start": 55593669, "stop": 55593671, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "conservative_inframe_deletion", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001825"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "977"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16611553"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "409725"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS1060502543"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS1060502543", "ASP579DEL"], "members": [{"id": "ga4gh:VA.XPzy9z4cABZxmQLg-CRPjWc5hpHOUGhV", "label": "NC_000004.11:g.55593669_55593671delGAT", "digest": "XPzy9z4cABZxmQLg-CRPjWc5hpHOUGhV", "type": "Allele", "location": {"id": "ga4gh:SL.ENwHq9QYyFh2BPejuW9jERYAudfp61wy", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54727500, "end": 54727505}, "state": {"type": "ReferenceLengthExpression", "length": 2, "sequence": "AT", "repeatSubunitLength": 3}}], "definingContext": {"id": "ga4gh:VA.ItfiDcQiNGwNXNXDfnVx1QqOG4KXoE0Y", "label": "D579del", "digest": "ItfiDcQiNGwNXNXDfnVx1QqOG4KXoE0Y", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000288135.5:c.1735_1737delGAT"}, {"syntax": "hgvs.c", "value": "NM_000222.2:c.1735_1737delGAT"}, {"syntax": "hgvs.p", "value": "NP_000213.1:p.Asp579del"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55593669_55593671delGAT"}], "location": {"id": "ga4gh:SL.fUZ4ob5L7L9mHtSne_5VZ_iV0bx-5W3R", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 578, "end": 579}, "state": {"type": "ReferenceLengthExpression", "length": 0, "sequence": "", "repeatSubunitLength": 1}}}, "therapeutic": {"id": "civic.tid:157", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:357977"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:647", "type": "Disease", "label": "Pancreatic NET", "mappings": [{"coding": {"system": "ncit", "code": "C27720"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:660", "type": "Disease", "label": "Renal cell carcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C9385"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C71622"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"]}, "tumorType": {"id": "civic.did:2", "label": "Gastrointestinal Stromal Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3868"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9253"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4231", "description": "In a study, 1 participant with stage IV squamous cell lung carcinoma was sequenced at EGFR exons 18 to 21 and was found to have V774M mutation, and was treated with the 1st generation TKI erlotinib. The patient (M, 80, smoker) had progressive disease as response, progression free survival (PFS) of 1.6 months, overall survival (OS) of 6.7 months and was not alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1503", "label": "Wu et al., 2011, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Wu et al., 2011, Clin. Cancer Res.", "pmid": 21531810}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "refutes", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:1770", "label": "EGFR V774M", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 5.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55249022, "stop": 55249022, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1894"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA158928427"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["VAL774MET"], "definingContext": {"id": "ga4gh:VA.EO6uY5e3axTFPV8g9g0-aVWOd1bhbkjh", "label": "V774M", "digest": "EO6uY5e3axTFPV8g9g0-aVWOd1bhbkjh", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2320G>A"}], "location": {"id": "ga4gh:SL.cgV6PLNk8QmTSLVtfsY2d8jl3wxonI2M", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 773, "end": 774}, "state": {"type": "LiteralSequenceExpression", "sequence": "M"}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4239", "description": "In a study, 1 participant with stage IIIB lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have K806E mutation, and was treated with the 1st generation TKI gefitinib. The patient (M, 77, nonsmoker) had progressive disease as response, progression free survival (PFS) of 1.6 months, overall survival (OS) of 28.1 months and was alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1503", "label": "Wu et al., 2011, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Wu et al., 2011, Clin. Cancer Res.", "pmid": 21531810}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "refutes", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:1771", "label": "EGFR K806E", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 5.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "G", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55249118, "stop": 55249118, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1895"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA4266068"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS754652044"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["LYS806GLU", "RS754652044"], "members": [{"id": "ga4gh:VA.Cn2EzZOKCBDwyde6WKoQaUmVfhZgG4S8", "label": "NC_000007.13:g.55249118A>G", "digest": "Cn2EzZOKCBDwyde6WKoQaUmVfhZgG4S8", "type": "Allele", "location": {"id": "ga4gh:SL.jdmVhimmHP10eC9EqjGKWSI1oGaAi3yH", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55181424, "end": 55181425}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.vqyAV-va6B-a0uMjtH4sHZGsgdLPnjnR", "label": "K806E", "digest": "vqyAV-va6B-a0uMjtH4sHZGsgdLPnjnR", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2416A>G"}, {"syntax": "hgvs.c", "value": "NM_001346898.1:c.2416A>G"}, {"syntax": "hgvs.p", "value": "NP_001333827.1:p.Lys806Glu"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55249118A>G"}], "location": {"id": "ga4gh:SL.Ow9FJdehwwzUN6uyaKbp2XFMu7CYWYUs", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 805, "end": 806}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "civic.tid:14", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:328134"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1855"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4244", "description": "In a study, 1 participant with stage IV lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have N826Y mutation, and was treated with the 1st generation TKI gefitinib. The patient (F, 46, nonsmoker) had progressive disease as response, progression free survival (PFS) of 3.3 months, overall survival (OS) of 13.9 months and was not alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1503", "label": "Wu et al., 2011, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Wu et al., 2011, Clin. Cancer Res.", "pmid": 21531810}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "refutes", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:1772", "label": "EGFR N826Y", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 5.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55259418, "stop": 55259418, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1896"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA367580076"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ASN826TYR"], "members": [{"id": "ga4gh:VA.BfZKU7FgNWy6faNLFWWYwdoE7p9TOkD5", "label": "NC_000007.13:g.55259418A>T", "digest": "BfZKU7FgNWy6faNLFWWYwdoE7p9TOkD5", "type": "Allele", "location": {"id": "ga4gh:SL.FtVdamlfs_lon8_O8BgisVpNgRN2nB4t", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55191724, "end": 55191725}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.GwG90xmuJHnnb6MzyQXsajJeXEvz7Buv", "label": "N826Y", "digest": "GwG90xmuJHnnb6MzyQXsajJeXEvz7Buv", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2476A>T"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55259418A>T"}, {"syntax": "hgvs.g", "value": "NC_000007.14:g.55191725A>T"}, {"syntax": "hgvs.c", "value": "NM_005228.3:c.2476A>T"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Asn826Tyr"}], "location": {"id": "ga4gh:SL.0kN8JtPieMqdQzFDj6NqP-80Lh0dQXit", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 825, "end": 826}, "state": {"type": "LiteralSequenceExpression", "sequence": "Y"}}}, "therapeutic": {"id": "civic.tid:14", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:328134"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1855"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4256", "description": "In a study, 1 participant with stage IV lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have N842S mutation, and was treated with the 1st generation TKI gefitinib. The patient (F, 73, nonsmoker) progressive disease as response, progression free survival (PFS) of 0.9 months, overall survival (OS) of 9.7 months and was not alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1503", "label": "Wu et al., 2011, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Wu et al., 2011, Clin. Cancer Res.", "pmid": 21531810}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "refutes", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:1775", "label": "EGFR N842S", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 5.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "G", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55259467, "stop": 55259467, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1899"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA367580172"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ASN842SER"], "definingContext": {"id": "ga4gh:VA.KKmSUWibWtBX1i5-BI83gLmiWnCIwksF", "label": "N842S", "digest": "KKmSUWibWtBX1i5-BI83gLmiWnCIwksF", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2525A>G"}], "location": {"id": "ga4gh:SL.cJgMSqFD9D4vdemjnecT03Fp7Q3KgMTk", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 841, "end": 842}, "state": {"type": "LiteralSequenceExpression", "sequence": "S"}}}, "therapeutic": {"id": "civic.tid:14", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:328134"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1855"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4260", "description": "In a study, 1 participant with stage IIIB lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have T847I mutation, and was treated with the 1st generation TKI gefitinib. The patient (M, 77, smoker) progressive disease as response, progression free survival (PFS) of 1.1 months, overall survival (OS) of 1.1 months and was not alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1503", "label": "Wu et al., 2011, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Wu et al., 2011, Clin. Cancer Res.", "pmid": 21531810}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "refutes", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:1371", "label": "EGFR T847I", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 5.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "chromosome": "7", "start": 55259482, "stop": 55259482, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1463"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA367580204"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.2nLX0LZ-5ntA7tiS63vvt2Fw-M0pK3_y", "label": "T847I", "digest": "2nLX0LZ-5ntA7tiS63vvt2Fw-M0pK3_y", "type": "Allele", "location": {"id": "ga4gh:SL.ExDBKiJn-OjElNHokWx-9ZTM-vn9yMWh", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 846, "end": 847}, "state": {"type": "LiteralSequenceExpression", "sequence": "I"}}}, "therapeutic": {"id": "civic.tid:14", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:328134"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1855"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4264", "description": "In a study, 1 participant with stage IV lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have V851I mutation, and was treated with the 1st generation TKI gefitinib. The patient (F, 69, nonsmoker) progressive disease as response, progression free survival (PFS) of 0.7 months, overall survival (OS) of 1.6 months and was not alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common mutations (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1503", "label": "Wu et al., 2011, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Wu et al., 2011, Clin. Cancer Res.", "pmid": 21531810}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "refutes", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:1374", "label": "EGFR V851I", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 5.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "chromosome": "7", "start": 55259493, "stop": 55259493, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1466"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA367580229"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.yk9Rocz0MjefOe7nB64z2r1LmYgE8LEa", "label": "V851I", "digest": "yk9Rocz0MjefOe7nB64z2r1LmYgE8LEa", "type": "Allele", "location": {"id": "ga4gh:SL.Xf2XiQb385r5bqYrD5014fZQwHAhrfbh", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 850, "end": 851}, "state": {"type": "LiteralSequenceExpression", "sequence": "I"}}}, "therapeutic": {"id": "civic.tid:14", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:328134"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1855"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4589", "description": "This retrospective study of a phase 2 clinical trial (NCT01068769) examined regorafenib safety and efficacy in advanced gastrointestinal stromal tumor (GIST) patients refractory to at least imatinib and sunitinib. Three patients whose GIST harbored KIT D820Y experienced clinical benefit (defined as complete response, partial response, stable disease >16 weeks) in response to regorafenib. One patient remained on study without disease progression for >11 months, one patient developed disease progression at 5.7 months, and the other patient underwent surgical removal of all residual disease after 7 months, but continued on regorafenib. Immunoblotting of matched pre- and post- treatment GIST biopsies from these patients demonstrated decreased levels of KIT phosphorylation in response to regorafenib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2045", "label": "George et al., 2012, J. Clin. Oncol.", "type": "Document", "title": "PubMed: George et al., 2012, J. Clin. Oncol.", "pmid": 22614970}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:29", "label": "KIT", "description": "c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3815"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["C-Kit", "CD117", "KIT", "MASTC", "PBT", "SCFR"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:960", "label": "KIT D820Y", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 14.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "T", "representative_transcript": "ENST00000288135.5", "chromosome": "4", "start": 55599332, "stop": 55599332, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "986"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602408"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "375928"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS1057519710"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS1057519710", "ASP820TYR"], "members": [{"id": "ga4gh:VA.5r-C3LlZD9ZUxpzHonsY_73ObMcsnLfe", "label": "NC_000004.11:g.55599332G>T", "digest": "5r-C3LlZD9ZUxpzHonsY_73ObMcsnLfe", "type": "Allele", "location": {"id": "ga4gh:SL.U-4Q2T2UMOZypgIGPT5ywR4z_1iS_0S2", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54733165, "end": 54733166}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.eRIxjMxh82kLJLDQDT9QFEkAStdnxgEA", "label": "D820Y", "digest": "eRIxjMxh82kLJLDQDT9QFEkAStdnxgEA", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_000222.2:c.2458G>T"}, {"syntax": "hgvs.p", "value": "NP_000213.1:p.Asp820Tyr"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55599332G>T"}, {"syntax": "hgvs.c", "value": "ENST00000288135.5:c.2458G>T"}], "location": {"id": "ga4gh:SL.IP0kMJA-uoNQiQegymLJcTzqq32pKPm2", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 819, "end": 820}, "state": {"type": "LiteralSequenceExpression", "sequence": "Y"}}}, "therapeutic": {"id": "civic.tid:27", "label": "Regorafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1312397"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C78204"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide", "BAY 73-4506", "REGORAFENIB ANHYDROUS", "Stivarga"]}, "tumorType": {"id": "civic.did:2", "label": "Gastrointestinal Stromal Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3868"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9253"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4595", "description": "This retrospective study of a phase 2 clinical trial (NCT01068769) examined regorafenib safety and efficacy in advanced gastrointestinal stromal tumor (GIST) patients refractory to at least imatinib and sunitinib. One patient whose GIST harbored KIT N882K did not experienced disease progression for >7 months following treatment by regorafenib. Immunoblotting of matched pre- and post- treatment GIST biopsies from this patient demonstrated decreased levels of KIT phosphorylation in response to regorafenib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2045", "label": "George et al., 2012, J. Clin. Oncol.", "type": "Document", "title": "PubMed: George et al., 2012, J. Clin. Oncol.", "pmid": 22614970}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:29", "label": "KIT", "description": "c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3815"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["C-Kit", "CD117", "KIT", "MASTC", "PBT", "SCFR"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:1237", "label": "KIT N822K", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 29.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "A", "representative_transcript": "ENST00000288135.5", "chromosome": "4", "start": 55599340, "stop": 55599340, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1263"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602411"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "375931"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913514"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ASN822LYS", "RS121913514"], "members": [{"id": "ga4gh:VA.3i1HI4wqippKn-gtuyM4kiLBVQD0N763", "label": "NC_000004.11:g.55599340T>A", "digest": "3i1HI4wqippKn-gtuyM4kiLBVQD0N763", "type": "Allele", "location": {"id": "ga4gh:SL.hQJlf-hzQ4szaLAhFocudRE99wMKEJfi", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54733173, "end": 54733174}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.z_WJsSByobbgzhHAaWw4kVBhNnyADN57", "label": "N822K", "digest": "z_WJsSByobbgzhHAaWw4kVBhNnyADN57", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_000222.2:c.2466T>A"}, {"syntax": "hgvs.p", "value": "NP_000213.1:p.Asn822Lys"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55599340T>A"}, {"syntax": "hgvs.c", "value": "ENST00000288135.5:c.2466T>A"}], "location": {"id": "ga4gh:SL.B6627_40nR9hpf23ICFLQ0TZsfFxpBNq", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 821, "end": 822}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:27", "label": "Regorafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1312397"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C78204"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide", "BAY 73-4506", "REGORAFENIB ANHYDROUS", "Stivarga"]}, "tumorType": {"id": "civic.did:2", "label": "Gastrointestinal Stromal Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3868"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9253"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:5960", "description": "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Among 2 patients with BRAF V600E mutant colorectal cancer, 1 had a partial response.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2414", "label": "Hainsworth et al., 2018, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Hainsworth et al., 2018, J. Clin. Oncol.", "pmid": 29320312}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:12", "label": "BRAF V600E", "description": "BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 1353.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453136, "stop": 140453136, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "12"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123643"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13961"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376069"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS113488022", "V640E", "VAL640GLU", "VAL600GLU"], "members": [{"id": "ga4gh:VA.LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "label": "NC_000007.13:g.140453136A>T", "digest": "LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "type": "Allele", "location": {"id": "ga4gh:SL.XutGzMvqbzN-vnxmPt2MJf7ehxmB0opi", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753335, "end": 140753336}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "label": "V600E", "digest": "4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004333.4:c.1799T>A"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Val600Glu"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140453136A>T"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1799T>A"}], "location": {"id": "ga4gh:SL.ZA1XNKhCT_7m2UtmnYb8ZYOVS4eplMEK", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:5964", "description": "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2414", "label": "Hainsworth et al., 2018, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Hainsworth et al., 2018, J. Clin. Oncol.", "pmid": 29320312}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "refutes", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:1080", "label": "BRAF G464V", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 5.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "A", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140481417, "stop": 140481417, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1106"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA135076"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "40364"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913348"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLY464VAL", "RS121913348"], "members": [{"id": "ga4gh:VA.I9LKfPzaUhApamrAvxR8l-h35ClCPlWM", "label": "NC_000007.13:g.140481417C>A", "digest": "I9LKfPzaUhApamrAvxR8l-h35ClCPlWM", "type": "Allele", "location": {"id": "ga4gh:SL.MvpzfivsYDKoUmHX-3ZDpicCNNcAm-ps", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140781616, "end": 140781617}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.ndj14P-veygd615fbOXvDAHlbb7e7VkC", "label": "G464V", "digest": "ndj14P-veygd615fbOXvDAHlbb7e7VkC", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004333.4:c.1391G>T"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Gly464Val"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140481417C>A"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1391G>T"}], "location": {"id": "ga4gh:SL.ffi2U28riqtvEwhz2fBAGL4cyx8nJy8j", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 463, "end": 464}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:216", "label": "Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9305"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:162"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:5965", "description": "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2414", "label": "Hainsworth et al., 2018, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Hainsworth et al., 2018, J. Clin. Oncol.", "pmid": 29320312}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "refutes", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:966", "label": "BRAF G469A", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 5.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "G", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140481402, "stop": 140481402, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "992"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123655"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13971"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913355"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913355", "GLY469ALA"], "members": [{"id": "ga4gh:VA.YwoIl4DlhzbwIuiH2l18Mp_rutItWTSc", "label": "NC_000007.13:g.140481402C>G", "digest": "YwoIl4DlhzbwIuiH2l18Mp_rutItWTSc", "type": "Allele", "location": {"id": "ga4gh:SL.aa1GxLCX05tKa5SEdEvyWGjvwCdYwPcz", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140781601, "end": 140781602}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.IexfZ1vNskNZUuT4_0kdYA5zNJ6YnSHo", "label": "G469A", "digest": "IexfZ1vNskNZUuT4_0kdYA5zNJ6YnSHo", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004333.4:c.1406G>C"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Gly469Ala"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140481402C>G"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1406G>C"}], "location": {"id": "ga4gh:SL.BY8zrg6VJVWbywxAE-gQbP8o87KlqRk7", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 468, "end": 469}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:216", "label": "Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9305"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:162"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:5966", "description": "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2414", "label": "Hainsworth et al., 2018, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Hainsworth et al., 2018, J. Clin. Oncol.", "pmid": 29320312}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "refutes", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:2097", "label": "BRAF G496A", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 5.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"type": "coordinates"}}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "2221"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.yXbTtwcVS1lWxG_fNV2f7g8fKYKuorVo", "label": "G496A", "digest": "yXbTtwcVS1lWxG_fNV2f7g8fKYKuorVo", "type": "Allele", "location": {"id": "ga4gh:SL.EVQ2rd6zgZGVLzGXF1vx1AHaFUjhl56G", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 517, "end": 518}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:216", "label": "Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9305"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:162"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:5967", "description": "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2414", "label": "Hainsworth et al., 2018, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Hainsworth et al., 2018, J. Clin. Oncol.", "pmid": 29320312}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "refutes", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:1160", "label": "BRAF N581S", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 5.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "C", "chromosome": "7", "start": 140453193, "stop": 140453193, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1186"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA180747"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913370"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913370", "N189S", "N9S"], "definingContext": {"id": "ga4gh:VA.oe04bY-MmU0wogVjdwNio7uEm3uV91ha", "label": "N581S", "digest": "oe04bY-MmU0wogVjdwNio7uEm3uV91ha", "type": "Allele", "location": {"id": "ga4gh:SL.-DofOquJGQk20Qd1KuBr4_TJjGWPjVmW", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 580, "end": 581}, "state": {"type": "LiteralSequenceExpression", "sequence": "S"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:216", "label": "Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9305"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:162"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:5968", "description": "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2414", "label": "Hainsworth et al., 2018, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Hainsworth et al., 2018, J. Clin. Oncol.", "pmid": 29320312}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "refutes", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:2098", "label": "BRAF G466V", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 14.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "A", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140481411, "stop": 140481411, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "2222"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123647"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13967"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913351"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLY466VAL", "RS121913351"], "members": [{"id": "ga4gh:VA.rTU_Q-4E6SYZRuGw6uLmg0sekqgcyAB6", "label": "NC_000007.13:g.140481411C>A", "digest": "rTU_Q-4E6SYZRuGw6uLmg0sekqgcyAB6", "type": "Allele", "location": {"id": "ga4gh:SL.b-COuHbMMBebWWHMv6wspiXtC1AcHJ9F", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140781610, "end": 140781611}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.WTGRt27yQDZ0lXw7Gz-FskGnJkr2Eenj", "label": "G466V", "digest": "WTGRt27yQDZ0lXw7Gz-FskGnJkr2Eenj", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000007.13:g.140481411C>A"}, {"syntax": "hgvs.c", "value": "NM_004333.4:c.1397G>T"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Gly466Val"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1397G>T"}], "location": {"id": "ga4gh:SL.ZjNtMaJuKuzhEq3QJ6sLiXfNfCB_ToNz", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 465, "end": 466}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:216", "label": "Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9305"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:162"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:5969", "description": "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2414", "label": "Hainsworth et al., 2018, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Hainsworth et al., 2018, J. Clin. Oncol.", "pmid": 29320312}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "refutes", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:1535", "label": "BRAF G596R", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 6.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "G", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453149, "stop": 140453149, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1627"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602422"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "375943"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913361"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["G24R", "G204R", "RS121913361", "GLY596ARG"], "members": [{"id": "ga4gh:VA.DNO4gptcvGZgvp72BqGaqssDoBa1QwEb", "label": "NC_000007.13:g.140453149C>G", "digest": "DNO4gptcvGZgvp72BqGaqssDoBa1QwEb", "type": "Allele", "location": {"id": "ga4gh:SL._B1JAcpMBsijHUaAi9aQ0jbmsZG_X4Sg", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753348, "end": 140753349}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.lq8WTBtfiMWK1cPiVyabWb29ttWOdPSD", "label": "G596R", "digest": "lq8WTBtfiMWK1cPiVyabWb29ttWOdPSD", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004333.4:c.1786G>C"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Gly596Arg"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140453149C>G"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1786G>C"}], "location": {"id": "ga4gh:SL.g7kb4XxsPZQufg5Lp1ks1AXGS1sgby6b", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 595, "end": 596}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:216", "label": "Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9305"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:162"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:5970", "description": "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2414", "label": "Hainsworth et al., 2018, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Hainsworth et al., 2018, J. Clin. Oncol.", "pmid": 29320312}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "refutes", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:2099", "label": "BRAF G606E", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 5.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453118, "stop": 140453118, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "2223"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA369542941"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLY606GLU"], "definingContext": {"id": "ga4gh:VA.M3V-HxXqjjOJqZLztrjIybdbyqQGfxeB", "label": "G606E", "digest": "M3V-HxXqjjOJqZLztrjIybdbyqQGfxeB", "type": "Allele", "location": {"id": "ga4gh:SL.FUsg6Ed_mq2vzmjN86y8Rx8rusW13vpL", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 605, "end": 606}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:216", "label": "Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9305"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:162"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:5971", "description": "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2414", "label": "Hainsworth et al., 2018, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Hainsworth et al., 2018, J. Clin. Oncol.", "pmid": 29320312}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "refutes", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:579", "label": "BRAF L597Q", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 14.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453145, "stop": 140453145, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "583"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602257"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "76687"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913366"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913366", "LEU597GLN"], "members": [{"id": "ga4gh:VA.zATpR7iDy-_AbeeQ93IgDZwYYZwApall", "label": "NC_000007.13:g.140453145A>T", "digest": "zATpR7iDy-_AbeeQ93IgDZwYYZwApall", "type": "Allele", "location": {"id": "ga4gh:SL.cGEXoAH8CN1Vt-bvqUWZ8VkN24o8W6en", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753344, "end": 140753345}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.ACflef8GdM92PuUEXZWrBIw7zckEaek7", "label": "L597Q", "digest": "ACflef8GdM92PuUEXZWrBIw7zckEaek7", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004333.4:c.1790T>A"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Leu597Gln"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140453145A>T"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1790T>A"}], "location": {"id": "ga4gh:SL.SfkS-rvyLn3M9HwlYokvq8Bm6IWEWHdt", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 596, "end": 597}, "state": {"type": "LiteralSequenceExpression", "sequence": "Q"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:216", "label": "Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9305"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:162"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:5972", "description": "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2414", "label": "Hainsworth et al., 2018, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Hainsworth et al., 2018, J. Clin. Oncol.", "pmid": 29320312}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "refutes", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:2100", "label": "BRAF P731T", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 5.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "T", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140434507, "stop": 140434507, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "2224"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA369537254"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["PRO731THR"], "definingContext": {"id": "ga4gh:VA.Frb5q41YpGvLyG0t5728JBo007ggRnCG", "label": "P731T", "digest": "Frb5q41YpGvLyG0t5728JBo007ggRnCG", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000288602.6:c.2193G>T"}], "location": {"id": "ga4gh:SL.oNrrnK4214Qf998J2NGHak-uU6uTlP2Z", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 730, "end": 731}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:216", "label": "Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9305"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:162"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:5987", "description": "A 48-year-old female was diagnosed with metastatic pancreatic ductal adenocarcinoma and subsequently started on standard of care chemotherapy, during which her hepatic lesions progressed. Detailed molecular profiling was performed on a biopsy from a liver lesion that demonstrated an IDH1 mutation, R132H. The patient subsequently received a mutant IDH1 inhibitor (AG-120), but with no response.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1360", "label": "Brody et al., 2016, Cancer Biol. Ther.", "type": "Document", "title": "PubMed: Brody et al., 2016, Cancer Biol. Ther.", "pmid": 27466707}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:26", "label": "IDH1", "description": "IDH1 mutations have been observed in a number of cancer types, including sarcomas, hematologic malignancies, colon cancer and brain cancer. Mutations in the two isocitrate dehydrogenase enzymes involved in cytoplasmic (IDH1) and mitochondrial (IDH2) conversion of alpha-ketoglutarate to D-2-hydroxyglutarate have been described as mutually exclusive in many of these cancer types. The most frequent mutations involve R132 (IDH1) and R172 (IDH2) involve the active site and result in neomorphic enzyme activity. The implications of mutations in this gene vary greatly by cancer type. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 mutations have been associated with worse outcome, shorter overall survival, and normal karyotype. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Unlike the association with cytogenetically normal AML, in glioblastoma, IDH1 mutations have been associated with specific cytogenetic abnormalities, 1p and 19q deletions.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:5382"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3417"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["HEL-216", "HEL-S-26", "IDCD", "IDH", "IDH1", "IDP", "IDPC", "PICD"]}}, "direction": "refutes", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:416", "label": "IDH1 R132H", "description": "IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 9.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000415913.1", "chromosome": "2", "start": 209113112, "stop": 209113112, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "420"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA170874"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "156444"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913500"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ARG132HIS", "RS121913500"], "members": [{"id": "ga4gh:VA.y3AcrkM1rtuFjcKurTbKEBQGYa40qvZ2", "label": "NC_000002.11:g.209113112C>T", "digest": "y3AcrkM1rtuFjcKurTbKEBQGYa40qvZ2", "type": "Allele", "location": {"id": "ga4gh:SL.i6qLHldpS-d8QaHyYj47QgixNmVG6Ew9", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.pnAqCRBrTsUoBghSD1yp_jXWSmlbdh4g"}, "start": 208248387, "end": 208248388}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.Wks7qWMMqFTj1uw9ZUHDeHXj-coBFGll", "label": "R132H", "digest": "Wks7qWMMqFTj1uw9ZUHDeHXj-coBFGll", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_001282386.1:c.395G>A"}, {"syntax": "hgvs.p", "value": "NP_005887.2:p.Arg132His"}, {"syntax": "hgvs.g", "value": "NC_000002.11:g.209113112C>T"}, {"syntax": "hgvs.c", "value": "ENST00000415913.1:c.395G>A"}], "location": {"id": "ga4gh:SL.6S6Nay-qWJnCSbbpF3hcBRTeoYOc4CJD", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.VZMxTY2iB2G_EuwlpVZ0AnX6R-am08GZ"}, "start": 131, "end": 132}, "state": {"type": "LiteralSequenceExpression", "sequence": "H"}}}, "therapeutic": {"id": "civic.tid:454", "label": "Ivosidenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:2049873"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:580", "type": "Disease", "label": "Cholangiocarcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C4436"}, "relation": "relatedMatch"}]}, {"id": "hemonc:552", "type": "Disease", "label": "Acute myeloid leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3171"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C114383"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["AG-120", "Tibsovo"]}, "tumorType": {"id": "civic.did:141", "label": "Pancreatic Ductal Adenocarcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9120"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3498"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:6006", "description": "Patients with recurrent pancreatic adenocarcinoma was treated with gemcitabine + nab-paclitaxel, FOLFIRINOX and docetaxel + irinotecan. After failure of these treatment, a tumor specimen from the pancreaticoduodenectomy was analysed, which revealed an activating mutation in exon 19 (L747_P753>S) of EGFR. Mutations were also detected in CDKN2A, TP53, and amplifications of PRKCI and TERC. He began erlotinib at 150mg daily. CT imaging  revealed a partial response by RECIST at 8, 24 and 32 weeks after starting erlotinib. At 40 weeks CT imaging revealed unequivocal disease progression. After disease progression to erlotinib, a repeat liver biopsy revealed an EGFR T790M mutation. He began treatment with osimertinib at 80mg daily. After 8 weeks of this treatment CT imaging revealed unequivocal disease progression.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2359", "label": "Cecchini et al., 2017, J Natl Compr Canc Netw", "type": "Document", "title": "PubMed: Cecchini et al., 2017, J Natl Compr Canc Netw", "pmid": 28874593}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "refutes", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:34", "label": "EGFR T790M", "description": "EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 406.25}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55249071, "stop": 55249071, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "34"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA090928"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16613"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434569"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["THR790MET", "RS121434569"], "members": [{"id": "ga4gh:VA.OvEfBRaS34JkfM0_ZHJVDQEjqtwzyjyp", "label": "NC_000007.13:g.55249071C>T", "digest": "OvEfBRaS34JkfM0_ZHJVDQEjqtwzyjyp", "type": "Allele", "location": {"id": "ga4gh:SL.ZCgOjF-_T0EOBXGc-6yICYui-jgFzJfY", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55181377, "end": 55181378}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.faKID4aj8rP8NKZpWL4mWDToEztTUmbr", "label": "T790M", "digest": "faKID4aj8rP8NKZpWL4mWDToEztTUmbr", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2369C>T"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2369C>T"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Thr790Met"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55249071C>T"}], "location": {"id": "ga4gh:SL.C1y_lDZe8e9pKy3jcj3oJKw_7252Hrxa", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 789, "end": 790}, "state": {"type": "LiteralSequenceExpression", "sequence": "M"}}}, "therapeutic": {"id": "civic.tid:187", "label": "Osimertinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1721560"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C116377"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-", "AZD-9291", "AZD9291", "Mereletinib", "Tagrisso"]}, "tumorType": {"id": "civic.did:158", "label": "Pancreatic Adenocarcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C8294"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:4074"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:6049", "description": "Of the 33 patients with desmoid fibromatosis treated with meloxicam, a COX-2 selective inhibitor, one showed complete remission (CR), 7 partial remission (PR), 12 stable disease (SD), and 13 progressive disease (PD). The following 3 point mutations were identified in 21 of the 33 cases (64%): T41A (16 cases), S45F (4 cases) and S45P (one case). All four cases with S45F mutation exhibited strong nuclear expression of \u03b2-catenin. S45F mutation was significantly associated with a poor response (all cases; PD) (p = 0.017)", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2444", "label": "Hamada et al., 2014, PLoS ONE", "type": "Document", "title": "PubMed: Hamada et al., 2014, PLoS ONE", "pmid": 24788118}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:1290", "label": "CTNNB1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:2514"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1499"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CTNNB", "CTNNB1", "EVR7", "MRD19", "NEDSDV", "armadillo"]}}, "direction": "refutes", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:1260", "label": "CTNNB1 S45F", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 80.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000349496.5", "chromosome": "3", "start": 41266137, "stop": 41266137, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1286"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA127283"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "17588"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913409"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913409", "SER45PHE"], "members": [{"id": "ga4gh:VA.wPaeM1o9r1fSzqTO2BUv8ahkT5-xhLAR", "label": "NC_000003.11:g.41266137C>T", "digest": "wPaeM1o9r1fSzqTO2BUv8ahkT5-xhLAR", "type": "Allele", "location": {"id": "ga4gh:SL.XEC11T5d3ulojykhVs3_liz_ofsJm7LT", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 41224645, "end": 41224646}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.WQ0oDBX2ozrBALdHujC1yKq77v82sE76", "label": "S45F", "digest": "WQ0oDBX2ozrBALdHujC1yKq77v82sE76", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_001904.3:c.134C>T"}, {"syntax": "hgvs.p", "value": "NP_001895.1:p.Ser45Phe"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.41266137C>T"}, {"syntax": "hgvs.c", "value": "ENST00000349496.5:c.134C>T"}], "location": {"id": "ga4gh:SL.eBsXtbQnHJdSpuUhz2ZeAFLDNMCUvUz-", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.FhMJAgGb9jn2O4_xxRn3C1JNlL0MKKsM"}, "start": 44, "end": 45}, "state": {"type": "LiteralSequenceExpression", "sequence": "F"}}}, "therapeutic": {"id": "civic.tid:572", "label": "Meloxicam", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:41493"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C61439"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide", "Mobec", "Mobic", "Mobicox", "Movalis", "Movatec"]}, "tumorType": {"id": "civic.did:2967", "label": "Desmoid Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9182"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:0080366"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:7021", "description": "A 17-year-old Native American female with B-ALL had persistent MRD at the end of induction. In addition to a complex karyotype, sequencing revealed a novel F694L mutation in JAK2, a p.Cys119_Ile121delinsTrpGlyLeu in IKZF1, and a IGH-CRLF2 translocation, all consistent with BCR-ABL1 like B-ALL. In addition to conventional cytotoxic therapy, the patient was started on 40 mg/m2/day ruxolitinib TKI BID for 2 weeks on, 2 weeks off, and MRD diminished to <0.01% prior to allogeneic transplant. The patient was in remission with 100% engraftment from a full match sibling at day 100 post-transplant.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2719", "label": "Mayfield et al., 2017, Pediatr Blood Cancer", "type": "Document", "title": "PubMed: Mayfield et al., 2017, Pediatr Blood Cancer", "pmid": 27860260}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:28", "label": "JAK2", "description": "JAK2 is a kinase that is misregulated or mutated in a number of myeloproliferative diseases and cancers. The mutation V617F is the most clinically relevant variant, and is seen in around half of myeloproliferative disorders. The variant is a known activating mutation, and activated JAK2 is sufficient to drive myeloproliferative disorders in mouse models. V617F, while most recurrent, is not the only mechanism by which JAK2 can be activated in patients. JAK2 is now one of the first diagnostic markers tested upon diagnosis with a myeloproliferative disorder.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6192"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3717"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["JAK2", "JTK10"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:2460", "label": "JAK2 F694L", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 5.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"type": "coordinates"}}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "2587"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.ODP2b_SMQ4vV_8RE98J9PkWN89LrXpQD", "label": "F694L", "digest": "ODP2b_SMQ4vV_8RE98J9PkWN89LrXpQD", "type": "Allele", "location": {"id": "ga4gh:SL.mQeV8owas7bf3BwO_NFrgWpELyy1p16t", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.-OkqBNmqypFmiUe8izaIgIwkeOz5Z__6"}, "start": 693, "end": 694}, "state": {"type": "LiteralSequenceExpression", "sequence": "L"}}}, "therapeutic": {"id": "civic.tid:386", "label": "Ruxolitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1193326"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:605", "type": "Disease", "label": "Graft versus host disease", "mappings": [{"coding": {"system": "ncit", "code": "C3063"}, "relation": "relatedMatch"}]}, {"id": "hemonc:655", "type": "Disease", "label": "Polycythemia vera", "mappings": [{"coding": {"system": "ncit", "code": "C3336"}, "relation": "relatedMatch"}]}, {"id": "hemonc:635", "type": "Disease", "label": "Myelofibrosis", "mappings": [{"coding": {"system": "ncit", "code": "C3248"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C77888"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(3R)-3-cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)propanenitrile", "INCB-18424", "INCB18424", "Jakafi", "Oral JAK Inhibitor INCB18424"]}, "tumorType": {"id": "civic.did:2953", "label": "Childhood B-cell Acute Lymphoblastic Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9140"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:0080146"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:8185", "description": "The effective cohort in this study was 11 CLL patients who were first treated with ibrutinib and then on progression treated with venetoclax until progression. Patient samples were sequenced before and after progression on venetoclax. The previously described BCL2 G101V mutation was observed in 1 patient at progression", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:3376", "label": "Lucas et al., 2020, Blood", "type": "Document", "title": "PubMed: Lucas et al., 2020, Blood", "pmid": 32232486}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:59", "label": "BCL2", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:990"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:596"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["BCL2", "Bcl-2", "PPP1R50"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:2829", "label": "BCL2 G101V", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 8.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "A", "representative_transcript": "ENST00000398117.1", "chromosome": "18", "start": 60985598, "stop": 60985598, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "2960"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA402632336"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLY101VAL"], "definingContext": {"id": "ga4gh:VA.SJLMw1klgo7k0ba5nCHmM1DDC24VhEKL", "label": "G101V", "digest": "SJLMw1klgo7k0ba5nCHmM1DDC24VhEKL", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000398117.1:c.302G>T"}], "location": {"id": "ga4gh:SL.s20SE6Fg5cNsBD8quE_A50pF_WGEb1PM", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.ht6Jrp_WdHFgzv2MpF-GxPV6L3on-xuM"}, "start": 100, "end": 101}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "civic.tid:574", "label": "Venetoclax", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1747556"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:552", "type": "Disease", "label": "Acute myeloid leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3171"}, "relation": "relatedMatch"}]}, {"id": "hemonc:581", "type": "Disease", "label": "Chronic lymphocytic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3163"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C103147"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-(4-((2-(4-Chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide", "ABT-0199", "ABT-199", "ABT199", "GDC-0199", "RG7601", "Venclexta", "Venclyxto"]}, "tumorType": {"id": "civic.did:191", "label": "Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C27911"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:6354"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:8375", "description": "This study identified BCL2 F104I mutation in one Follicular Lymphoma patient who developed resistance to venetoclax. Codon 104 is located at the venetoclax binding site of BCL2.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:3502", "label": "Blombery et al., 2019, Br. J. Haematol.", "type": "Document", "title": "PubMed: Blombery et al., 2019, Br. J. Haematol.", "pmid": 31234236}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:59", "label": "BCL2", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:990"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:596"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["BCL2", "Bcl-2", "PPP1R50"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:2951", "label": "BCL2 F104I", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 8.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000398117.1", "chromosome": "18", "start": 60985590, "stop": 60985590, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "3082"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA402632320"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["PHE104ILE"], "members": [{"id": "ga4gh:VA.TIzqjN-2xpWUQZJQvNrO89Q2wezQDUOY", "label": "NC_000018.10:g.63318357A>T", "digest": "TIzqjN-2xpWUQZJQvNrO89Q2wezQDUOY", "type": "Allele", "location": {"id": "ga4gh:SL.YTE-G9ItxWKWg3ZKw7d7EkCLpE2VP4cm", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vWwFhJ5lQDMhh-czg06YtlWqu0lvFAZV"}, "start": 63318356, "end": 63318357}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.Rts0zMM5MXBu5AjIqDXwPGM5ysYCoAiV", "label": "F104I", "digest": "Rts0zMM5MXBu5AjIqDXwPGM5ysYCoAiV", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000018.10:g.63318357A>T"}, {"syntax": "hgvs.g", "value": "NC_000018.9:g.60985590A>T"}, {"syntax": "hgvs.c", "value": "NM_000633.3:c.310T>A"}, {"syntax": "hgvs.p", "value": "NP_000624.2:p.Phe104Ile"}], "location": {"id": "ga4gh:SL.k1PMrP4IVJT-YVKggi-ZTph22lo6f9VJ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.ht6Jrp_WdHFgzv2MpF-GxPV6L3on-xuM"}, "start": 103, "end": 104}, "state": {"type": "LiteralSequenceExpression", "sequence": "I"}}}, "therapeutic": {"id": "civic.tid:574", "label": "Venetoclax", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1747556"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:552", "type": "Disease", "label": "Acute myeloid leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3171"}, "relation": "relatedMatch"}]}, {"id": "hemonc:581", "type": "Disease", "label": "Chronic lymphocytic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3163"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C103147"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-(4-((2-(4-Chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide", "ABT-0199", "ABT-199", "ABT199", "GDC-0199", "RG7601", "Venclexta", "Venclyxto"]}, "tumorType": {"id": "civic.did:51", "label": "Follicular Lymphoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3209"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:0050873"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:8933", "description": "One 56 year old female with advanced recurrent low grade serous ovarian cancer with NRAS Q61K mutation had a partial response to trametinib, with short follow-up.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:3765", "label": "Champer et al., 2019, Gynecol Oncol Rep", "type": "Document", "title": "PubMed: Champer et al., 2019, Gynecol Oncol Rep", "pmid": 30809568}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:36", "label": "NRAS", "description": "Mutations in the RAS family of proteins have frequently been observed across cancer types. The amino acid positions G12, G13 and Q61 account for the overwhelming majority of these mutations. The isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, targeting these RAS mutants has also been very elusive, and has not yet become common practice in the clinic.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:7989"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:4893"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["ALPS4", "CMNS", "KRAS", "N-ras", "NCMS", "NRAS", "NRAS1", "NS6"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:423", "label": "NRAS Q61K", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 24.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "T", "representative_transcript": "ENST00000369535.4", "chromosome": "1", "start": 115256530, "stop": 115256530, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "427"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA151263"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "73058"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913254"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLN61LYS", "RS121913254"], "members": [{"id": "ga4gh:VA.0FZuBwcgG87LilkjaTvU6aa38MO2gExn", "label": "NC_000001.10:g.115256530G>T", "digest": "0FZuBwcgG87LilkjaTvU6aa38MO2gExn", "type": "Allele", "location": {"id": "ga4gh:SL.4cQp_FS38Pdvn5eWaYtU4glYRQCpT-ch", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Ya6Rs7DHhDeg7YaOSg1EoNi3U_nQ9SvO"}, "start": 114713908, "end": 114713909}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.3cSh2D__C3zMdKiikDmDtr0F88wpN4RP", "label": "Q61K", "digest": "3cSh2D__C3zMdKiikDmDtr0F88wpN4RP", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_002524.4:c.181C>A"}, {"syntax": "hgvs.p", "value": "NP_002515.1:p.Gln61Lys"}, {"syntax": "hgvs.g", "value": "NC_000001.10:g.115256530G>T"}, {"syntax": "hgvs.c", "value": "ENST00000369535.4:c.181C>A"}], "location": {"id": "ga4gh:SL.M2SLz3Ru3LNVsb6q5XgLmSlH8XXS68v2", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.974-EgvIQKi6ptqsI6XUZthCv-Py3S18"}, "start": 60, "end": 61}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:19", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1425098"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C77908"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["GSK1120212", "JTP-74057", "MEK Inhibitor GSK1120212", "Mekinist", "N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide"]}, "tumorType": {"id": "civic.did:1432", "label": "Ovary Serous Adenocarcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C7550"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:5744"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:9225", "description": "In a retrospective study of 2316 Chinese patients with stage IV non-small cell lung carcinoma, a 65 year old female with the EGFR exon 20 insertion A763_Y764insFQEA received osimertinib as second-line treatment. The patient achieved a partial response with greater than 50% reduction in tumour size, and progression-free survival of 5.1 months. The patient had previously achieved partial response on gefinitib, but experienced disease progression after 9.0 months at which point a rebiopsy was found to harbor a T790M mutation.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:3023", "label": "Fang et al., 2019, BMC Cancer", "type": "Document", "title": "PubMed: Fang et al., 2019, BMC Cancer", "pmid": 31208370}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:1423", "label": "EGFR A763_Y764insFQEA", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 5.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"reference_build": "GRCh37", "variant_bases": "TCCAGGAAGCCT", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55248992, "stop": 55248993, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "inframe_insertion", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001821"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1515"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA135833"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS397517106"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS397517106"], "members": [{"id": "ga4gh:VA.oSxjHCKMtTr6wu2ZXawt0RmhOw0957dC", "label": "NC_000007.13:g.55248992_55248993insTCCAGGAAGCCT", "digest": "oSxjHCKMtTr6wu2ZXawt0RmhOw0957dC", "type": "Allele", "location": {"id": "ga4gh:SL.P8LgsnVBoOpZw85CyJQLBIsTWUPlQfwe", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55181287, "end": 55181299}, "state": {"type": "ReferenceLengthExpression", "length": 24, "sequence": "TCCAGGAAGCCTTCCAGGAAGCCT", "repeatSubunitLength": 12}}], "definingContext": {"id": "ga4gh:VA.gEDB2tymESJ1V5hQf1bdbW7I_4tSmIym", "label": "A763_Y764insFQEA", "digest": "gEDB2tymESJ1V5hQf1bdbW7I_4tSmIym", "type": "Allele", "expressions": [{"syntax": "hgvs.p", "value": "NP_001333827.1:p.Ala763_Tyr764insPheGlnGluAla"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55248992_55248993insTCCAGGAAGCCT"}, {"syntax": "hgvs.c", "value": "NM_001346898.1:c.2290_2291insTCCAGGAAGCCT"}], "location": {"id": "ga4gh:SL.90VTN4hg154mlFxNUUZgvPlTe-RCepXu", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 761, "end": 763}, "state": {"type": "ReferenceLengthExpression", "length": 6, "sequence": "EAFQEA", "repeatSubunitLength": 4}}}, "therapeutic": {"id": "civic.tid:187", "label": "Osimertinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1721560"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C116377"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-", "AZD-9291", "AZD9291", "Mereletinib", "Tagrisso"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:9377", "description": "A phase I safety and dose-escalation study (NCT01897571) was completed for tazemetostat in relapsed or refractory B-cell non-Hodgkin lymphoma or advanced solid tumors. Durable objective responses, including complete responses, were observed in eight (38%) of 21 patients with B-cell non-Hodgkin lymphoma and two (5%) of 43 patients with solid tumours. EZH2 mutation status was assessed retrospectively. Two DLBCL patients had mutations. One of these (with a Y646H mutation) had a durable partial response before disease progression after 16 months on study. The variant in the second patient was not reported and the duration of therapy for this patient that did not respond was among the shortest in the trial.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2517", "label": "Italiano et al., 2018, Lancet Oncol.", "type": "Document", "title": "PubMed: Italiano et al., 2018, Lancet Oncol.", "pmid": 29650362}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:63", "label": "EZH2", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3527"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2146"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["ENX-1", "ENX1", "EZH2", "EZH2b", "KMT6", "KMT6A", "WVS", "WVS2"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:3232", "label": "EZH2 Y646H", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 8.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "G", "representative_transcript": "ENST00000320356.7", "chromosome": "7", "start": 148508728, "stop": 148508728, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "3364"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602260"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "76769"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["TYR646HIS", "Y641H", "TYR641HIS"], "members": [{"id": "ga4gh:VA.hkQn3tpRuH5Zk6CG939qILRZYM-wahQU", "label": "NC_000007.14:g.148811636A>G", "digest": "hkQn3tpRuH5Zk6CG939qILRZYM-wahQU", "type": "Allele", "location": {"id": "ga4gh:SL.8t7xrYWQWa9rNRzmMtC-8oWaD0kDWrzq", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 148811635, "end": 148811636}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.V5nIcscw2N7qKJiju-FumJo77k_Zz9mq", "label": "Y646H", "digest": "V5nIcscw2N7qKJiju-FumJo77k_Zz9mq", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000320356.7:c.1936T>C"}, {"syntax": "hgvs.g", "value": "NC_000007.14:g.148811636A>G"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.148508728A>G"}, {"syntax": "hgvs.p", "value": "ENSP00000320147.2:p.Tyr646His"}, {"syntax": "hgvs.c", "value": "ENST00000460911.5:c.1921T>C"}, {"syntax": "hgvs.p", "value": "ENSP00000419711.1:p.Tyr641His"}, {"syntax": "hgvs.c", "value": "NM_004456.5:c.1936T>C"}, {"syntax": "hgvs.p", "value": "NP_004447.2:p.Tyr646His"}, {"syntax": "hgvs.c", "value": "NM_001203247.2:c.1921T>C"}, {"syntax": "hgvs.p", "value": "NP_001190176.1:p.Tyr641His"}], "location": {"id": "ga4gh:SL.5DlaGJrlH6seUdneVWj-QDGIqUJjtRB1", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fZuyp1_QKM5vGWsn-O-CrPHPm5jR403J"}, "start": 645, "end": 646}, "state": {"type": "LiteralSequenceExpression", "sequence": "H"}}}, "therapeutic": {"id": "civic.tid:411", "label": "Tazemetostat", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:2274378"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": []}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C107506"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["E7438", "EPZ-6438", "EPZ6438", "N-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(oxan-4-yl)amino)-4-methyl-4'-((morpholin-4-yl)methyl)(1,1'-biphenyl)-3-carboxamide", "N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide"]}, "tumorType": {"id": "civic.did:45", "label": "Diffuse Large B-cell Lymphoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C8851"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:0050745"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:9592", "description": "A 58-year-old male with NTRK-fusion positive gastrointestinal stromal tumour (GIST) demonstrated initial response to Larotrectinib but progressed after developing a gatekeeper mutation (TRKC F617L).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2978", "label": "Hong et al., 2019, Ann. Oncol.", "type": "Document", "title": "PubMed: Hong et al., 2019, Ann. Oncol.", "pmid": 30624546}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:3985", "label": "NTRK3", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8033"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:4916"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["GP145-TrkC", "NTRK3", "TRKC", "gp145(trkC)"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:3336", "label": "NTRK3 F617L", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 5.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"type": "coordinates"}}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "3468"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.G7O8w4ROPFvzzXZxeNBlqUdWAXD2WDQe", "label": "F617L", "digest": "G7O8w4ROPFvzzXZxeNBlqUdWAXD2WDQe", "type": "Allele", "location": {"id": "ga4gh:SL.mejOR5sU-7NrMQcukQFY_i-S0ANdeZr6", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.VEFUaQaUEQIKI8eVRTz0YI-j-_lXy-rp"}, "start": 616, "end": 617}, "state": {"type": "LiteralSequenceExpression", "sequence": "L"}}}, "therapeutic": {"id": "civic.tid:573", "label": "Larotrectinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:2105628"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:44382", "type": "Disease", "label": "Malignant solid neoplasm", "mappings": [{"coding": {"system": "ncit", "code": "C132146"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C115977"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-", "3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide", "ARRY 470", "LOXO 101", "LOXO-101"]}, "tumorType": {"id": "civic.did:2", "label": "Gastrointestinal Stromal Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3868"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9253"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1191", "description": "Case Report of a 84-year-old woman with stage IVb CRC after progression under 5-fluorouracil and bevacizumab.\nNGS revealed a frameshift mutation in APC, a missense mutation in KRAS. Variants of uncertain significance were: a missense variant in ERBB2 and a missense variant in KDR at amino acid 961 converting the wild type residue, Arginine, to Tryptophan (frequency 28.25%). Because of the high frequency of the KDR (VEGFR2) mutation, the patient was considered a suitable candidate for a VEGFR inhibitor and received regorafenib monotherapy, which is approved for this situation, at 80mg daily which was later reduced to 40mg daily and had CEA normalization as well as partial metabolic and radiologic response. The patient remained almost asymptomatic and without disease progression after 39 weeks.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:822", "label": "Loaiza-Bonilla et al., 2016, Cureus", "type": "Document", "title": "PubMed: Loaiza-Bonilla et al., 2016, Cureus", "pmid": 27004155}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:3153", "label": "KDR", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6307"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3791"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD309", "FLK1", "KDR", "VEGFR", "VEGFR2"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:498", "label": "KDR R961W", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 2.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000263923.4", "chromosome": "4", "start": 55961059, "stop": 55961059, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "502"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA2924278"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS530419081"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ARG961TRP", "RS530419081"], "members": [{"id": "ga4gh:VA.wxuwNDS7ihRW_or8TKB-iRjadhyx-JUi", "label": "NC_000004.11:g.55961059G>A", "digest": "wxuwNDS7ihRW_or8TKB-iRjadhyx-JUi", "type": "Allele", "location": {"id": "ga4gh:SL.c6B1wJ5vi3CH-rngQruuDxscM3BbaeBj", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 55094891, "end": 55094892}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.lKWykzghuXOzjApRBycgWqfcfIRymK0V", "label": "R961W", "digest": "lKWykzghuXOzjApRBycgWqfcfIRymK0V", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_002253.2:c.2881C>T"}, {"syntax": "hgvs.p", "value": "NP_002244.1:p.Arg961Trp"}, {"syntax": "hgvs.c", "value": "ENST00000263923.4:c.2881C>T"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55961059G>A"}], "location": {"id": "ga4gh:SL.2Puvuy_8QCe_EWt-Ry-MVlMqtYmHouzP", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dmXAmrNjuPan7_P4BXez22C4deLKtGdv"}, "start": 960, "end": 961}, "state": {"type": "LiteralSequenceExpression", "sequence": "W"}}}, "therapeutic": {"id": "civic.tid:27", "label": "Regorafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1312397"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C78204"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide", "BAY 73-4506", "REGORAFENIB ANHYDROUS", "Stivarga"]}, "tumorType": {"id": "civic.did:57", "label": "Colorectal Adenocarcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C5105"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:0050861"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1396", "description": "Case report of a patient with stage IV lung adenocarcinoma and a 15\u2013base pair deletion in EGFR exon 19. Partial response with erlotinib was achieved for 15 months after initial chemotherapy. After further progression, rebiopsy additionally identified the EGFR T790M mutation and the patient received several cycles of chemotherapy and targeted therapy including afatinib, cetuximab, erlotinib, AZD9291. She was treated with AZD9291 for 9 months until disease progression. Repeat biopsy detected EGFRC797S mutation additionally to both aforementioned EGFR aberrations. In addition, PTEN Y27C and CTNNB1 S37F mutations were present in all 3 samples, and a TSC2 N486I was seen in the third biopsy sample only", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:946", "label": "Yu et al., 2015, JAMA Oncol", "type": "Document", "title": "PubMed: Yu et al., 2015, JAMA Oncol", "pmid": 26181354}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:411", "label": "EGFR C797S", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 17.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "A", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55249091, "stop": 55249091, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "415"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602785"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376342"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS1057519861"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["CYS797SER", "RS1057519861"], "members": [{"id": "ga4gh:VA.1kk6T2qb1Qy4vtWB0ZpWWcCDsmol6TaT", "label": "NC_000007.13:g.55249091T>A", "digest": "1kk6T2qb1Qy4vtWB0ZpWWcCDsmol6TaT", "type": "Allele", "location": {"id": "ga4gh:SL.QutBr2a72ttD2JGX7gsn83DPaLlXLS56", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55181397, "end": 55181398}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.G0JEKgjyKjGHeACGy7ouzmtYjBOUvKQd", "label": "C797S", "digest": "G0JEKgjyKjGHeACGy7ouzmtYjBOUvKQd", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2389T>A"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55249091T>A"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2389T>A"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Cys797Ser"}], "location": {"id": "ga4gh:SL.oirojchlpx4TkwB6RIkiiq69FXRdtka0", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 796, "end": 797}, "state": {"type": "LiteralSequenceExpression", "sequence": "S"}}}, "therapeutic": {"id": "civic.tid:187", "label": "Osimertinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1721560"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C116377"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-", "AZD-9291", "AZD9291", "Mereletinib", "Tagrisso"]}, "tumorType": {"id": "civic.did:30", "label": "Lung Adenocarcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3512"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3910"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1397", "description": "Case report of a patient with stage IV lung adenocarcinoma and a 15\u2013base pair deletion in EGFR exon 19. Partial response with erlotinib was achieved for 15 months after initial chemotherapy. After further progression, rebiopsy additionally identified the EGFR T790M mutation and the patient received several cycles of chemotherapy and targeted therapy including afatinib, cetuximab, erlotinib, AZD9291. She was treated with AZD9291 for 9 months until disease progression.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:946", "label": "Yu et al., 2015, JAMA Oncol", "type": "Document", "title": "PubMed: Yu et al., 2015, JAMA Oncol", "pmid": 26181354}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:34", "label": "EGFR T790M", "description": "EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 406.25}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55249071, "stop": 55249071, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "34"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA090928"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16613"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434569"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["THR790MET", "RS121434569"], "members": [{"id": "ga4gh:VA.OvEfBRaS34JkfM0_ZHJVDQEjqtwzyjyp", "label": "NC_000007.13:g.55249071C>T", "digest": "OvEfBRaS34JkfM0_ZHJVDQEjqtwzyjyp", "type": "Allele", "location": {"id": "ga4gh:SL.ZCgOjF-_T0EOBXGc-6yICYui-jgFzJfY", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55181377, "end": 55181378}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.faKID4aj8rP8NKZpWL4mWDToEztTUmbr", "label": "T790M", "digest": "faKID4aj8rP8NKZpWL4mWDToEztTUmbr", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2369C>T"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2369C>T"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Thr790Met"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55249071C>T"}], "location": {"id": "ga4gh:SL.C1y_lDZe8e9pKy3jcj3oJKw_7252Hrxa", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 789, "end": 790}, "state": {"type": "LiteralSequenceExpression", "sequence": "M"}}}, "therapeutic": {"id": "civic.tid:187", "label": "Osimertinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1721560"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C116377"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-", "AZD-9291", "AZD9291", "Mereletinib", "Tagrisso"]}, "tumorType": {"id": "civic.did:30", "label": "Lung Adenocarcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3512"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3910"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1550", "description": "Phase 1 study with the dual PI3K/mTOR inhibitor apitolisib. 120 patients were treated at doses between 2 and 70mg. Of 45 evaluable patients receiving 40mg, two patients with E545K PIK3CA mutation (one head and neck squamous cell carcinoma patient and a patient with ovarian cancer) had unconfirmed partial responses. Of the 14 evaluable patients with PIK3CA mutations total, there were 3 PRs (1 confirmed), 8 SD, and 3 PD as best radiological responses.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1026", "label": "Dolly et al., 2016, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Dolly et al., 2016, Clin. Cancer Res.", "pmid": 26787751}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:104", "label": "PIK3CA E545K", "description": "PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 77.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000263967.3", "chromosome": "3", "start": 178936091, "stop": 178936091, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "104"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123334"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13655"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS104886003"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLU545LYS", "RS104886003"], "members": [{"id": "ga4gh:VA.uqD1zF6cMOYhBp8ur5oLTMqV0jxiC2a7", "label": "NC_000003.11:g.178936091G>A", "digest": "uqD1zF6cMOYhBp8ur5oLTMqV0jxiC2a7", "type": "Allele", "location": {"id": "ga4gh:SL.5l5tuxgJGb8y7CQzkKLPUvS-Cx4kr2ju", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 179218302, "end": 179218303}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.uw7DyLM7r98pn66LOXU3tAknmkV7jiJ0", "label": "E545K", "digest": "uw7DyLM7r98pn66LOXU3tAknmkV7jiJ0", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006218.3:c.1633G>A"}, {"syntax": "hgvs.p", "value": "NP_006209.2:p.Glu545Lys"}, {"syntax": "hgvs.c", "value": "ENST00000263967.3:c.1633G>A"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.178936091G>A"}], "location": {"id": "ga4gh:SL.SrEa0lPyesLrOX0M_aW51d-JdJhU-D3p", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 544, "end": 545}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:377", "label": "Apitolisib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C91731"}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C91731"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["GDC 0980", "GDC-0980", "GNE 390", "RG 7422"]}, "tumorType": {"id": "civic.did:216", "label": "Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9305"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:162"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1787", "description": "In a meta-analysis of 7 clinical trials evaluating the efficacy of erlotinib, one patient was described with the exon 19 mutation E746G from the BeTa study. Progression-free (415 days) and overall (462 days) survival suggested sensitivity in this patient. No statistical analysis was reported for this variant and PFS or OS, citing small sample size across the studies.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1244", "label": "Klughammer et al., 2016, J Thorac Oncol", "type": "Document", "title": "PubMed: Klughammer et al., 2016, J Thorac Oncol", "pmid": 26773740}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:705", "label": "EGFR E746G", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 2.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "G", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55242467, "stop": 55242467, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "724"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA367584149"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLU746GLY"], "members": [{"id": "ga4gh:VA.JTlGMMLFQKZeJ_Nxg1Dq2Oxfb7mbfps_", "label": "NC_000007.13:g.55242467A>G", "digest": "JTlGMMLFQKZeJ_Nxg1Dq2Oxfb7mbfps_", "type": "Allele", "location": {"id": "ga4gh:SL.U1YeUbdKohCbI0cwBKq9Ckt-L7nG4gzj", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55174773, "end": 55174774}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.3Wrljv0ivrleDq2gw98Ssfbj-IUMtaFC", "label": "E746G", "digest": "3Wrljv0ivrleDq2gw98Ssfbj-IUMtaFC", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2237A>G"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55242467A>G"}, {"syntax": "hgvs.c", "value": "NM_005228.3:c.2237A>G"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Glu746Gly"}], "location": {"id": "ga4gh:SL.TBBWNLw0ob09Fjx7Opy4s8-Hdp4uW6Uz", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 745, "end": 746}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:30", "label": "Lung Adenocarcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3512"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3910"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2474", "description": "This case study examines one patient from a larger cohort of 397 patients with incurable (i.e. metastatic or unresectable) CD117-positive Gastrointestinal stromal tumors (GISTs) enrolled in the North American phase III study SWOG S0033/CALGB 150105. Patients in this cohort were treated with either 400mg or 800mg of imatinib per day. This patient's GIST harbored PDGFRA exon 12 V561D. The patient was treated with 800mg of imatinib per day, and had not progressed or died as of 31 months of follow up (vs median TTP of 12.8 months for WT).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1586", "label": "Heinrich et al., 2008, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Heinrich et al., 2008, J. Clin. Oncol.", "pmid": 18955451}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:38", "label": "PDGFRA", "description": "Commonly mutated in GI tract tumors, PDGFR family genes (mutually exclusive to KIT mutations) are a hallmark of gastrointestinal stromal tumors. Gene fusions involving the PDGFRA kinase domain are highly correlated with eosinophilia, and the WHO classifies myeloid and lymphoid neoplasms with these characteristics as a distinct disorder. Mutations in the 842 region of PDGFRA have been often found to confer resistance to the tyrosine kinase inhibitor, imatinib.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8803"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5156"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD140A", "PDGFR-2", "PDGFR2", "PDGFRA"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:915", "label": "PDGFRA V561D", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 8.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "A", "representative_transcript": "ENST00000257290.5", "chromosome": "4", "start": 55141036, "stop": 55141036, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "941"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123203"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13546"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121908586"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121908586"], "members": [{"id": "ga4gh:VA.RVDCfTK9KrX96TVgvOUcAv--OnQUdV8O", "label": "NC_000004.11:g.55141036T>A", "digest": "RVDCfTK9KrX96TVgvOUcAv--OnQUdV8O", "type": "Allele", "location": {"id": "ga4gh:SL.h44ZIUE0VWLc8ONz8JwqUOUCvADE8Ozc", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54274868, "end": 54274869}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.OFhYwJu_e2ktWF9N-_SrpmKx44fbeyto", "label": "V561D", "digest": "OFhYwJu_e2ktWF9N-_SrpmKx44fbeyto", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006206.5:c.1682T>A"}, {"syntax": "hgvs.p", "value": "NP_006197.1:p.Val561Asp"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55141036T>A"}, {"syntax": "hgvs.c", "value": "ENST00000257290.5:c.1682T>A"}], "location": {"id": "ga4gh:SL.QB_e8RED6euCq3v0AQJcTcXmXd4p286t", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.XpQn9sZLGv_GU3uiWO7YHq9-_alGjrVX"}, "start": 560, "end": 561}, "state": {"type": "LiteralSequenceExpression", "sequence": "D"}}}, "therapeutic": {"id": "civic.tid:5", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:282388"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "Disease", "label": "Systemic mastocytosis", "mappings": [{"coding": {"system": "ncit", "code": "C9235"}, "relation": "relatedMatch"}]}, {"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}, {"id": "hemonc:634", "type": "Disease", "label": "Myelodysplastic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C3247"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:33893", "type": "Disease", "label": "Chronic myelogenous leukemia pediatric"}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}, {"id": "hemonc:616", "type": "Disease", "label": "Hypereosinophilic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C27038"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C62035"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"]}, "tumorType": {"id": "civic.did:2", "label": "Gastrointestinal Stromal Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3868"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9253"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2624", "description": "Mutational profiling was performed on EGFR exons 18-24 from a group of 10 retrospectively chosen patients who had shown partial response or clinical improvement in response to gefitinib. Of 7 tumors with EGFR mutations, 1 was L858R. The patient was a female former smoker who had lung adenocarcinoma histology, and demonstrated response for 5 months, with overall survival 8 months.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1509", "label": "Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A.", "type": "Document", "title": "PubMed: Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A.", "pmid": 15329413}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:33", "label": "EGFR L858R", "description": "EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 379.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "G", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55259515, "stop": 55259515, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "33"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA126713"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16609"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376282"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376280"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434568"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121434568", "LEU858ARG"], "members": [{"id": "ga4gh:VA.TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "label": "NC_000007.13:g.55259515T>G", "digest": "TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "type": "Allele", "location": {"id": "ga4gh:SL.ulUNwZvajob7nzyrlpOd6uUWZIYCsoWb", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55191821, "end": 55191822}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "label": "L858R", "digest": "z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000007.13:g.55259515T>G"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2573T>G"}, {"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2573T>G"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Leu858Arg"}], "location": {"id": "ga4gh:SL.yVGJnwqxV6oCGqC_8nNb58D_wPXJeNJo", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 857, "end": 858}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:14", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:328134"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1855"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"]}, "tumorType": {"id": "civic.did:30", "label": "Lung Adenocarcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3512"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3910"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2934", "description": "Resistance to crizotinib developed in a patient with metastatic lung adenocarcinoma harboring a CD74-ROS1 rearrangement who had initially shown a dramatic response to treatment. A biopsy of a resistant tumor showed an acquired G2032R mutation in the ROS1 kinase domain. Although this mutation does not lie at the gatekeeper residue, it confers resistance to ROS1 kinase inhibition through steric interference with drug binding. The same resistance mutation was observed at all the metastatic sites that were examined at autopsy, suggesting that this mutation was an early event in the clonal evolution of resistance.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:381", "label": "Awad et al., 2013, N. Engl. J. Med.", "type": "Document", "title": "PubMed: Awad et al., 2013, N. Engl. J. Med.", "pmid": 23724914}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:4941", "label": "ROS1", "description": "ROS1 is a receptor tyrosine kinase that is frequently involved in genetic rearrangement in a variety of human cancers (e.g. NSCLC, gastric cancer, ovarian cancer, cholangiocarcinoma, colorectal cancer, angiosarcoma...). The resulting fusion protein harbors the constitutively active ROS1 kinase domain and drives cellular proliferation (Davies et. al.). In NSCLC about 1% harbor a ROS1 rearrangement. These patients are predominantely female and have a lower T-stage (Warth et. al.). Treatment with crizotinib leads to a reported objective response rate of appr. 70% and a median duration of response of 18 months (Shaw et. al.). Resistance mechanisms to crizotinib have been described and involve mutations in the kinase domain. More selective inhibitors of ROS1 might overcome this resistance (Davare et. al.).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:10261"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:6098"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["MCF3", "ROS", "ROS1", "c-ros-1"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:1245", "label": "ROS1 G2032R", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 2.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000368508.3", "chromosome": "6", "start": 117638347, "stop": 117638347, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1271"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602597"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376139"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLY2032ARG"], "members": [{"id": "ga4gh:VA.iY_MFdYHOf2KSIK9-sMyyAv1-bKoDEgh", "label": "NC_000006.11:g.117638347C>T", "digest": "iY_MFdYHOf2KSIK9-sMyyAv1-bKoDEgh", "type": "Allele", "location": {"id": "ga4gh:SL.8ZSE5mrfH5sI3M8aACzBvgx15jeKZ6tz", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.0iKlIQk2oZLoeOG9P1riRU6hvL5Ux8TV"}, "start": 117317183, "end": 117317184}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.JRnQFCP5vJihU__dTBGoK--avM7RksbU", "label": "G2032R", "digest": "JRnQFCP5vJihU__dTBGoK--avM7RksbU", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000006.11:g.117638347C>T"}, {"syntax": "hgvs.c", "value": "NM_002944.2:c.6094G>A"}, {"syntax": "hgvs.p", "value": "NP_002935.2:p.Gly2032Arg"}, {"syntax": "hgvs.c", "value": "ENST00000368508.3:c.6094G>A"}], "location": {"id": "ga4gh:SL.B5jQ-MWJhBnBHavLhhTtxEpeJA7pmV-p", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.22Sf5cMxU4cVHRP44TPGjT-lO17K4Dfc"}, "start": 2025, "end": 2026}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:12", "label": "Crizotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1148495"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:25958", "type": "Disease", "label": "Anaplastic large cell lymphoma pediatric"}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C74061"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine", "2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-", "MET Tyrosine Kinase Inhibitor PF-02341066", "PF-02341066", "PF-2341066", "Xalkori"]}, "tumorType": {"id": "civic.did:30", "label": "Lung Adenocarcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3512"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3910"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:3842", "description": "One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored NRAS G13R, was wildtype for KRAS, BRAF and PIK3CA, and had individual response data. This patient was was a 50 year old male treated with panitumumab monotherapy as 3rd line therapy (discontinued for toxic/biochemical reasons) who experienced stable disease (PFS: 22 weeks; OS: 74 weeks). Authors considered stable disease as both clinical benefit and non-response", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:76", "label": "De Roock et al., 2010, Lancet Oncol.", "type": "Document", "title": "PubMed: De Roock et al., 2010, Lancet Oncol.", "pmid": 20619739}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:36", "label": "NRAS", "description": "Mutations in the RAS family of proteins have frequently been observed across cancer types. The amino acid positions G12, G13 and Q61 account for the overwhelming majority of these mutations. The isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, targeting these RAS mutants has also been very elusive, and has not yet become common practice in the clinic.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:7989"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:4893"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["ALPS4", "CMNS", "KRAS", "N-ras", "NCMS", "NRAS", "NRAS1", "NS6"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:870", "label": "NRAS G13R", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 5.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "G", "representative_transcript": "ENST00000369535.4", "chromosome": "1", "start": 115258745, "stop": 115258745, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "896"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA151261"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13899"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434595"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLY13ARG", "RS121434595"], "members": [{"id": "ga4gh:VA.OkF17wkfQIzpgiosoi26NK_ASE6hQRCi", "label": "NC_000001.10:g.115258745C>G", "digest": "OkF17wkfQIzpgiosoi26NK_ASE6hQRCi", "type": "Allele", "location": {"id": "ga4gh:SL.ZRBXXXd2_j6WxIL-XqG3ngx4RX8-nFGq", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Ya6Rs7DHhDeg7YaOSg1EoNi3U_nQ9SvO"}, "start": 114716123, "end": 114716124}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.oRl-S1OOU_B-iA5pyGRW43sUHiR1VSBM", "label": "G13R", "digest": "oRl-S1OOU_B-iA5pyGRW43sUHiR1VSBM", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_002524.4:c.37G>C"}, {"syntax": "hgvs.p", "value": "NP_002515.1:p.Gly13Arg"}, {"syntax": "hgvs.g", "value": "NC_000001.10:g.115258745C>G"}, {"syntax": "hgvs.c", "value": "ENST00000369535.4:c.37G>C"}], "location": {"id": "ga4gh:SL.t-hocVsezBIy119fFcy8ti1HtURU7Brr", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.974-EgvIQKi6ptqsI6XUZthCv-Py3S18"}, "start": 12, "end": 13}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:28", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:263034"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1857"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["ABX-EGF", "ABX-EGF Monoclonal Antibody", "ABX-EGF, Clone E7.6.3", "E7.6.3", "Human IgG2K Monoclonal Antibody", "MoAb ABX-EGF", "MoAb E7.6.3", "Monoclonal Antibody ABX-EGF", "Monoclonal Antibody E7.6.3", "Vectibix"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4047", "description": "Three patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored PIK3CA N345K, were wildtype for KRAS, BRAF and NRAS, and had individual response data. Patient characteristics are as follows: a 48 year old female treated with cetuximab + irinotecan as 3rd line therapy who experienced stable disease (PFS: 72 weeks, OS: 105 weeks); a 46 year old male treated with cetuximab monotherapy as 5th line therapy who experienced stable disease (PFS: 24 weeks, OS: 57 weeks); a 61 year old female treated with cetuximab + irinotecan as 3rd line therapy who experienced progressive disease (PFS: 12 weeks, OS: 45 weeks). The response rate was 0/3 and the clinical benefit rate was 2/3 according to author criteria.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:76", "label": "De Roock et al., 2010, Lancet Oncol.", "type": "Document", "title": "PubMed: De Roock et al., 2010, Lancet Oncol.", "pmid": 20619739}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:904", "label": "PIK3CA N345K", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 2.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "A", "representative_transcript": "ENST00000263967.3", "chromosome": "3", "start": 178921553, "stop": 178921553, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "930"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602517"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376050"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913284"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ASN345LYS", "RS121913284"], "members": [{"id": "ga4gh:VA.tfgawi1GKnwuikAqBVZGFxX12380TJcV", "label": "NC_000003.11:g.178921553T>A", "digest": "tfgawi1GKnwuikAqBVZGFxX12380TJcV", "type": "Allele", "location": {"id": "ga4gh:SL.Fcj7fe7dpPv72YE0bu_9dNFMSb39DWox", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 179203764, "end": 179203765}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.xPcFxFAA4wJ6KmjXbmE7LD8zaew9FsYQ", "label": "N345K", "digest": "xPcFxFAA4wJ6KmjXbmE7LD8zaew9FsYQ", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006218.3:c.1035T>A"}, {"syntax": "hgvs.p", "value": "NP_006209.2:p.Asn345Lys"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.178921553T>A"}, {"syntax": "hgvs.c", "value": "ENST00000263967.3:c.1035T>A"}], "location": {"id": "ga4gh:SL.zT9adO1ef0E5paG2ZPYO4QfQCMaTPp_Q", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 344, "end": 345}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:16", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:318341"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}, {"id": "mesh:D006258", "type": "Disease", "label": "Head and Neck Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C4013"}, "relation": "relatedMatch"}]}, {"id": "mesh:D002294", "type": "Disease", "label": "Carcinoma, Squamous Cell", "mappings": [{"coding": {"system": "ncit", "code": "C2929"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1723"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4475", "description": "In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with L298V evaluated, 1/1 had a complete hematologic response and 0/1 had a major cytogenetic response.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1996", "label": "Cortes et al., 2011, Blood", "type": "Document", "title": "PubMed: Cortes et al., 2011, Blood", "pmid": 21865346}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:4", "label": "ABL1", "description": "ABL1 is most relevant to cancer in its role in the BCR-ABL fusion protein that has become a signature of chronic myeloid leukemia (CML). Cells harboring this fusion have shown sensitivity to imatinib, greatly improving the prognostic outlook of the disease. However, additional mutations in ABL1 have been shown to confer resistance to imatinib. In these resistance cases, second-generation tyrosine kinase inhibitors such as dasatinib and nilotinib have exhibited some efficacy and are currently undergoing clinical trials for treating acquired resistance in CML.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:76"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:25"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["ABL", "ABL1", "BCR-ABL", "CHDSKM", "JTK7", "bcr/abl", "c-ABL", "c-ABL1", "p150", "v-abl"]}}, "direction": "refutes", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:1414", "label": "ABL1 L298V", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 2.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "G", "representative_transcript": "ENST00000318560.5", "chromosome": "9", "start": 133747585, "stop": 133747585, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1506"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA375249299"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["LEU298VAL", "L317V"], "members": [{"id": "ga4gh:VA.HLqqg7A6OGvMeb65fshCIrWZlg4ZPwCf", "label": "NC_000009.11:g.133747585C>G", "digest": "HLqqg7A6OGvMeb65fshCIrWZlg4ZPwCf", "type": "Allele", "location": {"id": "ga4gh:SL.7pBGpA8jo1ePhb_gux1rPrFZgj8qpYFF", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.KEO-4XBcm1cxeo_DIQ8_ofqGUkp4iZhI"}, "start": 130872197, "end": 130872198}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.x1exGVdc87tTVQw-I4xTINaBw8zgMrxq", "label": "L298V", "digest": "x1exGVdc87tTVQw-I4xTINaBw8zgMrxq", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000318560.5:c.892C>G"}, {"syntax": "hgvs.g", "value": "NC_000009.11:g.133747585C>G"}, {"syntax": "hgvs.c", "value": "NM_005157.5:c.892C>G"}, {"syntax": "hgvs.p", "value": "NP_005148.2:p.Leu298Val"}], "location": {"id": "ga4gh:SL.BpIRuJ1L1NaWkyTz_pdzq6RJmjjHi5Xz", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dmFigTG-0fY6I54swb7PoDuxCeT6O3Wg"}, "start": 297, "end": 298}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "civic.tid:520", "label": "Bosutinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1307619"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "EFO:0000339", "type": "Disease", "label": "chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C60809"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-Anilino-3-quinolinecarbonitrile", "4-Anilinobenzo(g)quinoline-3-carbonitrile", "4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile", "Bosulif", "SKI 606", "SKI-606"]}, "tumorType": {"id": "civic.did:4", "label": "Chronic Myeloid Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3174"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:8552"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4768", "description": "This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with C475V, 1/1 had a CHR and 1/1 had a MCyR. 9 patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1997", "label": "Khoury et al., 2012, Blood", "type": "Document", "title": "PubMed: Khoury et al., 2012, Blood", "pmid": 22371878}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:4", "label": "ABL1", "description": "ABL1 is most relevant to cancer in its role in the BCR-ABL fusion protein that has become a signature of chronic myeloid leukemia (CML). Cells harboring this fusion have shown sensitivity to imatinib, greatly improving the prognostic outlook of the disease. However, additional mutations in ABL1 have been shown to confer resistance to imatinib. In these resistance cases, second-generation tyrosine kinase inhibitors such as dasatinib and nilotinib have exhibited some efficacy and are currently undergoing clinical trials for treating acquired resistance in CML.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:76"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:25"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["ABL", "ABL1", "BCR-ABL", "CHDSKM", "JTK7", "bcr/abl", "c-ABL", "c-ABL1", "p150", "v-abl"]}}, "direction": "refutes", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:1547", "label": "ABL1 C475V", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 5.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"reference_build": "GRCh37", "representative_transcript": "ENST00000318560.5", "chromosome": "9", "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "splice_donor_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001575"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1639"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA913189156"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["CYS475VAL"], "members": [{"id": "ga4gh:VA.oJS0EW8cM_vPpPqVw967wikaND4KUKbU", "label": "NC_000009.11:g.133753954_133755455delinsGT", "digest": "oJS0EW8cM_vPpPqVw967wikaND4KUKbU", "type": "Allele", "location": {"id": "ga4gh:SL.bQ8BJVg0RMuasV9BcU34NoETr6t_m8-w", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.KEO-4XBcm1cxeo_DIQ8_ofqGUkp4iZhI"}, "start": 130878566, "end": 130880068}, "state": {"type": "LiteralSequenceExpression", "sequence": "GT"}}], "definingContext": {"id": "ga4gh:VA.2jXGz3OTtHeOcxyRwmUM0bQzi56pm4_p", "label": "C475V", "digest": "2jXGz3OTtHeOcxyRwmUM0bQzi56pm4_p", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000318560.5:c.1423_1424delinsGT"}, {"syntax": "hgvs.g", "value": "NC_000009.11:g.133753954_133755455delinsGT"}, {"syntax": "hgvs.c", "value": "NM_005157.6:c.1423_1424delinsGT"}], "location": {"id": "ga4gh:SL.hTk2GispstRJDP8WAIZybwX8TPRBP9z9", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dmFigTG-0fY6I54swb7PoDuxCeT6O3Wg"}, "start": 474, "end": 475}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "civic.tid:520", "label": "Bosutinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1307619"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "EFO:0000339", "type": "Disease", "label": "chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C60809"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-Anilino-3-quinolinecarbonitrile", "4-Anilinobenzo(g)quinoline-3-carbonitrile", "4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile", "Bosulif", "SKI 606", "SKI-606"]}, "tumorType": {"id": "civic.did:4", "label": "Chronic Myeloid Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3174"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:8552"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:6977", "description": "In a study of 39 chronic phase CML patients with BCR-ABL variants, C475V was seen in a single imatinib resistant patient that was also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1997", "label": "Khoury et al., 2012, Blood", "type": "Document", "title": "PubMed: Khoury et al., 2012, Blood", "pmid": 22371878}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:4", "label": "ABL1", "description": "ABL1 is most relevant to cancer in its role in the BCR-ABL fusion protein that has become a signature of chronic myeloid leukemia (CML). Cells harboring this fusion have shown sensitivity to imatinib, greatly improving the prognostic outlook of the disease. However, additional mutations in ABL1 have been shown to confer resistance to imatinib. In these resistance cases, second-generation tyrosine kinase inhibitors such as dasatinib and nilotinib have exhibited some efficacy and are currently undergoing clinical trials for treating acquired resistance in CML.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:76"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:25"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["ABL", "ABL1", "BCR-ABL", "CHDSKM", "JTK7", "bcr/abl", "c-ABL", "c-ABL1", "p150", "v-abl"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:1547", "label": "ABL1 C475V", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 5.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"reference_build": "GRCh37", "representative_transcript": "ENST00000318560.5", "chromosome": "9", "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "splice_donor_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001575"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1639"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA913189156"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["CYS475VAL"], "members": [{"id": "ga4gh:VA.oJS0EW8cM_vPpPqVw967wikaND4KUKbU", "label": "NC_000009.11:g.133753954_133755455delinsGT", "digest": "oJS0EW8cM_vPpPqVw967wikaND4KUKbU", "type": "Allele", "location": {"id": "ga4gh:SL.bQ8BJVg0RMuasV9BcU34NoETr6t_m8-w", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.KEO-4XBcm1cxeo_DIQ8_ofqGUkp4iZhI"}, "start": 130878566, "end": 130880068}, "state": {"type": "LiteralSequenceExpression", "sequence": "GT"}}], "definingContext": {"id": "ga4gh:VA.2jXGz3OTtHeOcxyRwmUM0bQzi56pm4_p", "label": "C475V", "digest": "2jXGz3OTtHeOcxyRwmUM0bQzi56pm4_p", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000318560.5:c.1423_1424delinsGT"}, {"syntax": "hgvs.g", "value": "NC_000009.11:g.133753954_133755455delinsGT"}, {"syntax": "hgvs.c", "value": "NM_005157.6:c.1423_1424delinsGT"}], "location": {"id": "ga4gh:SL.hTk2GispstRJDP8WAIZybwX8TPRBP9z9", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dmFigTG-0fY6I54swb7PoDuxCeT6O3Wg"}, "start": 474, "end": 475}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "civic.tid:537", "label": "Imatinib Mesylate", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:282388"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "Disease", "label": "Systemic mastocytosis", "mappings": [{"coding": {"system": "ncit", "code": "C9235"}, "relation": "relatedMatch"}]}, {"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}, {"id": "hemonc:634", "type": "Disease", "label": "Myelodysplastic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C3247"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:33893", "type": "Disease", "label": "Chronic myelogenous leukemia pediatric"}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}, {"id": "hemonc:616", "type": "Disease", "label": "Hypereosinophilic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C27038"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1687"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate", "CGP 57148", "CGP57148B", "Gleevec", "Glivec", "STI 571", "STI-571", "STI571"]}, "tumorType": {"id": "civic.did:4", "label": "Chronic Myeloid Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3174"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:8552"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:9221", "description": "In a retrospective study of 2316 Chinese patients with stage IV non-small cell lung carcinoma, a 69 year old male with the novel EGFR exon 20 insertion N771_P772insL received osimertinib as first-line treatment. The patient achieved stable disease as best response with greater than 10% reduction in tumour size, and progression-free survival of 4.9 months.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:3023", "label": "Fang et al., 2019, BMC Cancer", "type": "Document", "title": "PubMed: Fang et al., 2019, BMC Cancer", "pmid": 31208370}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "case study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00008"}, "variant": {"id": "civic.mpid:3172", "label": "EGFR N771_P772insL", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 2.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"type": "coordinates"}}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "3304"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.bUxTmOvDNXrcfywycCCUaensXetRKU6Q", "label": "N771_P772insL", "digest": "bUxTmOvDNXrcfywycCCUaensXetRKU6Q", "type": "Allele", "location": {"id": "ga4gh:SL.Fk0Y3EwBYKgm78VBkw9PUfLQDeGXsfx9", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 771, "end": 771}, "state": {"type": "LiteralSequenceExpression", "sequence": "L"}}}, "therapeutic": {"id": "civic.tid:187", "label": "Osimertinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1721560"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C116377"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-", "AZD-9291", "AZD9291", "Mereletinib", "Tagrisso"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2251", "description": "In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1421", "label": "Rowley et al., 2002, Oncogene", "type": "Document", "title": "PubMed: Rowley et al., 2002, Oncogene", "pmid": 12483530}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:79", "label": "KRAS G12D", "description": "While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 162.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398284, "stop": 25398284, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "79"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA122538"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12582"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913529"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913529", "GLY12ASP"], "members": [{"id": "ga4gh:VA.qOYg4yYK-1Je25G30BkV3dWKtKDIAFEJ", "label": "NC_000012.11:g.25398284C>T", "digest": "qOYg4yYK-1Je25G30BkV3dWKtKDIAFEJ", "type": "Allele", "location": {"id": "ga4gh:SL.iF0OXeO-tnumYbGkzaFEQ7cOZI_UCI1s", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245349, "end": 25245350}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.CB571ja_KfZM_Hjn9zjjgV1an3tDWRcl", "label": "G12D", "digest": "CB571ja_KfZM_Hjn9zjjgV1an3tDWRcl", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004985.4:c.35G>A"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly12Asp"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398284C>T"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.35G>A"}], "location": {"id": "ga4gh:SL.OndkjmujtyUEZSjjCv0C-gpwnVbRgfj8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "D"}}}, "therapeutic": {"id": "civic.tid:328", "label": "Melphalan", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:6718"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:633", "type": "Disease", "label": "Multiple myeloma", "mappings": [{"coding": {"system": "ncit", "code": "C3242"}, "relation": "relatedMatch"}]}, {"id": "hemonc:645", "type": "Disease", "label": "Ovarian cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7431"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C633"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[bis(2-chloroethyl)amino]-L-phenylalanine", "Alanine Nitrogen Mustard", "CB-3025", "L-PAM", "L-Phenylalanine Mustard", "L-Sarcolysin", "L-Sarcolysin Phenylalanine Mustard", "L-Sarcolysine", "Melphalanum", "P-di(chloroethyl)amino-L-phenylalanine", "Phenylalanine Mustard", "Phenylalanine Nitrogen Mustard", "Sarcoclorin", "Sarkolysin", "WR-19813"]}, "tumorType": {"id": "civic.did:41", "label": "Multiple Myeloma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3242"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9538"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2262", "description": "In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1421", "label": "Rowley et al., 2002, Oncogene", "type": "Document", "title": "PubMed: Rowley et al., 2002, Oncogene", "pmid": 12483530}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:78", "label": "KRAS G12C", "description": "While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 136.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "A", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398285, "stop": 25398285, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "78"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA122528"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12578"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913530"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLY12CYS", "RS121913530"], "members": [{"id": "ga4gh:VA.ONAtlY1naHPhc7I2cFH6POy4zmWKukHw", "label": "NC_000012.11:g.25398285C>A", "digest": "ONAtlY1naHPhc7I2cFH6POy4zmWKukHw", "type": "Allele", "location": {"id": "ga4gh:SL.AiE9G9ocxKfBfR5PRN_ktoggZzig8OcG", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245350, "end": 25245351}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.94GquHCCcRi74uwlI5PGJsf6FsR2M7Ef", "label": "G12C", "digest": "94GquHCCcRi74uwlI5PGJsf6FsR2M7Ef", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004985.4:c.34G>T"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly12Cys"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398285C>A"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.34G>T"}], "location": {"id": "ga4gh:SL.OndkjmujtyUEZSjjCv0C-gpwnVbRgfj8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "civic.tid:328", "label": "Melphalan", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:6718"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:633", "type": "Disease", "label": "Multiple myeloma", "mappings": [{"coding": {"system": "ncit", "code": "C3242"}, "relation": "relatedMatch"}]}, {"id": "hemonc:645", "type": "Disease", "label": "Ovarian cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7431"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C633"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[bis(2-chloroethyl)amino]-L-phenylalanine", "Alanine Nitrogen Mustard", "CB-3025", "L-PAM", "L-Phenylalanine Mustard", "L-Sarcolysin", "L-Sarcolysin Phenylalanine Mustard", "L-Sarcolysine", "Melphalanum", "P-di(chloroethyl)amino-L-phenylalanine", "Phenylalanine Mustard", "Phenylalanine Nitrogen Mustard", "Sarcoclorin", "Sarkolysin", "WR-19813"]}, "tumorType": {"id": "civic.did:41", "label": "Multiple Myeloma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3242"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9538"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:3852", "description": "In an in vitro study, Colo-320, SW48, and CaCO2 cell lines expressing HRAS G13D mutation were associated with resistance to cetuximab treatment, as compared to Colo-320, SW48, and CaCO2 cells expressing wild-type HRAS.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:457", "label": "Boidot et al., 2016, Int J Colorectal Dis", "type": "Document", "title": "PubMed: Boidot et al., 2016, Int J Colorectal Dis", "pmid": 26561417}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:2747", "label": "HRAS", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:5173"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3265"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["C-BAS/HAS", "C-H-RAS", "C-HA-RAS1", "CTLO", "H-RASIDX", "HAMSV", "HRAS", "HRAS1", "RASH1", "p21ras"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:270", "label": "HRAS G13D", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 7.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000451590.1", "chromosome": "11", "start": 534285, "stop": 534285, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "274"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA256488"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12604"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS104894226"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS104894226", "GLY13ASP"], "members": [{"id": "ga4gh:VA.KK4PAcAHPt9-mfcEPHaC04FDYb0S5dda", "label": "NC_000011.9:g.534285C>T", "digest": "KK4PAcAHPt9-mfcEPHaC04FDYb0S5dda", "type": "Allele", "location": {"id": "ga4gh:SL.AFDSMpEdwo7XrLkWFBH7nz1KSjhAyhKd", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.2NkFm8HK88MqeNkCgj78KidCAXgnsfV1"}, "start": 534284, "end": 534285}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.6prtJS5RIQA0aNPe0B9tvAkg-eGZSOkD", "label": "G13D", "digest": "6prtJS5RIQA0aNPe0B9tvAkg-eGZSOkD", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000011.9:g.534285C>T"}, {"syntax": "hgvs.p", "value": "NP_005334.1:p.Gly13Asp"}, {"syntax": "hgvs.c", "value": "NM_005343.3:c.38G>A"}, {"syntax": "hgvs.c", "value": "ENST00000451590.1:c.38G>A"}], "location": {"id": "ga4gh:SL.klLpG5KB05t7h-nfpOQHOQedmddFHEXF", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.WdfMyMhCb_VBdWP9v5VevpsqEsRczr--"}, "start": 12, "end": 13}, "state": {"type": "LiteralSequenceExpression", "sequence": "D"}}}, "therapeutic": {"id": "civic.tid:16", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:318341"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}, {"id": "mesh:D006258", "type": "Disease", "label": "Head and Neck Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C4013"}, "relation": "relatedMatch"}]}, {"id": "mesh:D002294", "type": "Disease", "label": "Carcinoma, Squamous Cell", "mappings": [{"coding": {"system": "ncit", "code": "C2929"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1723"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:3878", "description": "In an in vitro study, a Lim1215 colorectal cancer cell line endogenously expressing KRAS G13D mutation demonstrated resistance to cetuximab treatment, compared to Lim1215 parental cells expressing wild-type KRAS. Resistance was determined by assessing cell viability.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2008", "label": "Misale et al., 2012, Nature", "type": "Document", "title": "PubMed: Misale et al., 2012, Nature", "pmid": 22722830}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:81", "label": "KRAS G13D", "description": "While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, results are conflicting with retrospective analyses suggesting a better response to EGFR-Inhibition. A recent prospective phase-II study (12 patients, Schirripa et. al. 2015) could not reproduce this finding and another prospective phase II trial is currently ongoing.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 108.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398281, "stop": 25398281, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "81"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA122534"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12580"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS112445441"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS112445441", "GLY13ASP"], "members": [{"id": "ga4gh:VA.wQro48c_oFxB35UNb2O1Z7Vj6rXnJywl", "label": "NC_000012.11:g.25398281C>T", "digest": "wQro48c_oFxB35UNb2O1Z7Vj6rXnJywl", "type": "Allele", "location": {"id": "ga4gh:SL.rZcsm5bnq3ptyk4298opou7vY9O0etcL", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245346, "end": 25245347}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.h-3tyZSdsQNs9NHrhuwcACnnMnpuT-8Z", "label": "G13D", "digest": "h-3tyZSdsQNs9NHrhuwcACnnMnpuT-8Z", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_033360.3:c.38G>A"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly13Asp"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398281C>T"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.38G>A"}], "location": {"id": "ga4gh:SL.U-3sSsoejW41eQ2Aev0wiG5tEuDiQZTB", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 12, "end": 13}, "state": {"type": "LiteralSequenceExpression", "sequence": "D"}}}, "therapeutic": {"id": "civic.tid:16", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:318341"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}, {"id": "mesh:D006258", "type": "Disease", "label": "Head and Neck Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C4013"}, "relation": "relatedMatch"}]}, {"id": "mesh:D002294", "type": "Disease", "label": "Carcinoma, Squamous Cell", "mappings": [{"coding": {"system": "ncit", "code": "C2929"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1723"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4190", "description": "In an in vitro study, a Ba/F3 cell line expressing EGFR G719S demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR G719S and EGFR L858R expressing cells were 16 nmol/L and 6 nmol/L, respectively.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1528", "label": "Kancha et al., 2009, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Kancha et al., 2009, Clin. Cancer Res.", "pmid": 19147750}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:134", "label": "EGFR G719S", "description": "While not as recurrent as the L858R mutation, EGFR G719S has also been shown to be an activating mutation. In lung cancer cell lines, it also confers sensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 23.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55241707, "stop": 55241707, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "134"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA126722"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16612"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS28929495"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLY719SER", "RS28929495"], "members": [{"id": "ga4gh:VA.BgeJO2Em242qDE22Rl4fhxKTBAaOhHd_", "label": "NC_000007.13:g.55241707G>A", "digest": "BgeJO2Em242qDE22Rl4fhxKTBAaOhHd_", "type": "Allele", "location": {"id": "ga4gh:SL.3ef7PSUNlYokdBlpq6tC1bumRwrpn8UI", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55174013, "end": 55174014}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.qCfvg6opeady22T6oD9f05NpU8wpMBoY", "label": "G719S", "digest": "qCfvg6opeady22T6oD9f05NpU8wpMBoY", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2155G>A"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55241707G>A"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2155G>A"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Gly719Ser"}], "location": {"id": "ga4gh:SL.UiwCoIGhPuuRY9R_vCfqyuseQTBpzHA3", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 718, "end": 719}, "state": {"type": "LiteralSequenceExpression", "sequence": "S"}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4197", "description": "In an in vitro study, a Ba/F3 cell line expressing EGFR V742A demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR V742A and EGFR L858R expressing cells were 21 nmol/L and 6 nmol/L, respectively.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1528", "label": "Kancha et al., 2009, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Kancha et al., 2009, Clin. Cancer Res.", "pmid": 19147750}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:975", "label": "EGFR V742A", "extensions": [{"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "C", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55242455, "stop": 55242455, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1001"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602541"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376079"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913466"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913466"], "members": [{"id": "ga4gh:VA.LJO07wHGFVrqdUAjfaATaXw7RCX2yGXj", "label": "NC_000007.13:g.55242455T>C", "digest": "LJO07wHGFVrqdUAjfaATaXw7RCX2yGXj", "type": "Allele", "location": {"id": "ga4gh:SL.OAjyc19VS4XfzdvkMWlWaiP8yq-ZHlv_", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55174761, "end": 55174762}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.0uXk2BedgK7lLpK7JU_3IVhrqUhuj2gl", "label": "V742A", "digest": "0uXk2BedgK7lLpK7JU_3IVhrqUhuj2gl", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_005228.4:c.2225T>C"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Val742Ala"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55242455T>C"}, {"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2225T>C"}], "location": {"id": "ga4gh:SL.a9txrVgGNOkbZj6R2f4ihlEhqg4XHMsU", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 741, "end": 742}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4266", "description": "In an in vitro study, a Ba/F3 cell line expressing EGFR L747_P753>S demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR L747_P753>S and EGFR L858R expressing cells were 5 nmol/L and 6 nmol/L, respectively.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1528", "label": "Kancha et al., 2009, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Kancha et al., 2009, Clin. Cancer Res.", "pmid": 19147750}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:986", "label": "EGFR L747_P753delinsS", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 7.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "TAAGAGAAGCAACATCTC", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55242470, "stop": 55242487, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "inframe_deletion", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001822"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1012"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA126710"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16608"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913438"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913438"], "definingContext": {"id": "ga4gh:VA.-c6XnKqvtA5dL94gYBHlQhqCq5rHn11h", "label": "L747_P753delinsS", "digest": "-c6XnKqvtA5dL94gYBHlQhqCq5rHn11h", "type": "Allele", "location": {"id": "ga4gh:SL.w39a-eLibeKXZnSrcZ4FTN09Mwklmg4L", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 746, "end": 753}, "state": {"type": "LiteralSequenceExpression", "sequence": "S"}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4275", "description": "In an in vitro study, a Ba/F3 cell line expressing EGFR D770_N771insSVD demonstrated reduced sensitivity to erlotinib treatment (IC50=3.187\ufffdM), comparable to Ba/F3 cells expressing EGFR L858R and T790M co-mutation (T790M is a known resistant mutation to 1st and 2nd generation EGFR tyrosine kinase inhibitors; IC50=4.155\ufffdM). Resistance was determined by assessing cell proliferation, EGFR, AKT and ERK phosphorylation.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1230", "label": "Yasuda et al., 2013, Sci Transl Med", "type": "Document", "title": "PubMed: Yasuda et al., 2013, Sci Transl Med", "pmid": 24353160}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1353", "label": "EGFR D770_N771insSVD", "extensions": [{"type": "Extension", "name": "CIViC representative coordinate", "value": {"reference_build": "GRCh37", "variant_bases": "GCGTGGACA", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55249013, "stop": 55249014, "type": "coordinates"}}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1445"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA135844"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "45253"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ASP770_ASN771INSSERVALASP", "S768_D770DUP"], "members": [{"id": "ga4gh:VA.6sntoW-8thXpkUTd2ZTJAIECYGTolIv0", "label": "NC_000007.14:g.55181312_55181320dup", "digest": "6sntoW-8thXpkUTd2ZTJAIECYGTolIv0", "type": "Allele", "location": {"id": "ga4gh:SL.TwaZxfqAbfa7l-WhVBhYN5eQW6uW8l8P", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55181309, "end": 55181320}, "state": {"type": "ReferenceLengthExpression", "length": 20, "sequence": "CAGCGTGGACAGCGTGGACA", "repeatSubunitLength": 9}}], "definingContext": {"id": "ga4gh:VA.SjC5nkzEERtLzWmG_ekJpwHCw_r66QNL", "label": "D770_N771insSVD", "digest": "SjC5nkzEERtLzWmG_ekJpwHCw_r66QNL", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000007.14:g.55181312_55181320dup"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55249005_55249013dup"}, {"syntax": "hgvs.c", "value": "ENST00000275493.7:c.2303_2311dup"}, {"syntax": "hgvs.p", "value": "ENSP00000275493.2:p.Asp770_Asn771insSerValAsp"}, {"syntax": "hgvs.c", "value": "NM_005228.5:c.2303_2311dup"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Asp770_Asn771insSerValAsp"}], "location": {"id": "ga4gh:SL.QR6diEZJ-hgyRcOijIE7ngFwCM3rHS-6", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 767, "end": 770}, "state": {"type": "ReferenceLengthExpression", "length": 6, "sequence": "SVDSVD", "repeatSubunitLength": 3}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4276", "description": "In an in vitro study, a Ba/F3 cell line expressing EGFR H773_V774insH demonstrated reduced sensitivity to erlotinib treatment (IC50=3.902\ufffdM), comparable to Ba/F3 cells expressing EGFR L858R and T790M co-mutation (T790M is a known resistant mutation to 1st and 2nd generation EGFR tyrosine kinase inhibitors; IC50=4.155\ufffdM). Resistance was determined by assessing cell proliferation, EGFR, AKT and ERK phosphorylation.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1230", "label": "Yasuda et al., 2013, Sci Transl Med", "type": "Document", "title": "PubMed: Yasuda et al., 2013, Sci Transl Med", "pmid": 24353160}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1354", "label": "EGFR H773_V774insH", "extensions": [{"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "variant_bases": "CAC", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55249021, "stop": 55249022, "type": "coordinates"}}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1446"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA135866"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.0YXGiKmzO-QSfh9dOIZ4_a0ixoO-wA_c", "label": "H773_V774insH", "digest": "0YXGiKmzO-QSfh9dOIZ4_a0ixoO-wA_c", "type": "Allele", "expressions": [{"syntax": "hgvs.p", "value": "p.His773dup"}, {"syntax": "hgvs.p", "value": "c.55249019_55249021dup"}], "location": {"id": "ga4gh:SL.2zIQBe-QoMyhFamCz1aGxe44jofL62A7", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 772, "end": 773}, "state": {"type": "ReferenceLengthExpression", "length": 2, "sequence": "HH", "repeatSubunitLength": 1}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4468", "description": "In an in vitro study, a Ba/F3 cell line expressing EGFR R776C demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR V742A and EGFR L858R expressing cells were 47 nmol/L and 6 nmol/L, respectively.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1528", "label": "Kancha et al., 2009, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Kancha et al., 2009, Clin. Cancer Res.", "pmid": 19147750}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1155", "label": "EGFR R776C", "extensions": [{"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55249028, "stop": 55249028, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1181"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA367578749"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["R723C", "R731C"], "definingContext": {"id": "ga4gh:VA.agg93mBDvZSlGxAjx-Ut4lKtWALOUM6-", "label": "R776C", "digest": "agg93mBDvZSlGxAjx-Ut4lKtWALOUM6-", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2326C>T"}], "location": {"id": "ga4gh:SL.Qacb5ULA77xifPXnLCH4WcHqpRIbchbt", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 775, "end": 776}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4487", "description": "In an in vitro study, a HCT116 cell line expressing ARID1A Q456* mutation demonstrated increased sensitivity to dasatinib treatment, compared to HCT116 cells expressing wild-type ARID1A. Sensitivity was determined by assessing cell survival.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1706", "label": "Miller et al., 2016, Mol. Cancer Ther.", "type": "Document", "title": "PubMed: Miller et al., 2016, Mol. Cancer Ther.", "pmid": 27364904}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:6559", "label": "ARID1A", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:11110"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:8289"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["ARID1A", "B120", "BAF250", "BAF250a", "BM029", "C1orf4", "CSS2", "ELD", "MRD14", "OSA1", "P270", "SMARCF1", "hELD", "hOSA1"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1418", "label": "ARID1A Q456*", "extensions": [{"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000324856.7", "chromosome": "1", "start": 27057658, "stop": 27057658, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "stop_gained", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001587"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1510"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA339267901"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["Q73X"], "definingContext": {"id": "ga4gh:VA.oSznnUIpccvmv2eY1I9GGPGr6aiLp3i-", "label": "Q456*", "digest": "oSznnUIpccvmv2eY1I9GGPGr6aiLp3i-", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000324856.7:c.1366C>T"}], "location": {"id": "ga4gh:SL.u0bXeM9BsWJfmfPBd6q_tjtQyze6kGNq", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Xtsz5dT90bJbR0_r5EawKzOdC11qEH0y"}, "start": 455, "end": 456}, "state": {"type": "LiteralSequenceExpression", "sequence": "*"}}}, "therapeutic": {"id": "civic.tid:20", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1546019"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C38713"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate", "BMS-354825", "Dasatinib Hydrate", "Dasatinib Monohydrate", "Sprycel"]}, "tumorType": {"id": "civic.did:88", "label": "Ovarian Clear Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C40077"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:0050934"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4495", "description": "In an in vitro study, a Ba/F3 cell line expressing EGFR A864T demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR A864T and EGFR L858R expressing cells were 49 nmol/L and 6 nmol/L, respectively.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1528", "label": "Kancha et al., 2009, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Kancha et al., 2009, Clin. Cancer Res.", "pmid": 19147750}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1161", "label": "EGFR A864T", "extensions": [{"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55259532, "stop": 55259532, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1187"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA367580302"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS1171287261"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["A811T", "ALA864THR", "RS1171287261", "A819T"], "members": [{"id": "ga4gh:VA.hkOqsdDLVDnp-BJNY00StmlrTLKjVjio", "label": "NC_000007.13:g.55259532G>A", "digest": "hkOqsdDLVDnp-BJNY00StmlrTLKjVjio", "type": "Allele", "location": {"id": "ga4gh:SL.cyi2MTX94Uy0kk5Pte80jwfKzFA0esYf", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55191838, "end": 55191839}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.mctN1XKtsH9my2Xn35zRO8iCHD_lcVUw", "label": "A864T", "digest": "mctN1XKtsH9my2Xn35zRO8iCHD_lcVUw", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2590G>A"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55259532G>A"}, {"syntax": "hgvs.c", "value": "NM_005228.3:c.2590G>A"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Ala864Thr"}], "location": {"id": "ga4gh:SL.p21JpD5pNQg8S6Yuop9OIqU2IKN6y_OQ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 863, "end": 864}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4496", "description": "In an in vitro study, a Ba/F3 cell line expressing EGFR N826S demonstrated reduced sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR N826S and EGFR L858R expressing cells were 505 nmol/L and 6 nmol/L, respectively.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1528", "label": "Kancha et al., 2009, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Kancha et al., 2009, Clin. Cancer Res.", "pmid": 19147750}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1162", "label": "EGFR N826S", "extensions": [{"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "G", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55259419, "stop": 55259419, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1188"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA367580077"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["N773S", "N781S"], "definingContext": {"id": "ga4gh:VA.-J43l0HcwpbHDhJ9u4G-AKrssAApQikW", "label": "N826S", "digest": "-J43l0HcwpbHDhJ9u4G-AKrssAApQikW", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2477A>G"}], "location": {"id": "ga4gh:SL.0kN8JtPieMqdQzFDj6NqP-80Lh0dQXit", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 825, "end": 826}, "state": {"type": "LiteralSequenceExpression", "sequence": "S"}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4497", "description": "In an in vitro study, Ba/F3 and BID007 cell lines expressing EGFR A763_Y764insFQEA demonstrated increased sensitivity to erlotinib treatment (IC50=0.048\ufffdM and 0.082\ufffdM, respectively), comparable to Ba/F3 and NCI-H3255 cells expressing EGFR L858R (a known sensitizing mutation to EGFR tyrosine kinase inhibitors; IC50=0.006\ufffdM and 0.068\ufffdM, respectively). Sensitivity was determined by assessing cell proliferation, EGFR, AKT and ERK phosphorylation, levels of BIM (a marker of EGFR TKI-induced cell killing) and cell viability.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1230", "label": "Yasuda et al., 2013, Sci Transl Med", "type": "Document", "title": "PubMed: Yasuda et al., 2013, Sci Transl Med", "pmid": 24353160}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1423", "label": "EGFR A763_Y764insFQEA", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 5.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"reference_build": "GRCh37", "variant_bases": "TCCAGGAAGCCT", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55248992, "stop": 55248993, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "inframe_insertion", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001821"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1515"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA135833"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS397517106"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS397517106"], "members": [{"id": "ga4gh:VA.oSxjHCKMtTr6wu2ZXawt0RmhOw0957dC", "label": "NC_000007.13:g.55248992_55248993insTCCAGGAAGCCT", "digest": "oSxjHCKMtTr6wu2ZXawt0RmhOw0957dC", "type": "Allele", "location": {"id": "ga4gh:SL.P8LgsnVBoOpZw85CyJQLBIsTWUPlQfwe", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55181287, "end": 55181299}, "state": {"type": "ReferenceLengthExpression", "length": 24, "sequence": "TCCAGGAAGCCTTCCAGGAAGCCT", "repeatSubunitLength": 12}}], "definingContext": {"id": "ga4gh:VA.gEDB2tymESJ1V5hQf1bdbW7I_4tSmIym", "label": "A763_Y764insFQEA", "digest": "gEDB2tymESJ1V5hQf1bdbW7I_4tSmIym", "type": "Allele", "expressions": [{"syntax": "hgvs.p", "value": "NP_001333827.1:p.Ala763_Tyr764insPheGlnGluAla"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55248992_55248993insTCCAGGAAGCCT"}, {"syntax": "hgvs.c", "value": "NM_001346898.1:c.2290_2291insTCCAGGAAGCCT"}], "location": {"id": "ga4gh:SL.90VTN4hg154mlFxNUUZgvPlTe-RCepXu", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 761, "end": 763}, "state": {"type": "ReferenceLengthExpression", "length": 6, "sequence": "EAFQEA", "repeatSubunitLength": 4}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4653", "description": "In an in vitro study, mouse embryonic fibroblasts (MEFs), null for the Smo mouse gene expressing SMO L412F mutation, demonstrated resistance to vismodegib treatment (IC50: >320 nmol/L vs. 8.23 nmol/L) compared to MEFs expressing wild-type SMO. Resistance was determined by assessing GLI1 mRNA expression levels.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:493", "label": "Atwood et al., 2015, Cancer Cell", "type": "Document", "title": "PubMed: Atwood et al., 2015, Cancer Cell", "pmid": 25759020}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5365", "label": "SMO", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:11119"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:6608"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CRJS", "FZD11", "Gx", "PHLS", "SMO", "SMOH"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1478", "label": "SMO L412F", "extensions": [{"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000249373.3", "chromosome": "7", "start": 128846398, "stop": 128846398, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1570"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA10584652"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "245609"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "members": [{"id": "ga4gh:VA.6kcO_sqNNSHOo6fR6cZJ6_o992202o97", "label": "NC_000007.13:g.128846398C>T", "digest": "6kcO_sqNNSHOo6fR6cZJ6_o992202o97", "type": "Allele", "location": {"id": "ga4gh:SL.xuaPDRPulmJSAqoCc1WSSSBhcVvY0fhY", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 129206556, "end": 129206557}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.R0T5AO-RyfsUgTSJjMtVEJepwCIg3u4G", "label": "L412F", "digest": "R0T5AO-RyfsUgTSJjMtVEJepwCIg3u4G", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_005631.4:c.1234C>T"}, {"syntax": "hgvs.p", "value": "NP_005622.1:p.Leu412Phe"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.128846398C>T"}, {"syntax": "hgvs.c", "value": "ENST00000249373.3:c.1234C>T"}], "location": {"id": "ga4gh:SL.HaUWVAQ8OlnrYBux8-vxkoJ_iekFUNdS", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.WZ7_owJHaml6kJ-2GfPtgYh1GA40K9tc"}, "start": 411, "end": 412}, "state": {"type": "LiteralSequenceExpression", "sequence": "F"}}}, "therapeutic": {"id": "civic.tid:190", "label": "Vismodegib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1242987"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:587", "type": "Disease", "label": "Cutaneous basal cell carcinoma"}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C74038"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide", "Erivedge", "GDC-0449", "Hedgehog Antagonist GDC-0449"]}, "tumorType": {"id": "civic.did:314", "label": "Basal Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2921"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:2513"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4799", "description": "In an in vitro study, a Ba/F3 cell line expressing EGFR M766_A767insAI demonstrated reduced sensitivity to erlotinib treatment (IC50=3.403\ufffdM), comparable to Ba/F3 cells expressing EGFR L858R and T790M co-mutation (T790M is a known resistant mutation to 1st and 2nd generation EGFR tyrosine kinase inhibitors; IC50=4.155\ufffdM). Resistance was determined by assessing cell proliferation, EGFR, AKT and ERK phosphorylation.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1230", "label": "Yasuda et al., 2013, Sci Transl Med", "type": "Document", "title": "PubMed: Yasuda et al., 2013, Sci Transl Med", "pmid": 24353160}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1572", "label": "EGFR M766_A767insAI", "extensions": [{"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "variant_bases": "GCCATA", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55249000, "stop": 55249001, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "inframe_insertion", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001821"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1664"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA645561560"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.f-RVaOLRHdp_AVv5B5NquWvNFKKaT63z", "label": "M766_A767insAI", "digest": "f-RVaOLRHdp_AVv5B5NquWvNFKKaT63z", "type": "Allele", "location": {"id": "ga4gh:SL.4oJ3UsRkwZZfnzeAvk5Qst5Bxlsvuwet", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 766, "end": 767}, "state": {"type": "ReferenceLengthExpression", "length": 3, "sequence": "AIA", "repeatSubunitLength": 2}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4800", "description": "In an in vitro study, a Ba/F3 cell line expressing EGFR Y764_V765insHH demonstrated reduced sensitivity to erlotinib treatment (IC50=3.845\ufffdM), comparable to Ba/F3 cells expressing EGFR L858R and T790M co-mutation (T790M is a known resistant mutation to 1st and 2nd generations EGFR tyrosine kinase inhibitors; IC50=4.155\ufffdM). Resistance was determined by assessing cell proliferation, EGFR, AKT and ERK phosphorylation.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1230", "label": "Yasuda et al., 2013, Sci Transl Med", "type": "Document", "title": "PubMed: Yasuda et al., 2013, Sci Transl Med", "pmid": 24353160}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1573", "label": "EGFR Y764_V765insHH", "extensions": [{"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "variant_bases": "CACCAC", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55248994, "stop": 55248995, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "inframe_insertion", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001821"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1665"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA2573051277"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.6JzX0On5ia1HbNeLXDQQDi4kBtiRcGwD", "label": "Y764_V765insHH", "digest": "6JzX0On5ia1HbNeLXDQQDi4kBtiRcGwD", "type": "Allele", "location": {"id": "ga4gh:SL.1GxiiO9OxuQ1ovbzVtnhmmofJg-fEXO6", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 764, "end": 764}, "state": {"type": "LiteralSequenceExpression", "sequence": "HH"}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:241", "description": "The L755S mutation was shown to confer resistance to lapatinib in MCF10A cell lines retrovirally transduced with wildtype or mutant ERBB2.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:170", "label": "Bose et al., 2013, Cancer Discov", "type": "Document", "title": "PubMed: Bose et al., 2013, Cancer Discov", "pmid": 23220880}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:20", "label": "ERBB2", "description": "ERBB2, commonly referred to as HER2, is amplified and/or overexpressed in 20-30% of invasive breast carcinomas. HER2-positive breast cancer is treated in a separate manner from other subtypes of breast cancer and commonly presents as more aggressive disease. Metastatic HER2-positive breast cancer is now commonly treated with HER2-targeted therapy. Apart from being amplified/overexpressed, ERBB2 activating mutations have been shown to have clinical importance in HER2-negative breast cancer. These mutations have shown sensitivity to the tyrosine kinase inhibitor neratinib, and highlight the importance of clinical sequencing efforts in treating breast cancer.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3430"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2064"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD340", "ERBB2", "HER-2", "HER-2/neu", "HER2", "MLN 19", "MLN-19", "NEU", "NGL", "TKR1", "VSCN2", "c-ERB-2", "c-ERB2", "p185(erbB2)"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:39", "label": "ERBB2 L755S", "description": "ERBB2 L755S was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was not shown to be an activating mutation, unlike many of the other variants queried. This mutation was also shown to confer resistance to the tyrosine kinase inhibitor lapatinib in MCF10A cell lines.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 21.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "C", "representative_transcript": "ENST00000269571.5", "chromosome": "17", "start": 37880220, "stop": 37880220, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "39"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602502"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376035"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["L740S", "L725S", "LEU755SER"], "members": [{"id": "ga4gh:VA.dVIAjDU-R5S4mY5tx8S0-PYENKi_RqfY", "label": "NC_000017.10:g.37880220T>C", "digest": "dVIAjDU-R5S4mY5tx8S0-PYENKi_RqfY", "type": "Allele", "location": {"id": "ga4gh:SL.8Q3DWDdzdXC5itI0LxkyadxCo92bbL-q", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dLZ15tNO1Ur0IcGjwc3Sdi_0A6Yf4zm7"}, "start": 39723966, "end": 39723967}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.OBWeCw368Dbx427Y2EMTin4quydJHGx1", "label": "L755S", "digest": "OBWeCw368Dbx427Y2EMTin4quydJHGx1", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000269571.5:c.2264T>C"}, {"syntax": "hgvs.g", "value": "NC_000017.10:g.37880220T>C"}, {"syntax": "hgvs.c", "value": "NM_004448.3:c.2264T>C"}, {"syntax": "hgvs.p", "value": "NP_004439.2:p.Leu755Ser"}], "location": {"id": "ga4gh:SL.PgQkgAUmQEctpQViVRSAfB_wJOvorTRs", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.AF1UFydIo02-bMplonKSfxlWY2q6ze3m"}, "start": 754, "end": 755}, "state": {"type": "LiteralSequenceExpression", "sequence": "S"}}}, "therapeutic": {"id": "civic.tid:45", "label": "Lapatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:480167"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:572", "type": "Disease", "label": "Breast cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9335"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C26653"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["GSK572016", "GW 2016", "GW2016", "GW572016"]}, "tumorType": {"id": "civic.did:22", "label": "Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9335"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1612"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:281", "description": "In MCF10A cell lines retrovirally transduced with wildtype or mutant ERBB2, cells expressing the in-frame deletion of amino acids 755-759 were shown to be sensitive to neratinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:170", "label": "Bose et al., 2013, Cancer Discov", "type": "Document", "title": "PubMed: Bose et al., 2013, Cancer Discov", "pmid": 23220880}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:20", "label": "ERBB2", "description": "ERBB2, commonly referred to as HER2, is amplified and/or overexpressed in 20-30% of invasive breast carcinomas. HER2-positive breast cancer is treated in a separate manner from other subtypes of breast cancer and commonly presents as more aggressive disease. Metastatic HER2-positive breast cancer is now commonly treated with HER2-targeted therapy. Apart from being amplified/overexpressed, ERBB2 activating mutations have been shown to have clinical importance in HER2-negative breast cancer. These mutations have shown sensitivity to the tyrosine kinase inhibitor neratinib, and highlight the importance of clinical sequencing efforts in treating breast cancer.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3430"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2064"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD340", "ERBB2", "HER-2", "HER-2/neu", "HER2", "MLN 19", "MLN-19", "NEU", "NGL", "TKR1", "VSCN2", "c-ERB-2", "c-ERB2", "p185(erbB2)"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:37", "label": "ERBB2 L755_T759del", "description": "ERBB2 in-frame deletion of 755-759 was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 5.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "TTGAGGGAAAACACA", "representative_transcript": "ENST00000269571.5", "chromosome": "17", "start": 37880219, "stop": 37880233, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "inframe_deletion", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001822"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "37"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA645372623"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "375990"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS1131692241"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["LEU755_THR759DEL", "RS1131692241"], "members": [{"id": "ga4gh:VA.ZrW-Mvx0bd3oi01MmwUX6rILArWpRtLU", "label": "NC_000017.10:g.37880219_37880233del", "digest": "ZrW-Mvx0bd3oi01MmwUX6rILArWpRtLU", "type": "Allele", "location": {"id": "ga4gh:SL.TnnOPHmOREldLR0QCpg3WlKMKZDf0FYJ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dLZ15tNO1Ur0IcGjwc3Sdi_0A6Yf4zm7"}, "start": 39723965, "end": 39723981}, "state": {"type": "ReferenceLengthExpression", "length": 1, "sequence": "T", "repeatSubunitLength": 15}}], "definingContext": {"id": "ga4gh:VA.3Rk_RElDfX820edkQOHsTTYRogr0EMEY", "label": "L755_T759del", "digest": "3Rk_RElDfX820edkQOHsTTYRogr0EMEY", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000269571.5:c.2263_2277del"}, {"syntax": "hgvs.g", "value": "NC_000017.10:g.37880219_37880233del"}, {"syntax": "hgvs.p", "value": "NP_004439.2:p.Leu755_Thr759del"}, {"syntax": "hgvs.c", "value": "NM_004448.3:c.2263_2277delTTGAGGGAAAACACA"}], "location": {"id": "ga4gh:SL.kOTzy0aLlw0yqnmf29Zk8wh65zHQwere", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.AF1UFydIo02-bMplonKSfxlWY2q6ze3m"}, "start": 754, "end": 759}, "state": {"type": "ReferenceLengthExpression", "length": 0, "sequence": "", "repeatSubunitLength": 5}}}, "therapeutic": {"id": "civic.tid:52", "label": "Neratinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1940643"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C49094"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide", "2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-", "HKI 272", "HKI-272", "PB 272", "PB-272"]}, "tumorType": {"id": "civic.did:22", "label": "Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9335"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1612"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:282", "description": "In MCF10A cell lines, the G309A mutation was shown to be sensitive to neratinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:170", "label": "Bose et al., 2013, Cancer Discov", "type": "Document", "title": "PubMed: Bose et al., 2013, Cancer Discov", "pmid": 23220880}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:20", "label": "ERBB2", "description": "ERBB2, commonly referred to as HER2, is amplified and/or overexpressed in 20-30% of invasive breast carcinomas. HER2-positive breast cancer is treated in a separate manner from other subtypes of breast cancer and commonly presents as more aggressive disease. Metastatic HER2-positive breast cancer is now commonly treated with HER2-targeted therapy. Apart from being amplified/overexpressed, ERBB2 activating mutations have been shown to have clinical importance in HER2-negative breast cancer. These mutations have shown sensitivity to the tyrosine kinase inhibitor neratinib, and highlight the importance of clinical sequencing efforts in treating breast cancer.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3430"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2064"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD340", "ERBB2", "HER-2", "HER-2/neu", "HER2", "MLN 19", "MLN-19", "NEU", "NGL", "TKR1", "VSCN2", "c-ERB-2", "c-ERB2", "p185(erbB2)"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:38", "label": "ERBB2 G309A", "description": "ERBB2 G309A was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 5.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "C", "representative_transcript": "ENST00000269571.5", "chromosome": "17", "start": 37868205, "stop": 37868205, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "38"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602660"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376205"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS1057519787"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["G279A", "GLY279ALA", "RS1057519787", "G294A", "GLY294ALA", "GLY309ALA"], "members": [{"id": "ga4gh:VA.qRqRxPAg_vog-5oBtkoP40uXoiD6f1o9", "label": "NC_000017.10:g.37868205G>C", "digest": "qRqRxPAg_vog-5oBtkoP40uXoiD6f1o9", "type": "Allele", "location": {"id": "ga4gh:SL.LutCH7B8U_IAPLLUdwlbnVZXLCMoX0pH", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dLZ15tNO1Ur0IcGjwc3Sdi_0A6Yf4zm7"}, "start": 39711951, "end": 39711952}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.3qXus_os1JlM31GUM6Oir-V2DMKcgjir", "label": "G309A", "digest": "3qXus_os1JlM31GUM6Oir-V2DMKcgjir", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000269571.5:c.926G>C"}, {"syntax": "hgvs.g", "value": "NC_000017.10:g.37868205G>C"}, {"syntax": "hgvs.c", "value": "NM_004448.3:c.926G>C"}, {"syntax": "hgvs.p", "value": "NP_004439.2:p.Gly309Ala"}], "location": {"id": "ga4gh:SL.PtSIaEcLY6aUDu8BhG9_wEpc9XTci9j0", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.AF1UFydIo02-bMplonKSfxlWY2q6ze3m"}, "start": 308, "end": 309}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}}, "therapeutic": {"id": "civic.tid:52", "label": "Neratinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1940643"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C49094"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide", "2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-", "HKI 272", "HKI-272", "PB 272", "PB-272"]}, "tumorType": {"id": "civic.did:22", "label": "Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9335"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1612"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:283", "description": "The L755S mutation showed mild response to neratinib in MCF10A cell lines retrovirally transduced with wildtype or mutant ERBB2.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:170", "label": "Bose et al., 2013, Cancer Discov", "type": "Document", "title": "PubMed: Bose et al., 2013, Cancer Discov", "pmid": 23220880}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:20", "label": "ERBB2", "description": "ERBB2, commonly referred to as HER2, is amplified and/or overexpressed in 20-30% of invasive breast carcinomas. HER2-positive breast cancer is treated in a separate manner from other subtypes of breast cancer and commonly presents as more aggressive disease. Metastatic HER2-positive breast cancer is now commonly treated with HER2-targeted therapy. Apart from being amplified/overexpressed, ERBB2 activating mutations have been shown to have clinical importance in HER2-negative breast cancer. These mutations have shown sensitivity to the tyrosine kinase inhibitor neratinib, and highlight the importance of clinical sequencing efforts in treating breast cancer.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3430"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2064"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD340", "ERBB2", "HER-2", "HER-2/neu", "HER2", "MLN 19", "MLN-19", "NEU", "NGL", "TKR1", "VSCN2", "c-ERB-2", "c-ERB2", "p185(erbB2)"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:39", "label": "ERBB2 L755S", "description": "ERBB2 L755S was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was not shown to be an activating mutation, unlike many of the other variants queried. This mutation was also shown to confer resistance to the tyrosine kinase inhibitor lapatinib in MCF10A cell lines.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 21.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "C", "representative_transcript": "ENST00000269571.5", "chromosome": "17", "start": 37880220, "stop": 37880220, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "39"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602502"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376035"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["L740S", "L725S", "LEU755SER"], "members": [{"id": "ga4gh:VA.dVIAjDU-R5S4mY5tx8S0-PYENKi_RqfY", "label": "NC_000017.10:g.37880220T>C", "digest": "dVIAjDU-R5S4mY5tx8S0-PYENKi_RqfY", "type": "Allele", "location": {"id": "ga4gh:SL.8Q3DWDdzdXC5itI0LxkyadxCo92bbL-q", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dLZ15tNO1Ur0IcGjwc3Sdi_0A6Yf4zm7"}, "start": 39723966, "end": 39723967}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.OBWeCw368Dbx427Y2EMTin4quydJHGx1", "label": "L755S", "digest": "OBWeCw368Dbx427Y2EMTin4quydJHGx1", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000269571.5:c.2264T>C"}, {"syntax": "hgvs.g", "value": "NC_000017.10:g.37880220T>C"}, {"syntax": "hgvs.c", "value": "NM_004448.3:c.2264T>C"}, {"syntax": "hgvs.p", "value": "NP_004439.2:p.Leu755Ser"}], "location": {"id": "ga4gh:SL.PgQkgAUmQEctpQViVRSAfB_wJOvorTRs", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.AF1UFydIo02-bMplonKSfxlWY2q6ze3m"}, "start": 754, "end": 755}, "state": {"type": "LiteralSequenceExpression", "sequence": "S"}}}, "therapeutic": {"id": "civic.tid:52", "label": "Neratinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1940643"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C49094"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide", "2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-", "HKI 272", "HKI-272", "PB 272", "PB-272"]}, "tumorType": {"id": "civic.did:22", "label": "Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9335"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1612"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:284", "description": "MCF10A cells transduced with ERBB2 harboring an L755W mutation were sensitive to the irreversible kinase inhibitor neratinib in an matrigel colony forming assay.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:170", "label": "Bose et al., 2013, Cancer Discov", "type": "Document", "title": "PubMed: Bose et al., 2013, Cancer Discov", "pmid": 23220880}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:20", "label": "ERBB2", "description": "ERBB2, commonly referred to as HER2, is amplified and/or overexpressed in 20-30% of invasive breast carcinomas. HER2-positive breast cancer is treated in a separate manner from other subtypes of breast cancer and commonly presents as more aggressive disease. Metastatic HER2-positive breast cancer is now commonly treated with HER2-targeted therapy. Apart from being amplified/overexpressed, ERBB2 activating mutations have been shown to have clinical importance in HER2-negative breast cancer. These mutations have shown sensitivity to the tyrosine kinase inhibitor neratinib, and highlight the importance of clinical sequencing efforts in treating breast cancer.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3430"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2064"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD340", "ERBB2", "HER-2", "HER-2/neu", "HER2", "MLN 19", "MLN-19", "NEU", "NGL", "TKR1", "VSCN2", "c-ERB-2", "c-ERB2", "p185(erbB2)"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:40", "label": "ERBB2 L755W", "description": "ERBB2 L755W was one of the first ERBB2 variants to be functionally classified (Bose et al., 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 5.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "G", "representative_transcript": "ENST00000269571.5", "chromosome": "17", "start": 37880220, "stop": 37880220, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "40"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602786"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376343"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913470"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913470", "LEU755TRP", "L725W", "L740W"], "members": [{"id": "ga4gh:VA.09btnK6vbvehB2QPIfRQABfIvDicrPaS", "label": "NC_000017.10:g.37880220T>G", "digest": "09btnK6vbvehB2QPIfRQABfIvDicrPaS", "type": "Allele", "location": {"id": "ga4gh:SL.8Q3DWDdzdXC5itI0LxkyadxCo92bbL-q", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dLZ15tNO1Ur0IcGjwc3Sdi_0A6Yf4zm7"}, "start": 39723966, "end": 39723967}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.2XB0gWD22mwf9GWjDWeGLXxWbnODisBZ", "label": "L755W", "digest": "2XB0gWD22mwf9GWjDWeGLXxWbnODisBZ", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000269571.5:c.2264T>G"}, {"syntax": "hgvs.g", "value": "NC_000017.10:g.37880220T>G"}, {"syntax": "hgvs.c", "value": "NM_004448.3:c.2264T>G"}, {"syntax": "hgvs.p", "value": "NP_004439.2:p.Leu755Trp"}], "location": {"id": "ga4gh:SL.PgQkgAUmQEctpQViVRSAfB_wJOvorTRs", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.AF1UFydIo02-bMplonKSfxlWY2q6ze3m"}, "start": 754, "end": 755}, "state": {"type": "LiteralSequenceExpression", "sequence": "W"}}}, "therapeutic": {"id": "civic.tid:52", "label": "Neratinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1940643"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C49094"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide", "2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-", "HKI 272", "HKI-272", "PB 272", "PB-272"]}, "tumorType": {"id": "civic.did:22", "label": "Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9335"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1612"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:285", "description": "In MCF10A cell lines, the in-frame insertion of a single amino acid at position 780 was shown to be sensitive to neratinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:170", "label": "Bose et al., 2013, Cancer Discov", "type": "Document", "title": "PubMed: Bose et al., 2013, Cancer Discov", "pmid": 23220880}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:20", "label": "ERBB2", "description": "ERBB2, commonly referred to as HER2, is amplified and/or overexpressed in 20-30% of invasive breast carcinomas. HER2-positive breast cancer is treated in a separate manner from other subtypes of breast cancer and commonly presents as more aggressive disease. Metastatic HER2-positive breast cancer is now commonly treated with HER2-targeted therapy. Apart from being amplified/overexpressed, ERBB2 activating mutations have been shown to have clinical importance in HER2-negative breast cancer. These mutations have shown sensitivity to the tyrosine kinase inhibitor neratinib, and highlight the importance of clinical sequencing efforts in treating breast cancer.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3430"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2064"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD340", "ERBB2", "HER-2", "HER-2/neu", "HER2", "MLN 19", "MLN-19", "NEU", "NGL", "TKR1", "VSCN2", "c-ERB-2", "c-ERB2", "p185(erbB2)"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:41", "label": "ERBB2 P780INS", "description": "ERBB2 P780 insertion was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 activating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 12.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "variant_bases": "GGCTCCCCA", "representative_transcript": "ENST00000269571.5", "chromosome": "17", "start": 37881011, "stop": 37881012, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "inframe_insertion", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001821"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "41"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA135401"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["PRO780INS"], "members": [{"id": "ga4gh:VA.Rm70dGCbAO_X7QjFjqL_xO-RSe4Pqc4D", "label": "NC_000017.10:g.37881011_37881012insGGCTCCCCA", "digest": "Rm70dGCbAO_X7QjFjqL_xO-RSe4Pqc4D", "type": "Allele", "location": {"id": "ga4gh:SL.a2qHNw71BGPT8WBkidMfSE5Jv8QgsBoj", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dLZ15tNO1Ur0IcGjwc3Sdi_0A6Yf4zm7"}, "start": 39724749, "end": 39724758}, "state": {"type": "ReferenceLengthExpression", "length": 18, "sequence": "GGCTCCCCAGGCTCCCCA", "repeatSubunitLength": 9}}], "definingContext": {"id": "ga4gh:VA.3_K2bUPsnVGTVB9lwXogZ0hyDBSYHbcr", "label": "P780INS", "digest": "3_K2bUPsnVGTVB9lwXogZ0hyDBSYHbcr", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000269571.5:c.2340_2341insGGCTCCCCA"}, {"syntax": "hgvs.g", "value": "NC_000017.10:g.37881011_37881012insGGCTCCCCA"}], "location": {"id": "ga4gh:SL.2pCi07aKnN42HAGWlaQ58MA1ofT6A0x6", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.AF1UFydIo02-bMplonKSfxlWY2q6ze3m"}, "start": 779, "end": 782}, "state": {"type": "LiteralSequenceExpression", "sequence": "INS"}}}, "therapeutic": {"id": "civic.tid:52", "label": "Neratinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1940643"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C49094"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide", "2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-", "HKI 272", "HKI-272", "PB 272", "PB-272"]}, "tumorType": {"id": "civic.did:22", "label": "Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9335"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1612"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:287", "description": "In MCF10A cell lines, the R896C mutation was shown to be sensitive to neratinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:170", "label": "Bose et al., 2013, Cancer Discov", "type": "Document", "title": "PubMed: Bose et al., 2013, Cancer Discov", "pmid": 23220880}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:20", "label": "ERBB2", "description": "ERBB2, commonly referred to as HER2, is amplified and/or overexpressed in 20-30% of invasive breast carcinomas. HER2-positive breast cancer is treated in a separate manner from other subtypes of breast cancer and commonly presents as more aggressive disease. Metastatic HER2-positive breast cancer is now commonly treated with HER2-targeted therapy. Apart from being amplified/overexpressed, ERBB2 activating mutations have been shown to have clinical importance in HER2-negative breast cancer. These mutations have shown sensitivity to the tyrosine kinase inhibitor neratinib, and highlight the importance of clinical sequencing efforts in treating breast cancer.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3430"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2064"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD340", "ERBB2", "HER-2", "HER-2/neu", "HER2", "MLN 19", "MLN-19", "NEU", "NGL", "TKR1", "VSCN2", "c-ERB-2", "c-ERB2", "p185(erbB2)"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:43", "label": "ERBB2 R896C", "description": "ERBB2 R896C was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 5.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000269571.5", "chromosome": "17", "start": 37881616, "stop": 37881616, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "43"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA8534359"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "375995"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS758222990"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ARG896CYS", "RS758222990", "R881C", "R866C"], "members": [{"id": "ga4gh:VA.Hiuwn5F1dw2qNfj4AqEjJ5lWuazpA1Yh", "label": "NC_000017.10:g.37881616C>T", "digest": "Hiuwn5F1dw2qNfj4AqEjJ5lWuazpA1Yh", "type": "Allele", "location": {"id": "ga4gh:SL.BehCpTu_pPcnS8B3WxmDPxZjBS_3YTSY", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dLZ15tNO1Ur0IcGjwc3Sdi_0A6Yf4zm7"}, "start": 39725362, "end": 39725363}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.gcv-1HgGQuITFTUbxvUXvN5CSHV05r8y", "label": "R896C", "digest": "gcv-1HgGQuITFTUbxvUXvN5CSHV05r8y", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000269571.5:c.2686C>T"}, {"syntax": "hgvs.g", "value": "NC_000017.10:g.37881616C>T"}, {"syntax": "hgvs.c", "value": "NM_004448.3:c.2686C>T"}, {"syntax": "hgvs.p", "value": "NP_004439.2:p.Arg896Cys"}], "location": {"id": "ga4gh:SL.5yaR0_2I5K5mWFj5vEOkHFedn-mugUVw", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.AF1UFydIo02-bMplonKSfxlWY2q6ze3m"}, "start": 895, "end": 896}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "civic.tid:52", "label": "Neratinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1940643"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C49094"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide", "2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-", "HKI 272", "HKI-272", "PB 272", "PB-272"]}, "tumorType": {"id": "civic.did:22", "label": "Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9335"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1612"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:288", "description": "In MCF10A cell lines, the V777L mutation was shown to be sensitive to neratinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:170", "label": "Bose et al., 2013, Cancer Discov", "type": "Document", "title": "PubMed: Bose et al., 2013, Cancer Discov", "pmid": 23220880}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:20", "label": "ERBB2", "description": "ERBB2, commonly referred to as HER2, is amplified and/or overexpressed in 20-30% of invasive breast carcinomas. HER2-positive breast cancer is treated in a separate manner from other subtypes of breast cancer and commonly presents as more aggressive disease. Metastatic HER2-positive breast cancer is now commonly treated with HER2-targeted therapy. Apart from being amplified/overexpressed, ERBB2 activating mutations have been shown to have clinical importance in HER2-negative breast cancer. These mutations have shown sensitivity to the tyrosine kinase inhibitor neratinib, and highlight the importance of clinical sequencing efforts in treating breast cancer.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3430"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2064"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD340", "ERBB2", "HER-2", "HER-2/neu", "HER2", "MLN 19", "MLN-19", "NEU", "NGL", "TKR1", "VSCN2", "c-ERB-2", "c-ERB2", "p185(erbB2)"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:44", "label": "ERBB2 V777L", "description": "ERBB2 V777L was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 9.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "T", "representative_transcript": "ENST00000269571.5", "chromosome": "17", "start": 37881000, "stop": 37881000, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "44"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA135387"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "44991"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913471"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913471", "V747L", "VAL777LEU", "V762L"], "members": [{"id": "ga4gh:VA.Ah8Gv3S4OY1KAMxFCn0s9zf-X8mu_khw", "label": "NC_000017.10:g.37881000G>T", "digest": "Ah8Gv3S4OY1KAMxFCn0s9zf-X8mu_khw", "type": "Allele", "location": {"id": "ga4gh:SL.uNUogwDrVQFAqquTU_nFPRDnW0_JNUEg", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dLZ15tNO1Ur0IcGjwc3Sdi_0A6Yf4zm7"}, "start": 39724746, "end": 39724747}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.qpMYXHyIVBSnFOjXV9INRoMEOxTudrhd", "label": "V777L", "digest": "qpMYXHyIVBSnFOjXV9INRoMEOxTudrhd", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004448.3:c.2329G>T"}, {"syntax": "hgvs.p", "value": "NP_004439.2:p.Val777Leu"}, {"syntax": "hgvs.c", "value": "ENST00000269571.5:c.2329G>T"}, {"syntax": "hgvs.g", "value": "NC_000017.10:g.37881000G>T"}], "location": {"id": "ga4gh:SL.8jArVDSNzsnMSUiyAYt-aiJ9IP59JK2M", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.AF1UFydIo02-bMplonKSfxlWY2q6ze3m"}, "start": 776, "end": 777}, "state": {"type": "LiteralSequenceExpression", "sequence": "L"}}}, "therapeutic": {"id": "civic.tid:52", "label": "Neratinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1940643"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C49094"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide", "2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-", "HKI 272", "HKI-272", "PB 272", "PB-272"]}, "tumorType": {"id": "civic.did:22", "label": "Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9335"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1612"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:289", "description": "In MCF10A cell lines, the V842I mutation was shown to be sensitive to neratinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:170", "label": "Bose et al., 2013, Cancer Discov", "type": "Document", "title": "PubMed: Bose et al., 2013, Cancer Discov", "pmid": 23220880}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:20", "label": "ERBB2", "description": "ERBB2, commonly referred to as HER2, is amplified and/or overexpressed in 20-30% of invasive breast carcinomas. HER2-positive breast cancer is treated in a separate manner from other subtypes of breast cancer and commonly presents as more aggressive disease. Metastatic HER2-positive breast cancer is now commonly treated with HER2-targeted therapy. Apart from being amplified/overexpressed, ERBB2 activating mutations have been shown to have clinical importance in HER2-negative breast cancer. These mutations have shown sensitivity to the tyrosine kinase inhibitor neratinib, and highlight the importance of clinical sequencing efforts in treating breast cancer.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3430"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2064"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD340", "ERBB2", "HER-2", "HER-2/neu", "HER2", "MLN 19", "MLN-19", "NEU", "NGL", "TKR1", "VSCN2", "c-ERB-2", "c-ERB2", "p185(erbB2)"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:45", "label": "ERBB2 V842I", "description": "ERBB2 V842I was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 9.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000269571.5", "chromosome": "17", "start": 37881332, "stop": 37881332, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "45"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602468"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "375994"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS1057519738"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["VAL842ILE", "VAL827ILE", "V812I", "RS1057519738", "VAL812ILE", "V827I"], "members": [{"id": "ga4gh:VA.GnSg3oEGp9qgKV3Jb7SD6OJnSlvdkVIX", "label": "NC_000017.10:g.37881332G>A", "digest": "GnSg3oEGp9qgKV3Jb7SD6OJnSlvdkVIX", "type": "Allele", "location": {"id": "ga4gh:SL.xamFUJGbhgEw5bb0qVAapu8nhtwHYmCy", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dLZ15tNO1Ur0IcGjwc3Sdi_0A6Yf4zm7"}, "start": 39725078, "end": 39725079}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA._kGTpkql40oDm2ag7kILxnsXwv1AMFHM", "label": "V842I", "digest": "_kGTpkql40oDm2ag7kILxnsXwv1AMFHM", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000269571.5:c.2524G>A"}, {"syntax": "hgvs.c", "value": "NM_004448.3:c.2524G>A"}, {"syntax": "hgvs.p", "value": "NP_004439.2:p.Val842Ile"}, {"syntax": "hgvs.g", "value": "NC_000017.10:g.37881332G>A"}], "location": {"id": "ga4gh:SL.7EnlxYIuWjhsRPEhTNzS3roO46wmWXd1", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.AF1UFydIo02-bMplonKSfxlWY2q6ze3m"}, "start": 841, "end": 842}, "state": {"type": "LiteralSequenceExpression", "sequence": "I"}}}, "therapeutic": {"id": "civic.tid:52", "label": "Neratinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1940643"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C49094"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide", "2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-", "HKI 272", "HKI-272", "PB 272", "PB-272"]}, "tumorType": {"id": "civic.did:22", "label": "Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9335"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1612"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:6376", "description": "In this in vitro study, the H1915 non-small cell lung cancer cell line (homozygous for a R351W mutation) was shown to be susceptible to imatinib. This line showed a significant reduction in colony formation (P = 0.0004) and MTT assay, which tests for NADH activity (P < 0.001), with imatinib vs vehicle treatment. There was no significant difference in a lung cancer cell line without a known driver (H2126) nor in an immortalized bronchial epithelial line (Beas-2B) with either drug treatment in colony forming and MTT assays. Additionally, reduction in cell viability upon kinase inhibitor treatment was rescued with tetracycline-induced overexpression of resistant ABL1-T315I (P < 0.001) confirming the genetic dependency of this cell line on ABL1. Moreover, siRNA facilitated depletion of ABL1 expression resulted in significantly increased cytotoxicity (P < 0.004) with no significant change in H2126 or Beas-2B lines for 2/3 siRNAs supporting ABL1 as the primary drug target. Significant tumor reduction was observed in murine NSCLC xenografts of the H1915 cell line treated with imatinib compared to vehicle treatment (P = 0.0016). No change in tumor growth was observed in xenografts of the H650 cell line containing a wildtype ABL1 locus. In both in vitro and in vivo experiments, doxycycline-inducible expression of drug-resistant ABL1-T315I rescued imatinib-mediated inhibitory effects supporting the specificity of drug responses.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2128", "label": "Testoni et al., 2016, EMBO Mol Med", "type": "Document", "title": "PubMed: Testoni et al., 2016, EMBO Mol Med", "pmid": 26758680}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:4", "label": "ABL1", "description": "ABL1 is most relevant to cancer in its role in the BCR-ABL fusion protein that has become a signature of chronic myeloid leukemia (CML). Cells harboring this fusion have shown sensitivity to imatinib, greatly improving the prognostic outlook of the disease. However, additional mutations in ABL1 have been shown to confer resistance to imatinib. In these resistance cases, second-generation tyrosine kinase inhibitors such as dasatinib and nilotinib have exhibited some efficacy and are currently undergoing clinical trials for treating acquired resistance in CML.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:76"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:25"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["ABL", "ABL1", "BCR-ABL", "CHDSKM", "JTK7", "bcr/abl", "c-ABL", "c-ABL1", "p150", "v-abl"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1564", "label": "ABL1 R351W", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 9.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000372348.2", "chromosome": "9", "start": 133748333, "stop": 133748333, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1656"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA5285359"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS779478267"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["R332W", "RS779478267", "ARG351TRP"], "members": [{"id": "ga4gh:VA.qNy2ihAiYylsrp7IghhTWDJvKaKK3KiN", "label": "NC_000009.11:g.133748333C>T", "digest": "qNy2ihAiYylsrp7IghhTWDJvKaKK3KiN", "type": "Allele", "location": {"id": "ga4gh:SL.qx--aO3ZvD1SATUlgeQNw4TqMUhh2VAg", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.KEO-4XBcm1cxeo_DIQ8_ofqGUkp4iZhI"}, "start": 130872945, "end": 130872946}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.JLMC4T56srjVEPQebuy8nw8Ao2_B7TMh", "label": "R351W", "digest": "JLMC4T56srjVEPQebuy8nw8Ao2_B7TMh", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000372348.2:c.1051C>T"}, {"syntax": "hgvs.g", "value": "NC_000009.11:g.133748333C>T"}, {"syntax": "hgvs.c", "value": "NM_007313.2:c.1051C>T"}, {"syntax": "hgvs.p", "value": "NP_009297.2:p.Arg351Trp"}], "location": {"id": "ga4gh:SL.NWrm5KTUAe-zkYX0qCzBM2SIkYhSMGVL", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dmFigTG-0fY6I54swb7PoDuxCeT6O3Wg"}, "start": 331, "end": 332}, "state": {"type": "LiteralSequenceExpression", "sequence": "W"}}}, "therapeutic": {"id": "civic.tid:5", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:282388"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "Disease", "label": "Systemic mastocytosis", "mappings": [{"coding": {"system": "ncit", "code": "C9235"}, "relation": "relatedMatch"}]}, {"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}, {"id": "hemonc:634", "type": "Disease", "label": "Myelodysplastic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C3247"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:33893", "type": "Disease", "label": "Chronic myelogenous leukemia pediatric"}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}, {"id": "hemonc:616", "type": "Disease", "label": "Hypereosinophilic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C27038"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C62035"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:7416", "description": "A preclinical study tested the effects of a tyrosine kinase inhibitor (TKI) on Ba/F3 cell lines with representative primary imatinib-sensitizing mutation del 557-558, which induced IL-3 independent growth, and secondary mutation T670I. The cells were tested for Imatinib resistance. Ba/F3 cells with del 557-558/T670I mutations (IC50 = >10000 nM) showed resistance towards Imatinib compared to Ba/F3 cells with del 557-558 alone (IC50 = 27 +- 8 nM). Similarly, patient-derived GIST-T1/670 cells with 560-578 deletion/T670I mutations (IC50 > 5000 nM) did show resistance towards Imatinib compared to GIST-T1 cells with 560-578 deletion (IC50 = 30 nM). Del 557-558/T670I cells were implanted into mice and treated with Imatinib. Imatinib was not effective in treating the del 557-558/T670I cells in mice as tumor volume progressively increased. In addition, Ba/F3 cells were mutagenized with N-ethyl-N-nitrosourea and incubated with varying concentrations of Imatinib. In Imatinib incubated cells, T670I mutations were seen in approximately 80% of the resistant cell populations.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2042", "label": "Garner et al., 2014, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Garner et al., 2014, Clin. Cancer Res.", "pmid": 25239608}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:29", "label": "KIT", "description": "c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3815"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["C-Kit", "CD117", "KIT", "MASTC", "PBT", "SCFR"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1241", "label": "KIT T670I", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 21.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000288135.5", "chromosome": "4", "start": 55595519, "stop": 55595519, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1267"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602525"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376058"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913516"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["THR670ILE", "RS121913516"], "members": [{"id": "ga4gh:VA.dTZgbPkwISVGYwXmm_4WCyPX9W-LSOOh", "label": "NC_000004.11:g.55595519C>T", "digest": "dTZgbPkwISVGYwXmm_4WCyPX9W-LSOOh", "type": "Allele", "location": {"id": "ga4gh:SL.reFRinn6ZsNtpwqaKz6HHHpO34YKczpW", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54729352, "end": 54729353}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.f55Nm2_RKZg7Hnpo-JVhQVAliadbUqMJ", "label": "T670I", "digest": "f55Nm2_RKZg7Hnpo-JVhQVAliadbUqMJ", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_000222.2:c.2009C>T"}, {"syntax": "hgvs.p", "value": "NP_000213.1:p.Thr670Ile"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55595519C>T"}, {"syntax": "hgvs.c", "value": "ENST00000288135.5:c.2009C>T"}], "location": {"id": "ga4gh:SL.jq2-jclk1pqHSIl0gTtHsMPBMD7VcMmN", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 669, "end": 670}, "state": {"type": "LiteralSequenceExpression", "sequence": "I"}}}, "therapeutic": {"id": "civic.tid:5", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:282388"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "Disease", "label": "Systemic mastocytosis", "mappings": [{"coding": {"system": "ncit", "code": "C9235"}, "relation": "relatedMatch"}]}, {"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}, {"id": "hemonc:634", "type": "Disease", "label": "Myelodysplastic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C3247"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:33893", "type": "Disease", "label": "Chronic myelogenous leukemia pediatric"}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}, {"id": "hemonc:616", "type": "Disease", "label": "Hypereosinophilic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C27038"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C62035"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"]}, "tumorType": {"id": "civic.did:2", "label": "Gastrointestinal Stromal Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3868"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9253"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:43", "description": "In CHO cells with PDGFRA D842I mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:80", "label": "Heinrich et al., 2012, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Heinrich et al., 2012, Clin. Cancer Res.", "pmid": 22745105}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:38", "label": "PDGFRA", "description": "Commonly mutated in GI tract tumors, PDGFR family genes (mutually exclusive to KIT mutations) are a hallmark of gastrointestinal stromal tumors. Gene fusions involving the PDGFRA kinase domain are highly correlated with eosinophilia, and the WHO classifies myeloid and lymphoid neoplasms with these characteristics as a distinct disorder. Mutations in the 842 region of PDGFRA have been often found to confer resistance to the tyrosine kinase inhibitor, imatinib.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8803"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5156"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD140A", "PDGFR-2", "PDGFR2", "PDGFRA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:98", "label": "PDGFRA D842I", "description": "PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 4.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "GA", "variant_bases": "AT", "representative_transcript": "ENST00000257290.5", "chromosome": "4", "start": 55152092, "stop": 55152093, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "98"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602522"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376055"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ASP842ILE"], "members": [{"id": "ga4gh:VA.dOrQNVGg8EmEB_EVKOJTu3HnUBXJXo3Q", "label": "NC_000004.11:g.55152092_55152093delinsAT", "digest": "dOrQNVGg8EmEB_EVKOJTu3HnUBXJXo3Q", "type": "Allele", "location": {"id": "ga4gh:SL.wIHkSFWwzABvkGRNEZpgNRgQofedfTw7", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54285924, "end": 54285926}, "state": {"type": "LiteralSequenceExpression", "sequence": "AT"}}], "definingContext": {"id": "ga4gh:VA.DDmzW1KwTZr-rNSz5vKFLXR5SPHXOJfQ", "label": "D842I", "digest": "DDmzW1KwTZr-rNSz5vKFLXR5SPHXOJfQ", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000257290.5:c.2524_2525delinsAT"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55152092_55152093delinsAT"}, {"syntax": "hgvs.p", "value": "NP_006197.1:p.Asp842Ile"}, {"syntax": "hgvs.c", "value": "NM_006206.5:c.2524_2525delGAinsAT"}], "location": {"id": "ga4gh:SL.GHXCPrbd_qdPUoHjPwzv5iVFapJ0cn-o", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.XpQn9sZLGv_GU3uiWO7YHq9-_alGjrVX"}, "start": 841, "end": 842}, "state": {"type": "LiteralSequenceExpression", "sequence": "I"}}}, "therapeutic": {"id": "civic.tid:21", "label": "Crenolanib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C64639"}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64639"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-Piperidinamine, 1-[2-[5-[(3-methyl-3-oxetanyl)methoxy]-1Hbenzimidazol-1-yl]-8-quinolinyl]-", "CP-868,596", "CP-868596", "PDGFR Inhibitor CP-868596", "[1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine"]}, "tumorType": {"id": "civic.did:2", "label": "Gastrointestinal Stromal Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3868"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9253"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:44", "description": "In CHO cells with PDGFRA D842V mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:80", "label": "Heinrich et al., 2012, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Heinrich et al., 2012, Clin. Cancer Res.", "pmid": 22745105}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:38", "label": "PDGFRA", "description": "Commonly mutated in GI tract tumors, PDGFR family genes (mutually exclusive to KIT mutations) are a hallmark of gastrointestinal stromal tumors. Gene fusions involving the PDGFRA kinase domain are highly correlated with eosinophilia, and the WHO classifies myeloid and lymphoid neoplasms with these characteristics as a distinct disorder. Mutations in the 842 region of PDGFRA have been often found to confer resistance to the tyrosine kinase inhibitor, imatinib.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8803"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5156"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD140A", "PDGFR-2", "PDGFR2", "PDGFRA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:99", "label": "PDGFRA D842V", "description": "PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. Exogenous expression of the A842V mutation resulted in constitutive tyrosine phosphorylation of PDGFRA in the absence of ligand in 293T cells and cytokine-independent proliferation of the IL-3-dependent Ba/F3 cell line, both evidence that this is an activating mutation. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 100.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000257290.5", "chromosome": "4", "start": 55152093, "stop": 55152093, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "99"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123194"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13543"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121908585"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ASP842VAL", "RS121908585"], "members": [{"id": "ga4gh:VA.bDwkJ2filJ3ZGiUFybGFfyaCKdIVK86v", "label": "NC_000004.11:g.55152093A>T", "digest": "bDwkJ2filJ3ZGiUFybGFfyaCKdIVK86v", "type": "Allele", "location": {"id": "ga4gh:SL.LxO2YLfQbI_-TK7GOmSoOpMNiSy_Hgan", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54285925, "end": 54285926}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.vIjnL-aLYl0BSB6JutpdD7yW_qIXtdk8", "label": "D842V", "digest": "vIjnL-aLYl0BSB6JutpdD7yW_qIXtdk8", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006206.4:c.2525A>T"}, {"syntax": "hgvs.p", "value": "NP_006197.1:p.Asp842Val"}, {"syntax": "hgvs.c", "value": "ENST00000257290.5:c.2525A>T"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55152093A>T"}], "location": {"id": "ga4gh:SL.GHXCPrbd_qdPUoHjPwzv5iVFapJ0cn-o", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.XpQn9sZLGv_GU3uiWO7YHq9-_alGjrVX"}, "start": 841, "end": 842}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "civic.tid:21", "label": "Crenolanib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C64639"}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64639"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-Piperidinamine, 1-[2-[5-[(3-methyl-3-oxetanyl)methoxy]-1Hbenzimidazol-1-yl]-8-quinolinyl]-", "CP-868,596", "CP-868596", "PDGFR Inhibitor CP-868596", "[1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine"]}, "tumorType": {"id": "civic.did:2", "label": "Gastrointestinal Stromal Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3868"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9253"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:45", "description": "In CHO cells with PDGFRA D842Y mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:80", "label": "Heinrich et al., 2012, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Heinrich et al., 2012, Clin. Cancer Res.", "pmid": 22745105}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:38", "label": "PDGFRA", "description": "Commonly mutated in GI tract tumors, PDGFR family genes (mutually exclusive to KIT mutations) are a hallmark of gastrointestinal stromal tumors. Gene fusions involving the PDGFRA kinase domain are highly correlated with eosinophilia, and the WHO classifies myeloid and lymphoid neoplasms with these characteristics as a distinct disorder. Mutations in the 842 region of PDGFRA have been often found to confer resistance to the tyrosine kinase inhibitor, imatinib.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8803"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5156"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD140A", "PDGFR-2", "PDGFR2", "PDGFRA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:100", "label": "PDGFRA D842Y", "description": "PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 4.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "T", "representative_transcript": "ENST00000257290.5", "chromosome": "4", "start": 55152092, "stop": 55152092, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "100"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602703"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376250"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913265"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913265", "ASP842TYR"], "members": [{"id": "ga4gh:VA.mRZyvqwMPskdNAV-3VaYmixKq04lFkkR", "label": "NC_000004.11:g.55152092G>T", "digest": "mRZyvqwMPskdNAV-3VaYmixKq04lFkkR", "type": "Allele", "location": {"id": "ga4gh:SL.VEYyMt_XFnT32E-ThGgoGXmfFexg1IoG", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54285924, "end": 54285925}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.cVs1QfV1pO2MBLoGqWYA4-h_JgffN7Dw", "label": "D842Y", "digest": "cVs1QfV1pO2MBLoGqWYA4-h_JgffN7Dw", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000257290.5:c.2524G>T"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55152092G>T"}, {"syntax": "hgvs.c", "value": "NM_006206.5:c.2524G>T"}, {"syntax": "hgvs.p", "value": "NP_006197.1:p.Asp842Tyr"}], "location": {"id": "ga4gh:SL.GHXCPrbd_qdPUoHjPwzv5iVFapJ0cn-o", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.XpQn9sZLGv_GU3uiWO7YHq9-_alGjrVX"}, "start": 841, "end": 842}, "state": {"type": "LiteralSequenceExpression", "sequence": "Y"}}}, "therapeutic": {"id": "civic.tid:21", "label": "Crenolanib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C64639"}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64639"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-Piperidinamine, 1-[2-[5-[(3-methyl-3-oxetanyl)methoxy]-1Hbenzimidazol-1-yl]-8-quinolinyl]-", "CP-868,596", "CP-868596", "PDGFR Inhibitor CP-868596", "[1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine"]}, "tumorType": {"id": "civic.did:2", "label": "Gastrointestinal Stromal Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3868"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9253"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:47", "description": "In CHO cells with PDGFRA DI842-843VM mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:80", "label": "Heinrich et al., 2012, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Heinrich et al., 2012, Clin. Cancer Res.", "pmid": 22745105}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:38", "label": "PDGFRA", "description": "Commonly mutated in GI tract tumors, PDGFR family genes (mutually exclusive to KIT mutations) are a hallmark of gastrointestinal stromal tumors. Gene fusions involving the PDGFRA kinase domain are highly correlated with eosinophilia, and the WHO classifies myeloid and lymphoid neoplasms with these characteristics as a distinct disorder. Mutations in the 842 region of PDGFRA have been often found to confer resistance to the tyrosine kinase inhibitor, imatinib.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8803"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5156"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD140A", "PDGFR-2", "PDGFR2", "PDGFRA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:102", "label": "PDGFRA D842_I843delinsVM", "description": "PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. The DI842-843VM variant is the result of a double point mutation. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 4.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "ACATC", "variant_bases": "TCATG", "representative_transcript": "ENST00000257290.5", "chromosome": "4", "start": 55152093, "stop": 55152097, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "102"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA658820703"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "members": [{"id": "ga4gh:VA.Qqd_XpOAO1JVCqTKc-LoZxI5C59xD8v3", "label": "NC_000004.11:g.55152093_55152097delinsTCATG", "digest": "Qqd_XpOAO1JVCqTKc-LoZxI5C59xD8v3", "type": "Allele", "location": {"id": "ga4gh:SL.6mpoqlVIVsVQDVnDgGhZ_lhrFLfRPcH0", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54285925, "end": 54285930}, "state": {"type": "LiteralSequenceExpression", "sequence": "TCATG"}}], "definingContext": {"id": "ga4gh:VA.4G7gD_AxyPSHHh0FQpz9oMj3jFE2-UnI", "label": "D842_I843delinsVM", "digest": "4G7gD_AxyPSHHh0FQpz9oMj3jFE2-UnI", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000004.11:g.55152093_55152097delinsTCATG"}], "location": {"id": "ga4gh:SL.Y008F_LZF_ge7YX4Rmqr0-TQ4dyHLd5N", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.XpQn9sZLGv_GU3uiWO7YHq9-_alGjrVX"}, "start": 841, "end": 843}, "state": {"type": "LiteralSequenceExpression", "sequence": "VM"}}}, "therapeutic": {"id": "civic.tid:21", "label": "Crenolanib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C64639"}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64639"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-Piperidinamine, 1-[2-[5-[(3-methyl-3-oxetanyl)methoxy]-1Hbenzimidazol-1-yl]-8-quinolinyl]-", "CP-868,596", "CP-868596", "PDGFR Inhibitor CP-868596", "[1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine"]}, "tumorType": {"id": "civic.did:2", "label": "Gastrointestinal Stromal Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3868"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9253"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:136", "description": "Cells harboring KRAS G12V mutation were insensitive to cetuximab treatment in isogenic SW48 cells and in a mouse xenograft model.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:123", "label": "De Roock et al., 2010, JAMA", "type": "Document", "title": "PubMed: De Roock et al., 2010, JAMA", "pmid": 20978259}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:421", "label": "KRAS G12V", "description": "KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 67.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "A", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398284, "stop": 25398284, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "425"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA122540"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12583"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913529"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913529", "GLY12VAL"], "members": [{"id": "ga4gh:VA.-SzXMvMSRoSJgvsIDz-7M7VTFdo4FCtA", "label": "NC_000012.11:g.25398284C>A", "digest": "-SzXMvMSRoSJgvsIDz-7M7VTFdo4FCtA", "type": "Allele", "location": {"id": "ga4gh:SL.iF0OXeO-tnumYbGkzaFEQ7cOZI_UCI1s", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245349, "end": 25245350}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.JTtvYJD7yl02AOq09HjSZDUnfg4gYdUb", "label": "G12V", "digest": "JTtvYJD7yl02AOq09HjSZDUnfg4gYdUb", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004985.4:c.35G>T"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly12Val"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398284C>A"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.35G>T"}], "location": {"id": "ga4gh:SL.OndkjmujtyUEZSjjCv0C-gpwnVbRgfj8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "civic.tid:16", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:318341"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}, {"id": "mesh:D006258", "type": "Disease", "label": "Head and Neck Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C4013"}, "relation": "relatedMatch"}]}, {"id": "mesh:D002294", "type": "Disease", "label": "Carcinoma, Squamous Cell", "mappings": [{"coding": {"system": "ncit", "code": "C2929"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1723"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:142", "description": "SH-SY5Y and Kelly cells with mutant ALK (F1174L) and Ba/F3 cells overexpressing ALK harboring the F1174L mutation are sensitive to TAE684-mediated growth inhibition.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:79", "label": "George et al., 2008, Nature", "type": "Document", "title": "PubMed: George et al., 2008, Nature", "pmid": 18923525}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:1", "label": "ALK", "description": "ALK amplifications, fusions and mutations have been shown to be driving events in non-small cell lung cancer. While crizontinib has demonstrated efficacy in treating the amplification, mutations in ALK have been shown to confer resistance to current tyrosine kinase inhibitors. Second-generation TKI's have seen varied success in treating these resistant cases, and the HSP90 inhibitor 17-AAG has been shown to be cytostatic in ALK-altered cell lines.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:427"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:238"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["ALK", "ALK1", "CD246", "NBLST3"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:8", "label": "ALK F1174L", "description": "ALK F1174L has been observed as recurrent in neuroblastoma, non-small cell lung cancer (NSCLC), and other cancer types. Neuroblastoma cells containing this mutation have shown resistance to low doses of criztonib. However, increased dosage can overcome this resistance in cell lines studies. TAE684 has also proven effective in both NSCLC and neuroblastoma F1174L containing cells.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 33.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "T", "representative_transcript": "ENST00000389048.3", "chromosome": "2", "start": 29443695, "stop": 29443695, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "8"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA279586"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "217851"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS863225281"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["PHE1174LEU", "RS863225281"], "members": [{"id": "ga4gh:VA.ivl5YUYPCfDa2igYKGlCTZec5eKC7oYY", "label": "NC_000002.11:g.29443695G>T", "digest": "ivl5YUYPCfDa2igYKGlCTZec5eKC7oYY", "type": "Allele", "location": {"id": "ga4gh:SL.Nn_joIP_IBbU0SOamVk3VuamNXOVBxPt", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.pnAqCRBrTsUoBghSD1yp_jXWSmlbdh4g"}, "start": 29220828, "end": 29220829}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.nTPnpFtWudqItR2YaGBsaJwRgGobSWAr", "label": "F1174L", "digest": "nTPnpFtWudqItR2YaGBsaJwRgGobSWAr", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004304.4:c.3522C>A"}, {"syntax": "hgvs.p", "value": "NP_004295.2:p.Phe1174Leu"}, {"syntax": "hgvs.g", "value": "NC_000002.11:g.29443695G>T"}, {"syntax": "hgvs.c", "value": "ENST00000389048.3:c.3522C>A"}], "location": {"id": "ga4gh:SL.n1vbI2DGWZjLWoNdaUdc1ISSHenlCMar", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.q9CnK-HKWh9eqhOi8FlzR7M0pCmUrWPs"}, "start": 1173, "end": 1174}, "state": {"type": "LiteralSequenceExpression", "sequence": "L"}}}, "therapeutic": {"id": "civic.tid:18", "label": "TAE684", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C171615"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:13", "label": "Neuroblastoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3270"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:769"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:145", "description": "Cells harboring KRAS G13D mutation were sensitive to cetuximab treatment in isogenic SW48 cells and in a mouse xenograft model.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:123", "label": "De Roock et al., 2010, JAMA", "type": "Document", "title": "PubMed: De Roock et al., 2010, JAMA", "pmid": 20978259}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:81", "label": "KRAS G13D", "description": "While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, results are conflicting with retrospective analyses suggesting a better response to EGFR-Inhibition. A recent prospective phase-II study (12 patients, Schirripa et. al. 2015) could not reproduce this finding and another prospective phase II trial is currently ongoing.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 108.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398281, "stop": 25398281, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "81"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA122534"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12580"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS112445441"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS112445441", "GLY13ASP"], "members": [{"id": "ga4gh:VA.wQro48c_oFxB35UNb2O1Z7Vj6rXnJywl", "label": "NC_000012.11:g.25398281C>T", "digest": "wQro48c_oFxB35UNb2O1Z7Vj6rXnJywl", "type": "Allele", "location": {"id": "ga4gh:SL.rZcsm5bnq3ptyk4298opou7vY9O0etcL", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245346, "end": 25245347}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.h-3tyZSdsQNs9NHrhuwcACnnMnpuT-8Z", "label": "G13D", "digest": "h-3tyZSdsQNs9NHrhuwcACnnMnpuT-8Z", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_033360.3:c.38G>A"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly13Asp"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398281C>T"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.38G>A"}], "location": {"id": "ga4gh:SL.U-3sSsoejW41eQ2Aev0wiG5tEuDiQZTB", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 12, "end": 13}, "state": {"type": "LiteralSequenceExpression", "sequence": "D"}}}, "therapeutic": {"id": "civic.tid:16", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:318341"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}, {"id": "mesh:D006258", "type": "Disease", "label": "Head and Neck Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C4013"}, "relation": "relatedMatch"}]}, {"id": "mesh:D002294", "type": "Disease", "label": "Carcinoma, Squamous Cell", "mappings": [{"coding": {"system": "ncit", "code": "C2929"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1723"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:266", "description": "In 3T3 fibroblasts expressing the G253C mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:179", "label": "Hammerman et al., 2011, Cancer Discov", "type": "Document", "title": "PubMed: Hammerman et al., 2011, Cancer Discov", "pmid": 22328973}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:51", "label": "DDR2", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:2731"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:4921"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["DDR2", "MIG20a", "NTRKR3", "TKT", "TYRO10", "WRCN"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:141", "label": "DDR2 G253C", "description": "Activating mutations in DDR2, including G253C, has been shown to be sensitive to dasatinib in cell lines.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 4.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "T", "representative_transcript": "ENST00000367922.3", "chromosome": "1", "start": 162729671, "stop": 162729671, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "141"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602599"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376142"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLY253CYS"], "members": [{"id": "ga4gh:VA.-ScaioMxrp8mxgP3Tp7DtEfTGu6375fH", "label": "NC_000001.10:g.162729671G>T", "digest": "-ScaioMxrp8mxgP3Tp7DtEfTGu6375fH", "type": "Allele", "location": {"id": "ga4gh:SL.oiNLm3K0Bxq1VSKzScandH5ZjJ8YskGk", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Ya6Rs7DHhDeg7YaOSg1EoNi3U_nQ9SvO"}, "start": 162759880, "end": 162759881}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.7TRGMSKN5fWIl83GrqlUuH067_nzq2Ue", "label": "G253C", "digest": "7TRGMSKN5fWIl83GrqlUuH067_nzq2Ue", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000367922.3:c.757G>T"}, {"syntax": "hgvs.g", "value": "NC_000001.10:g.162729671G>T"}], "location": {"id": "ga4gh:SL.cFNDUAWaQNIZMh4-don_YUUvfctmQRWe", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.jSEEnTyrC7lL5C5cfpvGjdh6y2lzauuM"}, "start": 252, "end": 253}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "civic.tid:20", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1546019"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C38713"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate", "BMS-354825", "Dasatinib Hydrate", "Dasatinib Monohydrate", "Sprycel"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:267", "description": "In 3T3 fibroblasts expressing the G505S mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:179", "label": "Hammerman et al., 2011, Cancer Discov", "type": "Document", "title": "PubMed: Hammerman et al., 2011, Cancer Discov", "pmid": 22328973}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:51", "label": "DDR2", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:2731"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:4921"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["DDR2", "MIG20a", "NTRKR3", "TKT", "TYRO10", "WRCN"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:142", "label": "DDR2 G505S", "description": "Activating mutations in DDR2, including G505S, has been shown to be sensitive to dasatinib in cell lines.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 4.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000367922.3", "chromosome": "1", "start": 162741822, "stop": 162741822, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "142"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA1217584"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "282994"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS115169993"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS115169993", "GLY505SER"], "members": [{"id": "ga4gh:VA.rApoXQuxYq5OctzPeImgjNoJGeuiPWGZ", "label": "NC_000001.10:g.162741822G>A", "digest": "rApoXQuxYq5OctzPeImgjNoJGeuiPWGZ", "type": "Allele", "location": {"id": "ga4gh:SL.Ez9Q2o0YulVxvksyPH1JzjvPYcbIMEfY", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Ya6Rs7DHhDeg7YaOSg1EoNi3U_nQ9SvO"}, "start": 162772031, "end": 162772032}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.yeBaKHej0oOU-HQXwo2bgD34rdfEUw3I", "label": "G505S", "digest": "yeBaKHej0oOU-HQXwo2bgD34rdfEUw3I", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006182.2:c.1513G>A"}, {"syntax": "hgvs.p", "value": "NP_006173.2:p.Gly505Ser"}, {"syntax": "hgvs.c", "value": "ENST00000367922.3:c.1513G>A"}, {"syntax": "hgvs.g", "value": "NC_000001.10:g.162741822G>A"}], "location": {"id": "ga4gh:SL.kCbgliY9dRhqGQ1YHPeJ3KIjB8GNPhPD", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.jSEEnTyrC7lL5C5cfpvGjdh6y2lzauuM"}, "start": 504, "end": 505}, "state": {"type": "LiteralSequenceExpression", "sequence": "S"}}}, "therapeutic": {"id": "civic.tid:20", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1546019"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C38713"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate", "BMS-354825", "Dasatinib Hydrate", "Dasatinib Monohydrate", "Sprycel"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:268", "description": "In 3T3 fibroblasts expressing the G774V mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:179", "label": "Hammerman et al., 2011, Cancer Discov", "type": "Document", "title": "PubMed: Hammerman et al., 2011, Cancer Discov", "pmid": 22328973}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:51", "label": "DDR2", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:2731"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:4921"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["DDR2", "MIG20a", "NTRKR3", "TKT", "TYRO10", "WRCN"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:144", "label": "DDR2 G774V", "description": "Activating mutations in DDR2, including G774V, has been shown to be sensitive to dasatinib in cell lines.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 4.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "T", "representative_transcript": "ENST00000367922.3", "chromosome": "1", "start": 162748407, "stop": 162748407, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "144"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602601"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376144"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLY774VAL"], "members": [{"id": "ga4gh:VA.ZpOoSt3RkPj273LkdQHAQU9sqJTDGDsp", "label": "NC_000001.10:g.162748407G>T", "digest": "ZpOoSt3RkPj273LkdQHAQU9sqJTDGDsp", "type": "Allele", "location": {"id": "ga4gh:SL.Ey0aveHHDirMQUwZa3MFp9uMqZ4dh2fj", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Ya6Rs7DHhDeg7YaOSg1EoNi3U_nQ9SvO"}, "start": 162778616, "end": 162778617}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.zlSzFuyYdGFRpE3HEobLc8ZJL0jYhCtz", "label": "G774V", "digest": "zlSzFuyYdGFRpE3HEobLc8ZJL0jYhCtz", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000367922.3:c.2321G>T"}, {"syntax": "hgvs.g", "value": "NC_000001.10:g.162748407G>T"}], "location": {"id": "ga4gh:SL.vuRI_n-O114ZA2oN51VJi9l9BbrSSlGq", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.jSEEnTyrC7lL5C5cfpvGjdh6y2lzauuM"}, "start": 773, "end": 774}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "civic.tid:20", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1546019"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C38713"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate", "BMS-354825", "Dasatinib Hydrate", "Dasatinib Monohydrate", "Sprycel"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:269", "description": "In 3T3 fibroblasts expressing the I638F mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:179", "label": "Hammerman et al., 2011, Cancer Discov", "type": "Document", "title": "PubMed: Hammerman et al., 2011, Cancer Discov", "pmid": 22328973}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:51", "label": "DDR2", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:2731"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:4921"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["DDR2", "MIG20a", "NTRKR3", "TKT", "TYRO10", "WRCN"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:143", "label": "DDR2 I638F", "description": "DDR2 I638F has been shown to be a loss of function mutation, but also confers sensitivity to dasatinib in cell lines.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 4.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000367922.3", "chromosome": "1", "start": 162745497, "stop": 162745497, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "143"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602600"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376143"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ILE638PHE"], "members": [{"id": "ga4gh:VA.uQujclzyHLBIg9aP-IJLieWPM9T5M51Y", "label": "NC_000001.10:g.162745497A>T", "digest": "uQujclzyHLBIg9aP-IJLieWPM9T5M51Y", "type": "Allele", "location": {"id": "ga4gh:SL.j2yt5mw4d1emBDtv22Nhdp1CmLPCab9T", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Ya6Rs7DHhDeg7YaOSg1EoNi3U_nQ9SvO"}, "start": 162775706, "end": 162775707}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.sgIUBySpu1PNSLUWeXVseRioYm_Ubcr0", "label": "I638F", "digest": "sgIUBySpu1PNSLUWeXVseRioYm_Ubcr0", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000367922.3:c.1912A>T"}, {"syntax": "hgvs.g", "value": "NC_000001.10:g.162745497A>T"}], "location": {"id": "ga4gh:SL.tBnRYq6v0I8H5Zn6GIfaJAxrhLaqF1Oh", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.jSEEnTyrC7lL5C5cfpvGjdh6y2lzauuM"}, "start": 637, "end": 638}, "state": {"type": "LiteralSequenceExpression", "sequence": "F"}}}, "therapeutic": {"id": "civic.tid:20", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1546019"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C38713"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate", "BMS-354825", "Dasatinib Hydrate", "Dasatinib Monohydrate", "Sprycel"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:270", "description": "In 3T3 fibroblasts expressing the L239R mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:179", "label": "Hammerman et al., 2011, Cancer Discov", "type": "Document", "title": "PubMed: Hammerman et al., 2011, Cancer Discov", "pmid": 22328973}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:51", "label": "DDR2", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:2731"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:4921"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["DDR2", "MIG20a", "NTRKR3", "TKT", "TYRO10", "WRCN"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:140", "label": "DDR2 L239R", "description": "Activating mutations in DDR2, including L239R, has been shown to be sensitive to dasatinib in cell lines.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 4.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "G", "representative_transcript": "ENST00000367922.3", "chromosome": "1", "start": 162729630, "stop": 162729630, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "140"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602598"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376141"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["LEU239ARG"], "members": [{"id": "ga4gh:VA.Zc5D_PitlkEw4AztGGBgWk0WQOLom9IY", "label": "NC_000001.10:g.162729630T>G", "digest": "Zc5D_PitlkEw4AztGGBgWk0WQOLom9IY", "type": "Allele", "location": {"id": "ga4gh:SL.C4-xZwCfJMKPBHzYjz_RNPBZ1dldd9gU", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Ya6Rs7DHhDeg7YaOSg1EoNi3U_nQ9SvO"}, "start": 162759839, "end": 162759840}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.nVJvd8GJEzum0-o0PaGqAcQ8MWF-aKFO", "label": "L239R", "digest": "nVJvd8GJEzum0-o0PaGqAcQ8MWF-aKFO", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000367922.3:c.716T>G"}, {"syntax": "hgvs.g", "value": "NC_000001.10:g.162729630T>G"}], "location": {"id": "ga4gh:SL.XC1Gpkepk-u3IU_vzcEunrQ8nI-OdMuH", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.jSEEnTyrC7lL5C5cfpvGjdh6y2lzauuM"}, "start": 238, "end": 239}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:20", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1546019"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C38713"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate", "BMS-354825", "Dasatinib Hydrate", "Dasatinib Monohydrate", "Sprycel"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:271", "description": "In 3T3 fibroblasts expressing the L63V mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:179", "label": "Hammerman et al., 2011, Cancer Discov", "type": "Document", "title": "PubMed: Hammerman et al., 2011, Cancer Discov", "pmid": 22328973}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:51", "label": "DDR2", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:2731"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:4921"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["DDR2", "MIG20a", "NTRKR3", "TKT", "TYRO10", "WRCN"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:139", "label": "DDR2 L63V", "description": "Activating mutations in DDR2, including L63V, has been shown to be sensitive to dasatinib in cell lines.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 4.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "G", "representative_transcript": "ENST00000367922.3", "chromosome": "1", "start": 162724415, "stop": 162724415, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "139"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA1217196"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["LEU63VAL"], "members": [{"id": "ga4gh:VA.rC1Ksowb7DJ4T0lL7t8w_5YBBXtCdN9w", "label": "NC_000001.10:g.162724415C>G", "digest": "rC1Ksowb7DJ4T0lL7t8w_5YBBXtCdN9w", "type": "Allele", "location": {"id": "ga4gh:SL.DYAQSERORUfzpOZEWi_m0oX_kbBhs33z", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Ya6Rs7DHhDeg7YaOSg1EoNi3U_nQ9SvO"}, "start": 162754624, "end": 162754625}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.PlpviNQbOUz-qyJCdtTjjALs2Hia0mf9", "label": "L63V", "digest": "PlpviNQbOUz-qyJCdtTjjALs2Hia0mf9", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006182.2:c.187C>G"}, {"syntax": "hgvs.p", "value": "NP_006173.2:p.Leu63Val"}, {"syntax": "hgvs.c", "value": "ENST00000367922.3:c.187C>G"}, {"syntax": "hgvs.g", "value": "NC_000001.10:g.162724415C>G"}], "location": {"id": "ga4gh:SL._ed6WJQ3p4PQt4r-vbg59oHbNKW_6q0S", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.jSEEnTyrC7lL5C5cfpvGjdh6y2lzauuM"}, "start": 62, "end": 63}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "civic.tid:20", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1546019"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C38713"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate", "BMS-354825", "Dasatinib Hydrate", "Dasatinib Monohydrate", "Sprycel"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:274", "description": "Gefinitib has been shown to be effective in treating cell lines with G719S missense mutations.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:181", "label": "Paez et al., 2004, Science", "type": "Document", "title": "PubMed: Paez et al., 2004, Science", "pmid": 15118125}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:134", "label": "EGFR G719S", "description": "While not as recurrent as the L858R mutation, EGFR G719S has also been shown to be an activating mutation. In lung cancer cell lines, it also confers sensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 23.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55241707, "stop": 55241707, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "134"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA126722"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16612"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS28929495"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLY719SER", "RS28929495"], "members": [{"id": "ga4gh:VA.BgeJO2Em242qDE22Rl4fhxKTBAaOhHd_", "label": "NC_000007.13:g.55241707G>A", "digest": "BgeJO2Em242qDE22Rl4fhxKTBAaOhHd_", "type": "Allele", "location": {"id": "ga4gh:SL.3ef7PSUNlYokdBlpq6tC1bumRwrpn8UI", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55174013, "end": 55174014}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.qCfvg6opeady22T6oD9f05NpU8wpMBoY", "label": "G719S", "digest": "qCfvg6opeady22T6oD9f05NpU8wpMBoY", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2155G>A"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55241707G>A"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2155G>A"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Gly719Ser"}], "location": {"id": "ga4gh:SL.UiwCoIGhPuuRY9R_vCfqyuseQTBpzHA3", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 718, "end": 719}, "state": {"type": "LiteralSequenceExpression", "sequence": "S"}}}, "therapeutic": {"id": "civic.tid:14", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:328134"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1855"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:276", "description": "Gefinitib has been shown to be effective in treating cell lines with L858R missense mutations.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:181", "label": "Paez et al., 2004, Science", "type": "Document", "title": "PubMed: Paez et al., 2004, Science", "pmid": 15118125}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:33", "label": "EGFR L858R", "description": "EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 379.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "G", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55259515, "stop": 55259515, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "33"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA126713"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16609"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376282"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376280"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434568"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121434568", "LEU858ARG"], "members": [{"id": "ga4gh:VA.TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "label": "NC_000007.13:g.55259515T>G", "digest": "TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "type": "Allele", "location": {"id": "ga4gh:SL.ulUNwZvajob7nzyrlpOd6uUWZIYCsoWb", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55191821, "end": 55191822}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "label": "L858R", "digest": "z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000007.13:g.55259515T>G"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2573T>G"}, {"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2573T>G"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Leu858Arg"}], "location": {"id": "ga4gh:SL.yVGJnwqxV6oCGqC_8nNb58D_wPXJeNJo", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 857, "end": 858}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:14", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:328134"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1855"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:280", "description": "In MCF10A cell lines, the D769Y mutation was shown to be sensitive to neratinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:170", "label": "Bose et al., 2013, Cancer Discov", "type": "Document", "title": "PubMed: Bose et al., 2013, Cancer Discov", "pmid": 23220880}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:20", "label": "ERBB2", "description": "ERBB2, commonly referred to as HER2, is amplified and/or overexpressed in 20-30% of invasive breast carcinomas. HER2-positive breast cancer is treated in a separate manner from other subtypes of breast cancer and commonly presents as more aggressive disease. Metastatic HER2-positive breast cancer is now commonly treated with HER2-targeted therapy. Apart from being amplified/overexpressed, ERBB2 activating mutations have been shown to have clinical importance in HER2-negative breast cancer. These mutations have shown sensitivity to the tyrosine kinase inhibitor neratinib, and highlight the importance of clinical sequencing efforts in treating breast cancer.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3430"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2064"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD340", "ERBB2", "HER-2", "HER-2/neu", "HER2", "MLN 19", "MLN-19", "NEU", "NGL", "TKR1", "VSCN2", "c-ERB-2", "c-ERB2", "p185(erbB2)"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:36", "label": "ERBB2 D769Y", "description": "ERBB2 D769Y was one of the first ERBB2 variants to be functionally classified (Bose et al., 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 4.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "T", "representative_transcript": "ENST00000269571.5", "chromosome": "17", "start": 37880261, "stop": 37880261, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "36"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602466"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "375992"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913468"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["D769Y", "RS121913468", "ASP769TYR", "D739Y", "ASP754TYR", "D754Y", "ASP739TYR"], "members": [{"id": "ga4gh:VA.5HRAwzu-IQyBv4LnaA1QfrIVTcLvUg_1", "label": "NC_000017.10:g.37880261G>T", "digest": "5HRAwzu-IQyBv4LnaA1QfrIVTcLvUg_1", "type": "Allele", "location": {"id": "ga4gh:SL.uTAw7QYWNXk9jShMC_OXgxVynGH4nmd5", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dLZ15tNO1Ur0IcGjwc3Sdi_0A6Yf4zm7"}, "start": 39724007, "end": 39724008}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.jb9AbGifHQ0xMDV25gsn5Vq7fWROZKDM", "label": "D769Y", "digest": "jb9AbGifHQ0xMDV25gsn5Vq7fWROZKDM", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000269571.5:c.2305G>T"}, {"syntax": "hgvs.g", "value": "NC_000017.10:g.37880261G>T"}, {"syntax": "hgvs.c", "value": "NM_004448.3:c.2305G>T"}, {"syntax": "hgvs.p", "value": "NP_004439.2:p.Asp769Tyr"}], "location": {"id": "ga4gh:SL.vSe5IX70lhIBI0LX9C0mP_Qejmq6UvJs", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.AF1UFydIo02-bMplonKSfxlWY2q6ze3m"}, "start": 768, "end": 769}, "state": {"type": "LiteralSequenceExpression", "sequence": "Y"}}}, "therapeutic": {"id": "civic.tid:52", "label": "Neratinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1940643"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C49094"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide", "2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-", "HKI 272", "HKI-272", "PB 272", "PB-272"]}, "tumorType": {"id": "civic.did:22", "label": "Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9335"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1612"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:310", "description": "Breast cancer cell lines with E542K/E545K mutations showed increased sensitivity to CH5132799 than cells with wild-type PIK3CA gene.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:195", "label": "Tanaka et al., 2011, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Tanaka et al., 2011, Clin. Cancer Res.", "pmid": 21558396}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:103", "label": "PIK3CA E542K", "description": "PIK3CA E545K/E542K variants are the second most recurrent PIK3CA mutations in breast cancer and are highly recurrent mutations in many other cancer types. Colorectal cancer patients with the PIK3CA E545K variant, and possibly other variants in the E545 region, may indicate poor prognosis relative to patients with other PIK3CA variants or wild-type PIK3CA. The literature also suggests that E545/E542 variants may confer resistance to EGFR inhibitors (e.g., cetuximab). An FDA approved treatment regimen including a targeted PIK3CA inhibitor is available for specific subtypes of breast cancer. While PIK3CA variants are highly prevalent in many other cancer types, targeted therapies for PIK3CA variants are still in early clinical trial phases in other cancer types.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 75.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000263967.3", "chromosome": "3", "start": 178936082, "stop": 178936082, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "103"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA333572"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "31944"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913273"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLU542LYS", "RS121913273"], "members": [{"id": "ga4gh:VA.52-4tAq0Ya9SeMU4eZSgO0bfqvkd_VE4", "label": "NC_000003.11:g.178936082G>A", "digest": "52-4tAq0Ya9SeMU4eZSgO0bfqvkd_VE4", "type": "Allele", "location": {"id": "ga4gh:SL.65wPuIVC66WPYQqTnuNP-taUZ03NOwmJ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 179218293, "end": 179218294}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.D6daDiDNn1u-e4YtntaYQnxlZ_0T6gtD", "label": "E542K", "digest": "D6daDiDNn1u-e4YtntaYQnxlZ_0T6gtD", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006218.3:c.1624G>A"}, {"syntax": "hgvs.p", "value": "NP_006209.2:p.Glu542Lys"}, {"syntax": "hgvs.c", "value": "ENST00000263967.3:c.1624G>A"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.178936082G>A"}], "location": {"id": "ga4gh:SL.DdVC73cqPrOnzCRvVc8N9tA3ecV5Qunt", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 541, "end": 542}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:66", "label": "PI3K-alpha Inhibitor MEN1611", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C158603"}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C158603"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["5-(7-Methylsulfonyl-2-morpholin-4-yl-5,6-dihydropyrrolo[2,3-d]pyrimidin-4-yl)pyrimidin-2-amine", "Alpha-selective PI3K Inhibitor MEN1611", "CH 5132799", "CH-5132799", "CH5132799", "MEN 1611", "MEN-1611", "MEN1611", "PA 799", "PA-799", "PA799", "PI3Kalpha Inhibitor MEN1611"]}, "tumorType": {"id": "civic.did:22", "label": "Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9335"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1612"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:314", "description": "Breast cancer cell lines with H1047R mutation showed increased sensitivity to CH5132799 than cells with wild-type PIK3CA gene.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:195", "label": "Tanaka et al., 2011, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Tanaka et al., 2011, Clin. Cancer Res.", "pmid": 21558396}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:107", "label": "PIK3CA H1047R", "description": "PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 96.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "G", "representative_transcript": "ENST00000263967.3", "chromosome": "3", "start": 178952085, "stop": 178952085, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "107"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123326"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13652"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913279"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913279", "HIS1047ARG"], "members": [{"id": "ga4gh:VA.82Pw7U7NM7ac2koW_yITXOGSKcwg_Qqj", "label": "NC_000003.11:g.178952085A>G", "digest": "82Pw7U7NM7ac2koW_yITXOGSKcwg_Qqj", "type": "Allele", "location": {"id": "ga4gh:SL.p0VJw5IIPnKzEpQMcdBaU3xesud6QODJ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 179234296, "end": 179234297}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.hcSlm-m3AKXOL7kHM3LghXQfvAjZOmYx", "label": "H1047R", "digest": "hcSlm-m3AKXOL7kHM3LghXQfvAjZOmYx", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006218.3:c.3140A>G"}, {"syntax": "hgvs.p", "value": "NP_006209.2:p.His1047Arg"}, {"syntax": "hgvs.c", "value": "ENST00000263967.3:c.3140A>G"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.178952085A>G"}], "location": {"id": "ga4gh:SL.DBBb47ourtRut09MJ_TAvlocEwpTjF9z", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 1046, "end": 1047}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:66", "label": "PI3K-alpha Inhibitor MEN1611", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C158603"}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C158603"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["5-(7-Methylsulfonyl-2-morpholin-4-yl-5,6-dihydropyrrolo[2,3-d]pyrimidin-4-yl)pyrimidin-2-amine", "Alpha-selective PI3K Inhibitor MEN1611", "CH 5132799", "CH-5132799", "CH5132799", "MEN 1611", "MEN-1611", "MEN1611", "PA 799", "PA-799", "PA799", "PI3Kalpha Inhibitor MEN1611"]}, "tumorType": {"id": "civic.did:22", "label": "Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9335"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1612"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:317", "description": "Cells with PTEN deficiency have been shown to exhibit slowed growth in reponse to PI3K-mTOR inhibitors.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:198", "label": "Courtney et al., 2010, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Courtney et al., 2010, J. Clin. Oncol.", "pmid": 20085938}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:41", "label": "PTEN", "description": "PTEN is a multi-functional tumor suppressor that is very commonly lost in human cancer. Observed in prostate cancer, glioblastoma, endometrial, lung and breast cancer to varying degrees. Up to 70% of prostate cancer patients have been observed to have loss of expression of the gene. It is a part of the PI3K/AKT/mTOR pathway and mTOR inhibitors have been relatively ineffective in treating patients with PTEN loss. New appoaches using microRNAs are currently being investigated.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:9588"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5728"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["10q23del", "BZS", "CWS1", "DEC", "GLM2", "MHAM", "MMAC1", "PTEN", "PTEN1", "PTENbeta", "TEP1"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:110", "label": "PTEN R233*", "description": "PTEN R233* has been shown to be a loss of function mutation, and PTEN loss has been the subject of considerable research in breast cancer. PTEN loss may sensitize cells to PI3K-mTOR inhibition. While still being debated, there is data to support that PTEN loss is both associated with poorer prognosis, and no change in prognosis.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 19.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000371953.3", "chromosome": "10", "start": 89717672, "stop": 89717672, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "stop_gained", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001587"}, {"label": "loss_of_function_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0002054"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "110"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA000549"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "7813"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121909219"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121909219", "R233X", "ARG233TER"], "members": [{"id": "ga4gh:VA.7JtXrcqxF1zV7U79gffUctQxbqe9N372", "label": "NC_000010.10:g.89717672C>T", "digest": "7JtXrcqxF1zV7U79gffUctQxbqe9N372", "type": "Allele", "location": {"id": "ga4gh:SL.v1osWld6Z4-ALD8O96AFa-k121dvSpjO", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.ss8r_wB0-b9r44TQTMmVTI92884QvBiB"}, "start": 87957914, "end": 87957915}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.qYIEqox4sLJ-fy_5tU_Xfm7to-y5tF9y", "label": "R233*", "digest": "qYIEqox4sLJ-fy_5tU_Xfm7to-y5tF9y", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_000314.6:c.697C>T"}, {"syntax": "hgvs.p", "value": "NP_000305.3:p.Arg233Ter"}, {"syntax": "hgvs.c", "value": "ENST00000371953.3:c.697C>T"}, {"syntax": "hgvs.g", "value": "NC_000010.10:g.89717672C>T"}], "location": {"id": "ga4gh:SL.gMOBQYW6DppZl5JbOtUt0vDE_0Rnlg_1", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.w7LxW0PSaVPNsPFvOL24weFjHcfaHyOi"}, "start": 232, "end": 233}, "state": {"type": "LiteralSequenceExpression", "sequence": "*"}}}, "therapeutic": {"id": "civic.tid:67", "label": "MTOR Inhibitor", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C2201"}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C2201"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:22", "label": "Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9335"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1612"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:439", "description": "The AKT1 Q79K mutation has been shown to confer resistance to BRAF inhibitors (vemurafenib) in melanoma cell line M229.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:261", "label": "Shi et al., 2014, Cancer Discov", "type": "Document", "title": "PubMed: Shi et al., 2014, Cancer Discov", "pmid": 24265152}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:2", "label": "AKT1", "description": "AKT1, also referred to as protein kinase B, is a known oncogene. AKT activation relies on the PI3K pathway, and is recognized as a critical node in the pathway. The E17 hotspot is the most characterized of AKT1 mutations, and has been shown to result in activation of the protein. Mutations in AKT1 have also been shown to confer resistance to allosteric kinase inhibitors in vitro.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:391"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:207"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["AKT", "AKT1", "PKB", "PKB-ALPHA", "PRKBA", "RAC", "RAC-ALPHA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:169", "label": "AKT1 Q79K", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 16.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "T", "representative_transcript": "ENST00000407796.2", "chromosome": "14", "start": 105243048, "stop": 105243048, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "169"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602625"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376168"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS1057519804"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS1057519804", "GLN79LYS", "Q17K"], "members": [{"id": "ga4gh:VA._FsX8vVR1C-jMiRgJX02CDSaclfGir3N", "label": "NC_000014.8:g.105243048G>T", "digest": "_FsX8vVR1C-jMiRgJX02CDSaclfGir3N", "type": "Allele", "location": {"id": "ga4gh:SL.3aaJAnaiyOBfpjFMV7GuwwO23IHjh4zQ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.eK4D2MosgK_ivBkgi6FVPg5UXs1bYESm"}, "start": 104776710, "end": 104776711}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.Wpny1uCajSwqyosBpgHrpj66_am_42P3", "label": "Q79K", "digest": "Wpny1uCajSwqyosBpgHrpj66_am_42P3", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000014.8:g.105243048G>T"}, {"syntax": "hgvs.c", "value": "NM_001014432.1:c.235C>A"}, {"syntax": "hgvs.p", "value": "NP_001014432.1:p.Gln79Lys"}, {"syntax": "hgvs.c", "value": "ENST00000407796.2:c.235C>A"}], "location": {"id": "ga4gh:SL.yCJndQuCYYFMkmq_34dv0sqS_zpJ8wMk", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.GTSPIWYvuDZU59cW1RECFEU1FMiKdEyc"}, "start": 78, "end": 79}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:7", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3224"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1909"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:786", "description": "Whole genome sequencing of a case of colon carcinoma revealed a G724S mutation in the EGFR gene. In-vitro, this mutation was shown to be oncogenic and sensitive to Cetuximab, yet relatively insensitive towards small molecules.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:523", "label": "Cho et al., 2014, Mol. Cancer", "type": "Document", "title": "PubMed: Cho et al., 2014, Mol. Cancer", "pmid": 24894453}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:313", "label": "EGFR G724S", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 4.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55241722, "stop": 55241722, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "317"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602800"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376360"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS1051753269"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS1051753269", "GLY724SER"], "members": [{"id": "ga4gh:VA.ld_wVo9E6a9M_TjJPshKeee-HBFSUMa_", "label": "NC_000007.13:g.55241722G>A", "digest": "ld_wVo9E6a9M_TjJPshKeee-HBFSUMa_", "type": "Allele", "location": {"id": "ga4gh:SL.ZDfCnHOqlnRocyQ-64_mr7H4sIdJPTLw", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55174028, "end": 55174029}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.ByS5CyJT-HAxdF-E8gGmIDJHbnMJlT2U", "label": "G724S", "digest": "ByS5CyJT-HAxdF-E8gGmIDJHbnMJlT2U", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2170G>A"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55241722G>A"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2170G>A"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Gly724Ser"}], "location": {"id": "ga4gh:SL.g7rHd4ViIfTw3ofpFri381vxsGKBLT5e", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 723, "end": 724}, "state": {"type": "LiteralSequenceExpression", "sequence": "S"}}}, "therapeutic": {"id": "civic.tid:16", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:318341"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}, {"id": "mesh:D006258", "type": "Disease", "label": "Head and Neck Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C4013"}, "relation": "relatedMatch"}]}, {"id": "mesh:D002294", "type": "Disease", "label": "Carcinoma, Squamous Cell", "mappings": [{"coding": {"system": "ncit", "code": "C2929"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1723"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:787", "description": "Whole genome sequencing of a case of colon carcinoma revealed a G724S mutation in the EGFR gene. In-vitro, this mutation was shown to be oncogenic and sensitive to Cetuximab, yet relatively insensitive towards small molecules. The same in-vitro results could be reproduced for the G719S mutation.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:523", "label": "Cho et al., 2014, Mol. Cancer", "type": "Document", "title": "PubMed: Cho et al., 2014, Mol. Cancer", "pmid": 24894453}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:134", "label": "EGFR G719S", "description": "While not as recurrent as the L858R mutation, EGFR G719S has also been shown to be an activating mutation. In lung cancer cell lines, it also confers sensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 23.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55241707, "stop": 55241707, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "134"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA126722"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16612"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS28929495"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLY719SER", "RS28929495"], "members": [{"id": "ga4gh:VA.BgeJO2Em242qDE22Rl4fhxKTBAaOhHd_", "label": "NC_000007.13:g.55241707G>A", "digest": "BgeJO2Em242qDE22Rl4fhxKTBAaOhHd_", "type": "Allele", "location": {"id": "ga4gh:SL.3ef7PSUNlYokdBlpq6tC1bumRwrpn8UI", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55174013, "end": 55174014}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.qCfvg6opeady22T6oD9f05NpU8wpMBoY", "label": "G719S", "digest": "qCfvg6opeady22T6oD9f05NpU8wpMBoY", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2155G>A"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55241707G>A"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2155G>A"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Gly719Ser"}], "location": {"id": "ga4gh:SL.UiwCoIGhPuuRY9R_vCfqyuseQTBpzHA3", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 718, "end": 719}, "state": {"type": "LiteralSequenceExpression", "sequence": "S"}}}, "therapeutic": {"id": "civic.tid:16", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:318341"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}, {"id": "mesh:D006258", "type": "Disease", "label": "Head and Neck Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C4013"}, "relation": "relatedMatch"}]}, {"id": "mesh:D002294", "type": "Disease", "label": "Carcinoma, Squamous Cell", "mappings": [{"coding": {"system": "ncit", "code": "C2929"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1723"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:979", "description": "In pre-clinical studies, an IDH1 inhibitor (AG-5198) impaired growth of glioma / anaplastic oligodendroglioma cell lines with IDH1 R132H mutations.  A phase I clinical trial of the AG-120 IDH1 inhibitor in IDH1 mutant positive solid tumors, including glioma is currently underway.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:678", "label": "Rohle et al., 2013, Science", "type": "Document", "title": "PubMed: Rohle et al., 2013, Science", "pmid": 23558169}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:26", "label": "IDH1", "description": "IDH1 mutations have been observed in a number of cancer types, including sarcomas, hematologic malignancies, colon cancer and brain cancer. Mutations in the two isocitrate dehydrogenase enzymes involved in cytoplasmic (IDH1) and mitochondrial (IDH2) conversion of alpha-ketoglutarate to D-2-hydroxyglutarate have been described as mutually exclusive in many of these cancer types. The most frequent mutations involve R132 (IDH1) and R172 (IDH2) involve the active site and result in neomorphic enzyme activity. The implications of mutations in this gene vary greatly by cancer type. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 mutations have been associated with worse outcome, shorter overall survival, and normal karyotype. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Unlike the association with cytogenetically normal AML, in glioblastoma, IDH1 mutations have been associated with specific cytogenetic abnormalities, 1p and 19q deletions.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:5382"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3417"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["HEL-216", "HEL-S-26", "IDCD", "IDH", "IDH1", "IDP", "IDPC", "PICD"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:416", "label": "IDH1 R132H", "description": "IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 9.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000415913.1", "chromosome": "2", "start": 209113112, "stop": 209113112, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "420"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA170874"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "156444"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913500"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ARG132HIS", "RS121913500"], "members": [{"id": "ga4gh:VA.y3AcrkM1rtuFjcKurTbKEBQGYa40qvZ2", "label": "NC_000002.11:g.209113112C>T", "digest": "y3AcrkM1rtuFjcKurTbKEBQGYa40qvZ2", "type": "Allele", "location": {"id": "ga4gh:SL.i6qLHldpS-d8QaHyYj47QgixNmVG6Ew9", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.pnAqCRBrTsUoBghSD1yp_jXWSmlbdh4g"}, "start": 208248387, "end": 208248388}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.Wks7qWMMqFTj1uw9ZUHDeHXj-coBFGll", "label": "R132H", "digest": "Wks7qWMMqFTj1uw9ZUHDeHXj-coBFGll", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_001282386.1:c.395G>A"}, {"syntax": "hgvs.p", "value": "NP_005887.2:p.Arg132His"}, {"syntax": "hgvs.g", "value": "NC_000002.11:g.209113112C>T"}, {"syntax": "hgvs.c", "value": "ENST00000415913.1:c.395G>A"}], "location": {"id": "ga4gh:SL.6S6Nay-qWJnCSbbpF3hcBRTeoYOc4CJD", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.VZMxTY2iB2G_EuwlpVZ0AnX6R-am08GZ"}, "start": 131, "end": 132}, "state": {"type": "LiteralSequenceExpression", "sequence": "H"}}}, "therapeutic": {"id": "civic.tid:473", "label": "AGI-5198", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "iuphar.ligand:9240"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:241", "label": "Oligodendroglioma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3288"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3181"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1080", "description": "In this preclinical study of the effects of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer. The S492R mutation was sensitive to Sym004 and panitumumab treatment but resistant to cetuximab. Experiments include flow cytometry binding assay, kinase phosphorylation, cell viability, downstream signalling.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:746", "label": "S\u00e1nchez-Mart\u00edn et al., 2016, Clin. Cancer Res.", "type": "Document", "title": "PubMed: S\u00e1nchez-Mart\u00edn et al., 2016, Clin. Cancer Res.", "pmid": 26888827}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:449", "label": "EGFR S492R", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 23.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "A", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55228009, "stop": 55228009, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "453"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602784"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376341"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS1057519860"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS1057519860", "SER492ARG"], "members": [{"id": "ga4gh:VA.QG6TP28zEwR_a3FLB3zjhZRMKqm3Oq9M", "label": "NC_000007.13:g.55228009C>A", "digest": "QG6TP28zEwR_a3FLB3zjhZRMKqm3Oq9M", "type": "Allele", "location": {"id": "ga4gh:SL.6zbdcNSn1HVtMHloyKL-LY9V__Ok18Xr", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55160315, "end": 55160316}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.89xcJTIpW8049gcHbnSmPqYc_wfbunTN", "label": "S492R", "digest": "89xcJTIpW8049gcHbnSmPqYc_wfbunTN", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.1476C>A"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55228009C>A"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Ser492Arg"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.1476C>A"}], "location": {"id": "ga4gh:SL.nTVXt4-Pfk2XJdxFumGxAA71rB4iBqZM", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 491, "end": 492}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:16", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:318341"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}, {"id": "mesh:D006258", "type": "Disease", "label": "Head and Neck Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C4013"}, "relation": "relatedMatch"}]}, {"id": "mesh:D002294", "type": "Disease", "label": "Carcinoma, Squamous Cell", "mappings": [{"coding": {"system": "ncit", "code": "C2929"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1723"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1329", "description": "Efficacy of the second generation ALK inhibitor PF-06463922 was tested on ALK mutation F1174L containing neuroblastoma-derived cells.  COG-N-453x and SH-SY5Y xenografts showed some inhibition when treated with crizotinib, but showed complete growth inhibition with PF-06463922 treatment.  This corresponded to 0% event free survival (EFS) in these mice by 6 weeks with crizotinib treatment, but 100% EFS with PF-06463922 treatment. Comparison of crizotinib and PF-06463922 growth inhibition in F1174L cells SH-SY5Y, NBSD 415-IMDM and KELLY showed increased sensitivity to PF-06463922, as compared to crizotinib. Inhibition effects were not seen on neuroblastoma cells with wild type ALK (NB-EBc1, SK-N-BE(2)C). Decreased phosphorylation on ALK tyrosine 1278 was seen with PF-06463922 over crizotinib at 10 and 100 nM concentrations in SH-SY5Y cells. PF-06463922 was well tolerated in the in-vivo models.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:919", "label": "Infarinato et al., 2016, Cancer Discov", "type": "Document", "title": "PubMed: Infarinato et al., 2016, Cancer Discov", "pmid": 26554404}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:1", "label": "ALK", "description": "ALK amplifications, fusions and mutations have been shown to be driving events in non-small cell lung cancer. While crizontinib has demonstrated efficacy in treating the amplification, mutations in ALK have been shown to confer resistance to current tyrosine kinase inhibitors. Second-generation TKI's have seen varied success in treating these resistant cases, and the HSP90 inhibitor 17-AAG has been shown to be cytostatic in ALK-altered cell lines.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:427"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:238"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["ALK", "ALK1", "CD246", "NBLST3"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:8", "label": "ALK F1174L", "description": "ALK F1174L has been observed as recurrent in neuroblastoma, non-small cell lung cancer (NSCLC), and other cancer types. Neuroblastoma cells containing this mutation have shown resistance to low doses of criztonib. However, increased dosage can overcome this resistance in cell lines studies. TAE684 has also proven effective in both NSCLC and neuroblastoma F1174L containing cells.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 33.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "T", "representative_transcript": "ENST00000389048.3", "chromosome": "2", "start": 29443695, "stop": 29443695, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "8"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA279586"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "217851"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS863225281"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["PHE1174LEU", "RS863225281"], "members": [{"id": "ga4gh:VA.ivl5YUYPCfDa2igYKGlCTZec5eKC7oYY", "label": "NC_000002.11:g.29443695G>T", "digest": "ivl5YUYPCfDa2igYKGlCTZec5eKC7oYY", "type": "Allele", "location": {"id": "ga4gh:SL.Nn_joIP_IBbU0SOamVk3VuamNXOVBxPt", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.pnAqCRBrTsUoBghSD1yp_jXWSmlbdh4g"}, "start": 29220828, "end": 29220829}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.nTPnpFtWudqItR2YaGBsaJwRgGobSWAr", "label": "F1174L", "digest": "nTPnpFtWudqItR2YaGBsaJwRgGobSWAr", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004304.4:c.3522C>A"}, {"syntax": "hgvs.p", "value": "NP_004295.2:p.Phe1174Leu"}, {"syntax": "hgvs.g", "value": "NC_000002.11:g.29443695G>T"}, {"syntax": "hgvs.c", "value": "ENST00000389048.3:c.3522C>A"}], "location": {"id": "ga4gh:SL.n1vbI2DGWZjLWoNdaUdc1ISSHenlCMar", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.q9CnK-HKWh9eqhOi8FlzR7M0pCmUrWPs"}, "start": 1173, "end": 1174}, "state": {"type": "LiteralSequenceExpression", "sequence": "L"}}}, "therapeutic": {"id": "civic.tid:241", "label": "Lorlatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:2103164"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C113655"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-", "7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile", "Lorbrena", "PF-06463922"]}, "tumorType": {"id": "civic.did:13", "label": "Neuroblastoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3270"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:769"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1331", "description": "In NB-1643 and LAN-5 neuroblastoma cell lines containing R1275Q mutation, PF-06463922 showed 51 and 19 fold greater effect on cell viability over crizotinib treatment respectively. ALK wild-type neuroblastoma cell lines did not show differential sensitivity to the treatments within the sensitivity range of R1275Q cells, and had IC50 values above 3800 nM to the inhibitors. NB-1653 cells induced tumors in CB17 SCID mice and crizotinib treatment inhibited tumor growth over vehicle treatment, but PF-06463922 induced complete tumor regression.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:919", "label": "Infarinato et al., 2016, Cancer Discov", "type": "Document", "title": "PubMed: Infarinato et al., 2016, Cancer Discov", "pmid": 26554404}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:1", "label": "ALK", "description": "ALK amplifications, fusions and mutations have been shown to be driving events in non-small cell lung cancer. While crizontinib has demonstrated efficacy in treating the amplification, mutations in ALK have been shown to confer resistance to current tyrosine kinase inhibitors. Second-generation TKI's have seen varied success in treating these resistant cases, and the HSP90 inhibitor 17-AAG has been shown to be cytostatic in ALK-altered cell lines.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:427"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:238"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["ALK", "ALK1", "CD246", "NBLST3"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:9", "label": "ALK R1275Q", "description": "ALK R1275Q has been observed as a recurrent mutation in  neuroblastoma, non-small cell lung cancer (NSCLC), as well as other cancer types. Neuroblastoma cells with this mutation have shown sensitivity to the ALK-inhibitor TAE684. This and the geldanamycin deriviative 17-DMAG have been shown to be effective in NSCLC cell lines.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 23.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000389048.3", "chromosome": "2", "start": 29432664, "stop": 29432664, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "9"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA341482"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "18083"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS113994087"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS113994087", "ARG1275GLN"], "members": [{"id": "ga4gh:VA.t3vU-1OKU2n8Hp6J5zIgf-fdOngWPcJI", "label": "NC_000002.11:g.29432664C>T", "digest": "t3vU-1OKU2n8Hp6J5zIgf-fdOngWPcJI", "type": "Allele", "location": {"id": "ga4gh:SL.-qNrY8pBD7rUqlnqrgBF-ZRDSEJspR0m", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.pnAqCRBrTsUoBghSD1yp_jXWSmlbdh4g"}, "start": 29209797, "end": 29209798}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.gX5hniEm7ni0BSgk4ACRN6yU5ARPwd1n", "label": "R1275Q", "digest": "gX5hniEm7ni0BSgk4ACRN6yU5ARPwd1n", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004304.4:c.3824G>A"}, {"syntax": "hgvs.p", "value": "NP_004295.2:p.Arg1275Gln"}, {"syntax": "hgvs.g", "value": "NC_000002.11:g.29432664C>T"}, {"syntax": "hgvs.c", "value": "ENST00000389048.3:c.3824G>A"}], "location": {"id": "ga4gh:SL.zbNZWCvHj679lMb2bPXhsYkuglQbHXmT", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.q9CnK-HKWh9eqhOi8FlzR7M0pCmUrWPs"}, "start": 1274, "end": 1275}, "state": {"type": "LiteralSequenceExpression", "sequence": "Q"}}}, "therapeutic": {"id": "civic.tid:241", "label": "Lorlatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:2103164"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C113655"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-", "7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile", "Lorbrena", "PF-06463922"]}, "tumorType": {"id": "civic.did:13", "label": "Neuroblastoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3270"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:769"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1543", "description": "MCF-7 breast cancer cell line was exposed to mTOR inhibitors AZD8055 or rapamycin until resistance developed. Deep sequencing revealed an MTOR F2108L mutation in rapamycin-resistant clones (RR2 cells). Downstream signalling was independent of inhibitor presence in these clones and expression of the mutations in MDA-MB-468 cells led to resistance.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1025", "label": "Rodrik-Outmezguine et al., 2016, Nature", "type": "Document", "title": "PubMed: Rodrik-Outmezguine et al., 2016, Nature", "pmid": 27279227}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:2073", "label": "MTOR", "description": "mTOR deregulation has been observed in many cancer types. As a part of the PI3K/Akt pathway, there is a broad interest in mTOR biology across cancer types. mTOR inhibition has been investigated for nearly a decade. Everolimus, temsirolimus and zotarolimus are three of the more commonly used mTOR inhibitors used in clinical treatment today, with modest success.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3942"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2475"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["FRAP", "FRAP1", "FRAP2", "MTOR", "RAFT1", "RAPT1", "SKS"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:466", "label": "MTOR F2108L", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 16.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "T", "representative_transcript": "ENST00000361445.4", "chromosome": "1", "start": 11187094, "stop": 11187094, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "470"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA338391533"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["PHE2108LEU"], "members": [{"id": "ga4gh:VA.YzvPymRhPJHK8FLUDsT0HFqARWO-r49u", "label": "NC_000001.10:g.11187094G>T", "digest": "YzvPymRhPJHK8FLUDsT0HFqARWO-r49u", "type": "Allele", "location": {"id": "ga4gh:SL.zlC7-kDtULKJWt-8NcQ-Uea_444z5iiH", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Ya6Rs7DHhDeg7YaOSg1EoNi3U_nQ9SvO"}, "start": 11127036, "end": 11127037}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.iGp4rv95TedqkgeFdQkddUfWM9rhGQjW", "label": "F2108L", "digest": "iGp4rv95TedqkgeFdQkddUfWM9rhGQjW", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000361445.4:c.6324C>A"}, {"syntax": "hgvs.g", "value": "NC_000001.10:g.11187094G>T"}], "location": {"id": "ga4gh:SL.Md1B3J4jJX8mCK2G31QBGlGeXgERC5VR", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Q9u3Vt0PamiHV4LTrj6mkhp1icb-eMhd"}, "start": 2107, "end": 2108}, "state": {"type": "LiteralSequenceExpression", "sequence": "L"}}}, "therapeutic": {"id": "civic.tid:469", "label": "Sirolimus", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:35302"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:37829", "type": "Disease", "label": "PEComa", "mappings": [{"coding": {"system": "ncit", "code": "C38150"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1212"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,2", "AY 22989", "RAPA", "RAPAMYCIN", "Rapamune", "SILA 9268A", "WY-090217"]}, "tumorType": {"id": "civic.did:22", "label": "Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9335"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1612"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1544", "description": "MCF-7 breast cancer cell line was exposed to mTOR inhibitor AZD8055 until resistance developed. Deep sequencing revealed an MTOR M2327I mutation in the AZD8055-resistant clone. Downstream signalling was independent of inhibitor presence in these clones and expression of the mutation in MDA-MB-468 cells led to resistance. Tumor volume grew more rapidly in mice with xenografts of M2327I mTOR mutant MCF7 cells treated with AZD8055 than rapamycin or RapaLink-1 treatment.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1025", "label": "Rodrik-Outmezguine et al., 2016, Nature", "type": "Document", "title": "PubMed: Rodrik-Outmezguine et al., 2016, Nature", "pmid": 27279227}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:2073", "label": "MTOR", "description": "mTOR deregulation has been observed in many cancer types. As a part of the PI3K/Akt pathway, there is a broad interest in mTOR biology across cancer types. mTOR inhibition has been investigated for nearly a decade. Everolimus, temsirolimus and zotarolimus are three of the more commonly used mTOR inhibitors used in clinical treatment today, with modest success.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3942"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2475"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["FRAP", "FRAP1", "FRAP2", "MTOR", "RAFT1", "RAPT1", "SKS"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:605", "label": "MTOR M2327I", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 7.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "A", "representative_transcript": "ENST00000361445.4", "chromosome": "1", "start": 11177096, "stop": 11177096, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "609"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA338383476"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["MET2327ILE"], "members": [{"id": "ga4gh:VA.NW63t35IZzJXFt6Crk_2pImoz-GOQPCW", "label": "NC_000001.10:g.11177096C>A", "digest": "NW63t35IZzJXFt6Crk_2pImoz-GOQPCW", "type": "Allele", "location": {"id": "ga4gh:SL._gJtxTHYbHMFz1MyHU9MW9lZK_JU8_-0", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Ya6Rs7DHhDeg7YaOSg1EoNi3U_nQ9SvO"}, "start": 11117038, "end": 11117039}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.etYcoHTPoYDuh7bksTnvMCL4QYxAp2r-", "label": "M2327I", "digest": "etYcoHTPoYDuh7bksTnvMCL4QYxAp2r-", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000361445.4:c.6981G>T"}, {"syntax": "hgvs.g", "value": "NC_000001.10:g.11177096C>A"}], "location": {"id": "ga4gh:SL.KQtX8E0HK4Ep7W-Lkqa0VQyk9F_ufe1N", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Q9u3Vt0PamiHV4LTrj6mkhp1icb-eMhd"}, "start": 2326, "end": 2327}, "state": {"type": "LiteralSequenceExpression", "sequence": "I"}}}, "therapeutic": {"id": "civic.tid:124", "label": "MTOR Kinase Inhibitor AZD8055", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C78856"}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C78856"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["AZD-8055", "AZD8055"]}, "tumorType": {"id": "civic.did:22", "label": "Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9335"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1612"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1547", "description": "MCF-7 breast cancer cell line was exposed to mTOR inhibitor rapamycin until resistance developed. Deep sequencing revealed an MTOR A2034V mutation in the resistant clone. Downstream signalling was independent of inhibitor presence in these clones and expression of the mutation in MDA-MB-468 cells led to resistance. Xenografts of these cells were more resistant to rapamycin than AZD8055 or RapaLink-1 treatment.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1025", "label": "Rodrik-Outmezguine et al., 2016, Nature", "type": "Document", "title": "PubMed: Rodrik-Outmezguine et al., 2016, Nature", "pmid": 27279227}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:2073", "label": "MTOR", "description": "mTOR deregulation has been observed in many cancer types. As a part of the PI3K/Akt pathway, there is a broad interest in mTOR biology across cancer types. mTOR inhibition has been investigated for nearly a decade. Everolimus, temsirolimus and zotarolimus are three of the more commonly used mTOR inhibitors used in clinical treatment today, with modest success.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3942"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2475"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["FRAP", "FRAP1", "FRAP2", "MTOR", "RAFT1", "RAPT1", "SKS"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:606", "label": "MTOR A2034V", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 8.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000361445.4", "chromosome": "1", "start": 11187796, "stop": 11187796, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "610"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA338393920"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ALA2034VAL"], "members": [{"id": "ga4gh:VA.2tAfBpJYe_IEFnBXkOlxShs4QCnUlByR", "label": "NC_000001.10:g.11187796G>A", "digest": "2tAfBpJYe_IEFnBXkOlxShs4QCnUlByR", "type": "Allele", "location": {"id": "ga4gh:SL.x9edwOeRbkgjh3rTxStiwdz-zbTCfdYx", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Ya6Rs7DHhDeg7YaOSg1EoNi3U_nQ9SvO"}, "start": 11127738, "end": 11127739}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.Dd5gRdU68wwsD7z_TMol9hrQk4e2sCUj", "label": "A2034V", "digest": "Dd5gRdU68wwsD7z_TMol9hrQk4e2sCUj", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000361445.4:c.6101C>T"}, {"syntax": "hgvs.g", "value": "NC_000001.10:g.11187796G>A"}], "location": {"id": "ga4gh:SL.77oOnj43-qlfKhBr_52Qn2QxADfFf1tq", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Q9u3Vt0PamiHV4LTrj6mkhp1icb-eMhd"}, "start": 2033, "end": 2034}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "civic.tid:469", "label": "Sirolimus", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:35302"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:37829", "type": "Disease", "label": "PEComa", "mappings": [{"coding": {"system": "ncit", "code": "C38150"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1212"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,2", "AY 22989", "RAPA", "RAPAMYCIN", "Rapamune", "SILA 9268A", "WY-090217"]}, "tumorType": {"id": "civic.did:22", "label": "Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9335"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1612"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1668", "description": "Using a mutation screen in the BRAFV600E melanoma cell line A375, the L505H variant was identified as conferring resistance to vemurafenib. Analysis of the mutation in T293 cell lines found that the L505H mutant alone or with V600e had greater kinase activity and increased the levels of phospho-MEK. Finally, transduction of Ba/F3 cells with BRAF V600E/L505H IL3 independent proliferation.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1129", "label": "Wagenaar et al., 2014, Pigment Cell Melanoma Res", "type": "Document", "title": "PubMed: Wagenaar et al., 2014, Pigment Cell Melanoma Res", "pmid": 24112705}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:654", "label": "BRAF L505H", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 19.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140477794, "stop": 140477794, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "658"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA369588358"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["LEU505HIS"], "members": [{"id": "ga4gh:VA.43-Xxx0D3goljjHCEmergHzgd7JyiMu2", "label": "NC_000007.13:g.140477794A>T", "digest": "43-Xxx0D3goljjHCEmergHzgd7JyiMu2", "type": "Allele", "location": {"id": "ga4gh:SL.NdyGTQ_TbJEFwW7RKeAJHmafXTzBWFel", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140777993, "end": 140777994}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.R-CzRnCKUtxncxoPJnYt7vibvUbvdm5l", "label": "L505H", "digest": "R-CzRnCKUtxncxoPJnYt7vibvUbvdm5l", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1514T>A"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140477794A>T"}, {"syntax": "hgvs.c", "value": "NM_004333.4:c.1514T>A"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Leu505His"}], "location": {"id": "ga4gh:SL.RD4uWTa4sWzi0s95cUuCuSMVQ0WvDTjK", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 504, "end": 505}, "state": {"type": "LiteralSequenceExpression", "sequence": "H"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:7", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3224"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1909"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1900", "description": "A JAK1 S703I mutation was found to activate the JAK-STAT signaling pathway in vitro and in vivo in hepatocellular carcinoma. Ruxolitinib causes the suppression of JAK-STAT signaling pathway in PDX models bearing JAK1 S703I mutation and delays tumor progression.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1332", "label": "Yang et al., 2016, Oncotarget", "type": "Document", "title": "PubMed: Yang et al., 2016, Oncotarget", "pmid": 26701727}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:3090", "label": "JAK1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6190"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3716"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["AIIDE", "JAK1", "JAK1A", "JAK1B", "JTK3"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:800", "label": "JAK1 S703I", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 4.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "A", "representative_transcript": "ENST00000342505.4", "chromosome": "1", "start": 65311203, "stop": 65311203, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "822"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA340667333"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["SER703ILE"], "members": [{"id": "ga4gh:VA.LbpM1YAJJmeieRCnh36kTujr49f5HVHH", "label": "NC_000001.10:g.65311203C>A", "digest": "LbpM1YAJJmeieRCnh36kTujr49f5HVHH", "type": "Allele", "location": {"id": "ga4gh:SL.40t9vDp9vZOctrX9G1UOI7MMOYzYjdGu", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Ya6Rs7DHhDeg7YaOSg1EoNi3U_nQ9SvO"}, "start": 64845519, "end": 64845520}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.bePfHihaIAWO8UXctjBgLEUiAj5n6HRN", "label": "S703I", "digest": "bePfHihaIAWO8UXctjBgLEUiAj5n6HRN", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000342505.4:c.2108G>T"}, {"syntax": "hgvs.g", "value": "NC_000001.10:g.65311203C>A"}], "location": {"id": "ga4gh:SL.Wbl1N7oFakd54BD2HaklHA68M2G_b2ms", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cu-mo9BHF4qdXH41R2iO9Zjkgjg9NZ94"}, "start": 702, "end": 703}, "state": {"type": "LiteralSequenceExpression", "sequence": "I"}}}, "therapeutic": {"id": "civic.tid:386", "label": "Ruxolitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1193326"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:605", "type": "Disease", "label": "Graft versus host disease", "mappings": [{"coding": {"system": "ncit", "code": "C3063"}, "relation": "relatedMatch"}]}, {"id": "hemonc:655", "type": "Disease", "label": "Polycythemia vera", "mappings": [{"coding": {"system": "ncit", "code": "C3336"}, "relation": "relatedMatch"}]}, {"id": "hemonc:635", "type": "Disease", "label": "Myelofibrosis", "mappings": [{"coding": {"system": "ncit", "code": "C3248"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C77888"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(3R)-3-cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)propanenitrile", "INCB-18424", "INCB18424", "Jakafi", "Oral JAK Inhibitor INCB18424"]}, "tumorType": {"id": "civic.did:196", "label": "Hepatocellular Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3099"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:684"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2041", "description": "This preclinical study tested the efficacy on several breast cancer cell lines of GDC-0941 (pictilisib), a selective inhibitor of all four isoforms of class I PI3-kinases over a range of IC50 values. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. MDA-MB-231 is a basal-type breast cancer cell line which harbors KRAS G13D, and it had an ICD50 of 20uM. To evaluate in vivo efficacy, cells were injected in the mammary fat pad of SCID mice and allowed to grow. Mice injected with MDA-MB-231 and treated with pictilisib saw no reduction in tumor volume compared to untreated control. There was no effect on G1 arrest in pictilisib treated cells; however, phosphorylated AKT (S473) was substantially reduced following pictilisib. Authors note that basal breast cancer cell lines were generally more resistant to pictilisib than luminal lines (p=0.02), and concluded that this cell line was resistant to pictilisib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1435", "label": "O'Brien et al., 2010, Clin. Cancer Res.", "type": "Document", "title": "PubMed: O'Brien et al., 2010, Clin. Cancer Res.", "pmid": 20453058}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:81", "label": "KRAS G13D", "description": "While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, results are conflicting with retrospective analyses suggesting a better response to EGFR-Inhibition. A recent prospective phase-II study (12 patients, Schirripa et. al. 2015) could not reproduce this finding and another prospective phase II trial is currently ongoing.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 108.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398281, "stop": 25398281, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "81"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA122534"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12580"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS112445441"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS112445441", "GLY13ASP"], "members": [{"id": "ga4gh:VA.wQro48c_oFxB35UNb2O1Z7Vj6rXnJywl", "label": "NC_000012.11:g.25398281C>T", "digest": "wQro48c_oFxB35UNb2O1Z7Vj6rXnJywl", "type": "Allele", "location": {"id": "ga4gh:SL.rZcsm5bnq3ptyk4298opou7vY9O0etcL", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245346, "end": 25245347}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.h-3tyZSdsQNs9NHrhuwcACnnMnpuT-8Z", "label": "G13D", "digest": "h-3tyZSdsQNs9NHrhuwcACnnMnpuT-8Z", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_033360.3:c.38G>A"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly13Asp"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398281C>T"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.38G>A"}], "location": {"id": "ga4gh:SL.U-3sSsoejW41eQ2Aev0wiG5tEuDiQZTB", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 12, "end": 13}, "state": {"type": "LiteralSequenceExpression", "sequence": "D"}}}, "therapeutic": {"id": "civic.tid:141", "label": "Pictilisib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C165479"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:22", "label": "Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9335"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1612"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2062", "description": "This preclinical study tested the efficacy on several breast cancer cell lines of GDC-0941 (pictilisib), a selective inhibitor of all four isoforms of class I PI3-kinases at a range of IC50 values. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. MDA-MB-361 is a HER2 amplified breast cancer cell line harboring PIK3CA E545K, and it had an IC50 of 0.14uM. To asses the effect of pictilisib on cell cycle progression and apoptosis, fluorescence based cell cycle and flow cytometry were used to measure the proportion of cells in various phases and the relative presence of Annexin V, a marker of apoptosis. Untreated, 68% of cells were in G1 or sub-G1. Following treatment with 1.0uM pictilisib, the proportion of cells in G1 or sub-G1 rose to 78%, and the amount of Annexin V detected rose 3 fold. A substantial reduction in phosphorylated AKT (S473) was also noted. Authors concluded that pictilisib had a modest effect on cell cycle progression and encouraged apoptosis in this cell line, and that this cell line is sensitive to pictilisib. Authors further noted that HER2 amplified cell lines were generally more sensitive, regardless of mutation, to pictilisib than basal-like breast cancer cell lines (p=0.002).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1435", "label": "O'Brien et al., 2010, Clin. Cancer Res.", "type": "Document", "title": "PubMed: O'Brien et al., 2010, Clin. Cancer Res.", "pmid": 20453058}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:104", "label": "PIK3CA E545K", "description": "PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 77.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000263967.3", "chromosome": "3", "start": 178936091, "stop": 178936091, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "104"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123334"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13655"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS104886003"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLU545LYS", "RS104886003"], "members": [{"id": "ga4gh:VA.uqD1zF6cMOYhBp8ur5oLTMqV0jxiC2a7", "label": "NC_000003.11:g.178936091G>A", "digest": "uqD1zF6cMOYhBp8ur5oLTMqV0jxiC2a7", "type": "Allele", "location": {"id": "ga4gh:SL.5l5tuxgJGb8y7CQzkKLPUvS-Cx4kr2ju", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 179218302, "end": 179218303}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.uw7DyLM7r98pn66LOXU3tAknmkV7jiJ0", "label": "E545K", "digest": "uw7DyLM7r98pn66LOXU3tAknmkV7jiJ0", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006218.3:c.1633G>A"}, {"syntax": "hgvs.p", "value": "NP_006209.2:p.Glu545Lys"}, {"syntax": "hgvs.c", "value": "ENST00000263967.3:c.1633G>A"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.178936091G>A"}], "location": {"id": "ga4gh:SL.SrEa0lPyesLrOX0M_aW51d-JdJhU-D3p", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 544, "end": 545}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:141", "label": "Pictilisib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C165479"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:368", "label": "Her2-receptor Positive Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C53556"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:0060079"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2085", "description": "This preclinical study tested the efficacy on several breast cancer cell lines of GDC-0941 (pictilisib), a selective inhibitor of all four isoforms of class I PI3-kinases at a range of IC50 values. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. BT-474 is a HER2 amplified breast cancer cell line harboring PIK3CA K111N, and it had an IC50 of 0.23uM. To evaluate in vivo efficacy, cells were injected in the mammary fat pad of SCID mice and allowed to grow. Mice subsequently treated with 100mg/kg pictilisib experienced a 69% tumor reduction, and those treated with 150mg/kg experienced an 82% tumor reduction, with respect to untreated control. Authors note that pictilisib was well tolerated and observed no toxicities or significant weight loss. Authors further note that HER2 amplified cell lines were generally more sensitive, regardless of mutation, to pictilisib than basal-like cell lines (p=0.002).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1435", "label": "O'Brien et al., 2010, Clin. Cancer Res.", "type": "Document", "title": "PubMed: O'Brien et al., 2010, Clin. Cancer Res.", "pmid": 20453058}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1208", "label": "PIK3CA K111N", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 13.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "C", "representative_transcript": "ENST00000263967.3", "chromosome": "3", "start": 178916946, "stop": 178916946, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1234"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602917"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376483"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS1057519934"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["LYS111ASN", "RS1057519934"], "members": [{"id": "ga4gh:VA.6gJ0sZTUPrjLKyzA7MbI4GufROt86Qef", "label": "NC_000003.11:g.178916946G>C", "digest": "6gJ0sZTUPrjLKyzA7MbI4GufROt86Qef", "type": "Allele", "location": {"id": "ga4gh:SL.OrbI2eAivw_NYF0pKrtb6EtIvymAX9fl", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 179199157, "end": 179199158}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.CNXNKSAtu44QlqQ-CS7tVeV5X3xvh0fP", "label": "K111N", "digest": "CNXNKSAtu44QlqQ-CS7tVeV5X3xvh0fP", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006218.3:c.333G>C"}, {"syntax": "hgvs.p", "value": "NP_006209.2:p.Lys111Asn"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.178916946G>C"}, {"syntax": "hgvs.c", "value": "ENST00000263967.3:c.333G>C"}], "location": {"id": "ga4gh:SL.S2OWTTUCKH1qcBAiJeW3zkx8rPaf2dFh", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 110, "end": 111}, "state": {"type": "LiteralSequenceExpression", "sequence": "N"}}}, "therapeutic": {"id": "civic.tid:141", "label": "Pictilisib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C165479"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:368", "label": "Her2-receptor Positive Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C53556"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:0060079"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2096", "description": "This preclinical study tested the efficacy on several breast cancer cell lines of GDC-0941 (pictilisib), a selective inhibitor of all four isoforms of class I PI3-kinases at a range of IC50 values. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. KPL4 is a HER2 amplified breast cancer cell line harboring PIK3CA H1047R, and it had an IC50 of 0.28uM. To evaluate in vivo efficacy, cells were injected in the mammary fat pad of SCID mice, and allowed to grow. Subsequently, pictilisib was administered orally daily for 14 days. Mice treated with 100mg/kg experienced a 76% tumor reduction, and those treated with 150mg/kg experienced a 90% tumor reduction, with respect to untreated control. Phosphorylated AKT (S473) was substantially reduced with pictilisib administration. Three other HER2 amplified breast cancer cell lines harbored PIK3CA H1047R: UACC-893, HCC1954, MDA-MB-453, which had IC50s of 0.41uM, 0.49uM, and 0.64uM, suggesting that PIK3CA H1047R induces sensitivity to pictilisib in HER2 amplified breast cancer. Authors note that pictilisib was well tolerated in vivo and further note that HER2 amplified cell lines were generally more sensitive, regardless of mutation, to pictilisib than basal-like cell lines (p=0.002).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1435", "label": "O'Brien et al., 2010, Clin. Cancer Res.", "type": "Document", "title": "PubMed: O'Brien et al., 2010, Clin. Cancer Res.", "pmid": 20453058}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:107", "label": "PIK3CA H1047R", "description": "PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 96.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "G", "representative_transcript": "ENST00000263967.3", "chromosome": "3", "start": 178952085, "stop": 178952085, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "107"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123326"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13652"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913279"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913279", "HIS1047ARG"], "members": [{"id": "ga4gh:VA.82Pw7U7NM7ac2koW_yITXOGSKcwg_Qqj", "label": "NC_000003.11:g.178952085A>G", "digest": "82Pw7U7NM7ac2koW_yITXOGSKcwg_Qqj", "type": "Allele", "location": {"id": "ga4gh:SL.p0VJw5IIPnKzEpQMcdBaU3xesud6QODJ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 179234296, "end": 179234297}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.hcSlm-m3AKXOL7kHM3LghXQfvAjZOmYx", "label": "H1047R", "digest": "hcSlm-m3AKXOL7kHM3LghXQfvAjZOmYx", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006218.3:c.3140A>G"}, {"syntax": "hgvs.p", "value": "NP_006209.2:p.His1047Arg"}, {"syntax": "hgvs.c", "value": "ENST00000263967.3:c.3140A>G"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.178952085A>G"}], "location": {"id": "ga4gh:SL.DBBb47ourtRut09MJ_TAvlocEwpTjF9z", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 1046, "end": 1047}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:141", "label": "Pictilisib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C165479"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:368", "label": "Her2-receptor Positive Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C53556"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:0060079"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2160", "description": "In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to reversible tyrosine kinase inhibitor drugs. Cells with an EGFR L858R/T790M mutation demonstrated a reduced response to lapatinib (IC50: >4000nM vs. 534nM) compared to wildtype EGFR cells. Similarly, NIH-3T3 ectopically expression EGFR-L858R/T790M showed reduced sensistivity to lapatinib compared to EGFR wt or L585R mutant cells. These results were further confirmed in a Ba/F3 cell line model", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1525", "label": "Li et al., 2008, Oncogene", "type": "Document", "title": "PubMed: Li et al., 2008, Oncogene", "pmid": 18408761}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:34", "label": "EGFR T790M", "description": "EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 406.25}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55249071, "stop": 55249071, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "34"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA090928"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16613"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434569"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["THR790MET", "RS121434569"], "members": [{"id": "ga4gh:VA.OvEfBRaS34JkfM0_ZHJVDQEjqtwzyjyp", "label": "NC_000007.13:g.55249071C>T", "digest": "OvEfBRaS34JkfM0_ZHJVDQEjqtwzyjyp", "type": "Allele", "location": {"id": "ga4gh:SL.ZCgOjF-_T0EOBXGc-6yICYui-jgFzJfY", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55181377, "end": 55181378}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.faKID4aj8rP8NKZpWL4mWDToEztTUmbr", "label": "T790M", "digest": "faKID4aj8rP8NKZpWL4mWDToEztTUmbr", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2369C>T"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2369C>T"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Thr790Met"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55249071C>T"}], "location": {"id": "ga4gh:SL.C1y_lDZe8e9pKy3jcj3oJKw_7252Hrxa", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 789, "end": 790}, "state": {"type": "LiteralSequenceExpression", "sequence": "M"}}}, "therapeutic": {"id": "civic.tid:45", "label": "Lapatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:480167"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:572", "type": "Disease", "label": "Breast cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9335"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C26653"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["GSK572016", "GW 2016", "GW2016", "GW572016"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:3012", "description": "Murine Ba/F3 cell line has a restrictive sensitivity to Quizartinib (AC220), a second generation class II tyrosine kinase inhibitor (IC50 for proliferation = 172nM, IC50 for induction of apoptosis = 888nM).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1732", "label": "Kampa-Schittenhelm et al., 2013, Mol. Cancer", "type": "Document", "title": "PubMed: Kampa-Schittenhelm et al., 2013, Mol. Cancer", "pmid": 23497317}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:24", "label": "FLT3", "description": "FLT3 is an important cytokine receptor involved in normal hematopoiesis. Mutations in this gene are common in acute myeloid leukemia (AML) and screening for mutations in this gene has been recommended by the World Health Organization in patients with AML, particularly in cases of cytogenetically normal AML (CN-AML). FLT3 mutations commonly co-occur with mutations such as NPM1 that are associated with CN-AML and likely modulate prognostic impact. While FLT3-ITD mutations have been associated with poorer prognosis in AML, the prognostic impact of FLT3-TKD mutations are still up for debate.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3765"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2322"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD135", "FLK-2", "FLK2", "FLT3", "STK1"]}}, "direction": "refutes", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1276", "label": "FLT3 D835V", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 19.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "A", "representative_transcript": "ENST00000241453.7", "chromosome": "13", "start": 28592641, "stop": 28592641, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1302"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA126344"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16272"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121909646"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ASP835VAL", "RS121909646"], "members": [{"id": "ga4gh:VA.d1XMqI0hKulE40Z2rW3jkkLDMVh_2_O1", "label": "NC_000013.10:g.28592641T>A", "digest": "d1XMqI0hKulE40Z2rW3jkkLDMVh_2_O1", "type": "Allele", "location": {"id": "ga4gh:SL.nXY0j3isNbco1FUwE39fcdoIjffTxgkq", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ._0wi-qoDrvram155UmcSC-zA5ZK4fpLT"}, "start": 28018503, "end": 28018504}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.2UJEemVtXP1RM3bMtSQbin9I91Uyiylm", "label": "D835V", "digest": "2UJEemVtXP1RM3bMtSQbin9I91Uyiylm", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000241453.7:c.2504A>T"}, {"syntax": "hgvs.c", "value": "NM_004119.2:c.2504A>T"}, {"syntax": "hgvs.p", "value": "NP_004110.2:p.Asp835Val"}, {"syntax": "hgvs.g", "value": "NC_000013.10:g.28592641T>A"}], "location": {"id": "ga4gh:SL.JUgz5GWLTcSTPLIVCaYEGo7KsH5QpwgJ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.0dtDG7QKyvW7BntvQVpLS83mYRA58LKH"}, "start": 834, "end": 835}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "civic.tid:505", "label": "Quizartinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C68936"}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C68936"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(2E)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3S)-Oxolan-3-Yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)but-2-Enamide", "AC-220", "AC010220", "AC220", "N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo [2,1-b] [1,3] Benzothiazol 2-yl]phenyl}urea"]}, "tumorType": {"id": "civic.did:3", "label": "Acute Myeloid Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3171"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9119"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:3989", "description": "In an in vitro study to identify cetuximab-resistant clones following continuous drug treatment, a resistant clone of the Lim1215 colorectal cancer cell line was identified to have the KRAS G12R mutation. No G12R was detected in the parental line despite high-resolution evaluation. Additionally, endogenously expressing KRAS G12R (knock-in) mutation demonstrated resistance to cetuximab treatment, compared to Lim1215 parental cells expressing wild-type KRAS. Resistance was determined by assessing cell viability.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2008", "label": "Misale et al., 2012, Nature", "type": "Document", "title": "PubMed: Misale et al., 2012, Nature", "pmid": 22722830}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:526", "label": "KRAS G12R", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 32.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "G", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398285, "stop": 25398285, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "530"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA122531"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12579"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913530"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLY12ARG", "RS121913530"], "members": [{"id": "ga4gh:VA.kEM90GlJNzSYfDBfTs8c2yFQV8uAXPis", "label": "NC_000012.11:g.25398285C>G", "digest": "kEM90GlJNzSYfDBfTs8c2yFQV8uAXPis", "type": "Allele", "location": {"id": "ga4gh:SL.AiE9G9ocxKfBfR5PRN_ktoggZzig8OcG", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245350, "end": 25245351}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.l8Oir2v3p-jxHGny73WMctRV_zRFj8Mg", "label": "G12R", "digest": "l8Oir2v3p-jxHGny73WMctRV_zRFj8Mg", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004985.4:c.34G>C"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly12Arg"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398285C>G"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.34G>C"}], "location": {"id": "ga4gh:SL.OndkjmujtyUEZSjjCv0C-gpwnVbRgfj8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:16", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:318341"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}, {"id": "mesh:D006258", "type": "Disease", "label": "Head and Neck Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C4013"}, "relation": "relatedMatch"}]}, {"id": "mesh:D002294", "type": "Disease", "label": "Carcinoma, Squamous Cell", "mappings": [{"coding": {"system": "ncit", "code": "C2929"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1723"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4489", "description": "In an in vitro study, the WM2664 and WM239A cell lines expressing BRAF V600D were associated with increased sensitivity to vemurafenib treatment, as compared to cell lines expressing BRAF wild-type. Sensitivity was determined by proliferation assay. In addition, vemurafenib treatment strongly inhibited MEK and ERK phosphorylation in WM2664 cells.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:351", "label": "Yang et al., 2010, Cancer Res.", "type": "Document", "title": "PubMed: Yang et al., 2010, Cancer Res.", "pmid": 20551065}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:11", "label": "BRAF V600D", "description": "Patients harboring mutations in valine 600 residue of BRAF have been shown to be sensitive to dabrafenib. For more information on the V600 locus, see the V600E entry.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 47.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "CA", "variant_bases": "AT", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453135, "stop": 140453136, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "11"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602419"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "375939"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913377"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["VAL600ASP", "RS121913377"], "members": [{"id": "ga4gh:VA.nojfgZgtcwQ9Ylm0GuBuGnUT7Ug-_AKX", "label": "NC_000007.13:g.140453135_140453136delinsAT", "digest": "nojfgZgtcwQ9Ylm0GuBuGnUT7Ug-_AKX", "type": "Allele", "location": {"id": "ga4gh:SL.jW40gDuxQ9chCROKZs12FE7cHlX538EU", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753334, "end": 140753336}, "state": {"type": "LiteralSequenceExpression", "sequence": "AT"}}], "definingContext": {"id": "ga4gh:VA.TG8unESalMAFNryF_mfZWfWumrv-uI-U", "label": "V600D", "digest": "TG8unESalMAFNryF_mfZWfWumrv-uI-U", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000007.13:g.140453135_140453136delinsAT"}, {"syntax": "hgvs.c", "value": "NM_004333.4:c.1799_1800delTGinsAT"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Val600Asp"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1799_1800delTGinsAT"}], "location": {"id": "ga4gh:SL.ZA1XNKhCT_7m2UtmnYb8ZYOVS4eplMEK", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "D"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:7", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3224"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1909"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4510", "description": "A preclinical study tested the effects of a tyrosine kinase inhibitor (TKI) on Ba/F3 cell lines with representative primary regorafenib-sensitizing mutation del 557-558, which induced IL-3 independent growth, and secondary mutation T670I. The cells were tested for Regorafenib resistance. Ba/F3 cells with del 557-558/T670I mutations (IC50 = 132 +- 25 nM) did show resistance towards  Regorafenib  compared to Ba/F3 cells with del 557-558 alone (IC50 = 30 +- 14 nM). In addition, Ba/F3 cells were mutagenized with N-ethyl-N-nitrosourea and incubated with varying concentrations of Regorafenib. In Regorafenib incubated cells, T670I mutations were seen in approximately 10% of the resistant cell populations. The results suggest that T670I does induce regorafenib resistance in del 557-558/T670I cells.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2042", "label": "Garner et al., 2014, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Garner et al., 2014, Clin. Cancer Res.", "pmid": 25239608}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:29", "label": "KIT", "description": "c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3815"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["C-Kit", "CD117", "KIT", "MASTC", "PBT", "SCFR"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1241", "label": "KIT T670I", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 21.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000288135.5", "chromosome": "4", "start": 55595519, "stop": 55595519, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1267"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602525"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376058"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913516"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["THR670ILE", "RS121913516"], "members": [{"id": "ga4gh:VA.dTZgbPkwISVGYwXmm_4WCyPX9W-LSOOh", "label": "NC_000004.11:g.55595519C>T", "digest": "dTZgbPkwISVGYwXmm_4WCyPX9W-LSOOh", "type": "Allele", "location": {"id": "ga4gh:SL.reFRinn6ZsNtpwqaKz6HHHpO34YKczpW", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54729352, "end": 54729353}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.f55Nm2_RKZg7Hnpo-JVhQVAliadbUqMJ", "label": "T670I", "digest": "f55Nm2_RKZg7Hnpo-JVhQVAliadbUqMJ", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_000222.2:c.2009C>T"}, {"syntax": "hgvs.p", "value": "NP_000213.1:p.Thr670Ile"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55595519C>T"}, {"syntax": "hgvs.c", "value": "ENST00000288135.5:c.2009C>T"}], "location": {"id": "ga4gh:SL.jq2-jclk1pqHSIl0gTtHsMPBMD7VcMmN", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 669, "end": 670}, "state": {"type": "LiteralSequenceExpression", "sequence": "I"}}}, "therapeutic": {"id": "civic.tid:27", "label": "Regorafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1312397"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C78204"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide", "BAY 73-4506", "REGORAFENIB ANHYDROUS", "Stivarga"]}, "tumorType": {"id": "civic.did:2", "label": "Gastrointestinal Stromal Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3868"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9253"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4787", "description": "In this in vitro study, the H1915 non-small cell lung cancer cell line (homozygous for a R351W mutation) was shown to be susceptible to dasatinib. This line showed a significant reduction in colony formation (P < 0.001) and MTT assay, which tests for NADH activity (P = 1.09 x 10^5), with dasatinib vs vehicle treatment. There was no significant difference in a lung cancer cell line without a known driver (H2126) nor in an immortalized bronchial epithelial line (Beas-2B) with either drug treatment in colony forming and MTT assays. Additionally, reduction in cell viability upon kinase inhibitor treatment could be rescued with tetracycline-induced overexpression of resistant ABL1-T315I (P < 0.001) confirming the genetic dependency of this cell line on ABL1. Moreover, a significant increased in cytotoxicity was noted with siRNA facilitated depletion of ABL1 (P < 0.005) with no significant change in H2126 or Beas-2B lines supporting ABL1 as the primary drug target.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2128", "label": "Testoni et al., 2016, EMBO Mol Med", "type": "Document", "title": "PubMed: Testoni et al., 2016, EMBO Mol Med", "pmid": 26758680}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:4", "label": "ABL1", "description": "ABL1 is most relevant to cancer in its role in the BCR-ABL fusion protein that has become a signature of chronic myeloid leukemia (CML). Cells harboring this fusion have shown sensitivity to imatinib, greatly improving the prognostic outlook of the disease. However, additional mutations in ABL1 have been shown to confer resistance to imatinib. In these resistance cases, second-generation tyrosine kinase inhibitors such as dasatinib and nilotinib have exhibited some efficacy and are currently undergoing clinical trials for treating acquired resistance in CML.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:76"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:25"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["ABL", "ABL1", "BCR-ABL", "CHDSKM", "JTK7", "bcr/abl", "c-ABL", "c-ABL1", "p150", "v-abl"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1564", "label": "ABL1 R351W", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 9.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000372348.2", "chromosome": "9", "start": 133748333, "stop": 133748333, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1656"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA5285359"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS779478267"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["R332W", "RS779478267", "ARG351TRP"], "members": [{"id": "ga4gh:VA.qNy2ihAiYylsrp7IghhTWDJvKaKK3KiN", "label": "NC_000009.11:g.133748333C>T", "digest": "qNy2ihAiYylsrp7IghhTWDJvKaKK3KiN", "type": "Allele", "location": {"id": "ga4gh:SL.qx--aO3ZvD1SATUlgeQNw4TqMUhh2VAg", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.KEO-4XBcm1cxeo_DIQ8_ofqGUkp4iZhI"}, "start": 130872945, "end": 130872946}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.JLMC4T56srjVEPQebuy8nw8Ao2_B7TMh", "label": "R351W", "digest": "JLMC4T56srjVEPQebuy8nw8Ao2_B7TMh", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000372348.2:c.1051C>T"}, {"syntax": "hgvs.g", "value": "NC_000009.11:g.133748333C>T"}, {"syntax": "hgvs.c", "value": "NM_007313.2:c.1051C>T"}, {"syntax": "hgvs.p", "value": "NP_009297.2:p.Arg351Trp"}], "location": {"id": "ga4gh:SL.NWrm5KTUAe-zkYX0qCzBM2SIkYhSMGVL", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dmFigTG-0fY6I54swb7PoDuxCeT6O3Wg"}, "start": 331, "end": 332}, "state": {"type": "LiteralSequenceExpression", "sequence": "W"}}}, "therapeutic": {"id": "civic.tid:20", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1546019"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C38713"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate", "BMS-354825", "Dasatinib Hydrate", "Dasatinib Monohydrate", "Sprycel"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:6206", "description": "This preclinical study tested the sensitivity of HER2-positive breast cancer cell line BT-474 (heterozygous for PIK3CA K111N) retrovirally transduced with PIK3CA H1047R to NVP-BEZ235 (dactolisib; a dual PI3K/mTOR inhibitor). The study found that dactolisib was effective in inhibiting outgrowth of H1047R mutant-containing cells. Dactolisib was also combined with trastuzumab and/or lapatinib with similar abrogation of growth for PIK3CA H1047R expressing cells. Additionally, growth of untransduced BT-474 control cells was prevented by treatment with any monotherapy or combination of trastuzumab, lapatinib, or dactolisib. Authors concluded that PIK3CA H1047R induces resistance to lapatinib and trastuzumab in HER2 positive breast cancer cells, but resistance can be reversed by dactolisib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2486", "label": "Eichhorn et al., 2008, Cancer Res.", "type": "Document", "title": "PubMed: Eichhorn et al., 2008, Cancer Res.", "pmid": 19010894}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "refutes", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:107", "label": "PIK3CA H1047R", "description": "PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 96.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "G", "representative_transcript": "ENST00000263967.3", "chromosome": "3", "start": 178952085, "stop": 178952085, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "107"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123326"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13652"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913279"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913279", "HIS1047ARG"], "members": [{"id": "ga4gh:VA.82Pw7U7NM7ac2koW_yITXOGSKcwg_Qqj", "label": "NC_000003.11:g.178952085A>G", "digest": "82Pw7U7NM7ac2koW_yITXOGSKcwg_Qqj", "type": "Allele", "location": {"id": "ga4gh:SL.p0VJw5IIPnKzEpQMcdBaU3xesud6QODJ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 179234296, "end": 179234297}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.hcSlm-m3AKXOL7kHM3LghXQfvAjZOmYx", "label": "H1047R", "digest": "hcSlm-m3AKXOL7kHM3LghXQfvAjZOmYx", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006218.3:c.3140A>G"}, {"syntax": "hgvs.p", "value": "NP_006209.2:p.His1047Arg"}, {"syntax": "hgvs.c", "value": "ENST00000263967.3:c.3140A>G"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.178952085A>G"}], "location": {"id": "ga4gh:SL.DBBb47ourtRut09MJ_TAvlocEwpTjF9z", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 1046, "end": 1047}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:343", "label": "Dactolisib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C74072"}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C74072"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["BEZ235", "Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-", "NVPBEZ235"]}, "tumorType": {"id": "civic.did:368", "label": "Her2-receptor Positive Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C53556"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:0060079"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:6380", "description": "Demonstrates that activating mutations in CSF3R are sufficient to drive a myeloproliferative disorder resembling aCML and CNL that is sensitive to pharmacologic JAK inhibition.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2521", "label": "Fleischman et al., 2013, Blood", "type": "Document", "title": "PubMed: Fleischman et al., 2013, Blood", "pmid": 24081659}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:1239", "label": "CSF3R", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:2439"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1441"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD114", "CSF3R", "GCSFR", "SCN7"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:2260", "label": "CSF3R T618I", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 14.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000373103.1", "chromosome": "1", "start": 36933434, "stop": 36933434, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "2387"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA204418"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "208339"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["THR618ILE"], "members": [{"id": "ga4gh:VA.PqIGMb_ZLJSkL_CUXQwwU2JVvWFC3gsQ", "label": "NC_000001.10:g.36933434G>A", "digest": "PqIGMb_ZLJSkL_CUXQwwU2JVvWFC3gsQ", "type": "Allele", "location": {"id": "ga4gh:SL.61Arkbj-enko68XltIfqq23i3ZfS1FLC", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Ya6Rs7DHhDeg7YaOSg1EoNi3U_nQ9SvO"}, "start": 36467832, "end": 36467833}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.TzXHm8W6Y2yQ-vVTzhhsaeCmd7dG53MQ", "label": "T618I", "digest": "TzXHm8W6Y2yQ-vVTzhhsaeCmd7dG53MQ", "type": "Allele", "expressions": [{"syntax": "hgvs.p", "value": "NP_724781.1:p.Thr618Ile"}, {"syntax": "hgvs.c", "value": "NM_156039.3:c.1853C>T"}, {"syntax": "hgvs.c", "value": "ENST00000373103.1:c.1853G>A"}, {"syntax": "hgvs.g", "value": "NC_000001.10:g.36933434G>A"}, {"syntax": "hgvs.g", "value": "NC_000001.11:g.36467833G>A"}], "location": {"id": "ga4gh:SL.Rvinur1IdQxw7SP8IkgCBzsFrU4BMNo6", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.DED83_tWyJUC7C4oX5dwag6RxdJZ20RL"}, "start": 617, "end": 618}, "state": {"type": "LiteralSequenceExpression", "sequence": "I"}}}, "therapeutic": {"id": "civic.tid:386", "label": "Ruxolitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1193326"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:605", "type": "Disease", "label": "Graft versus host disease", "mappings": [{"coding": {"system": "ncit", "code": "C3063"}, "relation": "relatedMatch"}]}, {"id": "hemonc:655", "type": "Disease", "label": "Polycythemia vera", "mappings": [{"coding": {"system": "ncit", "code": "C3336"}, "relation": "relatedMatch"}]}, {"id": "hemonc:635", "type": "Disease", "label": "Myelofibrosis", "mappings": [{"coding": {"system": "ncit", "code": "C3248"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C77888"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(3R)-3-cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)propanenitrile", "INCB-18424", "INCB18424", "Jakafi", "Oral JAK Inhibitor INCB18424"]}, "tumorType": {"id": "civic.did:2127", "label": "Chronic Neutrophilic Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3179"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:0080187"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:6952", "description": "Experiment with immunodeficient mice transplanted with melanoma cell lines indicates EZH2 inhibitor JQEZ5 might be effective in combination with a B-RAF inhibitor in RAF-mutant melanoma.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2307", "label": "Souroullas et al., 2016, Nat. Med.", "type": "Document", "title": "PubMed: Souroullas et al., 2016, Nat. Med.", "pmid": 27135738}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:63", "label": "EZH2", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3527"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2146"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["ENX-1", "ENX1", "EZH2", "EZH2b", "KMT6", "KMT6A", "WVS", "WVS2"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:2858", "label": "EZH2 Y646F", "description": "Y646F has been reported as one of the most recurrent alterations of EZH2 in DLBCL, FL and other malignancies. This mutation is thought to alter methyltransferase activity of EZH2 and confer sensitivity to EZH2 inhibitors such as tazemetostat.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 14.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "A", "representative_transcript": "ENST00000320356.7", "chromosome": "7", "start": 148508727, "stop": 148508727, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "2989"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602259"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "76768"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["TYR641PHE", "Y641F", "TYR646PHE"], "members": [{"id": "ga4gh:VA.Q_sL4G2qb2BhSUg_tlGZrQyOA7062sAt", "label": "NC_000007.14:g.148811635T>A", "digest": "Q_sL4G2qb2BhSUg_tlGZrQyOA7062sAt", "type": "Allele", "location": {"id": "ga4gh:SL.hTPdaswDMkwuHxMm7SgRnhis9FUCHRNI", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 148811634, "end": 148811635}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.lBiBkFGa4jG5y2kIbDYYJyZpQTfmHfss", "label": "Y646F", "digest": "lBiBkFGa4jG5y2kIbDYYJyZpQTfmHfss", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000320356.7:c.1937A>T"}, {"syntax": "hgvs.g", "value": "NC_000007.14:g.148811635T>A"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.148508727T>A"}, {"syntax": "hgvs.p", "value": "ENSP00000320147.2:p.Tyr646Phe"}, {"syntax": "hgvs.c", "value": "ENST00000460911.5:c.1922A>T"}, {"syntax": "hgvs.p", "value": "ENSP00000419711.1:p.Tyr641Phe"}, {"syntax": "hgvs.c", "value": "NM_004456.5:c.1937A>T"}, {"syntax": "hgvs.p", "value": "NP_004447.2:p.Tyr646Phe"}, {"syntax": "hgvs.c", "value": "NM_001203247.2:c.1922A>T"}, {"syntax": "hgvs.p", "value": "NP_001190176.1:p.Tyr641Phe"}], "location": {"id": "ga4gh:SL.5DlaGJrlH6seUdneVWj-QDGIqUJjtRB1", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fZuyp1_QKM5vGWsn-O-CrPHPm5jR403J"}, "start": 645, "end": 646}, "state": {"type": "LiteralSequenceExpression", "sequence": "F"}}}, "therapeutic": {"id": "civic.tid:541", "label": "JQEZ5", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "iuphar.ligand:9332"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:206", "label": "Skin Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3510"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:8923"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:7401", "description": "A preclinical study was done in order to test the effects of a tyrosine kinase inhibitor (TKI) on the ponatinib-sensitive KIT-mutant cell line GIST-T1 derived from Gastrointestinal Stromal Tumor (GIST) patients with primary mutation 560-578 deletion and additional secondary mutation D816E. The cells were tested for Ponatinib resistance. GIST-T1/816 cells containing del 560-578 and D816E mutations (IC50: 23 nM) did not show resistance towards Ponatinib compared to GIST-T1 cells with only del 560-578 mutation (IC50: 5 nM). Ponatinib reduced phosphorylation in KIT, AKT, and ERK at higher concentrations. According to the results, the authors suggest that Ponatinib remained highly active in GIST cell lines with secondary mutation D816E.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2042", "label": "Garner et al., 2014, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Garner et al., 2014, Clin. Cancer Res.", "pmid": 25239608}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:29", "label": "KIT", "description": "c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3815"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["C-Kit", "CD117", "KIT", "MASTC", "PBT", "SCFR"]}}, "direction": "refutes", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1467", "label": "KIT D816E", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 8.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "G", "representative_transcript": "ENST00000288135.5", "chromosome": "4", "start": 55599322, "stop": 55599322, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1559"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA356911882"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ASP816GLU", "D812E"], "members": [{"id": "ga4gh:VA.-pKa_dW6P9dwY91Zyws9f9lv_-_DmTip", "label": "NC_000004.11:g.55599322C>G", "digest": "-pKa_dW6P9dwY91Zyws9f9lv_-_DmTip", "type": "Allele", "location": {"id": "ga4gh:SL.eBE-q3oPpsVR9rzas_5Ts09m8ajJ-6_N", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54733155, "end": 54733156}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.H4vDYwRAHa6PZ1PusyHnqW4XJKyZxgeJ", "label": "D816E", "digest": "H4vDYwRAHa6PZ1PusyHnqW4XJKyZxgeJ", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000288135.5:c.2448C>G"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55599322C>G"}, {"syntax": "hgvs.c", "value": "NM_000222.2:c.2448C>G"}, {"syntax": "hgvs.p", "value": "NP_000213.1:p.Asp816Glu"}], "location": {"id": "ga4gh:SL.EFk3ET7Ws47inqLJnNWEsA-GhUEwihbN", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 815, "end": 816}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "civic.tid:55", "label": "Ponatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1364347"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C95777"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["AP-24534", "AP24534", "Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)"]}, "tumorType": {"id": "civic.did:2", "label": "Gastrointestinal Stromal Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3868"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9253"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:7413", "description": "Ponatinib possesses potent activity against A829P KIT mutant cells in preclinical experiments. A preclinical study tested the effect of a tyrosine kinase inhibitor (TKI) on Ba/F3 cell lines with representative primary ponatinib-sensitizing mutation del 557-558, which induced IL-3 independent growth, and secondary mutation A829P. The cells were tested for Ponatinib resistance. Ba/F3 cells with del 557-558 and A829P mutations (IC50 for growth inhibition: 2 nM) did not show resistance towards Ponatinib compared to Ba/F3 cells with the del 557-558 mutation alone (IC50: 3 nM).  Ponatinib was shown to inhibit KIT phosphorylation in moderate concentrations. Similarly, GIST-T1/829 cells with 560-578 deletion/A829P mutations (IC50 = 16 nM) were not resistant to Ponatinib compared to GIST T1 cells with 560-578 deletion alone (IC50 = 5 nM). Ponatinib inhibited phosphorylation in KIT, ERK, and AKT at moderate to high concentrations in GIST-T1/829 cells.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2042", "label": "Garner et al., 2014, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Garner et al., 2014, Clin. Cancer Res.", "pmid": 25239608}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:29", "label": "KIT", "description": "c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3815"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["C-Kit", "CD117", "KIT", "MASTC", "PBT", "SCFR"]}}, "direction": "refutes", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:964", "label": "KIT A829P", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 8.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "C", "chromosome": "4", "start": 55602664, "stop": 55602664, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "990"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602413"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "375933"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS1057519713"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS1057519713", "ALA829PRO"], "members": [{"id": "ga4gh:VA.cUbjTZryet9fNqHGWeMkca4YkUqxy4Hv", "label": "NC_000004.11:g.55602664G>C", "digest": "cUbjTZryet9fNqHGWeMkca4YkUqxy4Hv", "type": "Allele", "location": {"id": "ga4gh:SL.Ka7UdfdsKx2RClKMihb3UCFxaw144RIc", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54736497, "end": 54736498}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.Y-lqMmld8_rx2I8cgd4MwDiGbK9RNdY_", "label": "A829P", "digest": "Y-lqMmld8_rx2I8cgd4MwDiGbK9RNdY_", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000004.11:g.55602664G>C"}, {"syntax": "hgvs.c", "value": "NM_000222.2:c.2485G>C"}, {"syntax": "hgvs.p", "value": "NP_000213.1:p.Ala829Pro"}], "location": {"id": "ga4gh:SL.8zUm96TlRUhMxgqClvHpbRXLXvSY-xZO", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 828, "end": 829}, "state": {"type": "LiteralSequenceExpression", "sequence": "P"}}}, "therapeutic": {"id": "civic.tid:55", "label": "Ponatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1364347"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C95777"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["AP-24534", "AP24534", "Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)"]}, "tumorType": {"id": "civic.did:2", "label": "Gastrointestinal Stromal Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3868"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9253"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:8106", "description": "Gilteritinib inhibited the cell growth of Ba/F3 cells expressing D835Y (IC50 1.6 nM; 95% CI: 1.1\u20132.4 nM) compared to controls (IC50 420nM; 95% CI: 350\u2013500 nM). Additionally, immunoblots showed gliteritinib reduced phosphorylation of FLT3 and downstream targets in Ba/F3 D835Y cells in a dose dependent manner. Furthermore, in nude mice xenografted with Ba/F3 cells expressing D835Y, gilteritinib showed antitumor efficacy at 10 mg/kg and 30 mg/kg, and induced tumor regression at 30 mg/k. Computational modelling demonstrated that gilteritinib interacts with activated FLT3 at the ATP-binding site, which is distant from the D835 containing activation loop. This inhibitory mechanism allows for kinase inhibition to occur in the face of D835 mutation.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:3332", "label": "Mori et al., 2017, Invest New Drugs", "type": "Document", "title": "PubMed: Mori et al., 2017, Invest New Drugs", "pmid": 28516360}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:24", "label": "FLT3", "description": "FLT3 is an important cytokine receptor involved in normal hematopoiesis. Mutations in this gene are common in acute myeloid leukemia (AML) and screening for mutations in this gene has been recommended by the World Health Organization in patients with AML, particularly in cases of cytogenetically normal AML (CN-AML). FLT3 mutations commonly co-occur with mutations such as NPM1 that are associated with CN-AML and likely modulate prognostic impact. While FLT3-ITD mutations have been associated with poorer prognosis in AML, the prognostic impact of FLT3-TKD mutations are still up for debate.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3765"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2322"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD135", "FLK-2", "FLK2", "FLT3", "STK1"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:2880", "label": "FLT3 D835Y", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 6.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"type": "coordinates"}}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "3011"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.1hPW7A1Ucjjqoj-8nHIaO7J9py4rPU-B", "label": "D835Y", "digest": "1hPW7A1Ucjjqoj-8nHIaO7J9py4rPU-B", "type": "Allele", "location": {"id": "ga4gh:SL.JUgz5GWLTcSTPLIVCaYEGo7KsH5QpwgJ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.0dtDG7QKyvW7BntvQVpLS83mYRA58LKH"}, "start": 834, "end": 835}, "state": {"type": "LiteralSequenceExpression", "sequence": "Y"}}}, "therapeutic": {"id": "civic.tid:641", "label": "Gilteritinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:2105806"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C116722"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide", "ASP-2215", "ASP2215", "Xospata"]}, "tumorType": {"id": "civic.did:216", "label": "Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9305"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:162"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:8337", "description": "The authors used saturation mutagenesis of FLT3/ITD followed by selection of transfected cells in FLT3 TKI. The FLT3/ITD Y842C mutation produced high-level resistance to KW2449, sorafenib, sunitinib and AGS324 in vitro but remained sensitive to lestaurtinib and midostaurin. Balb/c mice transplanted with the FLT3/ITD Y842C mutation confirmed resistance to sorafenib in vivo but not to lestaurtinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:3472", "label": "Williams et al., 2013, Leukemia", "type": "Document", "title": "PubMed: Williams et al., 2013, Leukemia", "pmid": 22858906}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:24", "label": "FLT3", "description": "FLT3 is an important cytokine receptor involved in normal hematopoiesis. Mutations in this gene are common in acute myeloid leukemia (AML) and screening for mutations in this gene has been recommended by the World Health Organization in patients with AML, particularly in cases of cytogenetically normal AML (CN-AML). FLT3 mutations commonly co-occur with mutations such as NPM1 that are associated with CN-AML and likely modulate prognostic impact. While FLT3-ITD mutations have been associated with poorer prognosis in AML, the prognostic impact of FLT3-TKD mutations are still up for debate.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3765"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2322"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD135", "FLK-2", "FLK2", "FLT3", "STK1"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:2939", "label": "FLT3 Y842C", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 20.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"type": "coordinates"}}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "3070"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.s6EXIFpOIE4Bu60Si0TcHRecbTr1Iux8", "label": "Y842C", "digest": "s6EXIFpOIE4Bu60Si0TcHRecbTr1Iux8", "type": "Allele", "location": {"id": "ga4gh:SL.v49CEsmpXzpqqDo9j07qHUhf597WMTPC", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.0dtDG7QKyvW7BntvQVpLS83mYRA58LKH"}, "start": 841, "end": 842}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "civic.tid:6", "label": "Sorafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:495881"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:65823", "type": "Disease", "label": "Thyroid cancer differentiated"}, {"id": "hemonc:612", "type": "Disease", "label": "Hepatocellular carcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C3099"}, "relation": "relatedMatch"}]}, {"id": "hemonc:660", "type": "Disease", "label": "Renal cell carcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C9385"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C61948"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["BA4 43 9006", "BAY 43-9006", "Bay-439006"]}, "tumorType": {"id": "civic.did:3", "label": "Acute Myeloid Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3171"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9119"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:8339", "description": "A screen using saturation mutagenesis of FLT3/ITD followed by selection of transfected TF1 cells in FLT3 TKIs identified Y842C. Cytotoxicity assessed by MTT demonstrated Ba/F3 cells expressing FLT3/ITD Y842C treated with Lestaurtinib responded similarly to FLT3/ITD control cells (IC50: 2nM). Immunoblotting revealed Lestaurtinib inhibited FLT3 autophosphorylation and the activation of downstream pathways in Ba/F3 FLT3/ITD Y842C and control cells. These FLT3/ITD Y842C cells also responded to Lestaurtinib treatment in vivo after transplantation into Balb/c mice as measured by minimal bioluminescence and reduced spleen weight compared to vehicle and sorafenib treated mice.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:3472", "label": "Williams et al., 2013, Leukemia", "type": "Document", "title": "PubMed: Williams et al., 2013, Leukemia", "pmid": 22858906}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:24", "label": "FLT3", "description": "FLT3 is an important cytokine receptor involved in normal hematopoiesis. Mutations in this gene are common in acute myeloid leukemia (AML) and screening for mutations in this gene has been recommended by the World Health Organization in patients with AML, particularly in cases of cytogenetically normal AML (CN-AML). FLT3 mutations commonly co-occur with mutations such as NPM1 that are associated with CN-AML and likely modulate prognostic impact. While FLT3-ITD mutations have been associated with poorer prognosis in AML, the prognostic impact of FLT3-TKD mutations are still up for debate.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3765"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2322"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD135", "FLK-2", "FLK2", "FLT3", "STK1"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:2939", "label": "FLT3 Y842C", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 20.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"type": "coordinates"}}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "3070"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.s6EXIFpOIE4Bu60Si0TcHRecbTr1Iux8", "label": "Y842C", "digest": "s6EXIFpOIE4Bu60Si0TcHRecbTr1Iux8", "type": "Allele", "location": {"id": "ga4gh:SL.v49CEsmpXzpqqDo9j07qHUhf597WMTPC", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.0dtDG7QKyvW7BntvQVpLS83mYRA58LKH"}, "start": 841, "end": 842}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "civic.tid:260", "label": "Lestaurtinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C48402"}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C48402"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["9,12-Epoxy-1H-diindolo(1,2,3-fg:3',2',1'-kl)pyrrolo(3,4-i)(1,6)benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9S,10S,12R)-", "CEP-701", "KT-5555", "SPM-924"]}, "tumorType": {"id": "civic.did:3", "label": "Acute Myeloid Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3171"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9119"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:12", "description": "A375 cells expressing MAP2K1 P124S mutation conferred an approximately 5-fold increased resistance to selumetinib (AZD6244) induced growth inhibition when compared to untransduced cells, cells expressing wild-type MAP2K1 or cells expressing a constitutively active form. This mutation also attenuated pERK inhibition by selumetinib in these cells.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:58", "label": "Emery et al., 2009, Proc. Natl. Acad. Sci. U.S.A.", "type": "Document", "title": "PubMed: Emery et al., 2009, Proc. Natl. Acad. Sci. U.S.A.", "pmid": 19915144}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:31", "label": "MAP2K1", "description": "MAP2K1 is a dual-specificity kinase known for it's involvement in the ERK pathway by activation of ERK1 and ERK2. MAP2K1 activating mutations have been observed in a number of cancers including ovarian,  melanoma and lung. These activating mutations are generally found in the N-terminal negative regulatory region or the ATP-binding region of the N-terminal lobe.  Inhibitors of MEK genes have been shown to inhibit tumor growth in these cases.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6840"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5604"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CFC3", "MAP2K1", "MAPKK1", "MEK1", "MEL", "MKK1", "PRKMK1"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:82", "label": "MAP2K1 P124S", "description": "MAP2K1 P124S is a recurrent mutation in melanoma, and is seen in bladder and colon cancer to a lesser degree. The P124S mutation has been shown to contribute to AZD6244 resistance in melanoma cell lines, but considerably less so than its Q56P counterpart.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 3.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000307102.5", "chromosome": "15", "start": 66729162, "stop": 66729162, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "82"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602456"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "375981"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["PRO124SER"], "members": [{"id": "ga4gh:VA.F09xajG--KAkKrLSqY3GbzhBDLlDBgID", "label": "NC_000015.9:g.66729162C>T", "digest": "F09xajG--KAkKrLSqY3GbzhBDLlDBgID", "type": "Allele", "location": {"id": "ga4gh:SL.Pk1thHNDxot9-SgtZhzN97zfsItapgY4", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.AsXvWL1-2i5U_buw6_niVIxD6zTbAuS6"}, "start": 66436823, "end": 66436824}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.njz7hubZZ60U9GYC7GAeufZZ4gnoHdEu", "label": "P124S", "digest": "njz7hubZZ60U9GYC7GAeufZZ4gnoHdEu", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000307102.5:c.370C>T"}, {"syntax": "hgvs.g", "value": "NC_000015.9:g.66729162C>T"}, {"syntax": "hgvs.c", "value": "NM_002755.3:c.370C>T"}, {"syntax": "hgvs.p", "value": "NP_002746.1:p.Pro124Ser"}], "location": {"id": "ga4gh:SL.bJ_6m5x0EDWRN2YnyhcXXOcSmmaS2g1D", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.StlJo3M4b8cS253ufe9nPpWqQHBDOSPs"}, "start": 123, "end": 124}, "state": {"type": "LiteralSequenceExpression", "sequence": "S"}}}, "therapeutic": {"id": "civic.tid:63", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:2289380"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C66939"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["ARRY-142886", "AZD6244", "MEK Inhibitor AZD6244"]}, "tumorType": {"id": "civic.did:7", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3224"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1909"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:13", "description": "A375 cells expressing MAP2K1 Q56P mutation conferred an approximately 100-fold increased resistance to selumetinib (AZD6244) induced growth inhibition when compared to untransduced cells, cells expressing wild-type MAP2K1, or cells expressing a constitutively active form. This mutation also attenuated pERK inhibition by selumetinib in these cells.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:58", "label": "Emery et al., 2009, Proc. Natl. Acad. Sci. U.S.A.", "type": "Document", "title": "PubMed: Emery et al., 2009, Proc. Natl. Acad. Sci. U.S.A.", "pmid": 19915144}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:31", "label": "MAP2K1", "description": "MAP2K1 is a dual-specificity kinase known for it's involvement in the ERK pathway by activation of ERK1 and ERK2. MAP2K1 activating mutations have been observed in a number of cancers including ovarian,  melanoma and lung. These activating mutations are generally found in the N-terminal negative regulatory region or the ATP-binding region of the N-terminal lobe.  Inhibitors of MEK genes have been shown to inhibit tumor growth in these cases.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6840"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5604"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CFC3", "MAP2K1", "MAPKK1", "MEK1", "MEL", "MKK1", "PRKMK1"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:83", "label": "MAP2K1 Q56P", "description": "MAP2K1 Q56P is a recurrent mutation in melanoma and gastric cancer. This mutation has been shown to confer considerable resistance to AZD6244 treatment of melanoma cell lines.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 3.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "C", "representative_transcript": "ENST00000307102.5", "chromosome": "15", "start": 66727451, "stop": 66727451, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "83"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602453"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "375978"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLN56PRO"], "members": [{"id": "ga4gh:VA.Lt3qHSMi3ikqiU8QcxPPZa1PaVO6hUTc", "label": "NC_000015.9:g.66727451A>C", "digest": "Lt3qHSMi3ikqiU8QcxPPZa1PaVO6hUTc", "type": "Allele", "location": {"id": "ga4gh:SL.jaMTAD_Y79dyzGBYXUIH2WMeQtFslUxY", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.AsXvWL1-2i5U_buw6_niVIxD6zTbAuS6"}, "start": 66435112, "end": 66435113}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.1UWRQGqaZI7G0ECXWsKXmqj6agf8ntK5", "label": "Q56P", "digest": "1UWRQGqaZI7G0ECXWsKXmqj6agf8ntK5", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000307102.5:c.167A>C"}, {"syntax": "hgvs.g", "value": "NC_000015.9:g.66727451A>C"}, {"syntax": "hgvs.c", "value": "NM_002755.3:c.167A>C"}, {"syntax": "hgvs.p", "value": "NP_002746.1:p.Gln56Pro"}], "location": {"id": "ga4gh:SL.gD9dUrbXEr7Mtg5oc46vshtPFN0N33aW", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.StlJo3M4b8cS253ufe9nPpWqQHBDOSPs"}, "start": 55, "end": 56}, "state": {"type": "LiteralSequenceExpression", "sequence": "P"}}}, "therapeutic": {"id": "civic.tid:63", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:2289380"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C66939"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["ARRY-142886", "AZD6244", "MEK Inhibitor AZD6244"]}, "tumorType": {"id": "civic.did:7", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3224"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1909"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:20", "description": "TG101348 effectively inhibits STAT5 signaling in JAK2 V617F cells.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:65", "label": "Wernig et al., 2008, Cancer Cell", "type": "Document", "title": "PubMed: Wernig et al., 2008, Cancer Cell", "pmid": 18394554}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:28", "label": "JAK2", "description": "JAK2 is a kinase that is misregulated or mutated in a number of myeloproliferative diseases and cancers. The mutation V617F is the most clinically relevant variant, and is seen in around half of myeloproliferative disorders. The variant is a known activating mutation, and activated JAK2 is sufficient to drive myeloproliferative disorders in mouse models. V617F, while most recurrent, is not the only mechanism by which JAK2 can be activated in patients. JAK2 is now one of the first diagnostic markers tested upon diagnosis with a myeloproliferative disorder.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6192"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3717"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["JAK2", "JTK10"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:64", "label": "JAK2 V617F", "description": "JAK2 V617F is a highly recurrent mutation in myeloproliferative diseases. It is found in around 98% of patients with polycythemia vera, and just over half of the patients with essential thrombocythemia and primary myelofibrosis. While less associated with cancer, when it is seen, it is more likely to be in myeloid leukemias than lymphoid leukemias. The V617F mutation is an activating mutation, resulting in increased kinase activity. The mutation seems to be restricted to hematologic malignancies. Treatment of JAK mutant diseases with ruxolitinib has seen some clinical success.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 103.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "T", "representative_transcript": "ENST00000381652.3", "chromosome": "9", "start": 5073770, "stop": 5073770, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}, {"label": "gain_of_function_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0002053"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "64"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA124183"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "14662"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS77375493"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["VAL617PHE", "RS77375493"], "members": [{"id": "ga4gh:VA.JqSAq9kDz_jPpo6tO2tUA5O3qI_uGqO6", "label": "NC_000009.11:g.5073770G>T", "digest": "JqSAq9kDz_jPpo6tO2tUA5O3qI_uGqO6", "type": "Allele", "location": {"id": "ga4gh:SL.Q63BDR9AqGifLedv3GSuxkv2BQ4eM4bd", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.KEO-4XBcm1cxeo_DIQ8_ofqGUkp4iZhI"}, "start": 5073769, "end": 5073770}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.hl9CoYsN5bzvyKb-7Nc_sUCs_0oe6Xvp", "label": "V617F", "digest": "hl9CoYsN5bzvyKb-7Nc_sUCs_0oe6Xvp", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000009.11:g.5073770G>T"}, {"syntax": "hgvs.c", "value": "NM_004972.3:c.1849G>T"}, {"syntax": "hgvs.p", "value": "NP_004963.1:p.Val617Phe"}, {"syntax": "hgvs.c", "value": "ENST00000381652.3:c.1849G>T"}], "location": {"id": "ga4gh:SL.vxtxGvjTqkluBrNMEnr2fuAu5Ej1qGtO", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.-OkqBNmqypFmiUe8izaIgIwkeOz5Z__6"}, "start": 616, "end": 617}, "state": {"type": "LiteralSequenceExpression", "sequence": "F"}}}, "therapeutic": {"id": "civic.tid:9", "label": "Fedratinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:2197490"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C88293"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["Benzenesulfonamide, N-(1,1-dimethylethyl)-3-((5-methyl-2-((4-(2-(1-pyrrolidinyl)ethoxy)phenyl)amino)-4-pyrimidinyl)amino)-", "SAR302503", "TG101348"]}, "tumorType": {"id": "civic.did:9", "label": "Polycythemia Vera", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3336"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:8997"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:32", "description": "Ba/F3 cells expressing the RANBP2-ALK fusion containing an F1174L mutation were more resistant to crizotinib treatment than Ba/F3 cells expressing RANBP2-ALK without this mutation.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:73", "label": "Sasaki et al., 2010, Cancer Res.", "type": "Document", "title": "PubMed: Sasaki et al., 2010, Cancer Res.", "pmid": 21030459}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:1", "label": "ALK", "description": "ALK amplifications, fusions and mutations have been shown to be driving events in non-small cell lung cancer. While crizontinib has demonstrated efficacy in treating the amplification, mutations in ALK have been shown to confer resistance to current tyrosine kinase inhibitors. Second-generation TKI's have seen varied success in treating these resistant cases, and the HSP90 inhibitor 17-AAG has been shown to be cytostatic in ALK-altered cell lines.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:427"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:238"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["ALK", "ALK1", "CD246", "NBLST3"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:8", "label": "ALK F1174L", "description": "ALK F1174L has been observed as recurrent in neuroblastoma, non-small cell lung cancer (NSCLC), and other cancer types. Neuroblastoma cells containing this mutation have shown resistance to low doses of criztonib. However, increased dosage can overcome this resistance in cell lines studies. TAE684 has also proven effective in both NSCLC and neuroblastoma F1174L containing cells.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 33.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "T", "representative_transcript": "ENST00000389048.3", "chromosome": "2", "start": 29443695, "stop": 29443695, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "8"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA279586"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "217851"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS863225281"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["PHE1174LEU", "RS863225281"], "members": [{"id": "ga4gh:VA.ivl5YUYPCfDa2igYKGlCTZec5eKC7oYY", "label": "NC_000002.11:g.29443695G>T", "digest": "ivl5YUYPCfDa2igYKGlCTZec5eKC7oYY", "type": "Allele", "location": {"id": "ga4gh:SL.Nn_joIP_IBbU0SOamVk3VuamNXOVBxPt", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.pnAqCRBrTsUoBghSD1yp_jXWSmlbdh4g"}, "start": 29220828, "end": 29220829}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.nTPnpFtWudqItR2YaGBsaJwRgGobSWAr", "label": "F1174L", "digest": "nTPnpFtWudqItR2YaGBsaJwRgGobSWAr", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004304.4:c.3522C>A"}, {"syntax": "hgvs.p", "value": "NP_004295.2:p.Phe1174Leu"}, {"syntax": "hgvs.g", "value": "NC_000002.11:g.29443695G>T"}, {"syntax": "hgvs.c", "value": "ENST00000389048.3:c.3522C>A"}], "location": {"id": "ga4gh:SL.n1vbI2DGWZjLWoNdaUdc1ISSHenlCMar", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.q9CnK-HKWh9eqhOi8FlzR7M0pCmUrWPs"}, "start": 1173, "end": 1174}, "state": {"type": "LiteralSequenceExpression", "sequence": "L"}}}, "therapeutic": {"id": "civic.tid:12", "label": "Crizotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1148495"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:25958", "type": "Disease", "label": "Anaplastic large cell lymphoma pediatric"}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C74061"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine", "2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-", "MET Tyrosine Kinase Inhibitor PF-02341066", "PF-02341066", "PF-2341066", "Xalkori"]}, "tumorType": {"id": "civic.did:12", "label": "Inflammatory Myofibroblastic Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C6481"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:0050905"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:33", "description": "Ba/F3 cells expressing the EML4-ALK fusion containing an F1174L mutation were more resistant to crizotinib treatment than Ba/F3 cells expressing EML4-ALK without this mutation.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:73", "label": "Sasaki et al., 2010, Cancer Res.", "type": "Document", "title": "PubMed: Sasaki et al., 2010, Cancer Res.", "pmid": 21030459}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:1", "label": "ALK", "description": "ALK amplifications, fusions and mutations have been shown to be driving events in non-small cell lung cancer. While crizontinib has demonstrated efficacy in treating the amplification, mutations in ALK have been shown to confer resistance to current tyrosine kinase inhibitors. Second-generation TKI's have seen varied success in treating these resistant cases, and the HSP90 inhibitor 17-AAG has been shown to be cytostatic in ALK-altered cell lines.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:427"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:238"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["ALK", "ALK1", "CD246", "NBLST3"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:8", "label": "ALK F1174L", "description": "ALK F1174L has been observed as recurrent in neuroblastoma, non-small cell lung cancer (NSCLC), and other cancer types. Neuroblastoma cells containing this mutation have shown resistance to low doses of criztonib. However, increased dosage can overcome this resistance in cell lines studies. TAE684 has also proven effective in both NSCLC and neuroblastoma F1174L containing cells.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 33.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "T", "representative_transcript": "ENST00000389048.3", "chromosome": "2", "start": 29443695, "stop": 29443695, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "8"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA279586"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "217851"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS863225281"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["PHE1174LEU", "RS863225281"], "members": [{"id": "ga4gh:VA.ivl5YUYPCfDa2igYKGlCTZec5eKC7oYY", "label": "NC_000002.11:g.29443695G>T", "digest": "ivl5YUYPCfDa2igYKGlCTZec5eKC7oYY", "type": "Allele", "location": {"id": "ga4gh:SL.Nn_joIP_IBbU0SOamVk3VuamNXOVBxPt", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.pnAqCRBrTsUoBghSD1yp_jXWSmlbdh4g"}, "start": 29220828, "end": 29220829}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.nTPnpFtWudqItR2YaGBsaJwRgGobSWAr", "label": "F1174L", "digest": "nTPnpFtWudqItR2YaGBsaJwRgGobSWAr", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004304.4:c.3522C>A"}, {"syntax": "hgvs.p", "value": "NP_004295.2:p.Phe1174Leu"}, {"syntax": "hgvs.g", "value": "NC_000002.11:g.29443695G>T"}, {"syntax": "hgvs.c", "value": "ENST00000389048.3:c.3522C>A"}], "location": {"id": "ga4gh:SL.n1vbI2DGWZjLWoNdaUdc1ISSHenlCMar", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.q9CnK-HKWh9eqhOi8FlzR7M0pCmUrWPs"}, "start": 1173, "end": 1174}, "state": {"type": "LiteralSequenceExpression", "sequence": "L"}}}, "therapeutic": {"id": "civic.tid:12", "label": "Crizotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1148495"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:25958", "type": "Disease", "label": "Anaplastic large cell lymphoma pediatric"}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C74061"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine", "2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-", "MET Tyrosine Kinase Inhibitor PF-02341066", "PF-02341066", "PF-2341066", "Xalkori"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:37", "description": "CH5424802 (Alectinib) is effective in inhibiting the activity of the F1174L ALK mutant in a kinase activity assay and proliferation assay using neuroblastoma KELLY cells.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:77", "label": "Sakamoto et al., 2011, Cancer Cell", "type": "Document", "title": "PubMed: Sakamoto et al., 2011, Cancer Cell", "pmid": 21575866}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:1", "label": "ALK", "description": "ALK amplifications, fusions and mutations have been shown to be driving events in non-small cell lung cancer. While crizontinib has demonstrated efficacy in treating the amplification, mutations in ALK have been shown to confer resistance to current tyrosine kinase inhibitors. Second-generation TKI's have seen varied success in treating these resistant cases, and the HSP90 inhibitor 17-AAG has been shown to be cytostatic in ALK-altered cell lines.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:427"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:238"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["ALK", "ALK1", "CD246", "NBLST3"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:8", "label": "ALK F1174L", "description": "ALK F1174L has been observed as recurrent in neuroblastoma, non-small cell lung cancer (NSCLC), and other cancer types. Neuroblastoma cells containing this mutation have shown resistance to low doses of criztonib. However, increased dosage can overcome this resistance in cell lines studies. TAE684 has also proven effective in both NSCLC and neuroblastoma F1174L containing cells.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 33.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "T", "representative_transcript": "ENST00000389048.3", "chromosome": "2", "start": 29443695, "stop": 29443695, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "8"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA279586"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "217851"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS863225281"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["PHE1174LEU", "RS863225281"], "members": [{"id": "ga4gh:VA.ivl5YUYPCfDa2igYKGlCTZec5eKC7oYY", "label": "NC_000002.11:g.29443695G>T", "digest": "ivl5YUYPCfDa2igYKGlCTZec5eKC7oYY", "type": "Allele", "location": {"id": "ga4gh:SL.Nn_joIP_IBbU0SOamVk3VuamNXOVBxPt", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.pnAqCRBrTsUoBghSD1yp_jXWSmlbdh4g"}, "start": 29220828, "end": 29220829}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.nTPnpFtWudqItR2YaGBsaJwRgGobSWAr", "label": "F1174L", "digest": "nTPnpFtWudqItR2YaGBsaJwRgGobSWAr", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004304.4:c.3522C>A"}, {"syntax": "hgvs.p", "value": "NP_004295.2:p.Phe1174Leu"}, {"syntax": "hgvs.g", "value": "NC_000002.11:g.29443695G>T"}, {"syntax": "hgvs.c", "value": "ENST00000389048.3:c.3522C>A"}], "location": {"id": "ga4gh:SL.n1vbI2DGWZjLWoNdaUdc1ISSHenlCMar", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.q9CnK-HKWh9eqhOi8FlzR7M0pCmUrWPs"}, "start": 1173, "end": 1174}, "state": {"type": "LiteralSequenceExpression", "sequence": "L"}}}, "therapeutic": {"id": "civic.tid:17", "label": "Alectinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1727455"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C101790"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["5H-benzo(b)carbazole-3-carbonitrile, 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-(4-(4-morpholinyl)-1-piperidinyl)-11-oxo-", "AF-802", "AF802", "ALK Inhibitor RO5424802", "Alecensa", "CH5424802", "RG7853", "RO5424802"]}, "tumorType": {"id": "civic.did:13", "label": "Neuroblastoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3270"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:769"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:38", "description": "High levels of crizotinib can overcome drug resistance of Ba/F3 cells expressing the EML4-ALK fusion containing the F1174L mutation.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:78", "label": "Heuckmann et al., 2011, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Heuckmann et al., 2011, Clin. Cancer Res.", "pmid": 21948233}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:1", "label": "ALK", "description": "ALK amplifications, fusions and mutations have been shown to be driving events in non-small cell lung cancer. While crizontinib has demonstrated efficacy in treating the amplification, mutations in ALK have been shown to confer resistance to current tyrosine kinase inhibitors. Second-generation TKI's have seen varied success in treating these resistant cases, and the HSP90 inhibitor 17-AAG has been shown to be cytostatic in ALK-altered cell lines.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:427"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:238"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["ALK", "ALK1", "CD246", "NBLST3"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:8", "label": "ALK F1174L", "description": "ALK F1174L has been observed as recurrent in neuroblastoma, non-small cell lung cancer (NSCLC), and other cancer types. Neuroblastoma cells containing this mutation have shown resistance to low doses of criztonib. However, increased dosage can overcome this resistance in cell lines studies. TAE684 has also proven effective in both NSCLC and neuroblastoma F1174L containing cells.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 33.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "T", "representative_transcript": "ENST00000389048.3", "chromosome": "2", "start": 29443695, "stop": 29443695, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "8"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA279586"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "217851"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS863225281"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["PHE1174LEU", "RS863225281"], "members": [{"id": "ga4gh:VA.ivl5YUYPCfDa2igYKGlCTZec5eKC7oYY", "label": "NC_000002.11:g.29443695G>T", "digest": "ivl5YUYPCfDa2igYKGlCTZec5eKC7oYY", "type": "Allele", "location": {"id": "ga4gh:SL.Nn_joIP_IBbU0SOamVk3VuamNXOVBxPt", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.pnAqCRBrTsUoBghSD1yp_jXWSmlbdh4g"}, "start": 29220828, "end": 29220829}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.nTPnpFtWudqItR2YaGBsaJwRgGobSWAr", "label": "F1174L", "digest": "nTPnpFtWudqItR2YaGBsaJwRgGobSWAr", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004304.4:c.3522C>A"}, {"syntax": "hgvs.p", "value": "NP_004295.2:p.Phe1174Leu"}, {"syntax": "hgvs.g", "value": "NC_000002.11:g.29443695G>T"}, {"syntax": "hgvs.c", "value": "ENST00000389048.3:c.3522C>A"}], "location": {"id": "ga4gh:SL.n1vbI2DGWZjLWoNdaUdc1ISSHenlCMar", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.q9CnK-HKWh9eqhOi8FlzR7M0pCmUrWPs"}, "start": 1173, "end": 1174}, "state": {"type": "LiteralSequenceExpression", "sequence": "L"}}}, "therapeutic": {"id": "civic.tid:12", "label": "Crizotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1148495"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:25958", "type": "Disease", "label": "Anaplastic large cell lymphoma pediatric"}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C74061"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine", "2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-", "MET Tyrosine Kinase Inhibitor PF-02341066", "PF-02341066", "PF-2341066", "Xalkori"]}, "tumorType": {"id": "civic.did:13", "label": "Neuroblastoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3270"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:769"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:39", "description": "TAE684 inhibits growth of Ba/F3 cells expressing ALK mutations; however, cells with the R1275Q mutation were inhibited at a higher IC50 than those expressing F1174L.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:79", "label": "George et al., 2008, Nature", "type": "Document", "title": "PubMed: George et al., 2008, Nature", "pmid": 18923525}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:1", "label": "ALK", "description": "ALK amplifications, fusions and mutations have been shown to be driving events in non-small cell lung cancer. While crizontinib has demonstrated efficacy in treating the amplification, mutations in ALK have been shown to confer resistance to current tyrosine kinase inhibitors. Second-generation TKI's have seen varied success in treating these resistant cases, and the HSP90 inhibitor 17-AAG has been shown to be cytostatic in ALK-altered cell lines.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:427"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:238"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["ALK", "ALK1", "CD246", "NBLST3"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:9", "label": "ALK R1275Q", "description": "ALK R1275Q has been observed as a recurrent mutation in  neuroblastoma, non-small cell lung cancer (NSCLC), as well as other cancer types. Neuroblastoma cells with this mutation have shown sensitivity to the ALK-inhibitor TAE684. This and the geldanamycin deriviative 17-DMAG have been shown to be effective in NSCLC cell lines.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 23.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000389048.3", "chromosome": "2", "start": 29432664, "stop": 29432664, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "9"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA341482"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "18083"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS113994087"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS113994087", "ARG1275GLN"], "members": [{"id": "ga4gh:VA.t3vU-1OKU2n8Hp6J5zIgf-fdOngWPcJI", "label": "NC_000002.11:g.29432664C>T", "digest": "t3vU-1OKU2n8Hp6J5zIgf-fdOngWPcJI", "type": "Allele", "location": {"id": "ga4gh:SL.-qNrY8pBD7rUqlnqrgBF-ZRDSEJspR0m", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.pnAqCRBrTsUoBghSD1yp_jXWSmlbdh4g"}, "start": 29209797, "end": 29209798}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.gX5hniEm7ni0BSgk4ACRN6yU5ARPwd1n", "label": "R1275Q", "digest": "gX5hniEm7ni0BSgk4ACRN6yU5ARPwd1n", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004304.4:c.3824G>A"}, {"syntax": "hgvs.p", "value": "NP_004295.2:p.Arg1275Gln"}, {"syntax": "hgvs.g", "value": "NC_000002.11:g.29432664C>T"}, {"syntax": "hgvs.c", "value": "ENST00000389048.3:c.3824G>A"}], "location": {"id": "ga4gh:SL.zbNZWCvHj679lMb2bPXhsYkuglQbHXmT", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.q9CnK-HKWh9eqhOi8FlzR7M0pCmUrWPs"}, "start": 1274, "end": 1275}, "state": {"type": "LiteralSequenceExpression", "sequence": "Q"}}}, "therapeutic": {"id": "civic.tid:18", "label": "TAE684", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C171615"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:13", "label": "Neuroblastoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3270"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:769"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:40", "description": "Sorafenib can inhibit ARF-mediated MEK phosphorylation and soft agar colony formation of AALE cells expressing ARAF S214C in vitro.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:6", "label": "Imielinski et al., 2014, J. Clin. Invest.", "type": "Document", "title": "PubMed: Imielinski et al., 2014, J. Clin. Invest.", "pmid": 24569458}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:3", "label": "ARAF", "description": "ARAF has recently become increasingly considered for its oncogenic potential. Its potential as a target for informing clinical action was demonstrated by a single case of advanced lung adenocarcinoma harboring an S214C mutation that, when treated with sorafenib, acheived near-complete clinical remission. This finding has brought new focus on ARAF as a marker that should be assayed for in cancer treatment.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:646"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:369"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["A-RAF", "ARAF", "ARAF1", "PKS2", "RAFA1"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:10", "label": "ARAF S214C", "description": "ARAF S214C has been found to be a recurrent oncogenic mutation in non-small cell lung cancer. It has been shown to confer sensitivity to sorafenib and trametenib in cell lines. In a case study of advanced stage lung adenocarcinoma harboring this mutation, sorafenib also acheived near-complete clinical remission. This case has brought more interest to the variant from a research and clinical perspective.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 14.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "G", "representative_transcript": "ENST00000377045.4", "chromosome": "X", "start": 47426121, "stop": 47426121, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "10"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602595"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376137"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS1057519786"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["SER214CYS", "RS1057519786"], "members": [{"id": "ga4gh:VA.iS-EX0f5LOqsa0vLfz5koLPOY2J8iimH", "label": "NC_000023.10:g.47426121C>G", "digest": "iS-EX0f5LOqsa0vLfz5koLPOY2J8iimH", "type": "Allele", "location": {"id": "ga4gh:SL.I48cKOrIIUt0O4UbzkNapyx8qDxIvS-k", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.w0WZEvgJF0zf_P4yyTzjjv9oW1z61HHP"}, "start": 47566721, "end": 47566722}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.0XRP9ec08nseaod7LSuyfLDce-hpvEfm", "label": "S214C", "digest": "0XRP9ec08nseaod7LSuyfLDce-hpvEfm", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000023.10:g.47426121C>G"}, {"syntax": "hgvs.c", "value": "NM_001654.4:c.641C>G"}, {"syntax": "hgvs.p", "value": "NP_001645.1:p.Ser214Cys"}, {"syntax": "hgvs.c", "value": "ENST00000377045.4:c.641C>G"}], "location": {"id": "ga4gh:SL.aLNS5vmoCkYAlgAlZOUGVDsai7ucgVL1", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.zWUEijoFMvm7vDgj6af1ZwwBERSNnm4a"}, "start": 213, "end": 214}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "civic.tid:6", "label": "Sorafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:495881"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:65823", "type": "Disease", "label": "Thyroid cancer differentiated"}, {"id": "hemonc:612", "type": "Disease", "label": "Hepatocellular carcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C3099"}, "relation": "relatedMatch"}]}, {"id": "hemonc:660", "type": "Disease", "label": "Renal cell carcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C9385"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C61948"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["BA4 43 9006", "BAY 43-9006", "Bay-439006"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:41", "description": "Trametinib can inhibit ARF-mediated ERK phosphorylation and soft agar colony formation of AALE cells expressing ARAF S214C in vitro.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:6", "label": "Imielinski et al., 2014, J. Clin. Invest.", "type": "Document", "title": "PubMed: Imielinski et al., 2014, J. Clin. Invest.", "pmid": 24569458}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:3", "label": "ARAF", "description": "ARAF has recently become increasingly considered for its oncogenic potential. Its potential as a target for informing clinical action was demonstrated by a single case of advanced lung adenocarcinoma harboring an S214C mutation that, when treated with sorafenib, acheived near-complete clinical remission. This finding has brought new focus on ARAF as a marker that should be assayed for in cancer treatment.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:646"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:369"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["A-RAF", "ARAF", "ARAF1", "PKS2", "RAFA1"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:10", "label": "ARAF S214C", "description": "ARAF S214C has been found to be a recurrent oncogenic mutation in non-small cell lung cancer. It has been shown to confer sensitivity to sorafenib and trametenib in cell lines. In a case study of advanced stage lung adenocarcinoma harboring this mutation, sorafenib also acheived near-complete clinical remission. This case has brought more interest to the variant from a research and clinical perspective.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 14.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "G", "representative_transcript": "ENST00000377045.4", "chromosome": "X", "start": 47426121, "stop": 47426121, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "10"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602595"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376137"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS1057519786"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["SER214CYS", "RS1057519786"], "members": [{"id": "ga4gh:VA.iS-EX0f5LOqsa0vLfz5koLPOY2J8iimH", "label": "NC_000023.10:g.47426121C>G", "digest": "iS-EX0f5LOqsa0vLfz5koLPOY2J8iimH", "type": "Allele", "location": {"id": "ga4gh:SL.I48cKOrIIUt0O4UbzkNapyx8qDxIvS-k", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.w0WZEvgJF0zf_P4yyTzjjv9oW1z61HHP"}, "start": 47566721, "end": 47566722}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.0XRP9ec08nseaod7LSuyfLDce-hpvEfm", "label": "S214C", "digest": "0XRP9ec08nseaod7LSuyfLDce-hpvEfm", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000023.10:g.47426121C>G"}, {"syntax": "hgvs.c", "value": "NM_001654.4:c.641C>G"}, {"syntax": "hgvs.p", "value": "NP_001645.1:p.Ser214Cys"}, {"syntax": "hgvs.c", "value": "ENST00000377045.4:c.641C>G"}], "location": {"id": "ga4gh:SL.aLNS5vmoCkYAlgAlZOUGVDsai7ucgVL1", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.zWUEijoFMvm7vDgj6af1ZwwBERSNnm4a"}, "start": 213, "end": 214}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "civic.tid:19", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1425098"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C77908"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["GSK1120212", "JTP-74057", "MEK Inhibitor GSK1120212", "Mekinist", "N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:42", "description": "The melanoma cell line WM3211, which harbors the L576P mutation, is sensitive to dasatinib. Molecular modeling indicated the L576P mutation alters the conformation of KIT but did not alter the binding affinity of dasatinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:74", "label": "Woodman et al., 2009, Mol. Cancer Ther.", "type": "Document", "title": "PubMed: Woodman et al., 2009, Mol. Cancer Ther.", "pmid": 19671763}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:29", "label": "KIT", "description": "c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3815"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["C-Kit", "CD117", "KIT", "MASTC", "PBT", "SCFR"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:72", "label": "KIT L576P", "description": "KIT L576P is an exon 11 mutation that lies within the juxtamembrane domain. It is one of the most recurrent KIT mutations in melanoma, and both in vitro and in vivo studies have shown sensitivity to imatinib.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 16.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "C", "representative_transcript": "ENST00000288135.5", "chromosome": "4", "start": 55593661, "stop": 55593661, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "72"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602401"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "375919"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913513"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913513", "LEU576PRO"], "members": [{"id": "ga4gh:VA.cDfuVZGVVrXoZw4OCMvPzRoE-wmxPCe7", "label": "NC_000004.11:g.55593661T>C", "digest": "cDfuVZGVVrXoZw4OCMvPzRoE-wmxPCe7", "type": "Allele", "location": {"id": "ga4gh:SL.L4ctgq33nZK-3qpkyZ3AGmnjLX5oDTT3", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54727494, "end": 54727495}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.HWknWoV4xcSvDuWAAwCjl8LfzvkYKaur", "label": "L576P", "digest": "HWknWoV4xcSvDuWAAwCjl8LfzvkYKaur", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_000222.2:c.1727T>C"}, {"syntax": "hgvs.p", "value": "NP_000213.1:p.Leu576Pro"}, {"syntax": "hgvs.c", "value": "ENST00000288135.5:c.1727T>C"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55593661T>C"}], "location": {"id": "ga4gh:SL.CsgoOC4XNjQhj2UDGEcredbnxi0kTV5V", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 575, "end": 576}, "state": {"type": "LiteralSequenceExpression", "sequence": "P"}}}, "therapeutic": {"id": "civic.tid:20", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1546019"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C38713"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate", "BMS-354825", "Dasatinib Hydrate", "Dasatinib Monohydrate", "Sprycel"]}, "tumorType": {"id": "civic.did:7", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3224"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1909"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:46", "description": "In CHO cells with the PDGFRA deletion I843 mutation that have shown imatinib sensitivity, crenolanib showed no significant difference from imatinib in kinase activity inhibition.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:80", "label": "Heinrich et al., 2012, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Heinrich et al., 2012, Clin. Cancer Res.", "pmid": 22745105}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:38", "label": "PDGFRA", "description": "Commonly mutated in GI tract tumors, PDGFR family genes (mutually exclusive to KIT mutations) are a hallmark of gastrointestinal stromal tumors. Gene fusions involving the PDGFRA kinase domain are highly correlated with eosinophilia, and the WHO classifies myeloid and lymphoid neoplasms with these characteristics as a distinct disorder. Mutations in the 842 region of PDGFRA have been often found to confer resistance to the tyrosine kinase inhibitor, imatinib.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8803"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5156"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD140A", "PDGFR-2", "PDGFR2", "PDGFRA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:101", "label": "PDGFRA I843DEL", "description": "PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 5.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "ATC", "representative_transcript": "ENST00000257290.5", "chromosome": "4", "start": 55152095, "stop": 55152097, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "inframe_deletion", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001822"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "101"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA645526434"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["DELI843"], "members": [{"id": "ga4gh:VA.KY9h0Q9COGvfRX97m5HCWt82wDRxf5Wv", "label": "NC_000004.11:g.55152095_55152097del", "digest": "KY9h0Q9COGvfRX97m5HCWt82wDRxf5Wv", "type": "Allele", "location": {"id": "ga4gh:SL.EPTSjHG051j9PTTFFPy2b3yd8lATyfCL", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54285926, "end": 54285932}, "state": {"type": "ReferenceLengthExpression", "length": 3, "sequence": "CAT", "repeatSubunitLength": 3}}], "definingContext": {"id": "ga4gh:VA.PUuPMPVN95EbZEIqc7U026NTR8THV8mm", "label": "I843DEL", "digest": "PUuPMPVN95EbZEIqc7U026NTR8THV8mm", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000257290.5:c.2527_2529delATC"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55152095_55152097del"}], "location": {"id": "ga4gh:SL.Mr44tA-ZG7AzeOHLln6_o7wjOU4cz01i", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.XpQn9sZLGv_GU3uiWO7YHq9-_alGjrVX"}, "start": 842, "end": 845}, "state": {"type": "LiteralSequenceExpression", "sequence": "DEL"}}}, "therapeutic": {"id": "civic.tid:21", "label": "Crenolanib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C64639"}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64639"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-Piperidinamine, 1-[2-[5-[(3-methyl-3-oxetanyl)methoxy]-1Hbenzimidazol-1-yl]-8-quinolinyl]-", "CP-868,596", "CP-868596", "PDGFR Inhibitor CP-868596", "[1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine"]}, "tumorType": {"id": "civic.did:2", "label": "Gastrointestinal Stromal Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3868"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9253"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:48", "description": "The SMS-KCNR cell line harboring the R1275Q mutation was resistant to TAE684.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:79", "label": "George et al., 2008, Nature", "type": "Document", "title": "PubMed: George et al., 2008, Nature", "pmid": 18923525}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:1", "label": "ALK", "description": "ALK amplifications, fusions and mutations have been shown to be driving events in non-small cell lung cancer. While crizontinib has demonstrated efficacy in treating the amplification, mutations in ALK have been shown to confer resistance to current tyrosine kinase inhibitors. Second-generation TKI's have seen varied success in treating these resistant cases, and the HSP90 inhibitor 17-AAG has been shown to be cytostatic in ALK-altered cell lines.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:427"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:238"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["ALK", "ALK1", "CD246", "NBLST3"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:9", "label": "ALK R1275Q", "description": "ALK R1275Q has been observed as a recurrent mutation in  neuroblastoma, non-small cell lung cancer (NSCLC), as well as other cancer types. Neuroblastoma cells with this mutation have shown sensitivity to the ALK-inhibitor TAE684. This and the geldanamycin deriviative 17-DMAG have been shown to be effective in NSCLC cell lines.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 23.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000389048.3", "chromosome": "2", "start": 29432664, "stop": 29432664, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "9"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA341482"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "18083"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS113994087"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS113994087", "ARG1275GLN"], "members": [{"id": "ga4gh:VA.t3vU-1OKU2n8Hp6J5zIgf-fdOngWPcJI", "label": "NC_000002.11:g.29432664C>T", "digest": "t3vU-1OKU2n8Hp6J5zIgf-fdOngWPcJI", "type": "Allele", "location": {"id": "ga4gh:SL.-qNrY8pBD7rUqlnqrgBF-ZRDSEJspR0m", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.pnAqCRBrTsUoBghSD1yp_jXWSmlbdh4g"}, "start": 29209797, "end": 29209798}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.gX5hniEm7ni0BSgk4ACRN6yU5ARPwd1n", "label": "R1275Q", "digest": "gX5hniEm7ni0BSgk4ACRN6yU5ARPwd1n", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004304.4:c.3824G>A"}, {"syntax": "hgvs.p", "value": "NP_004295.2:p.Arg1275Gln"}, {"syntax": "hgvs.g", "value": "NC_000002.11:g.29432664C>T"}, {"syntax": "hgvs.c", "value": "ENST00000389048.3:c.3824G>A"}], "location": {"id": "ga4gh:SL.zbNZWCvHj679lMb2bPXhsYkuglQbHXmT", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.q9CnK-HKWh9eqhOi8FlzR7M0pCmUrWPs"}, "start": 1274, "end": 1275}, "state": {"type": "LiteralSequenceExpression", "sequence": "Q"}}}, "therapeutic": {"id": "civic.tid:18", "label": "TAE684", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C171615"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:13", "label": "Neuroblastoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3270"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:769"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:75", "description": "Medullary thyroid cancer cells with RET C634W mutation are insensitive to motesanib, compared to wild-type RET.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:90", "label": "Coxon et al., 2012, J. Endocrinol. Invest.", "type": "Document", "title": "PubMed: Coxon et al., 2012, J. Endocrinol. Invest.", "pmid": 21422803}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:42", "label": "RET", "description": "RET mutations and the RET fusion RET-PTC lead to activation of this tyrosine kinase receptor and are associated with thyroid cancers. RET point mutations are the most common mutations identified in medullary thyroid cancer (MTC) with germline and somatic mutations in RET associated with hereditary and sporadic forms, respectively. The most common somatic form mutation is M918T (exon 16) and a variety of other mutations effecting exons 10, 11 and 15 have been described. The prognostic significance of these mutations have been hotly debated in the field, however, data suggests that some RET mutation may confer drug resistance. Highly selective and well-tolerated RET inhibitors, selpercatinib (LOXO-292) and pralsetinib (BLU-667), have been FDA approved recently for the treatment of RET fusion-positive non-small-cell lung cancer, RET fusion-positive thyroid cancer and RET-mutant medullary thyroid cancer.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:9967"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5979"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CDHF12", "CDHR16", "HSCR1", "MEN2A", "MEN2B", "MTC1", "PTC", "RET", "RET-ELE1"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:112", "label": "RET C634W", "description": "RET C634W has been implicated as an alternate mechanism of activating RET in medullary thyroid cancer. While there currently are no RET-specific inhibiting agents, promiscuous kinase inhibitors have seen some success in treating RET overactivity. Data suggests however, that the C634W mutation may lead to drug resistance, especially against the VEGFR-inhibitor motesanib.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 3.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "G", "representative_transcript": "ENST00000355710.3", "chromosome": "10", "start": 43609950, "stop": 43609950, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "112"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA008378"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13918"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["CYS634TRP"], "members": [{"id": "ga4gh:VA.9e-zqee7Vj5xK_ns_lS1tKPbAO4rXpfb", "label": "NC_000010.10:g.43609950C>G", "digest": "9e-zqee7Vj5xK_ns_lS1tKPbAO4rXpfb", "type": "Allele", "location": {"id": "ga4gh:SL.lpWi8LJCiZOxkrWOT0WhZFrAgadpMsGw", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.ss8r_wB0-b9r44TQTMmVTI92884QvBiB"}, "start": 43114501, "end": 43114502}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.OurSLkt-_oA8MN7BGcYG8PgCv2lEWPjJ", "label": "C634W", "digest": "OurSLkt-_oA8MN7BGcYG8PgCv2lEWPjJ", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_020975.4:c.1902C>G"}, {"syntax": "hgvs.p", "value": "NP_065681.1:p.Cys634Trp"}, {"syntax": "hgvs.c", "value": "ENST00000355710.3:c.1902C>G"}, {"syntax": "hgvs.g", "value": "NC_000010.10:g.43609950C>G"}], "location": {"id": "ga4gh:SL.muc0CsstbbDzfAvd6rbixLnqEEM5oj_-", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.jMu9-ItXSycQsm4hyABeW_UfSNRXRVnl"}, "start": 633, "end": 634}, "state": {"type": "LiteralSequenceExpression", "sequence": "W"}}}, "therapeutic": {"id": "civic.tid:23", "label": "Motesanib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C71896"}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C71896"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:15", "label": "Thyroid Gland Medullary Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3879"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3973"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:76", "description": "Medullary thyroid cancer cells with RET M918T mutation are insensitive to motesanib, compared to wild-type RET.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:90", "label": "Coxon et al., 2012, J. Endocrinol. Invest.", "type": "Document", "title": "PubMed: Coxon et al., 2012, J. Endocrinol. Invest.", "pmid": 21422803}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:42", "label": "RET", "description": "RET mutations and the RET fusion RET-PTC lead to activation of this tyrosine kinase receptor and are associated with thyroid cancers. RET point mutations are the most common mutations identified in medullary thyroid cancer (MTC) with germline and somatic mutations in RET associated with hereditary and sporadic forms, respectively. The most common somatic form mutation is M918T (exon 16) and a variety of other mutations effecting exons 10, 11 and 15 have been described. The prognostic significance of these mutations have been hotly debated in the field, however, data suggests that some RET mutation may confer drug resistance. Highly selective and well-tolerated RET inhibitors, selpercatinib (LOXO-292) and pralsetinib (BLU-667), have been FDA approved recently for the treatment of RET fusion-positive non-small-cell lung cancer, RET fusion-positive thyroid cancer and RET-mutant medullary thyroid cancer.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:9967"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5979"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CDHF12", "CDHR16", "HSCR1", "MEN2A", "MEN2B", "MTC1", "PTC", "RET", "RET-ELE1"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:113", "label": "RET M918T", "description": "RET M819T is the most common somatically acquired mutation in medullary thyroid cancer (MTC). While there currently are no RET-specific inhibiting agents, promiscuous kinase inhibitors have seen some success in treating RET overactivity. Data suggests however, that the M918T mutation may lead to drug resistance, especially against the VEGFR-inhibitor motesanib. It has also been suggested that RET M819T leads to more aggressive MTC with a poorer prognosis.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 86.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "C", "representative_transcript": "ENST00000355710.3", "chromosome": "10", "start": 43617416, "stop": 43617416, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "113"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA009082"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13919"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS74799832"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["MET918THR", "RS74799832"], "members": [{"id": "ga4gh:VA.fMYV9MzRrcjzLBqEnsYUV96pUNCnjvyA", "label": "NC_000010.10:g.43617416T>C", "digest": "fMYV9MzRrcjzLBqEnsYUV96pUNCnjvyA", "type": "Allele", "location": {"id": "ga4gh:SL.mSXkkaJ2fQpHLkFwfJEItXTi9eYahAiZ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.ss8r_wB0-b9r44TQTMmVTI92884QvBiB"}, "start": 43121967, "end": 43121968}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.w2q9R8i1OYhtNg-QS5vngW71qwbI40pu", "label": "M918T", "digest": "w2q9R8i1OYhtNg-QS5vngW71qwbI40pu", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_020975.4:c.2753T>C"}, {"syntax": "hgvs.p", "value": "NP_065681.1:p.Met918Thr"}, {"syntax": "hgvs.c", "value": "ENST00000355710.3:c.2753T>C"}, {"syntax": "hgvs.g", "value": "NC_000010.10:g.43617416T>C"}], "location": {"id": "ga4gh:SL.TyVSPbGxZ3uxiWHhkhT0hAi1rEoyMc0-", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.jMu9-ItXSycQsm4hyABeW_UfSNRXRVnl"}, "start": 917, "end": 918}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}}, "therapeutic": {"id": "civic.tid:23", "label": "Motesanib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C71896"}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C71896"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:15", "label": "Thyroid Gland Medullary Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3879"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3973"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:77", "description": "The use of AZD1480 on RET-mutated/rearranged cell lines in vitro led to strong repression of tyroid cancer cell growth.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:91", "label": "Couto et al., 2012, PLoS ONE", "type": "Document", "title": "PubMed: Couto et al., 2012, PLoS ONE", "pmid": 23056499}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:42", "label": "RET", "description": "RET mutations and the RET fusion RET-PTC lead to activation of this tyrosine kinase receptor and are associated with thyroid cancers. RET point mutations are the most common mutations identified in medullary thyroid cancer (MTC) with germline and somatic mutations in RET associated with hereditary and sporadic forms, respectively. The most common somatic form mutation is M918T (exon 16) and a variety of other mutations effecting exons 10, 11 and 15 have been described. The prognostic significance of these mutations have been hotly debated in the field, however, data suggests that some RET mutation may confer drug resistance. Highly selective and well-tolerated RET inhibitors, selpercatinib (LOXO-292) and pralsetinib (BLU-667), have been FDA approved recently for the treatment of RET fusion-positive non-small-cell lung cancer, RET fusion-positive thyroid cancer and RET-mutant medullary thyroid cancer.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:9967"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5979"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CDHF12", "CDHR16", "HSCR1", "MEN2A", "MEN2B", "MTC1", "PTC", "RET", "RET-ELE1"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:113", "label": "RET M918T", "description": "RET M819T is the most common somatically acquired mutation in medullary thyroid cancer (MTC). While there currently are no RET-specific inhibiting agents, promiscuous kinase inhibitors have seen some success in treating RET overactivity. Data suggests however, that the M918T mutation may lead to drug resistance, especially against the VEGFR-inhibitor motesanib. It has also been suggested that RET M819T leads to more aggressive MTC with a poorer prognosis.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 86.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "C", "representative_transcript": "ENST00000355710.3", "chromosome": "10", "start": 43617416, "stop": 43617416, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "113"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA009082"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13919"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS74799832"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["MET918THR", "RS74799832"], "members": [{"id": "ga4gh:VA.fMYV9MzRrcjzLBqEnsYUV96pUNCnjvyA", "label": "NC_000010.10:g.43617416T>C", "digest": "fMYV9MzRrcjzLBqEnsYUV96pUNCnjvyA", "type": "Allele", "location": {"id": "ga4gh:SL.mSXkkaJ2fQpHLkFwfJEItXTi9eYahAiZ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.ss8r_wB0-b9r44TQTMmVTI92884QvBiB"}, "start": 43121967, "end": 43121968}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.w2q9R8i1OYhtNg-QS5vngW71qwbI40pu", "label": "M918T", "digest": "w2q9R8i1OYhtNg-QS5vngW71qwbI40pu", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_020975.4:c.2753T>C"}, {"syntax": "hgvs.p", "value": "NP_065681.1:p.Met918Thr"}, {"syntax": "hgvs.c", "value": "ENST00000355710.3:c.2753T>C"}, {"syntax": "hgvs.g", "value": "NC_000010.10:g.43617416T>C"}], "location": {"id": "ga4gh:SL.TyVSPbGxZ3uxiWHhkhT0hAi1rEoyMc0-", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.jMu9-ItXSycQsm4hyABeW_UfSNRXRVnl"}, "start": 917, "end": 918}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}}, "therapeutic": {"id": "civic.tid:24", "label": "JAK2 Inhibitor AZD1480", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C91394"}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C91394"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["AZD-1480", "AZD1480"]}, "tumorType": {"id": "civic.did:15", "label": "Thyroid Gland Medullary Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3879"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3973"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:90", "description": "In the setting of BRAF(V600E), NF1 loss resulted in elevated activation of RAS-GTP and resistance to RAF inhibitors.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:98", "label": "Nissan et al., 2014, Cancer Res.", "type": "Document", "title": "PubMed: Nissan et al., 2014, Cancer Res.", "pmid": 24576830}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:12", "label": "BRAF V600E", "description": "BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 1353.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453136, "stop": 140453136, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "12"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123643"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13961"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376069"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS113488022", "V640E", "VAL640GLU", "VAL600GLU"], "members": [{"id": "ga4gh:VA.LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "label": "NC_000007.13:g.140453136A>T", "digest": "LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "type": "Allele", "location": {"id": "ga4gh:SL.XutGzMvqbzN-vnxmPt2MJf7ehxmB0opi", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753335, "end": 140753336}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "label": "V600E", "digest": "4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004333.4:c.1799T>A"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Val600Glu"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140453136A>T"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1799T>A"}], "location": {"id": "ga4gh:SL.ZA1XNKhCT_7m2UtmnYb8ZYOVS4eplMEK", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:7", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3224"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1909"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:125", "description": "Cells lines expressing ALK harboring the F1174L mutation are less sensitive to growth inhibition by crizotinib than cells expressing the R1275Q mutation. The authors conclude that this effect should be surmountable with higher doses of crizotinib and/or with higher-affinity inhibitors.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:119", "label": "Bresler et al., 2011, Sci Transl Med", "type": "Document", "title": "PubMed: Bresler et al., 2011, Sci Transl Med", "pmid": 22072639}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:1", "label": "ALK", "description": "ALK amplifications, fusions and mutations have been shown to be driving events in non-small cell lung cancer. While crizontinib has demonstrated efficacy in treating the amplification, mutations in ALK have been shown to confer resistance to current tyrosine kinase inhibitors. Second-generation TKI's have seen varied success in treating these resistant cases, and the HSP90 inhibitor 17-AAG has been shown to be cytostatic in ALK-altered cell lines.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:427"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:238"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["ALK", "ALK1", "CD246", "NBLST3"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:8", "label": "ALK F1174L", "description": "ALK F1174L has been observed as recurrent in neuroblastoma, non-small cell lung cancer (NSCLC), and other cancer types. Neuroblastoma cells containing this mutation have shown resistance to low doses of criztonib. However, increased dosage can overcome this resistance in cell lines studies. TAE684 has also proven effective in both NSCLC and neuroblastoma F1174L containing cells.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 33.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "T", "representative_transcript": "ENST00000389048.3", "chromosome": "2", "start": 29443695, "stop": 29443695, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "8"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA279586"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "217851"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS863225281"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["PHE1174LEU", "RS863225281"], "members": [{"id": "ga4gh:VA.ivl5YUYPCfDa2igYKGlCTZec5eKC7oYY", "label": "NC_000002.11:g.29443695G>T", "digest": "ivl5YUYPCfDa2igYKGlCTZec5eKC7oYY", "type": "Allele", "location": {"id": "ga4gh:SL.Nn_joIP_IBbU0SOamVk3VuamNXOVBxPt", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.pnAqCRBrTsUoBghSD1yp_jXWSmlbdh4g"}, "start": 29220828, "end": 29220829}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.nTPnpFtWudqItR2YaGBsaJwRgGobSWAr", "label": "F1174L", "digest": "nTPnpFtWudqItR2YaGBsaJwRgGobSWAr", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004304.4:c.3522C>A"}, {"syntax": "hgvs.p", "value": "NP_004295.2:p.Phe1174Leu"}, {"syntax": "hgvs.g", "value": "NC_000002.11:g.29443695G>T"}, {"syntax": "hgvs.c", "value": "ENST00000389048.3:c.3522C>A"}], "location": {"id": "ga4gh:SL.n1vbI2DGWZjLWoNdaUdc1ISSHenlCMar", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.q9CnK-HKWh9eqhOi8FlzR7M0pCmUrWPs"}, "start": 1173, "end": 1174}, "state": {"type": "LiteralSequenceExpression", "sequence": "L"}}}, "therapeutic": {"id": "civic.tid:12", "label": "Crizotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1148495"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:25958", "type": "Disease", "label": "Anaplastic large cell lymphoma pediatric"}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C74061"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine", "2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-", "MET Tyrosine Kinase Inhibitor PF-02341066", "PF-02341066", "PF-2341066", "Xalkori"]}, "tumorType": {"id": "civic.did:13", "label": "Neuroblastoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3270"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:769"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:143", "description": "Cells lines expressing ALK harboring the F1174L mutation are less sensitive to growth inhibition by crizotinib than cells expressing the R1275Q mutation.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:119", "label": "Bresler et al., 2011, Sci Transl Med", "type": "Document", "title": "PubMed: Bresler et al., 2011, Sci Transl Med", "pmid": 22072639}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:1", "label": "ALK", "description": "ALK amplifications, fusions and mutations have been shown to be driving events in non-small cell lung cancer. While crizontinib has demonstrated efficacy in treating the amplification, mutations in ALK have been shown to confer resistance to current tyrosine kinase inhibitors. Second-generation TKI's have seen varied success in treating these resistant cases, and the HSP90 inhibitor 17-AAG has been shown to be cytostatic in ALK-altered cell lines.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:427"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:238"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["ALK", "ALK1", "CD246", "NBLST3"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:9", "label": "ALK R1275Q", "description": "ALK R1275Q has been observed as a recurrent mutation in  neuroblastoma, non-small cell lung cancer (NSCLC), as well as other cancer types. Neuroblastoma cells with this mutation have shown sensitivity to the ALK-inhibitor TAE684. This and the geldanamycin deriviative 17-DMAG have been shown to be effective in NSCLC cell lines.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 23.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000389048.3", "chromosome": "2", "start": 29432664, "stop": 29432664, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "9"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA341482"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "18083"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS113994087"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS113994087", "ARG1275GLN"], "members": [{"id": "ga4gh:VA.t3vU-1OKU2n8Hp6J5zIgf-fdOngWPcJI", "label": "NC_000002.11:g.29432664C>T", "digest": "t3vU-1OKU2n8Hp6J5zIgf-fdOngWPcJI", "type": "Allele", "location": {"id": "ga4gh:SL.-qNrY8pBD7rUqlnqrgBF-ZRDSEJspR0m", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.pnAqCRBrTsUoBghSD1yp_jXWSmlbdh4g"}, "start": 29209797, "end": 29209798}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.gX5hniEm7ni0BSgk4ACRN6yU5ARPwd1n", "label": "R1275Q", "digest": "gX5hniEm7ni0BSgk4ACRN6yU5ARPwd1n", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004304.4:c.3824G>A"}, {"syntax": "hgvs.p", "value": "NP_004295.2:p.Arg1275Gln"}, {"syntax": "hgvs.g", "value": "NC_000002.11:g.29432664C>T"}, {"syntax": "hgvs.c", "value": "ENST00000389048.3:c.3824G>A"}], "location": {"id": "ga4gh:SL.zbNZWCvHj679lMb2bPXhsYkuglQbHXmT", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.q9CnK-HKWh9eqhOi8FlzR7M0pCmUrWPs"}, "start": 1274, "end": 1275}, "state": {"type": "LiteralSequenceExpression", "sequence": "Q"}}}, "therapeutic": {"id": "civic.tid:12", "label": "Crizotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1148495"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:25958", "type": "Disease", "label": "Anaplastic large cell lymphoma pediatric"}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C74061"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine", "2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-", "MET Tyrosine Kinase Inhibitor PF-02341066", "PF-02341066", "PF-2341066", "Xalkori"]}, "tumorType": {"id": "civic.did:13", "label": "Neuroblastoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3270"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:769"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:231", "description": "Breast cancer cell lines with the AKT1 E17K mutation did not show sensitivity to AKT inhibitor MK-2206, unlike cell lines with PIK3CA mutations.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:163", "label": "Beaver et al., 2013, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Beaver et al., 2013, Clin. Cancer Res.", "pmid": 23888070}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:2", "label": "AKT1", "description": "AKT1, also referred to as protein kinase B, is a known oncogene. AKT activation relies on the PI3K pathway, and is recognized as a critical node in the pathway. The E17 hotspot is the most characterized of AKT1 mutations, and has been shown to result in activation of the protein. Mutations in AKT1 have also been shown to confer resistance to allosteric kinase inhibitors in vitro.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:391"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:207"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["AKT", "AKT1", "PKB", "PKB-ALPHA", "PRKBA", "RAC", "RAC-ALPHA"]}}, "direction": "refutes", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:4", "label": "AKT1 E17K", "description": "AKT1 E17K is a recurrent mutation that has been observed in breast, colorectal, lung, and ovarian cancer. It has been convincingly shown to be an activating mutation resulting in PI3K/AKT/mTOR pathway activity. It has been suggested that this mutation decreases the cell's sensitivity to AKT1 allosteric kinase inhibitors. This, and other AKT1 mutations, are the subject of much research and development for therapeutics.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 33.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000407796.2", "chromosome": "14", "start": 105246551, "stop": 105246551, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "4"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123660"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13983"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS34409589"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLU17LYS", "RS34409589"], "members": [{"id": "ga4gh:VA.swSBQXaa6uybP38HHxbddf9Cvl8JzGEW", "label": "NC_000014.8:g.105246551C>T", "digest": "swSBQXaa6uybP38HHxbddf9Cvl8JzGEW", "type": "Allele", "location": {"id": "ga4gh:SL.q0g2bHXjBdLjnq8rFLJEU3GpNY9o7FeQ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.eK4D2MosgK_ivBkgi6FVPg5UXs1bYESm"}, "start": 104780213, "end": 104780214}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.u-DUjTNvYupRf-vStLK0YPNPV6jEYG1O", "label": "E17K", "digest": "u-DUjTNvYupRf-vStLK0YPNPV6jEYG1O", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000014.8:g.105246551C>T"}, {"syntax": "hgvs.c", "value": "NM_001014432.1:c.49G>A"}, {"syntax": "hgvs.p", "value": "NP_001014432.1:p.Glu17Lys"}, {"syntax": "hgvs.c", "value": "ENST00000407796.2:c.49G>A"}], "location": {"id": "ga4gh:SL._hc6YN89fA0LVGrpJMVLnhhbELQEYuMw", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.GTSPIWYvuDZU59cW1RECFEU1FMiKdEyc"}, "start": 16, "end": 17}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:43", "label": "Akt Inhibitor MK2206", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C90581"}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C90581"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1,2,4-Triazolo(3,4-f)(1,6)naphthyridin-3(2H)-one, 8-(4-(1-aminocyclobutyl)phenyl)-9-phenyl-", "MK 2206", "MK-2206", "MK-2206 FREE BASE", "MK2206"]}, "tumorType": {"id": "civic.did:22", "label": "Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9335"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1612"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:249", "description": "KIT V654A results in imatinib resistance in GIST patient-derived cell lines.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:62", "label": "Heinrich et al., 2006, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Heinrich et al., 2006, J. Clin. Oncol.", "pmid": 16954519}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:29", "label": "KIT", "description": "c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3815"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["C-Kit", "CD117", "KIT", "MASTC", "PBT", "SCFR"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:73", "label": "KIT V654A", "description": "KIT V654A is an exon 13 mutation that lies within the tyrosine kinase 1 domain of the protein. It has been shown to be an activating mutation by in vitro studies. This mutation is associated with imatinib resistance in melanoma patients. However, second generation TKI's such as sunitinib and midostaurin (PKC 412) have seen success in acheiving tumor response.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 18.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "C", "representative_transcript": "ENST00000288135.5", "chromosome": "4", "start": 55594258, "stop": 55594258, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "73"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602402"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "375921"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913523"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913523", "VAL654ALA"], "members": [{"id": "ga4gh:VA.-ZkJiZCgRrCAPN4FwwvYTLTyNSVGxv91", "label": "NC_000004.11:g.55594258T>C", "digest": "-ZkJiZCgRrCAPN4FwwvYTLTyNSVGxv91", "type": "Allele", "location": {"id": "ga4gh:SL.aqVlFVOU1rwA9qOLXQOR_RM3nwtjLODh", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54728091, "end": 54728092}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.9mxRMKbFtCe8j6s8x9imRCuq0xIpXRt6", "label": "V654A", "digest": "9mxRMKbFtCe8j6s8x9imRCuq0xIpXRt6", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_000222.2:c.1961T>C"}, {"syntax": "hgvs.p", "value": "NP_000213.1:p.Val654Ala"}, {"syntax": "hgvs.c", "value": "ENST00000288135.5:c.1961T>C"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55594258T>C"}], "location": {"id": "ga4gh:SL.um97SDid7E4raxzVp8ci7g1w8NKAoJs8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 653, "end": 654}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}}, "therapeutic": {"id": "civic.tid:5", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:282388"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "Disease", "label": "Systemic mastocytosis", "mappings": [{"coding": {"system": "ncit", "code": "C9235"}, "relation": "relatedMatch"}]}, {"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}, {"id": "hemonc:634", "type": "Disease", "label": "Myelodysplastic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C3247"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:33893", "type": "Disease", "label": "Chronic myelogenous leukemia pediatric"}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}, {"id": "hemonc:616", "type": "Disease", "label": "Hypereosinophilic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C27038"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C62035"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"]}, "tumorType": {"id": "civic.did:2", "label": "Gastrointestinal Stromal Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3868"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9253"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:311", "description": "Rapamycin inhibits transformation induced by mutation in PIK3CA.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:196", "label": "Kang et al., 2005, Proc. Natl. Acad. Sci. U.S.A.", "type": "Document", "title": "PubMed: Kang et al., 2005, Proc. Natl. Acad. Sci. U.S.A.", "pmid": 15647370}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:103", "label": "PIK3CA E542K", "description": "PIK3CA E545K/E542K variants are the second most recurrent PIK3CA mutations in breast cancer and are highly recurrent mutations in many other cancer types. Colorectal cancer patients with the PIK3CA E545K variant, and possibly other variants in the E545 region, may indicate poor prognosis relative to patients with other PIK3CA variants or wild-type PIK3CA. The literature also suggests that E545/E542 variants may confer resistance to EGFR inhibitors (e.g., cetuximab). An FDA approved treatment regimen including a targeted PIK3CA inhibitor is available for specific subtypes of breast cancer. While PIK3CA variants are highly prevalent in many other cancer types, targeted therapies for PIK3CA variants are still in early clinical trial phases in other cancer types.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 75.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000263967.3", "chromosome": "3", "start": 178936082, "stop": 178936082, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "103"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA333572"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "31944"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913273"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLU542LYS", "RS121913273"], "members": [{"id": "ga4gh:VA.52-4tAq0Ya9SeMU4eZSgO0bfqvkd_VE4", "label": "NC_000003.11:g.178936082G>A", "digest": "52-4tAq0Ya9SeMU4eZSgO0bfqvkd_VE4", "type": "Allele", "location": {"id": "ga4gh:SL.65wPuIVC66WPYQqTnuNP-taUZ03NOwmJ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 179218293, "end": 179218294}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.D6daDiDNn1u-e4YtntaYQnxlZ_0T6gtD", "label": "E542K", "digest": "D6daDiDNn1u-e4YtntaYQnxlZ_0T6gtD", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006218.3:c.1624G>A"}, {"syntax": "hgvs.p", "value": "NP_006209.2:p.Glu542Lys"}, {"syntax": "hgvs.c", "value": "ENST00000263967.3:c.1624G>A"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.178936082G>A"}], "location": {"id": "ga4gh:SL.DdVC73cqPrOnzCRvVc8N9tA3ecV5Qunt", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 541, "end": 542}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:469", "label": "Sirolimus", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:35302"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:37829", "type": "Disease", "label": "PEComa", "mappings": [{"coding": {"system": "ncit", "code": "C38150"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1212"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,2", "AY 22989", "RAPA", "RAPAMYCIN", "Rapamune", "SILA 9268A", "WY-090217"]}, "tumorType": {"id": "civic.did:22", "label": "Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9335"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1612"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:319", "description": "Breast tumors in a mouse model with R172H mutation (homologous to human R175H) are more responsive to doxorubicin than breast tumors with wild type TP53.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:199", "label": "Jackson et al., 2012, Cancer Cell", "type": "Document", "title": "PubMed: Jackson et al., 2012, Cancer Cell", "pmid": 22698404}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:45", "label": "TP53", "description": "TP53 mutations are universal across cancer types. The loss of a tumor suppressor is most often through large deleterious events, such as frameshift mutations, or premature stop codons. In TP53 however, many of the observed mutations in cancer are found to be single nucleotide missense variants. These variants are broadly distributed throughout the gene, but with the majority localizing in the DNA binding domain. There is no single hotspot in the DNA binding domain, but a majority of mutations occur in amino acid positions 175, 245, 248, 273, and 282 (NM_000546) (Olivier et al., 2010). To fulfill its proper biological function four TP53 polypeptides must form a tetramer which functions as a transcription factor, therefore even if one out of four polypeptides has inactivating mutation it may lead to dominant negative phenotype of variable degree. While a large proportion of cancer genomics research is focused on somatic variants, TP53 is also of note in the germline. Germline TP53 mutations are the hallmark of Li-Fraumeni syndrome, and many (both germline and somatic) variants have been found to have a prognostic impact on patient outcomes. The significance of many polymorphisms for susceptibility and prognosis of disease is still very much up for debate.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:11998"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:7157"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["BCC7", "BMFS5", "LFS1", "P53", "TP53", "TRP53"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:116", "label": "TP53 R175H", "description": "While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant. This variant is rare in population databases (ACMG code: PM2; 0.000003980 total exome AF gnomAD v2.1.1).", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 25.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000269305.4", "chromosome": "17", "start": 7578406, "stop": 7578406, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "116"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA000251"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12374"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS28934578"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ARG175HIS", "R43H", "RS28934578", "R136H"], "members": [{"id": "ga4gh:VA.tKbKBAAo6GbAm7D1Mj2R3F8I1VB1GGlM", "label": "NC_000017.10:g.7578406C>T", "digest": "tKbKBAAo6GbAm7D1Mj2R3F8I1VB1GGlM", "type": "Allele", "location": {"id": "ga4gh:SL.O7SQ86ULNh8AzYhfV1RBO-pLEcsHfyjs", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dLZ15tNO1Ur0IcGjwc3Sdi_0A6Yf4zm7"}, "start": 7675087, "end": 7675088}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.gEgxg9Gliq2KY7z_YaGqP3MSHsuOOEMI", "label": "R175H", "digest": "gEgxg9Gliq2KY7z_YaGqP3MSHsuOOEMI", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_000546.5:c.524G>A"}, {"syntax": "hgvs.p", "value": "NP_000537.3:p.Arg175His"}, {"syntax": "hgvs.g", "value": "NC_000017.10:g.7578406C>T"}, {"syntax": "hgvs.c", "value": "ENST00000269305.4:c.524G>A"}], "location": {"id": "ga4gh:SL.I8qo71Hywhe4fsS5du2jYELlR8IE6a88", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.KAxM06sYzBF6zFftFaYq9E_18wsnn7al"}, "start": 174, "end": 175}, "state": {"type": "LiteralSequenceExpression", "sequence": "H"}}}, "therapeutic": {"id": "civic.tid:68", "label": "Doxorubicin", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:142433"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:552", "type": "Disease", "label": "Acute myeloid leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3171"}, "relation": "relatedMatch"}]}, {"id": "hemonc:675", "type": "Disease", "label": "Thyroid cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7510"}, "relation": "relatedMatch"}]}, {"id": "hemonc:572", "type": "Disease", "label": "Breast cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9335"}, "relation": "relatedMatch"}]}, {"id": "hemonc:569", "type": "Disease", "label": "Bladder cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9334"}, "relation": "relatedMatch"}]}, {"id": "hemonc:601", "type": "Disease", "label": "Gastric cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9331"}, "relation": "relatedMatch"}]}, {"id": "hemonc:614", "type": "Disease", "label": "Hodgkin lymphoma", "mappings": [{"coding": {"system": "ncit", "code": "C9357"}, "relation": "relatedMatch"}]}, {"id": "hemonc:666", "type": "Disease", "label": "Small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C4917"}, "relation": "relatedMatch"}]}, {"id": "hemonc:645", "type": "Disease", "label": "Ovarian cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7431"}, "relation": "relatedMatch"}]}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C456"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione", "(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione", "14-Hydroxydaunomycin", "Adriablastin", "Hydroxydaunomycin", "Hydroxyl Daunorubicin", "Hydroxyldaunorubicin"]}, "tumorType": {"id": "civic.did:22", "label": "Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9335"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1612"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:651", "description": "When 293T cells stably transduced with PDGFRA A842V were treated with imatinib, tyrosine phosphorylation was maintained at 1 and 10umol/L concentrations that inhibited phosphorylation of wildtype PDGFRA, consistent with resistance to this inhibitor.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:411", "label": "Hirota et al., 2003, Gastroenterology", "type": "Document", "title": "PubMed: Hirota et al., 2003, Gastroenterology", "pmid": 12949711}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:38", "label": "PDGFRA", "description": "Commonly mutated in GI tract tumors, PDGFR family genes (mutually exclusive to KIT mutations) are a hallmark of gastrointestinal stromal tumors. Gene fusions involving the PDGFRA kinase domain are highly correlated with eosinophilia, and the WHO classifies myeloid and lymphoid neoplasms with these characteristics as a distinct disorder. Mutations in the 842 region of PDGFRA have been often found to confer resistance to the tyrosine kinase inhibitor, imatinib.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8803"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5156"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD140A", "PDGFR-2", "PDGFR2", "PDGFRA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:99", "label": "PDGFRA D842V", "description": "PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. Exogenous expression of the A842V mutation resulted in constitutive tyrosine phosphorylation of PDGFRA in the absence of ligand in 293T cells and cytokine-independent proliferation of the IL-3-dependent Ba/F3 cell line, both evidence that this is an activating mutation. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 100.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000257290.5", "chromosome": "4", "start": 55152093, "stop": 55152093, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "99"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123194"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13543"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121908585"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ASP842VAL", "RS121908585"], "members": [{"id": "ga4gh:VA.bDwkJ2filJ3ZGiUFybGFfyaCKdIVK86v", "label": "NC_000004.11:g.55152093A>T", "digest": "bDwkJ2filJ3ZGiUFybGFfyaCKdIVK86v", "type": "Allele", "location": {"id": "ga4gh:SL.LxO2YLfQbI_-TK7GOmSoOpMNiSy_Hgan", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54285925, "end": 54285926}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.vIjnL-aLYl0BSB6JutpdD7yW_qIXtdk8", "label": "D842V", "digest": "vIjnL-aLYl0BSB6JutpdD7yW_qIXtdk8", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006206.4:c.2525A>T"}, {"syntax": "hgvs.p", "value": "NP_006197.1:p.Asp842Val"}, {"syntax": "hgvs.c", "value": "ENST00000257290.5:c.2525A>T"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55152093A>T"}], "location": {"id": "ga4gh:SL.GHXCPrbd_qdPUoHjPwzv5iVFapJ0cn-o", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.XpQn9sZLGv_GU3uiWO7YHq9-_alGjrVX"}, "start": 841, "end": 842}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "civic.tid:5", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:282388"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "Disease", "label": "Systemic mastocytosis", "mappings": [{"coding": {"system": "ncit", "code": "C9235"}, "relation": "relatedMatch"}]}, {"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}, {"id": "hemonc:634", "type": "Disease", "label": "Myelodysplastic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C3247"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:33893", "type": "Disease", "label": "Chronic myelogenous leukemia pediatric"}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}, {"id": "hemonc:616", "type": "Disease", "label": "Hypereosinophilic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C27038"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C62035"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"]}, "tumorType": {"id": "civic.did:2", "label": "Gastrointestinal Stromal Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3868"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9253"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:652", "description": "293T cells stably transduced with PDGFRA V561A showed constitutive tyrosine phosphorylation in the absense of ligand; however, when treated with imatinib, this phosphorylation was inhibited similarly to that of wildtype PDGFRA, consistent with sensitivity to this inhibitor.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:411", "label": "Hirota et al., 2003, Gastroenterology", "type": "Document", "title": "PubMed: Hirota et al., 2003, Gastroenterology", "pmid": 12949711}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:38", "label": "PDGFRA", "description": "Commonly mutated in GI tract tumors, PDGFR family genes (mutually exclusive to KIT mutations) are a hallmark of gastrointestinal stromal tumors. Gene fusions involving the PDGFRA kinase domain are highly correlated with eosinophilia, and the WHO classifies myeloid and lymphoid neoplasms with these characteristics as a distinct disorder. Mutations in the 842 region of PDGFRA have been often found to confer resistance to the tyrosine kinase inhibitor, imatinib.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8803"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5156"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD140A", "PDGFR-2", "PDGFR2", "PDGFRA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:243", "label": "PDGFRA V561A", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 3.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "C", "representative_transcript": "ENST00000257290.5", "chromosome": "4", "start": 55141036, "stop": 55141036, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "247"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602796"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376354"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121908586"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["VAL561ALA", "RS121908586"], "members": [{"id": "ga4gh:VA.uVADAvdFFVKPUoYjXWtcZk-7eEB20U14", "label": "NC_000004.11:g.55141036T>C", "digest": "uVADAvdFFVKPUoYjXWtcZk-7eEB20U14", "type": "Allele", "location": {"id": "ga4gh:SL.h44ZIUE0VWLc8ONz8JwqUOUCvADE8Ozc", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54274868, "end": 54274869}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.QwfCHl9dSG9oCUd4Imi709UyiFTHVbxt", "label": "V561A", "digest": "QwfCHl9dSG9oCUd4Imi709UyiFTHVbxt", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000257290.5:c.1682T>C"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55141036T>C"}, {"syntax": "hgvs.c", "value": "NM_006206.5:c.1682T>C"}, {"syntax": "hgvs.p", "value": "NP_006197.1:p.Val561Ala"}], "location": {"id": "ga4gh:SL.QB_e8RED6euCq3v0AQJcTcXmXd4p286t", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.XpQn9sZLGv_GU3uiWO7YHq9-_alGjrVX"}, "start": 560, "end": 561}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}}, "therapeutic": {"id": "civic.tid:5", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:282388"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "Disease", "label": "Systemic mastocytosis", "mappings": [{"coding": {"system": "ncit", "code": "C9235"}, "relation": "relatedMatch"}]}, {"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}, {"id": "hemonc:634", "type": "Disease", "label": "Myelodysplastic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C3247"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:33893", "type": "Disease", "label": "Chronic myelogenous leukemia pediatric"}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}, {"id": "hemonc:616", "type": "Disease", "label": "Hypereosinophilic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C27038"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C62035"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"]}, "tumorType": {"id": "civic.did:2", "label": "Gastrointestinal Stromal Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3868"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9253"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:755", "description": "D473 mutations were identified in 5/30 resistant basal cell carcinomas. Crystal structure indicated this mutation interacts with a water molecule in the ligand binding pocket, putatively altering its interaction with the SMO inhibitor vismodegib. SMO-/- mouse embryonic fibroblasts expressing the SMO D473G mutant maintained hedgehog signaling in the presence of the drug and had IC50 values >40 fold higher than cells expressing wildtype SMO.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:493", "label": "Atwood et al., 2015, Cancer Cell", "type": "Document", "title": "PubMed: Atwood et al., 2015, Cancer Cell", "pmid": 25759020}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5365", "label": "SMO", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:11119"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:6608"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CRJS", "FZD11", "Gx", "PHLS", "SMO", "SMOH"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:295", "label": "SMO D473H", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 13.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "C", "representative_transcript": "ENST00000249373.3", "chromosome": "7", "start": 128849189, "stop": 128849189, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "299"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602418"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "375938"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ASP473HIS"], "members": [{"id": "ga4gh:VA.ZVCK9HOdFlJ6l05ZamMYMa40CxbnW_68", "label": "NC_000007.13:g.128849189G>C", "digest": "ZVCK9HOdFlJ6l05ZamMYMa40CxbnW_68", "type": "Allele", "location": {"id": "ga4gh:SL.9oTXJyrlvxQPTIZcX1gLo-h1CCliO1La", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 129209347, "end": 129209348}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.bmjdTLZ7ZUlYK_if1ufZE9kODAOrc9bv", "label": "D473H", "digest": "bmjdTLZ7ZUlYK_if1ufZE9kODAOrc9bv", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_005631.4:c.1417G>A"}, {"syntax": "hgvs.p", "value": "NP_005622.1:p.Asp473His"}, {"syntax": "hgvs.c", "value": "ENST00000249373.3:c.1417G>A"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.128849189G>C"}], "location": {"id": "ga4gh:SL.RZjuMMfOUQOz28W5DoaOxGhNAgw91ydS", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.WZ7_owJHaml6kJ-2GfPtgYh1GA40K9tc"}, "start": 472, "end": 473}, "state": {"type": "LiteralSequenceExpression", "sequence": "H"}}}, "therapeutic": {"id": "civic.tid:190", "label": "Vismodegib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1242987"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:587", "type": "Disease", "label": "Cutaneous basal cell carcinoma"}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C74038"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide", "Erivedge", "GDC-0449", "Hedgehog Antagonist GDC-0449"]}, "tumorType": {"id": "civic.did:314", "label": "Basal Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2921"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:2513"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:762", "description": "CO-1686 (Rociletinib) more effectively induced apoptosis in EGFR mutated (T790M and others) NSCLC cell lines than those harboring wildtype EGFR. CO-1686 also more effectively reduced tumor volume of mouse xenografts harboring the T790M than those with wildtype EGFR.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:505", "label": "Walter et al., 2013, Cancer Discov", "type": "Document", "title": "PubMed: Walter et al., 2013, Cancer Discov", "pmid": 24065731}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:34", "label": "EGFR T790M", "description": "EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 406.25}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55249071, "stop": 55249071, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "34"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA090928"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16613"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434569"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["THR790MET", "RS121434569"], "members": [{"id": "ga4gh:VA.OvEfBRaS34JkfM0_ZHJVDQEjqtwzyjyp", "label": "NC_000007.13:g.55249071C>T", "digest": "OvEfBRaS34JkfM0_ZHJVDQEjqtwzyjyp", "type": "Allele", "location": {"id": "ga4gh:SL.ZCgOjF-_T0EOBXGc-6yICYui-jgFzJfY", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55181377, "end": 55181378}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.faKID4aj8rP8NKZpWL4mWDToEztTUmbr", "label": "T790M", "digest": "faKID4aj8rP8NKZpWL4mWDToEztTUmbr", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2369C>T"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2369C>T"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Thr790Met"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55249071C>T"}], "location": {"id": "ga4gh:SL.C1y_lDZe8e9pKy3jcj3oJKw_7252Hrxa", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 789, "end": 790}, "state": {"type": "LiteralSequenceExpression", "sequence": "M"}}}, "therapeutic": {"id": "civic.tid:91", "label": "Rociletinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C99905"}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C99905"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["CO-1686", "N-(3-((2-((4-(4-Acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)prop-2-enamide"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:963", "description": "Cell line, xenograft, and transgenic models were used to establish Osimertinib as an inhibitor of both EGFR mutation sensitizing (L858M, del exon 19) and T790M resistance mutants. Preclinically, the drug inhibits signaling pathways and cellular growth in both EGFRm(+) and EGFRm(+)/T790M(+) mutant cell lines in vitro, with lower activity against wild-type EGFR lines. Sustained tumor regression was observed in EGFR-mutant tumor xenograft and transgenic models. Treatment of 2 patients with advanced EGFRm(+) T790M(+) NSCLC was reported as proof of principle.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:665", "label": "Cross et al., 2014, Cancer Discov", "type": "Document", "title": "PubMed: Cross et al., 2014, Cancer Discov", "pmid": 24893891}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:34", "label": "EGFR T790M", "description": "EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 406.25}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55249071, "stop": 55249071, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "34"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA090928"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16613"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434569"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["THR790MET", "RS121434569"], "members": [{"id": "ga4gh:VA.OvEfBRaS34JkfM0_ZHJVDQEjqtwzyjyp", "label": "NC_000007.13:g.55249071C>T", "digest": "OvEfBRaS34JkfM0_ZHJVDQEjqtwzyjyp", "type": "Allele", "location": {"id": "ga4gh:SL.ZCgOjF-_T0EOBXGc-6yICYui-jgFzJfY", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55181377, "end": 55181378}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.faKID4aj8rP8NKZpWL4mWDToEztTUmbr", "label": "T790M", "digest": "faKID4aj8rP8NKZpWL4mWDToEztTUmbr", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2369C>T"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2369C>T"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Thr790Met"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55249071C>T"}], "location": {"id": "ga4gh:SL.C1y_lDZe8e9pKy3jcj3oJKw_7252Hrxa", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 789, "end": 790}, "state": {"type": "LiteralSequenceExpression", "sequence": "M"}}}, "therapeutic": {"id": "civic.tid:187", "label": "Osimertinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1721560"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C116377"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-", "AZD-9291", "AZD9291", "Mereletinib", "Tagrisso"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1083", "description": "In this preclinical study on the effects of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer. In NIH3T3 cells expressing EGFR with a K467T mutation, Sym004 and panitumumab bound the mutated receptor and inhibited EGFR phosphorylation in the presence of ligand while cetuximab neither bound to nor inhibited EGFR phosphorylation of the mutated receptor.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:746", "label": "S\u00e1nchez-Mart\u00edn et al., 2016, Clin. Cancer Res.", "type": "Document", "title": "PubMed: S\u00e1nchez-Mart\u00edn et al., 2016, Clin. Cancer Res.", "pmid": 26888827}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:451", "label": "EGFR K467T", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 6.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "C", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55227933, "stop": 55227933, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "455"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA367579521"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["LYS467THR"], "members": [{"id": "ga4gh:VA.LcsgXQz9tg9L1IhLmuqBLjEtjKdWCYKc", "label": "NC_000007.13:g.55227933A>C", "digest": "LcsgXQz9tg9L1IhLmuqBLjEtjKdWCYKc", "type": "Allele", "location": {"id": "ga4gh:SL.eBKpn65TE1pbNbj0tkTMAmQj6MnfHSC6", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55160239, "end": 55160240}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.8RLiNB1eIg73BkCjoRLKf7HPCl5SEoRr", "label": "K467T", "digest": "8RLiNB1eIg73BkCjoRLKf7HPCl5SEoRr", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.1400A>C"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55227933A>C"}, {"syntax": "hgvs.c", "value": "NM_005228.3:c.1400A>C"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Lys467Thr"}], "location": {"id": "ga4gh:SL.0UAgn7k37sf6X1wF4YabizqIsNhrBbMb", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 466, "end": 467}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}}, "therapeutic": {"id": "civic.tid:16", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:318341"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}, {"id": "mesh:D006258", "type": "Disease", "label": "Head and Neck Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C4013"}, "relation": "relatedMatch"}]}, {"id": "mesh:D002294", "type": "Disease", "label": "Carcinoma, Squamous Cell", "mappings": [{"coding": {"system": "ncit", "code": "C2929"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1723"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1099", "description": "Saridegib treatment induced tumor reduction and significantly prolonged survival in a Shh-driven mouse medulloblastoma model, and was found to be active in cells with the D473H point mutation.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:758", "label": "Lee et al., 2012, Proc. Natl. Acad. Sci. U.S.A.", "type": "Document", "title": "PubMed: Lee et al., 2012, Proc. Natl. Acad. Sci. U.S.A.", "pmid": 22550175}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5365", "label": "SMO", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:11119"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:6608"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CRJS", "FZD11", "Gx", "PHLS", "SMO", "SMOH"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:295", "label": "SMO D473H", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 13.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "C", "representative_transcript": "ENST00000249373.3", "chromosome": "7", "start": 128849189, "stop": 128849189, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "299"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602418"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "375938"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ASP473HIS"], "members": [{"id": "ga4gh:VA.ZVCK9HOdFlJ6l05ZamMYMa40CxbnW_68", "label": "NC_000007.13:g.128849189G>C", "digest": "ZVCK9HOdFlJ6l05ZamMYMa40CxbnW_68", "type": "Allele", "location": {"id": "ga4gh:SL.9oTXJyrlvxQPTIZcX1gLo-h1CCliO1La", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 129209347, "end": 129209348}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.bmjdTLZ7ZUlYK_if1ufZE9kODAOrc9bv", "label": "D473H", "digest": "bmjdTLZ7ZUlYK_if1ufZE9kODAOrc9bv", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_005631.4:c.1417G>A"}, {"syntax": "hgvs.p", "value": "NP_005622.1:p.Asp473His"}, {"syntax": "hgvs.c", "value": "ENST00000249373.3:c.1417G>A"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.128849189G>C"}], "location": {"id": "ga4gh:SL.RZjuMMfOUQOz28W5DoaOxGhNAgw91ydS", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.WZ7_owJHaml6kJ-2GfPtgYh1GA40K9tc"}, "start": 472, "end": 473}, "state": {"type": "LiteralSequenceExpression", "sequence": "H"}}}, "therapeutic": {"id": "civic.tid:274", "label": "Patidegib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C80063"}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C80063"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["FIN-5", "IP9 Free Base", "IPI-926", "IPI-926 Free Base", "Saridegib", "Smoothened Antagonist IPI-926"]}, "tumorType": {"id": "civic.did:361", "label": "Medulloblastoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3222"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:0050902"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1141", "description": "Preclinical study analyzing the differential response to MEK inhibitors in KRAS and BRAF mutant cancer cell lines and mouse xenografts. Inhibition of active, phosphorylated MEK by GDC-0973 (cobimetinib) is required for strong inhibition of the MAPK pathway in BRAF-mutant tumours. This study provides mechanistic rationale for improved efficacy of cobimetinib in BRAF-mutant models compared to MEK inhibitors acting through an alternative mechanism (GDC-0623 and G-573).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:790", "label": "Hatzivassiliou et al., 2013, Nature", "type": "Document", "title": "PubMed: Hatzivassiliou et al., 2013, Nature", "pmid": 23934108}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:12", "label": "BRAF V600E", "description": "BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 1353.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453136, "stop": 140453136, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "12"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123643"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13961"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376069"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS113488022", "V640E", "VAL640GLU", "VAL600GLU"], "members": [{"id": "ga4gh:VA.LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "label": "NC_000007.13:g.140453136A>T", "digest": "LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "type": "Allele", "location": {"id": "ga4gh:SL.XutGzMvqbzN-vnxmPt2MJf7ehxmB0opi", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753335, "end": 140753336}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "label": "V600E", "digest": "4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004333.4:c.1799T>A"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Val600Glu"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140453136A>T"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1799T>A"}], "location": {"id": "ga4gh:SL.ZA1XNKhCT_7m2UtmnYb8ZYOVS4eplMEK", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "civic.tid:342", "label": "Cobimetinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1722365"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C68923"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["Cotellic", "GDC-0973", "MEK Inhibitor GDC-0973", "XL518"]}, "tumorType": {"id": "civic.did:216", "label": "Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9305"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:162"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1322", "description": "The endometrial cancer cell lines, AN3CA and MFE296, which carry the N550K FGFR2 mutation, were found to be sensitive to FGFR inhibition with PD174074 (10 to 40x more sensitive than cell lines with wild type FGFR2.).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:952", "label": "Byron et al., 2008, Cancer Res.", "type": "Document", "title": "PubMed: Byron et al., 2008, Cancer Res.", "pmid": 18757403}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:22", "label": "FGFR2", "description": "The FGFR proteins are involved in a wide array of pathways known to play a signficant role in cancer. Activation of these receptors can lead to activation of the RAS-MAPK pathway and the PI3K-AKT pathway, among others. The mechanisms by which FGFR can be misregulated vary between cancers. Amplification of the receptors has been observed in lung and breast cancers, coding mutations and deletions have been seen in many cancers, and more recently, FGFR fusions that lead to pathway actiation have been demonstrated to have oncogenic potential across multiple cancer types. The targeted therapeutics ponatinib, dovitinib and pazopanib have seen success in treating over-active FGFR signalling, prompting use of diagnostic sequencing targeting the FGFR genes, especially in lung cancer patients.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3689"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2263"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["BBDS", "BEK", "BFR-1", "CD332", "CEK3", "CFD1", "ECT1", "FGFR2", "JWS", "K-SAM", "KGFR", "TK14", "TK25"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:541", "label": "FGFR2 N550K", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 3.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000457416.2", "chromosome": "10", "start": 123258034, "stop": 123258034, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}, {"label": "gain_of_function_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0002053"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "545"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602614"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376157"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913476"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913476", "N549K", "ASN550LYS"], "members": [{"id": "ga4gh:VA.3JCPC-5LHzvPx-YhbWozK0gx7AN31TV8", "label": "NC_000010.10:g.123258034A>T", "digest": "3JCPC-5LHzvPx-YhbWozK0gx7AN31TV8", "type": "Allele", "location": {"id": "ga4gh:SL.sXsrkdpqeX0ECHyRXA9oCJy4PuoXNC9t", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.ss8r_wB0-b9r44TQTMmVTI92884QvBiB"}, "start": 121498519, "end": 121498520}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.7XNN_JZ2zFm-wISzwyfBSUnzAgGjXVmq", "label": "N550K", "digest": "7XNN_JZ2zFm-wISzwyfBSUnzAgGjXVmq", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_022970.3:c.1650T>A"}, {"syntax": "hgvs.p", "value": "NP_075259.4:p.Asn550Lys"}, {"syntax": "hgvs.c", "value": "ENST00000457416.2:c.1650T>A"}, {"syntax": "hgvs.g", "value": "NC_000010.10:g.123258034A>T"}], "location": {"id": "ga4gh:SL.F0i--0j0FpDqaIHcubLpWp2VKhUjS70E", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.hAWsXlUEul8pcUbRmOHRQ6osiUdGIiWs"}, "start": 548, "end": 549}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:36", "label": "PD173074", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "iuphar.ligand:5037"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:108", "label": "Endometrial Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C27815"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1380"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1327", "description": "The SH-SY5Y neuroblastoma cell line containing the F1174L ALK mutation was found to undergo cell death when treated with the ALK/IGF1R inhibitor AZD3463. These cells were more sensitive than other neuroblastoma cell lines containing wild-type ALK. Marked inhibition of soft agar colony formation of SH-SY5Y cells was also observed with drug treatment. AZD3463 inhibited Akt signaling in these cells within two hours of treatment, and activated apoptosis and autophagy pathways. Treatment of SH-SY5Y cells implanted into left kidneys of nude mice resulted in almost complete tumor regression.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:917", "label": "Wang et al., 2016, Sci Rep", "type": "Document", "title": "PubMed: Wang et al., 2016, Sci Rep", "pmid": 26786851}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:1", "label": "ALK", "description": "ALK amplifications, fusions and mutations have been shown to be driving events in non-small cell lung cancer. While crizontinib has demonstrated efficacy in treating the amplification, mutations in ALK have been shown to confer resistance to current tyrosine kinase inhibitors. Second-generation TKI's have seen varied success in treating these resistant cases, and the HSP90 inhibitor 17-AAG has been shown to be cytostatic in ALK-altered cell lines.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:427"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:238"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["ALK", "ALK1", "CD246", "NBLST3"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:8", "label": "ALK F1174L", "description": "ALK F1174L has been observed as recurrent in neuroblastoma, non-small cell lung cancer (NSCLC), and other cancer types. Neuroblastoma cells containing this mutation have shown resistance to low doses of criztonib. However, increased dosage can overcome this resistance in cell lines studies. TAE684 has also proven effective in both NSCLC and neuroblastoma F1174L containing cells.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 33.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "T", "representative_transcript": "ENST00000389048.3", "chromosome": "2", "start": 29443695, "stop": 29443695, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "8"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA279586"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "217851"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS863225281"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["PHE1174LEU", "RS863225281"], "members": [{"id": "ga4gh:VA.ivl5YUYPCfDa2igYKGlCTZec5eKC7oYY", "label": "NC_000002.11:g.29443695G>T", "digest": "ivl5YUYPCfDa2igYKGlCTZec5eKC7oYY", "type": "Allele", "location": {"id": "ga4gh:SL.Nn_joIP_IBbU0SOamVk3VuamNXOVBxPt", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.pnAqCRBrTsUoBghSD1yp_jXWSmlbdh4g"}, "start": 29220828, "end": 29220829}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.nTPnpFtWudqItR2YaGBsaJwRgGobSWAr", "label": "F1174L", "digest": "nTPnpFtWudqItR2YaGBsaJwRgGobSWAr", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004304.4:c.3522C>A"}, {"syntax": "hgvs.p", "value": "NP_004295.2:p.Phe1174Leu"}, {"syntax": "hgvs.g", "value": "NC_000002.11:g.29443695G>T"}, {"syntax": "hgvs.c", "value": "ENST00000389048.3:c.3522C>A"}], "location": {"id": "ga4gh:SL.n1vbI2DGWZjLWoNdaUdc1ISSHenlCMar", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.q9CnK-HKWh9eqhOi8FlzR7M0pCmUrWPs"}, "start": 1173, "end": 1174}, "state": {"type": "LiteralSequenceExpression", "sequence": "L"}}}, "therapeutic": {"id": "civic.tid:319", "label": "AZD3463", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "iuphar.ligand:7706"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:13", "label": "Neuroblastoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3270"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:769"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1330", "description": "Patient derived xenografts of neuroblastoma Felix cells with F1245C ALK mutation in CB17 SCID mice showed growth inhibition with crizotinib treatment over control, and mice had improved duration of event-free survival (EFS) with crizotinib treatment over vehicle, but EFS with crizotinib went down to 0% by six weeks.  In contrast, PF-06463922 treatment induced complete tumor regression and EFS rate of 100% at six weeks.  PF-06463922 inhibited viability in Felix cells at 37x efficacy over crizotinib, with IC50 values of 21.8 +/- 0.4 and 814.0 +/- 119 respectively.  PF-06463922 was well tolerated in the animal models.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:919", "label": "Infarinato et al., 2016, Cancer Discov", "type": "Document", "title": "PubMed: Infarinato et al., 2016, Cancer Discov", "pmid": 26554404}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:1", "label": "ALK", "description": "ALK amplifications, fusions and mutations have been shown to be driving events in non-small cell lung cancer. While crizontinib has demonstrated efficacy in treating the amplification, mutations in ALK have been shown to confer resistance to current tyrosine kinase inhibitors. Second-generation TKI's have seen varied success in treating these resistant cases, and the HSP90 inhibitor 17-AAG has been shown to be cytostatic in ALK-altered cell lines.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:427"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:238"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["ALK", "ALK1", "CD246", "NBLST3"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:545", "label": "ALK F1245C", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 10.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "C", "representative_transcript": "ENST00000389048.3", "chromosome": "2", "start": 29436859, "stop": 29436859, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "549"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA279597"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "217856"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS863225283"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["PHE1245CYS", "RS863225283"], "members": [{"id": "ga4gh:VA.BPCPJboEVkn3wbp34En6MYWPWHdU1Lhl", "label": "NC_000002.11:g.29436859A>C", "digest": "BPCPJboEVkn3wbp34En6MYWPWHdU1Lhl", "type": "Allele", "location": {"id": "ga4gh:SL.4KybjY8kLxVLTSwIFNz4yL-DGyUbpHby", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.pnAqCRBrTsUoBghSD1yp_jXWSmlbdh4g"}, "start": 29213992, "end": 29213993}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.La7Bq3laHrg2hFa_24-oJyLcI-qe2bR9", "label": "F1245C", "digest": "La7Bq3laHrg2hFa_24-oJyLcI-qe2bR9", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004304.4:c.3734T>G"}, {"syntax": "hgvs.p", "value": "NP_004295.2:p.Phe1245Cys"}, {"syntax": "hgvs.g", "value": "NC_000002.11:g.29436859A>C"}, {"syntax": "hgvs.c", "value": "ENST00000389048.3:c.3734T>G"}], "location": {"id": "ga4gh:SL.PjeevFCGEbzNOcnHnO4yLte9_QUI2Ig2", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.q9CnK-HKWh9eqhOi8FlzR7M0pCmUrWPs"}, "start": 1244, "end": 1245}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "civic.tid:241", "label": "Lorlatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:2103164"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C113655"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-", "7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile", "Lorbrena", "PF-06463922"]}, "tumorType": {"id": "civic.did:13", "label": "Neuroblastoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3270"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:769"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1447", "description": "Doxycycline dependent expression of the PIK3CA H1047R mutation in mouse type II alveolar epithelial cells drove lung cancer in a reversible fashion, indicating the driver properties of this p110alpha catalytic domain mutation. Administration of pan-p110 isoform and mTOR inhibitor BEZ235 to H1047R mice with established tumors resulted in reduced tumor phospho-Akt and phosoho-S6 levels, and significant regression of tumor volume.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:193", "label": "Engelman et al., 2008, Nat. Med.", "type": "Document", "title": "PubMed: Engelman et al., 2008, Nat. Med.", "pmid": 19029981}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:107", "label": "PIK3CA H1047R", "description": "PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 96.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "G", "representative_transcript": "ENST00000263967.3", "chromosome": "3", "start": 178952085, "stop": 178952085, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "107"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123326"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13652"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913279"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913279", "HIS1047ARG"], "members": [{"id": "ga4gh:VA.82Pw7U7NM7ac2koW_yITXOGSKcwg_Qqj", "label": "NC_000003.11:g.178952085A>G", "digest": "82Pw7U7NM7ac2koW_yITXOGSKcwg_Qqj", "type": "Allele", "location": {"id": "ga4gh:SL.p0VJw5IIPnKzEpQMcdBaU3xesud6QODJ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 179234296, "end": 179234297}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.hcSlm-m3AKXOL7kHM3LghXQfvAjZOmYx", "label": "H1047R", "digest": "hcSlm-m3AKXOL7kHM3LghXQfvAjZOmYx", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006218.3:c.3140A>G"}, {"syntax": "hgvs.p", "value": "NP_006209.2:p.His1047Arg"}, {"syntax": "hgvs.c", "value": "ENST00000263967.3:c.3140A>G"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.178952085A>G"}], "location": {"id": "ga4gh:SL.DBBb47ourtRut09MJ_TAvlocEwpTjF9z", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 1046, "end": 1047}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:343", "label": "Dactolisib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C74072"}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C74072"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["BEZ235", "Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-", "NVPBEZ235"]}, "tumorType": {"id": "civic.did:30", "label": "Lung Adenocarcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3512"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3910"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1537", "description": "Cells were derived from a 26-year old patient with vemurafenib resistant BRAF-mutated (V600E) cutaneous melanoma (designated 20 092 cells). Five of his metastases evaluated using whole genome sequencing contained a GNAQ (Q209P) mutation. 20 092 cells were insensitive to BRAF inhibition (PLX4720) in both proliferation assays and evaluation of pERK compared to BRAF V600E mutated, GNAQ wild-type A375P cells. Using GNAQ (Q209P) siRNA in 22 092 cells, ERK activity was suppressed and cell sensitivity to PLX4720 was increased.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1021", "label": "Turajlic et al., 2014, Ann. Oncol.", "type": "Document", "title": "PubMed: Turajlic et al., 2014, Ann. Oncol.", "pmid": 24504448}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:2317", "label": "GNAQ", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:4390"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2776"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CMAL", "CMC1", "G-ALPHA-q", "GAQ", "GNAQ", "SWS"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:600", "label": "GNAQ Q209P", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 8.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "G", "representative_transcript": "ENST00000286548.4", "chromosome": "9", "start": 80409488, "stop": 80409488, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "604"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602436"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "375957"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913492"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLN209PRO", "RS121913492"], "members": [{"id": "ga4gh:VA.EPdRwsN7yg5aPaPPN2nluuwTe1i6SRBV", "label": "NC_000009.11:g.80409488T>G", "digest": "EPdRwsN7yg5aPaPPN2nluuwTe1i6SRBV", "type": "Allele", "location": {"id": "ga4gh:SL.XP6bNaRMIVbqhVX480hxi08JFegiXDnV", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.KEO-4XBcm1cxeo_DIQ8_ofqGUkp4iZhI"}, "start": 77794571, "end": 77794572}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.g1Biz7O3dGH6mgD4S-SLGy94fL8cns9W", "label": "Q209P", "digest": "g1Biz7O3dGH6mgD4S-SLGy94fL8cns9W", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000009.11:g.80409488T>G"}, {"syntax": "hgvs.c", "value": "NM_002072.4:c.626A>C"}, {"syntax": "hgvs.p", "value": "NP_002063.2:p.Gln209Pro"}, {"syntax": "hgvs.c", "value": "ENST00000286548.4:c.626A>C"}], "location": {"id": "ga4gh:SL.duMUDbKDrF84xb5ocya-iRXvi4h90Ra3", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.EpurV-J9bhHIbKgOgfj7FaQhcbl9tAbN"}, "start": 208, "end": 209}, "state": {"type": "LiteralSequenceExpression", "sequence": "P"}}}, "therapeutic": {"id": "civic.tid:30", "label": "PLX4720", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "drugbank:DB06999"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:206", "label": "Skin Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3510"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:8923"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1986", "description": "Cell proliferation analysis showed that the ERBB2-H878Y mutant had the highest sensitivity against lapatinib among all mutations tested. Another mutation, ERBB2-V777L also remained sensitive to lapatinib with a cellular IC50 value similar to that of wild type ERBB2. Remaining mutations showed a shift towards significant higher cellular IC50 values compared to the wild type receptor. Since levels of up to 1 \u00b5M of lapatinib may be achieved in patients, ERBB2-V773A, ERBB2-T862A and ERBB2-N857S mutations might respond to higher doses of lapatinib. In contrast, ERBB2-L755S, ERBB2-L755P and ERBB2-T798M caused strong lapatinib resistance.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1396", "label": "Kancha et al., 2011, PLoS ONE", "type": "Document", "title": "PubMed: Kancha et al., 2011, PLoS ONE", "pmid": 22046346}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:20", "label": "ERBB2", "description": "ERBB2, commonly referred to as HER2, is amplified and/or overexpressed in 20-30% of invasive breast carcinomas. HER2-positive breast cancer is treated in a separate manner from other subtypes of breast cancer and commonly presents as more aggressive disease. Metastatic HER2-positive breast cancer is now commonly treated with HER2-targeted therapy. Apart from being amplified/overexpressed, ERBB2 activating mutations have been shown to have clinical importance in HER2-negative breast cancer. These mutations have shown sensitivity to the tyrosine kinase inhibitor neratinib, and highlight the importance of clinical sequencing efforts in treating breast cancer.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3430"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2064"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD340", "ERBB2", "HER-2", "HER-2/neu", "HER2", "MLN 19", "MLN-19", "NEU", "NGL", "TKR1", "VSCN2", "c-ERB-2", "c-ERB2", "p185(erbB2)"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:845", "label": "ERBB2 T862A", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 3.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "G", "representative_transcript": "ENST00000269571.5", "chromosome": "17", "start": 37881392, "stop": 37881392, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "871"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA399304738"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["THR862ALA"], "members": [{"id": "ga4gh:VA.vhq5ifNdKqsndDf53CX0kWxgWggPBRXn", "label": "NC_000017.10:g.37881392A>G", "digest": "vhq5ifNdKqsndDf53CX0kWxgWggPBRXn", "type": "Allele", "location": {"id": "ga4gh:SL.Ui4Qr54C5-ivhU9pV2inc4PuqYdRJS8W", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dLZ15tNO1Ur0IcGjwc3Sdi_0A6Yf4zm7"}, "start": 39725138, "end": 39725139}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.jZ-VSq92McC75CR2OXHbr0KZTPST1sHY", "label": "T862A", "digest": "jZ-VSq92McC75CR2OXHbr0KZTPST1sHY", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000269571.5:c.2584A>G"}, {"syntax": "hgvs.g", "value": "NC_000017.10:g.37881392A>G"}, {"syntax": "hgvs.c", "value": "NM_001289937.1:c.2584A>G"}, {"syntax": "hgvs.p", "value": "NP_001276866.1:p.Thr862Ala"}], "location": {"id": "ga4gh:SL.l3mHAT53w9p4JInZT7ezZk671YIaPJNX", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.AF1UFydIo02-bMplonKSfxlWY2q6ze3m"}, "start": 861, "end": 862}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}}, "therapeutic": {"id": "civic.tid:45", "label": "Lapatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:480167"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:572", "type": "Disease", "label": "Breast cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9335"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C26653"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["GSK572016", "GW 2016", "GW2016", "GW572016"]}, "tumorType": {"id": "civic.did:1322", "label": "Stomach Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4911"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:5517"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2036", "description": "As part of a pre-clinical experiment, the efficacy of ado-trastuzumab emtansine (T-DM1) was compared to that of trastuzumab against various HER2 positive cell lines. MCF7-neo/HER2 cell line harboring PIK3CA E545K was associated with similar sensitivity to T-DM1 as PIK3CA wild-type cell line SK-BR-3; reduced cell viability was observed at concentrations >0.01 ug/mL in both cell lines. Conversely, the cell line harboring PIK3CA E545K was resistant to trastuzumab in vitro at all concentrations tested (0-10 ug/mL). Further, treatment with T-DM1 on nude mice xenografted with PIK3CA E545K-harboring cells resulted in inhibition of tumor growth. A single dose of T-DM1 >3mg/kg was sufficient to induce tumor suppression lasting >20 days after administration.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1468", "label": "Baselga et al., 2016, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Baselga et al., 2016, Clin. Cancer Res.", "pmid": 26920887}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "refutes", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:104", "label": "PIK3CA E545K", "description": "PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 77.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000263967.3", "chromosome": "3", "start": 178936091, "stop": 178936091, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "104"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123334"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13655"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS104886003"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLU545LYS", "RS104886003"], "members": [{"id": "ga4gh:VA.uqD1zF6cMOYhBp8ur5oLTMqV0jxiC2a7", "label": "NC_000003.11:g.178936091G>A", "digest": "uqD1zF6cMOYhBp8ur5oLTMqV0jxiC2a7", "type": "Allele", "location": {"id": "ga4gh:SL.5l5tuxgJGb8y7CQzkKLPUvS-Cx4kr2ju", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 179218302, "end": 179218303}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.uw7DyLM7r98pn66LOXU3tAknmkV7jiJ0", "label": "E545K", "digest": "uw7DyLM7r98pn66LOXU3tAknmkV7jiJ0", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006218.3:c.1633G>A"}, {"syntax": "hgvs.p", "value": "NP_006209.2:p.Glu545Lys"}, {"syntax": "hgvs.c", "value": "ENST00000263967.3:c.1633G>A"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.178936091G>A"}], "location": {"id": "ga4gh:SL.SrEa0lPyesLrOX0M_aW51d-JdJhU-D3p", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 544, "end": 545}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:457", "label": "Trastuzumab Emtansine", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1371041"}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C82492"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["ADO-TRASTUZUMAB EMTANSINE", "Ado Trastuzumab Emtansine", "Immunoglobulin G1, Anti-(Human P185neu Receptor) (Human-Mouse Monoclonal RhuMab HER2 Gamma1-Chain), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer, Tetraamide With N2'-(3-((1-((4-carboxycyclohexyl)methyl)-2,5-dioxo-3-pyrrolidinyl)thio)-1-oxopropyl)-N2'-deacetylMaytansine", "Kadcyla", "PRO132365", "RO5304020", "T-DM1", "Trastuzumab-DM1", "Trastuzumab-MCC-DM1", "Trastuzumab-MCC-DM1 Antibody-Drug Conjugate", "Trastuzumab-MCC-DM1 Immunoconjugate"]}, "tumorType": {"id": "civic.did:368", "label": "Her2-receptor Positive Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C53556"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:0060079"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2078", "description": "This preclinical study tested the efficacy on several HER2 amplified breast cancer cell lines of GDC-0941 (pictilisib), a selective inhibitor of all four isoforms of class I PI3-kinases at a range of IC50 values. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. Two HER2 amplified breast cancer cell lines harboring PIK3CA C420R were tested for sensitivity to pictilisib. EFM-192A had an IC50 of 0.32uM and JIMT-1 had an IC50 of 0.86uM. Authors note that HER2 amplified cell lines were generally more sensitive, regardless of mutation, to pictilisib than basal-like cell lines (p=0.002).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1435", "label": "O'Brien et al., 2010, Clin. Cancer Res.", "type": "Document", "title": "PubMed: O'Brien et al., 2010, Clin. Cancer Res.", "pmid": 20453058}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:905", "label": "PIK3CA C420R", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 15.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "C", "representative_transcript": "ENST00000263967.3", "chromosome": "3", "start": 178927980, "stop": 178927980, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "931"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA180900"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "31945"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913272"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913272", "CYS420ARG"], "members": [{"id": "ga4gh:VA.FlWk9g7sLbC8jhlkETg-iAbLifrcCblI", "label": "NC_000003.11:g.178927980T>C", "digest": "FlWk9g7sLbC8jhlkETg-iAbLifrcCblI", "type": "Allele", "location": {"id": "ga4gh:SL.bS8dt3-rIEVr55ZRfkP8_zkpelSgcLlN", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 179210191, "end": 179210192}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.sW9clODd77-lRPaz7mtJ9uDSRsUl9X95", "label": "C420R", "digest": "sW9clODd77-lRPaz7mtJ9uDSRsUl9X95", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006218.3:c.1258T>C"}, {"syntax": "hgvs.p", "value": "NP_006209.2:p.Cys420Arg"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.178927980T>C"}, {"syntax": "hgvs.c", "value": "ENST00000263967.3:c.1258T>C"}], "location": {"id": "ga4gh:SL.8wBa2QJy6PBZLWfYP-48VOsHavtiOe3x", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 419, "end": 420}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:141", "label": "Pictilisib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C165479"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:368", "label": "Her2-receptor Positive Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C53556"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:0060079"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2089", "description": "This preclinical study tested the efficacy on several breast cancer cell lines of GDC-0941 (pictilisib), a selective inhibitor of all four isoforms of class I PI3-kinases at a range of IC50 values. Sensitivity and resistance was categorized as less than and more than an IC50 of 1 umol/L, respectively, with a maximum tested concentration of 20 umol/L. EFM-19 is a luminal type breast cancer cell line harboring PIK3CA H1047L, and it had an IC50 of 0.09uM, suggesting sensitivity. Authors note that luminal-like cell lines were generally more sensitive, regardless of mutation, to pictilisib than basal-like (p=.02)", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1435", "label": "O'Brien et al., 2010, Clin. Cancer Res.", "type": "Document", "title": "PubMed: O'Brien et al., 2010, Clin. Cancer Res.", "pmid": 20453058}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1125", "label": "PIK3CA H1047L", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 12.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000263967.3", "chromosome": "3", "start": 178952085, "stop": 178952085, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1151"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123328"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13653"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913279"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["HIS1047LEU", "RS121913279"], "members": [{"id": "ga4gh:VA.Ol69g1SmOdYaopX-zIp42cHsWZCWrCj7", "label": "NC_000003.11:g.178952085A>T", "digest": "Ol69g1SmOdYaopX-zIp42cHsWZCWrCj7", "type": "Allele", "location": {"id": "ga4gh:SL.p0VJw5IIPnKzEpQMcdBaU3xesud6QODJ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 179234296, "end": 179234297}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.UF5ba9AU6uHA2aqXR1FLbadsmNFgWhUY", "label": "H1047L", "digest": "UF5ba9AU6uHA2aqXR1FLbadsmNFgWhUY", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006218.3:c.3140A>T"}, {"syntax": "hgvs.p", "value": "NP_006209.2:p.His1047Leu"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.178952085A>T"}, {"syntax": "hgvs.c", "value": "ENST00000263967.3:c.3140A>T"}], "location": {"id": "ga4gh:SL.DBBb47ourtRut09MJ_TAvlocEwpTjF9z", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 1046, "end": 1047}, "state": {"type": "LiteralSequenceExpression", "sequence": "L"}}}, "therapeutic": {"id": "civic.tid:141", "label": "Pictilisib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C165479"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:22", "label": "Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9335"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1612"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2103", "description": "As part of a pre-clinical experiment, the efficacy of ado-trastuzumab emtansine (T-DM1) was compared to that of trastuzumab against various HER2 positive cell lines. HCC1954 and KPL-4 cell lines expressing PIK3CA H1047R were associated with similar sensitivity to T-DM1 as PIK3CA wild-type cell line SK-BR-3; reduced cell viability was observed at concentrations > 0.01 ug/mL in all three cell lines. Conversely, the cell lines harboring PIK3CA H1047R were resistant to trastuzumab in vitro at all concentrations tested (0-10 ug/mL). Further, treatment with T-DM1 on SCID mice xenografted with KPL-4 (PIK3CA H1047R cells) resulted in inhibition of tumor growth. A single dose of T-DM1 >5mg/kg was sufficient to induce tumor regression >20 days after administration.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1468", "label": "Baselga et al., 2016, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Baselga et al., 2016, Clin. Cancer Res.", "pmid": 26920887}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "refutes", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:107", "label": "PIK3CA H1047R", "description": "PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 96.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "G", "representative_transcript": "ENST00000263967.3", "chromosome": "3", "start": 178952085, "stop": 178952085, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "107"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123326"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13652"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913279"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913279", "HIS1047ARG"], "members": [{"id": "ga4gh:VA.82Pw7U7NM7ac2koW_yITXOGSKcwg_Qqj", "label": "NC_000003.11:g.178952085A>G", "digest": "82Pw7U7NM7ac2koW_yITXOGSKcwg_Qqj", "type": "Allele", "location": {"id": "ga4gh:SL.p0VJw5IIPnKzEpQMcdBaU3xesud6QODJ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 179234296, "end": 179234297}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.hcSlm-m3AKXOL7kHM3LghXQfvAjZOmYx", "label": "H1047R", "digest": "hcSlm-m3AKXOL7kHM3LghXQfvAjZOmYx", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006218.3:c.3140A>G"}, {"syntax": "hgvs.p", "value": "NP_006209.2:p.His1047Arg"}, {"syntax": "hgvs.c", "value": "ENST00000263967.3:c.3140A>G"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.178952085A>G"}], "location": {"id": "ga4gh:SL.DBBb47ourtRut09MJ_TAvlocEwpTjF9z", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 1046, "end": 1047}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:457", "label": "Trastuzumab Emtansine", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1371041"}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C82492"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["ADO-TRASTUZUMAB EMTANSINE", "Ado Trastuzumab Emtansine", "Immunoglobulin G1, Anti-(Human P185neu Receptor) (Human-Mouse Monoclonal RhuMab HER2 Gamma1-Chain), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer, Tetraamide With N2'-(3-((1-((4-carboxycyclohexyl)methyl)-2,5-dioxo-3-pyrrolidinyl)thio)-1-oxopropyl)-N2'-deacetylMaytansine", "Kadcyla", "PRO132365", "RO5304020", "T-DM1", "Trastuzumab-DM1", "Trastuzumab-MCC-DM1", "Trastuzumab-MCC-DM1 Antibody-Drug Conjugate", "Trastuzumab-MCC-DM1 Immunoconjugate"]}, "tumorType": {"id": "civic.did:368", "label": "Her2-receptor Positive Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C53556"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:0060079"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2161", "description": "In an in vitro study using NCI-H322 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. PF00299804 inhibited the growth of Ba/F3 cell lines containing the EFGR T790M resistance mutation as well as H1975 and H3255 cell lines that contain both EGFR L858R and T790M mutations and H820 containing an EGFR exon 19 deletion (Del 747_L751, Ins S) and a T790M mutation. All three cell lines were resistant to gefitinib in vitro, but sensitive to PF00299804 (IC50 <1 \u03bcmol/L for all three cell lines).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1515", "label": "Engelman et al., 2007, Cancer Res.", "type": "Document", "title": "PubMed: Engelman et al., 2007, Cancer Res.", "pmid": 18089823}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:34", "label": "EGFR T790M", "description": "EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 406.25}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55249071, "stop": 55249071, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "34"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA090928"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16613"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434569"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["THR790MET", "RS121434569"], "members": [{"id": "ga4gh:VA.OvEfBRaS34JkfM0_ZHJVDQEjqtwzyjyp", "label": "NC_000007.13:g.55249071C>T", "digest": "OvEfBRaS34JkfM0_ZHJVDQEjqtwzyjyp", "type": "Allele", "location": {"id": "ga4gh:SL.ZCgOjF-_T0EOBXGc-6yICYui-jgFzJfY", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55181377, "end": 55181378}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.faKID4aj8rP8NKZpWL4mWDToEztTUmbr", "label": "T790M", "digest": "faKID4aj8rP8NKZpWL4mWDToEztTUmbr", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2369C>T"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2369C>T"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Thr790Met"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55249071C>T"}], "location": {"id": "ga4gh:SL.C1y_lDZe8e9pKy3jcj3oJKw_7252Hrxa", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 789, "end": 790}, "state": {"type": "LiteralSequenceExpression", "sequence": "M"}}}, "therapeutic": {"id": "civic.tid:44", "label": "Dacomitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:2058848"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C53398"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(2E)-N-(4-((3-Chloro-4-Fluorophenyl)Amino)-7-Methoxyquinazolin-6-yl)-4-Piperidin-1-ylbut-2-Enamide", "EGFR Inhibitor PF-00299804", "PF-00299804", "PF-00299804-03", "PF-299804", "Vizimpro"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2221", "description": "Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. Cells were treated with doxorubicin to induce double-strand (DSB) and p21 induction was monitored by qPCR. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the T2666A variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 91% of cells by FISH. Western blot showed null ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1541", "label": "Navrkalova et al., 2013, Haematologica", "type": "Document", "title": "PubMed: Navrkalova et al., 2013, Haematologica", "pmid": 23585524}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:69", "label": "ATM", "description": "Ataxia-telangiectasia (A-T) is a recessive disorder resulting from germline mutation of the A-T mutated (ATM) gene on chromosome 11q. Upon sensing double-stranded breaks (DSB), the wild-type kinase encoded by ATM initiates the DNA-damage response by phosphorylating histone H2AX and, subsequently, various other proteins, such as BRCA1 and the MRE11\u2013RAD50\u2013NBS1 (MRN) complex, which are recruited to the damaged site. Additionally, ATM phosphorylates p53, resulting in expression of the cyclin-dependent kinase inhibitor p21 and leading to senescence or apoptosis. Somatic variants can result in inhibition or loss of these functions and can cause resistance to therapies that rely on inducing apoptosis via DSBs. Germline variants in A-T patients result in a predisposition to cancer, most frequently hematologic or breast. PARP inhibition has been studied for its potential in treating ATM mutated breast cancer patients.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:795"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:472"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["AT1", "ATA", "ATC", "ATD", "ATDC", "ATE", "ATM", "TEL1", "TELO1"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:875", "label": "ATM T2666A", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 3.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "G", "representative_transcript": "ENST00000278616.4", "chromosome": "11", "start": 108204681, "stop": 108204681, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "901"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA349494"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "219594"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "members": [{"id": "ga4gh:VA.XqVWUSZN8mHXHdYBIVVgw4eeWIBISmLD", "label": "NC_000011.9:g.108204681A>G", "digest": "XqVWUSZN8mHXHdYBIVVgw4eeWIBISmLD", "type": "Allele", "location": {"id": "ga4gh:SL.9yG1SuASaPSBrhEFiuuLWVBpsLSlUtDM", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.2NkFm8HK88MqeNkCgj78KidCAXgnsfV1"}, "start": 108333953, "end": 108333954}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.vs_b4epP1iTi5V-79vJ89r4Iui3XQH1d", "label": "T2666A", "digest": "vs_b4epP1iTi5V-79vJ89r4Iui3XQH1d", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000011.9:g.108204681A>G"}], "location": {"id": "ga4gh:SL.CBqtZey_ssOfIZ-Z4InRmodQF5z1HSg8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6k1y4bTo7pEJ-a1GaniRBaCJXXGkBGFO"}, "start": 2665, "end": 2666}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}}, "therapeutic": {"id": "civic.tid:68", "label": "Doxorubicin", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:142433"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:552", "type": "Disease", "label": "Acute myeloid leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3171"}, "relation": "relatedMatch"}]}, {"id": "hemonc:675", "type": "Disease", "label": "Thyroid cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7510"}, "relation": "relatedMatch"}]}, {"id": "hemonc:572", "type": "Disease", "label": "Breast cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9335"}, "relation": "relatedMatch"}]}, {"id": "hemonc:569", "type": "Disease", "label": "Bladder cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9334"}, "relation": "relatedMatch"}]}, {"id": "hemonc:601", "type": "Disease", "label": "Gastric cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9331"}, "relation": "relatedMatch"}]}, {"id": "hemonc:614", "type": "Disease", "label": "Hodgkin lymphoma", "mappings": [{"coding": {"system": "ncit", "code": "C9357"}, "relation": "relatedMatch"}]}, {"id": "hemonc:666", "type": "Disease", "label": "Small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C4917"}, "relation": "relatedMatch"}]}, {"id": "hemonc:645", "type": "Disease", "label": "Ovarian cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7431"}, "relation": "relatedMatch"}]}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C456"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione", "(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione", "14-Hydroxydaunomycin", "Adriablastin", "Hydroxydaunomycin", "Hydroxyl Daunorubicin", "Hydroxyldaunorubicin"]}, "tumorType": {"id": "civic.did:52", "label": "Chronic Lymphocytic Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3163"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1040"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2223", "description": "Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the R3008C variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. In a patient sample with the R3008C variant of ATM in trans with a wild-type allele, confirmed by sanger sequencing, western blot showed stable ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance. The authors propose that this variant has a dominant-negative effect.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1541", "label": "Navrkalova et al., 2013, Haematologica", "type": "Document", "title": "PubMed: Navrkalova et al., 2013, Haematologica", "pmid": 23585524}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:69", "label": "ATM", "description": "Ataxia-telangiectasia (A-T) is a recessive disorder resulting from germline mutation of the A-T mutated (ATM) gene on chromosome 11q. Upon sensing double-stranded breaks (DSB), the wild-type kinase encoded by ATM initiates the DNA-damage response by phosphorylating histone H2AX and, subsequently, various other proteins, such as BRCA1 and the MRE11\u2013RAD50\u2013NBS1 (MRN) complex, which are recruited to the damaged site. Additionally, ATM phosphorylates p53, resulting in expression of the cyclin-dependent kinase inhibitor p21 and leading to senescence or apoptosis. Somatic variants can result in inhibition or loss of these functions and can cause resistance to therapies that rely on inducing apoptosis via DSBs. Germline variants in A-T patients result in a predisposition to cancer, most frequently hematologic or breast. PARP inhibition has been studied for its potential in treating ATM mutated breast cancer patients.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:795"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:472"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["AT1", "ATA", "ATC", "ATD", "ATDC", "ATE", "ATM", "TEL1", "TELO1"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:877", "label": "ATM R3008C", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 3.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000278616.4", "chromosome": "11", "start": 108236086, "stop": 108236086, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "903"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA294307"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "members": [{"id": "ga4gh:VA.AiNeHFTueb0ysDP-cxMusGIBu0XViGWL", "label": "NC_000011.9:g.108236086C>T", "digest": "AiNeHFTueb0ysDP-cxMusGIBu0XViGWL", "type": "Allele", "location": {"id": "ga4gh:SL.1GI2mJYy_U9c56QdQ7MxKGaw5NrfPhzv", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.2NkFm8HK88MqeNkCgj78KidCAXgnsfV1"}, "start": 108365358, "end": 108365359}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.kGTBlvpvN0KYmiSSgtCpZ1wHPXgq_5LW", "label": "R3008C", "digest": "kGTBlvpvN0KYmiSSgtCpZ1wHPXgq_5LW", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000011.9:g.108236086C>T"}], "location": {"id": "ga4gh:SL.lr4UjlqWKrsBSL0XFb034tjiaZtRT7_h", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6k1y4bTo7pEJ-a1GaniRBaCJXXGkBGFO"}, "start": 3007, "end": 3008}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "civic.tid:68", "label": "Doxorubicin", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:142433"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:552", "type": "Disease", "label": "Acute myeloid leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3171"}, "relation": "relatedMatch"}]}, {"id": "hemonc:675", "type": "Disease", "label": "Thyroid cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7510"}, "relation": "relatedMatch"}]}, {"id": "hemonc:572", "type": "Disease", "label": "Breast cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9335"}, "relation": "relatedMatch"}]}, {"id": "hemonc:569", "type": "Disease", "label": "Bladder cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9334"}, "relation": "relatedMatch"}]}, {"id": "hemonc:601", "type": "Disease", "label": "Gastric cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9331"}, "relation": "relatedMatch"}]}, {"id": "hemonc:614", "type": "Disease", "label": "Hodgkin lymphoma", "mappings": [{"coding": {"system": "ncit", "code": "C9357"}, "relation": "relatedMatch"}]}, {"id": "hemonc:666", "type": "Disease", "label": "Small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C4917"}, "relation": "relatedMatch"}]}, {"id": "hemonc:645", "type": "Disease", "label": "Ovarian cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7431"}, "relation": "relatedMatch"}]}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C456"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione", "(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione", "14-Hydroxydaunomycin", "Adriablastin", "Hydroxydaunomycin", "Hydroxyl Daunorubicin", "Hydroxyldaunorubicin"]}, "tumorType": {"id": "civic.did:52", "label": "Chronic Lymphocytic Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3163"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1040"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2346", "description": "As part of a pre-clinical experiment, the efficacy of ado-trastuzumab emtansine (T-DM1) was compared to that of trastuzumab against various HER2 positive cell lines. EFM-192A cell line expressing PIK3CA C420R was associated with similar sensitivity to T-DM1 as PIK3CA wild-type cell line SK-BR-3; substantially reduced cell viability was observed at concentrations > 0.01 ug/mL in both cell lines. Conversely, when treated with trastuzumab, the cell line harboring PIK3CA C420R experienced a smaller reduction in cell viability.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1468", "label": "Baselga et al., 2016, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Baselga et al., 2016, Clin. Cancer Res.", "pmid": 26920887}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "refutes", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:905", "label": "PIK3CA C420R", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 15.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "C", "representative_transcript": "ENST00000263967.3", "chromosome": "3", "start": 178927980, "stop": 178927980, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "931"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA180900"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "31945"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913272"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913272", "CYS420ARG"], "members": [{"id": "ga4gh:VA.FlWk9g7sLbC8jhlkETg-iAbLifrcCblI", "label": "NC_000003.11:g.178927980T>C", "digest": "FlWk9g7sLbC8jhlkETg-iAbLifrcCblI", "type": "Allele", "location": {"id": "ga4gh:SL.bS8dt3-rIEVr55ZRfkP8_zkpelSgcLlN", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 179210191, "end": 179210192}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.sW9clODd77-lRPaz7mtJ9uDSRsUl9X95", "label": "C420R", "digest": "sW9clODd77-lRPaz7mtJ9uDSRsUl9X95", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006218.3:c.1258T>C"}, {"syntax": "hgvs.p", "value": "NP_006209.2:p.Cys420Arg"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.178927980T>C"}, {"syntax": "hgvs.c", "value": "ENST00000263967.3:c.1258T>C"}], "location": {"id": "ga4gh:SL.8wBa2QJy6PBZLWfYP-48VOsHavtiOe3x", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 419, "end": 420}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:457", "label": "Trastuzumab Emtansine", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1371041"}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C82492"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["ADO-TRASTUZUMAB EMTANSINE", "Ado Trastuzumab Emtansine", "Immunoglobulin G1, Anti-(Human P185neu Receptor) (Human-Mouse Monoclonal RhuMab HER2 Gamma1-Chain), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer, Tetraamide With N2'-(3-((1-((4-carboxycyclohexyl)methyl)-2,5-dioxo-3-pyrrolidinyl)thio)-1-oxopropyl)-N2'-deacetylMaytansine", "Kadcyla", "PRO132365", "RO5304020", "T-DM1", "Trastuzumab-DM1", "Trastuzumab-MCC-DM1", "Trastuzumab-MCC-DM1 Antibody-Drug Conjugate", "Trastuzumab-MCC-DM1 Immunoconjugate"]}, "tumorType": {"id": "civic.did:368", "label": "Her2-receptor Positive Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C53556"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:0060079"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2626", "description": "In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to reversible tyrosine kinase inhibitor drugs. Cells with an EGFR L858R mutation demonstrated an improved response to lapatinib (IC50: 63nM vs. 534nM) compared to wildtype EGFR cells.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1525", "label": "Li et al., 2008, Oncogene", "type": "Document", "title": "PubMed: Li et al., 2008, Oncogene", "pmid": 18408761}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:33", "label": "EGFR L858R", "description": "EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 379.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "G", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55259515, "stop": 55259515, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "33"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA126713"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16609"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376282"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376280"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434568"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121434568", "LEU858ARG"], "members": [{"id": "ga4gh:VA.TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "label": "NC_000007.13:g.55259515T>G", "digest": "TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "type": "Allele", "location": {"id": "ga4gh:SL.ulUNwZvajob7nzyrlpOd6uUWZIYCsoWb", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55191821, "end": 55191822}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "label": "L858R", "digest": "z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000007.13:g.55259515T>G"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2573T>G"}, {"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2573T>G"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Leu858Arg"}], "location": {"id": "ga4gh:SL.yVGJnwqxV6oCGqC_8nNb58D_wPXJeNJo", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 857, "end": 858}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:45", "label": "Lapatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:480167"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:572", "type": "Disease", "label": "Breast cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9335"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C26653"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["GSK572016", "GW 2016", "GW2016", "GW572016"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2627", "description": "In an in vitro study using NCI-H322 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated an improved response to Dacomitinib (IC50: 0.007umol/L vs. >10umol/L) compared to wildtype EGFR cells or compared to reversible TKI drug gefitinib (IC50: 0.075umol/L vs. wild-type >10umol/L).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1515", "label": "Engelman et al., 2007, Cancer Res.", "type": "Document", "title": "PubMed: Engelman et al., 2007, Cancer Res.", "pmid": 18089823}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:33", "label": "EGFR L858R", "description": "EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 379.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "G", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55259515, "stop": 55259515, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "33"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA126713"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16609"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376282"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376280"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434568"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121434568", "LEU858ARG"], "members": [{"id": "ga4gh:VA.TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "label": "NC_000007.13:g.55259515T>G", "digest": "TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "type": "Allele", "location": {"id": "ga4gh:SL.ulUNwZvajob7nzyrlpOd6uUWZIYCsoWb", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55191821, "end": 55191822}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "label": "L858R", "digest": "z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000007.13:g.55259515T>G"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2573T>G"}, {"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2573T>G"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Leu858Arg"}], "location": {"id": "ga4gh:SL.yVGJnwqxV6oCGqC_8nNb58D_wPXJeNJo", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 857, "end": 858}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:44", "label": "Dacomitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:2058848"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C53398"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(2E)-N-(4-((3-Chloro-4-Fluorophenyl)Amino)-7-Methoxyquinazolin-6-yl)-4-Piperidin-1-ylbut-2-Enamide", "EGFR Inhibitor PF-00299804", "PF-00299804", "PF-00299804-03", "PF-299804", "Vizimpro"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2628", "description": "In an in vitro study using NCI-H3255 cells (EGFR L858R), inhibition of cell growth was used as an assay to determine sensitivity to tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated sensitivity to neratinib (IC50: 0.0049 \u03bcmol/L) compared to EGFRwt A549 cells (IC50 > 1 \u03bcmol/L).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1526", "label": "Shimamura et al., 2006, Cancer Res.", "type": "Document", "title": "PubMed: Shimamura et al., 2006, Cancer Res.", "pmid": 16818618}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:33", "label": "EGFR L858R", "description": "EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 379.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "G", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55259515, "stop": 55259515, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "33"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA126713"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16609"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376282"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376280"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434568"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121434568", "LEU858ARG"], "members": [{"id": "ga4gh:VA.TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "label": "NC_000007.13:g.55259515T>G", "digest": "TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "type": "Allele", "location": {"id": "ga4gh:SL.ulUNwZvajob7nzyrlpOd6uUWZIYCsoWb", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55191821, "end": 55191822}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "label": "L858R", "digest": "z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000007.13:g.55259515T>G"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2573T>G"}, {"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2573T>G"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Leu858Arg"}], "location": {"id": "ga4gh:SL.yVGJnwqxV6oCGqC_8nNb58D_wPXJeNJo", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 857, "end": 858}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:52", "label": "Neratinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1940643"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C49094"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide", "2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-", "HKI 272", "HKI-272", "PB 272", "PB-272"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2631", "description": "In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated an improved response to canertinib (IC50: 1nM vs. 198nM) compared to wildtype EGFR cells.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1525", "label": "Li et al., 2008, Oncogene", "type": "Document", "title": "PubMed: Li et al., 2008, Oncogene", "pmid": 18408761}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:33", "label": "EGFR L858R", "description": "EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 379.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "G", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55259515, "stop": 55259515, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "33"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA126713"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16609"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376282"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376280"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434568"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121434568", "LEU858ARG"], "members": [{"id": "ga4gh:VA.TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "label": "NC_000007.13:g.55259515T>G", "digest": "TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "type": "Allele", "location": {"id": "ga4gh:SL.ulUNwZvajob7nzyrlpOd6uUWZIYCsoWb", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55191821, "end": 55191822}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "label": "L858R", "digest": "z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000007.13:g.55259515T>G"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2573T>G"}, {"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2573T>G"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Leu858Arg"}], "location": {"id": "ga4gh:SL.yVGJnwqxV6oCGqC_8nNb58D_wPXJeNJo", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 857, "end": 858}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:465", "label": "Canertinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C77588"}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C77588"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["2-propenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-", "N-{4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2832", "description": "Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the K293* variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the K293* variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 92% of cells by FISH. Western blot showed null ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1541", "label": "Navrkalova et al., 2013, Haematologica", "type": "Document", "title": "PubMed: Navrkalova et al., 2013, Haematologica", "pmid": 23585524}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:69", "label": "ATM", "description": "Ataxia-telangiectasia (A-T) is a recessive disorder resulting from germline mutation of the A-T mutated (ATM) gene on chromosome 11q. Upon sensing double-stranded breaks (DSB), the wild-type kinase encoded by ATM initiates the DNA-damage response by phosphorylating histone H2AX and, subsequently, various other proteins, such as BRCA1 and the MRE11\u2013RAD50\u2013NBS1 (MRN) complex, which are recruited to the damaged site. Additionally, ATM phosphorylates p53, resulting in expression of the cyclin-dependent kinase inhibitor p21 and leading to senescence or apoptosis. Somatic variants can result in inhibition or loss of these functions and can cause resistance to therapies that rely on inducing apoptosis via DSBs. Germline variants in A-T patients result in a predisposition to cancer, most frequently hematologic or breast. PARP inhibition has been studied for its potential in treating ATM mutated breast cancer patients.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:795"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:472"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["AT1", "ATA", "ATC", "ATD", "ATDC", "ATE", "ATM", "TEL1", "TELO1"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1129", "label": "ATM K293*", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 3.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000278616.4", "chromosome": "11", "start": 108115729, "stop": 108115729, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "stop_gained", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001587"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1155"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16041383"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "370378"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS1057516442"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["LYS293TER", "RS1057516442", "K293X"], "members": [{"id": "ga4gh:VA.Ar77eWNyZXgo3CSxufOO2wU8Vm0busUU", "label": "NC_000011.9:g.108115729A>T", "digest": "Ar77eWNyZXgo3CSxufOO2wU8Vm0busUU", "type": "Allele", "location": {"id": "ga4gh:SL.2f3XAGOjCQsjQ-C4xY_Ny4yt_raBXIjE", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.2NkFm8HK88MqeNkCgj78KidCAXgnsfV1"}, "start": 108245001, "end": 108245002}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.0goBbxWDcX2RErSu_FxEutgB8hoERqcf", "label": "K293*", "digest": "0goBbxWDcX2RErSu_FxEutgB8hoERqcf", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000278616.4:c.877A>T"}, {"syntax": "hgvs.c", "value": "NM_000051.3:c.877A>T"}, {"syntax": "hgvs.p", "value": "NP_000042.3:p.Lys293Ter"}, {"syntax": "hgvs.g", "value": "NC_000011.9:g.108115729A>T"}], "location": {"id": "ga4gh:SL.snf3OHPBqQf-mWpb40HvjR6QDJEKz-SJ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6k1y4bTo7pEJ-a1GaniRBaCJXXGkBGFO"}, "start": 292, "end": 293}, "state": {"type": "LiteralSequenceExpression", "sequence": "*"}}}, "therapeutic": {"id": "civic.tid:68", "label": "Doxorubicin", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:142433"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:552", "type": "Disease", "label": "Acute myeloid leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3171"}, "relation": "relatedMatch"}]}, {"id": "hemonc:675", "type": "Disease", "label": "Thyroid cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7510"}, "relation": "relatedMatch"}]}, {"id": "hemonc:572", "type": "Disease", "label": "Breast cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9335"}, "relation": "relatedMatch"}]}, {"id": "hemonc:569", "type": "Disease", "label": "Bladder cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9334"}, "relation": "relatedMatch"}]}, {"id": "hemonc:601", "type": "Disease", "label": "Gastric cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9331"}, "relation": "relatedMatch"}]}, {"id": "hemonc:614", "type": "Disease", "label": "Hodgkin lymphoma", "mappings": [{"coding": {"system": "ncit", "code": "C9357"}, "relation": "relatedMatch"}]}, {"id": "hemonc:666", "type": "Disease", "label": "Small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C4917"}, "relation": "relatedMatch"}]}, {"id": "hemonc:645", "type": "Disease", "label": "Ovarian cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7431"}, "relation": "relatedMatch"}]}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C456"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione", "(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione", "14-Hydroxydaunomycin", "Adriablastin", "Hydroxydaunomycin", "Hydroxyl Daunorubicin", "Hydroxyldaunorubicin"]}, "tumorType": {"id": "civic.did:52", "label": "Chronic Lymphocytic Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3163"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1040"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2835", "description": "Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the F1025L variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the F1025L variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 93% of cells by FISH. Western blot showed stable ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1541", "label": "Navrkalova et al., 2013, Haematologica", "type": "Document", "title": "PubMed: Navrkalova et al., 2013, Haematologica", "pmid": 23585524}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:69", "label": "ATM", "description": "Ataxia-telangiectasia (A-T) is a recessive disorder resulting from germline mutation of the A-T mutated (ATM) gene on chromosome 11q. Upon sensing double-stranded breaks (DSB), the wild-type kinase encoded by ATM initiates the DNA-damage response by phosphorylating histone H2AX and, subsequently, various other proteins, such as BRCA1 and the MRE11\u2013RAD50\u2013NBS1 (MRN) complex, which are recruited to the damaged site. Additionally, ATM phosphorylates p53, resulting in expression of the cyclin-dependent kinase inhibitor p21 and leading to senescence or apoptosis. Somatic variants can result in inhibition or loss of these functions and can cause resistance to therapies that rely on inducing apoptosis via DSBs. Germline variants in A-T patients result in a predisposition to cancer, most frequently hematologic or breast. PARP inhibition has been studied for its potential in treating ATM mutated breast cancer patients.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:795"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:472"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["AT1", "ATA", "ATC", "ATD", "ATDC", "ATE", "ATM", "TEL1", "TELO1"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1132", "label": "ATM F1025L", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 3.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "G", "representative_transcript": "ENST00000278616.4", "chromosome": "11", "start": 108142131, "stop": 108142131, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1158"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA382547708"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["PHE1025LEU"], "members": [{"id": "ga4gh:VA.UcJGm0ko0nt_oDyRi4b24V47t4QrPKlu", "label": "NC_000011.9:g.108142131T>G", "digest": "UcJGm0ko0nt_oDyRi4b24V47t4QrPKlu", "type": "Allele", "location": {"id": "ga4gh:SL.mjzk876QWZkaXgvCLuGgu8AEUPlKRuAX", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.2NkFm8HK88MqeNkCgj78KidCAXgnsfV1"}, "start": 108271403, "end": 108271404}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.RScVHeblYLYAS7gdAEQK-t7BcmRvgWgk", "label": "F1025L", "digest": "RScVHeblYLYAS7gdAEQK-t7BcmRvgWgk", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000278616.4:c.3075T>G"}, {"syntax": "hgvs.g", "value": "NC_000011.9:g.108142131T>G"}, {"syntax": "hgvs.c", "value": "NM_000051.3:c.3075T>G"}, {"syntax": "hgvs.p", "value": "NP_000042.3:p.Phe1025Leu"}], "location": {"id": "ga4gh:SL.DFjTQQGcbEmfzNWeH_AW3ns5HOOZSVOl", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6k1y4bTo7pEJ-a1GaniRBaCJXXGkBGFO"}, "start": 1024, "end": 1025}, "state": {"type": "LiteralSequenceExpression", "sequence": "L"}}}, "therapeutic": {"id": "civic.tid:68", "label": "Doxorubicin", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:142433"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:552", "type": "Disease", "label": "Acute myeloid leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3171"}, "relation": "relatedMatch"}]}, {"id": "hemonc:675", "type": "Disease", "label": "Thyroid cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7510"}, "relation": "relatedMatch"}]}, {"id": "hemonc:572", "type": "Disease", "label": "Breast cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9335"}, "relation": "relatedMatch"}]}, {"id": "hemonc:569", "type": "Disease", "label": "Bladder cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9334"}, "relation": "relatedMatch"}]}, {"id": "hemonc:601", "type": "Disease", "label": "Gastric cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9331"}, "relation": "relatedMatch"}]}, {"id": "hemonc:614", "type": "Disease", "label": "Hodgkin lymphoma", "mappings": [{"coding": {"system": "ncit", "code": "C9357"}, "relation": "relatedMatch"}]}, {"id": "hemonc:666", "type": "Disease", "label": "Small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C4917"}, "relation": "relatedMatch"}]}, {"id": "hemonc:645", "type": "Disease", "label": "Ovarian cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7431"}, "relation": "relatedMatch"}]}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C456"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione", "(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione", "14-Hydroxydaunomycin", "Adriablastin", "Hydroxydaunomycin", "Hydroxyl Daunorubicin", "Hydroxyldaunorubicin"]}, "tumorType": {"id": "civic.did:52", "label": "Chronic Lymphocytic Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3163"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1040"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2839", "description": "Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the E2187* variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the E2187* variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 96% of cells by FISH. Western blot showed null ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1541", "label": "Navrkalova et al., 2013, Haematologica", "type": "Document", "title": "PubMed: Navrkalova et al., 2013, Haematologica", "pmid": 23585524}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:69", "label": "ATM", "description": "Ataxia-telangiectasia (A-T) is a recessive disorder resulting from germline mutation of the A-T mutated (ATM) gene on chromosome 11q. Upon sensing double-stranded breaks (DSB), the wild-type kinase encoded by ATM initiates the DNA-damage response by phosphorylating histone H2AX and, subsequently, various other proteins, such as BRCA1 and the MRE11\u2013RAD50\u2013NBS1 (MRN) complex, which are recruited to the damaged site. Additionally, ATM phosphorylates p53, resulting in expression of the cyclin-dependent kinase inhibitor p21 and leading to senescence or apoptosis. Somatic variants can result in inhibition or loss of these functions and can cause resistance to therapies that rely on inducing apoptosis via DSBs. Germline variants in A-T patients result in a predisposition to cancer, most frequently hematologic or breast. PARP inhibition has been studied for its potential in treating ATM mutated breast cancer patients.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:795"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:472"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["AT1", "ATA", "ATC", "ATD", "ATDC", "ATE", "ATM", "TEL1", "TELO1"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1136", "label": "ATM E2187*", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 3.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "T", "representative_transcript": "ENST00000278616.4", "chromosome": "11", "start": 108192134, "stop": 108192134, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "stop_gained", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001587"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1162"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA382554382"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLU2187TER", "E2187X"], "members": [{"id": "ga4gh:VA.h_HcsftQpXOQwpIKtwFK7443k7oifj2V", "label": "NC_000011.9:g.108192134G>T", "digest": "h_HcsftQpXOQwpIKtwFK7443k7oifj2V", "type": "Allele", "location": {"id": "ga4gh:SL.QamJZ43w-cpVGZpA1iWWhiTRHH7aCoHx", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.2NkFm8HK88MqeNkCgj78KidCAXgnsfV1"}, "start": 108321406, "end": 108321407}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.Ltn_kvUMVkzDGqbh3LjobtQLV2OIaQYH", "label": "E2187*", "digest": "Ltn_kvUMVkzDGqbh3LjobtQLV2OIaQYH", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000278616.4:c.6559G>T"}, {"syntax": "hgvs.g", "value": "NC_000011.9:g.108192134G>T"}, {"syntax": "hgvs.c", "value": "NM_000051.3:c.6559G>T"}, {"syntax": "hgvs.p", "value": "NP_000042.3:p.Glu2187Ter"}], "location": {"id": "ga4gh:SL.tCIdsINgQ3nxiZ0zV7l_1T0Oa-JwpJit", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6k1y4bTo7pEJ-a1GaniRBaCJXXGkBGFO"}, "start": 2186, "end": 2187}, "state": {"type": "LiteralSequenceExpression", "sequence": "*"}}}, "therapeutic": {"id": "civic.tid:68", "label": "Doxorubicin", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:142433"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:552", "type": "Disease", "label": "Acute myeloid leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3171"}, "relation": "relatedMatch"}]}, {"id": "hemonc:675", "type": "Disease", "label": "Thyroid cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7510"}, "relation": "relatedMatch"}]}, {"id": "hemonc:572", "type": "Disease", "label": "Breast cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9335"}, "relation": "relatedMatch"}]}, {"id": "hemonc:569", "type": "Disease", "label": "Bladder cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9334"}, "relation": "relatedMatch"}]}, {"id": "hemonc:601", "type": "Disease", "label": "Gastric cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9331"}, "relation": "relatedMatch"}]}, {"id": "hemonc:614", "type": "Disease", "label": "Hodgkin lymphoma", "mappings": [{"coding": {"system": "ncit", "code": "C9357"}, "relation": "relatedMatch"}]}, {"id": "hemonc:666", "type": "Disease", "label": "Small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C4917"}, "relation": "relatedMatch"}]}, {"id": "hemonc:645", "type": "Disease", "label": "Ovarian cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7431"}, "relation": "relatedMatch"}]}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C456"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione", "(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione", "14-Hydroxydaunomycin", "Adriablastin", "Hydroxydaunomycin", "Hydroxyl Daunorubicin", "Hydroxyldaunorubicin"]}, "tumorType": {"id": "civic.did:52", "label": "Chronic Lymphocytic Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3163"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1040"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2840", "description": "Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the L2427P variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the L2427P variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 94% of cells by FISH. Western blot showed stable ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1541", "label": "Navrkalova et al., 2013, Haematologica", "type": "Document", "title": "PubMed: Navrkalova et al., 2013, Haematologica", "pmid": 23585524}], "predicate": "predictsResistanceTo", "qualifiers": {"geneContext": {"id": "civic.gid:69", "label": "ATM", "description": "Ataxia-telangiectasia (A-T) is a recessive disorder resulting from germline mutation of the A-T mutated (ATM) gene on chromosome 11q. Upon sensing double-stranded breaks (DSB), the wild-type kinase encoded by ATM initiates the DNA-damage response by phosphorylating histone H2AX and, subsequently, various other proteins, such as BRCA1 and the MRE11\u2013RAD50\u2013NBS1 (MRN) complex, which are recruited to the damaged site. Additionally, ATM phosphorylates p53, resulting in expression of the cyclin-dependent kinase inhibitor p21 and leading to senescence or apoptosis. Somatic variants can result in inhibition or loss of these functions and can cause resistance to therapies that rely on inducing apoptosis via DSBs. Germline variants in A-T patients result in a predisposition to cancer, most frequently hematologic or breast. PARP inhibition has been studied for its potential in treating ATM mutated breast cancer patients.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:795"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:472"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["AT1", "ATA", "ATC", "ATD", "ATDC", "ATE", "ATM", "TEL1", "TELO1"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1137", "label": "ATM L2427P", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 3.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "C", "representative_transcript": "ENST00000278616.4", "chromosome": "11", "start": 108199938, "stop": 108199938, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1163"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA382559785"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["LEU2427PRO"], "members": [{"id": "ga4gh:VA.tYRtC-EJVMtiZIrMcrIf6_wAc5zeUshA", "label": "NC_000011.9:g.108199938T>C", "digest": "tYRtC-EJVMtiZIrMcrIf6_wAc5zeUshA", "type": "Allele", "location": {"id": "ga4gh:SL.dEVvrODGMjd7ofdjSVFD6LjBll3mgUQp", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.2NkFm8HK88MqeNkCgj78KidCAXgnsfV1"}, "start": 108329210, "end": 108329211}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.3tBg_bl0mWBNV8E8WkCYVhePW5b_gGSu", "label": "L2427P", "digest": "3tBg_bl0mWBNV8E8WkCYVhePW5b_gGSu", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000278616.4:c.7280T>C"}, {"syntax": "hgvs.g", "value": "NC_000011.9:g.108199938T>C"}, {"syntax": "hgvs.c", "value": "NM_000051.3:c.7280T>C"}, {"syntax": "hgvs.p", "value": "NP_000042.3:p.Leu2427Pro"}], "location": {"id": "ga4gh:SL.bmKKTKX6x3oBKFTe7J5yQCHRqwa6Ibrq", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6k1y4bTo7pEJ-a1GaniRBaCJXXGkBGFO"}, "start": 2426, "end": 2427}, "state": {"type": "LiteralSequenceExpression", "sequence": "P"}}}, "therapeutic": {"id": "civic.tid:68", "label": "Doxorubicin", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:142433"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:552", "type": "Disease", "label": "Acute myeloid leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3171"}, "relation": "relatedMatch"}]}, {"id": "hemonc:675", "type": "Disease", "label": "Thyroid cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7510"}, "relation": "relatedMatch"}]}, {"id": "hemonc:572", "type": "Disease", "label": "Breast cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9335"}, "relation": "relatedMatch"}]}, {"id": "hemonc:569", "type": "Disease", "label": "Bladder cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9334"}, "relation": "relatedMatch"}]}, {"id": "hemonc:601", "type": "Disease", "label": "Gastric cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9331"}, "relation": "relatedMatch"}]}, {"id": "hemonc:614", "type": "Disease", "label": "Hodgkin lymphoma", "mappings": [{"coding": {"system": "ncit", "code": "C9357"}, "relation": "relatedMatch"}]}, {"id": "hemonc:666", "type": "Disease", "label": "Small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C4917"}, "relation": "relatedMatch"}]}, {"id": "hemonc:645", "type": "Disease", "label": "Ovarian cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7431"}, "relation": "relatedMatch"}]}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C456"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione", "(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione", "14-Hydroxydaunomycin", "Adriablastin", "Hydroxydaunomycin", "Hydroxyl Daunorubicin", "Hydroxyldaunorubicin"]}, "tumorType": {"id": "civic.did:52", "label": "Chronic Lymphocytic Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3163"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1040"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2841", "description": "Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the F2732V variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the F2732V variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 98% of cells by FISH. Western blot showed stable ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1541", "label": "Navrkalova et al., 2013, Haematologica", "type": "Document", "title": "PubMed: Navrkalova et al., 2013, Haematologica", "pmid": 23585524}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:69", "label": "ATM", "description": "Ataxia-telangiectasia (A-T) is a recessive disorder resulting from germline mutation of the A-T mutated (ATM) gene on chromosome 11q. Upon sensing double-stranded breaks (DSB), the wild-type kinase encoded by ATM initiates the DNA-damage response by phosphorylating histone H2AX and, subsequently, various other proteins, such as BRCA1 and the MRE11\u2013RAD50\u2013NBS1 (MRN) complex, which are recruited to the damaged site. Additionally, ATM phosphorylates p53, resulting in expression of the cyclin-dependent kinase inhibitor p21 and leading to senescence or apoptosis. Somatic variants can result in inhibition or loss of these functions and can cause resistance to therapies that rely on inducing apoptosis via DSBs. Germline variants in A-T patients result in a predisposition to cancer, most frequently hematologic or breast. PARP inhibition has been studied for its potential in treating ATM mutated breast cancer patients.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:795"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:472"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["AT1", "ATA", "ATC", "ATD", "ATDC", "ATE", "ATM", "TEL1", "TELO1"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1138", "label": "ATM F2732V", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 3.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "G", "representative_transcript": "ENST00000278616.4", "chromosome": "11", "start": 108206614, "stop": 108206614, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1164"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16619250"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "422531"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS876659619"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS876659619", "PHE2732VAL"], "members": [{"id": "ga4gh:VA.39mrzeSwVZD8ynRILk_UXGfZebGjRzxb", "label": "NC_000011.9:g.108206614T>G", "digest": "39mrzeSwVZD8ynRILk_UXGfZebGjRzxb", "type": "Allele", "location": {"id": "ga4gh:SL.5XOXEOz6Y9J58nU8Cz2KhsLF4NshXsds", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.2NkFm8HK88MqeNkCgj78KidCAXgnsfV1"}, "start": 108335886, "end": 108335887}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.eMWFcLpHjpM38bKJsHEa37tbbviFQLWR", "label": "F2732V", "digest": "eMWFcLpHjpM38bKJsHEa37tbbviFQLWR", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000278616.4:c.8194T>G"}, {"syntax": "hgvs.g", "value": "NC_000011.9:g.108206614T>G"}, {"syntax": "hgvs.c", "value": "NM_000051.3:c.8194T>G"}, {"syntax": "hgvs.p", "value": "NP_000042.3:p.Phe2732Val"}], "location": {"id": "ga4gh:SL.kJbRBC7E2iwnStjWjHqMkCqrfnzny_Rf", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6k1y4bTo7pEJ-a1GaniRBaCJXXGkBGFO"}, "start": 2731, "end": 2732}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "civic.tid:68", "label": "Doxorubicin", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:142433"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:552", "type": "Disease", "label": "Acute myeloid leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3171"}, "relation": "relatedMatch"}]}, {"id": "hemonc:675", "type": "Disease", "label": "Thyroid cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7510"}, "relation": "relatedMatch"}]}, {"id": "hemonc:572", "type": "Disease", "label": "Breast cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9335"}, "relation": "relatedMatch"}]}, {"id": "hemonc:569", "type": "Disease", "label": "Bladder cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9334"}, "relation": "relatedMatch"}]}, {"id": "hemonc:601", "type": "Disease", "label": "Gastric cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9331"}, "relation": "relatedMatch"}]}, {"id": "hemonc:614", "type": "Disease", "label": "Hodgkin lymphoma", "mappings": [{"coding": {"system": "ncit", "code": "C9357"}, "relation": "relatedMatch"}]}, {"id": "hemonc:666", "type": "Disease", "label": "Small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C4917"}, "relation": "relatedMatch"}]}, {"id": "hemonc:645", "type": "Disease", "label": "Ovarian cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7431"}, "relation": "relatedMatch"}]}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C456"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione", "(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione", "14-Hydroxydaunomycin", "Adriablastin", "Hydroxydaunomycin", "Hydroxyl Daunorubicin", "Hydroxyldaunorubicin"]}, "tumorType": {"id": "civic.did:52", "label": "Chronic Lymphocytic Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3163"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1040"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2845", "description": "Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the D1682H variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the D1682H variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 93% of cells by FISH. Western blot showed stable ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1541", "label": "Navrkalova et al., 2013, Haematologica", "type": "Document", "title": "PubMed: Navrkalova et al., 2013, Haematologica", "pmid": 23585524}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:69", "label": "ATM", "description": "Ataxia-telangiectasia (A-T) is a recessive disorder resulting from germline mutation of the A-T mutated (ATM) gene on chromosome 11q. Upon sensing double-stranded breaks (DSB), the wild-type kinase encoded by ATM initiates the DNA-damage response by phosphorylating histone H2AX and, subsequently, various other proteins, such as BRCA1 and the MRE11\u2013RAD50\u2013NBS1 (MRN) complex, which are recruited to the damaged site. Additionally, ATM phosphorylates p53, resulting in expression of the cyclin-dependent kinase inhibitor p21 and leading to senescence or apoptosis. Somatic variants can result in inhibition or loss of these functions and can cause resistance to therapies that rely on inducing apoptosis via DSBs. Germline variants in A-T patients result in a predisposition to cancer, most frequently hematologic or breast. PARP inhibition has been studied for its potential in treating ATM mutated breast cancer patients.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:795"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:472"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["AT1", "ATA", "ATC", "ATD", "ATDC", "ATE", "ATM", "TEL1", "TELO1"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1142", "label": "ATM D1682H", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 3.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "C", "representative_transcript": "ENST00000278616.4", "chromosome": "11", "start": 108170479, "stop": 108170479, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1168"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA115932"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "3026"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434217"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121434217", "ASP1682HIS"], "members": [{"id": "ga4gh:VA.aL2x-TKJppKG-bdufLV8zOvN3zaZAMxN", "label": "NC_000011.9:g.108170479G>C", "digest": "aL2x-TKJppKG-bdufLV8zOvN3zaZAMxN", "type": "Allele", "location": {"id": "ga4gh:SL.sxs2Bfx1qwE4uEPl9AX5QsTFhyDhG6Rg", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.2NkFm8HK88MqeNkCgj78KidCAXgnsfV1"}, "start": 108299751, "end": 108299752}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.8u4HlEgD7--0mPx5PlVIkkkfRX-XAssV", "label": "D1682H", "digest": "8u4HlEgD7--0mPx5PlVIkkkfRX-XAssV", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_000051.3:c.5044G>C"}, {"syntax": "hgvs.p", "value": "NP_000042.3:p.Asp1682His"}, {"syntax": "hgvs.g", "value": "NC_000011.9:g.108170479G>C"}, {"syntax": "hgvs.c", "value": "ENST00000278616.4:c.5044G>C"}], "location": {"id": "ga4gh:SL.erUKKBi-tVPlMws1fPMgW5lC_SKnhPdV", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6k1y4bTo7pEJ-a1GaniRBaCJXXGkBGFO"}, "start": 1681, "end": 1682}, "state": {"type": "LiteralSequenceExpression", "sequence": "H"}}}, "therapeutic": {"id": "civic.tid:68", "label": "Doxorubicin", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:142433"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:552", "type": "Disease", "label": "Acute myeloid leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3171"}, "relation": "relatedMatch"}]}, {"id": "hemonc:675", "type": "Disease", "label": "Thyroid cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7510"}, "relation": "relatedMatch"}]}, {"id": "hemonc:572", "type": "Disease", "label": "Breast cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9335"}, "relation": "relatedMatch"}]}, {"id": "hemonc:569", "type": "Disease", "label": "Bladder cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9334"}, "relation": "relatedMatch"}]}, {"id": "hemonc:601", "type": "Disease", "label": "Gastric cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9331"}, "relation": "relatedMatch"}]}, {"id": "hemonc:614", "type": "Disease", "label": "Hodgkin lymphoma", "mappings": [{"coding": {"system": "ncit", "code": "C9357"}, "relation": "relatedMatch"}]}, {"id": "hemonc:666", "type": "Disease", "label": "Small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C4917"}, "relation": "relatedMatch"}]}, {"id": "hemonc:645", "type": "Disease", "label": "Ovarian cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7431"}, "relation": "relatedMatch"}]}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C456"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione", "(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione", "14-Hydroxydaunomycin", "Adriablastin", "Hydroxydaunomycin", "Hydroxyl Daunorubicin", "Hydroxyldaunorubicin"]}, "tumorType": {"id": "civic.did:52", "label": "Chronic Lymphocytic Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3163"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1040"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2846", "description": "Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the A2062V variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the A2062V variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 87% of cells by FISH. Western blot showed stable ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1541", "label": "Navrkalova et al., 2013, Haematologica", "type": "Document", "title": "PubMed: Navrkalova et al., 2013, Haematologica", "pmid": 23585524}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:69", "label": "ATM", "description": "Ataxia-telangiectasia (A-T) is a recessive disorder resulting from germline mutation of the A-T mutated (ATM) gene on chromosome 11q. Upon sensing double-stranded breaks (DSB), the wild-type kinase encoded by ATM initiates the DNA-damage response by phosphorylating histone H2AX and, subsequently, various other proteins, such as BRCA1 and the MRE11\u2013RAD50\u2013NBS1 (MRN) complex, which are recruited to the damaged site. Additionally, ATM phosphorylates p53, resulting in expression of the cyclin-dependent kinase inhibitor p21 and leading to senescence or apoptosis. Somatic variants can result in inhibition or loss of these functions and can cause resistance to therapies that rely on inducing apoptosis via DSBs. Germline variants in A-T patients result in a predisposition to cancer, most frequently hematologic or breast. PARP inhibition has been studied for its potential in treating ATM mutated breast cancer patients.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:795"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:472"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["AT1", "ATA", "ATC", "ATD", "ATDC", "ATE", "ATM", "TEL1", "TELO1"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1143", "label": "ATM A2062V", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 3.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000278616.4", "chromosome": "11", "start": 108186827, "stop": 108186827, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1169"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA382550752"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ALA2062VAL"], "members": [{"id": "ga4gh:VA.lAG3HU8SN-8j2txBnS7_nalqwCsLew0q", "label": "NC_000011.9:g.108186827C>T", "digest": "lAG3HU8SN-8j2txBnS7_nalqwCsLew0q", "type": "Allele", "location": {"id": "ga4gh:SL.fFYv2op1uHMlAfk_V1zgC5P82M_XpJng", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.2NkFm8HK88MqeNkCgj78KidCAXgnsfV1"}, "start": 108316099, "end": 108316100}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.UPvDB6gPY3cnHiKJbCh-YANbaPazXiYX", "label": "A2062V", "digest": "UPvDB6gPY3cnHiKJbCh-YANbaPazXiYX", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000278616.4:c.6185C>T"}, {"syntax": "hgvs.g", "value": "NC_000011.9:g.108186827C>T"}, {"syntax": "hgvs.c", "value": "NM_000051.3:c.6185C>T"}, {"syntax": "hgvs.p", "value": "NP_000042.3:p.Ala2062Val"}], "location": {"id": "ga4gh:SL.uR1h3yjyr-lOC_TNDHWgcqgpybKFCvwS", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6k1y4bTo7pEJ-a1GaniRBaCJXXGkBGFO"}, "start": 2061, "end": 2062}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "civic.tid:68", "label": "Doxorubicin", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:142433"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:552", "type": "Disease", "label": "Acute myeloid leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3171"}, "relation": "relatedMatch"}]}, {"id": "hemonc:675", "type": "Disease", "label": "Thyroid cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7510"}, "relation": "relatedMatch"}]}, {"id": "hemonc:572", "type": "Disease", "label": "Breast cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9335"}, "relation": "relatedMatch"}]}, {"id": "hemonc:569", "type": "Disease", "label": "Bladder cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9334"}, "relation": "relatedMatch"}]}, {"id": "hemonc:601", "type": "Disease", "label": "Gastric cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9331"}, "relation": "relatedMatch"}]}, {"id": "hemonc:614", "type": "Disease", "label": "Hodgkin lymphoma", "mappings": [{"coding": {"system": "ncit", "code": "C9357"}, "relation": "relatedMatch"}]}, {"id": "hemonc:666", "type": "Disease", "label": "Small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C4917"}, "relation": "relatedMatch"}]}, {"id": "hemonc:645", "type": "Disease", "label": "Ovarian cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7431"}, "relation": "relatedMatch"}]}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C456"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione", "(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione", "14-Hydroxydaunomycin", "Adriablastin", "Hydroxydaunomycin", "Hydroxyl Daunorubicin", "Hydroxyldaunorubicin"]}, "tumorType": {"id": "civic.did:52", "label": "Chronic Lymphocytic Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3163"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1040"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2849", "description": "Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the C2488Y variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the C2488Y variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 90% of cells by FISH. Western blot showed stable ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1541", "label": "Navrkalova et al., 2013, Haematologica", "type": "Document", "title": "PubMed: Navrkalova et al., 2013, Haematologica", "pmid": 23585524}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "germline", "geneContext": {"id": "civic.gid:69", "label": "ATM", "description": "Ataxia-telangiectasia (A-T) is a recessive disorder resulting from germline mutation of the A-T mutated (ATM) gene on chromosome 11q. Upon sensing double-stranded breaks (DSB), the wild-type kinase encoded by ATM initiates the DNA-damage response by phosphorylating histone H2AX and, subsequently, various other proteins, such as BRCA1 and the MRE11\u2013RAD50\u2013NBS1 (MRN) complex, which are recruited to the damaged site. Additionally, ATM phosphorylates p53, resulting in expression of the cyclin-dependent kinase inhibitor p21 and leading to senescence or apoptosis. Somatic variants can result in inhibition or loss of these functions and can cause resistance to therapies that rely on inducing apoptosis via DSBs. Germline variants in A-T patients result in a predisposition to cancer, most frequently hematologic or breast. PARP inhibition has been studied for its potential in treating ATM mutated breast cancer patients.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:795"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:472"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["AT1", "ATA", "ATC", "ATD", "ATDC", "ATE", "ATM", "TEL1", "TELO1"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1146", "label": "ATM C2488Y", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 3.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000278616.4", "chromosome": "11", "start": 108201096, "stop": 108201096, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1172"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA196568"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "187037"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS774281788"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["CYS2488TYR", "RS774281788"], "members": [{"id": "ga4gh:VA.zqaGzhlafiGlcmXVqwfdZ2EwAKM3xG4b", "label": "NC_000011.9:g.108201096G>A", "digest": "zqaGzhlafiGlcmXVqwfdZ2EwAKM3xG4b", "type": "Allele", "location": {"id": "ga4gh:SL.oIwOcc70Ia3GBfaLWxr9J3X4VSmBFJ3y", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.2NkFm8HK88MqeNkCgj78KidCAXgnsfV1"}, "start": 108330368, "end": 108330369}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.lSYwWxXvBE5uh7PPbtPQMOaPIm5gs58O", "label": "C2488Y", "digest": "lSYwWxXvBE5uh7PPbtPQMOaPIm5gs58O", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_000051.3:c.7463G>A"}, {"syntax": "hgvs.p", "value": "NP_000042.3:p.Cys2488Tyr"}, {"syntax": "hgvs.g", "value": "NC_000011.9:g.108201096G>A"}, {"syntax": "hgvs.c", "value": "ENST00000278616.4:c.7463G>A"}], "location": {"id": "ga4gh:SL.SQFsgUdS_8ZbyNUawqAh6tqU8dmafCOV", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6k1y4bTo7pEJ-a1GaniRBaCJXXGkBGFO"}, "start": 2487, "end": 2488}, "state": {"type": "LiteralSequenceExpression", "sequence": "Y"}}}, "therapeutic": {"id": "civic.tid:68", "label": "Doxorubicin", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:142433"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:552", "type": "Disease", "label": "Acute myeloid leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3171"}, "relation": "relatedMatch"}]}, {"id": "hemonc:675", "type": "Disease", "label": "Thyroid cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7510"}, "relation": "relatedMatch"}]}, {"id": "hemonc:572", "type": "Disease", "label": "Breast cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9335"}, "relation": "relatedMatch"}]}, {"id": "hemonc:569", "type": "Disease", "label": "Bladder cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9334"}, "relation": "relatedMatch"}]}, {"id": "hemonc:601", "type": "Disease", "label": "Gastric cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9331"}, "relation": "relatedMatch"}]}, {"id": "hemonc:614", "type": "Disease", "label": "Hodgkin lymphoma", "mappings": [{"coding": {"system": "ncit", "code": "C9357"}, "relation": "relatedMatch"}]}, {"id": "hemonc:666", "type": "Disease", "label": "Small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C4917"}, "relation": "relatedMatch"}]}, {"id": "hemonc:645", "type": "Disease", "label": "Ovarian cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7431"}, "relation": "relatedMatch"}]}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C456"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione", "(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione", "14-Hydroxydaunomycin", "Adriablastin", "Hydroxydaunomycin", "Hydroxyl Daunorubicin", "Hydroxyldaunorubicin"]}, "tumorType": {"id": "civic.did:52", "label": "Chronic Lymphocytic Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3163"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1040"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2866", "description": "As part of a pre-clinical experiment, the efficacy of ado-trastuzumab emtansine (T-DM1) was evaluated against various HER2 positive cell lines. BT-474 cell line expressing PIK3CA K111N was associated with similar sensitivity to T-DM1 as PIK3CA wild-type cell line SK-BR-3; reduced cell viability was observed at concentrations > 0.01 ug/mL in both cell lines. Conversely, when treated with trastuzumab, the cell line harboring PIK3CA K111N experienced a smaller reduction in cell viability. Further, treatment with T-DM1 on SCID mice xenografted with PIK3CA K111N cells resulted in inhibition of tumor growth. A single dose of T-DM1 >5mg/kg was sufficient to induce tumor regression >20 days after administration.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1468", "label": "Baselga et al., 2016, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Baselga et al., 2016, Clin. Cancer Res.", "pmid": 26920887}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "refutes", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1208", "label": "PIK3CA K111N", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 13.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "C", "representative_transcript": "ENST00000263967.3", "chromosome": "3", "start": 178916946, "stop": 178916946, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1234"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602917"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376483"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS1057519934"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["LYS111ASN", "RS1057519934"], "members": [{"id": "ga4gh:VA.6gJ0sZTUPrjLKyzA7MbI4GufROt86Qef", "label": "NC_000003.11:g.178916946G>C", "digest": "6gJ0sZTUPrjLKyzA7MbI4GufROt86Qef", "type": "Allele", "location": {"id": "ga4gh:SL.OrbI2eAivw_NYF0pKrtb6EtIvymAX9fl", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 179199157, "end": 179199158}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.CNXNKSAtu44QlqQ-CS7tVeV5X3xvh0fP", "label": "K111N", "digest": "CNXNKSAtu44QlqQ-CS7tVeV5X3xvh0fP", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006218.3:c.333G>C"}, {"syntax": "hgvs.p", "value": "NP_006209.2:p.Lys111Asn"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.178916946G>C"}, {"syntax": "hgvs.c", "value": "ENST00000263967.3:c.333G>C"}], "location": {"id": "ga4gh:SL.S2OWTTUCKH1qcBAiJeW3zkx8rPaf2dFh", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 110, "end": 111}, "state": {"type": "LiteralSequenceExpression", "sequence": "N"}}}, "therapeutic": {"id": "civic.tid:457", "label": "Trastuzumab Emtansine", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1371041"}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C82492"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["ADO-TRASTUZUMAB EMTANSINE", "Ado Trastuzumab Emtansine", "Immunoglobulin G1, Anti-(Human P185neu Receptor) (Human-Mouse Monoclonal RhuMab HER2 Gamma1-Chain), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer, Tetraamide With N2'-(3-((1-((4-carboxycyclohexyl)methyl)-2,5-dioxo-3-pyrrolidinyl)thio)-1-oxopropyl)-N2'-deacetylMaytansine", "Kadcyla", "PRO132365", "RO5304020", "T-DM1", "Trastuzumab-DM1", "Trastuzumab-MCC-DM1", "Trastuzumab-MCC-DM1 Antibody-Drug Conjugate", "Trastuzumab-MCC-DM1 Immunoconjugate"]}, "tumorType": {"id": "civic.did:368", "label": "Her2-receptor Positive Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C53556"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:0060079"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2867", "description": "As part of a pre-clinical experiment, the efficacy of ado-trastuzumab emtansine (T-DM1) was evaluated against various HER2 positive cell lines. ZR-75-30 cell line expressing PIK3CA I391M was associated with similar sensitivity to T-DM1 as PIK3CA wild-type cell line SK-BR-3; reduced cell viability was observed at concentrations > 0.01 ug/mL in both cell lines. When treated with trastuzumab, the cell line harboring PIK3CA I391M experienced similar reduction in cell viability.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1468", "label": "Baselga et al., 2016, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Baselga et al., 2016, Clin. Cancer Res.", "pmid": 26920887}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "refutes", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1209", "label": "PIK3CA I391M", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 5.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "G", "representative_transcript": "ENST00000263967.3", "chromosome": "3", "start": 178927410, "stop": 178927410, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1235"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA161490"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "135038"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS2230461"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS2230461", "ILE391MET"], "members": [{"id": "ga4gh:VA.92GgQJ9SyMwgEKR7HcY1JK-Gk9pMyxuH", "label": "NC_000003.11:g.178927410A>G", "digest": "92GgQJ9SyMwgEKR7HcY1JK-Gk9pMyxuH", "type": "Allele", "location": {"id": "ga4gh:SL.hm27ysUg2ccFcVDWhdhR9qe13sTWz4FV", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 179209621, "end": 179209622}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.fGV1lcwx7D7AdFDdsuuKs2aXLLM27-rK", "label": "I391M", "digest": "fGV1lcwx7D7AdFDdsuuKs2aXLLM27-rK", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006218.3:c.1173A>G"}, {"syntax": "hgvs.p", "value": "NP_006209.2:p.Ile391Met"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.178927410A>G"}, {"syntax": "hgvs.c", "value": "ENST00000263967.3:c.1173A>G"}], "location": {"id": "ga4gh:SL.mjYAO2_9fysPZUSpwjzywXPyzSm2bpzf", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 390, "end": 391}, "state": {"type": "LiteralSequenceExpression", "sequence": "M"}}}, "therapeutic": {"id": "civic.tid:457", "label": "Trastuzumab Emtansine", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1371041"}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C82492"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["ADO-TRASTUZUMAB EMTANSINE", "Ado Trastuzumab Emtansine", "Immunoglobulin G1, Anti-(Human P185neu Receptor) (Human-Mouse Monoclonal RhuMab HER2 Gamma1-Chain), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer, Tetraamide With N2'-(3-((1-((4-carboxycyclohexyl)methyl)-2,5-dioxo-3-pyrrolidinyl)thio)-1-oxopropyl)-N2'-deacetylMaytansine", "Kadcyla", "PRO132365", "RO5304020", "T-DM1", "Trastuzumab-DM1", "Trastuzumab-MCC-DM1", "Trastuzumab-MCC-DM1 Antibody-Drug Conjugate", "Trastuzumab-MCC-DM1 Immunoconjugate"]}, "tumorType": {"id": "civic.did:368", "label": "Her2-receptor Positive Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C53556"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:0060079"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2943", "description": "Preclinical data supporting resistance of Exon 4 mutations, in particular A146T, to cetuximab and sensitivity to PD0325901. This study involved treatment of mice bearing A146T KRAS xenografts treated with PD0325901 or cetuximab.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1632", "label": "Janakiraman et al., 2010, Cancer Res.", "type": "Document", "title": "PubMed: Janakiraman et al., 2010, Cancer Res.", "pmid": 20570890}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:880", "label": "KRAS A146T", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 21.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25378562, "stop": 25378562, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "906"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA245262"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "197243"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913527"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ALA146THR", "RS121913527"], "members": [{"id": "ga4gh:VA.dRZVQAPaJ8h7wfuTG5HaD69QUyyYOplp", "label": "NC_000012.11:g.25378562C>T", "digest": "dRZVQAPaJ8h7wfuTG5HaD69QUyyYOplp", "type": "Allele", "location": {"id": "ga4gh:SL.UzP04NGn-qox4aCssMK1oUP9drq8jlls", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25225627, "end": 25225628}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.jE0GOODNLuUU_g7JbEolZH92pMyM1Sv9", "label": "A146T", "digest": "jE0GOODNLuUU_g7JbEolZH92pMyM1Sv9", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004985.4:c.436G>A"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Ala146Thr"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25378562C>T"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.436G>A"}], "location": {"id": "ga4gh:SL._CquPzCaBRsKIPLk44LfCpdfLFit4ep6", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 145, "end": 146}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}}, "therapeutic": {"id": "civic.tid:16", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:318341"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}, {"id": "mesh:D006258", "type": "Disease", "label": "Head and Neck Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C4013"}, "relation": "relatedMatch"}]}, {"id": "mesh:D002294", "type": "Disease", "label": "Carcinoma, Squamous Cell", "mappings": [{"coding": {"system": "ncit", "code": "C2929"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1723"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2985", "description": "Authors tested various cervical cancer cell lines (CaSki, SiHa and HeLa) for their responses to cisplatin, radiation therapy, and GDC-0941. CaSki cells that are heterozygous for the PIK3CA-E545K mutation were significantly more resistant to cisplatin or cisplatin plus radiation than either HeLa or SiHa cells that express only wild-type PIK3CA. Similarly, HeLa cells engineered to stably express PIK3CA E545K were more resistant to cisplatin or cisplatin plus radiation than cells expressing only wild-type PIK3CA or with PIK3CA depleted. Cells expressing the PIK3CA-E545K mutation also had constitutive PI3K pathway activation and increased cellular migration and each of these phenotypes was reversed by treatment with the PI3K inhibitor GDC-0941 (pictilisib).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1708", "label": "Arjumand et al., 2016, Oncotarget", "type": "Document", "title": "PubMed: Arjumand et al., 2016, Oncotarget", "pmid": 27489350}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:104", "label": "PIK3CA E545K", "description": "PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 77.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000263967.3", "chromosome": "3", "start": 178936091, "stop": 178936091, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "104"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123334"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13655"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS104886003"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLU545LYS", "RS104886003"], "members": [{"id": "ga4gh:VA.uqD1zF6cMOYhBp8ur5oLTMqV0jxiC2a7", "label": "NC_000003.11:g.178936091G>A", "digest": "uqD1zF6cMOYhBp8ur5oLTMqV0jxiC2a7", "type": "Allele", "location": {"id": "ga4gh:SL.5l5tuxgJGb8y7CQzkKLPUvS-Cx4kr2ju", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 179218302, "end": 179218303}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.uw7DyLM7r98pn66LOXU3tAknmkV7jiJ0", "label": "E545K", "digest": "uw7DyLM7r98pn66LOXU3tAknmkV7jiJ0", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006218.3:c.1633G>A"}, {"syntax": "hgvs.p", "value": "NP_006209.2:p.Glu545Lys"}, {"syntax": "hgvs.c", "value": "ENST00000263967.3:c.1633G>A"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.178936091G>A"}], "location": {"id": "ga4gh:SL.SrEa0lPyesLrOX0M_aW51d-JdJhU-D3p", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 544, "end": 545}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:326", "label": "Cisplatin", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:2555"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:671", "type": "Disease", "label": "Testicular cancer", "mappings": [{"coding": {"system": "ncit", "code": "C5053"}, "relation": "relatedMatch"}]}, {"id": "hemonc:645", "type": "Disease", "label": "Ovarian cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7431"}, "relation": "relatedMatch"}]}, {"id": "hemonc:569", "type": "Disease", "label": "Bladder cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9334"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C376"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(SP-4-2)-Diamminedichloroplatinum", "Abiplatin", "Blastolem", "Briplatin", "CDDP", "Cis-diammine-dichloroplatinum", "Cis-diamminedichloridoplatinum", "Cis-diamminedichloro Platinum (II)", "Cis-diamminedichloroplatinum", "Cis-dichloroammine Platinum (II)", "Cis-platinous Diamine Dichloride", "Cis-platinum", "Cis-platinum II", "Cis-platinum II Diamine Dichloride", "Cismaplat", "Cisplatina", "Cisplatinum", "Cisplatyl", "Citoplatino", "Citosin", "Cysplatyna", "DDP", "Lederplatin", "Metaplatin", "Neoplatin", "Peyrone's Chloride", "Peyrone's Salt", "Placis", "Plastistil", "Platamine", "Platiblastin", "Platiblastin-S", "Platinex", "Platinol", "Platinol- AQ", "Platinol-AQ", "Platinol-AQ VHA Plus", "Platinoxan", "Platinum", "Platinum Diamminodichloride", "Platinum, Diaminedichloro-, Cis- (8CI)", "Platiran", "Platistin", "Platosin"]}, "tumorType": {"id": "civic.did:159", "label": "Cervical Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9311"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:4362"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:3007", "description": "Murine Ba/F3 cells with FLT3-D835V mutations were evaluated as non-responsive to MLN518 (Tandutinib). Cells with single FLT3 (D835V) mutants were resistant to MLN518(IC50 > 10uM) whereas cells with FLT3 (ITD) mutants were not resistant to MLN518 (IC50 0.55uM).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:367", "label": "Clark et al., 2004, Blood", "type": "Document", "title": "PubMed: Clark et al., 2004, Blood", "pmid": 15256420}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:24", "label": "FLT3", "description": "FLT3 is an important cytokine receptor involved in normal hematopoiesis. Mutations in this gene are common in acute myeloid leukemia (AML) and screening for mutations in this gene has been recommended by the World Health Organization in patients with AML, particularly in cases of cytogenetically normal AML (CN-AML). FLT3 mutations commonly co-occur with mutations such as NPM1 that are associated with CN-AML and likely modulate prognostic impact. While FLT3-ITD mutations have been associated with poorer prognosis in AML, the prognostic impact of FLT3-TKD mutations are still up for debate.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3765"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2322"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD135", "FLK-2", "FLK2", "FLT3", "STK1"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1276", "label": "FLT3 D835V", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 19.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "A", "representative_transcript": "ENST00000241453.7", "chromosome": "13", "start": 28592641, "stop": 28592641, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1302"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA126344"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16272"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121909646"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ASP835VAL", "RS121909646"], "members": [{"id": "ga4gh:VA.d1XMqI0hKulE40Z2rW3jkkLDMVh_2_O1", "label": "NC_000013.10:g.28592641T>A", "digest": "d1XMqI0hKulE40Z2rW3jkkLDMVh_2_O1", "type": "Allele", "location": {"id": "ga4gh:SL.nXY0j3isNbco1FUwE39fcdoIjffTxgkq", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ._0wi-qoDrvram155UmcSC-zA5ZK4fpLT"}, "start": 28018503, "end": 28018504}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.2UJEemVtXP1RM3bMtSQbin9I91Uyiylm", "label": "D835V", "digest": "2UJEemVtXP1RM3bMtSQbin9I91Uyiylm", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000241453.7:c.2504A>T"}, {"syntax": "hgvs.c", "value": "NM_004119.2:c.2504A>T"}, {"syntax": "hgvs.p", "value": "NP_004110.2:p.Asp835Val"}, {"syntax": "hgvs.g", "value": "NC_000013.10:g.28592641T>A"}], "location": {"id": "ga4gh:SL.JUgz5GWLTcSTPLIVCaYEGo7KsH5QpwgJ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.0dtDG7QKyvW7BntvQVpLS83mYRA58LKH"}, "start": 834, "end": 835}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "civic.tid:503", "label": "Tandutinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C48404"}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C48404"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-Piperazinecarboxamide, 4-(6-Methoxy-7-(3-(1-piperidinyl)propoxy)-4-quinazolinyl)-N-(4-(1-methylethoxy)phenyl)-", "CT53518", "MLN 518", "MLN518"]}, "tumorType": {"id": "civic.did:3", "label": "Acute Myeloid Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3171"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9119"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:3008", "description": "Murine Ba/F3 cells with FLT3 D835V mutation were assessed as not sensitive to SU11248 (Sunitinib) with dose required to inhibit proliferation of cells to 50% of untreated controls ED50 = 110nM.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1731", "label": "Yee et al., 2004, Blood", "type": "Document", "title": "PubMed: Yee et al., 2004, Blood", "pmid": 15304385}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:24", "label": "FLT3", "description": "FLT3 is an important cytokine receptor involved in normal hematopoiesis. Mutations in this gene are common in acute myeloid leukemia (AML) and screening for mutations in this gene has been recommended by the World Health Organization in patients with AML, particularly in cases of cytogenetically normal AML (CN-AML). FLT3 mutations commonly co-occur with mutations such as NPM1 that are associated with CN-AML and likely modulate prognostic impact. While FLT3-ITD mutations have been associated with poorer prognosis in AML, the prognostic impact of FLT3-TKD mutations are still up for debate.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3765"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2322"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD135", "FLK-2", "FLK2", "FLT3", "STK1"]}}, "direction": "refutes", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1276", "label": "FLT3 D835V", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 19.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "A", "representative_transcript": "ENST00000241453.7", "chromosome": "13", "start": 28592641, "stop": 28592641, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1302"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA126344"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16272"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121909646"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ASP835VAL", "RS121909646"], "members": [{"id": "ga4gh:VA.d1XMqI0hKulE40Z2rW3jkkLDMVh_2_O1", "label": "NC_000013.10:g.28592641T>A", "digest": "d1XMqI0hKulE40Z2rW3jkkLDMVh_2_O1", "type": "Allele", "location": {"id": "ga4gh:SL.nXY0j3isNbco1FUwE39fcdoIjffTxgkq", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ._0wi-qoDrvram155UmcSC-zA5ZK4fpLT"}, "start": 28018503, "end": 28018504}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.2UJEemVtXP1RM3bMtSQbin9I91Uyiylm", "label": "D835V", "digest": "2UJEemVtXP1RM3bMtSQbin9I91Uyiylm", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000241453.7:c.2504A>T"}, {"syntax": "hgvs.c", "value": "NM_004119.2:c.2504A>T"}, {"syntax": "hgvs.p", "value": "NP_004110.2:p.Asp835Val"}, {"syntax": "hgvs.g", "value": "NC_000013.10:g.28592641T>A"}], "location": {"id": "ga4gh:SL.JUgz5GWLTcSTPLIVCaYEGo7KsH5QpwgJ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.0dtDG7QKyvW7BntvQVpLS83mYRA58LKH"}, "start": 834, "end": 835}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "civic.tid:157", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:357977"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:647", "type": "Disease", "label": "Pancreatic NET", "mappings": [{"coding": {"system": "ncit", "code": "C27720"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:660", "type": "Disease", "label": "Renal cell carcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C9385"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C71622"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"]}, "tumorType": {"id": "civic.did:3", "label": "Acute Myeloid Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3171"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9119"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:3733", "description": "In an in vitro study, a RKO cell line expressing BRAF V600E (a known vemurafenib sensitizing mutation) and PIK3CA H1047R co-mutation demonstrated reduced sensitivity to vemurafenib treatment. Resistance was determined by assessing cellular proliferation and AKT phosphorylation.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:108", "label": "Yang et al., 2012, Cancer Res.", "type": "Document", "title": "PubMed: Yang et al., 2012, Cancer Res.", "pmid": 22180495}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:107", "label": "PIK3CA H1047R", "description": "PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 96.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "G", "representative_transcript": "ENST00000263967.3", "chromosome": "3", "start": 178952085, "stop": 178952085, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "107"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123326"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13652"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913279"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913279", "HIS1047ARG"], "members": [{"id": "ga4gh:VA.82Pw7U7NM7ac2koW_yITXOGSKcwg_Qqj", "label": "NC_000003.11:g.178952085A>G", "digest": "82Pw7U7NM7ac2koW_yITXOGSKcwg_Qqj", "type": "Allele", "location": {"id": "ga4gh:SL.p0VJw5IIPnKzEpQMcdBaU3xesud6QODJ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 179234296, "end": 179234297}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.hcSlm-m3AKXOL7kHM3LghXQfvAjZOmYx", "label": "H1047R", "digest": "hcSlm-m3AKXOL7kHM3LghXQfvAjZOmYx", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006218.3:c.3140A>G"}, {"syntax": "hgvs.p", "value": "NP_006209.2:p.His1047Arg"}, {"syntax": "hgvs.c", "value": "ENST00000263967.3:c.3140A>G"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.178952085A>G"}], "location": {"id": "ga4gh:SL.DBBb47ourtRut09MJ_TAvlocEwpTjF9z", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 1046, "end": 1047}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:3958", "description": "In an in vitro study, a MCAS cell line expressing KRAS G12D mutation was associated with reduced sensitivity to cetuximab treatment as compared to RMUG-L and OMC-1 cells expressing wild-type KRAS. Resistance was determined by assessing cell growth. Further, in an in vivo experiment, KRAS G12D expressing MCAS xenografts in nude mice had reduced response to cetuximab, as compared to KRAS wild-type expressing RMUG-L xenografts. Resistance was determined by assessing tumor growth.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2024", "label": "Sato et al., 2012, Oncol. Rep.", "type": "Document", "title": "PubMed: Sato et al., 2012, Oncol. Rep.", "pmid": 22246397}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:79", "label": "KRAS G12D", "description": "While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 162.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398284, "stop": 25398284, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "79"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA122538"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12582"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913529"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913529", "GLY12ASP"], "members": [{"id": "ga4gh:VA.qOYg4yYK-1Je25G30BkV3dWKtKDIAFEJ", "label": "NC_000012.11:g.25398284C>T", "digest": "qOYg4yYK-1Je25G30BkV3dWKtKDIAFEJ", "type": "Allele", "location": {"id": "ga4gh:SL.iF0OXeO-tnumYbGkzaFEQ7cOZI_UCI1s", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245349, "end": 25245350}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.CB571ja_KfZM_Hjn9zjjgV1an3tDWRcl", "label": "G12D", "digest": "CB571ja_KfZM_Hjn9zjjgV1an3tDWRcl", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004985.4:c.35G>A"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly12Asp"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398284C>T"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.35G>A"}], "location": {"id": "ga4gh:SL.OndkjmujtyUEZSjjCv0C-gpwnVbRgfj8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "D"}}}, "therapeutic": {"id": "civic.tid:16", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:318341"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}, {"id": "mesh:D006258", "type": "Disease", "label": "Head and Neck Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C4013"}, "relation": "relatedMatch"}]}, {"id": "mesh:D002294", "type": "Disease", "label": "Carcinoma, Squamous Cell", "mappings": [{"coding": {"system": "ncit", "code": "C2929"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1723"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"]}, "tumorType": {"id": "civic.did:20", "label": "Ovarian Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C7431"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:2394"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4125", "description": "In an in vitro study, an IL3 independent Ba/F3 cell line expressing KIT P551_E554delPMYE primary activating mutation demonstrated sensitivity to ponatinib treatment (IC50: 15nM). IC50 was determined by assessing cell viability.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2042", "label": "Garner et al., 2014, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Garner et al., 2014, Clin. Cancer Res.", "pmid": 25239608}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:29", "label": "KIT", "description": "c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3815"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["C-Kit", "CD117", "KIT", "MASTC", "PBT", "SCFR"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1405", "label": "KIT P551_E554delPMYE", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 6.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"reference_build": "GRCh37", "chromosome": "4", "start": 55593585, "stop": 55593596, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "inframe_deletion", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001822"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1497"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.q2Z3eJWZiOmwqZadMmvOiSpF8WqML1Z4", "label": "P551_E554delPMYE", "digest": "q2Z3eJWZiOmwqZadMmvOiSpF8WqML1Z4", "type": "Allele", "location": {"id": "ga4gh:SL.LME36D34M_ODcEFzHsOho6G0GnT_Y9ij", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 550, "end": 554}, "state": {"type": "ReferenceLengthExpression", "length": 0, "sequence": "", "repeatSubunitLength": 4}}}, "therapeutic": {"id": "civic.tid:55", "label": "Ponatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1364347"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C95777"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["AP-24534", "AP24534", "Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)"]}, "tumorType": {"id": "civic.did:2", "label": "Gastrointestinal Stromal Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3868"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9253"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4167", "description": "A preclinical study tested the effect of a tyrosine kinase inhibitor (TKI) on Ba/F3 cell lines with primary ponatinib-sensitizing del 557-558 mutation, which induced IL-3 independent growth, and secondary mutation N822K. The cells were tested for Ponatinib resistance. Ba/F3 cells with del 557-558 and N822K mutations did not show resistance towards Ponatinib (IC50 for growth inhibition: 3 nM) compared to Ba/F3 cells with del 557-558  alone (IC50: 3 nM). Ponatinib inhibited KIT phosphorylation at moderate concentrations. The results suggest that N822K does not induce Ponatinib resistance.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2042", "label": "Garner et al., 2014, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Garner et al., 2014, Clin. Cancer Res.", "pmid": 25239608}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:29", "label": "KIT", "description": "c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3815"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["C-Kit", "CD117", "KIT", "MASTC", "PBT", "SCFR"]}}, "direction": "refutes", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1237", "label": "KIT N822K", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 29.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "A", "representative_transcript": "ENST00000288135.5", "chromosome": "4", "start": 55599340, "stop": 55599340, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1263"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602411"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "375931"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913514"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ASN822LYS", "RS121913514"], "members": [{"id": "ga4gh:VA.3i1HI4wqippKn-gtuyM4kiLBVQD0N763", "label": "NC_000004.11:g.55599340T>A", "digest": "3i1HI4wqippKn-gtuyM4kiLBVQD0N763", "type": "Allele", "location": {"id": "ga4gh:SL.hQJlf-hzQ4szaLAhFocudRE99wMKEJfi", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54733173, "end": 54733174}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.z_WJsSByobbgzhHAaWw4kVBhNnyADN57", "label": "N822K", "digest": "z_WJsSByobbgzhHAaWw4kVBhNnyADN57", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_000222.2:c.2466T>A"}, {"syntax": "hgvs.p", "value": "NP_000213.1:p.Asn822Lys"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55599340T>A"}, {"syntax": "hgvs.c", "value": "ENST00000288135.5:c.2466T>A"}], "location": {"id": "ga4gh:SL.B6627_40nR9hpf23ICFLQ0TZsfFxpBNq", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 821, "end": 822}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:55", "label": "Ponatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1364347"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C95777"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["AP-24534", "AP24534", "Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)"]}, "tumorType": {"id": "civic.did:2", "label": "Gastrointestinal Stromal Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3868"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9253"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4169", "description": "A preclinical study tested the effects of tyrosine kinase inhibitor (TKI) on Ba/F3 cell lines with primary regorafenib-sensitizing mutation del 557-558, which induced IL-3 independent growth, and secondary mutation N822K. The cells were tested for Regorafenib resistance. Ba/F3 cells with del 557-558 and N822K mutations did show resistance towards Regorafenib (IC50 for growth inhibition: 131 +- 9 nM) compared to Ba/F3 cells with the del 557-558 mutation (IC50 for growth inhibition: 30 +- 14 nM). Regorafenib inhibited KIT phosphorylation only at high concentrations. The results suggest that N822K does induce Regorafenib resistance.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2042", "label": "Garner et al., 2014, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Garner et al., 2014, Clin. Cancer Res.", "pmid": 25239608}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:29", "label": "KIT", "description": "c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3815"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["C-Kit", "CD117", "KIT", "MASTC", "PBT", "SCFR"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1237", "label": "KIT N822K", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 29.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "A", "representative_transcript": "ENST00000288135.5", "chromosome": "4", "start": 55599340, "stop": 55599340, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1263"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602411"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "375931"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913514"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ASN822LYS", "RS121913514"], "members": [{"id": "ga4gh:VA.3i1HI4wqippKn-gtuyM4kiLBVQD0N763", "label": "NC_000004.11:g.55599340T>A", "digest": "3i1HI4wqippKn-gtuyM4kiLBVQD0N763", "type": "Allele", "location": {"id": "ga4gh:SL.hQJlf-hzQ4szaLAhFocudRE99wMKEJfi", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54733173, "end": 54733174}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.z_WJsSByobbgzhHAaWw4kVBhNnyADN57", "label": "N822K", "digest": "z_WJsSByobbgzhHAaWw4kVBhNnyADN57", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_000222.2:c.2466T>A"}, {"syntax": "hgvs.p", "value": "NP_000213.1:p.Asn822Lys"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55599340T>A"}, {"syntax": "hgvs.c", "value": "ENST00000288135.5:c.2466T>A"}], "location": {"id": "ga4gh:SL.B6627_40nR9hpf23ICFLQ0TZsfFxpBNq", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 821, "end": 822}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:27", "label": "Regorafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1312397"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C78204"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide", "BAY 73-4506", "REGORAFENIB ANHYDROUS", "Stivarga"]}, "tumorType": {"id": "civic.did:2", "label": "Gastrointestinal Stromal Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3868"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9253"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4186", "description": "In an in vitro study, a Ba/F3 cell line expressing EGFR R108K demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Variant function was assessed by EGFR auto-phosphorylation. Sensitivity was assessed by cell viability assay using stable transfection of each variant and increasing concentrations of erlotinib (0\u201310 uM).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1608", "label": "Lee et al., 2006, PLoS Med.", "type": "Document", "title": "PubMed: Lee et al., 2006, PLoS Med.", "pmid": 17177598}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:968", "label": "EGFR R108K", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 3.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55211080, "stop": 55211080, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "994"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602662"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376207"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ARG108LYS"], "members": [{"id": "ga4gh:VA.cclOCtlaAETiRtYzU6QY-LGk5ATfum0f", "label": "NC_000007.13:g.55211080G>A", "digest": "cclOCtlaAETiRtYzU6QY-LGk5ATfum0f", "type": "Allele", "location": {"id": "ga4gh:SL.NQlsK19nhomqlOXZBK6vdxLdeziv2x2-", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55143386, "end": 55143387}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.XCljzXKud2-YTFZpRtliTP9qYDmEK0Uf", "label": "R108K", "digest": "XCljzXKud2-YTFZpRtliTP9qYDmEK0Uf", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_005228.4:c.323G>A"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Arg108Lys"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55211080G>A"}, {"syntax": "hgvs.c", "value": "ENST00000275493.2:c.323G>A"}], "location": {"id": "ga4gh:SL.qmsGH6dD_WH3Xhm8NMX8SnO-bQIFK8qQ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 107, "end": 108}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:695", "label": "High Grade Glioma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4822"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3070"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4187", "description": "In an in vitro study, a Ba/F3 cell line expressing EGFR T263P demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Variant function was assessed by EGFR auto-phosphorylation. Sensitivity was assessed by cell viability assay using stable transfection of each variant and increasing concentrations of erlotinib (0\u201310 uM).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1608", "label": "Lee et al., 2006, PLoS Med.", "type": "Document", "title": "PubMed: Lee et al., 2006, PLoS Med.", "pmid": 17177598}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:969", "label": "EGFR T263P", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 3.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "C", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55221743, "stop": 55221743, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "995"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602663"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376208"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["THR263PRO"], "members": [{"id": "ga4gh:VA.fc9rHa81gnCL3jYhzYsf-LcCFI2TGLS0", "label": "NC_000007.13:g.55221743A>C", "digest": "fc9rHa81gnCL3jYhzYsf-LcCFI2TGLS0", "type": "Allele", "location": {"id": "ga4gh:SL.AuoYf36QmHPohDHj-4OPFc5kBvzjxtaK", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55154049, "end": 55154050}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.xsllQ0N-39GqRwxwNSLpDHWzoRGKF4xi", "label": "T263P", "digest": "xsllQ0N-39GqRwxwNSLpDHWzoRGKF4xi", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_005228.4:c.787A>C"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Thr263Pro"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55221743A>C"}, {"syntax": "hgvs.c", "value": "ENST00000275493.2:c.787A>C"}], "location": {"id": "ga4gh:SL.k14vdObNMTeelB8VHB9qBEMi4EDhwhx_", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 262, "end": 263}, "state": {"type": "LiteralSequenceExpression", "sequence": "P"}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:695", "label": "High Grade Glioma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4822"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3070"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4188", "description": "In an in vitro study, a Ba/F3 cell line expressing EGFR A289V demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Variant function was assessed by EGFR auto-phosphorylation. Sensitivity was assessed by cell viability assay using stable transfection of each variant and increasing concentrations of erlotinib (0\u201310 uM).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1608", "label": "Lee et al., 2006, PLoS Med.", "type": "Document", "title": "PubMed: Lee et al., 2006, PLoS Med.", "pmid": 17177598}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:970", "label": "EGFR A289V", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 3.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55221822, "stop": 55221822, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "996"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602664"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376209"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS149840192"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS149840192", "ALA289VAL"], "members": [{"id": "ga4gh:VA.CqnBJVAyCnzcVlkrlk0nWStjH81lQdHo", "label": "NC_000007.13:g.55221822C>T", "digest": "CqnBJVAyCnzcVlkrlk0nWStjH81lQdHo", "type": "Allele", "location": {"id": "ga4gh:SL.h7F2VBnzKexlTJxak9vzxjmwG9KSaLY6", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55154128, "end": 55154129}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.wa3epWpNdw29kmUeALMl455EnLRAK5of", "label": "A289V", "digest": "wa3epWpNdw29kmUeALMl455EnLRAK5of", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_005228.4:c.866C>T"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Ala289Val"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55221822C>T"}, {"syntax": "hgvs.c", "value": "ENST00000275493.2:c.866C>T"}], "location": {"id": "ga4gh:SL._VbHdMmTtCiKNdejhhM6bPPVRuk2Nvr_", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 288, "end": 289}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:695", "label": "High Grade Glioma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4822"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3070"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4265", "description": "MCF-7 cells were transduced with YFP tagged EGFR with E746_A750delELREA mutation, or YFP EGFR wildtype, and stained for ectopic YFP EGFR and phospho-Akt as a readout for EGFR pathway activity. Increased p-Akt stain was seen with ectopic mutant EGFR over wildtype cells. Parallel erlotinib incubations of cells with wildtype EGFR induced recompartmentalization of ectopic EGFR protien only at high concentration (10uM). Addition of erlotinib to mutant EGFR cell incubations reduced p-Akt signal and induced recompartmentalization of ectopic EGFR protien at considerably lower conecntration (100 nM) erlotinib.  These results indicate the EGFR L858R variant as a growth pathway driver targetable by erlotinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1991", "label": "de Gunst et al., 2007, Mol. Cancer", "type": "Document", "title": "PubMed: de Gunst et al., 2007, Mol. Cancer", "pmid": 17877814}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:33", "label": "EGFR L858R", "description": "EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 379.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "G", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55259515, "stop": 55259515, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "33"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA126713"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16609"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376282"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376280"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434568"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121434568", "LEU858ARG"], "members": [{"id": "ga4gh:VA.TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "label": "NC_000007.13:g.55259515T>G", "digest": "TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "type": "Allele", "location": {"id": "ga4gh:SL.ulUNwZvajob7nzyrlpOd6uUWZIYCsoWb", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55191821, "end": 55191822}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "label": "L858R", "digest": "z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000007.13:g.55259515T>G"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2573T>G"}, {"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2573T>G"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Leu858Arg"}], "location": {"id": "ga4gh:SL.yVGJnwqxV6oCGqC_8nNb58D_wPXJeNJo", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 857, "end": 858}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:216", "label": "Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9305"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:162"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4279", "description": "In an in vitro study performed after identification of the mutation in a malignant peritoneal mesothelioma patient, COS-7 cells expressing EGFR R831H demonstrated increased EGFR phosphotyrosine after EGF treatment over wildtype EGFR expressing cells. Cells expressing mutant EGFR also showed increased sensitivity to erlotinib treatment compared to cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2081", "label": "Foster et al., 2010, World J Surg Oncol", "type": "Document", "title": "PubMed: Foster et al., 2010, World J Surg Oncol", "pmid": 20942962}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:991", "label": "EGFR R831H", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 3.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55259434, "stop": 55259434, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1017"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA4266102"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "560007"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS150036236"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ARG831HIS", "RS150036236"], "members": [{"id": "ga4gh:VA.h69k-uuYrY-JlH2mCe1wemen9jw0fmaB", "label": "NC_000007.13:g.55259434G>A", "digest": "h69k-uuYrY-JlH2mCe1wemen9jw0fmaB", "type": "Allele", "location": {"id": "ga4gh:SL.0_aCzRsjCFz2xdyaX-mzadES3Q0P9GCL", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55191740, "end": 55191741}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.uAXyLGve5dgDX0RyrrrJQR3gX4v1yS1C", "label": "R831H", "digest": "uAXyLGve5dgDX0RyrrrJQR3gX4v1yS1C", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2492G>A"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55259434G>A"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2492G>A"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Arg831His"}, {"syntax": "hgvs.g", "value": "NC_000007.14:g.55191741G>A"}], "location": {"id": "ga4gh:SL._zgtvjcidygSMcn5y3lrrpSfnx-oT1eJ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 830, "end": 831}, "state": {"type": "LiteralSequenceExpression", "sequence": "H"}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:216", "label": "Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9305"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:162"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4286", "description": "In an in vitro study, Ba/F3 and NCI-H3255 cell lines expressing EGFR L858R demonstrated increased sensitivity to erlotinib treatment (IC50=0.006 and 0.068 \u00b5M). Sensitivity was determined by assessing cell proliferation, EGFR, AKT and ERK phosphorylation, levels of BIM (a marker of EGFR TKI-induced cell killing) and cell viability.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1230", "label": "Yasuda et al., 2013, Sci Transl Med", "type": "Document", "title": "PubMed: Yasuda et al., 2013, Sci Transl Med", "pmid": 24353160}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:33", "label": "EGFR L858R", "description": "EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 379.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "G", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55259515, "stop": 55259515, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "33"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA126713"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16609"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376282"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376280"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434568"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121434568", "LEU858ARG"], "members": [{"id": "ga4gh:VA.TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "label": "NC_000007.13:g.55259515T>G", "digest": "TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "type": "Allele", "location": {"id": "ga4gh:SL.ulUNwZvajob7nzyrlpOd6uUWZIYCsoWb", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55191821, "end": 55191822}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "label": "L858R", "digest": "z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000007.13:g.55259515T>G"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2573T>G"}, {"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2573T>G"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Leu858Arg"}], "location": {"id": "ga4gh:SL.yVGJnwqxV6oCGqC_8nNb58D_wPXJeNJo", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 857, "end": 858}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4292", "description": "In an in vitro study, Ba/F3 cell line expressing EGFR L858R did not show sensitivity to cetuximab treatment, while cells expressing EGFR-RAD51 fusion were sensitive. Sensitivity was determined by assessing cell viability, AKT and ERK phosphorylation and EGFR auto-phosphorylation.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2086", "label": "Konduri et al., 2016, Cancer Discov", "type": "Document", "title": "PubMed: Konduri et al., 2016, Cancer Discov", "pmid": 27102076}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "refutes", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:33", "label": "EGFR L858R", "description": "EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 379.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "G", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55259515, "stop": 55259515, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "33"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA126713"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16609"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376282"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376280"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434568"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121434568", "LEU858ARG"], "members": [{"id": "ga4gh:VA.TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "label": "NC_000007.13:g.55259515T>G", "digest": "TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "type": "Allele", "location": {"id": "ga4gh:SL.ulUNwZvajob7nzyrlpOd6uUWZIYCsoWb", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55191821, "end": 55191822}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "label": "L858R", "digest": "z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000007.13:g.55259515T>G"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2573T>G"}, {"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2573T>G"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Leu858Arg"}], "location": {"id": "ga4gh:SL.yVGJnwqxV6oCGqC_8nNb58D_wPXJeNJo", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 857, "end": 858}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:16", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:318341"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}, {"id": "mesh:D006258", "type": "Disease", "label": "Head and Neck Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C4013"}, "relation": "relatedMatch"}]}, {"id": "mesh:D002294", "type": "Disease", "label": "Carcinoma, Squamous Cell", "mappings": [{"coding": {"system": "ncit", "code": "C2929"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1723"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"]}, "tumorType": {"id": "civic.did:30", "label": "Lung Adenocarcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3512"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3910"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4295", "description": "In an in vitro study, a Ba/F3 cell line expressing EGFR L858R demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Variant function was assessed by EGFR auto-phosphorylation. Sensitivity was assessed by cell viability assay using stable transfection of each variant and increasing concentrations of erlotinib (0\u201310 uM).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1608", "label": "Lee et al., 2006, PLoS Med.", "type": "Document", "title": "PubMed: Lee et al., 2006, PLoS Med.", "pmid": 17177598}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:33", "label": "EGFR L858R", "description": "EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 379.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "G", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55259515, "stop": 55259515, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "33"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA126713"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16609"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376282"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376280"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434568"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121434568", "LEU858ARG"], "members": [{"id": "ga4gh:VA.TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "label": "NC_000007.13:g.55259515T>G", "digest": "TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "type": "Allele", "location": {"id": "ga4gh:SL.ulUNwZvajob7nzyrlpOd6uUWZIYCsoWb", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55191821, "end": 55191822}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "label": "L858R", "digest": "z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000007.13:g.55259515T>G"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2573T>G"}, {"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2573T>G"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Leu858Arg"}], "location": {"id": "ga4gh:SL.yVGJnwqxV6oCGqC_8nNb58D_wPXJeNJo", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 857, "end": 858}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:695", "label": "High Grade Glioma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4822"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3070"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4299", "description": "In an in vitro study, a Ba/F3 cell line expressing EGFR L861Q demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Variant function was assessed by EGFR auto-phosphorylation. Sensitivity was assessed by cell viability assay using stable transfection of each variant and increasing concentrations of erlotinib (0\u201310 uM).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1608", "label": "Lee et al., 2006, PLoS Med.", "type": "Document", "title": "PubMed: Lee et al., 2006, PLoS Med.", "pmid": 17177598}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:994", "label": "EGFR L861Q", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 10.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "A", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55259524, "stop": 55259524, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1020"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA176021"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "163380"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913444"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913444"], "members": [{"id": "ga4gh:VA.gosyXp1_96gY3LXwM9FTcZ77whCb9je0", "label": "NC_000007.13:g.55259524T>A", "digest": "gosyXp1_96gY3LXwM9FTcZ77whCb9je0", "type": "Allele", "location": {"id": "ga4gh:SL.TVFNAFf4th9p_qt2bsc8B9wqdctqBx4P", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55191830, "end": 55191831}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.dHgO6rd84GcjW82xzZ4P0NIE9yfgcYr_", "label": "L861Q", "digest": "dHgO6rd84GcjW82xzZ4P0NIE9yfgcYr_", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_005228.4:c.2582T>A"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Leu861Gln"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55259524T>A"}, {"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2582T>A"}], "location": {"id": "ga4gh:SL.wYr958J0kHH8yi78nvyE2QQukosbaxSX", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 860, "end": 861}, "state": {"type": "LiteralSequenceExpression", "sequence": "Q"}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:695", "label": "High Grade Glioma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4822"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3070"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4301", "description": "In an in vitro study performed after identification of the mutation in a malignant peritoneal mesothelioma patient, COS-7 cells expressing EGFR E868G demonstrated increased EGFR phosphotyrosine after EGF treatment over wildtype EGFR expressing cells. Cells expressing mutant EGFR also showed increased sensitivity to erlotinib treatment compared to cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2081", "label": "Foster et al., 2010, World J Surg Oncol", "type": "Document", "title": "PubMed: Foster et al., 2010, World J Surg Oncol", "pmid": 20942962}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1390", "label": "EGFR E868G", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 3.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "G", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55259545, "stop": 55259545, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1482"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA367580333"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLU868GLY"], "members": [{"id": "ga4gh:VA.xzmDAi2gLCL4nFWP8LyRoe7O-sbghi2I", "label": "NC_000007.14:g.55191852A>G", "digest": "xzmDAi2gLCL4nFWP8LyRoe7O-sbghi2I", "type": "Allele", "location": {"id": "ga4gh:SL.3rMyjHqKPr4hl2wD23PreT0dpk5HBfOc", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55191851, "end": 55191852}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.nMH3BuPyRjSEw_vrDUT-Fi2gU1sWkN_r", "label": "E868G", "digest": "nMH3BuPyRjSEw_vrDUT-Fi2gU1sWkN_r", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2603A>G"}, {"syntax": "hgvs.g", "value": "NC_000007.14:g.55191852A>G"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55259545A>G"}, {"syntax": "hgvs.c", "value": "ENST00000275493.7:c.2603A>G"}, {"syntax": "hgvs.p", "value": "ENSP00000275493.2:p.Glu868Gly"}, {"syntax": "hgvs.c", "value": "NM_005228.5:c.2603A>G"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Glu868Gly"}], "location": {"id": "ga4gh:SL.1QBKmYT2KpB9-1sUtD2pWFNljFH4DIOK", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 867, "end": 868}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:216", "label": "Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9305"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:162"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4488", "description": "In an in vitro study, WM2664, a BRAF V600D expressing cell line, demonstrated improved sensitivity to vemurafenib treatment, compared to BRAF wild-type expressing cells. Sensitivity was determined by assessing cell proliferation (WM2664, GI50: 1.5uM; vs. BRAF expressing cells (n=9) GI50: 10-41uM).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1952", "label": "Tsai et al., 2008, Proc. Natl. Acad. Sci. U.S.A.", "type": "Document", "title": "PubMed: Tsai et al., 2008, Proc. Natl. Acad. Sci. U.S.A.", "pmid": 18287029}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:11", "label": "BRAF V600D", "description": "Patients harboring mutations in valine 600 residue of BRAF have been shown to be sensitive to dabrafenib. For more information on the V600 locus, see the V600E entry.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 47.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "CA", "variant_bases": "AT", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453135, "stop": 140453136, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "11"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602419"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "375939"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913377"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["VAL600ASP", "RS121913377"], "members": [{"id": "ga4gh:VA.nojfgZgtcwQ9Ylm0GuBuGnUT7Ug-_AKX", "label": "NC_000007.13:g.140453135_140453136delinsAT", "digest": "nojfgZgtcwQ9Ylm0GuBuGnUT7Ug-_AKX", "type": "Allele", "location": {"id": "ga4gh:SL.jW40gDuxQ9chCROKZs12FE7cHlX538EU", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753334, "end": 140753336}, "state": {"type": "LiteralSequenceExpression", "sequence": "AT"}}], "definingContext": {"id": "ga4gh:VA.TG8unESalMAFNryF_mfZWfWumrv-uI-U", "label": "V600D", "digest": "TG8unESalMAFNryF_mfZWfWumrv-uI-U", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000007.13:g.140453135_140453136delinsAT"}, {"syntax": "hgvs.c", "value": "NM_004333.4:c.1799_1800delTGinsAT"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Val600Asp"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1799_1800delTGinsAT"}], "location": {"id": "ga4gh:SL.ZA1XNKhCT_7m2UtmnYb8ZYOVS4eplMEK", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "D"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:7", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3224"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1909"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4521", "description": "An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype AKT3 and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells virally induced to stably over-express AKT3 E17K were significantly more resistant to BRAF inhibition via vemurafenib than cells transduced with empty vectors (40% vs 20% survival, p = .0033).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1941", "label": "Shi et al., 2014, Cancer Discov", "type": "Document", "title": "PubMed: Shi et al., 2014, Cancer Discov", "pmid": 24265155}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:7936", "label": "AKT3", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:393"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:10000"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["AKT3", "MPPH", "MPPH2", "PKB-GAMMA", "PKBG", "PRKBG", "RAC-PK-gamma", "RAC-gamma", "STK-2"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1201", "label": "AKT3 E17K", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 3.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000366539.1", "chromosome": "1", "start": 243859016, "stop": 243859016, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1227"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA130584"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "39816"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS397514606"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLU17LYS", "RS397514606"], "members": [{"id": "ga4gh:VA.o3gT-GTSO0g3E1Khb-q3xkGKsDRh9TyT", "label": "NC_000001.10:g.243859016C>T", "digest": "o3gT-GTSO0g3E1Khb-q3xkGKsDRh9TyT", "type": "Allele", "location": {"id": "ga4gh:SL.XoXdL59ILdcys6EwEJV-HKbeZE4-DNRy", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Ya6Rs7DHhDeg7YaOSg1EoNi3U_nQ9SvO"}, "start": 243695713, "end": 243695714}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.kn7KhNQzOUwcWSt-upCJm2WmyKavjNKX", "label": "E17K", "digest": "kn7KhNQzOUwcWSt-upCJm2WmyKavjNKX", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_001206729.1:c.49G>A"}, {"syntax": "hgvs.p", "value": "NP_001193658.1:p.Glu17Lys"}, {"syntax": "hgvs.g", "value": "NC_000001.10:g.243859016C>T"}, {"syntax": "hgvs.c", "value": "ENST00000366539.1:c.49G>A"}], "location": {"id": "ga4gh:SL.VILbQaWAjQyJrt6jBNW0ocHsJCeccof5", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.ZRhjantUTin_GbnUsVDHmvaJqTCMnJ1Q"}, "start": 16, "end": 17}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:7", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3224"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1909"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4655", "description": "In an in vitro study performed after identification of the mutation in a malignant peritoneal mesothelioma patient, COS-7 cells expressing EGFR W731L demonstrated increased EGFR phosphotyrosine after EGF treatment over wildtype EGFR expressing cells. Cells expressing mutant EGFR also showed increased sensitivity to erlotinib treatment compared to cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2081", "label": "Foster et al., 2010, World J Surg Oncol", "type": "Document", "title": "PubMed: Foster et al., 2010, World J Surg Oncol", "pmid": 20942962}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1479", "label": "EGFR W731L", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 3.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "T", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55242422, "stop": 55242422, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1571"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA367583965"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS397517089"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS397517089", "W678L", "W686L"], "definingContext": {"id": "ga4gh:VA.8z472QFu8ITjr_wNVheZNQ9OuaiJTXB6", "label": "W731L", "digest": "8z472QFu8ITjr_wNVheZNQ9OuaiJTXB6", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2192G>T"}], "location": {"id": "ga4gh:SL.zFN70jafEf1njc0jyULtotdc9XlulTZf", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 730, "end": 731}, "state": {"type": "LiteralSequenceExpression", "sequence": "L"}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:216", "label": "Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9305"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:162"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4656", "description": "In an in vitro study performed after identification of the mutation in a malignant peritoneal mesothelioma patient, COS-7 cells expressing EGFR E734Q demonstrated increased EGFR phosphotyrosine after EGF treatment over wildtype EGFR expressing cells. Cells expressing mutant EGFR also showed increased sensitivity to erlotinib treatment compared to cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2081", "label": "Foster et al., 2010, World J Surg Oncol", "type": "Document", "title": "PubMed: Foster et al., 2010, World J Surg Oncol", "pmid": 20942962}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1480", "label": "EGFR E734Q", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 3.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "C", "representative_transcript": "ENST00000", "chromosome": "7", "start": 55242430, "stop": 55242430, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1572"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA367583997"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913420"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["E681Q", "RS121913420", "E689Q"], "definingContext": {"id": "ga4gh:VA.1CABFr0l6cgOqlxB2L0YiygFQcqdikiC", "label": "E734Q", "digest": "1CABFr0l6cgOqlxB2L0YiygFQcqdikiC", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2200G>C"}], "location": {"id": "ga4gh:SL.mguso1IosojNgs0T9LUgRDVzRLbjcQFl", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 733, "end": 734}, "state": {"type": "LiteralSequenceExpression", "sequence": "Q"}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:216", "label": "Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9305"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:162"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4657", "description": "In an in vitro study performed after identification of the mutation in a malignant peritoneal mesothelioma patient, COS-7 cells expressing EGFR T785A demonstrated increased EGFR phosphotyrosine after EGF treatment over wildtype EGFR expressing cells. Cells expressing mutant EGFR also showed increased sensitivity to erlotinib treatment compared to cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2081", "label": "Foster et al., 2010, World J Surg Oncol", "type": "Document", "title": "PubMed: Foster et al., 2010, World J Surg Oncol", "pmid": 20942962}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1481", "label": "EGFR T785A", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 3.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "G", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55249055, "stop": 55249055, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1573"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA367578819"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["T732A", "T740A"], "definingContext": {"id": "ga4gh:VA.Asa6gu4yCIQlLVkRXKKOdr7bqyzu19a4", "label": "T785A", "digest": "Asa6gu4yCIQlLVkRXKKOdr7bqyzu19a4", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2353A>G"}], "location": {"id": "ga4gh:SL.mJWBJ0eALhTzajlur2ikcZZL9wKG0aXa", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 784, "end": 785}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:216", "label": "Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9305"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:162"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4658", "description": "In an in vitro study performed after identification of the mutation in a malignant peritoneal mesothelioma patient, COS-7 cells expressing EGFR C797Y demonstrated increased EGFR phosphotyrosine after EGF treatment over wildtype EGFR expressing cells. Cells expressing mutant EGFR also showed increased sensitivity to erlotinib treatment compared to cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2081", "label": "Foster et al., 2010, World J Surg Oncol", "type": "Document", "title": "PubMed: Foster et al., 2010, World J Surg Oncol", "pmid": 20942962}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1482", "label": "EGFR C797Y", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 3.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55249092, "stop": 55249092, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1574"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA367578897"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["C744Y", "C752Y", "CYS797TYR"], "members": [{"id": "ga4gh:VA.hV1RMD1kB6btbMSK0FOa-Ciprh1o6rG5", "label": "NC_000007.13:g.55249092G>A", "digest": "hV1RMD1kB6btbMSK0FOa-Ciprh1o6rG5", "type": "Allele", "location": {"id": "ga4gh:SL.H5rG8ysTx91hBQt5-bgTLJmLC53WgIUy", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55181398, "end": 55181399}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.G2y2YQiJuP1Wo6cxvut31Qz2mcwY-UQH", "label": "C797Y", "digest": "G2y2YQiJuP1Wo6cxvut31Qz2mcwY-UQH", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2390G>A"}, {"syntax": "hgvs.c", "value": "NM_005228.3:c.2390G>A"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55249092G>A"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Cys797Tyr"}], "location": {"id": "ga4gh:SL.oirojchlpx4TkwB6RIkiiq69FXRdtka0", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 796, "end": 797}, "state": {"type": "LiteralSequenceExpression", "sequence": "Y"}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:216", "label": "Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9305"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:162"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4659", "description": "In an in vitro study performed after identification of the mutation in a malignant peritoneal mesothelioma patient, COS-7 cells expressing EGFR Y801H demonstrated increased EGFR phosphotyrosine after EGF treatment over wildtype EGFR expressing cells. Cells expressing mutant EGFR also showed increased sensitivity to erlotinib treatment compared to cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2081", "label": "Foster et al., 2010, World J Surg Oncol", "type": "Document", "title": "PubMed: Foster et al., 2010, World J Surg Oncol", "pmid": 20942962}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1483", "label": "EGFR Y801H", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 3.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "C", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55249103, "stop": 55249103, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1575"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA4266065"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["Y748H", "Y756H"], "definingContext": {"id": "ga4gh:VA.EQ8G49DwE48oaWUUBxdgexjaBeEkXaB2", "label": "Y801H", "digest": "EQ8G49DwE48oaWUUBxdgexjaBeEkXaB2", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2401T>C"}], "location": {"id": "ga4gh:SL.2-nb55lhkA2w2D5lV8p6ijiUXGfFaUV9", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 800, "end": 801}, "state": {"type": "LiteralSequenceExpression", "sequence": "H"}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:216", "label": "Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9305"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:162"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4783", "description": "An in vitro study of WM2664 (a human melanoma cell line) endogenously expressing wildtype PIK3R2 and BRAF V600D (a known BRAF inhibitor sensitizing mutation) found that cells virally induced to stably over-express PIK3R2 N561D were significantly more resistant to vemurafenib (a BRAF inhibitor) than cells transduced with an empty vector (40% vs 0% survival at the highest concentration, p < .0001).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1941", "label": "Shi et al., 2014, Cancer Discov", "type": "Document", "title": "PubMed: Shi et al., 2014, Cancer Discov", "pmid": 24265155}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:4290", "label": "PIK3R2", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8980"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5296"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["MPPH", "MPPH1", "P85B", "PIK3R2", "p85", "p85-BETA", "p85beta"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1560", "label": "PIK3R2 N561D", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 3.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"reference_build": "GRCh37", "type": "coordinates"}}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1652"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.PYayE9Sae7ylgUa_mz1BXQh5Hm5hn6bh", "label": "N561D", "digest": "PYayE9Sae7ylgUa_mz1BXQh5Hm5hn6bh", "type": "Allele", "location": {"id": "ga4gh:SL.zxXzXEMpBMH6lHnPQ292O68ToNUnw5Ln", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.AorkqvPJzuBM-GGFL1p-MOgExI2gg-jB"}, "start": 560, "end": 561}, "state": {"type": "LiteralSequenceExpression", "sequence": "D"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:7", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3224"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1909"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:5922", "description": "In an in vitro study performed after identification of the mutation in a malignant peritoneal mesothelioma patient, COS-7 cells expressing EGFR L858R demonstrated increased EGFR phosphotyrosine after EGF treatment over wildtype EGFR \n expressing cells. Cells expressing mutant EGFR also showed increased sensitivity to erlotinib treatment compared to cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2081", "label": "Foster et al., 2010, World J Surg Oncol", "type": "Document", "title": "PubMed: Foster et al., 2010, World J Surg Oncol", "pmid": 20942962}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:33", "label": "EGFR L858R", "description": "EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 379.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "G", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55259515, "stop": 55259515, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "33"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA126713"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16609"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376282"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376280"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434568"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121434568", "LEU858ARG"], "members": [{"id": "ga4gh:VA.TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "label": "NC_000007.13:g.55259515T>G", "digest": "TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "type": "Allele", "location": {"id": "ga4gh:SL.ulUNwZvajob7nzyrlpOd6uUWZIYCsoWb", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55191821, "end": 55191822}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "label": "L858R", "digest": "z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000007.13:g.55259515T>G"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2573T>G"}, {"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2573T>G"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Leu858Arg"}], "location": {"id": "ga4gh:SL.yVGJnwqxV6oCGqC_8nNb58D_wPXJeNJo", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 857, "end": 858}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:216", "label": "Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9305"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:162"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:6001", "description": "In this preclinical study, melanoma cell lines harboring the kinase-dead G469E- and D594G mutations were identified. These cell lines were resitant to MEK-Inhibition but underwent apoptosis after shRNA-mediated CRAF knowdown or Treatment with the pan-RAF Inhibitor sorafenib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:337", "label": "Smalley et al., 2009, Oncogene", "type": "Document", "title": "PubMed: Smalley et al., 2009, Oncogene", "pmid": 18794803}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:607", "label": "BRAF D594G", "description": "This BRAF mutation has a markedly reduced kinase activity and leads to paradoxical MEK-pathway activation via CRAF binding.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 43.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "C", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453154, "stop": 140453154, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "611"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123657"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13972"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913338"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913338", "ASP594GLY"], "members": [{"id": "ga4gh:VA.4qgowYAHzDVX5PXtEI_l6Z0WW8Mqg5fd", "label": "NC_000007.13:g.140453154T>C", "digest": "4qgowYAHzDVX5PXtEI_l6Z0WW8Mqg5fd", "type": "Allele", "location": {"id": "ga4gh:SL.mJCbLe5i4lmWMkSh9OiCLrL3l4H01ndP", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753353, "end": 140753354}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.AafX9u1lbbUrgWL3bD4zXKIjzyNlzMOJ", "label": "D594G", "digest": "AafX9u1lbbUrgWL3bD4zXKIjzyNlzMOJ", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004333.4:c.1781A>G"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Asp594Gly"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140453154T>C"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1781A>G"}], "location": {"id": "ga4gh:SL.WujfpJG33G8kDeus_PN9ykPrKhwkYmfB", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 593, "end": 594}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}}, "therapeutic": {"id": "civic.tid:6", "label": "Sorafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:495881"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:65823", "type": "Disease", "label": "Thyroid cancer differentiated"}, {"id": "hemonc:612", "type": "Disease", "label": "Hepatocellular carcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C3099"}, "relation": "relatedMatch"}]}, {"id": "hemonc:660", "type": "Disease", "label": "Renal cell carcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C9385"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C61948"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["BA4 43 9006", "BAY 43-9006", "Bay-439006"]}, "tumorType": {"id": "civic.did:206", "label": "Skin Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3510"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:8923"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:6002", "description": "In this preclinical study, melanoma cell lines harboring the kinase-dead G469E- and D594G mutations were identified. These cell lines were resitant to MEK-Inhibition but underwent apoptosis after shRNA-mediated CRAF knowdown or Treatment with the pan-RAF Inhibitor sorafenib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:337", "label": "Smalley et al., 2009, Oncogene", "type": "Document", "title": "PubMed: Smalley et al., 2009, Oncogene", "pmid": 18794803}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:607", "label": "BRAF D594G", "description": "This BRAF mutation has a markedly reduced kinase activity and leads to paradoxical MEK-pathway activation via CRAF binding.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 43.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "C", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453154, "stop": 140453154, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "611"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123657"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13972"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913338"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913338", "ASP594GLY"], "members": [{"id": "ga4gh:VA.4qgowYAHzDVX5PXtEI_l6Z0WW8Mqg5fd", "label": "NC_000007.13:g.140453154T>C", "digest": "4qgowYAHzDVX5PXtEI_l6Z0WW8Mqg5fd", "type": "Allele", "location": {"id": "ga4gh:SL.mJCbLe5i4lmWMkSh9OiCLrL3l4H01ndP", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753353, "end": 140753354}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.AafX9u1lbbUrgWL3bD4zXKIjzyNlzMOJ", "label": "D594G", "digest": "AafX9u1lbbUrgWL3bD4zXKIjzyNlzMOJ", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004333.4:c.1781A>G"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Asp594Gly"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140453154T>C"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1781A>G"}], "location": {"id": "ga4gh:SL.WujfpJG33G8kDeus_PN9ykPrKhwkYmfB", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 593, "end": 594}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}}, "therapeutic": {"id": "civic.tid:568", "label": "U0126", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "iuphar.ligand:5282"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:206", "label": "Skin Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3510"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:8923"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:6003", "description": "In this preclinical study, melanoma cell lines harboring the kinase-dead G469E- and D594G mutations were identified. These cell lines were resitant to MEK-Inhibition but underwent apoptosis after shRNA-mediated CRAF knowdown or Treatment with the pan-RAF Inhibitor sorafenib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:337", "label": "Smalley et al., 2009, Oncogene", "type": "Document", "title": "PubMed: Smalley et al., 2009, Oncogene", "pmid": 18794803}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:967", "label": "BRAF G469E", "description": "The BRAF G469E mutation has a markedly reduced kinase activity and thus activates the MEK pathway through CRAF binding.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 6.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "chromosome": "7", "start": 140481402, "stop": 140481402, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "993"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA279970"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913355"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913355"], "definingContext": {"id": "ga4gh:VA.PGcWom_sSoGg1kRbae1GyvMQtRJbSfHX", "label": "G469E", "digest": "PGcWom_sSoGg1kRbae1GyvMQtRJbSfHX", "type": "Allele", "location": {"id": "ga4gh:SL.BY8zrg6VJVWbywxAE-gQbP8o87KlqRk7", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 468, "end": 469}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "civic.tid:6", "label": "Sorafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:495881"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:65823", "type": "Disease", "label": "Thyroid cancer differentiated"}, {"id": "hemonc:612", "type": "Disease", "label": "Hepatocellular carcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C3099"}, "relation": "relatedMatch"}]}, {"id": "hemonc:660", "type": "Disease", "label": "Renal cell carcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C9385"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C61948"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["BA4 43 9006", "BAY 43-9006", "Bay-439006"]}, "tumorType": {"id": "civic.did:206", "label": "Skin Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3510"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:8923"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:6004", "description": "In this preclinical study, melanoma cell lines harboring the kinase-dead G469E- and D594G mutations were identified. These cell lines were resitant to MEK-Inhibition (U0126) but underwent apoptosis after shRNA-mediated CRAF knowdown or treatment with the pan-RAF inhibitor sorafenib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:337", "label": "Smalley et al., 2009, Oncogene", "type": "Document", "title": "PubMed: Smalley et al., 2009, Oncogene", "pmid": 18794803}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:967", "label": "BRAF G469E", "description": "The BRAF G469E mutation has a markedly reduced kinase activity and thus activates the MEK pathway through CRAF binding.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 6.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "chromosome": "7", "start": 140481402, "stop": 140481402, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "993"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA279970"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913355"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913355"], "definingContext": {"id": "ga4gh:VA.PGcWom_sSoGg1kRbae1GyvMQtRJbSfHX", "label": "G469E", "digest": "PGcWom_sSoGg1kRbae1GyvMQtRJbSfHX", "type": "Allele", "location": {"id": "ga4gh:SL.BY8zrg6VJVWbywxAE-gQbP8o87KlqRk7", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 468, "end": 469}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "civic.tid:568", "label": "U0126", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "iuphar.ligand:5282"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:206", "label": "Skin Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3510"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:8923"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:6174", "description": "Efficacy of osimertinib and its metabolite, AZ5104, at reducing phosphorylation of key proteins was evaluated by western blot. Osimertinib failed to induce substantial reductions in phosphorylated ERBB2 in NR6 mouse fibroblast cells transduced to co-express ERBB2 L869R and T798I or ERBB2 wt. AZ5104 blocked phosphorylation to a greater extent in the mutant and wildtype cells. MCF10A cells transduced with ERBB2 wt, ERBB2 T798I alone or ERBB2 L869R and T798I co-expressed did not show substantial reductions in phosphorylated ERBB2, AKT, ERK or S6. AZ5104 induced greater reductions. Authors note that AZ5104 is not being developed independently of osimertinib and only 10% of osimertinib is metabolized into AZ5104 in humans. Authors concluded that ERBB2 T798I is not sensitive to osimertinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2397", "label": "Hanker et al., 2017, Cancer Discov", "type": "Document", "title": "PubMed: Hanker et al., 2017, Cancer Discov", "pmid": 28274957}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:20", "label": "ERBB2", "description": "ERBB2, commonly referred to as HER2, is amplified and/or overexpressed in 20-30% of invasive breast carcinomas. HER2-positive breast cancer is treated in a separate manner from other subtypes of breast cancer and commonly presents as more aggressive disease. Metastatic HER2-positive breast cancer is now commonly treated with HER2-targeted therapy. Apart from being amplified/overexpressed, ERBB2 activating mutations have been shown to have clinical importance in HER2-negative breast cancer. These mutations have shown sensitivity to the tyrosine kinase inhibitor neratinib, and highlight the importance of clinical sequencing efforts in treating breast cancer.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3430"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2064"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD340", "ERBB2", "HER-2", "HER-2/neu", "HER2", "MLN 19", "MLN-19", "NEU", "NGL", "TKR1", "VSCN2", "c-ERB-2", "c-ERB2", "p185(erbB2)"]}}, "direction": "refutes", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:2204", "label": "ERBB2 T798I", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 3.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000269571.5", "chromosome": "17", "start": 37881064, "stop": 37881064, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "2331"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA399303242"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["THR798ILE"], "members": [{"id": "ga4gh:VA.2TNiBvPG853lYUGXjDyrTgztWMlF2G69", "label": "NC_000017.10:g.37881064C>T", "digest": "2TNiBvPG853lYUGXjDyrTgztWMlF2G69", "type": "Allele", "location": {"id": "ga4gh:SL.U2b4KDmmKBTFA97iXAOKDkyeizOcphur", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dLZ15tNO1Ur0IcGjwc3Sdi_0A6Yf4zm7"}, "start": 39724810, "end": 39724811}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.ZF_QNdczgo7JJFxJxiwvxzDUugqt_9nz", "label": "T798I", "digest": "ZF_QNdczgo7JJFxJxiwvxzDUugqt_9nz", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000269571.5:c.2393C>T"}, {"syntax": "hgvs.g", "value": "NC_000017.10:g.37881064C>T"}, {"syntax": "hgvs.c", "value": "NM_001289937.1:c.2393C>T"}, {"syntax": "hgvs.p", "value": "NP_001276866.1:p.Thr798Ile"}], "location": {"id": "ga4gh:SL.0nGMBEAND8n0bvUAldtc2uhVAFz49pFi", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.AF1UFydIo02-bMplonKSfxlWY2q6ze3m"}, "start": 797, "end": 798}, "state": {"type": "LiteralSequenceExpression", "sequence": "I"}}}, "therapeutic": {"id": "civic.tid:187", "label": "Osimertinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1721560"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C116377"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-", "AZD-9291", "AZD9291", "Mereletinib", "Tagrisso"]}, "tumorType": {"id": "civic.did:22", "label": "Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9335"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1612"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:6213", "description": "This preclinical study tested the sensitivity of HER2-positive breast cancer cell line BT-474 (heterozygous for PIK3CA K111N) retrovirally transduced with PIK3CA E545K to NVP-BEZ235 (dactolisib; a dual PI3K/mTOR inhibitor). The study found that dactolisib was effective in inhibiting outgrowth of E545K mutant-containing cells. Dactolisib was also combined with trastuzumab and/or lapatinib with similar abrogation of growth for PIK3CA E545K expressing cells. Growth of untransduced BT-474 control cells was prevented by treatment with any monotherapy or combination of trastuzumab, lapatinib, or dactolisib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2486", "label": "Eichhorn et al., 2008, Cancer Res.", "type": "Document", "title": "PubMed: Eichhorn et al., 2008, Cancer Res.", "pmid": 19010894}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "refutes", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:104", "label": "PIK3CA E545K", "description": "PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 77.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000263967.3", "chromosome": "3", "start": 178936091, "stop": 178936091, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "104"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123334"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13655"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS104886003"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLU545LYS", "RS104886003"], "members": [{"id": "ga4gh:VA.uqD1zF6cMOYhBp8ur5oLTMqV0jxiC2a7", "label": "NC_000003.11:g.178936091G>A", "digest": "uqD1zF6cMOYhBp8ur5oLTMqV0jxiC2a7", "type": "Allele", "location": {"id": "ga4gh:SL.5l5tuxgJGb8y7CQzkKLPUvS-Cx4kr2ju", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 179218302, "end": 179218303}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.uw7DyLM7r98pn66LOXU3tAknmkV7jiJ0", "label": "E545K", "digest": "uw7DyLM7r98pn66LOXU3tAknmkV7jiJ0", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006218.3:c.1633G>A"}, {"syntax": "hgvs.p", "value": "NP_006209.2:p.Glu545Lys"}, {"syntax": "hgvs.c", "value": "ENST00000263967.3:c.1633G>A"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.178936091G>A"}], "location": {"id": "ga4gh:SL.SrEa0lPyesLrOX0M_aW51d-JdJhU-D3p", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 544, "end": 545}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:343", "label": "Dactolisib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C74072"}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C74072"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["BEZ235", "Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-", "NVPBEZ235"]}, "tumorType": {"id": "civic.did:368", "label": "Her2-receptor Positive Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C53556"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:0060079"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:7553", "description": "In the study with a tumor from a patient with metastatic colorectal cancer BRAF (G466V) and wild-type RAS and NF1. Treatment with Panitumumab and irinotecan cause tumor regression. And in tumor cells of patient-derived xenograft generated from this patient, ERK signaling was sensitive to cetuximab and resistant to vemurafenib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:3005", "label": "Yao et al., 2017, Nature", "type": "Document", "title": "PubMed: Yao et al., 2017, Nature", "pmid": 28783719}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "refutes", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:2098", "label": "BRAF G466V", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 14.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "A", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140481411, "stop": 140481411, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "2222"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123647"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13967"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913351"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLY466VAL", "RS121913351"], "members": [{"id": "ga4gh:VA.rTU_Q-4E6SYZRuGw6uLmg0sekqgcyAB6", "label": "NC_000007.13:g.140481411C>A", "digest": "rTU_Q-4E6SYZRuGw6uLmg0sekqgcyAB6", "type": "Allele", "location": {"id": "ga4gh:SL.b-COuHbMMBebWWHMv6wspiXtC1AcHJ9F", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140781610, "end": 140781611}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.WTGRt27yQDZ0lXw7Gz-FskGnJkr2Eenj", "label": "G466V", "digest": "WTGRt27yQDZ0lXw7Gz-FskGnJkr2Eenj", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000007.13:g.140481411C>A"}, {"syntax": "hgvs.c", "value": "NM_004333.4:c.1397G>T"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Gly466Val"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1397G>T"}], "location": {"id": "ga4gh:SL.ZjNtMaJuKuzhEq3QJ6sLiXfNfCB_ToNz", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 465, "end": 466}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:7554", "description": "RAF inhibitor vemurafenib failed to inhibit ERK signaling in tumor cells and NIH3T3 that express class 3 BRAF mutations (G466V, G466E,  D594G, D594N, and G596R).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:3005", "label": "Yao et al., 2017, Nature", "type": "Document", "title": "PubMed: Yao et al., 2017, Nature", "pmid": 28783719}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "refutes", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:2098", "label": "BRAF G466V", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 14.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "A", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140481411, "stop": 140481411, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "2222"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123647"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13967"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913351"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLY466VAL", "RS121913351"], "members": [{"id": "ga4gh:VA.rTU_Q-4E6SYZRuGw6uLmg0sekqgcyAB6", "label": "NC_000007.13:g.140481411C>A", "digest": "rTU_Q-4E6SYZRuGw6uLmg0sekqgcyAB6", "type": "Allele", "location": {"id": "ga4gh:SL.b-COuHbMMBebWWHMv6wspiXtC1AcHJ9F", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140781610, "end": 140781611}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.WTGRt27yQDZ0lXw7Gz-FskGnJkr2Eenj", "label": "G466V", "digest": "WTGRt27yQDZ0lXw7Gz-FskGnJkr2Eenj", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000007.13:g.140481411C>A"}, {"syntax": "hgvs.c", "value": "NM_004333.4:c.1397G>T"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Gly466Val"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1397G>T"}], "location": {"id": "ga4gh:SL.ZjNtMaJuKuzhEq3QJ6sLiXfNfCB_ToNz", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 465, "end": 466}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:2627", "label": "Solid Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C8101"}], "type": "Disease"}}
{"id": "civic.eid:7556", "description": "RAF inhibitor vemurafenib failed to inhibit ERK signaling in tumor cells and NIH3T3 that express class 3 BRAF mutations (G466V, G466E, D594G, D594N, and G596R).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:3005", "label": "Yao et al., 2017, Nature", "type": "Document", "title": "PubMed: Yao et al., 2017, Nature", "pmid": 28783719}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "refutes", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:607", "label": "BRAF D594G", "description": "This BRAF mutation has a markedly reduced kinase activity and leads to paradoxical MEK-pathway activation via CRAF binding.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 43.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "C", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453154, "stop": 140453154, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "611"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123657"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13972"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913338"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913338", "ASP594GLY"], "members": [{"id": "ga4gh:VA.4qgowYAHzDVX5PXtEI_l6Z0WW8Mqg5fd", "label": "NC_000007.13:g.140453154T>C", "digest": "4qgowYAHzDVX5PXtEI_l6Z0WW8Mqg5fd", "type": "Allele", "location": {"id": "ga4gh:SL.mJCbLe5i4lmWMkSh9OiCLrL3l4H01ndP", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753353, "end": 140753354}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.AafX9u1lbbUrgWL3bD4zXKIjzyNlzMOJ", "label": "D594G", "digest": "AafX9u1lbbUrgWL3bD4zXKIjzyNlzMOJ", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004333.4:c.1781A>G"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Asp594Gly"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140453154T>C"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1781A>G"}], "location": {"id": "ga4gh:SL.WujfpJG33G8kDeus_PN9ykPrKhwkYmfB", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 593, "end": 594}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:216", "label": "Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9305"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:162"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:8336", "description": "The authors used saturation mutagenesis of FLT3/ITD followed by selection of transfected cells in FLT3 TKI. The FLT3/ITD Y842C mutation produced high-level resistance to KW2449, sorafenib, sunitinib and AGS324 in vitro but remained sensitive to lestaurtinib and midostaurin. Balb/c mice transplanted with the FLT3/ITD Y842C mutation confirmed resistance to sorafenib in vivo but not to lestaurtinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:3472", "label": "Williams et al., 2013, Leukemia", "type": "Document", "title": "PubMed: Williams et al., 2013, Leukemia", "pmid": 22858906}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:24", "label": "FLT3", "description": "FLT3 is an important cytokine receptor involved in normal hematopoiesis. Mutations in this gene are common in acute myeloid leukemia (AML) and screening for mutations in this gene has been recommended by the World Health Organization in patients with AML, particularly in cases of cytogenetically normal AML (CN-AML). FLT3 mutations commonly co-occur with mutations such as NPM1 that are associated with CN-AML and likely modulate prognostic impact. While FLT3-ITD mutations have been associated with poorer prognosis in AML, the prognostic impact of FLT3-TKD mutations are still up for debate.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3765"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2322"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD135", "FLK-2", "FLK2", "FLT3", "STK1"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:2939", "label": "FLT3 Y842C", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 20.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"type": "coordinates"}}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "3070"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.s6EXIFpOIE4Bu60Si0TcHRecbTr1Iux8", "label": "Y842C", "digest": "s6EXIFpOIE4Bu60Si0TcHRecbTr1Iux8", "type": "Allele", "location": {"id": "ga4gh:SL.v49CEsmpXzpqqDo9j07qHUhf597WMTPC", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.0dtDG7QKyvW7BntvQVpLS83mYRA58LKH"}, "start": 841, "end": 842}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "civic.tid:1629", "label": "FLT3/ABL/Aurora Kinase Inhibitor KW-2449", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C116858"}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C116858"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["KW-2449"]}, "tumorType": {"id": "civic.did:3", "label": "Acute Myeloid Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3171"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9119"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:8338", "description": "The authors used saturation mutagenesis of FLT3/ITD followed by selection of transfected cells in FLT3 TKI. The FLT3/ITD Y842C mutation produced high-level resistance to KW2449, sorafenib, sunitinib and AGS324 in vitro but remained sensitive to lestaurtinib and midostaurin. Balb/c mice transplanted with the FLT3/ITD Y842C mutation confirmed resistance to sorafenib in vivo but not to lestaurtinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:3472", "label": "Williams et al., 2013, Leukemia", "type": "Document", "title": "PubMed: Williams et al., 2013, Leukemia", "pmid": 22858906}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:24", "label": "FLT3", "description": "FLT3 is an important cytokine receptor involved in normal hematopoiesis. Mutations in this gene are common in acute myeloid leukemia (AML) and screening for mutations in this gene has been recommended by the World Health Organization in patients with AML, particularly in cases of cytogenetically normal AML (CN-AML). FLT3 mutations commonly co-occur with mutations such as NPM1 that are associated with CN-AML and likely modulate prognostic impact. While FLT3-ITD mutations have been associated with poorer prognosis in AML, the prognostic impact of FLT3-TKD mutations are still up for debate.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3765"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2322"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD135", "FLK-2", "FLK2", "FLT3", "STK1"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:2939", "label": "FLT3 Y842C", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 20.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"type": "coordinates"}}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "3070"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.s6EXIFpOIE4Bu60Si0TcHRecbTr1Iux8", "label": "Y842C", "digest": "s6EXIFpOIE4Bu60Si0TcHRecbTr1Iux8", "type": "Allele", "location": {"id": "ga4gh:SL.v49CEsmpXzpqqDo9j07qHUhf597WMTPC", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.0dtDG7QKyvW7BntvQVpLS83mYRA58LKH"}, "start": 841, "end": 842}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "civic.tid:157", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:357977"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:647", "type": "Disease", "label": "Pancreatic NET", "mappings": [{"coding": {"system": "ncit", "code": "C27720"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:660", "type": "Disease", "label": "Renal cell carcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C9385"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C71622"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"]}, "tumorType": {"id": "civic.did:3", "label": "Acute Myeloid Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3171"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9119"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:8340", "description": "A screen using saturation mutagenesis of FLT3/ITD followed by selection of transfected TF1 cells in FLT3 TKIs identified Y842C. Cytotoxicity assessed by MTT demonstrated Ba/F3 cells expressing FLT3/ITD Y842C treated with Midostaurin responded similarly to FLT3/ITD control cells (IC50: 4nM). Like in FLT3/ITD control cells, immunoblotting showed Midostaurin inhibited FLT3 autophosphorylation and the activation of downstream pathways in Ba/F3 FLT3/ITD Y842C cells.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:3472", "label": "Williams et al., 2013, Leukemia", "type": "Document", "title": "PubMed: Williams et al., 2013, Leukemia", "pmid": 22858906}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:24", "label": "FLT3", "description": "FLT3 is an important cytokine receptor involved in normal hematopoiesis. Mutations in this gene are common in acute myeloid leukemia (AML) and screening for mutations in this gene has been recommended by the World Health Organization in patients with AML, particularly in cases of cytogenetically normal AML (CN-AML). FLT3 mutations commonly co-occur with mutations such as NPM1 that are associated with CN-AML and likely modulate prognostic impact. While FLT3-ITD mutations have been associated with poorer prognosis in AML, the prognostic impact of FLT3-TKD mutations are still up for debate.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3765"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2322"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD135", "FLK-2", "FLK2", "FLT3", "STK1"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:2939", "label": "FLT3 Y842C", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 20.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"type": "coordinates"}}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "3070"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.s6EXIFpOIE4Bu60Si0TcHRecbTr1Iux8", "label": "Y842C", "digest": "s6EXIFpOIE4Bu60Si0TcHRecbTr1Iux8", "type": "Allele", "location": {"id": "ga4gh:SL.v49CEsmpXzpqqDo9j07qHUhf597WMTPC", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.0dtDG7QKyvW7BntvQVpLS83mYRA58LKH"}, "start": 841, "end": 842}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "civic.tid:323", "label": "Midostaurin", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1919083"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "Disease", "label": "Systemic mastocytosis", "mappings": [{"coding": {"system": "ncit", "code": "C9235"}, "relation": "relatedMatch"}]}, {"id": "hemonc:552", "type": "Disease", "label": "Acute myeloid leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3171"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1872"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["CGP 41251", "CGP41251", "N-Benzoyl-Staurosporine", "N-Benzoylstaurosporine", "PKC-412", "PKC412", "Rydapt"]}, "tumorType": {"id": "civic.did:3", "label": "Acute Myeloid Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3171"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9119"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:8341", "description": "A screen using saturation mutagenesis of FLT3/ITD followed by selection of transfected TF1 cells in FLT3 TKIs identified F691L. Cytotoxicity assessed by MTT demonstrated Ba/F3 cells expressing FLT3/ITD F691L conferred moderate resistance to lestaurtinib (IC50: 8nM) compared to FLT3/ITD control cells (IC50: 2nM). Immunoblotting showed lestaurtinib was able to partially inhibit FLT3 autophosphorylation and the activation of downstream pathways in Ba/F3 FLT3/ITD F691L cells. Structural modeling revealed F691 to be located in the ATP binding cleft. The authors hypothesize this amino acid change weakens inhibitor affinity as this residue likely makes direct contact with FLT3 TKIs.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:3472", "label": "Williams et al., 2013, Leukemia", "type": "Document", "title": "PubMed: Williams et al., 2013, Leukemia", "pmid": 22858906}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:24", "label": "FLT3", "description": "FLT3 is an important cytokine receptor involved in normal hematopoiesis. Mutations in this gene are common in acute myeloid leukemia (AML) and screening for mutations in this gene has been recommended by the World Health Organization in patients with AML, particularly in cases of cytogenetically normal AML (CN-AML). FLT3 mutations commonly co-occur with mutations such as NPM1 that are associated with CN-AML and likely modulate prognostic impact. While FLT3-ITD mutations have been associated with poorer prognosis in AML, the prognostic impact of FLT3-TKD mutations are still up for debate.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3765"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2322"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD135", "FLK-2", "FLK2", "FLT3", "STK1"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:2940", "label": "FLT3 F691L", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 6.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"type": "coordinates"}}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "3071"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.NVkWgPaa9dCPDndshGoWOCuQMYewzQko", "label": "F691L", "digest": "NVkWgPaa9dCPDndshGoWOCuQMYewzQko", "type": "Allele", "location": {"id": "ga4gh:SL.AnCd0VcHeire_BKaf72ZWX-qAENUVmEg", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.0dtDG7QKyvW7BntvQVpLS83mYRA58LKH"}, "start": 690, "end": 691}, "state": {"type": "LiteralSequenceExpression", "sequence": "L"}}}, "therapeutic": {"id": "civic.tid:260", "label": "Lestaurtinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C48402"}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C48402"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["9,12-Epoxy-1H-diindolo(1,2,3-fg:3',2',1'-kl)pyrrolo(3,4-i)(1,6)benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9S,10S,12R)-", "CEP-701", "KT-5555", "SPM-924"]}, "tumorType": {"id": "civic.did:3", "label": "Acute Myeloid Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3171"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9119"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:8342", "description": "A screen using saturation mutagenesis of FLT3/ITD followed by selection of transfected TF1 cells in the FLT3 TKI midostaurin identified F691L in 1 of 400 clones. Cytotoxicity assessed by MTT demonstrated Ba/F3 cells expressing FLT3/ITD F691L conferred moderate resistance to midostaurin (IC50: 18nM) compared to FLT3/ITD control cells (IC50: 4nM). Immunoblotting showed midostaurin was able to partially inhibit FLT3 autophosphorylation and the activation of downstream pathways in Ba/F3 FLT3/ITD F691L cells. Structural modeling revealed F691 to be located in the ATP binding cleft. The authors hypothesize this amino acid change weakens inhibitor affinity as this residue likely makes direct contact with FLT3 TKIs.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:3472", "label": "Williams et al., 2013, Leukemia", "type": "Document", "title": "PubMed: Williams et al., 2013, Leukemia", "pmid": 22858906}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:24", "label": "FLT3", "description": "FLT3 is an important cytokine receptor involved in normal hematopoiesis. Mutations in this gene are common in acute myeloid leukemia (AML) and screening for mutations in this gene has been recommended by the World Health Organization in patients with AML, particularly in cases of cytogenetically normal AML (CN-AML). FLT3 mutations commonly co-occur with mutations such as NPM1 that are associated with CN-AML and likely modulate prognostic impact. While FLT3-ITD mutations have been associated with poorer prognosis in AML, the prognostic impact of FLT3-TKD mutations are still up for debate.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3765"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2322"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD135", "FLK-2", "FLK2", "FLT3", "STK1"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:2940", "label": "FLT3 F691L", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 6.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"type": "coordinates"}}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "3071"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.NVkWgPaa9dCPDndshGoWOCuQMYewzQko", "label": "F691L", "digest": "NVkWgPaa9dCPDndshGoWOCuQMYewzQko", "type": "Allele", "location": {"id": "ga4gh:SL.AnCd0VcHeire_BKaf72ZWX-qAENUVmEg", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.0dtDG7QKyvW7BntvQVpLS83mYRA58LKH"}, "start": 690, "end": 691}, "state": {"type": "LiteralSequenceExpression", "sequence": "L"}}}, "therapeutic": {"id": "civic.tid:323", "label": "Midostaurin", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1919083"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "Disease", "label": "Systemic mastocytosis", "mappings": [{"coding": {"system": "ncit", "code": "C9235"}, "relation": "relatedMatch"}]}, {"id": "hemonc:552", "type": "Disease", "label": "Acute myeloid leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3171"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1872"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["CGP 41251", "CGP41251", "N-Benzoyl-Staurosporine", "N-Benzoylstaurosporine", "PKC-412", "PKC412", "Rydapt"]}, "tumorType": {"id": "civic.did:3", "label": "Acute Myeloid Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3171"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9119"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:8376", "description": "Rs4;11 cells overexpressing BCL2 F104I exhibited >40-fold greater resistance to venetoclax after 24-hour treatment (IC50 not reached) than Rs4;11 overexpressing BCL2 WT cells as determined by cell titer glo measured cytotoxicity assays. Plasmon resonance protein binding assays demonstrated marked impairment (300 fold) of venetoclax binding to F104I (Ki=5.9 nM) veresus WT (Ki=.018nM). The authors pointed out reduction in binding was a similar magnitude as that observed previously with the BCL2 G101V and F104L.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:3502", "label": "Blombery et al., 2019, Br. J. Haematol.", "type": "Document", "title": "PubMed: Blombery et al., 2019, Br. J. Haematol.", "pmid": 31234236}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:59", "label": "BCL2", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:990"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:596"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["BCL2", "Bcl-2", "PPP1R50"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:2951", "label": "BCL2 F104I", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 8.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000398117.1", "chromosome": "18", "start": 60985590, "stop": 60985590, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "3082"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA402632320"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["PHE104ILE"], "members": [{"id": "ga4gh:VA.TIzqjN-2xpWUQZJQvNrO89Q2wezQDUOY", "label": "NC_000018.10:g.63318357A>T", "digest": "TIzqjN-2xpWUQZJQvNrO89Q2wezQDUOY", "type": "Allele", "location": {"id": "ga4gh:SL.YTE-G9ItxWKWg3ZKw7d7EkCLpE2VP4cm", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vWwFhJ5lQDMhh-czg06YtlWqu0lvFAZV"}, "start": 63318356, "end": 63318357}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.Rts0zMM5MXBu5AjIqDXwPGM5ysYCoAiV", "label": "F104I", "digest": "Rts0zMM5MXBu5AjIqDXwPGM5ysYCoAiV", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000018.10:g.63318357A>T"}, {"syntax": "hgvs.g", "value": "NC_000018.9:g.60985590A>T"}, {"syntax": "hgvs.c", "value": "NM_000633.3:c.310T>A"}, {"syntax": "hgvs.p", "value": "NP_000624.2:p.Phe104Ile"}], "location": {"id": "ga4gh:SL.k1PMrP4IVJT-YVKggi-ZTph22lo6f9VJ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.ht6Jrp_WdHFgzv2MpF-GxPV6L3on-xuM"}, "start": 103, "end": 104}, "state": {"type": "LiteralSequenceExpression", "sequence": "I"}}}, "therapeutic": {"id": "civic.tid:574", "label": "Venetoclax", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1747556"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:552", "type": "Disease", "label": "Acute myeloid leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3171"}, "relation": "relatedMatch"}]}, {"id": "hemonc:581", "type": "Disease", "label": "Chronic lymphocytic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3163"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C103147"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-(4-((2-(4-Chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide", "ABT-0199", "ABT-199", "ABT199", "GDC-0199", "RG7601", "Venclexta", "Venclyxto"]}, "tumorType": {"id": "civic.did:51", "label": "Follicular Lymphoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3209"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:0050873"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:8642", "description": "Bladder cancer cell line 97-7 expressing endogenous FGFR3 S249C (IC50 44.6ug/ml) was resistant to cisplatin compared to two FGFR3 wild-type cell lines, 5637 (IC50 2.07ug/ml) and T24 (IC50 1.58ug/ml) as shown by a CCK-8 colorimetric cytotoxicity. Western blot revealed the ratio of phosphorylated-Akt/total Akt was higher in the 97-7 cells than in the wild-type cells, which was reversed by siRNA knockdown of FGFR3. Inhibition of Akt signaling by treatment with GDC0068 or LY294002 increased the cisplatin sensitivity of 97-7 cells (IC50 4.17ug/ml & 8.91ug/ml respectively).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:3631", "label": "Xie et al., 2019, Exp Ther Med", "type": "Document", "title": "PubMed: Xie et al., 2019, Exp Ther Med", "pmid": 31316618}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:23", "label": "FGFR3", "description": "The FGFR proteins are involved in a wide array of pathways known to play a signficant role in cancer. Activation of these receptors can lead to activation of the RAS-MAPK pathway and the PI3K-AKT pathway, among others. The mechanisms by which FGFR can be misregulated vary between cancers. Amplification of the receptors has been observed in lung and breast cancers, coding mutations and deletions have been seen in many cancers, and more recently, FGFR fusions that lead to pathway actiation have been demonstrated to have oncogenic potential across multiple cancer types. The targeted therapeutics ponatinib, dovitinib and pazopanib have seen success in treating over-active FGFR signalling, prompting use of diagnostic sequencing targeting the FGFR genes, especially in lung cancer patients.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3690"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2261"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["ACH", "CD333", "CEK2", "FGFR3", "HSFGFR3EX", "JTK4"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:624", "label": "FGFR3 S249C", "description": "This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 18.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "G", "representative_transcript": "ENST00000340107.4", "chromosome": "4", "start": 1803568, "stop": 1803568, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "628"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA126380"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16339"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913483"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913483", "SER249CYS"], "members": [{"id": "ga4gh:VA.Kq6y5fv8Y64R1JLVlTDN91_aJtXLk4z6", "label": "NC_000004.11:g.1803568C>G", "digest": "Kq6y5fv8Y64R1JLVlTDN91_aJtXLk4z6", "type": "Allele", "location": {"id": "ga4gh:SL.t_cbFhXGQQNSKZ8qMpd3pd4LvHKELIgd", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 1801840, "end": 1801841}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.ScwqpwMfwX2Vt2TkAnlqTatmdC2UwnMi", "label": "S249C", "digest": "ScwqpwMfwX2Vt2TkAnlqTatmdC2UwnMi", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000004.11:g.1803568C>G"}, {"syntax": "hgvs.c", "value": "NM_000142.4:c.746C>G"}, {"syntax": "hgvs.p", "value": "NP_000133.1:p.Ser249Cys"}, {"syntax": "hgvs.p", "value": "ENST00000340107.4c.746C>G"}], "location": {"id": "ga4gh:SL.Q9zQuJzbEtQG2B7hyCuLmZovGiNuWxiY", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.xO86teDIIalLkqprCQaXyuvdPqvBxBG3"}, "start": 248, "end": 249}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "civic.tid:326", "label": "Cisplatin", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:2555"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:671", "type": "Disease", "label": "Testicular cancer", "mappings": [{"coding": {"system": "ncit", "code": "C5053"}, "relation": "relatedMatch"}]}, {"id": "hemonc:645", "type": "Disease", "label": "Ovarian cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7431"}, "relation": "relatedMatch"}]}, {"id": "hemonc:569", "type": "Disease", "label": "Bladder cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9334"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C376"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(SP-4-2)-Diamminedichloroplatinum", "Abiplatin", "Blastolem", "Briplatin", "CDDP", "Cis-diammine-dichloroplatinum", "Cis-diamminedichloridoplatinum", "Cis-diamminedichloro Platinum (II)", "Cis-diamminedichloroplatinum", "Cis-dichloroammine Platinum (II)", "Cis-platinous Diamine Dichloride", "Cis-platinum", "Cis-platinum II", "Cis-platinum II Diamine Dichloride", "Cismaplat", "Cisplatina", "Cisplatinum", "Cisplatyl", "Citoplatino", "Citosin", "Cysplatyna", "DDP", "Lederplatin", "Metaplatin", "Neoplatin", "Peyrone's Chloride", "Peyrone's Salt", "Placis", "Plastistil", "Platamine", "Platiblastin", "Platiblastin-S", "Platinex", "Platinol", "Platinol- AQ", "Platinol-AQ", "Platinol-AQ VHA Plus", "Platinoxan", "Platinum", "Platinum Diamminodichloride", "Platinum, Diaminedichloro-, Cis- (8CI)", "Platiran", "Platistin", "Platosin"]}, "tumorType": {"id": "civic.did:642", "label": "Transitional Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2930"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:2671"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:8654", "description": "A screen using saturation mutagenesis of FLT3/ITD followed by selection of transfected TF1 cells in FLT3 TKIs identified Y842C. Cytotoxicity assessed by MTT demonstrated Ba/F3 cells expressing FLT3/ITD Y842C conferred high-level resistance to Quizartinib (AC220) (IC50: 20nM) compared to FLT3/ITD control cells (IC50: 1nM). Unlike in FLT3/ITD control cells, immunoblotting showed Quizartinib was unable to inhibit FLT3 autophosphorylation and the activation of downstream pathways in Ba/F3 FLT3/ITD Y842C cells. Structural modeling revealed Y842 to be located in the activation loop. The authors hypothesize altered conformation interferes with drug interaction.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:3472", "label": "Williams et al., 2013, Leukemia", "type": "Document", "title": "PubMed: Williams et al., 2013, Leukemia", "pmid": 22858906}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:24", "label": "FLT3", "description": "FLT3 is an important cytokine receptor involved in normal hematopoiesis. Mutations in this gene are common in acute myeloid leukemia (AML) and screening for mutations in this gene has been recommended by the World Health Organization in patients with AML, particularly in cases of cytogenetically normal AML (CN-AML). FLT3 mutations commonly co-occur with mutations such as NPM1 that are associated with CN-AML and likely modulate prognostic impact. While FLT3-ITD mutations have been associated with poorer prognosis in AML, the prognostic impact of FLT3-TKD mutations are still up for debate.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3765"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2322"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD135", "FLK-2", "FLK2", "FLT3", "STK1"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:2939", "label": "FLT3 Y842C", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 20.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"type": "coordinates"}}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "3070"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.s6EXIFpOIE4Bu60Si0TcHRecbTr1Iux8", "label": "Y842C", "digest": "s6EXIFpOIE4Bu60Si0TcHRecbTr1Iux8", "type": "Allele", "location": {"id": "ga4gh:SL.v49CEsmpXzpqqDo9j07qHUhf597WMTPC", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.0dtDG7QKyvW7BntvQVpLS83mYRA58LKH"}, "start": 841, "end": 842}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "civic.tid:505", "label": "Quizartinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C68936"}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C68936"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(2E)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3S)-Oxolan-3-Yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)but-2-Enamide", "AC-220", "AC010220", "AC220", "N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo [2,1-b] [1,3] Benzothiazol 2-yl]phenyl}urea"]}, "tumorType": {"id": "civic.did:3", "label": "Acute Myeloid Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3171"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9119"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:8841", "description": "This study described the similar crystal structures of BCL-2 wild-type and G101V when bound to venetoclax. Steady state competition surface plasmon resonance experiments demonstrated a ~177 fold decrease in venetoclax affinity for G101V (Ki=3.2nM) versus WT (Ki=.018nM). Resistance is acquired by a knock-on effect in the P2 pocket of V101 on an adjacent residue, E152 as affinity for venetoclax was restored in BCL2 G101V through the introduction of an E152A mutation (Ki =.002nM). Additionally, BCL2 G101V maintains similar affinity for apoptotic BH3 peptides, which assists in the prevention of apoptosis.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:3500", "label": "Birkinshaw et al., 2019, Nat Commun", "type": "Document", "title": "PubMed: Birkinshaw et al., 2019, Nat Commun", "pmid": 31160589}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:59", "label": "BCL2", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:990"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:596"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["BCL2", "Bcl-2", "PPP1R50"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:2829", "label": "BCL2 G101V", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 8.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "A", "representative_transcript": "ENST00000398117.1", "chromosome": "18", "start": 60985598, "stop": 60985598, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "2960"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA402632336"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLY101VAL"], "definingContext": {"id": "ga4gh:VA.SJLMw1klgo7k0ba5nCHmM1DDC24VhEKL", "label": "G101V", "digest": "SJLMw1klgo7k0ba5nCHmM1DDC24VhEKL", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000398117.1:c.302G>T"}], "location": {"id": "ga4gh:SL.s20SE6Fg5cNsBD8quE_A50pF_WGEb1PM", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.ht6Jrp_WdHFgzv2MpF-GxPV6L3on-xuM"}, "start": 100, "end": 101}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "civic.tid:574", "label": "Venetoclax", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1747556"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:552", "type": "Disease", "label": "Acute myeloid leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3171"}, "relation": "relatedMatch"}]}, {"id": "hemonc:581", "type": "Disease", "label": "Chronic lymphocytic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3163"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C103147"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-(4-((2-(4-Chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide", "ABT-0199", "ABT-199", "ABT199", "GDC-0199", "RG7601", "Venclexta", "Venclyxto"]}, "tumorType": {"id": "civic.did:52", "label": "Chronic Lymphocytic Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3163"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1040"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:9945", "description": "Foundation panel results of baseline tumour samples from 48 patients with diffuse large B cell lymphoma identified PIM1 mutations in 6 patient samples, 5 of which were the DLBCL-ABC subtype. Four out of the 5 DLBCL-ABC patients with PIM1 mutations had stable disease or progressive disease when treated with ibrutinib, suggesting innate resistance to ibrutinib therapy. Three PIM1 mutations L2V, P81S, and S97N were investigated in cell lines studies. Cells transduced with L2V, P81S, and S97N were resistant to ibrutinib compared to cells transduced with wild type PIM1. Combined treatment of PIM1 mutant lines with ibrutinib and a pan-PIM inhibitor, AZD-1208, partially rescued sensitivity to ibrutinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:4212", "label": "Kuo et al., 2016, Am J Cancer Res", "type": "Document", "title": "PubMed: Kuo et al., 2016, Am J Cancer Res", "pmid": 27904766}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:4286", "label": "PIM1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8986"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5292"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["PIM", "PIM1"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:3511", "label": "PIM1 L2V", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 3.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"type": "coordinates"}}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "3643"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.KVJuepxArnZIxmjv9aDZrGz8XOtc5lZ-", "label": "L2V", "digest": "KVJuepxArnZIxmjv9aDZrGz8XOtc5lZ-", "type": "Allele", "location": {"id": "ga4gh:SL.CKGoO3QBn_B7Pi3PZ_q0216vrHdbe-ge", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.YYsFK5YPS_hNBhUleRe0RwwGag5Ue36_"}, "start": 1, "end": 2}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "civic.tid:227", "label": "Ibrutinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1442981"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:682", "type": "Disease", "label": "Waldenstroem macroglobulinemia"}, {"id": "hemonc:605", "type": "Disease", "label": "Graft versus host disease", "mappings": [{"coding": {"system": "ncit", "code": "C3063"}, "relation": "relatedMatch"}]}, {"id": "hemonc:581", "type": "Disease", "label": "Chronic lymphocytic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3163"}, "relation": "relatedMatch"}]}, {"id": "hemonc:625", "type": "Disease", "label": "Mantle cell lymphoma", "mappings": [{"coding": {"system": "ncit", "code": "C4337"}, "relation": "relatedMatch"}]}, {"id": "hemonc:626", "type": "Disease", "label": "Marginal zone lymphoma", "mappings": [{"coding": {"system": "ncit", "code": "C4341"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C81934"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["2-Propen-1-one, 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)-", "BTK Inhibitor PCI-32765", "CRA-032765", "Imbruvica", "PCI-32765"]}, "tumorType": {"id": "civic.did:3090", "label": "Diffuse Large B-cell Lymphoma Activated B-cell Type", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "DOID:0080996"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:0080996"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:9946", "description": "Foundation panel results of baseline tumour samples from 48 patients with diffuse large B cell lymphoma identified PIM1 mutations in 6 patient samples, 5 of which were the DLBCL-ABC subtype. Four out of the 5 DLBCL-ABC patients with PIM1 mutations had stable disease or progressive disease when treated with ibrutinib, suggesting innate resistance to ibrutinib therapy. Three PIM1 mutations L2V, P81S, and S97N were investigated in cell lines studies. Cells transduced with L2V, P81S, and S97N were resistant to ibrutinib compared to cells transduced with wild type PIM1. Combined treatment of PIM1 mutant lines with ibrutinib and a pan-PIM inhibitor, AZD-1208, partially rescued sensitivity to ibrutinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:4212", "label": "Kuo et al., 2016, Am J Cancer Res", "type": "Document", "title": "PubMed: Kuo et al., 2016, Am J Cancer Res", "pmid": 27904766}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:4286", "label": "PIM1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8986"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5292"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["PIM", "PIM1"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:3512", "label": "PIM1 P81S", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 3.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"type": "coordinates"}}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "3644"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.NYlyFMD_xMKy4GoOfTjz0uJnar-liTcc", "label": "P81S", "digest": "NYlyFMD_xMKy4GoOfTjz0uJnar-liTcc", "type": "Allele", "location": {"id": "ga4gh:SL.wwzG_kYZfUhayIKGSfDTZGWbkQE3_C1-", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.YYsFK5YPS_hNBhUleRe0RwwGag5Ue36_"}, "start": 80, "end": 81}, "state": {"type": "LiteralSequenceExpression", "sequence": "S"}}}, "therapeutic": {"id": "civic.tid:227", "label": "Ibrutinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1442981"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:682", "type": "Disease", "label": "Waldenstroem macroglobulinemia"}, {"id": "hemonc:605", "type": "Disease", "label": "Graft versus host disease", "mappings": [{"coding": {"system": "ncit", "code": "C3063"}, "relation": "relatedMatch"}]}, {"id": "hemonc:581", "type": "Disease", "label": "Chronic lymphocytic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3163"}, "relation": "relatedMatch"}]}, {"id": "hemonc:625", "type": "Disease", "label": "Mantle cell lymphoma", "mappings": [{"coding": {"system": "ncit", "code": "C4337"}, "relation": "relatedMatch"}]}, {"id": "hemonc:626", "type": "Disease", "label": "Marginal zone lymphoma", "mappings": [{"coding": {"system": "ncit", "code": "C4341"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C81934"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["2-Propen-1-one, 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)-", "BTK Inhibitor PCI-32765", "CRA-032765", "Imbruvica", "PCI-32765"]}, "tumorType": {"id": "civic.did:3090", "label": "Diffuse Large B-cell Lymphoma Activated B-cell Type", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "DOID:0080996"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:0080996"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:9947", "description": "Foundation panel results of baseline tumour samples from 48 patients with diffuse large B cell lymphoma identified PIM1 mutations in 6 patient samples, 5 of which were the DLBCL-ABC subtype. Four out of the 5 DLBCL-ABC patients with PIM1 mutations had stable disease or progressive disease when treated with ibrutinib, suggesting innate resistance to ibrutinib therapy. Three PIM1 mutations L2V, P81S, and S97N were investigated in cell lines (TMD8) studies. Cells transduced with L2V, P81S, and S97N were resistant to ibrutinib compared to cells transduced with wild type PIM1. Combined treatment of PIM1 mutant lines with ibrutinib and a pan-PIM inhibitor, AZD-1208, partially rescued sensitivity to ibrutinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:4212", "label": "Kuo et al., 2016, Am J Cancer Res", "type": "Document", "title": "PubMed: Kuo et al., 2016, Am J Cancer Res", "pmid": 27904766}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:4286", "label": "PIM1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8986"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5292"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["PIM", "PIM1"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:3513", "label": "PIM1 S97N", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 3.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"type": "coordinates"}}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "3645"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.NG9oqFU6W_m1Ndxr5sVi96wetg7Hi2-r", "label": "S97N", "digest": "NG9oqFU6W_m1Ndxr5sVi96wetg7Hi2-r", "type": "Allele", "location": {"id": "ga4gh:SL._wpJntZMhor4T2yMSmnp1nOhLhY6A1oc", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.YYsFK5YPS_hNBhUleRe0RwwGag5Ue36_"}, "start": 96, "end": 97}, "state": {"type": "LiteralSequenceExpression", "sequence": "N"}}}, "therapeutic": {"id": "civic.tid:227", "label": "Ibrutinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1442981"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:682", "type": "Disease", "label": "Waldenstroem macroglobulinemia"}, {"id": "hemonc:605", "type": "Disease", "label": "Graft versus host disease", "mappings": [{"coding": {"system": "ncit", "code": "C3063"}, "relation": "relatedMatch"}]}, {"id": "hemonc:581", "type": "Disease", "label": "Chronic lymphocytic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3163"}, "relation": "relatedMatch"}]}, {"id": "hemonc:625", "type": "Disease", "label": "Mantle cell lymphoma", "mappings": [{"coding": {"system": "ncit", "code": "C4337"}, "relation": "relatedMatch"}]}, {"id": "hemonc:626", "type": "Disease", "label": "Marginal zone lymphoma", "mappings": [{"coding": {"system": "ncit", "code": "C4341"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C81934"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["2-Propen-1-one, 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)-", "BTK Inhibitor PCI-32765", "CRA-032765", "Imbruvica", "PCI-32765"]}, "tumorType": {"id": "civic.did:3090", "label": "Diffuse Large B-cell Lymphoma Activated B-cell Type", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "DOID:0080996"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:0080996"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:10066", "description": "In an in vitro study, a Ba/F3 cell line expressing EGFR G598V demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Variant function was assessed by EGFR auto-phosphorylation. Sensitivity was assessed by cell viability assay using stable transfection of each variant and increasing concentrations of erlotinib (0\u201310 uM).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1608", "label": "Lee et al., 2006, PLoS Med.", "type": "Document", "title": "PubMed: Lee et al., 2006, PLoS Med.", "pmid": 17177598}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:971", "label": "EGFR G598V", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 3.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "T", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55233043, "stop": 55233043, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "997"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA4265696"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376210"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS139236063"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS139236063"], "members": [{"id": "ga4gh:VA.kZ3qkdcbCC05W-WXRA8MCp4Y3W9F2Mki", "label": "NC_000007.13:g.55233043G>T", "digest": "kZ3qkdcbCC05W-WXRA8MCp4Y3W9F2Mki", "type": "Allele", "location": {"id": "ga4gh:SL.Aum789bbs4PStIZ7050qdefO9pvLV1ji", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55165349, "end": 55165350}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA._Q7EalvI40odOX-vo6vE3ukV045uIDKO", "label": "G598V", "digest": "_Q7EalvI40odOX-vo6vE3ukV045uIDKO", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000007.13:g.55233043G>T"}, {"syntax": "hgvs.c", "value": "NM_001346898.2:c.1793G>T"}, {"syntax": "hgvs.p", "value": "NP_001333827.1:p.Gly598Val"}], "location": {"id": "ga4gh:SL.7mfQ_5ik69GRoo3UzN520YTueyywVD0K", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 597, "end": 598}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:216", "label": "Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9305"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:162"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:10144", "description": "IDH1 R132C mutation confers a switch of function mutation where the mutated protein produces 2-hydroxyglutarate (2HG), rather than \u03b1-ketoglutarate (\u03b1KG). The novel metabolite induces a homologous recombination (HR) defect that sensitizes the tumor cells to poly (ADP-ribose) polymerase (PARP) inhibitors. PARP inhibitor sensititivity was tested in vivo in HeLa cells where the R132C mutation was create with CRISPR, the HCT116 colon cancer cell line where R132C mutation was created with recombinant adeno-associated virus (rAAV), and the HT1080 human sarcoma cell line which already has R132C. The results were then duplicated in non-commercial glioma cell lines: 6 IDH1 R132 mutant; 4 IDH1 wt.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1683", "label": "Sulkowski et al., 2017, Sci Transl Med", "type": "Document", "title": "PubMed: Sulkowski et al., 2017, Sci Transl Med", "pmid": 28148839}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:26", "label": "IDH1", "description": "IDH1 mutations have been observed in a number of cancer types, including sarcomas, hematologic malignancies, colon cancer and brain cancer. Mutations in the two isocitrate dehydrogenase enzymes involved in cytoplasmic (IDH1) and mitochondrial (IDH2) conversion of alpha-ketoglutarate to D-2-hydroxyglutarate have been described as mutually exclusive in many of these cancer types. The most frequent mutations involve R132 (IDH1) and R172 (IDH2) involve the active site and result in neomorphic enzyme activity. The implications of mutations in this gene vary greatly by cancer type. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 mutations have been associated with worse outcome, shorter overall survival, and normal karyotype. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Unlike the association with cytogenetically normal AML, in glioblastoma, IDH1 mutations have been associated with specific cytogenetic abnormalities, 1p and 19q deletions.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:5382"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3417"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["HEL-216", "HEL-S-26", "IDCD", "IDH", "IDH1", "IDP", "IDPC", "PICD"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:59", "label": "IDH1 R132C", "description": "IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 56.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000415913.1", "chromosome": "2", "start": 209113113, "stop": 209113113, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "59"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602374"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "375891"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913499"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ARG132CYS", "RS121913499"], "members": [{"id": "ga4gh:VA.BSWDYW013eVP-oPsbZ4EbaLXKQ3fbTQe", "label": "NC_000002.11:g.209113113G>A", "digest": "BSWDYW013eVP-oPsbZ4EbaLXKQ3fbTQe", "type": "Allele", "location": {"id": "ga4gh:SL.9sCi1wXjGTNOwjkt3L-5N-rswDF_dNui", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.pnAqCRBrTsUoBghSD1yp_jXWSmlbdh4g"}, "start": 208248388, "end": 208248389}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.348znVA1UKrjwKuq8LLOVrb77xWo5XUO", "label": "R132C", "digest": "348znVA1UKrjwKuq8LLOVrb77xWo5XUO", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_005896.3:c.394C>T"}, {"syntax": "hgvs.p", "value": "NP_005887.2:p.Arg132Cys"}, {"syntax": "hgvs.g", "value": "NC_000002.11:g.209113113G>A"}, {"syntax": "hgvs.c", "value": "ENST00000415913.1:c.394C>T"}], "location": {"id": "ga4gh:SL.6S6Nay-qWJnCSbbpF3hcBRTeoYOc4CJD", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.VZMxTY2iB2G_EuwlpVZ0AnX6R-am08GZ"}, "start": 131, "end": 132}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "civic.tid:42", "label": "Olaparib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1597582"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:645", "type": "Disease", "label": "Ovarian cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7431"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}, {"id": "hemonc:658", "type": "Disease", "label": "Prostate cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7378"}, "relation": "relatedMatch"}]}, {"id": "hemonc:572", "type": "Disease", "label": "Breast cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9335"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C71721"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["AZD 2281", "AZD-2281", "AZD2281", "KU-0059436", "Lynparza", "PARP Inhibitor AZD2281"]}, "tumorType": {"id": "civic.did:216", "label": "Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9305"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:162"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:99", "description": "This preclinical study examined vemurafenib efficacy on various colorectal cancer cell lines and in mouse xenograft experiments. Of the cell lines tested, six harbored BRAF V600E (and WT KRAS) and three harbored BRAF WT (but mutant KRAS). Of the six BRAF V600E expressing cell lines, four were sensitive to vemurafenib (IC50 ranging between 0.025 and 0.35 uM; HT29, Colo205, Colo741, LS411N). Cell lines expressing the BRAF V600E mutation responded better to vemurafenib treatment than cells wildtype for BRAF as measured by reduced cellular proliferation and inhibition of MET and ERK phosphorylation (none of the three BRAF wt cell lines had IC50s less than 10uM). Authors note that one of the vemurafenib-resistant cell lines harboring BRAF V600E (RKO) harbored a concurrent activating PIK3CA H1047R mutation. Nude, athymic mice with HT29 xenografts treated with vemurafenib experienced substantial tumor inhibition and increased lifespan at every dose tested, though authors found 75 mg/kg twice daily to be optimal (95% tumor growth inhibition, 90% increased lifespan compared to vehicle treated controls).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:108", "label": "Yang et al., 2012, Cancer Res.", "type": "Document", "title": "PubMed: Yang et al., 2012, Cancer Res.", "pmid": 22180495}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:12", "label": "BRAF V600E", "description": "BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 1353.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453136, "stop": 140453136, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "12"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123643"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13961"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376069"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS113488022", "V640E", "VAL640GLU", "VAL600GLU"], "members": [{"id": "ga4gh:VA.LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "label": "NC_000007.13:g.140453136A>T", "digest": "LX3ooHBAiZdKY4RfTXcliUmkj48mnD_M", "type": "Allele", "location": {"id": "ga4gh:SL.XutGzMvqbzN-vnxmPt2MJf7ehxmB0opi", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753335, "end": 140753336}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "label": "V600E", "digest": "4XBXAxSAk-WyAu5H0S1-plrk_SCTW1PO", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004333.4:c.1799T>A"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Val600Glu"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140453136A>T"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1799T>A"}], "location": {"id": "ga4gh:SL.ZA1XNKhCT_7m2UtmnYb8ZYOVS4eplMEK", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:707", "description": "A cell line with AKT E17K mutation was found to be sensitive to AKT inhibition with GSK2141795B  in this study.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:465", "label": "Lassen et al., 2014, Mol. Cancer", "type": "Document", "title": "PubMed: Lassen et al., 2014, Mol. Cancer", "pmid": 24735930}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:2", "label": "AKT1", "description": "AKT1, also referred to as protein kinase B, is a known oncogene. AKT activation relies on the PI3K pathway, and is recognized as a critical node in the pathway. The E17 hotspot is the most characterized of AKT1 mutations, and has been shown to result in activation of the protein. Mutations in AKT1 have also been shown to confer resistance to allosteric kinase inhibitors in vitro.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:391"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:207"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["AKT", "AKT1", "PKB", "PKB-ALPHA", "PRKBA", "RAC", "RAC-ALPHA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:4", "label": "AKT1 E17K", "description": "AKT1 E17K is a recurrent mutation that has been observed in breast, colorectal, lung, and ovarian cancer. It has been convincingly shown to be an activating mutation resulting in PI3K/AKT/mTOR pathway activity. It has been suggested that this mutation decreases the cell's sensitivity to AKT1 allosteric kinase inhibitors. This, and other AKT1 mutations, are the subject of much research and development for therapeutics.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 33.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000407796.2", "chromosome": "14", "start": 105246551, "stop": 105246551, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "4"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123660"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13983"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS34409589"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLU17LYS", "RS34409589"], "members": [{"id": "ga4gh:VA.swSBQXaa6uybP38HHxbddf9Cvl8JzGEW", "label": "NC_000014.8:g.105246551C>T", "digest": "swSBQXaa6uybP38HHxbddf9Cvl8JzGEW", "type": "Allele", "location": {"id": "ga4gh:SL.q0g2bHXjBdLjnq8rFLJEU3GpNY9o7FeQ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.eK4D2MosgK_ivBkgi6FVPg5UXs1bYESm"}, "start": 104780213, "end": 104780214}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.u-DUjTNvYupRf-vStLK0YPNPV6jEYG1O", "label": "E17K", "digest": "u-DUjTNvYupRf-vStLK0YPNPV6jEYG1O", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000014.8:g.105246551C>T"}, {"syntax": "hgvs.c", "value": "NM_001014432.1:c.49G>A"}, {"syntax": "hgvs.p", "value": "NP_001014432.1:p.Glu17Lys"}, {"syntax": "hgvs.c", "value": "ENST00000407796.2:c.49G>A"}], "location": {"id": "ga4gh:SL._hc6YN89fA0LVGrpJMVLnhhbELQEYuMw", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.GTSPIWYvuDZU59cW1RECFEU1FMiKdEyc"}, "start": 16, "end": 17}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:111", "label": "Uprosertib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C84870"}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C84870"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["2-Furancarboxamide, N-((1S)-2-Amino-1-((3,4-difluorophenyl)methyl)ethyl)-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-", "GSK2141795", "Oral Akt Inhibitor GSK2141795"]}, "tumorType": {"id": "civic.did:7", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3224"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1909"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:941", "description": "The presence of NQO1 C609T SNP (rs1800566) was associated with decreased protein expression and higher amrubicin sensitivity in 29 NSCLC and SCLC cell lines. 15 of these cell lines were genotyped for C609T (only 3 were T/T, and the rest were C/C or C/T). Cell lines with the T/T genotype had lower expression of NQ01 and greater response to amrubicinol.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:643", "label": "Takakuwa et al., 2011, J Thorac Oncol", "type": "Document", "title": "PubMed: Takakuwa et al., 2011, J Thorac Oncol", "pmid": 21964527}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "germline", "geneContext": {"id": "civic.gid:1463", "label": "NQO1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:2874"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1728"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["DHQU", "DIA4", "DTD", "NMOR1", "NMORI", "NQO1", "QR1"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:398", "label": "NQO1 P187S", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 2.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000320623.5", "chromosome": "16", "start": 69745145, "stop": 69745145, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "402"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA126904"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16809"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["PRO187SER"], "members": [{"id": "ga4gh:VA.wLURDNCy6u6aGEppsKH8cbrn1nZl5ZYX", "label": "NC_000016.9:g.69745145G>A", "digest": "wLURDNCy6u6aGEppsKH8cbrn1nZl5ZYX", "type": "Allele", "location": {"id": "ga4gh:SL.KNVUjfY8O1P2BBLCn6GVJG2EvB2WZnTH", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.yC_0RBj3fgBlvgyAuycbzdubtLxq-rE0"}, "start": 69711241, "end": 69711242}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.L3Wl4CsZWNIhlHzD5s6K2c8aq9FFLQLH", "label": "P187S", "digest": "L3Wl4CsZWNIhlHzD5s6K2c8aq9FFLQLH", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_000903.2:c.559C>T"}, {"syntax": "hgvs.p", "value": "NP_000894.1:p.Pro187Ser"}, {"syntax": "hgvs.g", "value": "NC_000016.9:g.69745145G>A"}], "location": {"id": "ga4gh:SL.3SYUmN2bu96Akn1E_PHzE5AXd12_TCNu", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.iknFoEOZsnfea5-rh13S9BQDM9qIu2FC"}, "start": 186, "end": 187}, "state": {"type": "LiteralSequenceExpression", "sequence": "S"}}}, "therapeutic": {"id": "civic.tid:181", "label": "Amrubicin", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C80089"}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C80089"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(+)-(7S,9S)-9-Acetyl-9-amino-7-((2-deoxy-beta-D-erythro-pentopyranosyl)oxy)- 6,11-dihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione"]}, "tumorType": {"id": "civic.did:23", "label": "Lung Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C7377"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1324"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:968", "description": "Cells harboring L858R were sensitive to afatinib. This study performed drug response assays using five human NSCLC cell lines with various combinations of EGFR mutations. In order to directly compare the sensitivity of multiple EGFR mutations to EGFR-TKIs the authors also generated multiple EGFR transduced Ba/F3 stable cell lines and evaluated sensitivity to EGFR-TKIs by MTS assay.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:669", "label": "Hirano et al., 2015, Oncotarget", "type": "Document", "title": "PubMed: Hirano et al., 2015, Oncotarget", "pmid": 26515464}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:33", "label": "EGFR L858R", "description": "EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 379.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "G", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55259515, "stop": 55259515, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "33"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA126713"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16609"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376282"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376280"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434568"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121434568", "LEU858ARG"], "members": [{"id": "ga4gh:VA.TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "label": "NC_000007.13:g.55259515T>G", "digest": "TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "type": "Allele", "location": {"id": "ga4gh:SL.ulUNwZvajob7nzyrlpOd6uUWZIYCsoWb", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55191821, "end": 55191822}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "label": "L858R", "digest": "z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000007.13:g.55259515T>G"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2573T>G"}, {"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2573T>G"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Leu858Arg"}], "location": {"id": "ga4gh:SL.yVGJnwqxV6oCGqC_8nNb58D_wPXJeNJo", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 857, "end": 858}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:146", "label": "Afatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1430438"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:25316", "type": "Disease", "label": "Non-small cell lung cancer squamous"}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C66940"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide", "BIBW 2992", "BIBW2992"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1171", "description": "HCC827 cell lines harboring activated PI3K (HCC827 p110\u03b1 E545K cells) were more resistant to gefitinib in vitro (IC50, 1 \u03bcM) compared with those harboring GFP alone (IC50, 0.01 \u03bcM). The presence of p110\u03b1 E545K also protected HCC827 cells from gefitinib-mediated apoptosis.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:808", "label": "Engelman et al., 2006, J. Clin. Invest.", "type": "Document", "title": "PubMed: Engelman et al., 2006, J. Clin. Invest.", "pmid": 16906227}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:104", "label": "PIK3CA E545K", "description": "PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 77.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000263967.3", "chromosome": "3", "start": 178936091, "stop": 178936091, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "104"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123334"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13655"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS104886003"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLU545LYS", "RS104886003"], "members": [{"id": "ga4gh:VA.uqD1zF6cMOYhBp8ur5oLTMqV0jxiC2a7", "label": "NC_000003.11:g.178936091G>A", "digest": "uqD1zF6cMOYhBp8ur5oLTMqV0jxiC2a7", "type": "Allele", "location": {"id": "ga4gh:SL.5l5tuxgJGb8y7CQzkKLPUvS-Cx4kr2ju", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 179218302, "end": 179218303}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.uw7DyLM7r98pn66LOXU3tAknmkV7jiJ0", "label": "E545K", "digest": "uw7DyLM7r98pn66LOXU3tAknmkV7jiJ0", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006218.3:c.1633G>A"}, {"syntax": "hgvs.p", "value": "NP_006209.2:p.Glu545Lys"}, {"syntax": "hgvs.c", "value": "ENST00000263967.3:c.1633G>A"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.178936091G>A"}], "location": {"id": "ga4gh:SL.SrEa0lPyesLrOX0M_aW51d-JdJhU-D3p", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 544, "end": 545}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:14", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:328134"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1855"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"]}, "tumorType": {"id": "civic.did:30", "label": "Lung Adenocarcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3512"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3910"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1309", "description": "15/127 patients with KIT-WT metastatic gastrointestinal stromal tumors were tested for PDGFRA mutations. 6 GISTs harbored PDGFRA mutations. 1 patient had a deletion of I843. CHO cells expressing this variant showed similar sensitivity to imatinib as cells expressing wildtype PDGFRA. 2/3 patients with a mutation determined to be sensitive in vitro achieved partial response on imatinib treatment. It is not noted whether the patient whose GISTs harbored I843del had partial response or progressive disease.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:412", "label": "Heinrich et al., 2003, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Heinrich et al., 2003, J. Clin. Oncol.", "pmid": 14645423}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:38", "label": "PDGFRA", "description": "Commonly mutated in GI tract tumors, PDGFR family genes (mutually exclusive to KIT mutations) are a hallmark of gastrointestinal stromal tumors. Gene fusions involving the PDGFRA kinase domain are highly correlated with eosinophilia, and the WHO classifies myeloid and lymphoid neoplasms with these characteristics as a distinct disorder. Mutations in the 842 region of PDGFRA have been often found to confer resistance to the tyrosine kinase inhibitor, imatinib.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8803"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5156"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD140A", "PDGFR-2", "PDGFR2", "PDGFRA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:101", "label": "PDGFRA I843DEL", "description": "PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 5.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "ATC", "representative_transcript": "ENST00000257290.5", "chromosome": "4", "start": 55152095, "stop": 55152097, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "inframe_deletion", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001822"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "101"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA645526434"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["DELI843"], "members": [{"id": "ga4gh:VA.KY9h0Q9COGvfRX97m5HCWt82wDRxf5Wv", "label": "NC_000004.11:g.55152095_55152097del", "digest": "KY9h0Q9COGvfRX97m5HCWt82wDRxf5Wv", "type": "Allele", "location": {"id": "ga4gh:SL.EPTSjHG051j9PTTFFPy2b3yd8lATyfCL", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54285926, "end": 54285932}, "state": {"type": "ReferenceLengthExpression", "length": 3, "sequence": "CAT", "repeatSubunitLength": 3}}], "definingContext": {"id": "ga4gh:VA.PUuPMPVN95EbZEIqc7U026NTR8THV8mm", "label": "I843DEL", "digest": "PUuPMPVN95EbZEIqc7U026NTR8THV8mm", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000257290.5:c.2527_2529delATC"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55152095_55152097del"}], "location": {"id": "ga4gh:SL.Mr44tA-ZG7AzeOHLln6_o7wjOU4cz01i", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.XpQn9sZLGv_GU3uiWO7YHq9-_alGjrVX"}, "start": 842, "end": 845}, "state": {"type": "LiteralSequenceExpression", "sequence": "DEL"}}}, "therapeutic": {"id": "civic.tid:5", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:282388"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "Disease", "label": "Systemic mastocytosis", "mappings": [{"coding": {"system": "ncit", "code": "C9235"}, "relation": "relatedMatch"}]}, {"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}, {"id": "hemonc:634", "type": "Disease", "label": "Myelodysplastic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C3247"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:33893", "type": "Disease", "label": "Chronic myelogenous leukemia pediatric"}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}, {"id": "hemonc:616", "type": "Disease", "label": "Hypereosinophilic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C27038"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C62035"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"]}, "tumorType": {"id": "civic.did:2", "label": "Gastrointestinal Stromal Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3868"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9253"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1319", "description": "Cell lines with various putative activating mutations were tested for sensitivity to rapamycin. The cell line JHUEM7 with the MTOR mutation S2215Y was hypersensitive to rapamycin treatment (IC50 of 0.23 nmol/L).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:911", "label": "Grabiner et al., 2014, Cancer Discov", "type": "Document", "title": "PubMed: Grabiner et al., 2014, Cancer Discov", "pmid": 24631838}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:2073", "label": "MTOR", "description": "mTOR deregulation has been observed in many cancer types. As a part of the PI3K/Akt pathway, there is a broad interest in mTOR biology across cancer types. mTOR inhibition has been investigated for nearly a decade. Everolimus, temsirolimus and zotarolimus are three of the more commonly used mTOR inhibitors used in clinical treatment today, with modest success.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3942"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2475"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["FRAP", "FRAP1", "FRAP2", "MTOR", "RAFT1", "RAPT1", "SKS"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:538", "label": "MTOR S2215Y", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 2.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "T", "representative_transcript": "ENST00000361445.4", "chromosome": "1", "start": 11184573, "stop": 11184573, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "542"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602587"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376129"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["SER2215TYR"], "members": [{"id": "ga4gh:VA.vLy655kG5H6doX1bP9ymaivrQpL8JWyG", "label": "NC_000001.10:g.11184573G>T", "digest": "vLy655kG5H6doX1bP9ymaivrQpL8JWyG", "type": "Allele", "location": {"id": "ga4gh:SL.DnKjRjah6ADd-4HLmiyd4EtghaXAtZh8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Ya6Rs7DHhDeg7YaOSg1EoNi3U_nQ9SvO"}, "start": 11124515, "end": 11124516}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.WB-zGNJFXSdBdIDJ23l_jwuKBwN31LhO", "label": "S2215Y", "digest": "WB-zGNJFXSdBdIDJ23l_jwuKBwN31LhO", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000361445.4:c.6644C>A"}, {"syntax": "hgvs.g", "value": "NC_000001.10:g.11184573G>T"}, {"syntax": "hgvs.c", "value": "NM_004958.3:c.6644C>A"}, {"syntax": "hgvs.p", "value": "NP_004949.1:p.Ser2215Tyr"}], "location": {"id": "ga4gh:SL.1a87lKjDWRwPz53ky2R3xeIL7gAosKRE", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Q9u3Vt0PamiHV4LTrj6mkhp1icb-eMhd"}, "start": 2214, "end": 2215}, "state": {"type": "LiteralSequenceExpression", "sequence": "Y"}}}, "therapeutic": {"id": "civic.tid:469", "label": "Sirolimus", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:35302"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:37829", "type": "Disease", "label": "PEComa", "mappings": [{"coding": {"system": "ncit", "code": "C38150"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1212"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,2", "AY 22989", "RAPA", "RAPAMYCIN", "Rapamune", "SILA 9268A", "WY-090217"]}, "tumorType": {"id": "civic.did:666", "label": "Endometrial Adenocarcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C6287"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:2870"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1320", "description": "Cell lines with various putative activating mutations were tested for sensitivity to rapamycin. The cell line MOLT16, with MTOR mutation C1483Y was hypersensitive to rapamycin treatment (IC50 of 0.75 nmol/L).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:911", "label": "Grabiner et al., 2014, Cancer Discov", "type": "Document", "title": "PubMed: Grabiner et al., 2014, Cancer Discov", "pmid": 24631838}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:2073", "label": "MTOR", "description": "mTOR deregulation has been observed in many cancer types. As a part of the PI3K/Akt pathway, there is a broad interest in mTOR biology across cancer types. mTOR inhibition has been investigated for nearly a decade. Everolimus, temsirolimus and zotarolimus are three of the more commonly used mTOR inhibitors used in clinical treatment today, with modest success.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3942"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2475"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["FRAP", "FRAP1", "FRAP2", "MTOR", "RAFT1", "RAPT1", "SKS"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:539", "label": "MTOR C1483Y", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 2.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000361445.4", "chromosome": "1", "start": 11217230, "stop": 11217230, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "543"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602888"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376453"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["CYS1483TYR"], "members": [{"id": "ga4gh:VA.eiAyAX9KncdZI1kkngPE4FbDqSVVwZQO", "label": "NC_000001.10:g.11217230C>T", "digest": "eiAyAX9KncdZI1kkngPE4FbDqSVVwZQO", "type": "Allele", "location": {"id": "ga4gh:SL.Zp-TYZZ6VSlLLv3oqh4ETx0bMVc98nGu", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Ya6Rs7DHhDeg7YaOSg1EoNi3U_nQ9SvO"}, "start": 11157172, "end": 11157173}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.UFLR64OviqlZaxoscbXSWh0BgAooooq_", "label": "C1483Y", "digest": "UFLR64OviqlZaxoscbXSWh0BgAooooq_", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000361445.4:c.4448G>A"}, {"syntax": "hgvs.g", "value": "NC_000001.10:g.11217230C>T"}, {"syntax": "hgvs.c", "value": "NM_004958.3:c.4448G>A"}, {"syntax": "hgvs.p", "value": "NP_004949.1:p.Cys1483Tyr"}], "location": {"id": "ga4gh:SL.GGW2lZlHBOm7U-IY0e6iyT7esWAyuXQ0", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Q9u3Vt0PamiHV4LTrj6mkhp1icb-eMhd"}, "start": 1482, "end": 1483}, "state": {"type": "LiteralSequenceExpression", "sequence": "Y"}}}, "therapeutic": {"id": "civic.tid:469", "label": "Sirolimus", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:35302"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:37829", "type": "Disease", "label": "PEComa", "mappings": [{"coding": {"system": "ncit", "code": "C38150"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1212"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,2", "AY 22989", "RAPA", "RAPAMYCIN", "Rapamune", "SILA 9268A", "WY-090217"]}, "tumorType": {"id": "civic.did:227", "label": "T-cell Acute Lymphoblastic Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3184"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:5603"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1321", "description": "Cell lines with various putative activating mutations were tested for sensitivity to rapamycin. The cell line SNU349, with MTOR mutation E1799K was hypersensitive to rapamycin treatment (IC50 of 0.19 nmol/L).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:911", "label": "Grabiner et al., 2014, Cancer Discov", "type": "Document", "title": "PubMed: Grabiner et al., 2014, Cancer Discov", "pmid": 24631838}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:2073", "label": "MTOR", "description": "mTOR deregulation has been observed in many cancer types. As a part of the PI3K/Akt pathway, there is a broad interest in mTOR biology across cancer types. mTOR inhibition has been investigated for nearly a decade. Everolimus, temsirolimus and zotarolimus are three of the more commonly used mTOR inhibitors used in clinical treatment today, with modest success.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3942"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2475"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["FRAP", "FRAP1", "FRAP2", "MTOR", "RAFT1", "RAPT1", "SKS"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:540", "label": "MTOR E1799K", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 2.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000361445.4", "chromosome": "1", "start": 11190804, "stop": 11190804, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "544"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA279594"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "217823"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS863225264"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS863225264", "GLU1799LYS"], "members": [{"id": "ga4gh:VA.qKROveePSsY4BjKh2VPXziCvuZ0Q4yUc", "label": "NC_000001.10:g.11190804C>T", "digest": "qKROveePSsY4BjKh2VPXziCvuZ0Q4yUc", "type": "Allele", "location": {"id": "ga4gh:SL.v7SdJa09usUtE4CFsGbyRayy2CmNYN8H", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Ya6Rs7DHhDeg7YaOSg1EoNi3U_nQ9SvO"}, "start": 11130746, "end": 11130747}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA._KtDFR_II5if6AwEx-_B46QD3UxXNYT3", "label": "E1799K", "digest": "_KtDFR_II5if6AwEx-_B46QD3UxXNYT3", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004958.3:c.5395G>A"}, {"syntax": "hgvs.p", "value": "NP_004949.1:p.Glu1799Lys"}, {"syntax": "hgvs.g", "value": "NC_000001.10:g.11190804C>T"}, {"syntax": "hgvs.c", "value": "ENST00000361445.4:c.5395G>A"}], "location": {"id": "ga4gh:SL.M7kMwnM0CecyMJAIpTvbjvllSbcEC1FU", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Q9u3Vt0PamiHV4LTrj6mkhp1icb-eMhd"}, "start": 1798, "end": 1799}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:469", "label": "Sirolimus", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:35302"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:37829", "type": "Disease", "label": "PEComa", "mappings": [{"coding": {"system": "ncit", "code": "C38150"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1212"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,2", "AY 22989", "RAPA", "RAPAMYCIN", "Rapamune", "SILA 9268A", "WY-090217"]}, "tumorType": {"id": "civic.did:48", "label": "Clear Cell Renal Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4033"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:4467"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1362", "description": "Two head and neck cancer cell lines with PIK3CA H1047R mutation were more sensitive to PI3K/mTOR inhibition with BEZ-235 (NVP-BEZ235, Dactolisib) than two wild type cell lines in vitro. One cell line with H1047R mutation was also found to be sensitive to BEZ-235 in vivo. PIK3CA (H1047R) mutation positive cell lines used were \"CAL-33\" and \"Detroit 562\". Wild type cell lines used here were \"SCC-9\" and \"PE/CA-PJ34(clone C12)\".", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:927", "label": "Lui et al., 2013, Cancer Discov", "type": "Document", "title": "PubMed: Lui et al., 2013, Cancer Discov", "pmid": 23619167}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:107", "label": "PIK3CA H1047R", "description": "PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 96.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "G", "representative_transcript": "ENST00000263967.3", "chromosome": "3", "start": 178952085, "stop": 178952085, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "107"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123326"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13652"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913279"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913279", "HIS1047ARG"], "members": [{"id": "ga4gh:VA.82Pw7U7NM7ac2koW_yITXOGSKcwg_Qqj", "label": "NC_000003.11:g.178952085A>G", "digest": "82Pw7U7NM7ac2koW_yITXOGSKcwg_Qqj", "type": "Allele", "location": {"id": "ga4gh:SL.p0VJw5IIPnKzEpQMcdBaU3xesud6QODJ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 179234296, "end": 179234297}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.hcSlm-m3AKXOL7kHM3LghXQfvAjZOmYx", "label": "H1047R", "digest": "hcSlm-m3AKXOL7kHM3LghXQfvAjZOmYx", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006218.3:c.3140A>G"}, {"syntax": "hgvs.p", "value": "NP_006209.2:p.His1047Arg"}, {"syntax": "hgvs.c", "value": "ENST00000263967.3:c.3140A>G"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.178952085A>G"}], "location": {"id": "ga4gh:SL.DBBb47ourtRut09MJ_TAvlocEwpTjF9z", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 1046, "end": 1047}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:343", "label": "Dactolisib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C74072"}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C74072"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["BEZ235", "Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-", "NVPBEZ235"]}, "tumorType": {"id": "civic.did:453", "label": "Head And Neck Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4013"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:11934"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1453", "description": "PI3K mutant E545K was overexpressed in the trastuzumab sensitive HER2 BT474 breast cancer cell line, and significant resistance to trastuzumab was induced in comparison to control cells.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:981", "label": "Serra et al., 2008, Cancer Res.", "type": "Document", "title": "PubMed: Serra et al., 2008, Cancer Res.", "pmid": 18829560}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:104", "label": "PIK3CA E545K", "description": "PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 77.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000263967.3", "chromosome": "3", "start": 178936091, "stop": 178936091, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "104"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123334"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13655"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS104886003"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLU545LYS", "RS104886003"], "members": [{"id": "ga4gh:VA.uqD1zF6cMOYhBp8ur5oLTMqV0jxiC2a7", "label": "NC_000003.11:g.178936091G>A", "digest": "uqD1zF6cMOYhBp8ur5oLTMqV0jxiC2a7", "type": "Allele", "location": {"id": "ga4gh:SL.5l5tuxgJGb8y7CQzkKLPUvS-Cx4kr2ju", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 179218302, "end": 179218303}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.uw7DyLM7r98pn66LOXU3tAknmkV7jiJ0", "label": "E545K", "digest": "uw7DyLM7r98pn66LOXU3tAknmkV7jiJ0", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006218.3:c.1633G>A"}, {"syntax": "hgvs.p", "value": "NP_006209.2:p.Glu545Lys"}, {"syntax": "hgvs.c", "value": "ENST00000263967.3:c.1633G>A"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.178936091G>A"}], "location": {"id": "ga4gh:SL.SrEa0lPyesLrOX0M_aW51d-JdJhU-D3p", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 544, "end": 545}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:84", "label": "Trastuzumab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:2103478"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D001943", "type": "Disease", "label": "Breast Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2910"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1647"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["ABP 980", "ALT02", "Anti-ERB-2", "Anti-HER2/c-erbB2 Monoclonal Antibody", "Anti-c-ERB-2", "Anti-c-erbB2 Monoclonal Antibody", "Anti-erbB-2", "Anti-erbB2 Monoclonal Antibody", "Anti-p185-HER2", "C-erb-2 Monoclonal Antibody", "HER2 Monoclonal Antibody", "Herceptin", "Herceptin Biosimilar PF-05280014", "Herceptin Trastuzumab Biosimilar PF-05280014", "Herzuma", "Immunoglobulin G 1 (Human-Mouse Monoclonal RhuMab HER2gamma1-Chain Antihuman P185(Sup C-erbB2) Receptor), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer", "Kanjinti", "MoAb HER2", "Monoclonal Antibody C-erb-2", "Monoclonal Antibody HER2", "Ogivri", "Ontruzant", "PF-05280014", "RO0452317", "RhuMAb HER2", "SB3", "Trastuzumab Biosimilar ABP 980", "Trastuzumab Biosimilar ALT02", "Trastuzumab Biosimilar EG12014", "Trastuzumab Biosimilar HLX02", "Trastuzumab Biosimilar PF-05280014", "Trastuzumab Biosimilar SB3", "Trastuzumab Biosimilar SIBP-01", "Trastuzumab-anns", "Trastuzumab-dkst", "Trastuzumab-dttb", "Trastuzumab-pkrb", "Trastuzumab-qyyp", "Trazimera"]}, "tumorType": {"id": "civic.did:368", "label": "Her2-receptor Positive Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C53556"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:0060079"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1465", "description": "The Cal-33 HNSCC cell line with H1047R mutation was found to have a low antiproliferative IC50 value for the alpha, gamma and delta isoform-specific PI3K inhibitor taselisib. Increasing taselisib concentration induced reduction of phospho-Akt levels in Call-33 cells, while upregulating the cleaved PARP apoptotic marker. Among a panel of 26 HNSCC cell lines, activating PI3K mutations were associated with taselisib sensitivity in comparison to wild-type PI3K or PTEN mutant cell lines.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:984", "label": "Zumsteg et al., 2016, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Zumsteg et al., 2016, Clin. Cancer Res.", "pmid": 26589432}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:107", "label": "PIK3CA H1047R", "description": "PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 96.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "G", "representative_transcript": "ENST00000263967.3", "chromosome": "3", "start": 178952085, "stop": 178952085, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "107"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123326"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13652"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913279"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913279", "HIS1047ARG"], "members": [{"id": "ga4gh:VA.82Pw7U7NM7ac2koW_yITXOGSKcwg_Qqj", "label": "NC_000003.11:g.178952085A>G", "digest": "82Pw7U7NM7ac2koW_yITXOGSKcwg_Qqj", "type": "Allele", "location": {"id": "ga4gh:SL.p0VJw5IIPnKzEpQMcdBaU3xesud6QODJ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 179234296, "end": 179234297}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.hcSlm-m3AKXOL7kHM3LghXQfvAjZOmYx", "label": "H1047R", "digest": "hcSlm-m3AKXOL7kHM3LghXQfvAjZOmYx", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006218.3:c.3140A>G"}, {"syntax": "hgvs.p", "value": "NP_006209.2:p.His1047Arg"}, {"syntax": "hgvs.c", "value": "ENST00000263967.3:c.3140A>G"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.178952085A>G"}], "location": {"id": "ga4gh:SL.DBBb47ourtRut09MJ_TAvlocEwpTjF9z", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 1046, "end": 1047}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:660", "label": "Taselisib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C116876"}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C116876"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["GDC-0032", "RO5537381"]}, "tumorType": {"id": "civic.did:37", "label": "Head And Neck Squamous Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C34447"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:5520"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1474", "description": "Preclinical study in melanoma cell lines. NRAS Q61K, in addition to the BRAF V600E mutation was associated with resistance to vemurafenib but sensitivity to AZD6244 (selumetinib) in vitro in the acquired resistant cell line M249-AR4 and in the patient-derived acquired resistant cell line M376.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:988", "label": "Atefi et al., 2011, PLoS ONE", "type": "Document", "title": "PubMed: Atefi et al., 2011, PLoS ONE", "pmid": 22194965}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:36", "label": "NRAS", "description": "Mutations in the RAS family of proteins have frequently been observed across cancer types. The amino acid positions G12, G13 and Q61 account for the overwhelming majority of these mutations. The isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, targeting these RAS mutants has also been very elusive, and has not yet become common practice in the clinic.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:7989"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:4893"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["ALPS4", "CMNS", "KRAS", "N-ras", "NCMS", "NRAS", "NRAS1", "NS6"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:423", "label": "NRAS Q61K", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 24.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "T", "representative_transcript": "ENST00000369535.4", "chromosome": "1", "start": 115256530, "stop": 115256530, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "427"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA151263"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "73058"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913254"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLN61LYS", "RS121913254"], "members": [{"id": "ga4gh:VA.0FZuBwcgG87LilkjaTvU6aa38MO2gExn", "label": "NC_000001.10:g.115256530G>T", "digest": "0FZuBwcgG87LilkjaTvU6aa38MO2gExn", "type": "Allele", "location": {"id": "ga4gh:SL.4cQp_FS38Pdvn5eWaYtU4glYRQCpT-ch", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Ya6Rs7DHhDeg7YaOSg1EoNi3U_nQ9SvO"}, "start": 114713908, "end": 114713909}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.3cSh2D__C3zMdKiikDmDtr0F88wpN4RP", "label": "Q61K", "digest": "3cSh2D__C3zMdKiikDmDtr0F88wpN4RP", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_002524.4:c.181C>A"}, {"syntax": "hgvs.p", "value": "NP_002515.1:p.Gln61Lys"}, {"syntax": "hgvs.g", "value": "NC_000001.10:g.115256530G>T"}, {"syntax": "hgvs.c", "value": "ENST00000369535.4:c.181C>A"}], "location": {"id": "ga4gh:SL.M2SLz3Ru3LNVsb6q5XgLmSlH8XXS68v2", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.974-EgvIQKi6ptqsI6XUZthCv-Py3S18"}, "start": 60, "end": 61}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:206", "label": "Skin Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3510"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:8923"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1475", "description": "Preclinical study in melanoma cell lines. NRAS Q61K, in addition to the BRAF V600E mutation was associated with resistance to vemurafenib but sensitivity to AZD6244 (selumetinib) in vitro in the acquired resistant cell line M249-AR4 and in the patient-derived acquired resistant cell line M376.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:988", "label": "Atefi et al., 2011, PLoS ONE", "type": "Document", "title": "PubMed: Atefi et al., 2011, PLoS ONE", "pmid": 22194965}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:36", "label": "NRAS", "description": "Mutations in the RAS family of proteins have frequently been observed across cancer types. The amino acid positions G12, G13 and Q61 account for the overwhelming majority of these mutations. The isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, targeting these RAS mutants has also been very elusive, and has not yet become common practice in the clinic.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:7989"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:4893"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["ALPS4", "CMNS", "KRAS", "N-ras", "NCMS", "NRAS", "NRAS1", "NS6"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:423", "label": "NRAS Q61K", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 24.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "T", "representative_transcript": "ENST00000369535.4", "chromosome": "1", "start": 115256530, "stop": 115256530, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "427"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA151263"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "73058"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913254"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLN61LYS", "RS121913254"], "members": [{"id": "ga4gh:VA.0FZuBwcgG87LilkjaTvU6aa38MO2gExn", "label": "NC_000001.10:g.115256530G>T", "digest": "0FZuBwcgG87LilkjaTvU6aa38MO2gExn", "type": "Allele", "location": {"id": "ga4gh:SL.4cQp_FS38Pdvn5eWaYtU4glYRQCpT-ch", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Ya6Rs7DHhDeg7YaOSg1EoNi3U_nQ9SvO"}, "start": 114713908, "end": 114713909}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.3cSh2D__C3zMdKiikDmDtr0F88wpN4RP", "label": "Q61K", "digest": "3cSh2D__C3zMdKiikDmDtr0F88wpN4RP", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_002524.4:c.181C>A"}, {"syntax": "hgvs.p", "value": "NP_002515.1:p.Gln61Lys"}, {"syntax": "hgvs.g", "value": "NC_000001.10:g.115256530G>T"}, {"syntax": "hgvs.c", "value": "ENST00000369535.4:c.181C>A"}], "location": {"id": "ga4gh:SL.M2SLz3Ru3LNVsb6q5XgLmSlH8XXS68v2", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.974-EgvIQKi6ptqsI6XUZthCv-Py3S18"}, "start": 60, "end": 61}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:63", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:2289380"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C66939"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["ARRY-142886", "AZD6244", "MEK Inhibitor AZD6244"]}, "tumorType": {"id": "civic.did:206", "label": "Skin Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3510"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:8923"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1727", "description": "ESR1 S463P variants were observed after extensive treatment with hormonal therapy (aromatase inhibition). Expression of the S463P mutant was found to induce modest activity in the absence of hormone. This mutation displayed elevated levels of Ser118 phosphorylation compared to wild-type ER\u03b1 and appeared to possess estrogen-independent activity.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:171", "label": "Toy et al., 2013, Nat. Genet.", "type": "Document", "title": "PubMed: Toy et al., 2013, Nat. Genet.", "pmid": 24185512}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:21", "label": "ESR1", "description": "ESR1 has been a focus in breast cancer for quite some time, but is also clinically relevant in endometrial, ovarian and other cancer types. The identification of ER-positive breast cancers that are resistant to hormone therapy have inspired clinical sequencing efforts to shed light on the mechanisms of this resistance. A number of mutations in the ligand binding domain of ESR1 have been implicated in hormone resistance and anti-estrogen therapies. These observations have spurred efforts to develop therapeutics that stimulate ESR1 protein degradation (e.g. Fulvestrant), rather than acting as a small molecule antagonist. These agents are currently in clinical trials and have seen some success.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3467"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2099"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["ER", "ESR", "ESR1", "ESRA", "ESTRR", "Era", "NR3A1"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:673", "label": "ESR1 S463P", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 2.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "C", "representative_transcript": "ENST00000440973.1", "chromosome": "6", "start": 152415537, "stop": 152415537, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "692"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602414"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "375934"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS1057519714"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS1057519714", "SER463PRO"], "members": [{"id": "ga4gh:VA.oZt72myh04HpfUkANVizgcqr23242JdE", "label": "NC_000006.11:g.152415537T>C", "digest": "oZt72myh04HpfUkANVizgcqr23242JdE", "type": "Allele", "location": {"id": "ga4gh:SL.heUkWGXiu8JNiBC4_uO2IYYnU3ktxAIU", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.0iKlIQk2oZLoeOG9P1riRU6hvL5Ux8TV"}, "start": 152094401, "end": 152094402}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.Nr8zItoiXcUTai9X6k8s3Ls8B4aZpFal", "label": "S463P", "digest": "Nr8zItoiXcUTai9X6k8s3Ls8B4aZpFal", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000440973.1:c.1387T>C"}, {"syntax": "hgvs.g", "value": "NC_000006.11:g.152415537T>C"}, {"syntax": "hgvs.c", "value": "NM_000125.3:c.1387T>C"}, {"syntax": "hgvs.p", "value": "NP_000116.2:p.Ser463Pro"}], "location": {"id": "ga4gh:SL.FMc2zg-5b8SFA9pAIz3FD1H1MGhlK-v0", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Dcv_jfZMRcmxme6pot93DNwG0ypAfGol"}, "start": 462, "end": 463}, "state": {"type": "LiteralSequenceExpression", "sequence": "P"}}}, "therapeutic": {"id": "civic.tid:407", "label": "Aromatase Inhibitor", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C1740"}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1740"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:28", "label": "Estrogen-receptor Positive Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "mondo:0006512"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:0060075"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2012", "description": "In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1420", "label": "Rowley et al., 2000, Blood", "type": "Document", "title": "PubMed: Rowley et al., 2000, Blood", "pmid": 11050000}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:148", "label": "KRAS G12A", "description": "KRAS G12A, like EGFR T790M, has been shown to be capable of driving acquired resistance to tyrosine kinase inhibitors in lung adenocarcinoma.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 63.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "G", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398284, "stop": 25398284, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "148"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA135567"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "45122"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913529"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913529", "GLY12ALA"], "members": [{"id": "ga4gh:VA.7-dFeRWXiDXaQi2ytNFtQt6FAxK65H7Q", "label": "NC_000012.11:g.25398284C>G", "digest": "7-dFeRWXiDXaQi2ytNFtQt6FAxK65H7Q", "type": "Allele", "location": {"id": "ga4gh:SL.iF0OXeO-tnumYbGkzaFEQ7cOZI_UCI1s", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245349, "end": 25245350}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.PtBjoq-ApuaPycxEHH7z31bGtezbAoyU", "label": "G12A", "digest": "PtBjoq-ApuaPycxEHH7z31bGtezbAoyU", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004985.4:c.35G>C"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly12Ala"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398284C>G"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.35G>C"}], "location": {"id": "ga4gh:SL.OndkjmujtyUEZSjjCv0C-gpwnVbRgfj8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}}, "therapeutic": {"id": "civic.tid:328", "label": "Melphalan", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:6718"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:633", "type": "Disease", "label": "Multiple myeloma", "mappings": [{"coding": {"system": "ncit", "code": "C3242"}, "relation": "relatedMatch"}]}, {"id": "hemonc:645", "type": "Disease", "label": "Ovarian cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7431"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C633"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[bis(2-chloroethyl)amino]-L-phenylalanine", "Alanine Nitrogen Mustard", "CB-3025", "L-PAM", "L-Phenylalanine Mustard", "L-Sarcolysin", "L-Sarcolysin Phenylalanine Mustard", "L-Sarcolysine", "Melphalanum", "P-di(chloroethyl)amino-L-phenylalanine", "Phenylalanine Mustard", "Phenylalanine Nitrogen Mustard", "Sarcoclorin", "Sarkolysin", "WR-19813"]}, "tumorType": {"id": "civic.did:41", "label": "Multiple Myeloma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3242"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9538"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2013", "description": "In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1421", "label": "Rowley et al., 2002, Oncogene", "type": "Document", "title": "PubMed: Rowley et al., 2002, Oncogene", "pmid": 12483530}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:148", "label": "KRAS G12A", "description": "KRAS G12A, like EGFR T790M, has been shown to be capable of driving acquired resistance to tyrosine kinase inhibitors in lung adenocarcinoma.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 63.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "G", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398284, "stop": 25398284, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "148"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA135567"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "45122"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913529"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913529", "GLY12ALA"], "members": [{"id": "ga4gh:VA.7-dFeRWXiDXaQi2ytNFtQt6FAxK65H7Q", "label": "NC_000012.11:g.25398284C>G", "digest": "7-dFeRWXiDXaQi2ytNFtQt6FAxK65H7Q", "type": "Allele", "location": {"id": "ga4gh:SL.iF0OXeO-tnumYbGkzaFEQ7cOZI_UCI1s", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245349, "end": 25245350}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.PtBjoq-ApuaPycxEHH7z31bGtezbAoyU", "label": "G12A", "digest": "PtBjoq-ApuaPycxEHH7z31bGtezbAoyU", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004985.4:c.35G>C"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly12Ala"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398284C>G"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.35G>C"}], "location": {"id": "ga4gh:SL.OndkjmujtyUEZSjjCv0C-gpwnVbRgfj8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}}, "therapeutic": {"id": "civic.tid:328", "label": "Melphalan", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:6718"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:633", "type": "Disease", "label": "Multiple myeloma", "mappings": [{"coding": {"system": "ncit", "code": "C3242"}, "relation": "relatedMatch"}]}, {"id": "hemonc:645", "type": "Disease", "label": "Ovarian cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7431"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C633"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[bis(2-chloroethyl)amino]-L-phenylalanine", "Alanine Nitrogen Mustard", "CB-3025", "L-PAM", "L-Phenylalanine Mustard", "L-Sarcolysin", "L-Sarcolysin Phenylalanine Mustard", "L-Sarcolysine", "Melphalanum", "P-di(chloroethyl)amino-L-phenylalanine", "Phenylalanine Mustard", "Phenylalanine Nitrogen Mustard", "Sarcoclorin", "Sarkolysin", "WR-19813"]}, "tumorType": {"id": "civic.did:41", "label": "Multiple Myeloma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3242"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9538"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2014", "description": "In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1422", "label": "Hoang et al., 2006, Blood", "type": "Document", "title": "PubMed: Hoang et al., 2006, Blood", "pmid": 16497971}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:148", "label": "KRAS G12A", "description": "KRAS G12A, like EGFR T790M, has been shown to be capable of driving acquired resistance to tyrosine kinase inhibitors in lung adenocarcinoma.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 63.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "G", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398284, "stop": 25398284, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "148"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA135567"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "45122"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913529"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913529", "GLY12ALA"], "members": [{"id": "ga4gh:VA.7-dFeRWXiDXaQi2ytNFtQt6FAxK65H7Q", "label": "NC_000012.11:g.25398284C>G", "digest": "7-dFeRWXiDXaQi2ytNFtQt6FAxK65H7Q", "type": "Allele", "location": {"id": "ga4gh:SL.iF0OXeO-tnumYbGkzaFEQ7cOZI_UCI1s", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245349, "end": 25245350}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.PtBjoq-ApuaPycxEHH7z31bGtezbAoyU", "label": "G12A", "digest": "PtBjoq-ApuaPycxEHH7z31bGtezbAoyU", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004985.4:c.35G>C"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly12Ala"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398284C>G"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.35G>C"}], "location": {"id": "ga4gh:SL.OndkjmujtyUEZSjjCv0C-gpwnVbRgfj8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}}, "therapeutic": {"id": "civic.tid:328", "label": "Melphalan", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:6718"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:633", "type": "Disease", "label": "Multiple myeloma", "mappings": [{"coding": {"system": "ncit", "code": "C3242"}, "relation": "relatedMatch"}]}, {"id": "hemonc:645", "type": "Disease", "label": "Ovarian cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7431"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C633"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[bis(2-chloroethyl)amino]-L-phenylalanine", "Alanine Nitrogen Mustard", "CB-3025", "L-PAM", "L-Phenylalanine Mustard", "L-Sarcolysin", "L-Sarcolysin Phenylalanine Mustard", "L-Sarcolysine", "Melphalanum", "P-di(chloroethyl)amino-L-phenylalanine", "Phenylalanine Mustard", "Phenylalanine Nitrogen Mustard", "Sarcoclorin", "Sarkolysin", "WR-19813"]}, "tumorType": {"id": "civic.did:41", "label": "Multiple Myeloma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3242"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9538"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2022", "description": "This preclinical study tested the efficacy on several breast cancer cell lines of GDC-0941 (pictilisib), a selective inhibitor of all four isoforms of class I PI3-kinases at a range of IC50 values. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. HCC202 is a HER2 positive, ER/PR negative breast cancer cell line harboring PIK3CA E542K, and it had an IC50 of 0.80uM. Authors further note that HER2 amplified cell lines were generally more sensitive, regardless of mutation, to pictilisib than basal-like cell lines (p=0.002).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1435", "label": "O'Brien et al., 2010, Clin. Cancer Res.", "type": "Document", "title": "PubMed: O'Brien et al., 2010, Clin. Cancer Res.", "pmid": 20453058}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:103", "label": "PIK3CA E542K", "description": "PIK3CA E545K/E542K variants are the second most recurrent PIK3CA mutations in breast cancer and are highly recurrent mutations in many other cancer types. Colorectal cancer patients with the PIK3CA E545K variant, and possibly other variants in the E545 region, may indicate poor prognosis relative to patients with other PIK3CA variants or wild-type PIK3CA. The literature also suggests that E545/E542 variants may confer resistance to EGFR inhibitors (e.g., cetuximab). An FDA approved treatment regimen including a targeted PIK3CA inhibitor is available for specific subtypes of breast cancer. While PIK3CA variants are highly prevalent in many other cancer types, targeted therapies for PIK3CA variants are still in early clinical trial phases in other cancer types.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 75.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000263967.3", "chromosome": "3", "start": 178936082, "stop": 178936082, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "103"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA333572"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "31944"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913273"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLU542LYS", "RS121913273"], "members": [{"id": "ga4gh:VA.52-4tAq0Ya9SeMU4eZSgO0bfqvkd_VE4", "label": "NC_000003.11:g.178936082G>A", "digest": "52-4tAq0Ya9SeMU4eZSgO0bfqvkd_VE4", "type": "Allele", "location": {"id": "ga4gh:SL.65wPuIVC66WPYQqTnuNP-taUZ03NOwmJ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 179218293, "end": 179218294}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.D6daDiDNn1u-e4YtntaYQnxlZ_0T6gtD", "label": "E542K", "digest": "D6daDiDNn1u-e4YtntaYQnxlZ_0T6gtD", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006218.3:c.1624G>A"}, {"syntax": "hgvs.p", "value": "NP_006209.2:p.Glu542Lys"}, {"syntax": "hgvs.c", "value": "ENST00000263967.3:c.1624G>A"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.178936082G>A"}], "location": {"id": "ga4gh:SL.DdVC73cqPrOnzCRvVc8N9tA3ecV5Qunt", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 541, "end": 542}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:141", "label": "Pictilisib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C165479"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:368", "label": "Her2-receptor Positive Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C53556"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:0060079"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2026", "description": "This preclinical study tested the efficacy on several breast cancer cell lines of GDC-0941 (pictilisib), which is a selective inhibitor of all four isoforms of class I PI3-kinases over a range of IC50 values. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. KPL-1 is a luminal-like breast cancer cell line harboring PIK3CA E542K, and it had an IC50 of 0.72uM. Authors note that luminal-like cell lines were generally more sensitive, regardless of mutation, to pictilisib than basal-like cell lines (p=0.02).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1435", "label": "O'Brien et al., 2010, Clin. Cancer Res.", "type": "Document", "title": "PubMed: O'Brien et al., 2010, Clin. Cancer Res.", "pmid": 20453058}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:103", "label": "PIK3CA E542K", "description": "PIK3CA E545K/E542K variants are the second most recurrent PIK3CA mutations in breast cancer and are highly recurrent mutations in many other cancer types. Colorectal cancer patients with the PIK3CA E545K variant, and possibly other variants in the E545 region, may indicate poor prognosis relative to patients with other PIK3CA variants or wild-type PIK3CA. The literature also suggests that E545/E542 variants may confer resistance to EGFR inhibitors (e.g., cetuximab). An FDA approved treatment regimen including a targeted PIK3CA inhibitor is available for specific subtypes of breast cancer. While PIK3CA variants are highly prevalent in many other cancer types, targeted therapies for PIK3CA variants are still in early clinical trial phases in other cancer types.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 75.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000263967.3", "chromosome": "3", "start": 178936082, "stop": 178936082, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "103"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA333572"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "31944"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913273"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLU542LYS", "RS121913273"], "members": [{"id": "ga4gh:VA.52-4tAq0Ya9SeMU4eZSgO0bfqvkd_VE4", "label": "NC_000003.11:g.178936082G>A", "digest": "52-4tAq0Ya9SeMU4eZSgO0bfqvkd_VE4", "type": "Allele", "location": {"id": "ga4gh:SL.65wPuIVC66WPYQqTnuNP-taUZ03NOwmJ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 179218293, "end": 179218294}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.D6daDiDNn1u-e4YtntaYQnxlZ_0T6gtD", "label": "E542K", "digest": "D6daDiDNn1u-e4YtntaYQnxlZ_0T6gtD", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006218.3:c.1624G>A"}, {"syntax": "hgvs.p", "value": "NP_006209.2:p.Glu542Lys"}, {"syntax": "hgvs.c", "value": "ENST00000263967.3:c.1624G>A"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.178936082G>A"}], "location": {"id": "ga4gh:SL.DdVC73cqPrOnzCRvVc8N9tA3ecV5Qunt", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 541, "end": 542}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:141", "label": "Pictilisib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C165479"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:22", "label": "Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9335"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1612"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2034", "description": "This preclinical study tested the efficacy on several breast cancer cell lines of GDC-0941 (pictilisib), a selective inhibitor of all four isoforms of class I PI3-kinases over a range of IC50 values. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. MCF7 is a luminal type breast cancer cell line harboring PIK3CA E545K, and it had an IC50 of 0.34uM. To evaluate in vivo efficacy, MCF7 cells were injected in the mammary fat pad of SCID mice and allowed to grow. Mice treated with 100mg/kg pictilisib experienced a 62% tumor reduction, and those treated with 150mg/kg experienced a 70% tumor reduction, with respect to untreated control. Authors note that pictilisib was well tolerated and observed no toxicities or significant weight loss. Authors further note that luminal-like cell lines were generally more sensitive, regardless of mutation, to pictilisib than basal-like (p=0.02).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1435", "label": "O'Brien et al., 2010, Clin. Cancer Res.", "type": "Document", "title": "PubMed: O'Brien et al., 2010, Clin. Cancer Res.", "pmid": 20453058}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:104", "label": "PIK3CA E545K", "description": "PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 77.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000263967.3", "chromosome": "3", "start": 178936091, "stop": 178936091, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "104"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123334"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13655"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS104886003"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLU545LYS", "RS104886003"], "members": [{"id": "ga4gh:VA.uqD1zF6cMOYhBp8ur5oLTMqV0jxiC2a7", "label": "NC_000003.11:g.178936091G>A", "digest": "uqD1zF6cMOYhBp8ur5oLTMqV0jxiC2a7", "type": "Allele", "location": {"id": "ga4gh:SL.5l5tuxgJGb8y7CQzkKLPUvS-Cx4kr2ju", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 179218302, "end": 179218303}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.uw7DyLM7r98pn66LOXU3tAknmkV7jiJ0", "label": "E545K", "digest": "uw7DyLM7r98pn66LOXU3tAknmkV7jiJ0", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006218.3:c.1633G>A"}, {"syntax": "hgvs.p", "value": "NP_006209.2:p.Glu545Lys"}, {"syntax": "hgvs.c", "value": "ENST00000263967.3:c.1633G>A"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.178936091G>A"}], "location": {"id": "ga4gh:SL.SrEa0lPyesLrOX0M_aW51d-JdJhU-D3p", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 544, "end": 545}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:141", "label": "Pictilisib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C165479"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:22", "label": "Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9335"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1612"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2102", "description": "This preclinical study tested the efficacy of GDC-0941, a selective inhibitor of class I PI3K, on several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. Three cell lines harbored PIK3CA H1047R. T-47D is a luminal type breast cancer cell line, and it had an IC50 of 0.22uM. Treatment with GDC-0941 resulted in a substantial reduction of phosphorylated AKT. BT-20 is a basal breast cancer cell line which had an ICD50 of 0.62uM. MFM-223 is basal cell line that had an ICD50 of 2.10uM, and experienced some reduction in pAKT. Authors note that luminal-like cell lines were generally more sensitive to GDC-0941 than basal-like (p=0.02).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1435", "label": "O'Brien et al., 2010, Clin. Cancer Res.", "type": "Document", "title": "PubMed: O'Brien et al., 2010, Clin. Cancer Res.", "pmid": 20453058}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:107", "label": "PIK3CA H1047R", "description": "PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 96.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "G", "representative_transcript": "ENST00000263967.3", "chromosome": "3", "start": 178952085, "stop": 178952085, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "107"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123326"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13652"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913279"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913279", "HIS1047ARG"], "members": [{"id": "ga4gh:VA.82Pw7U7NM7ac2koW_yITXOGSKcwg_Qqj", "label": "NC_000003.11:g.178952085A>G", "digest": "82Pw7U7NM7ac2koW_yITXOGSKcwg_Qqj", "type": "Allele", "location": {"id": "ga4gh:SL.p0VJw5IIPnKzEpQMcdBaU3xesud6QODJ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 179234296, "end": 179234297}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.hcSlm-m3AKXOL7kHM3LghXQfvAjZOmYx", "label": "H1047R", "digest": "hcSlm-m3AKXOL7kHM3LghXQfvAjZOmYx", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006218.3:c.3140A>G"}, {"syntax": "hgvs.p", "value": "NP_006209.2:p.His1047Arg"}, {"syntax": "hgvs.c", "value": "ENST00000263967.3:c.3140A>G"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.178952085A>G"}], "location": {"id": "ga4gh:SL.DBBb47ourtRut09MJ_TAvlocEwpTjF9z", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 1046, "end": 1047}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:141", "label": "Pictilisib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C165479"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:22", "label": "Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9335"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1612"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2162", "description": "The NSCLC cell line NCI-H1975 carrying the EGFR T790M mutation was resistant to erlotinib but showed increased sensitivity to HKI-272 (neratinib, IC50: 0.29 \u03bcmol/L).\nIn an in vitro study Ba/F3 cells transfected with either EGFR-L858R or EGFR-L858R/T790M were used to assay cell growth. Ba/F3 cells require IL-3 in order to proliferate, but cells transfected with an activated oncogene are IL-3 independent. Cells with an EGFR L858R/T790M mutation demonstrated an improved response to neratinib (IC50: 0.185umol/L vs. >10umol/L) compared to the same cells treated with erlotinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1526", "label": "Shimamura et al., 2006, Cancer Res.", "type": "Document", "title": "PubMed: Shimamura et al., 2006, Cancer Res.", "pmid": 16818618}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:34", "label": "EGFR T790M", "description": "EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 406.25}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55249071, "stop": 55249071, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "34"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA090928"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16613"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434569"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["THR790MET", "RS121434569"], "members": [{"id": "ga4gh:VA.OvEfBRaS34JkfM0_ZHJVDQEjqtwzyjyp", "label": "NC_000007.13:g.55249071C>T", "digest": "OvEfBRaS34JkfM0_ZHJVDQEjqtwzyjyp", "type": "Allele", "location": {"id": "ga4gh:SL.ZCgOjF-_T0EOBXGc-6yICYui-jgFzJfY", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55181377, "end": 55181378}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.faKID4aj8rP8NKZpWL4mWDToEztTUmbr", "label": "T790M", "digest": "faKID4aj8rP8NKZpWL4mWDToEztTUmbr", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2369C>T"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2369C>T"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Thr790Met"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55249071C>T"}], "location": {"id": "ga4gh:SL.C1y_lDZe8e9pKy3jcj3oJKw_7252Hrxa", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 789, "end": 790}, "state": {"type": "LiteralSequenceExpression", "sequence": "M"}}}, "therapeutic": {"id": "civic.tid:52", "label": "Neratinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1940643"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C49094"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide", "2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-", "HKI 272", "HKI-272", "PB 272", "PB-272"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2163", "description": "In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R/T790M mutation demonstrated an improved response to afatinib (IC50: 99nM vs. >4000nM) compared to the same cells treated with erlotinib. In an in vivo mouse xenograft study, the growth of cells with an EGFR-L858R/T790M mutation were more sensitive to treatment of afatinib (concentration: 15-20mg/kg) (median tumor volume = 75-150mm^3 vs. 1000mm^3), compared to reversible TKI lapatinib-treated xenografts. However, no complete responses were observed with afatinib alone.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1525", "label": "Li et al., 2008, Oncogene", "type": "Document", "title": "PubMed: Li et al., 2008, Oncogene", "pmid": 18408761}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:34", "label": "EGFR T790M", "description": "EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 406.25}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55249071, "stop": 55249071, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "34"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA090928"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16613"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434569"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["THR790MET", "RS121434569"], "members": [{"id": "ga4gh:VA.OvEfBRaS34JkfM0_ZHJVDQEjqtwzyjyp", "label": "NC_000007.13:g.55249071C>T", "digest": "OvEfBRaS34JkfM0_ZHJVDQEjqtwzyjyp", "type": "Allele", "location": {"id": "ga4gh:SL.ZCgOjF-_T0EOBXGc-6yICYui-jgFzJfY", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55181377, "end": 55181378}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.faKID4aj8rP8NKZpWL4mWDToEztTUmbr", "label": "T790M", "digest": "faKID4aj8rP8NKZpWL4mWDToEztTUmbr", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2369C>T"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2369C>T"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Thr790Met"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55249071C>T"}], "location": {"id": "ga4gh:SL.C1y_lDZe8e9pKy3jcj3oJKw_7252Hrxa", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 789, "end": 790}, "state": {"type": "LiteralSequenceExpression", "sequence": "M"}}}, "therapeutic": {"id": "civic.tid:146", "label": "Afatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1430438"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:25316", "type": "Disease", "label": "Non-small cell lung cancer squamous"}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C66940"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide", "BIBW 2992", "BIBW2992"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2164", "description": "In an in vitro study using purified EGFR protein, kinase activity was assayed and compared for wildtype EGFR, EGFR-T790M and EGFR-T790M/L858R using both reversible and irreversible TKI drugs. EFGR proteins with T790M or T790M/L858R mutations were more sensitive to afatinib treatment (IC50: 9.8nM and 24nM, respectively vs. IC50: >1000nM and >1000nM, respectively) compared to treatment with erlotinib or lapatinib treatment. In an in vitro study using NCI-H358 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to tyrosine kinase inhibitor drugs. Cells with an EGFR L858R/T790M mutation demonstrated an improved response to afatinib (GI50: 42.0nM vs. >1000nM) compared to the same cells treated with erlotinib. However, IC50s were intermediate compared to a more potent pan-HER inhibitor.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1527", "label": "Cha et al., 2012, Int. J. Cancer", "type": "Document", "title": "PubMed: Cha et al., 2012, Int. J. Cancer", "pmid": 21732342}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:34", "label": "EGFR T790M", "description": "EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 406.25}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55249071, "stop": 55249071, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "34"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA090928"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16613"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434569"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["THR790MET", "RS121434569"], "members": [{"id": "ga4gh:VA.OvEfBRaS34JkfM0_ZHJVDQEjqtwzyjyp", "label": "NC_000007.13:g.55249071C>T", "digest": "OvEfBRaS34JkfM0_ZHJVDQEjqtwzyjyp", "type": "Allele", "location": {"id": "ga4gh:SL.ZCgOjF-_T0EOBXGc-6yICYui-jgFzJfY", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55181377, "end": 55181378}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.faKID4aj8rP8NKZpWL4mWDToEztTUmbr", "label": "T790M", "digest": "faKID4aj8rP8NKZpWL4mWDToEztTUmbr", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2369C>T"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2369C>T"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Thr790Met"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55249071C>T"}], "location": {"id": "ga4gh:SL.C1y_lDZe8e9pKy3jcj3oJKw_7252Hrxa", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 789, "end": 790}, "state": {"type": "LiteralSequenceExpression", "sequence": "M"}}}, "therapeutic": {"id": "civic.tid:146", "label": "Afatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1430438"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:25316", "type": "Disease", "label": "Non-small cell lung cancer squamous"}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C66940"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide", "BIBW 2992", "BIBW2992"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2165", "description": "In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R/T790M mutation demonstrated an improved response to canertinib (IC50: 101nM vs. >4000nM) compared to the same cells treated with erlotinib. IC50 values of canertinib were comparable to afatinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1525", "label": "Li et al., 2008, Oncogene", "type": "Document", "title": "PubMed: Li et al., 2008, Oncogene", "pmid": 18408761}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:34", "label": "EGFR T790M", "description": "EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 406.25}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55249071, "stop": 55249071, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "34"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA090928"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16613"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434569"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["THR790MET", "RS121434569"], "members": [{"id": "ga4gh:VA.OvEfBRaS34JkfM0_ZHJVDQEjqtwzyjyp", "label": "NC_000007.13:g.55249071C>T", "digest": "OvEfBRaS34JkfM0_ZHJVDQEjqtwzyjyp", "type": "Allele", "location": {"id": "ga4gh:SL.ZCgOjF-_T0EOBXGc-6yICYui-jgFzJfY", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55181377, "end": 55181378}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.faKID4aj8rP8NKZpWL4mWDToEztTUmbr", "label": "T790M", "digest": "faKID4aj8rP8NKZpWL4mWDToEztTUmbr", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2369C>T"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2369C>T"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Thr790Met"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55249071C>T"}], "location": {"id": "ga4gh:SL.C1y_lDZe8e9pKy3jcj3oJKw_7252Hrxa", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 789, "end": 790}, "state": {"type": "LiteralSequenceExpression", "sequence": "M"}}}, "therapeutic": {"id": "civic.tid:465", "label": "Canertinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C77588"}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C77588"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["2-propenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-", "N-{4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2250", "description": "In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1420", "label": "Rowley et al., 2000, Blood", "type": "Document", "title": "PubMed: Rowley et al., 2000, Blood", "pmid": 11050000}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:79", "label": "KRAS G12D", "description": "While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 162.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398284, "stop": 25398284, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "79"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA122538"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12582"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913529"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913529", "GLY12ASP"], "members": [{"id": "ga4gh:VA.qOYg4yYK-1Je25G30BkV3dWKtKDIAFEJ", "label": "NC_000012.11:g.25398284C>T", "digest": "qOYg4yYK-1Je25G30BkV3dWKtKDIAFEJ", "type": "Allele", "location": {"id": "ga4gh:SL.iF0OXeO-tnumYbGkzaFEQ7cOZI_UCI1s", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245349, "end": 25245350}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.CB571ja_KfZM_Hjn9zjjgV1an3tDWRcl", "label": "G12D", "digest": "CB571ja_KfZM_Hjn9zjjgV1an3tDWRcl", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004985.4:c.35G>A"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly12Asp"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398284C>T"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.35G>A"}], "location": {"id": "ga4gh:SL.OndkjmujtyUEZSjjCv0C-gpwnVbRgfj8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "D"}}}, "therapeutic": {"id": "civic.tid:328", "label": "Melphalan", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:6718"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:633", "type": "Disease", "label": "Multiple myeloma", "mappings": [{"coding": {"system": "ncit", "code": "C3242"}, "relation": "relatedMatch"}]}, {"id": "hemonc:645", "type": "Disease", "label": "Ovarian cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7431"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C633"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[bis(2-chloroethyl)amino]-L-phenylalanine", "Alanine Nitrogen Mustard", "CB-3025", "L-PAM", "L-Phenylalanine Mustard", "L-Sarcolysin", "L-Sarcolysin Phenylalanine Mustard", "L-Sarcolysine", "Melphalanum", "P-di(chloroethyl)amino-L-phenylalanine", "Phenylalanine Mustard", "Phenylalanine Nitrogen Mustard", "Sarcoclorin", "Sarkolysin", "WR-19813"]}, "tumorType": {"id": "civic.did:41", "label": "Multiple Myeloma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3242"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9538"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2252", "description": "In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1422", "label": "Hoang et al., 2006, Blood", "type": "Document", "title": "PubMed: Hoang et al., 2006, Blood", "pmid": 16497971}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:79", "label": "KRAS G12D", "description": "While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 162.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398284, "stop": 25398284, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "79"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA122538"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12582"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913529"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913529", "GLY12ASP"], "members": [{"id": "ga4gh:VA.qOYg4yYK-1Je25G30BkV3dWKtKDIAFEJ", "label": "NC_000012.11:g.25398284C>T", "digest": "qOYg4yYK-1Je25G30BkV3dWKtKDIAFEJ", "type": "Allele", "location": {"id": "ga4gh:SL.iF0OXeO-tnumYbGkzaFEQ7cOZI_UCI1s", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245349, "end": 25245350}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.CB571ja_KfZM_Hjn9zjjgV1an3tDWRcl", "label": "G12D", "digest": "CB571ja_KfZM_Hjn9zjjgV1an3tDWRcl", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004985.4:c.35G>A"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly12Asp"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398284C>T"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.35G>A"}], "location": {"id": "ga4gh:SL.OndkjmujtyUEZSjjCv0C-gpwnVbRgfj8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "D"}}}, "therapeutic": {"id": "civic.tid:328", "label": "Melphalan", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:6718"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:633", "type": "Disease", "label": "Multiple myeloma", "mappings": [{"coding": {"system": "ncit", "code": "C3242"}, "relation": "relatedMatch"}]}, {"id": "hemonc:645", "type": "Disease", "label": "Ovarian cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7431"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C633"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[bis(2-chloroethyl)amino]-L-phenylalanine", "Alanine Nitrogen Mustard", "CB-3025", "L-PAM", "L-Phenylalanine Mustard", "L-Sarcolysin", "L-Sarcolysin Phenylalanine Mustard", "L-Sarcolysine", "Melphalanum", "P-di(chloroethyl)amino-L-phenylalanine", "Phenylalanine Mustard", "Phenylalanine Nitrogen Mustard", "Sarcoclorin", "Sarkolysin", "WR-19813"]}, "tumorType": {"id": "civic.did:41", "label": "Multiple Myeloma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3242"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9538"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2261", "description": "In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1420", "label": "Rowley et al., 2000, Blood", "type": "Document", "title": "PubMed: Rowley et al., 2000, Blood", "pmid": 11050000}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:78", "label": "KRAS G12C", "description": "While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 136.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "A", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398285, "stop": 25398285, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "78"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA122528"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12578"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913530"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLY12CYS", "RS121913530"], "members": [{"id": "ga4gh:VA.ONAtlY1naHPhc7I2cFH6POy4zmWKukHw", "label": "NC_000012.11:g.25398285C>A", "digest": "ONAtlY1naHPhc7I2cFH6POy4zmWKukHw", "type": "Allele", "location": {"id": "ga4gh:SL.AiE9G9ocxKfBfR5PRN_ktoggZzig8OcG", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245350, "end": 25245351}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.94GquHCCcRi74uwlI5PGJsf6FsR2M7Ef", "label": "G12C", "digest": "94GquHCCcRi74uwlI5PGJsf6FsR2M7Ef", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004985.4:c.34G>T"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly12Cys"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398285C>A"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.34G>T"}], "location": {"id": "ga4gh:SL.OndkjmujtyUEZSjjCv0C-gpwnVbRgfj8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "civic.tid:328", "label": "Melphalan", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:6718"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:633", "type": "Disease", "label": "Multiple myeloma", "mappings": [{"coding": {"system": "ncit", "code": "C3242"}, "relation": "relatedMatch"}]}, {"id": "hemonc:645", "type": "Disease", "label": "Ovarian cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7431"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C633"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[bis(2-chloroethyl)amino]-L-phenylalanine", "Alanine Nitrogen Mustard", "CB-3025", "L-PAM", "L-Phenylalanine Mustard", "L-Sarcolysin", "L-Sarcolysin Phenylalanine Mustard", "L-Sarcolysine", "Melphalanum", "P-di(chloroethyl)amino-L-phenylalanine", "Phenylalanine Mustard", "Phenylalanine Nitrogen Mustard", "Sarcoclorin", "Sarkolysin", "WR-19813"]}, "tumorType": {"id": "civic.did:41", "label": "Multiple Myeloma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3242"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9538"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2263", "description": "In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1422", "label": "Hoang et al., 2006, Blood", "type": "Document", "title": "PubMed: Hoang et al., 2006, Blood", "pmid": 16497971}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:78", "label": "KRAS G12C", "description": "While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 136.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "A", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398285, "stop": 25398285, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "78"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA122528"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12578"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913530"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLY12CYS", "RS121913530"], "members": [{"id": "ga4gh:VA.ONAtlY1naHPhc7I2cFH6POy4zmWKukHw", "label": "NC_000012.11:g.25398285C>A", "digest": "ONAtlY1naHPhc7I2cFH6POy4zmWKukHw", "type": "Allele", "location": {"id": "ga4gh:SL.AiE9G9ocxKfBfR5PRN_ktoggZzig8OcG", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245350, "end": 25245351}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.94GquHCCcRi74uwlI5PGJsf6FsR2M7Ef", "label": "G12C", "digest": "94GquHCCcRi74uwlI5PGJsf6FsR2M7Ef", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004985.4:c.34G>T"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly12Cys"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398285C>A"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.34G>T"}], "location": {"id": "ga4gh:SL.OndkjmujtyUEZSjjCv0C-gpwnVbRgfj8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "civic.tid:328", "label": "Melphalan", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:6718"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:633", "type": "Disease", "label": "Multiple myeloma", "mappings": [{"coding": {"system": "ncit", "code": "C3242"}, "relation": "relatedMatch"}]}, {"id": "hemonc:645", "type": "Disease", "label": "Ovarian cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7431"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C633"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[bis(2-chloroethyl)amino]-L-phenylalanine", "Alanine Nitrogen Mustard", "CB-3025", "L-PAM", "L-Phenylalanine Mustard", "L-Sarcolysin", "L-Sarcolysin Phenylalanine Mustard", "L-Sarcolysine", "Melphalanum", "P-di(chloroethyl)amino-L-phenylalanine", "Phenylalanine Mustard", "Phenylalanine Nitrogen Mustard", "Sarcoclorin", "Sarkolysin", "WR-19813"]}, "tumorType": {"id": "civic.did:41", "label": "Multiple Myeloma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3242"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9538"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2277", "description": "In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1420", "label": "Rowley et al., 2000, Blood", "type": "Document", "title": "PubMed: Rowley et al., 2000, Blood", "pmid": 11050000}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:887", "label": "KRAS G12S", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 38.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398285, "stop": 25398285, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "913"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA135565"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12584"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913530"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLY12SER", "RS121913530"], "members": [{"id": "ga4gh:VA.PnoqUPOSplj2ReUhO0vv3Uwz7urotLNW", "label": "NC_000012.11:g.25398285C>T", "digest": "PnoqUPOSplj2ReUhO0vv3Uwz7urotLNW", "type": "Allele", "location": {"id": "ga4gh:SL.AiE9G9ocxKfBfR5PRN_ktoggZzig8OcG", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245350, "end": 25245351}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.BqLbpvUuI1si3-JoDB-imd4p6DIJVXlO", "label": "G12S", "digest": "BqLbpvUuI1si3-JoDB-imd4p6DIJVXlO", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004985.4:c.34G>A"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly12Ser"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398285C>T"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.34G>A"}], "location": {"id": "ga4gh:SL.OndkjmujtyUEZSjjCv0C-gpwnVbRgfj8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "S"}}}, "therapeutic": {"id": "civic.tid:328", "label": "Melphalan", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:6718"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:633", "type": "Disease", "label": "Multiple myeloma", "mappings": [{"coding": {"system": "ncit", "code": "C3242"}, "relation": "relatedMatch"}]}, {"id": "hemonc:645", "type": "Disease", "label": "Ovarian cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7431"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C633"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[bis(2-chloroethyl)amino]-L-phenylalanine", "Alanine Nitrogen Mustard", "CB-3025", "L-PAM", "L-Phenylalanine Mustard", "L-Sarcolysin", "L-Sarcolysin Phenylalanine Mustard", "L-Sarcolysine", "Melphalanum", "P-di(chloroethyl)amino-L-phenylalanine", "Phenylalanine Mustard", "Phenylalanine Nitrogen Mustard", "Sarcoclorin", "Sarkolysin", "WR-19813"]}, "tumorType": {"id": "civic.did:41", "label": "Multiple Myeloma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3242"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9538"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2278", "description": "In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1421", "label": "Rowley et al., 2002, Oncogene", "type": "Document", "title": "PubMed: Rowley et al., 2002, Oncogene", "pmid": 12483530}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:887", "label": "KRAS G12S", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 38.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398285, "stop": 25398285, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "913"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA135565"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12584"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913530"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLY12SER", "RS121913530"], "members": [{"id": "ga4gh:VA.PnoqUPOSplj2ReUhO0vv3Uwz7urotLNW", "label": "NC_000012.11:g.25398285C>T", "digest": "PnoqUPOSplj2ReUhO0vv3Uwz7urotLNW", "type": "Allele", "location": {"id": "ga4gh:SL.AiE9G9ocxKfBfR5PRN_ktoggZzig8OcG", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245350, "end": 25245351}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.BqLbpvUuI1si3-JoDB-imd4p6DIJVXlO", "label": "G12S", "digest": "BqLbpvUuI1si3-JoDB-imd4p6DIJVXlO", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004985.4:c.34G>A"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly12Ser"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398285C>T"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.34G>A"}], "location": {"id": "ga4gh:SL.OndkjmujtyUEZSjjCv0C-gpwnVbRgfj8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "S"}}}, "therapeutic": {"id": "civic.tid:328", "label": "Melphalan", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:6718"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:633", "type": "Disease", "label": "Multiple myeloma", "mappings": [{"coding": {"system": "ncit", "code": "C3242"}, "relation": "relatedMatch"}]}, {"id": "hemonc:645", "type": "Disease", "label": "Ovarian cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7431"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C633"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[bis(2-chloroethyl)amino]-L-phenylalanine", "Alanine Nitrogen Mustard", "CB-3025", "L-PAM", "L-Phenylalanine Mustard", "L-Sarcolysin", "L-Sarcolysin Phenylalanine Mustard", "L-Sarcolysine", "Melphalanum", "P-di(chloroethyl)amino-L-phenylalanine", "Phenylalanine Mustard", "Phenylalanine Nitrogen Mustard", "Sarcoclorin", "Sarkolysin", "WR-19813"]}, "tumorType": {"id": "civic.did:41", "label": "Multiple Myeloma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3242"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9538"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2279", "description": "In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1422", "label": "Hoang et al., 2006, Blood", "type": "Document", "title": "PubMed: Hoang et al., 2006, Blood", "pmid": 16497971}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:887", "label": "KRAS G12S", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 38.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398285, "stop": 25398285, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "913"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA135565"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12584"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913530"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLY12SER", "RS121913530"], "members": [{"id": "ga4gh:VA.PnoqUPOSplj2ReUhO0vv3Uwz7urotLNW", "label": "NC_000012.11:g.25398285C>T", "digest": "PnoqUPOSplj2ReUhO0vv3Uwz7urotLNW", "type": "Allele", "location": {"id": "ga4gh:SL.AiE9G9ocxKfBfR5PRN_ktoggZzig8OcG", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245350, "end": 25245351}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.BqLbpvUuI1si3-JoDB-imd4p6DIJVXlO", "label": "G12S", "digest": "BqLbpvUuI1si3-JoDB-imd4p6DIJVXlO", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004985.4:c.34G>A"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly12Ser"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398285C>T"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.34G>A"}], "location": {"id": "ga4gh:SL.OndkjmujtyUEZSjjCv0C-gpwnVbRgfj8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "S"}}}, "therapeutic": {"id": "civic.tid:328", "label": "Melphalan", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:6718"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:633", "type": "Disease", "label": "Multiple myeloma", "mappings": [{"coding": {"system": "ncit", "code": "C3242"}, "relation": "relatedMatch"}]}, {"id": "hemonc:645", "type": "Disease", "label": "Ovarian cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7431"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C633"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[bis(2-chloroethyl)amino]-L-phenylalanine", "Alanine Nitrogen Mustard", "CB-3025", "L-PAM", "L-Phenylalanine Mustard", "L-Sarcolysin", "L-Sarcolysin Phenylalanine Mustard", "L-Sarcolysine", "Melphalanum", "P-di(chloroethyl)amino-L-phenylalanine", "Phenylalanine Mustard", "Phenylalanine Nitrogen Mustard", "Sarcoclorin", "Sarkolysin", "WR-19813"]}, "tumorType": {"id": "civic.did:41", "label": "Multiple Myeloma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3242"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9538"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2329", "description": "In an experimental in vitro study, glioma cells expressing IDH1 R132C were associated with sensitivity to AGI-5198 (IC50: 0.16M vs. IC50 > 100.00M), as compared to cells expressing wild-type IDH1. Sensitivity was determined by assessing cell growth.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:678", "label": "Rohle et al., 2013, Science", "type": "Document", "title": "PubMed: Rohle et al., 2013, Science", "pmid": 23558169}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:26", "label": "IDH1", "description": "IDH1 mutations have been observed in a number of cancer types, including sarcomas, hematologic malignancies, colon cancer and brain cancer. Mutations in the two isocitrate dehydrogenase enzymes involved in cytoplasmic (IDH1) and mitochondrial (IDH2) conversion of alpha-ketoglutarate to D-2-hydroxyglutarate have been described as mutually exclusive in many of these cancer types. The most frequent mutations involve R132 (IDH1) and R172 (IDH2) involve the active site and result in neomorphic enzyme activity. The implications of mutations in this gene vary greatly by cancer type. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 mutations have been associated with worse outcome, shorter overall survival, and normal karyotype. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Unlike the association with cytogenetically normal AML, in glioblastoma, IDH1 mutations have been associated with specific cytogenetic abnormalities, 1p and 19q deletions.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:5382"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3417"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["HEL-216", "HEL-S-26", "IDCD", "IDH", "IDH1", "IDP", "IDPC", "PICD"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:59", "label": "IDH1 R132C", "description": "IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 56.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000415913.1", "chromosome": "2", "start": 209113113, "stop": 209113113, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "59"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602374"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "375891"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913499"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ARG132CYS", "RS121913499"], "members": [{"id": "ga4gh:VA.BSWDYW013eVP-oPsbZ4EbaLXKQ3fbTQe", "label": "NC_000002.11:g.209113113G>A", "digest": "BSWDYW013eVP-oPsbZ4EbaLXKQ3fbTQe", "type": "Allele", "location": {"id": "ga4gh:SL.9sCi1wXjGTNOwjkt3L-5N-rswDF_dNui", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.pnAqCRBrTsUoBghSD1yp_jXWSmlbdh4g"}, "start": 208248388, "end": 208248389}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.348znVA1UKrjwKuq8LLOVrb77xWo5XUO", "label": "R132C", "digest": "348znVA1UKrjwKuq8LLOVrb77xWo5XUO", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_005896.3:c.394C>T"}, {"syntax": "hgvs.p", "value": "NP_005887.2:p.Arg132Cys"}, {"syntax": "hgvs.g", "value": "NC_000002.11:g.209113113G>A"}, {"syntax": "hgvs.c", "value": "ENST00000415913.1:c.394C>T"}], "location": {"id": "ga4gh:SL.6S6Nay-qWJnCSbbpF3hcBRTeoYOc4CJD", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.VZMxTY2iB2G_EuwlpVZ0AnX6R-am08GZ"}, "start": 131, "end": 132}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "civic.tid:473", "label": "AGI-5198", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "iuphar.ligand:9240"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:695", "label": "High Grade Glioma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4822"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3070"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2445", "description": "In an in vitro study of imatinib sensitivity, KIT N822H was cloned into a plasmid by site-directed mutagenesis of KIT WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. Cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Protein lysates from the transfected cells were examined for phosphorylated tyrosine, a measure of KIT activation. Cells expressing KIT N822H were as sensitive to imatinib as ligand activated wildtype KIT (IC50: 100-200 nmol/L).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:412", "label": "Heinrich et al., 2003, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Heinrich et al., 2003, J. Clin. Oncol.", "pmid": 14645423}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:29", "label": "KIT", "description": "c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3815"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["C-Kit", "CD117", "KIT", "MASTC", "PBT", "SCFR"]}}, "direction": "refutes", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:961", "label": "KIT N822H", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 2.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "C", "chromosome": "4", "start": 55599338, "stop": 55599338, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "987"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA356911968"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.y3WVsquUjcol6sWfGlcWtO1gal1UdU-4", "label": "N822H", "digest": "y3WVsquUjcol6sWfGlcWtO1gal1UdU-4", "type": "Allele", "location": {"id": "ga4gh:SL.B6627_40nR9hpf23ICFLQ0TZsfFxpBNq", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 821, "end": 822}, "state": {"type": "LiteralSequenceExpression", "sequence": "H"}}}, "therapeutic": {"id": "civic.tid:5", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:282388"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "Disease", "label": "Systemic mastocytosis", "mappings": [{"coding": {"system": "ncit", "code": "C9235"}, "relation": "relatedMatch"}]}, {"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}, {"id": "hemonc:634", "type": "Disease", "label": "Myelodysplastic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C3247"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:33893", "type": "Disease", "label": "Chronic myelogenous leukemia pediatric"}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}, {"id": "hemonc:616", "type": "Disease", "label": "Hypereosinophilic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C27038"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C62035"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"]}, "tumorType": {"id": "civic.did:216", "label": "Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9305"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:162"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2448", "description": "In an in vitro study of imatinib sensitivity, KIT N822K was cloned into a plasmid by site-directed mutagenesis of KIT WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. Cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Protein lysates from the transfected cells were examined for phosphorylated tyrosine, a measure of KIT activation. Cells expressing KIT N822K were as sensitive to imatinib as ligand activated wildtype KIT (IC50: 100-200 nmol/L).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:412", "label": "Heinrich et al., 2003, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Heinrich et al., 2003, J. Clin. Oncol.", "pmid": 14645423}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:29", "label": "KIT", "description": "c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3815"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["C-Kit", "CD117", "KIT", "MASTC", "PBT", "SCFR"]}}, "direction": "refutes", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1237", "label": "KIT N822K", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 29.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "A", "representative_transcript": "ENST00000288135.5", "chromosome": "4", "start": 55599340, "stop": 55599340, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1263"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602411"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "375931"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913514"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ASN822LYS", "RS121913514"], "members": [{"id": "ga4gh:VA.3i1HI4wqippKn-gtuyM4kiLBVQD0N763", "label": "NC_000004.11:g.55599340T>A", "digest": "3i1HI4wqippKn-gtuyM4kiLBVQD0N763", "type": "Allele", "location": {"id": "ga4gh:SL.hQJlf-hzQ4szaLAhFocudRE99wMKEJfi", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54733173, "end": 54733174}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.z_WJsSByobbgzhHAaWw4kVBhNnyADN57", "label": "N822K", "digest": "z_WJsSByobbgzhHAaWw4kVBhNnyADN57", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_000222.2:c.2466T>A"}, {"syntax": "hgvs.p", "value": "NP_000213.1:p.Asn822Lys"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55599340T>A"}, {"syntax": "hgvs.c", "value": "ENST00000288135.5:c.2466T>A"}], "location": {"id": "ga4gh:SL.B6627_40nR9hpf23ICFLQ0TZsfFxpBNq", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 821, "end": 822}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:5", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:282388"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "Disease", "label": "Systemic mastocytosis", "mappings": [{"coding": {"system": "ncit", "code": "C9235"}, "relation": "relatedMatch"}]}, {"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}, {"id": "hemonc:634", "type": "Disease", "label": "Myelodysplastic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C3247"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:33893", "type": "Disease", "label": "Chronic myelogenous leukemia pediatric"}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}, {"id": "hemonc:616", "type": "Disease", "label": "Hypereosinophilic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C27038"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C62035"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"]}, "tumorType": {"id": "civic.did:216", "label": "Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9305"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:162"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2451", "description": "In an in vitro study of imatinib sensitivity, KIT D816V was cloned into a plasmid by site-directed mutagenesis of KIT WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. Cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Protein lysates from the transfected cells were examined for phosphorylated tyrosine, a measure of KIT activation. Cells expressing KIT D816V were resistant to imatinib up to 10 umol/L.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:412", "label": "Heinrich et al., 2003, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Heinrich et al., 2003, J. Clin. Oncol.", "pmid": 14645423}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:29", "label": "KIT", "description": "c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3815"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["C-Kit", "CD117", "KIT", "MASTC", "PBT", "SCFR"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:65", "label": "KIT D816V", "description": "KIT D816V is a mutation observed in acute myeloid leukemia (AML). This variant has been linked to poorer prognosis and worse outcome in AML patients.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 67.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000288135.5", "chromosome": "4", "start": 55599321, "stop": 55599321, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "65"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123513"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13852"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913507"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913507", "ASP816VAL"], "members": [{"id": "ga4gh:VA.gdbp5quI5YscqYY01qlHfuJkT7R41cR7", "label": "NC_000004.11:g.55599321A>T", "digest": "gdbp5quI5YscqYY01qlHfuJkT7R41cR7", "type": "Allele", "location": {"id": "ga4gh:SL.K5_kmlkru2gtVBgRFCtI7EVKUJa1E28v", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54733154, "end": 54733155}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.rZDlEZBywJpTMBnXhLjN12Y9HQYHiOiP", "label": "D816V", "digest": "rZDlEZBywJpTMBnXhLjN12Y9HQYHiOiP", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_000222.2:c.2447A>T"}, {"syntax": "hgvs.p", "value": "NP_000213.1:p.Asp816Val"}, {"syntax": "hgvs.c", "value": "ENST00000288135.5:c.2447A>T"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55599321A>T"}], "location": {"id": "ga4gh:SL.EFk3ET7Ws47inqLJnNWEsA-GhUEwihbN", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 815, "end": 816}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "civic.tid:5", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:282388"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "Disease", "label": "Systemic mastocytosis", "mappings": [{"coding": {"system": "ncit", "code": "C9235"}, "relation": "relatedMatch"}]}, {"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}, {"id": "hemonc:634", "type": "Disease", "label": "Myelodysplastic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C3247"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:33893", "type": "Disease", "label": "Chronic myelogenous leukemia pediatric"}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}, {"id": "hemonc:616", "type": "Disease", "label": "Hypereosinophilic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C27038"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C62035"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"]}, "tumorType": {"id": "civic.did:216", "label": "Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9305"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:162"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2454", "description": "In an in vitro study of imatinib sensitivity, PDGFRA V561D was cloned into a plasmid by site-directed mutagenesis of PDGFRA WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. The cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Protein lysates from the transfected cells were examined for phosphorylated tyrosine, a measure of PDGFRA activation. Cells expressing PDGFRA V561D were as sensitive to imatinib as ligand activated wildtype PDGFRA (IC50: 100-200 nmol/L).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:412", "label": "Heinrich et al., 2003, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Heinrich et al., 2003, J. Clin. Oncol.", "pmid": 14645423}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:38", "label": "PDGFRA", "description": "Commonly mutated in GI tract tumors, PDGFR family genes (mutually exclusive to KIT mutations) are a hallmark of gastrointestinal stromal tumors. Gene fusions involving the PDGFRA kinase domain are highly correlated with eosinophilia, and the WHO classifies myeloid and lymphoid neoplasms with these characteristics as a distinct disorder. Mutations in the 842 region of PDGFRA have been often found to confer resistance to the tyrosine kinase inhibitor, imatinib.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8803"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5156"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD140A", "PDGFR-2", "PDGFR2", "PDGFRA"]}}, "direction": "refutes", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:915", "label": "PDGFRA V561D", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 8.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "A", "representative_transcript": "ENST00000257290.5", "chromosome": "4", "start": 55141036, "stop": 55141036, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "941"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123203"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13546"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121908586"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121908586"], "members": [{"id": "ga4gh:VA.RVDCfTK9KrX96TVgvOUcAv--OnQUdV8O", "label": "NC_000004.11:g.55141036T>A", "digest": "RVDCfTK9KrX96TVgvOUcAv--OnQUdV8O", "type": "Allele", "location": {"id": "ga4gh:SL.h44ZIUE0VWLc8ONz8JwqUOUCvADE8Ozc", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54274868, "end": 54274869}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.OFhYwJu_e2ktWF9N-_SrpmKx44fbeyto", "label": "V561D", "digest": "OFhYwJu_e2ktWF9N-_SrpmKx44fbeyto", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006206.5:c.1682T>A"}, {"syntax": "hgvs.p", "value": "NP_006197.1:p.Val561Asp"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55141036T>A"}, {"syntax": "hgvs.c", "value": "ENST00000257290.5:c.1682T>A"}], "location": {"id": "ga4gh:SL.QB_e8RED6euCq3v0AQJcTcXmXd4p286t", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.XpQn9sZLGv_GU3uiWO7YHq9-_alGjrVX"}, "start": 560, "end": 561}, "state": {"type": "LiteralSequenceExpression", "sequence": "D"}}}, "therapeutic": {"id": "civic.tid:5", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:282388"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "Disease", "label": "Systemic mastocytosis", "mappings": [{"coding": {"system": "ncit", "code": "C9235"}, "relation": "relatedMatch"}]}, {"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}, {"id": "hemonc:634", "type": "Disease", "label": "Myelodysplastic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C3247"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:33893", "type": "Disease", "label": "Chronic myelogenous leukemia pediatric"}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}, {"id": "hemonc:616", "type": "Disease", "label": "Hypereosinophilic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C27038"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C62035"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"]}, "tumorType": {"id": "civic.did:216", "label": "Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9305"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:162"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2463", "description": "In an in vitro study of imatinib sensitivity, PDGFRA D842V was cloned into a plasmid by site-directed mutagenesis of PDGFRA WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. The cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Protein lysates from the transfected cells were examined for phosphorylated tyrosine, a measure of PDGFRA activation. Cells expressing PDGFRA D842V required 10-20 fold higher concentrations of imatinib as ligand activated wildtype PDGFRA (IC50: 1-2 umol/L).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:412", "label": "Heinrich et al., 2003, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Heinrich et al., 2003, J. Clin. Oncol.", "pmid": 14645423}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:38", "label": "PDGFRA", "description": "Commonly mutated in GI tract tumors, PDGFR family genes (mutually exclusive to KIT mutations) are a hallmark of gastrointestinal stromal tumors. Gene fusions involving the PDGFRA kinase domain are highly correlated with eosinophilia, and the WHO classifies myeloid and lymphoid neoplasms with these characteristics as a distinct disorder. Mutations in the 842 region of PDGFRA have been often found to confer resistance to the tyrosine kinase inhibitor, imatinib.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8803"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5156"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD140A", "PDGFR-2", "PDGFR2", "PDGFRA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:99", "label": "PDGFRA D842V", "description": "PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. Exogenous expression of the A842V mutation resulted in constitutive tyrosine phosphorylation of PDGFRA in the absence of ligand in 293T cells and cytokine-independent proliferation of the IL-3-dependent Ba/F3 cell line, both evidence that this is an activating mutation. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 100.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000257290.5", "chromosome": "4", "start": 55152093, "stop": 55152093, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "99"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123194"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13543"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121908585"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ASP842VAL", "RS121908585"], "members": [{"id": "ga4gh:VA.bDwkJ2filJ3ZGiUFybGFfyaCKdIVK86v", "label": "NC_000004.11:g.55152093A>T", "digest": "bDwkJ2filJ3ZGiUFybGFfyaCKdIVK86v", "type": "Allele", "location": {"id": "ga4gh:SL.LxO2YLfQbI_-TK7GOmSoOpMNiSy_Hgan", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54285925, "end": 54285926}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.vIjnL-aLYl0BSB6JutpdD7yW_qIXtdk8", "label": "D842V", "digest": "vIjnL-aLYl0BSB6JutpdD7yW_qIXtdk8", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006206.4:c.2525A>T"}, {"syntax": "hgvs.p", "value": "NP_006197.1:p.Asp842Val"}, {"syntax": "hgvs.c", "value": "ENST00000257290.5:c.2525A>T"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55152093A>T"}], "location": {"id": "ga4gh:SL.GHXCPrbd_qdPUoHjPwzv5iVFapJ0cn-o", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.XpQn9sZLGv_GU3uiWO7YHq9-_alGjrVX"}, "start": 841, "end": 842}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "civic.tid:5", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:282388"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "Disease", "label": "Systemic mastocytosis", "mappings": [{"coding": {"system": "ncit", "code": "C9235"}, "relation": "relatedMatch"}]}, {"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}, {"id": "hemonc:634", "type": "Disease", "label": "Myelodysplastic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C3247"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:33893", "type": "Disease", "label": "Chronic myelogenous leukemia pediatric"}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}, {"id": "hemonc:616", "type": "Disease", "label": "Hypereosinophilic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C27038"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C62035"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"]}, "tumorType": {"id": "civic.did:216", "label": "Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9305"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:162"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2469", "description": "In an in vitro study of imatinib sensitivity, KIT V560G was cloned into a plasmid by site-directed mutagenesis of KIT WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. The cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Protein lysates from the transfected cells were examined for the presence of phosphorylated tyrosine, a measure of KIT activation. Cells expressing KIT V560G were as sensitive to imatinib as ligand activated wildtype KIT (IC50: 100-200 nmol/L).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:412", "label": "Heinrich et al., 2003, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Heinrich et al., 2003, J. Clin. Oncol.", "pmid": 14645423}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:29", "label": "KIT", "description": "c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3815"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["C-Kit", "CD117", "KIT", "MASTC", "PBT", "SCFR"]}}, "direction": "refutes", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:946", "label": "KIT V560G", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 5.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "G", "representative_transcript": "ENST00000288135.5", "chromosome": "4", "start": 55593613, "stop": 55593613, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "972"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602398"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "375916"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376735"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913521"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["VAL560GLY", "RS121913521"], "members": [{"id": "ga4gh:VA.G32dhPdaIXg3th_iu6aXOfQys2yMrMnx", "label": "NC_000004.11:g.55593613T>G", "digest": "G32dhPdaIXg3th_iu6aXOfQys2yMrMnx", "type": "Allele", "location": {"id": "ga4gh:SL.dSrWFS7PMfm4pI1lOMkuEOGD6Gh2p72S", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54727446, "end": 54727447}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.kCuETK6eIgIJRVKYvZom7D6xM6em05iA", "label": "V560G", "digest": "kCuETK6eIgIJRVKYvZom7D6xM6em05iA", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_000222.2:c.1679T>G"}, {"syntax": "hgvs.p", "value": "NP_000213.1:p.Val560Gly"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55593613T>G"}, {"syntax": "hgvs.c", "value": "ENST00000288135.5:c.1679T>G"}], "location": {"id": "ga4gh:SL.xjCeL58wMAH2q4KMEcgogvUiNRC5EJ4X", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 559, "end": 560}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}}, "therapeutic": {"id": "civic.tid:5", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:282388"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "Disease", "label": "Systemic mastocytosis", "mappings": [{"coding": {"system": "ncit", "code": "C9235"}, "relation": "relatedMatch"}]}, {"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}, {"id": "hemonc:634", "type": "Disease", "label": "Myelodysplastic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C3247"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:33893", "type": "Disease", "label": "Chronic myelogenous leukemia pediatric"}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}, {"id": "hemonc:616", "type": "Disease", "label": "Hypereosinophilic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C27038"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C62035"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"]}, "tumorType": {"id": "civic.did:216", "label": "Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9305"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:162"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2472", "description": "In an in vitro study of imatinib sensitivity, KIT K642E was cloned into a plasmid by site-directed mutagenesis of KIT WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. Cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Then, protein lysates from the transfected cells were examined for phosphorylated tyrosine, a measure of KIT activation. Cells expressing KIT K642E were as sensitive to imatinib as ligand activated wildtype KIT (IC50: 100-200 nmol/L).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:412", "label": "Heinrich et al., 2003, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Heinrich et al., 2003, J. Clin. Oncol.", "pmid": 14645423}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:29", "label": "KIT", "description": "c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3815"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["C-Kit", "CD117", "KIT", "MASTC", "PBT", "SCFR"]}}, "direction": "refutes", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:952", "label": "KIT K642E", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 10.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "G", "representative_transcript": "ENST00000288135.5", "chromosome": "4", "start": 55594221, "stop": 55594221, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "978"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123547"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13866"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913512"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["LYS642GLU", "RS121913512"], "members": [{"id": "ga4gh:VA.VzsVyqlcWS87LveLKdzeYwvmm7lz9ie1", "label": "NC_000004.11:g.55594221A>G", "digest": "VzsVyqlcWS87LveLKdzeYwvmm7lz9ie1", "type": "Allele", "location": {"id": "ga4gh:SL.7PW790jMHV75G4i43nyFnA0wBi4smstb", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54728054, "end": 54728055}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.c3eVCAN6jp3r4vtwc3oFyMhn2omrwVB4", "label": "K642E", "digest": "c3eVCAN6jp3r4vtwc3oFyMhn2omrwVB4", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_000222.2:c.1924A>G"}, {"syntax": "hgvs.p", "value": "NP_000213.1:p.Lys642Glu"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55594221A>G"}, {"syntax": "hgvs.c", "value": "ENST00000288135.5:c.1924A>G"}], "location": {"id": "ga4gh:SL.WREnGgCj6j4vnGFA-gtJI9XkOJ5R6-ix", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 641, "end": 642}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "civic.tid:5", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:282388"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "Disease", "label": "Systemic mastocytosis", "mappings": [{"coding": {"system": "ncit", "code": "C9235"}, "relation": "relatedMatch"}]}, {"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}, {"id": "hemonc:634", "type": "Disease", "label": "Myelodysplastic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C3247"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:33893", "type": "Disease", "label": "Chronic myelogenous leukemia pediatric"}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}, {"id": "hemonc:616", "type": "Disease", "label": "Hypereosinophilic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C27038"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C62035"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"]}, "tumorType": {"id": "civic.did:216", "label": "Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9305"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:162"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2481", "description": "In an in vitro study of imatinib sensitivity, KIT W557_K558del was cloned into a plasmid by site-directed mutagenesis of KIT WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. Cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Protein lysates from the transfected cells were examined for phosphorylated tyrosine, a measure of KIT activation. Cells expressing KIT W557_K558del were as sensitive to imatinib as ligand activated wildtype KIT (IC50: 100-200 nmol/L).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:412", "label": "Heinrich et al., 2003, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Heinrich et al., 2003, J. Clin. Oncol.", "pmid": 14645423}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:29", "label": "KIT", "description": "c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3815"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["C-Kit", "CD117", "KIT", "MASTC", "PBT", "SCFR"]}}, "direction": "refutes", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:935", "label": "KIT W557_K558del", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 14.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "TGGAAG", "representative_transcript": "ENST00000288135.5", "chromosome": "4", "start": 55593603, "stop": 55593608, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "conservative_inframe_deletion", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001825"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "961"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA356974"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "222957"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.-0OOWY5vOXkNYm5Z0RXu2KkfAlKQP2uY", "label": "W557_K558del", "digest": "-0OOWY5vOXkNYm5Z0RXu2KkfAlKQP2uY", "type": "Allele", "location": {"id": "ga4gh:SL.Qlyg5JEGgGMGca_5rxiWtYk7c8GWZc0P", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 556, "end": 558}, "state": {"type": "ReferenceLengthExpression", "length": 0, "sequence": "", "repeatSubunitLength": 2}}}, "therapeutic": {"id": "civic.tid:5", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:282388"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "Disease", "label": "Systemic mastocytosis", "mappings": [{"coding": {"system": "ncit", "code": "C9235"}, "relation": "relatedMatch"}]}, {"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}, {"id": "hemonc:634", "type": "Disease", "label": "Myelodysplastic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C3247"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:33893", "type": "Disease", "label": "Chronic myelogenous leukemia pediatric"}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}, {"id": "hemonc:616", "type": "Disease", "label": "Hypereosinophilic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C27038"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C62035"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"]}, "tumorType": {"id": "civic.did:216", "label": "Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9305"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:162"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2484", "description": "In an in vitro study of imatinib sensitivity, KIT Y503_F504insAY was cloned into a plasmid by site-directed mutagenesis of KIT WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. Cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Then, protein lysates from the transfected cells were examined for phosphorylated tyrosine, a measure of KIT activation. Cells expressing KIT Y503_F504insAY were as sensitive to imatinib as ligand activated wildtype KIT (IC50: 100-200 nmol/L).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:412", "label": "Heinrich et al., 2003, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Heinrich et al., 2003, J. Clin. Oncol.", "pmid": 14645423}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:29", "label": "KIT", "description": "c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3815"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["C-Kit", "CD117", "KIT", "MASTC", "PBT", "SCFR"]}}, "direction": "refutes", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:920", "label": "KIT Y503_F504insAY", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 2.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "variant_bases": "GCCTAT", "representative_transcript": "ENST00000288135.5", "chromosome": "4", "start": 55592185, "stop": 55592186, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "inframe_insertion", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001821"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "946"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA645516719"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "members": [{"id": "ga4gh:VA.q4LDx7kavJDEj27N93Bi2UNpTyw4a738", "label": "NC_000004.11:g.55592185_55592186insGCCTAT", "digest": "q4LDx7kavJDEj27N93Bi2UNpTyw4a738", "type": "Allele", "location": {"id": "ga4gh:SL.hanuInWbcBPSNYFacNGcUcnBSLGV2VH6", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54726012, "end": 54726019}, "state": {"type": "ReferenceLengthExpression", "length": 13, "sequence": "TGCCTATGCCTAT", "repeatSubunitLength": 6}}], "definingContext": {"id": "ga4gh:VA.KZM6qWVU3LTyhZ54Y_4LwrCKfPWTQ2z-", "label": "Y503_F504insAY", "digest": "KZM6qWVU3LTyhZ54Y_4LwrCKfPWTQ2z-", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000004.11:g.55592185_55592186insGCCTAT"}], "location": {"id": "ga4gh:SL.MVpLcK_uhnnilZkBz7MoAEUZAJgZcBS9", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 501, "end": 503}, "state": {"type": "ReferenceLengthExpression", "length": 4, "sequence": "AYAY", "repeatSubunitLength": 2}}}, "therapeutic": {"id": "civic.tid:5", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:282388"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "Disease", "label": "Systemic mastocytosis", "mappings": [{"coding": {"system": "ncit", "code": "C9235"}, "relation": "relatedMatch"}]}, {"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}, {"id": "hemonc:634", "type": "Disease", "label": "Myelodysplastic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C3247"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:33893", "type": "Disease", "label": "Chronic myelogenous leukemia pediatric"}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}, {"id": "hemonc:616", "type": "Disease", "label": "Hypereosinophilic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C27038"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C62035"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"]}, "tumorType": {"id": "civic.did:216", "label": "Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9305"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:162"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2625", "description": "In an in vitro study using PC9 cells (EGFR exon 19 deletion), inhibition of cell viability was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. PC9 cells demonstrated an increased sensitivity to gefitinib (IC50: 23.0 nmol/L vs 200.0 nmol/L) compared to NCI-H2073 cells (EGFR wild type).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:665", "label": "Cross et al., 2014, Cancer Discov", "type": "Document", "title": "PubMed: Cross et al., 2014, Cancer Discov", "pmid": 24893891}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:976", "label": "EGFR E746_A750del", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 19.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "GGAATTAAGAGAAGC", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55242465, "stop": 55242479, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "inframe_deletion", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001822"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1002"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA175996"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "163343"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913421"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913421", "E746_A750DELELREA"], "definingContext": {"id": "ga4gh:VA.Ey1-CesK8oo-eXa_cmB-4HfLUcltVDYL", "label": "E746_A750del", "digest": "Ey1-CesK8oo-eXa_cmB-4HfLUcltVDYL", "type": "Allele", "location": {"id": "ga4gh:SL.HiZy3E33xYU7hmo3ATl-_NSUCbexpZRq", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 745, "end": 750}, "state": {"type": "ReferenceLengthExpression", "length": 0, "sequence": "", "repeatSubunitLength": 5}}}, "therapeutic": {"id": "civic.tid:14", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:328134"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1855"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2629", "description": "In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated an improved response to afatinib (IC50: 0.7nM vs. 60nM) compared to wildtype EGFR cells.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1525", "label": "Li et al., 2008, Oncogene", "type": "Document", "title": "PubMed: Li et al., 2008, Oncogene", "pmid": 18408761}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:33", "label": "EGFR L858R", "description": "EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 379.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "G", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55259515, "stop": 55259515, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "33"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA126713"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16609"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376282"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376280"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434568"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121434568", "LEU858ARG"], "members": [{"id": "ga4gh:VA.TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "label": "NC_000007.13:g.55259515T>G", "digest": "TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "type": "Allele", "location": {"id": "ga4gh:SL.ulUNwZvajob7nzyrlpOd6uUWZIYCsoWb", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55191821, "end": 55191822}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "label": "L858R", "digest": "z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000007.13:g.55259515T>G"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2573T>G"}, {"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2573T>G"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Leu858Arg"}], "location": {"id": "ga4gh:SL.yVGJnwqxV6oCGqC_8nNb58D_wPXJeNJo", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 857, "end": 858}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:146", "label": "Afatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1430438"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:25316", "type": "Disease", "label": "Non-small cell lung cancer squamous"}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C66940"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide", "BIBW 2992", "BIBW2992"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2837", "description": "Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the D1930V variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the D1930V variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 88% of cells by FISH. Western blot showed null ATM expression. Treatment with doxorubicin resulted in p21 expression greater than 300% that of untreated wild-type controls. This was considered by the authors to be similar to treated wild-type controls with a median expression level 815% that of untreated controls suggesting this variant does not support resistance.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1541", "label": "Navrkalova et al., 2013, Haematologica", "type": "Document", "title": "PubMed: Navrkalova et al., 2013, Haematologica", "pmid": 23585524}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:69", "label": "ATM", "description": "Ataxia-telangiectasia (A-T) is a recessive disorder resulting from germline mutation of the A-T mutated (ATM) gene on chromosome 11q. Upon sensing double-stranded breaks (DSB), the wild-type kinase encoded by ATM initiates the DNA-damage response by phosphorylating histone H2AX and, subsequently, various other proteins, such as BRCA1 and the MRE11\u2013RAD50\u2013NBS1 (MRN) complex, which are recruited to the damaged site. Additionally, ATM phosphorylates p53, resulting in expression of the cyclin-dependent kinase inhibitor p21 and leading to senescence or apoptosis. Somatic variants can result in inhibition or loss of these functions and can cause resistance to therapies that rely on inducing apoptosis via DSBs. Germline variants in A-T patients result in a predisposition to cancer, most frequently hematologic or breast. PARP inhibition has been studied for its potential in treating ATM mutated breast cancer patients.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:795"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:472"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["AT1", "ATA", "ATC", "ATD", "ATDC", "ATE", "ATM", "TEL1", "TELO1"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1134", "label": "ATM D1930V", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 2.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000278616.4", "chromosome": "11", "start": 108180913, "stop": 108180913, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1160"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA382548326"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ASP1930VAL", "M72L", "MET72LEU"], "members": [{"id": "ga4gh:VA.l_SWvfwc8L1BoIQxVWnxwSoM421mjqcA", "label": "NC_000011.9:g.108180913A>T", "digest": "l_SWvfwc8L1BoIQxVWnxwSoM421mjqcA", "type": "Allele", "location": {"id": "ga4gh:SL.c14oX9oKybXkezwWoRoAm4TP8EhUghsD", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.2NkFm8HK88MqeNkCgj78KidCAXgnsfV1"}, "start": 108310185, "end": 108310186}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.MYUvUnqWUiso_P90pd64Dn8HwqXBqYrP", "label": "D1930V", "digest": "MYUvUnqWUiso_P90pd64Dn8HwqXBqYrP", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000278616.4:c.5789A>T"}, {"syntax": "hgvs.g", "value": "NC_000011.9:g.108180913A>T"}, {"syntax": "hgvs.c", "value": "NM_000051.3:c.5789A>T"}, {"syntax": "hgvs.p", "value": "NP_000042.3:p.Asp1930Val"}], "location": {"id": "ga4gh:SL.CUFXBGgtztPpgfaVycg3xI04YYams0UI", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6k1y4bTo7pEJ-a1GaniRBaCJXXGkBGFO"}, "start": 1929, "end": 1930}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "civic.tid:68", "label": "Doxorubicin", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:142433"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:552", "type": "Disease", "label": "Acute myeloid leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3171"}, "relation": "relatedMatch"}]}, {"id": "hemonc:675", "type": "Disease", "label": "Thyroid cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7510"}, "relation": "relatedMatch"}]}, {"id": "hemonc:572", "type": "Disease", "label": "Breast cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9335"}, "relation": "relatedMatch"}]}, {"id": "hemonc:569", "type": "Disease", "label": "Bladder cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9334"}, "relation": "relatedMatch"}]}, {"id": "hemonc:601", "type": "Disease", "label": "Gastric cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9331"}, "relation": "relatedMatch"}]}, {"id": "hemonc:614", "type": "Disease", "label": "Hodgkin lymphoma", "mappings": [{"coding": {"system": "ncit", "code": "C9357"}, "relation": "relatedMatch"}]}, {"id": "hemonc:666", "type": "Disease", "label": "Small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C4917"}, "relation": "relatedMatch"}]}, {"id": "hemonc:645", "type": "Disease", "label": "Ovarian cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7431"}, "relation": "relatedMatch"}]}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C456"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione", "(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione", "14-Hydroxydaunomycin", "Adriablastin", "Hydroxydaunomycin", "Hydroxyl Daunorubicin", "Hydroxyldaunorubicin"]}, "tumorType": {"id": "civic.did:52", "label": "Chronic Lymphocytic Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3163"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1040"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2888", "description": "28 acral or mucosal melanomas were examined for KIT expression and mutations (exons 11, 13, 17, and 18). Two of 19 melanomas examined harbored KIT mutations, with one subject harboring a D820Y mutation. Western blotting showed KIT phosphorylation (Y219) in this case and the SM3 cell line harboring the D820Y mutation. The SM3 cell line showed significant growth inhibition with sunitinib exposures of 1uM and 10uM while imatinib showed no activity. The authors comment that this indicates a potential role for sunitinib in growth inhibition of acral melanomas.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1648", "label": "Ashida et al., 2009, Int. J. Cancer", "type": "Document", "title": "PubMed: Ashida et al., 2009, Int. J. Cancer", "pmid": 19035443}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:29", "label": "KIT", "description": "c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3815"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["C-Kit", "CD117", "KIT", "MASTC", "PBT", "SCFR"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:960", "label": "KIT D820Y", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 14.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "T", "representative_transcript": "ENST00000288135.5", "chromosome": "4", "start": 55599332, "stop": 55599332, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "986"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602408"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "375928"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS1057519710"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS1057519710", "ASP820TYR"], "members": [{"id": "ga4gh:VA.5r-C3LlZD9ZUxpzHonsY_73ObMcsnLfe", "label": "NC_000004.11:g.55599332G>T", "digest": "5r-C3LlZD9ZUxpzHonsY_73ObMcsnLfe", "type": "Allele", "location": {"id": "ga4gh:SL.U-4Q2T2UMOZypgIGPT5ywR4z_1iS_0S2", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54733165, "end": 54733166}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.eRIxjMxh82kLJLDQDT9QFEkAStdnxgEA", "label": "D820Y", "digest": "eRIxjMxh82kLJLDQDT9QFEkAStdnxgEA", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_000222.2:c.2458G>T"}, {"syntax": "hgvs.p", "value": "NP_000213.1:p.Asp820Tyr"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55599332G>T"}, {"syntax": "hgvs.c", "value": "ENST00000288135.5:c.2458G>T"}], "location": {"id": "ga4gh:SL.IP0kMJA-uoNQiQegymLJcTzqq32pKPm2", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 819, "end": 820}, "state": {"type": "LiteralSequenceExpression", "sequence": "Y"}}}, "therapeutic": {"id": "civic.tid:157", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:357977"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:647", "type": "Disease", "label": "Pancreatic NET", "mappings": [{"coding": {"system": "ncit", "code": "C27720"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:660", "type": "Disease", "label": "Renal cell carcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C9385"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C71622"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"]}, "tumorType": {"id": "civic.did:7", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3224"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1909"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2936", "description": "Mutational profiling of 207 lung adenocarcinomas identified in 2 of with activating mutation in exon 2 of MEK1 (K57N) in the nonkinase portion of the kinase. Neither of these two tumors harbored known mutations in other genes encoding components of the EGFR signaling pathway (i.e., EGFR, HER2, KRAS, PIK3CA, and BRAF). Expression of mutant, but not wild-type, MEK1 leads to constitutive activity of extracellular signal-regulated kinase (ERK)-1/2 in human 293T cells and to growth factor-independent proliferation of murine Ba/F3 cells. A selective MEK inhibitor, AZD6244, inhibits mutant-induced ERK activity in 293T cells and growth of mutant-bearing Ba/F3 cells.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1685", "label": "Marks et al., 2008, Cancer Res.", "type": "Document", "title": "PubMed: Marks et al., 2008, Cancer Res.", "pmid": 18632602}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:31", "label": "MAP2K1", "description": "MAP2K1 is a dual-specificity kinase known for it's involvement in the ERK pathway by activation of ERK1 and ERK2. MAP2K1 activating mutations have been observed in a number of cancers including ovarian,  melanoma and lung. These activating mutations are generally found in the N-terminal negative regulatory region or the ATP-binding region of the N-terminal lobe.  Inhibitors of MEK genes have been shown to inhibit tumor growth in these cases.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6840"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5604"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CFC3", "MAP2K1", "MAPKK1", "MEK1", "MEL", "MKK1", "PRKMK1"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1246", "label": "MAP2K1 K57N", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 17.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "T", "representative_transcript": "ENST00000307102.5", "chromosome": "15", "start": 66727455, "stop": 66727455, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1272"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA356995"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "223140"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS869025608"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS869025608", "LYS57ASN"], "members": [{"id": "ga4gh:VA.aUmJ94g49f8LaTEPl1mZmycs0SolVrRM", "label": "NC_000015.9:g.66727455G>T", "digest": "aUmJ94g49f8LaTEPl1mZmycs0SolVrRM", "type": "Allele", "location": {"id": "ga4gh:SL.lUG_pd6WKhn-L0OAPB9wqzswNwEdJxNC", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.AsXvWL1-2i5U_buw6_niVIxD6zTbAuS6"}, "start": 66435116, "end": 66435117}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.NJDZJptyZzI8-GEidG5SNtTw6vBLEqAP", "label": "K57N", "digest": "NJDZJptyZzI8-GEidG5SNtTw6vBLEqAP", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_002755.3:c.171G>T"}, {"syntax": "hgvs.p", "value": "NP_002746.1:p.Lys57Asn"}, {"syntax": "hgvs.g", "value": "NC_000015.9:g.66727455G>T"}, {"syntax": "hgvs.c", "value": "ENST00000307102.5:c.171G>T"}, {"syntax": "hgvs.g", "value": "NG_008305.1:g.53245G>T"}], "location": {"id": "ga4gh:SL.bHHmP1_UKJrEDsiajMaJXKZ1WKFN04CB", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.StlJo3M4b8cS253ufe9nPpWqQHBDOSPs"}, "start": 56, "end": 57}, "state": {"type": "LiteralSequenceExpression", "sequence": "N"}}}, "therapeutic": {"id": "civic.tid:63", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:2289380"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C66939"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["ARRY-142886", "AZD6244", "MEK Inhibitor AZD6244"]}, "tumorType": {"id": "civic.did:30", "label": "Lung Adenocarcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3512"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3910"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:3710", "description": "In an in vitro study, a human colon adenocarcinoma SW48 cell line virally transduced to express KRAS G12A demonstrated resistance to regorafenib treatment (IC50: 330.13 nM vs. 114.28 nM, P<0.01, reported errantly as 3301.13nM in the source) compared to SW48 cells expressing KRAS wild-type. Resistance was determined by assessing cell viability. Authors concluded that KRAS G12A was more strongly resistant to regorafenib than KRAS wt and other KRAS G12/G13 mutations.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1935", "label": "Camaj et al., 2015, Future Oncol", "type": "Document", "title": "PubMed: Camaj et al., 2015, Future Oncol", "pmid": 26161928}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:148", "label": "KRAS G12A", "description": "KRAS G12A, like EGFR T790M, has been shown to be capable of driving acquired resistance to tyrosine kinase inhibitors in lung adenocarcinoma.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 63.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "G", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398284, "stop": 25398284, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "148"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA135567"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "45122"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913529"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913529", "GLY12ALA"], "members": [{"id": "ga4gh:VA.7-dFeRWXiDXaQi2ytNFtQt6FAxK65H7Q", "label": "NC_000012.11:g.25398284C>G", "digest": "7-dFeRWXiDXaQi2ytNFtQt6FAxK65H7Q", "type": "Allele", "location": {"id": "ga4gh:SL.iF0OXeO-tnumYbGkzaFEQ7cOZI_UCI1s", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245349, "end": 25245350}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.PtBjoq-ApuaPycxEHH7z31bGtezbAoyU", "label": "G12A", "digest": "PtBjoq-ApuaPycxEHH7z31bGtezbAoyU", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004985.4:c.35G>C"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly12Ala"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398284C>G"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.35G>C"}], "location": {"id": "ga4gh:SL.OndkjmujtyUEZSjjCv0C-gpwnVbRgfj8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}}, "therapeutic": {"id": "civic.tid:27", "label": "Regorafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1312397"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C78204"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide", "BAY 73-4506", "REGORAFENIB ANHYDROUS", "Stivarga"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:3722", "description": "An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype PIK3CA and BRAF V600E (a known BRAF inhibitor sensitizing mutation) used PIK3CA E545K as a positive control for testing resistance to BRAF inhibition by vemurafenib. M229 cells virally transduced with PIK3CA E545K were significantly more resistant to vemurafenib-mediated growth suppression than cells transduced with empty vectors (50% vs 20% survival at the highest concentration, p <.0001). Furthermore, E545K appears to confer more resistance to vemurafenib than PIK3CA D350G and similar levels of resistance as E545G. Resistance was determined by assessing cell survival.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1941", "label": "Shi et al., 2014, Cancer Discov", "type": "Document", "title": "PubMed: Shi et al., 2014, Cancer Discov", "pmid": 24265155}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:104", "label": "PIK3CA E545K", "description": "PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 77.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000263967.3", "chromosome": "3", "start": 178936091, "stop": 178936091, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "104"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123334"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13655"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS104886003"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLU545LYS", "RS104886003"], "members": [{"id": "ga4gh:VA.uqD1zF6cMOYhBp8ur5oLTMqV0jxiC2a7", "label": "NC_000003.11:g.178936091G>A", "digest": "uqD1zF6cMOYhBp8ur5oLTMqV0jxiC2a7", "type": "Allele", "location": {"id": "ga4gh:SL.5l5tuxgJGb8y7CQzkKLPUvS-Cx4kr2ju", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 179218302, "end": 179218303}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.uw7DyLM7r98pn66LOXU3tAknmkV7jiJ0", "label": "E545K", "digest": "uw7DyLM7r98pn66LOXU3tAknmkV7jiJ0", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006218.3:c.1633G>A"}, {"syntax": "hgvs.p", "value": "NP_006209.2:p.Glu545Lys"}, {"syntax": "hgvs.c", "value": "ENST00000263967.3:c.1633G>A"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.178936091G>A"}], "location": {"id": "ga4gh:SL.SrEa0lPyesLrOX0M_aW51d-JdJhU-D3p", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 544, "end": 545}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:7", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3224"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1909"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:3724", "description": "An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype PIK3CA and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells virally induced to stably over-express PIK3CA E545G were significantly more resistant to BRAF inhibition by vemurafenib than cells transduced with an empty vector (50% vs 20% survival at the highest concentration, p < .0001). Though statistics were not provided, E545G appears to confer similar levels of resistance to vemurafenib as the positive control variant, PIK3CA E545K.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1941", "label": "Shi et al., 2014, Cancer Discov", "type": "Document", "title": "PubMed: Shi et al., 2014, Cancer Discov", "pmid": 24265155}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:857", "label": "PIK3CA E545G", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 2.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "G", "representative_transcript": "ENST00000263967.3", "chromosome": "3", "start": 178936092, "stop": 178936092, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "883"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123336"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13656"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913274"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLU545GLY", "RS121913274"], "members": [{"id": "ga4gh:VA.xx5iQAtlm2hRJams6rLacyOblG2DvQCW", "label": "NC_000003.11:g.178936092A>G", "digest": "xx5iQAtlm2hRJams6rLacyOblG2DvQCW", "type": "Allele", "location": {"id": "ga4gh:SL.2TuCUU4hWBMFR43czvG3qITKGTs3xf3P", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 179218303, "end": 179218304}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.4-P9VYcskRjr1rJxwQxgXEpV3qkWldhv", "label": "E545G", "digest": "4-P9VYcskRjr1rJxwQxgXEpV3qkWldhv", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006218.3:c.1634A>G"}, {"syntax": "hgvs.p", "value": "NP_006209.2:p.Glu545Gly"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.178936092A>G"}, {"syntax": "hgvs.c", "value": "ENST00000263967.3:c.1634A>G"}], "location": {"id": "ga4gh:SL.SrEa0lPyesLrOX0M_aW51d-JdJhU-D3p", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 544, "end": 545}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:7", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3224"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1909"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:3924", "description": "In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS G12V mutation demonstrated resistance to regorafenib treatment (IC50: 241.90 nM vs. 114.28 nM, P<0.01) compared to SW48 cells expressing KRAS wildtype. Resistance was determined by assessing cell viability. Regorafenib significantly reduced BRAF, Erk1/2 and Elk phosphorylation compared to wildtype, as assessed by western blot. Authors concluded that KRAS G12A was more resistant to regorafenib than KRAS wt, and intermediately resistant compared to other common KRAS mutations.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1935", "label": "Camaj et al., 2015, Future Oncol", "type": "Document", "title": "PubMed: Camaj et al., 2015, Future Oncol", "pmid": 26161928}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:421", "label": "KRAS G12V", "description": "KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 67.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "A", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398284, "stop": 25398284, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "425"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA122540"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12583"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913529"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913529", "GLY12VAL"], "members": [{"id": "ga4gh:VA.-SzXMvMSRoSJgvsIDz-7M7VTFdo4FCtA", "label": "NC_000012.11:g.25398284C>A", "digest": "-SzXMvMSRoSJgvsIDz-7M7VTFdo4FCtA", "type": "Allele", "location": {"id": "ga4gh:SL.iF0OXeO-tnumYbGkzaFEQ7cOZI_UCI1s", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245349, "end": 25245350}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.JTtvYJD7yl02AOq09HjSZDUnfg4gYdUb", "label": "G12V", "digest": "JTtvYJD7yl02AOq09HjSZDUnfg4gYdUb", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004985.4:c.35G>T"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly12Val"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398284C>A"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.35G>T"}], "location": {"id": "ga4gh:SL.OndkjmujtyUEZSjjCv0C-gpwnVbRgfj8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "civic.tid:27", "label": "Regorafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1312397"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C78204"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide", "BAY 73-4506", "REGORAFENIB ANHYDROUS", "Stivarga"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:3957", "description": "In vitro studies of M229 (a human melanoma cell line) endogenously expressing wildtype KRAS and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells virally induced to stably over-express KRAS4a G12D or KRAS4b G12D  were more resistant to vemurafenib (a BRAF inhibitor) than cells transduced with empty vectors (90% vs 10% survival).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1941", "label": "Shi et al., 2014, Cancer Discov", "type": "Document", "title": "PubMed: Shi et al., 2014, Cancer Discov", "pmid": 24265155}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:79", "label": "KRAS G12D", "description": "While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 162.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398284, "stop": 25398284, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "79"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA122538"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12582"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913529"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913529", "GLY12ASP"], "members": [{"id": "ga4gh:VA.qOYg4yYK-1Je25G30BkV3dWKtKDIAFEJ", "label": "NC_000012.11:g.25398284C>T", "digest": "qOYg4yYK-1Je25G30BkV3dWKtKDIAFEJ", "type": "Allele", "location": {"id": "ga4gh:SL.iF0OXeO-tnumYbGkzaFEQ7cOZI_UCI1s", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245349, "end": 25245350}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.CB571ja_KfZM_Hjn9zjjgV1an3tDWRcl", "label": "G12D", "digest": "CB571ja_KfZM_Hjn9zjjgV1an3tDWRcl", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004985.4:c.35G>A"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly12Asp"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398284C>T"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.35G>A"}], "location": {"id": "ga4gh:SL.OndkjmujtyUEZSjjCv0C-gpwnVbRgfj8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "D"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:7", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3224"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1909"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:3973", "description": "In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS G12C mutation demonstrated resistance to regorafenib treatment (IC50: 386.22 nM vs. 114.28 nM, P<0.01) compared to SW48 cells expressing KRAS wild-type. Resistance was determined by assessing cell viability. In vivo, KRAS G12C expressing SW48 cells were injected into NOD/SCID mice. Treatment with regorafenib did not lead to a significant delay of tumor growth. Mice injected with KRAS wt cells did not significantly respond to regorafenib, although a trend was seen toward better response. IHC analysis of mouse tissue revealed no significant change in markers of proliferation (Ki67), angiogenesis (CD31) and apoptosis (TUNEL) in KRAS G12C expressing mice treated with regorafenib compared to KRAS wt expressing mice whose tumors displayed more pronounced changes. Authors concluded that G12C was more resistant to regorafenib than KRAS wt and other common KRAS G12/G13 mutants.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1935", "label": "Camaj et al., 2015, Future Oncol", "type": "Document", "title": "PubMed: Camaj et al., 2015, Future Oncol", "pmid": 26161928}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:78", "label": "KRAS G12C", "description": "While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 136.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "A", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398285, "stop": 25398285, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "78"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA122528"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12578"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913530"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLY12CYS", "RS121913530"], "members": [{"id": "ga4gh:VA.ONAtlY1naHPhc7I2cFH6POy4zmWKukHw", "label": "NC_000012.11:g.25398285C>A", "digest": "ONAtlY1naHPhc7I2cFH6POy4zmWKukHw", "type": "Allele", "location": {"id": "ga4gh:SL.AiE9G9ocxKfBfR5PRN_ktoggZzig8OcG", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245350, "end": 25245351}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.94GquHCCcRi74uwlI5PGJsf6FsR2M7Ef", "label": "G12C", "digest": "94GquHCCcRi74uwlI5PGJsf6FsR2M7Ef", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004985.4:c.34G>T"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly12Cys"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398285C>A"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.34G>T"}], "location": {"id": "ga4gh:SL.OndkjmujtyUEZSjjCv0C-gpwnVbRgfj8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "civic.tid:27", "label": "Regorafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1312397"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C78204"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide", "BAY 73-4506", "REGORAFENIB ANHYDROUS", "Stivarga"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4012", "description": "In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS G12S mutation demonstrated resistance to regorafenib treatment (IC50: 264.23 nM vs. 114.28 nM, P<0.01) compared to SW48 cells expressing KRAS wild-type. Resistance was determined by assessing cell viability. Authors concluded that KRAS G12S was more resistant to regorafenib than KRAS wt, and intermediately resistant compared to other common KRAS G12/G13 mutations.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1935", "label": "Camaj et al., 2015, Future Oncol", "type": "Document", "title": "PubMed: Camaj et al., 2015, Future Oncol", "pmid": 26161928}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:887", "label": "KRAS G12S", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 38.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398285, "stop": 25398285, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "913"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA135565"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12584"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913530"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLY12SER", "RS121913530"], "members": [{"id": "ga4gh:VA.PnoqUPOSplj2ReUhO0vv3Uwz7urotLNW", "label": "NC_000012.11:g.25398285C>T", "digest": "PnoqUPOSplj2ReUhO0vv3Uwz7urotLNW", "type": "Allele", "location": {"id": "ga4gh:SL.AiE9G9ocxKfBfR5PRN_ktoggZzig8OcG", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245350, "end": 25245351}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.BqLbpvUuI1si3-JoDB-imd4p6DIJVXlO", "label": "G12S", "digest": "BqLbpvUuI1si3-JoDB-imd4p6DIJVXlO", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004985.4:c.34G>A"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly12Ser"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398285C>T"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.34G>A"}], "location": {"id": "ga4gh:SL.OndkjmujtyUEZSjjCv0C-gpwnVbRgfj8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "S"}}}, "therapeutic": {"id": "civic.tid:27", "label": "Regorafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1312397"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C78204"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide", "BAY 73-4506", "REGORAFENIB ANHYDROUS", "Stivarga"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4056", "description": "In an in vitro study, Chinese hamster ovary cells expressing PDGFRA V561D mutation demonstrated sensitivity to sunitinib treatment (IC50<100), though this sensitivity was indistinguishable from Chinese hamster ovary cells expressing wild-type PDGFRA. Sensitivity was determined by assessing PDGFRA auto-phosphorylation.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:965", "label": "Heinrich et al., 2008, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Heinrich et al., 2008, J. Clin. Oncol.", "pmid": 18955458}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:38", "label": "PDGFRA", "description": "Commonly mutated in GI tract tumors, PDGFR family genes (mutually exclusive to KIT mutations) are a hallmark of gastrointestinal stromal tumors. Gene fusions involving the PDGFRA kinase domain are highly correlated with eosinophilia, and the WHO classifies myeloid and lymphoid neoplasms with these characteristics as a distinct disorder. Mutations in the 842 region of PDGFRA have been often found to confer resistance to the tyrosine kinase inhibitor, imatinib.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8803"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5156"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD140A", "PDGFR-2", "PDGFR2", "PDGFRA"]}}, "direction": "refutes", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:915", "label": "PDGFRA V561D", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 8.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "A", "representative_transcript": "ENST00000257290.5", "chromosome": "4", "start": 55141036, "stop": 55141036, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "941"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123203"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13546"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121908586"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121908586"], "members": [{"id": "ga4gh:VA.RVDCfTK9KrX96TVgvOUcAv--OnQUdV8O", "label": "NC_000004.11:g.55141036T>A", "digest": "RVDCfTK9KrX96TVgvOUcAv--OnQUdV8O", "type": "Allele", "location": {"id": "ga4gh:SL.h44ZIUE0VWLc8ONz8JwqUOUCvADE8Ozc", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54274868, "end": 54274869}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.OFhYwJu_e2ktWF9N-_SrpmKx44fbeyto", "label": "V561D", "digest": "OFhYwJu_e2ktWF9N-_SrpmKx44fbeyto", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006206.5:c.1682T>A"}, {"syntax": "hgvs.p", "value": "NP_006197.1:p.Val561Asp"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55141036T>A"}, {"syntax": "hgvs.c", "value": "ENST00000257290.5:c.1682T>A"}], "location": {"id": "ga4gh:SL.QB_e8RED6euCq3v0AQJcTcXmXd4p286t", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.XpQn9sZLGv_GU3uiWO7YHq9-_alGjrVX"}, "start": 560, "end": 561}, "state": {"type": "LiteralSequenceExpression", "sequence": "D"}}}, "therapeutic": {"id": "civic.tid:157", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:357977"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:647", "type": "Disease", "label": "Pancreatic NET", "mappings": [{"coding": {"system": "ncit", "code": "C27720"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:660", "type": "Disease", "label": "Renal cell carcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C9385"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C71622"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"]}, "tumorType": {"id": "civic.did:216", "label": "Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9305"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:162"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4060", "description": "In an in vitro study, Chinese hamster ovary cells expressing PDGFRA D842V mutation demonstrated reduced sensitivity to sunitinib treatment (IC50>1000 vs. IC50<100), compared to Chinese hamster ovary cells expressing wild-type PDGFRA. Sensitivity was determined by assessing PDGFRA auto-phosphorylation.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:965", "label": "Heinrich et al., 2008, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Heinrich et al., 2008, J. Clin. Oncol.", "pmid": 18955458}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:38", "label": "PDGFRA", "description": "Commonly mutated in GI tract tumors, PDGFR family genes (mutually exclusive to KIT mutations) are a hallmark of gastrointestinal stromal tumors. Gene fusions involving the PDGFRA kinase domain are highly correlated with eosinophilia, and the WHO classifies myeloid and lymphoid neoplasms with these characteristics as a distinct disorder. Mutations in the 842 region of PDGFRA have been often found to confer resistance to the tyrosine kinase inhibitor, imatinib.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8803"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5156"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD140A", "PDGFR-2", "PDGFR2", "PDGFRA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:99", "label": "PDGFRA D842V", "description": "PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. Exogenous expression of the A842V mutation resulted in constitutive tyrosine phosphorylation of PDGFRA in the absence of ligand in 293T cells and cytokine-independent proliferation of the IL-3-dependent Ba/F3 cell line, both evidence that this is an activating mutation. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 100.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000257290.5", "chromosome": "4", "start": 55152093, "stop": 55152093, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "99"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123194"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13543"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121908585"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ASP842VAL", "RS121908585"], "members": [{"id": "ga4gh:VA.bDwkJ2filJ3ZGiUFybGFfyaCKdIVK86v", "label": "NC_000004.11:g.55152093A>T", "digest": "bDwkJ2filJ3ZGiUFybGFfyaCKdIVK86v", "type": "Allele", "location": {"id": "ga4gh:SL.LxO2YLfQbI_-TK7GOmSoOpMNiSy_Hgan", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54285925, "end": 54285926}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.vIjnL-aLYl0BSB6JutpdD7yW_qIXtdk8", "label": "D842V", "digest": "vIjnL-aLYl0BSB6JutpdD7yW_qIXtdk8", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006206.4:c.2525A>T"}, {"syntax": "hgvs.p", "value": "NP_006197.1:p.Asp842Val"}, {"syntax": "hgvs.c", "value": "ENST00000257290.5:c.2525A>T"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55152093A>T"}], "location": {"id": "ga4gh:SL.GHXCPrbd_qdPUoHjPwzv5iVFapJ0cn-o", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.XpQn9sZLGv_GU3uiWO7YHq9-_alGjrVX"}, "start": 841, "end": 842}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "civic.tid:157", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:357977"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:647", "type": "Disease", "label": "Pancreatic NET", "mappings": [{"coding": {"system": "ncit", "code": "C27720"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:660", "type": "Disease", "label": "Renal cell carcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C9385"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C71622"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"]}, "tumorType": {"id": "civic.did:216", "label": "Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9305"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:162"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4077", "description": "In an in vitro study, Chinese hamster ovary cells expressing KIT V560D demonstrated comparable sensitivity to sunitinib treatment compared to cells expressing ligand activated wild-type KIT (IC50<100 nmol/L). Sensitivity was determined by assessing KIT auto-phosphorylation.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:965", "label": "Heinrich et al., 2008, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Heinrich et al., 2008, J. Clin. Oncol.", "pmid": 18955458}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:29", "label": "KIT", "description": "c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3815"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["C-Kit", "CD117", "KIT", "MASTC", "PBT", "SCFR"]}}, "direction": "refutes", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:945", "label": "KIT V560D", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 14.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "A", "representative_transcript": "ENST00000288135.5", "chromosome": "4", "start": 55593613, "stop": 55593613, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "971"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602396"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "375914"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913521"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["VAL560ASP", "RS121913521"], "members": [{"id": "ga4gh:VA.DEtz2mJjlbwY6JoXYkr8EqhQY7XknzpB", "label": "NC_000004.11:g.55593613T>A", "digest": "DEtz2mJjlbwY6JoXYkr8EqhQY7XknzpB", "type": "Allele", "location": {"id": "ga4gh:SL.dSrWFS7PMfm4pI1lOMkuEOGD6Gh2p72S", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54727446, "end": 54727447}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.6kMa53-8b1JK_9Ul0KIKRsixzhy2VhdG", "label": "V560D", "digest": "6kMa53-8b1JK_9Ul0KIKRsixzhy2VhdG", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000288135.5:c.1679T>A"}, {"syntax": "hgvs.c", "value": "NM_000222.2:c.1679T>A"}, {"syntax": "hgvs.p", "value": "NP_000213.1:p.Val560Asp"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55593613T>A"}], "location": {"id": "ga4gh:SL.xjCeL58wMAH2q4KMEcgogvUiNRC5EJ4X", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 559, "end": 560}, "state": {"type": "LiteralSequenceExpression", "sequence": "D"}}}, "therapeutic": {"id": "civic.tid:157", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:357977"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:647", "type": "Disease", "label": "Pancreatic NET", "mappings": [{"coding": {"system": "ncit", "code": "C27720"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:660", "type": "Disease", "label": "Renal cell carcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C9385"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C71622"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"]}, "tumorType": {"id": "civic.did:216", "label": "Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9305"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:162"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4100", "description": "In an in vitro study, Chinese hamster ovary cells expressing KIT A502_Y503INSAY demonstrated comparable sensitivity to sunitinib treatment compared to CHO cells expressing ligand activated wild-type KIT (IC50<100 nmol/L). Sensitivity was determined by assessing KIT auto-phosphorylation.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:965", "label": "Heinrich et al., 2008, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Heinrich et al., 2008, J. Clin. Oncol.", "pmid": 18955458}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:29", "label": "KIT", "description": "c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3815"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["C-Kit", "CD117", "KIT", "MASTC", "PBT", "SCFR"]}}, "direction": "refutes", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1466", "label": "KIT A502_Y503insAY", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 7.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"reference_build": "GRCh37", "variant_bases": "GCCTAT", "chromosome": "4", "start": 55592182, "stop": 55592183, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "inframe_insertion", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001821"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1558"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "unregistered"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.lFHRe-h8OLKmUpniCwsB22TGRKFo6SPV", "label": "A502_Y503insAY", "digest": "lFHRe-h8OLKmUpniCwsB22TGRKFo6SPV", "type": "Allele", "location": {"id": "ga4gh:SL.zSB7LotHY7CPxMvR0FrKJp6R88lpiPAI", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 502, "end": 502}, "state": {"type": "LiteralSequenceExpression", "sequence": "AY"}}}, "therapeutic": {"id": "civic.tid:157", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:357977"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:647", "type": "Disease", "label": "Pancreatic NET", "mappings": [{"coding": {"system": "ncit", "code": "C27720"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:660", "type": "Disease", "label": "Renal cell carcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C9385"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C71622"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"]}, "tumorType": {"id": "civic.did:216", "label": "Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9305"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:162"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4284", "description": "In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to reversible tyrosine kinase inhibitor drugs. Cells with an EGFR L858R mutation demonstrated an improved response to erlotinib (IC50: 40nM vs. 110nM) compared to EGFR wild type cells.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1525", "label": "Li et al., 2008, Oncogene", "type": "Document", "title": "PubMed: Li et al., 2008, Oncogene", "pmid": 18408761}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:33", "label": "EGFR L858R", "description": "EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 379.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "G", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55259515, "stop": 55259515, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "33"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA126713"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16609"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376282"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376280"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434568"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121434568", "LEU858ARG"], "members": [{"id": "ga4gh:VA.TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "label": "NC_000007.13:g.55259515T>G", "digest": "TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "type": "Allele", "location": {"id": "ga4gh:SL.ulUNwZvajob7nzyrlpOd6uUWZIYCsoWb", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55191821, "end": 55191822}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "label": "L858R", "digest": "z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000007.13:g.55259515T>G"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2573T>G"}, {"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2573T>G"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Leu858Arg"}], "location": {"id": "ga4gh:SL.yVGJnwqxV6oCGqC_8nNb58D_wPXJeNJo", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 857, "end": 858}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4285", "description": "In an in vitro study, a MCF-7 cell line expressing EGFR L858R mutation demonstrated sensitivity to erlotinib treatment, compared to MCF-7 cells expressing EGFR wild-type. Sensitivity was determined by assessing YFP signal-EGFR relocation.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1993", "label": "Harada et al., 2011, Oncogene", "type": "Document", "title": "PubMed: Harada et al., 2011, Oncogene", "pmid": 21132006}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:33", "label": "EGFR L858R", "description": "EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 379.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "G", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55259515, "stop": 55259515, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "33"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA126713"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16609"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376282"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376280"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434568"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121434568", "LEU858ARG"], "members": [{"id": "ga4gh:VA.TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "label": "NC_000007.13:g.55259515T>G", "digest": "TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "type": "Allele", "location": {"id": "ga4gh:SL.ulUNwZvajob7nzyrlpOd6uUWZIYCsoWb", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55191821, "end": 55191822}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "label": "L858R", "digest": "z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000007.13:g.55259515T>G"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2573T>G"}, {"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2573T>G"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Leu858Arg"}], "location": {"id": "ga4gh:SL.yVGJnwqxV6oCGqC_8nNb58D_wPXJeNJo", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 857, "end": 858}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:216", "label": "Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9305"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:162"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4291", "description": "In an in vitro study, Ba/F3 cell line expressing EGFR L858R was associated with sensitivity to erlotinib treatment (IC50 26.9 \u00b1 12.4). Sensitivity was determined by assessing cell viability, AKT and ERK phosphorylation, and EGFR auto-phosphorylation.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2086", "label": "Konduri et al., 2016, Cancer Discov", "type": "Document", "title": "PubMed: Konduri et al., 2016, Cancer Discov", "pmid": 27102076}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:33", "label": "EGFR L858R", "description": "EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 379.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "G", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55259515, "stop": 55259515, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "33"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA126713"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16609"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376282"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376280"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434568"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121434568", "LEU858ARG"], "members": [{"id": "ga4gh:VA.TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "label": "NC_000007.13:g.55259515T>G", "digest": "TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "type": "Allele", "location": {"id": "ga4gh:SL.ulUNwZvajob7nzyrlpOd6uUWZIYCsoWb", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55191821, "end": 55191822}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "label": "L858R", "digest": "z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000007.13:g.55259515T>G"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2573T>G"}, {"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2573T>G"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Leu858Arg"}], "location": {"id": "ga4gh:SL.yVGJnwqxV6oCGqC_8nNb58D_wPXJeNJo", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 857, "end": 858}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:30", "label": "Lung Adenocarcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3512"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3910"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4293", "description": "In an in vitro study using NCI-H3255 cells (EGFR L858R mutation), inhibition of EGFR phosphorylation was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. NCI-H3255 cells demonstrated increased sensitivity to erlotinib (IC50: 8 and 11 nM) compared to EGFRwt NCI-H2073 cells (IC50: 108 nM; 95%CI 52-223 nM).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:665", "label": "Cross et al., 2014, Cancer Discov", "type": "Document", "title": "PubMed: Cross et al., 2014, Cancer Discov", "pmid": 24893891}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:33", "label": "EGFR L858R", "description": "EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 379.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "G", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55259515, "stop": 55259515, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "33"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA126713"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16609"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376282"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376280"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434568"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121434568", "LEU858ARG"], "members": [{"id": "ga4gh:VA.TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "label": "NC_000007.13:g.55259515T>G", "digest": "TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "type": "Allele", "location": {"id": "ga4gh:SL.ulUNwZvajob7nzyrlpOd6uUWZIYCsoWb", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55191821, "end": 55191822}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "label": "L858R", "digest": "z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000007.13:g.55259515T>G"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2573T>G"}, {"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2573T>G"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Leu858Arg"}], "location": {"id": "ga4gh:SL.yVGJnwqxV6oCGqC_8nNb58D_wPXJeNJo", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 857, "end": 858}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:174", "label": "Lung Small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4917"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:5409"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4294", "description": "In an in vitro study using NCI-H3255 cells (EGFR L858R mutation), inhibition of EGFR phosphorylation was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. NCI-H3255 cells demonstrated increased sensitivity to AZD9291 (IC50: 60 and 49 nM) compared to EGFRwt NCI-H2073 cells (IC50: 1865 nM; 95%CI 872-3988 nM). In vivo experiments with NCI-H3255 xenograft models showed drastic tumour volume reduction upon treatment with 5mg/kg/day AZD9291.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:665", "label": "Cross et al., 2014, Cancer Discov", "type": "Document", "title": "PubMed: Cross et al., 2014, Cancer Discov", "pmid": 24893891}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:33", "label": "EGFR L858R", "description": "EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 379.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "G", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55259515, "stop": 55259515, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "33"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA126713"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16609"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376282"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376280"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434568"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121434568", "LEU858ARG"], "members": [{"id": "ga4gh:VA.TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "label": "NC_000007.13:g.55259515T>G", "digest": "TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "type": "Allele", "location": {"id": "ga4gh:SL.ulUNwZvajob7nzyrlpOd6uUWZIYCsoWb", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55191821, "end": 55191822}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "label": "L858R", "digest": "z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000007.13:g.55259515T>G"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2573T>G"}, {"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2573T>G"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Leu858Arg"}], "location": {"id": "ga4gh:SL.yVGJnwqxV6oCGqC_8nNb58D_wPXJeNJo", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 857, "end": 858}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:187", "label": "Osimertinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1721560"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C116377"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-", "AZD-9291", "AZD9291", "Mereletinib", "Tagrisso"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4498", "description": "In an in vitro study, a M229 cell line endogenously expressing BRAF V600E mutation (a known vemurafenib sensitizing mutation) and overexpressing AKT1 Q79K mutation was associated with resistance to vemurafenib treatment, as compared to cells expressing BRAF V600E mutation and wildtype AKT1. Resistance was determined by assessing cell survival.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1941", "label": "Shi et al., 2014, Cancer Discov", "type": "Document", "title": "PubMed: Shi et al., 2014, Cancer Discov", "pmid": 24265155}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:2", "label": "AKT1", "description": "AKT1, also referred to as protein kinase B, is a known oncogene. AKT activation relies on the PI3K pathway, and is recognized as a critical node in the pathway. The E17 hotspot is the most characterized of AKT1 mutations, and has been shown to result in activation of the protein. Mutations in AKT1 have also been shown to confer resistance to allosteric kinase inhibitors in vitro.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:391"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:207"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["AKT", "AKT1", "PKB", "PKB-ALPHA", "PRKBA", "RAC", "RAC-ALPHA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:169", "label": "AKT1 Q79K", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 16.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "T", "representative_transcript": "ENST00000407796.2", "chromosome": "14", "start": 105243048, "stop": 105243048, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "169"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602625"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376168"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS1057519804"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS1057519804", "GLN79LYS", "Q17K"], "members": [{"id": "ga4gh:VA._FsX8vVR1C-jMiRgJX02CDSaclfGir3N", "label": "NC_000014.8:g.105243048G>T", "digest": "_FsX8vVR1C-jMiRgJX02CDSaclfGir3N", "type": "Allele", "location": {"id": "ga4gh:SL.3aaJAnaiyOBfpjFMV7GuwwO23IHjh4zQ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.eK4D2MosgK_ivBkgi6FVPg5UXs1bYESm"}, "start": 104776710, "end": 104776711}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.Wpny1uCajSwqyosBpgHrpj66_am_42P3", "label": "Q79K", "digest": "Wpny1uCajSwqyosBpgHrpj66_am_42P3", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000014.8:g.105243048G>T"}, {"syntax": "hgvs.c", "value": "NM_001014432.1:c.235C>A"}, {"syntax": "hgvs.p", "value": "NP_001014432.1:p.Gln79Lys"}, {"syntax": "hgvs.c", "value": "ENST00000407796.2:c.235C>A"}], "location": {"id": "ga4gh:SL.yCJndQuCYYFMkmq_34dv0sqS_zpJ8wMk", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.GTSPIWYvuDZU59cW1RECFEU1FMiKdEyc"}, "start": 78, "end": 79}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:7", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3224"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1909"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4623", "description": "In an in vitro study, a SNU-251 cell line expressing BRCA1 W1815X truncating mutation demonstrated increased sensitivity to olaparib treatment with long-term exposure, compared to ovarian cell lines expressing BRCA1 wild-type. Sensitivity was determined by assessing cytotoxicity and doubling time. The authors note that the slow doubling time of SNU-251 cells was compensated for with a 2 week cytotoxicity assay as compared to the 1 week assay used for all other cell lines.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2114", "label": "Stordal et al., 2013, Mol Oncol", "type": "Document", "title": "PubMed: Stordal et al., 2013, Mol Oncol", "pmid": 23415752}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:6", "label": "BRCA1", "description": "BRCA1 mutations in the germline have become a hallmark for hereditary breast and ovarian cancers. Variants that have been demonstrated to reduce the function of the protein have been shown to increase the risk for these cancers, as well as prostate and pancreatic cancer. These findings have been the impetus for the increased popularity of genetic testing of healthy individuals to assess risk. Recent studies in ovarian cancer have also demonstrated that BRCA mutation status can predict treatment response. A number of trials assessing BRCA mutation status have shown an improved response to platinum agents, and more recently has led to the FDA-approval of PARP inhibitors for BRCA-positive ovarian cancers. These studies have resulted in the Society of Gynecologic Oncology to recommend germline BRCA testing in all patients with a diagnosis of ovarian cancer.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1100"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:672"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["BRCA1", "BRCAI", "BRCC1", "BROVCA1", "FANCS", "IRIS", "PNCA4", "PPP1R53", "PSCP", "RNF53"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1463", "label": "BRCA1 W1815X", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 2.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "chromosome": "17", "start": 41199682, "stop": 41199682, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "stop_gained", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001587"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1555"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA003600"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["W1768X", "W1576X", "W48X", "W1519X", "W306X", "W664X", "W632X", "W711X", "W125X", "W673X", "W1550X", "W1836X"], "definingContext": {"id": "ga4gh:VA.Yh630T52rfubi9P-9ZeGfWgX8A37cQu-", "label": "W1815X", "digest": "Yh630T52rfubi9P-9ZeGfWgX8A37cQu-", "type": "Allele", "location": {"id": "ga4gh:SL.4uMfBxJex6wAFouMEc1PDVIyiPgXUHUT", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.nUzIPnHMyQV52hzgBbKl5vlbSwx8M8_Y"}, "start": 1814, "end": 1815}, "state": {"type": "LiteralSequenceExpression", "sequence": "X"}}}, "therapeutic": {"id": "civic.tid:42", "label": "Olaparib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1597582"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:645", "type": "Disease", "label": "Ovarian cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7431"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}, {"id": "hemonc:658", "type": "Disease", "label": "Prostate cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7378"}, "relation": "relatedMatch"}]}, {"id": "hemonc:572", "type": "Disease", "label": "Breast cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9335"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C71721"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["AZD 2281", "AZD-2281", "AZD2281", "KU-0059436", "Lynparza", "PARP Inhibitor AZD2281"]}, "tumorType": {"id": "civic.did:1452", "label": "Endometrioid Ovary Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C7979"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:5828"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4784", "description": "An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype PIK3CA and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells virally induced to stably over-express PIK3CA D350G were significantly more resistant to BRAF inhibition by vemurafenib  than cells transduced with empty vectors (40% vs 20% survival at the highest concentration, p=.0148). Though statistics were not provided, D350G appears to confer less resistance to vemurafenib than the positive control variant, PIK3CA E545K.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1941", "label": "Shi et al., 2014, Cancer Discov", "type": "Document", "title": "PubMed: Shi et al., 2014, Cancer Discov", "pmid": 24265155}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1561", "label": "PIK3CA D350G", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 2.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "G", "representative_transcript": "ENST00000263967.3", "chromosome": "3", "start": 178921567, "stop": 178921567, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1653"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA355281594"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "521363"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ASP350GLY"], "members": [{"id": "ga4gh:VA.HeNVL0CH7SF1zNo-t9481BG864JWN9t7", "label": "NC_000003.11:g.178921567A>G", "digest": "HeNVL0CH7SF1zNo-t9481BG864JWN9t7", "type": "Allele", "location": {"id": "ga4gh:SL.8_RfOHmrvMSa_ooPUZ9erVfCoE7lxFiP", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 179203778, "end": 179203779}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA._chFLo966nAzZG0WZYXG5muaoZaM7jmL", "label": "D350G", "digest": "_chFLo966nAzZG0WZYXG5muaoZaM7jmL", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000263967.3:c.1049A>G"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.178921567A>G"}, {"syntax": "hgvs.c", "value": "NM_006218.2:c.1049A>G"}, {"syntax": "hgvs.p", "value": "NP_006209.2:p.Asp350Gly"}], "location": {"id": "ga4gh:SL.qWrPYvK5RFwVwySHKGYUtAUDUPtMNRD2", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 349, "end": 350}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:7", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3224"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1909"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:5346", "description": "In an in vitro study, Chinese hamster ovary cells expressing PDGFRA D842V mutation demonstrated reduced sensitivity to imatinib treatment (IC50=2,500 vs. IC50<100), compared to Chinese hamster ovary cells expressing wild-type PDGFRA. Sensitivity was determined by assessing PDGFRA auto-phosphorylation.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:965", "label": "Heinrich et al., 2008, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Heinrich et al., 2008, J. Clin. Oncol.", "pmid": 18955458}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:38", "label": "PDGFRA", "description": "Commonly mutated in GI tract tumors, PDGFR family genes (mutually exclusive to KIT mutations) are a hallmark of gastrointestinal stromal tumors. Gene fusions involving the PDGFRA kinase domain are highly correlated with eosinophilia, and the WHO classifies myeloid and lymphoid neoplasms with these characteristics as a distinct disorder. Mutations in the 842 region of PDGFRA have been often found to confer resistance to the tyrosine kinase inhibitor, imatinib.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8803"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5156"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD140A", "PDGFR-2", "PDGFR2", "PDGFRA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:99", "label": "PDGFRA D842V", "description": "PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. Exogenous expression of the A842V mutation resulted in constitutive tyrosine phosphorylation of PDGFRA in the absence of ligand in 293T cells and cytokine-independent proliferation of the IL-3-dependent Ba/F3 cell line, both evidence that this is an activating mutation. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 100.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000257290.5", "chromosome": "4", "start": 55152093, "stop": 55152093, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "99"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123194"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13543"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121908585"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ASP842VAL", "RS121908585"], "members": [{"id": "ga4gh:VA.bDwkJ2filJ3ZGiUFybGFfyaCKdIVK86v", "label": "NC_000004.11:g.55152093A>T", "digest": "bDwkJ2filJ3ZGiUFybGFfyaCKdIVK86v", "type": "Allele", "location": {"id": "ga4gh:SL.LxO2YLfQbI_-TK7GOmSoOpMNiSy_Hgan", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54285925, "end": 54285926}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.vIjnL-aLYl0BSB6JutpdD7yW_qIXtdk8", "label": "D842V", "digest": "vIjnL-aLYl0BSB6JutpdD7yW_qIXtdk8", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006206.4:c.2525A>T"}, {"syntax": "hgvs.p", "value": "NP_006197.1:p.Asp842Val"}, {"syntax": "hgvs.c", "value": "ENST00000257290.5:c.2525A>T"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55152093A>T"}], "location": {"id": "ga4gh:SL.GHXCPrbd_qdPUoHjPwzv5iVFapJ0cn-o", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.XpQn9sZLGv_GU3uiWO7YHq9-_alGjrVX"}, "start": 841, "end": 842}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "civic.tid:537", "label": "Imatinib Mesylate", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:282388"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "Disease", "label": "Systemic mastocytosis", "mappings": [{"coding": {"system": "ncit", "code": "C9235"}, "relation": "relatedMatch"}]}, {"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}, {"id": "hemonc:634", "type": "Disease", "label": "Myelodysplastic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C3247"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:33893", "type": "Disease", "label": "Chronic myelogenous leukemia pediatric"}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}, {"id": "hemonc:616", "type": "Disease", "label": "Hypereosinophilic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C27038"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1687"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate", "CGP 57148", "CGP57148B", "Gleevec", "Glivec", "STI 571", "STI-571", "STI571"]}, "tumorType": {"id": "civic.did:216", "label": "Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9305"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:162"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:5347", "description": "In an in vitro study, Chinese hamster ovary cells expressing PDGFRA V561D mutation demonstrated sensitivity to imatinib treatment (IC50<100), though this sensitivity was indistinguishable from Chinese hamster ovary cells expressing wild-type PDGFRA. Sensitivity was determined by assessing PDGFRA auto-phosphorylation.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:965", "label": "Heinrich et al., 2008, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Heinrich et al., 2008, J. Clin. Oncol.", "pmid": 18955458}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:38", "label": "PDGFRA", "description": "Commonly mutated in GI tract tumors, PDGFR family genes (mutually exclusive to KIT mutations) are a hallmark of gastrointestinal stromal tumors. Gene fusions involving the PDGFRA kinase domain are highly correlated with eosinophilia, and the WHO classifies myeloid and lymphoid neoplasms with these characteristics as a distinct disorder. Mutations in the 842 region of PDGFRA have been often found to confer resistance to the tyrosine kinase inhibitor, imatinib.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8803"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5156"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD140A", "PDGFR-2", "PDGFR2", "PDGFRA"]}}, "direction": "refutes", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:915", "label": "PDGFRA V561D", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 8.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "A", "representative_transcript": "ENST00000257290.5", "chromosome": "4", "start": 55141036, "stop": 55141036, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "941"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123203"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13546"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121908586"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121908586"], "members": [{"id": "ga4gh:VA.RVDCfTK9KrX96TVgvOUcAv--OnQUdV8O", "label": "NC_000004.11:g.55141036T>A", "digest": "RVDCfTK9KrX96TVgvOUcAv--OnQUdV8O", "type": "Allele", "location": {"id": "ga4gh:SL.h44ZIUE0VWLc8ONz8JwqUOUCvADE8Ozc", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54274868, "end": 54274869}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.OFhYwJu_e2ktWF9N-_SrpmKx44fbeyto", "label": "V561D", "digest": "OFhYwJu_e2ktWF9N-_SrpmKx44fbeyto", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006206.5:c.1682T>A"}, {"syntax": "hgvs.p", "value": "NP_006197.1:p.Val561Asp"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55141036T>A"}, {"syntax": "hgvs.c", "value": "ENST00000257290.5:c.1682T>A"}], "location": {"id": "ga4gh:SL.QB_e8RED6euCq3v0AQJcTcXmXd4p286t", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.XpQn9sZLGv_GU3uiWO7YHq9-_alGjrVX"}, "start": 560, "end": 561}, "state": {"type": "LiteralSequenceExpression", "sequence": "D"}}}, "therapeutic": {"id": "civic.tid:537", "label": "Imatinib Mesylate", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:282388"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "Disease", "label": "Systemic mastocytosis", "mappings": [{"coding": {"system": "ncit", "code": "C9235"}, "relation": "relatedMatch"}]}, {"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}, {"id": "hemonc:634", "type": "Disease", "label": "Myelodysplastic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C3247"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:33893", "type": "Disease", "label": "Chronic myelogenous leukemia pediatric"}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}, {"id": "hemonc:616", "type": "Disease", "label": "Hypereosinophilic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C27038"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1687"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate", "CGP 57148", "CGP57148B", "Gleevec", "Glivec", "STI 571", "STI-571", "STI571"]}, "tumorType": {"id": "civic.did:216", "label": "Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9305"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:162"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:5348", "description": "In an in vitro study, Chinese hamster ovary cells expressing KIT V560D mutation demonstrated sensitivity to imatinib treatment (IC50 = 100 vs IC50 = 1000) when compared to Chinese hamster ovary cells expressing ligand-activated wild-type KIT. Sensitivity was determined by assessing KIT auto-phosphorylation.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:965", "label": "Heinrich et al., 2008, J. Clin. Oncol.", "type": "Document", "title": "PubMed: Heinrich et al., 2008, J. Clin. Oncol.", "pmid": 18955458}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:29", "label": "KIT", "description": "c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3815"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["C-Kit", "CD117", "KIT", "MASTC", "PBT", "SCFR"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:945", "label": "KIT V560D", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 14.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "A", "representative_transcript": "ENST00000288135.5", "chromosome": "4", "start": 55593613, "stop": 55593613, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "971"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602396"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "375914"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913521"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["VAL560ASP", "RS121913521"], "members": [{"id": "ga4gh:VA.DEtz2mJjlbwY6JoXYkr8EqhQY7XknzpB", "label": "NC_000004.11:g.55593613T>A", "digest": "DEtz2mJjlbwY6JoXYkr8EqhQY7XknzpB", "type": "Allele", "location": {"id": "ga4gh:SL.dSrWFS7PMfm4pI1lOMkuEOGD6Gh2p72S", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54727446, "end": 54727447}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.6kMa53-8b1JK_9Ul0KIKRsixzhy2VhdG", "label": "V560D", "digest": "6kMa53-8b1JK_9Ul0KIKRsixzhy2VhdG", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000288135.5:c.1679T>A"}, {"syntax": "hgvs.c", "value": "NM_000222.2:c.1679T>A"}, {"syntax": "hgvs.p", "value": "NP_000213.1:p.Val560Asp"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55593613T>A"}], "location": {"id": "ga4gh:SL.xjCeL58wMAH2q4KMEcgogvUiNRC5EJ4X", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 559, "end": 560}, "state": {"type": "LiteralSequenceExpression", "sequence": "D"}}}, "therapeutic": {"id": "civic.tid:537", "label": "Imatinib Mesylate", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:282388"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "Disease", "label": "Systemic mastocytosis", "mappings": [{"coding": {"system": "ncit", "code": "C9235"}, "relation": "relatedMatch"}]}, {"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}, {"id": "hemonc:634", "type": "Disease", "label": "Myelodysplastic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C3247"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:33893", "type": "Disease", "label": "Chronic myelogenous leukemia pediatric"}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}, {"id": "hemonc:616", "type": "Disease", "label": "Hypereosinophilic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C27038"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1687"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate", "CGP 57148", "CGP57148B", "Gleevec", "Glivec", "STI 571", "STI-571", "STI571"]}, "tumorType": {"id": "civic.did:216", "label": "Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9305"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:162"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:7379", "description": "In this preclinial trial, the AML cell line Kasumi-1 with c-KIT N822K mutation was treated with Ponatinib. This drug effectively inhibits both KIT phosphorylation and viability for Kasumi-1 cells at IC50 values 20 nmol/L and 8 nmol/L respectively.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2913", "label": "Gozgit et al., 2011, Mol. Cancer Ther.", "type": "Document", "title": "PubMed: Gozgit et al., 2011, Mol. Cancer Ther.", "pmid": 21482694}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:29", "label": "KIT", "description": "c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3815"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["C-Kit", "CD117", "KIT", "MASTC", "PBT", "SCFR"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1237", "label": "KIT N822K", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 29.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "A", "representative_transcript": "ENST00000288135.5", "chromosome": "4", "start": 55599340, "stop": 55599340, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1263"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602411"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "375931"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913514"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ASN822LYS", "RS121913514"], "members": [{"id": "ga4gh:VA.3i1HI4wqippKn-gtuyM4kiLBVQD0N763", "label": "NC_000004.11:g.55599340T>A", "digest": "3i1HI4wqippKn-gtuyM4kiLBVQD0N763", "type": "Allele", "location": {"id": "ga4gh:SL.hQJlf-hzQ4szaLAhFocudRE99wMKEJfi", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.HxuclGHh0XCDuF8x6yQrpHUBL7ZntAHc"}, "start": 54733173, "end": 54733174}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.z_WJsSByobbgzhHAaWw4kVBhNnyADN57", "label": "N822K", "digest": "z_WJsSByobbgzhHAaWw4kVBhNnyADN57", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_000222.2:c.2466T>A"}, {"syntax": "hgvs.p", "value": "NP_000213.1:p.Asn822Lys"}, {"syntax": "hgvs.g", "value": "NC_000004.11:g.55599340T>A"}, {"syntax": "hgvs.c", "value": "ENST00000288135.5:c.2466T>A"}], "location": {"id": "ga4gh:SL.B6627_40nR9hpf23ICFLQ0TZsfFxpBNq", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 821, "end": 822}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:55", "label": "Ponatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1364347"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C95777"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["AP-24534", "AP24534", "Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)"]}, "tumorType": {"id": "civic.did:3", "label": "Acute Myeloid Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3171"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9119"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:7392", "description": "In an in vitro study, an IL3 independant Ba/F3 cell line expressing KIT V560D primary activating mutation demonstrated sensitivity to sunitinib treatment (IC50: 5nmol/L). IC50 was determined by assessing cell viability.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2042", "label": "Garner et al., 2014, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Garner et al., 2014, Clin. Cancer Res.", "pmid": 25239608}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:29", "label": "KIT", "description": "c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3815"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["C-Kit", "CD117", "KIT", "MASTC", "PBT", "SCFR"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1466", "label": "KIT A502_Y503insAY", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 7.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"reference_build": "GRCh37", "variant_bases": "GCCTAT", "chromosome": "4", "start": 55592182, "stop": 55592183, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "inframe_insertion", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001821"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1558"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "unregistered"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.lFHRe-h8OLKmUpniCwsB22TGRKFo6SPV", "label": "A502_Y503insAY", "digest": "lFHRe-h8OLKmUpniCwsB22TGRKFo6SPV", "type": "Allele", "location": {"id": "ga4gh:SL.zSB7LotHY7CPxMvR0FrKJp6R88lpiPAI", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 502, "end": 502}, "state": {"type": "LiteralSequenceExpression", "sequence": "AY"}}}, "therapeutic": {"id": "civic.tid:157", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:357977"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:647", "type": "Disease", "label": "Pancreatic NET", "mappings": [{"coding": {"system": "ncit", "code": "C27720"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:660", "type": "Disease", "label": "Renal cell carcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C9385"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C71622"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"]}, "tumorType": {"id": "civic.did:2", "label": "Gastrointestinal Stromal Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3868"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9253"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:7760", "description": "In a BRAF-mutation inducible model in the NIH3T3 cell line, class 3 BRAF mutations (G466V, G466E, D594G, D594N, and G596R) were resistant to vemurafenib but sensitive to MEK-inhibitor trametinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:3005", "label": "Yao et al., 2017, Nature", "type": "Document", "title": "PubMed: Yao et al., 2017, Nature", "pmid": 28783719}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:607", "label": "BRAF D594G", "description": "This BRAF mutation has a markedly reduced kinase activity and leads to paradoxical MEK-pathway activation via CRAF binding.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 43.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "C", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453154, "stop": 140453154, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "611"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123657"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13972"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913338"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913338", "ASP594GLY"], "members": [{"id": "ga4gh:VA.4qgowYAHzDVX5PXtEI_l6Z0WW8Mqg5fd", "label": "NC_000007.13:g.140453154T>C", "digest": "4qgowYAHzDVX5PXtEI_l6Z0WW8Mqg5fd", "type": "Allele", "location": {"id": "ga4gh:SL.mJCbLe5i4lmWMkSh9OiCLrL3l4H01ndP", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753353, "end": 140753354}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.AafX9u1lbbUrgWL3bD4zXKIjzyNlzMOJ", "label": "D594G", "digest": "AafX9u1lbbUrgWL3bD4zXKIjzyNlzMOJ", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004333.4:c.1781A>G"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Asp594Gly"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140453154T>C"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1781A>G"}], "location": {"id": "ga4gh:SL.WujfpJG33G8kDeus_PN9ykPrKhwkYmfB", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 593, "end": 594}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}}, "therapeutic": {"id": "civic.tid:19", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1425098"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C77908"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["GSK1120212", "JTP-74057", "MEK Inhibitor GSK1120212", "Mekinist", "N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide"]}, "tumorType": {"id": "civic.did:216", "label": "Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9305"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:162"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:7910", "description": "Lentiviral-mediated overexpression of PRPS1 N144S in Reh cells resulted in sensitivity to cytarabine (Ara-C) treatment as indicated by reduced cell viability and IC50 compared to empty vector and wildtype PRPS1 overexpression controls.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:3161", "label": "Li et al., 2015, Nat. Med.", "type": "Document", "title": "PubMed: Li et al., 2015, Nat. Med.", "pmid": 25962120}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:4566", "label": "PRPS1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:9462"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5631"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["ARTS", "CMTX5", "DFN2", "DFNX1", "PPRibP", "PRPS1", "PRS-I", "PRSI"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:2792", "label": "PRPS1 N144S", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 9.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"type": "coordinates"}}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "2923"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.RS-5wkQUMSii12AFq7BzKN8jw1xEtmvm", "label": "N144S", "digest": "RS-5wkQUMSii12AFq7BzKN8jw1xEtmvm", "type": "Allele", "location": {"id": "ga4gh:SL.Daz_55Q2sINEYcjrvPsHs2_p71IDwzmd", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.BE5LKtILBzKPUUNtki2arue68xFj1YAF"}, "start": 143, "end": 144}, "state": {"type": "LiteralSequenceExpression", "sequence": "S"}}}, "therapeutic": {"id": "civic.tid:173", "label": "Cytarabine", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:3041"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:575", "type": "Disease", "label": "CNS leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C5440"}, "relation": "relatedMatch"}]}, {"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:552", "type": "Disease", "label": "Acute myeloid leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3171"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C408"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": [".beta.-Cytosine Arabinoside", "1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone", "1-.beta.-D-Arabinofuranosylcytosine", "1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone", "1-Beta-D-arabinofuranosylcytosine", "1.beta.-D-Arabinofuranosylcytosine", "2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-", "2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-", "4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone", "ARA-cell", "Alexan", "Ara-C", "Arabine", "Arabinofuranosylcytosine", "Arabinosylcytosine", "Aracytidine", "Aracytin", "Aracytine", "Beta-Cytosine Arabinoside", "CHX-3311", "Cytarabinum", "Cytarbel", "Cytosar", "Cytosar-U", "Cytosine Arabinoside", "Cytosine-.beta.-arabinoside", "Cytosine-beta-arabinoside", "Erpalfa", "Starasid", "Tarabine PFS", "U 19920", "U-19920", "Udicil", "WR-28453"]}, "tumorType": {"id": "civic.did:3005", "label": "B-lymphoblastic Leukemia/lymphoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C8936"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:0080630"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:7911", "description": "Lentiviral-mediated overexpression of PRPS1 L191F in Reh cells resulted in sensitivity to cytarabine (Ara-C) treatment as indicated by reduced cell viability and IC50 compared to empty vector and wildtype PRPS1 overexpression controls.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:3161", "label": "Li et al., 2015, Nat. Med.", "type": "Document", "title": "PubMed: Li et al., 2015, Nat. Med.", "pmid": 25962120}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:4566", "label": "PRPS1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:9462"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5631"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["ARTS", "CMTX5", "DFN2", "DFNX1", "PPRibP", "PRPS1", "PRS-I", "PRSI"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:2788", "label": "PRPS1 L191F", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 9.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"type": "coordinates"}}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "2919"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.Q_J0gbOeMmSfH15pKqKaLPKC0eotBiTi", "label": "L191F", "digest": "Q_J0gbOeMmSfH15pKqKaLPKC0eotBiTi", "type": "Allele", "location": {"id": "ga4gh:SL.Sa63r8R14UqrMs_xD7kEFnx7Rpq19bjN", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.BE5LKtILBzKPUUNtki2arue68xFj1YAF"}, "start": 190, "end": 191}, "state": {"type": "LiteralSequenceExpression", "sequence": "F"}}}, "therapeutic": {"id": "civic.tid:173", "label": "Cytarabine", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:3041"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:575", "type": "Disease", "label": "CNS leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C5440"}, "relation": "relatedMatch"}]}, {"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:552", "type": "Disease", "label": "Acute myeloid leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3171"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C408"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": [".beta.-Cytosine Arabinoside", "1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone", "1-.beta.-D-Arabinofuranosylcytosine", "1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone", "1-Beta-D-arabinofuranosylcytosine", "1.beta.-D-Arabinofuranosylcytosine", "2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-", "2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-", "4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone", "ARA-cell", "Alexan", "Ara-C", "Arabine", "Arabinofuranosylcytosine", "Arabinosylcytosine", "Aracytidine", "Aracytin", "Aracytine", "Beta-Cytosine Arabinoside", "CHX-3311", "Cytarabinum", "Cytarbel", "Cytosar", "Cytosar-U", "Cytosine Arabinoside", "Cytosine-.beta.-arabinoside", "Cytosine-beta-arabinoside", "Erpalfa", "Starasid", "Tarabine PFS", "U 19920", "U-19920", "Udicil", "WR-28453"]}, "tumorType": {"id": "civic.did:3005", "label": "B-lymphoblastic Leukemia/lymphoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C8936"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:0080630"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:8108", "description": "A 35 year-old male patient (AML4) presented with a FLT3-ITD mutation at diagnosis and was refractory to induction and salvage chemotherapy. He then received quizartinib and underwent allogenic transplant, but relapsed after 6 months. He then responded to sorafenib, but had disease progression with a FLT3-D835Y mutation. The patient derived relapse sample containing ITD and D835Y mutations was sensitive to gilteritinib based on cytotoxicity assays using MTT. Additionally, immunoblot demonstrated gilteritinib reduced FLT3 phosphorylation in Ba/F3 cells expressing only D835Y with an IC50 of 1.4 nM.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:3336", "label": "Lee et al., 2017, Blood", "type": "Document", "title": "PubMed: Lee et al., 2017, Blood", "pmid": 27908881}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:24", "label": "FLT3", "description": "FLT3 is an important cytokine receptor involved in normal hematopoiesis. Mutations in this gene are common in acute myeloid leukemia (AML) and screening for mutations in this gene has been recommended by the World Health Organization in patients with AML, particularly in cases of cytogenetically normal AML (CN-AML). FLT3 mutations commonly co-occur with mutations such as NPM1 that are associated with CN-AML and likely modulate prognostic impact. While FLT3-ITD mutations have been associated with poorer prognosis in AML, the prognostic impact of FLT3-TKD mutations are still up for debate.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3765"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2322"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD135", "FLK-2", "FLK2", "FLT3", "STK1"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:2880", "label": "FLT3 D835Y", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 6.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"type": "coordinates"}}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "3011"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.1hPW7A1Ucjjqoj-8nHIaO7J9py4rPU-B", "label": "D835Y", "digest": "1hPW7A1Ucjjqoj-8nHIaO7J9py4rPU-B", "type": "Allele", "location": {"id": "ga4gh:SL.JUgz5GWLTcSTPLIVCaYEGo7KsH5QpwgJ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.0dtDG7QKyvW7BntvQVpLS83mYRA58LKH"}, "start": 834, "end": 835}, "state": {"type": "LiteralSequenceExpression", "sequence": "Y"}}}, "therapeutic": {"id": "civic.tid:641", "label": "Gilteritinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:2105806"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C116722"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide", "ASP-2215", "ASP2215", "Xospata"]}, "tumorType": {"id": "civic.did:3", "label": "Acute Myeloid Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3171"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9119"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:8351", "description": "A 62-year-old female patient (AML5) was refractory to conventional chemotherapy and developed disease progression to quizartinib due to a D835I mutation. Using MTT to measure cytotoxicity, gilteritinib inhibited this patient\u2019s relapse sample. Additionally, immunoblot demonstrated gilteritinib inhibited FLT3 phosphoryaltion at a concentration of 20 nM in the patient dereivd relapse cells.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:3336", "label": "Lee et al., 2017, Blood", "type": "Document", "title": "PubMed: Lee et al., 2017, Blood", "pmid": 27908881}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:24", "label": "FLT3", "description": "FLT3 is an important cytokine receptor involved in normal hematopoiesis. Mutations in this gene are common in acute myeloid leukemia (AML) and screening for mutations in this gene has been recommended by the World Health Organization in patients with AML, particularly in cases of cytogenetically normal AML (CN-AML). FLT3 mutations commonly co-occur with mutations such as NPM1 that are associated with CN-AML and likely modulate prognostic impact. While FLT3-ITD mutations have been associated with poorer prognosis in AML, the prognostic impact of FLT3-TKD mutations are still up for debate.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3765"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2322"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD135", "FLK-2", "FLK2", "FLT3", "STK1"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:2944", "label": "FLT3 D835I", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 2.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"type": "coordinates"}}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "3075"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.cyBNqXmq0xK-tns2uifEgMcyqNA1kcvc", "label": "D835I", "digest": "cyBNqXmq0xK-tns2uifEgMcyqNA1kcvc", "type": "Allele", "location": {"id": "ga4gh:SL.JUgz5GWLTcSTPLIVCaYEGo7KsH5QpwgJ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.0dtDG7QKyvW7BntvQVpLS83mYRA58LKH"}, "start": 834, "end": 835}, "state": {"type": "LiteralSequenceExpression", "sequence": "I"}}}, "therapeutic": {"id": "civic.tid:641", "label": "Gilteritinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:2105806"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C116722"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide", "ASP-2215", "ASP2215", "Xospata"]}, "tumorType": {"id": "civic.did:3", "label": "Acute Myeloid Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3171"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9119"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:8517", "description": "Ba/F3 cells were transfected to express FLT3-ITD or FLT3 tyrosine kinase domain mutations. Immunoblots revealed gilteritinib IC50s of 2nM, 1.6nM, and 5nM for D835H, FLT3-ITD, and wildtype (cell line: SEMK2) cells, respectively.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:3336", "label": "Lee et al., 2017, Blood", "type": "Document", "title": "PubMed: Lee et al., 2017, Blood", "pmid": 27908881}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:24", "label": "FLT3", "description": "FLT3 is an important cytokine receptor involved in normal hematopoiesis. Mutations in this gene are common in acute myeloid leukemia (AML) and screening for mutations in this gene has been recommended by the World Health Organization in patients with AML, particularly in cases of cytogenetically normal AML (CN-AML). FLT3 mutations commonly co-occur with mutations such as NPM1 that are associated with CN-AML and likely modulate prognostic impact. While FLT3-ITD mutations have been associated with poorer prognosis in AML, the prognostic impact of FLT3-TKD mutations are still up for debate.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3765"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2322"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD135", "FLK-2", "FLK2", "FLT3", "STK1"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:608", "label": "FLT3 D835H", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 9.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "G", "representative_transcript": "ENST00000241453.7", "chromosome": "13", "start": 28592642, "stop": 28592642, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "612"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA280208"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16273"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913488"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ASP835HIS", "RS121913488"], "members": [{"id": "ga4gh:VA.wV0gjNrVs2cIsNLtqJZUSkKM4zqcSp7e", "label": "NC_000013.10:g.28592642C>G", "digest": "wV0gjNrVs2cIsNLtqJZUSkKM4zqcSp7e", "type": "Allele", "location": {"id": "ga4gh:SL.h349NKXyd2oh8TNpC8OtaAz9DTlScEHk", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ._0wi-qoDrvram155UmcSC-zA5ZK4fpLT"}, "start": 28018504, "end": 28018505}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.u64XI1wlyPeueS_XwPKmPT_-ihpbM0tY", "label": "D835H", "digest": "u64XI1wlyPeueS_XwPKmPT_-ihpbM0tY", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004119.2:c.2503G>C"}, {"syntax": "hgvs.p", "value": "NP_004110.2:p.Asp835His"}, {"syntax": "hgvs.c", "value": "ENST00000241453.7:c.2503G>C"}, {"syntax": "hgvs.g", "value": "NC_000013.10:g.28592642C>G"}], "location": {"id": "ga4gh:SL.JUgz5GWLTcSTPLIVCaYEGo7KsH5QpwgJ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.0dtDG7QKyvW7BntvQVpLS83mYRA58LKH"}, "start": 834, "end": 835}, "state": {"type": "LiteralSequenceExpression", "sequence": "H"}}}, "therapeutic": {"id": "civic.tid:641", "label": "Gilteritinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:2105806"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C116722"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide", "ASP-2215", "ASP2215", "Xospata"]}, "tumorType": {"id": "civic.did:3", "label": "Acute Myeloid Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3171"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9119"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:8518", "description": "Ba/F3 cells were transfected to express FLT3-ITD or FLT3 tyrosine kinase domain mutations. Immunoblots revealed gilteritinib IC50s of 0.7nM, 1.6nM, and 5nM for D835H, FLT3-ITD, and wildtype (cell line: SEMK2) cells, respectively.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:3336", "label": "Lee et al., 2017, Blood", "type": "Document", "title": "PubMed: Lee et al., 2017, Blood", "pmid": 27908881}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:24", "label": "FLT3", "description": "FLT3 is an important cytokine receptor involved in normal hematopoiesis. Mutations in this gene are common in acute myeloid leukemia (AML) and screening for mutations in this gene has been recommended by the World Health Organization in patients with AML, particularly in cases of cytogenetically normal AML (CN-AML). FLT3 mutations commonly co-occur with mutations such as NPM1 that are associated with CN-AML and likely modulate prognostic impact. While FLT3-ITD mutations have been associated with poorer prognosis in AML, the prognostic impact of FLT3-TKD mutations are still up for debate.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3765"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2322"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD135", "FLK-2", "FLK2", "FLT3", "STK1"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1276", "label": "FLT3 D835V", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 19.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "A", "representative_transcript": "ENST00000241453.7", "chromosome": "13", "start": 28592641, "stop": 28592641, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1302"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA126344"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16272"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121909646"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ASP835VAL", "RS121909646"], "members": [{"id": "ga4gh:VA.d1XMqI0hKulE40Z2rW3jkkLDMVh_2_O1", "label": "NC_000013.10:g.28592641T>A", "digest": "d1XMqI0hKulE40Z2rW3jkkLDMVh_2_O1", "type": "Allele", "location": {"id": "ga4gh:SL.nXY0j3isNbco1FUwE39fcdoIjffTxgkq", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ._0wi-qoDrvram155UmcSC-zA5ZK4fpLT"}, "start": 28018503, "end": 28018504}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.2UJEemVtXP1RM3bMtSQbin9I91Uyiylm", "label": "D835V", "digest": "2UJEemVtXP1RM3bMtSQbin9I91Uyiylm", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000241453.7:c.2504A>T"}, {"syntax": "hgvs.c", "value": "NM_004119.2:c.2504A>T"}, {"syntax": "hgvs.p", "value": "NP_004110.2:p.Asp835Val"}, {"syntax": "hgvs.g", "value": "NC_000013.10:g.28592641T>A"}], "location": {"id": "ga4gh:SL.JUgz5GWLTcSTPLIVCaYEGo7KsH5QpwgJ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.0dtDG7QKyvW7BntvQVpLS83mYRA58LKH"}, "start": 834, "end": 835}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "civic.tid:641", "label": "Gilteritinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:2105806"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C116722"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide", "ASP-2215", "ASP2215", "Xospata"]}, "tumorType": {"id": "civic.did:3", "label": "Acute Myeloid Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3171"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9119"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:8547", "description": "As part of a pre-clinical experiment, the efficacy of trastuzumab was evaluated against various HER2 positive cell lines. MCF7-neo/HER2 cell line harboring PIK3CA E545K was associated with resistance to trastuzumab compared to PIK3CA wild-type cell line SK-BR-3, at all concentrations tested (0-10 ug/mL).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1468", "label": "Baselga et al., 2016, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Baselga et al., 2016, Clin. Cancer Res.", "pmid": 26920887}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:104", "label": "PIK3CA E545K", "description": "PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 77.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000263967.3", "chromosome": "3", "start": 178936091, "stop": 178936091, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "104"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123334"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13655"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS104886003"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLU545LYS", "RS104886003"], "members": [{"id": "ga4gh:VA.uqD1zF6cMOYhBp8ur5oLTMqV0jxiC2a7", "label": "NC_000003.11:g.178936091G>A", "digest": "uqD1zF6cMOYhBp8ur5oLTMqV0jxiC2a7", "type": "Allele", "location": {"id": "ga4gh:SL.5l5tuxgJGb8y7CQzkKLPUvS-Cx4kr2ju", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 179218302, "end": 179218303}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.uw7DyLM7r98pn66LOXU3tAknmkV7jiJ0", "label": "E545K", "digest": "uw7DyLM7r98pn66LOXU3tAknmkV7jiJ0", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006218.3:c.1633G>A"}, {"syntax": "hgvs.p", "value": "NP_006209.2:p.Glu545Lys"}, {"syntax": "hgvs.c", "value": "ENST00000263967.3:c.1633G>A"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.178936091G>A"}], "location": {"id": "ga4gh:SL.SrEa0lPyesLrOX0M_aW51d-JdJhU-D3p", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 544, "end": 545}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:84", "label": "Trastuzumab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:2103478"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D001943", "type": "Disease", "label": "Breast Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2910"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1647"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["ABP 980", "ALT02", "Anti-ERB-2", "Anti-HER2/c-erbB2 Monoclonal Antibody", "Anti-c-ERB-2", "Anti-c-erbB2 Monoclonal Antibody", "Anti-erbB-2", "Anti-erbB2 Monoclonal Antibody", "Anti-p185-HER2", "C-erb-2 Monoclonal Antibody", "HER2 Monoclonal Antibody", "Herceptin", "Herceptin Biosimilar PF-05280014", "Herceptin Trastuzumab Biosimilar PF-05280014", "Herzuma", "Immunoglobulin G 1 (Human-Mouse Monoclonal RhuMab HER2gamma1-Chain Antihuman P185(Sup C-erbB2) Receptor), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer", "Kanjinti", "MoAb HER2", "Monoclonal Antibody C-erb-2", "Monoclonal Antibody HER2", "Ogivri", "Ontruzant", "PF-05280014", "RO0452317", "RhuMAb HER2", "SB3", "Trastuzumab Biosimilar ABP 980", "Trastuzumab Biosimilar ALT02", "Trastuzumab Biosimilar EG12014", "Trastuzumab Biosimilar HLX02", "Trastuzumab Biosimilar PF-05280014", "Trastuzumab Biosimilar SB3", "Trastuzumab Biosimilar SIBP-01", "Trastuzumab-anns", "Trastuzumab-dkst", "Trastuzumab-dttb", "Trastuzumab-pkrb", "Trastuzumab-qyyp", "Trazimera"]}, "tumorType": {"id": "civic.did:368", "label": "Her2-receptor Positive Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C53556"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:0060079"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:8548", "description": "As part of a pre-clinical experiment, the efficacy of trastuzumab was evaluated against various HER2 positive cell lines. CC1954 and KPL-4 cell lines expressing PIK3CA H1047R were associated with resistance to trastuzumab compared to PIK3CA wild-type cell line SK-BR-3, at all concentrations tested (0-10 ug/mL).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1468", "label": "Baselga et al., 2016, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Baselga et al., 2016, Clin. Cancer Res.", "pmid": 26920887}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:107", "label": "PIK3CA H1047R", "description": "PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 96.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "G", "representative_transcript": "ENST00000263967.3", "chromosome": "3", "start": 178952085, "stop": 178952085, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "107"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123326"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13652"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913279"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913279", "HIS1047ARG"], "members": [{"id": "ga4gh:VA.82Pw7U7NM7ac2koW_yITXOGSKcwg_Qqj", "label": "NC_000003.11:g.178952085A>G", "digest": "82Pw7U7NM7ac2koW_yITXOGSKcwg_Qqj", "type": "Allele", "location": {"id": "ga4gh:SL.p0VJw5IIPnKzEpQMcdBaU3xesud6QODJ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 179234296, "end": 179234297}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.hcSlm-m3AKXOL7kHM3LghXQfvAjZOmYx", "label": "H1047R", "digest": "hcSlm-m3AKXOL7kHM3LghXQfvAjZOmYx", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006218.3:c.3140A>G"}, {"syntax": "hgvs.p", "value": "NP_006209.2:p.His1047Arg"}, {"syntax": "hgvs.c", "value": "ENST00000263967.3:c.3140A>G"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.178952085A>G"}], "location": {"id": "ga4gh:SL.DBBb47ourtRut09MJ_TAvlocEwpTjF9z", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 1046, "end": 1047}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:84", "label": "Trastuzumab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:2103478"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D001943", "type": "Disease", "label": "Breast Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2910"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1647"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["ABP 980", "ALT02", "Anti-ERB-2", "Anti-HER2/c-erbB2 Monoclonal Antibody", "Anti-c-ERB-2", "Anti-c-erbB2 Monoclonal Antibody", "Anti-erbB-2", "Anti-erbB2 Monoclonal Antibody", "Anti-p185-HER2", "C-erb-2 Monoclonal Antibody", "HER2 Monoclonal Antibody", "Herceptin", "Herceptin Biosimilar PF-05280014", "Herceptin Trastuzumab Biosimilar PF-05280014", "Herzuma", "Immunoglobulin G 1 (Human-Mouse Monoclonal RhuMab HER2gamma1-Chain Antihuman P185(Sup C-erbB2) Receptor), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer", "Kanjinti", "MoAb HER2", "Monoclonal Antibody C-erb-2", "Monoclonal Antibody HER2", "Ogivri", "Ontruzant", "PF-05280014", "RO0452317", "RhuMAb HER2", "SB3", "Trastuzumab Biosimilar ABP 980", "Trastuzumab Biosimilar ALT02", "Trastuzumab Biosimilar EG12014", "Trastuzumab Biosimilar HLX02", "Trastuzumab Biosimilar PF-05280014", "Trastuzumab Biosimilar SB3", "Trastuzumab Biosimilar SIBP-01", "Trastuzumab-anns", "Trastuzumab-dkst", "Trastuzumab-dttb", "Trastuzumab-pkrb", "Trastuzumab-qyyp", "Trazimera"]}, "tumorType": {"id": "civic.did:368", "label": "Her2-receptor Positive Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C53556"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:0060079"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:8549", "description": "As part of a pre-clinical experiment, the efficacy of trastuzumab was evaluated against various HER2 positive cell lines. EFM-192A cell line expressing PIK3CA C420R was associated with resistance to trastuzumab compared to PIK3CA wild-type cell line SK-BR-3, at all concentrations tested (0-10 ug/mL).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1468", "label": "Baselga et al., 2016, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Baselga et al., 2016, Clin. Cancer Res.", "pmid": 26920887}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:905", "label": "PIK3CA C420R", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 15.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "C", "representative_transcript": "ENST00000263967.3", "chromosome": "3", "start": 178927980, "stop": 178927980, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "931"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA180900"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "31945"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913272"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913272", "CYS420ARG"], "members": [{"id": "ga4gh:VA.FlWk9g7sLbC8jhlkETg-iAbLifrcCblI", "label": "NC_000003.11:g.178927980T>C", "digest": "FlWk9g7sLbC8jhlkETg-iAbLifrcCblI", "type": "Allele", "location": {"id": "ga4gh:SL.bS8dt3-rIEVr55ZRfkP8_zkpelSgcLlN", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 179210191, "end": 179210192}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.sW9clODd77-lRPaz7mtJ9uDSRsUl9X95", "label": "C420R", "digest": "sW9clODd77-lRPaz7mtJ9uDSRsUl9X95", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006218.3:c.1258T>C"}, {"syntax": "hgvs.p", "value": "NP_006209.2:p.Cys420Arg"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.178927980T>C"}, {"syntax": "hgvs.c", "value": "ENST00000263967.3:c.1258T>C"}], "location": {"id": "ga4gh:SL.8wBa2QJy6PBZLWfYP-48VOsHavtiOe3x", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 419, "end": 420}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:84", "label": "Trastuzumab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:2103478"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D001943", "type": "Disease", "label": "Breast Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2910"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1647"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["ABP 980", "ALT02", "Anti-ERB-2", "Anti-HER2/c-erbB2 Monoclonal Antibody", "Anti-c-ERB-2", "Anti-c-erbB2 Monoclonal Antibody", "Anti-erbB-2", "Anti-erbB2 Monoclonal Antibody", "Anti-p185-HER2", "C-erb-2 Monoclonal Antibody", "HER2 Monoclonal Antibody", "Herceptin", "Herceptin Biosimilar PF-05280014", "Herceptin Trastuzumab Biosimilar PF-05280014", "Herzuma", "Immunoglobulin G 1 (Human-Mouse Monoclonal RhuMab HER2gamma1-Chain Antihuman P185(Sup C-erbB2) Receptor), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer", "Kanjinti", "MoAb HER2", "Monoclonal Antibody C-erb-2", "Monoclonal Antibody HER2", "Ogivri", "Ontruzant", "PF-05280014", "RO0452317", "RhuMAb HER2", "SB3", "Trastuzumab Biosimilar ABP 980", "Trastuzumab Biosimilar ALT02", "Trastuzumab Biosimilar EG12014", "Trastuzumab Biosimilar HLX02", "Trastuzumab Biosimilar PF-05280014", "Trastuzumab Biosimilar SB3", "Trastuzumab Biosimilar SIBP-01", "Trastuzumab-anns", "Trastuzumab-dkst", "Trastuzumab-dttb", "Trastuzumab-pkrb", "Trastuzumab-qyyp", "Trazimera"]}, "tumorType": {"id": "civic.did:368", "label": "Her2-receptor Positive Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C53556"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:0060079"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:8662", "description": "As part of a pre-clinical experiment, the efficacy of trastuzumab was evaluated against various HER2 positive cell lines in cell viability assays. BT-474 cell line expressing PIK3CA K111N was associated with similar sensitivity to trastuzumab as PIK3CA wild-type cell line SK-BR-3, at all concentrations tested (0-10 ug/mL).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1468", "label": "Baselga et al., 2016, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Baselga et al., 2016, Clin. Cancer Res.", "pmid": 26920887}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "refutes", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1208", "label": "PIK3CA K111N", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 13.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "C", "representative_transcript": "ENST00000263967.3", "chromosome": "3", "start": 178916946, "stop": 178916946, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1234"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602917"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376483"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS1057519934"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["LYS111ASN", "RS1057519934"], "members": [{"id": "ga4gh:VA.6gJ0sZTUPrjLKyzA7MbI4GufROt86Qef", "label": "NC_000003.11:g.178916946G>C", "digest": "6gJ0sZTUPrjLKyzA7MbI4GufROt86Qef", "type": "Allele", "location": {"id": "ga4gh:SL.OrbI2eAivw_NYF0pKrtb6EtIvymAX9fl", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 179199157, "end": 179199158}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.CNXNKSAtu44QlqQ-CS7tVeV5X3xvh0fP", "label": "K111N", "digest": "CNXNKSAtu44QlqQ-CS7tVeV5X3xvh0fP", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006218.3:c.333G>C"}, {"syntax": "hgvs.p", "value": "NP_006209.2:p.Lys111Asn"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.178916946G>C"}, {"syntax": "hgvs.c", "value": "ENST00000263967.3:c.333G>C"}], "location": {"id": "ga4gh:SL.S2OWTTUCKH1qcBAiJeW3zkx8rPaf2dFh", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 110, "end": 111}, "state": {"type": "LiteralSequenceExpression", "sequence": "N"}}}, "therapeutic": {"id": "civic.tid:84", "label": "Trastuzumab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:2103478"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D001943", "type": "Disease", "label": "Breast Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2910"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1647"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["ABP 980", "ALT02", "Anti-ERB-2", "Anti-HER2/c-erbB2 Monoclonal Antibody", "Anti-c-ERB-2", "Anti-c-erbB2 Monoclonal Antibody", "Anti-erbB-2", "Anti-erbB2 Monoclonal Antibody", "Anti-p185-HER2", "C-erb-2 Monoclonal Antibody", "HER2 Monoclonal Antibody", "Herceptin", "Herceptin Biosimilar PF-05280014", "Herceptin Trastuzumab Biosimilar PF-05280014", "Herzuma", "Immunoglobulin G 1 (Human-Mouse Monoclonal RhuMab HER2gamma1-Chain Antihuman P185(Sup C-erbB2) Receptor), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer", "Kanjinti", "MoAb HER2", "Monoclonal Antibody C-erb-2", "Monoclonal Antibody HER2", "Ogivri", "Ontruzant", "PF-05280014", "RO0452317", "RhuMAb HER2", "SB3", "Trastuzumab Biosimilar ABP 980", "Trastuzumab Biosimilar ALT02", "Trastuzumab Biosimilar EG12014", "Trastuzumab Biosimilar HLX02", "Trastuzumab Biosimilar PF-05280014", "Trastuzumab Biosimilar SB3", "Trastuzumab Biosimilar SIBP-01", "Trastuzumab-anns", "Trastuzumab-dkst", "Trastuzumab-dttb", "Trastuzumab-pkrb", "Trastuzumab-qyyp", "Trazimera"]}, "tumorType": {"id": "civic.did:368", "label": "Her2-receptor Positive Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C53556"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:0060079"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:8663", "description": "As part of a pre-clinical experiment, the efficacy of trastuzumab was evaluated against various HER2 positive cell lines using cell viability assays. ZR-75-30 cell line expressing PIK3CA I391M was associated with similar sensitivity to trastuzumab compared to PIK3CA wild-type cell line SK-BR-3, at all concentrations tested (0-10 ug/mL).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1468", "label": "Baselga et al., 2016, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Baselga et al., 2016, Clin. Cancer Res.", "pmid": 26920887}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "refutes", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1209", "label": "PIK3CA I391M", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 5.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "G", "representative_transcript": "ENST00000263967.3", "chromosome": "3", "start": 178927410, "stop": 178927410, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1235"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA161490"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "135038"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS2230461"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS2230461", "ILE391MET"], "members": [{"id": "ga4gh:VA.92GgQJ9SyMwgEKR7HcY1JK-Gk9pMyxuH", "label": "NC_000003.11:g.178927410A>G", "digest": "92GgQJ9SyMwgEKR7HcY1JK-Gk9pMyxuH", "type": "Allele", "location": {"id": "ga4gh:SL.hm27ysUg2ccFcVDWhdhR9qe13sTWz4FV", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 179209621, "end": 179209622}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.fGV1lcwx7D7AdFDdsuuKs2aXLLM27-rK", "label": "I391M", "digest": "fGV1lcwx7D7AdFDdsuuKs2aXLLM27-rK", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006218.3:c.1173A>G"}, {"syntax": "hgvs.p", "value": "NP_006209.2:p.Ile391Met"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.178927410A>G"}, {"syntax": "hgvs.c", "value": "ENST00000263967.3:c.1173A>G"}], "location": {"id": "ga4gh:SL.mjYAO2_9fysPZUSpwjzywXPyzSm2bpzf", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 390, "end": 391}, "state": {"type": "LiteralSequenceExpression", "sequence": "M"}}}, "therapeutic": {"id": "civic.tid:84", "label": "Trastuzumab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:2103478"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D001943", "type": "Disease", "label": "Breast Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2910"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1647"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["ABP 980", "ALT02", "Anti-ERB-2", "Anti-HER2/c-erbB2 Monoclonal Antibody", "Anti-c-ERB-2", "Anti-c-erbB2 Monoclonal Antibody", "Anti-erbB-2", "Anti-erbB2 Monoclonal Antibody", "Anti-p185-HER2", "C-erb-2 Monoclonal Antibody", "HER2 Monoclonal Antibody", "Herceptin", "Herceptin Biosimilar PF-05280014", "Herceptin Trastuzumab Biosimilar PF-05280014", "Herzuma", "Immunoglobulin G 1 (Human-Mouse Monoclonal RhuMab HER2gamma1-Chain Antihuman P185(Sup C-erbB2) Receptor), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer", "Kanjinti", "MoAb HER2", "Monoclonal Antibody C-erb-2", "Monoclonal Antibody HER2", "Ogivri", "Ontruzant", "PF-05280014", "RO0452317", "RhuMAb HER2", "SB3", "Trastuzumab Biosimilar ABP 980", "Trastuzumab Biosimilar ALT02", "Trastuzumab Biosimilar EG12014", "Trastuzumab Biosimilar HLX02", "Trastuzumab Biosimilar PF-05280014", "Trastuzumab Biosimilar SB3", "Trastuzumab Biosimilar SIBP-01", "Trastuzumab-anns", "Trastuzumab-dkst", "Trastuzumab-dttb", "Trastuzumab-pkrb", "Trastuzumab-qyyp", "Trazimera"]}, "tumorType": {"id": "civic.did:368", "label": "Her2-receptor Positive Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C53556"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:0060079"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:795", "description": "In vivo studies confirmed the activity of PD0332991 (CDK4 inhibitor) on KRAS G12V mutant tumors. 17% (2/12) of mice treated with PD0332991 developed detectable lesions, whereas 75% of mice (3/4) treated with vehicle developed lesions at the end of the treatment.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:529", "label": "Puyol et al., 2010, Cancer Cell", "type": "Document", "title": "PubMed: Puyol et al., 2010, Cancer Cell", "pmid": 20609353}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:421", "label": "KRAS G12V", "description": "KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 67.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "A", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398284, "stop": 25398284, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "425"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA122540"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12583"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913529"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913529", "GLY12VAL"], "members": [{"id": "ga4gh:VA.-SzXMvMSRoSJgvsIDz-7M7VTFdo4FCtA", "label": "NC_000012.11:g.25398284C>A", "digest": "-SzXMvMSRoSJgvsIDz-7M7VTFdo4FCtA", "type": "Allele", "location": {"id": "ga4gh:SL.iF0OXeO-tnumYbGkzaFEQ7cOZI_UCI1s", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245349, "end": 25245350}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.JTtvYJD7yl02AOq09HjSZDUnfg4gYdUb", "label": "G12V", "digest": "JTtvYJD7yl02AOq09HjSZDUnfg4gYdUb", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004985.4:c.35G>T"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly12Val"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398284C>A"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.35G>T"}], "location": {"id": "ga4gh:SL.OndkjmujtyUEZSjjCv0C-gpwnVbRgfj8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "civic.tid:429", "label": "Palbociclib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1601374"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:572", "type": "Disease", "label": "Breast cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9335"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C49176"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one", "Ibrance", "PD 0332991", "PD 332991", "PD 991", "PD-0332991", "Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1361", "description": "Lentiviral transduction of PIK3CA H1047R mutation into head and neck cancer cell line SCC25 led to increased sensitivity to PI3K/mTOR inhibition with BEZ235 compared to unmanipulated cells (IC50 values 6 nM and 31 nM).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:926", "label": "Wirtz et al., 2015, JAMA Otolaryngol Head Neck Surg", "type": "Document", "title": "PubMed: Wirtz et al., 2015, JAMA Otolaryngol Head Neck Surg", "pmid": 25855885}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:107", "label": "PIK3CA H1047R", "description": "PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 96.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "G", "representative_transcript": "ENST00000263967.3", "chromosome": "3", "start": 178952085, "stop": 178952085, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "107"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123326"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13652"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913279"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913279", "HIS1047ARG"], "members": [{"id": "ga4gh:VA.82Pw7U7NM7ac2koW_yITXOGSKcwg_Qqj", "label": "NC_000003.11:g.178952085A>G", "digest": "82Pw7U7NM7ac2koW_yITXOGSKcwg_Qqj", "type": "Allele", "location": {"id": "ga4gh:SL.p0VJw5IIPnKzEpQMcdBaU3xesud6QODJ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 179234296, "end": 179234297}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.hcSlm-m3AKXOL7kHM3LghXQfvAjZOmYx", "label": "H1047R", "digest": "hcSlm-m3AKXOL7kHM3LghXQfvAjZOmYx", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006218.3:c.3140A>G"}, {"syntax": "hgvs.p", "value": "NP_006209.2:p.His1047Arg"}, {"syntax": "hgvs.c", "value": "ENST00000263967.3:c.3140A>G"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.178952085A>G"}], "location": {"id": "ga4gh:SL.DBBb47ourtRut09MJ_TAvlocEwpTjF9z", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 1046, "end": 1047}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:343", "label": "Dactolisib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C74072"}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C74072"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["BEZ235", "Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-", "NVPBEZ235"]}, "tumorType": {"id": "civic.did:453", "label": "Head And Neck Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4013"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:11934"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1376", "description": "In a cohort of 143 patients with primary invasive melanoma, copy-number gain of CDK4 was observed (FISH) in 37% of cases. PD0332991 efficacy (proliferation assay) was assessed in a panel of 47 melanoma cell lines. Four cell lines had an R24C activating mutation in CDK4, three of these were sensitive to PD0332991 (palbociclib).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:932", "label": "Young et al., 2014, Pigment Cell Melanoma Res", "type": "Document", "title": "PubMed: Young et al., 2014, Pigment Cell Melanoma Res", "pmid": 24495407}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:13", "label": "CDK4", "description": "CDK4, along with its partner CDK6, are key players in cell cycle progression. The complex has been implicated in a number of cancer types, and is the focus of therapeutic research and development. One targeted therapy for CDK inhibition is palbociclib, which may slow the growth of advanced stage breast cancers. It has also been shown, in mouse, that CDK inhibition may sensitize mutant PIK3CA tumors to PI3K inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1773"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1019"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CDK4", "CMM3", "PSK-J3"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:552", "label": "CDK4 R24C", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 1.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000257904.6", "chromosome": "12", "start": 58145431, "stop": 58145431, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "556"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA126982"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16928"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS11547328"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ARG24CYS", "RS11547328"], "members": [{"id": "ga4gh:VA.bjI9HGUGC9AqitBX-Deg93YJpxfcThbI", "label": "NC_000012.11:g.58145431G>A", "digest": "bjI9HGUGC9AqitBX-Deg93YJpxfcThbI", "type": "Allele", "location": {"id": "ga4gh:SL.cBjIhtvwVnG7qwhDwCnuTRaBQ6kcoG58", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 57751647, "end": 57751648}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.noySvPYtXGloUUO1xGLgYLFpsxfzstzK", "label": "R24C", "digest": "noySvPYtXGloUUO1xGLgYLFpsxfzstzK", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_000075.3:c.70C>T"}, {"syntax": "hgvs.p", "value": "NP_000066.1:p.Arg24Cys"}, {"syntax": "hgvs.c", "value": "ENST00000257904.6:c.70C>T"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.58145431G>A"}], "location": {"id": "ga4gh:SL.XqdOx0U6BaUF7Y-repc-EMNs6HxvydpP", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.24NR_FJ-O_EhYEwMPkA9xXuRQEEtWGKA"}, "start": 23, "end": 24}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "civic.tid:429", "label": "Palbociclib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1601374"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:572", "type": "Disease", "label": "Breast cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9335"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C49176"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one", "Ibrance", "PD 0332991", "PD 332991", "PD 991", "PD-0332991", "Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-"]}, "tumorType": {"id": "civic.did:206", "label": "Skin Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3510"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:8923"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1401", "description": "In a panel of head and neck cancer cell lines, 2 lines containing the PIK3CA mutation H1047R (Detroit562 and SNU-1076) were more sensitive to growth inhibition (IC50 1.10 and 6.82) by the PI3Kalpha specific inhibitor BYL719 (Alepelisib) than 3 of 4 lines with wild type PI3K (SNU-1066 IC50 1.13 \u03bcM; SNU-1041, 20.65 \u03bcM; FaDu, 19.67 \u03bcM; SCC25, 49.30 \u03bcM). In the H1047R mutant cell lines and the wildtype cell line tested, phospho-Akt and phospho-S6 levels were diminished with increasing BYL719 levels.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:949", "label": "Keam et al., 2015, Anticancer Res.", "type": "Document", "title": "PubMed: Keam et al., 2015, Anticancer Res.", "pmid": 25550549}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:107", "label": "PIK3CA H1047R", "description": "PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 96.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "G", "representative_transcript": "ENST00000263967.3", "chromosome": "3", "start": 178952085, "stop": 178952085, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "107"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123326"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13652"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913279"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913279", "HIS1047ARG"], "members": [{"id": "ga4gh:VA.82Pw7U7NM7ac2koW_yITXOGSKcwg_Qqj", "label": "NC_000003.11:g.178952085A>G", "digest": "82Pw7U7NM7ac2koW_yITXOGSKcwg_Qqj", "type": "Allele", "location": {"id": "ga4gh:SL.p0VJw5IIPnKzEpQMcdBaU3xesud6QODJ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 179234296, "end": 179234297}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.hcSlm-m3AKXOL7kHM3LghXQfvAjZOmYx", "label": "H1047R", "digest": "hcSlm-m3AKXOL7kHM3LghXQfvAjZOmYx", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006218.3:c.3140A>G"}, {"syntax": "hgvs.p", "value": "NP_006209.2:p.His1047Arg"}, {"syntax": "hgvs.c", "value": "ENST00000263967.3:c.3140A>G"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.178952085A>G"}], "location": {"id": "ga4gh:SL.DBBb47ourtRut09MJ_TAvlocEwpTjF9z", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 1046, "end": 1047}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:570", "label": "Alpelisib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:2169285"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:572", "type": "Disease", "label": "Breast cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9335"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C94214"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["BYL719", "Phosphoinositide 3-kinase Inhibitor BYL719", "Piqray"]}, "tumorType": {"id": "civic.did:453", "label": "Head And Neck Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4013"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:11934"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1987", "description": "The IC90 of ERBB2-V773A cell lines was approximately 0.5 \u00b5M and was considered as lapatinib-sensitive. Since levels of up to 1 \u00b5M of lapatinib may be achieved in patients, ERBB2-T773A might respond to higher doses of lapatinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1396", "label": "Kancha et al., 2011, PLoS ONE", "type": "Document", "title": "PubMed: Kancha et al., 2011, PLoS ONE", "pmid": 22046346}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:20", "label": "ERBB2", "description": "ERBB2, commonly referred to as HER2, is amplified and/or overexpressed in 20-30% of invasive breast carcinomas. HER2-positive breast cancer is treated in a separate manner from other subtypes of breast cancer and commonly presents as more aggressive disease. Metastatic HER2-positive breast cancer is now commonly treated with HER2-targeted therapy. Apart from being amplified/overexpressed, ERBB2 activating mutations have been shown to have clinical importance in HER2-negative breast cancer. These mutations have shown sensitivity to the tyrosine kinase inhibitor neratinib, and highlight the importance of clinical sequencing efforts in treating breast cancer.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3430"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2064"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD340", "ERBB2", "HER-2", "HER-2/neu", "HER2", "MLN 19", "MLN-19", "NEU", "NGL", "TKR1", "VSCN2", "c-ERB-2", "c-ERB2", "p185(erbB2)"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:846", "label": "ERBB2 V773A", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 1.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "C", "representative_transcript": "ENST00000269571.5", "chromosome": "17", "start": 37880989, "stop": 37880989, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "872"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA399302815"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["VAL773ALA"], "members": [{"id": "ga4gh:VA.kGWSnsI3sJ4TODkXDMV8iTYPTZN2zCVI", "label": "NC_000017.10:g.37880989T>C", "digest": "kGWSnsI3sJ4TODkXDMV8iTYPTZN2zCVI", "type": "Allele", "location": {"id": "ga4gh:SL.8f_nfbeQGXykuewMa6YYEEc9CPw3DTVd", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dLZ15tNO1Ur0IcGjwc3Sdi_0A6Yf4zm7"}, "start": 39724735, "end": 39724736}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.Y3-Q5RNC1RFsUDRxgMj6awwvxViQciB5", "label": "V773A", "digest": "Y3-Q5RNC1RFsUDRxgMj6awwvxViQciB5", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000269571.5:c.2318T>C"}, {"syntax": "hgvs.g", "value": "NC_000017.10:g.37880989T>C"}, {"syntax": "hgvs.c", "value": "NM_004448.3:c.2318T>C"}, {"syntax": "hgvs.p", "value": "NP_004439.2:p.Val773Ala"}], "location": {"id": "ga4gh:SL.H6Fx_nantIhnIjtB4RteuNk-d9CN4rd0", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.AF1UFydIo02-bMplonKSfxlWY2q6ze3m"}, "start": 772, "end": 773}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}}, "therapeutic": {"id": "civic.tid:45", "label": "Lapatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:480167"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:572", "type": "Disease", "label": "Breast cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9335"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C26653"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["GSK572016", "GW 2016", "GW2016", "GW572016"]}, "tumorType": {"id": "civic.did:22", "label": "Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9335"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1612"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1988", "description": "The IC90 of ERBB2-N857S cell lines was approximately 0.5 \u00b5M and was considered as lapatinib-sensitive. Since levels of up to 1 \u00b5M of lapatinib may be achieved in patients, ERBB2-N857S might respond to higher doses of lapatinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1396", "label": "Kancha et al., 2011, PLoS ONE", "type": "Document", "title": "PubMed: Kancha et al., 2011, PLoS ONE", "pmid": 22046346}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:20", "label": "ERBB2", "description": "ERBB2, commonly referred to as HER2, is amplified and/or overexpressed in 20-30% of invasive breast carcinomas. HER2-positive breast cancer is treated in a separate manner from other subtypes of breast cancer and commonly presents as more aggressive disease. Metastatic HER2-positive breast cancer is now commonly treated with HER2-targeted therapy. Apart from being amplified/overexpressed, ERBB2 activating mutations have been shown to have clinical importance in HER2-negative breast cancer. These mutations have shown sensitivity to the tyrosine kinase inhibitor neratinib, and highlight the importance of clinical sequencing efforts in treating breast cancer.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3430"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2064"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD340", "ERBB2", "HER-2", "HER-2/neu", "HER2", "MLN 19", "MLN-19", "NEU", "NGL", "TKR1", "VSCN2", "c-ERB-2", "c-ERB2", "p185(erbB2)"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:847", "label": "ERBB2 N857S", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 1.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "G", "representative_transcript": "ENST00000269571.5", "chromosome": "17", "start": 37881378, "stop": 37881378, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "873"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123601"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13880"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS28933370"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["N842S", "N827S", "RS28933370", "ASN857SER"], "members": [{"id": "ga4gh:VA.u7fmXZc2P1xlkCEZ4CeMR8Ag0UJjXX4-", "label": "NC_000017.10:g.37881378A>G", "digest": "u7fmXZc2P1xlkCEZ4CeMR8Ag0UJjXX4-", "type": "Allele", "location": {"id": "ga4gh:SL.jPpMLqUpT_16gkOE-VI5jxZFAGlc9Oc6", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dLZ15tNO1Ur0IcGjwc3Sdi_0A6Yf4zm7"}, "start": 39725124, "end": 39725125}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.D18mZ9X-y49Th_hlQ1IyRNRFgCDQ7PFn", "label": "N857S", "digest": "D18mZ9X-y49Th_hlQ1IyRNRFgCDQ7PFn", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000017.10:g.37881378A>G"}, {"syntax": "hgvs.p", "value": "NP_004439.2:p.Asn857Ser"}, {"syntax": "hgvs.c", "value": "NM_004448.3:c.2570A>G"}, {"syntax": "hgvs.c", "value": "ENST00000269571.5:c.2570A>G"}], "location": {"id": "ga4gh:SL.1hBBHupLqq6ndiDzArJrlxVuKRFu89_N", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.AF1UFydIo02-bMplonKSfxlWY2q6ze3m"}, "start": 856, "end": 857}, "state": {"type": "LiteralSequenceExpression", "sequence": "S"}}}, "therapeutic": {"id": "civic.tid:45", "label": "Lapatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:480167"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:572", "type": "Disease", "label": "Breast cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9335"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C26653"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["GSK572016", "GW 2016", "GW2016", "GW572016"]}, "tumorType": {"id": "civic.did:22", "label": "Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9335"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1612"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1989", "description": "Cell proliferation analysis of ERBB2 mutant expressing cell lines showed that the ERBB2-H878Y mutant, which is observed in 11% of hepatocellular carcinoma patients, had the highest sensitivity against lapatinib among all mutations tested (IC50<30nM).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1396", "label": "Kancha et al., 2011, PLoS ONE", "type": "Document", "title": "PubMed: Kancha et al., 2011, PLoS ONE", "pmid": 22046346}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:20", "label": "ERBB2", "description": "ERBB2, commonly referred to as HER2, is amplified and/or overexpressed in 20-30% of invasive breast carcinomas. HER2-positive breast cancer is treated in a separate manner from other subtypes of breast cancer and commonly presents as more aggressive disease. Metastatic HER2-positive breast cancer is now commonly treated with HER2-targeted therapy. Apart from being amplified/overexpressed, ERBB2 activating mutations have been shown to have clinical importance in HER2-negative breast cancer. These mutations have shown sensitivity to the tyrosine kinase inhibitor neratinib, and highlight the importance of clinical sequencing efforts in treating breast cancer.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3430"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2064"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CD340", "ERBB2", "HER-2", "HER-2/neu", "HER2", "MLN 19", "MLN-19", "NEU", "NGL", "TKR1", "VSCN2", "c-ERB-2", "c-ERB2", "p185(erbB2)"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:848", "label": "ERBB2 H878Y", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 1.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000269571.5", "chromosome": "17", "start": 37881440, "stop": 37881440, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "874"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA399305170"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "NONE FOUND"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["HIS878TYR"], "members": [{"id": "ga4gh:VA.LsogFlNbXp8aL8OmRPiklbXDm6HNJ6Bs", "label": "NC_000017.10:g.37881440C>T", "digest": "LsogFlNbXp8aL8OmRPiklbXDm6HNJ6Bs", "type": "Allele", "location": {"id": "ga4gh:SL.iZ0ZE0BFequOJPmasnkhS-DLUKB1gowq", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dLZ15tNO1Ur0IcGjwc3Sdi_0A6Yf4zm7"}, "start": 39725186, "end": 39725187}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.VfkOQDT8yWgi9bePVnLQfKBlNBJYrRdb", "label": "H878Y", "digest": "VfkOQDT8yWgi9bePVnLQfKBlNBJYrRdb", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000269571.5:c.2632C>T"}, {"syntax": "hgvs.g", "value": "NC_000017.10:g.37881440C>T"}, {"syntax": "hgvs.c", "value": "NM_001289937.1:c.2632C>T"}, {"syntax": "hgvs.p", "value": "NP_001276866.1:p.His878Tyr"}], "location": {"id": "ga4gh:SL.Vx81q4x-L6NRZfzmJyFdzZ2kKEyapvSk", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.AF1UFydIo02-bMplonKSfxlWY2q6ze3m"}, "start": 877, "end": 878}, "state": {"type": "LiteralSequenceExpression", "sequence": "Y"}}}, "therapeutic": {"id": "civic.tid:45", "label": "Lapatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:480167"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:572", "type": "Disease", "label": "Breast cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9335"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C26653"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["GSK572016", "GW 2016", "GW2016", "GW572016"]}, "tumorType": {"id": "civic.did:196", "label": "Hepatocellular Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3099"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:684"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:2058", "description": "As part of a preclinical study, the efficacy of PI-103 (a dual inhibitor of MTOR and Class IA PI3Ks) was evaluated for several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. HCC202 is a HER2 receptor amplified breast cancer cell line harboring PIK3CA E542K, and it had an IC50 of 0.43uM.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1435", "label": "O'Brien et al., 2010, Clin. Cancer Res.", "type": "Document", "title": "PubMed: O'Brien et al., 2010, Clin. Cancer Res.", "pmid": 20453058}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:103", "label": "PIK3CA E542K", "description": "PIK3CA E545K/E542K variants are the second most recurrent PIK3CA mutations in breast cancer and are highly recurrent mutations in many other cancer types. Colorectal cancer patients with the PIK3CA E545K variant, and possibly other variants in the E545 region, may indicate poor prognosis relative to patients with other PIK3CA variants or wild-type PIK3CA. The literature also suggests that E545/E542 variants may confer resistance to EGFR inhibitors (e.g., cetuximab). An FDA approved treatment regimen including a targeted PIK3CA inhibitor is available for specific subtypes of breast cancer. While PIK3CA variants are highly prevalent in many other cancer types, targeted therapies for PIK3CA variants are still in early clinical trial phases in other cancer types.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 75.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000263967.3", "chromosome": "3", "start": 178936082, "stop": 178936082, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "103"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA333572"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "31944"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913273"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLU542LYS", "RS121913273"], "members": [{"id": "ga4gh:VA.52-4tAq0Ya9SeMU4eZSgO0bfqvkd_VE4", "label": "NC_000003.11:g.178936082G>A", "digest": "52-4tAq0Ya9SeMU4eZSgO0bfqvkd_VE4", "type": "Allele", "location": {"id": "ga4gh:SL.65wPuIVC66WPYQqTnuNP-taUZ03NOwmJ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 179218293, "end": 179218294}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.D6daDiDNn1u-e4YtntaYQnxlZ_0T6gtD", "label": "E542K", "digest": "D6daDiDNn1u-e4YtntaYQnxlZ_0T6gtD", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006218.3:c.1624G>A"}, {"syntax": "hgvs.p", "value": "NP_006209.2:p.Glu542Lys"}, {"syntax": "hgvs.c", "value": "ENST00000263967.3:c.1624G>A"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.178936082G>A"}], "location": {"id": "ga4gh:SL.DdVC73cqPrOnzCRvVc8N9tA3ecV5Qunt", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 541, "end": 542}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:19830", "label": "PI-103", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "iuphar.ligand:5701"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:368", "label": "Her2-receptor Positive Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C53556"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:0060079"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:3889", "description": "In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS G13D mutation demonstrated resistance to regorafenib treatment (IC50: 172.23 nM vs. 114.28 nM, P<0.01) compared to SW48 cells expressing KRAS wild-type. Resistance was determined by assessing cell viability. Authors concluded that KRAS G13D is more resistant to regorafenib than KRAS wt, but more sensitive than common KRAS G12 mutations.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1935", "label": "Camaj et al., 2015, Future Oncol", "type": "Document", "title": "PubMed: Camaj et al., 2015, Future Oncol", "pmid": 26161928}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:81", "label": "KRAS G13D", "description": "While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, results are conflicting with retrospective analyses suggesting a better response to EGFR-Inhibition. A recent prospective phase-II study (12 patients, Schirripa et. al. 2015) could not reproduce this finding and another prospective phase II trial is currently ongoing.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 108.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398281, "stop": 25398281, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "81"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA122534"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12580"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS112445441"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS112445441", "GLY13ASP"], "members": [{"id": "ga4gh:VA.wQro48c_oFxB35UNb2O1Z7Vj6rXnJywl", "label": "NC_000012.11:g.25398281C>T", "digest": "wQro48c_oFxB35UNb2O1Z7Vj6rXnJywl", "type": "Allele", "location": {"id": "ga4gh:SL.rZcsm5bnq3ptyk4298opou7vY9O0etcL", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245346, "end": 25245347}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.h-3tyZSdsQNs9NHrhuwcACnnMnpuT-8Z", "label": "G13D", "digest": "h-3tyZSdsQNs9NHrhuwcACnnMnpuT-8Z", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_033360.3:c.38G>A"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly13Asp"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398281C>T"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.38G>A"}], "location": {"id": "ga4gh:SL.U-3sSsoejW41eQ2Aev0wiG5tEuDiQZTB", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 12, "end": 13}, "state": {"type": "LiteralSequenceExpression", "sequence": "D"}}}, "therapeutic": {"id": "civic.tid:27", "label": "Regorafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1312397"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C78204"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide", "BAY 73-4506", "REGORAFENIB ANHYDROUS", "Stivarga"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:3946", "description": "In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS G12D mutation demonstrated resistance to regorafenib treatment (IC50: 195.01nM vs. 114.28 nM P<0.01) compared to SW48 cells expressing KRAS wild-type. Resistance was determined by assessing cell viability. Authors concluded that KRAS G12D was more resistant to regorafenib than KRAS wt, and intermediately resistant compared to other common KRAS G12/G13 mutations.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1935", "label": "Camaj et al., 2015, Future Oncol", "type": "Document", "title": "PubMed: Camaj et al., 2015, Future Oncol", "pmid": 26161928}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:79", "label": "KRAS G12D", "description": "While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 162.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398284, "stop": 25398284, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "79"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA122538"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12582"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913529"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121913529", "GLY12ASP"], "members": [{"id": "ga4gh:VA.qOYg4yYK-1Je25G30BkV3dWKtKDIAFEJ", "label": "NC_000012.11:g.25398284C>T", "digest": "qOYg4yYK-1Je25G30BkV3dWKtKDIAFEJ", "type": "Allele", "location": {"id": "ga4gh:SL.iF0OXeO-tnumYbGkzaFEQ7cOZI_UCI1s", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245349, "end": 25245350}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.CB571ja_KfZM_Hjn9zjjgV1an3tDWRcl", "label": "G12D", "digest": "CB571ja_KfZM_Hjn9zjjgV1an3tDWRcl", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004985.4:c.35G>A"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly12Asp"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398284C>T"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.35G>A"}], "location": {"id": "ga4gh:SL.OndkjmujtyUEZSjjCv0C-gpwnVbRgfj8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "D"}}}, "therapeutic": {"id": "civic.tid:27", "label": "Regorafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1312397"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C78204"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide", "BAY 73-4506", "REGORAFENIB ANHYDROUS", "Stivarga"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:3991", "description": "In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS G12R mutation demonstrated resistance to regorafenib treatment (IC50: 181.77 nM vs. 114.28 nM, P<0.01) compared to SW48 cells expressing KRAS wild-type. Resistance was determined by assessing cell viability. Authors concluded that KRAS G12R was resistant to regorafenib compared to wildtype but was less resistant than other common KRAS G12/G13 mutations.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1935", "label": "Camaj et al., 2015, Future Oncol", "type": "Document", "title": "PubMed: Camaj et al., 2015, Future Oncol", "pmid": 26161928}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:30", "label": "KRAS", "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:3845"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:526", "label": "KRAS G12R", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 32.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "G", "representative_transcript": "ENST00000256078.4", "chromosome": "12", "start": 25398285, "stop": 25398285, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "530"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA122531"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "12579"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913530"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLY12ARG", "RS121913530"], "members": [{"id": "ga4gh:VA.kEM90GlJNzSYfDBfTs8c2yFQV8uAXPis", "label": "NC_000012.11:g.25398285C>G", "digest": "kEM90GlJNzSYfDBfTs8c2yFQV8uAXPis", "type": "Allele", "location": {"id": "ga4gh:SL.AiE9G9ocxKfBfR5PRN_ktoggZzig8OcG", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6wlJpONE3oNb4D69ULmEXhqyDZ4vwNfl"}, "start": 25245350, "end": 25245351}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.l8Oir2v3p-jxHGny73WMctRV_zRFj8Mg", "label": "G12R", "digest": "l8Oir2v3p-jxHGny73WMctRV_zRFj8Mg", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004985.4:c.34G>C"}, {"syntax": "hgvs.p", "value": "NP_004976.2:p.Gly12Arg"}, {"syntax": "hgvs.g", "value": "NC_000012.11:g.25398285C>G"}, {"syntax": "hgvs.c", "value": "ENST00000256078.4:c.34G>C"}], "location": {"id": "ga4gh:SL.OndkjmujtyUEZSjjCv0C-gpwnVbRgfj8", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:27", "label": "Regorafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1312397"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C78204"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide", "BAY 73-4506", "REGORAFENIB ANHYDROUS", "Stivarga"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4029", "description": "In an in vitro study, a M229 cell line endogenously expressing BRAF V600E mutation (a known vemurafenib sensitizing mutation) and overexpressing AKT1 E17K mutation was associated with resistance to vemurafenib treatment, as compared to cells expressing BRAF V600E mutation and wildtype AKT1. Resistance was determined by assessing cell survival.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1941", "label": "Shi et al., 2014, Cancer Discov", "type": "Document", "title": "PubMed: Shi et al., 2014, Cancer Discov", "pmid": 24265155}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:2", "label": "AKT1", "description": "AKT1, also referred to as protein kinase B, is a known oncogene. AKT activation relies on the PI3K pathway, and is recognized as a critical node in the pathway. The E17 hotspot is the most characterized of AKT1 mutations, and has been shown to result in activation of the protein. Mutations in AKT1 have also been shown to confer resistance to allosteric kinase inhibitors in vitro.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:391"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:207"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["AKT", "AKT1", "PKB", "PKB-ALPHA", "PRKBA", "RAC", "RAC-ALPHA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:4", "label": "AKT1 E17K", "description": "AKT1 E17K is a recurrent mutation that has been observed in breast, colorectal, lung, and ovarian cancer. It has been convincingly shown to be an activating mutation resulting in PI3K/AKT/mTOR pathway activity. It has been suggested that this mutation decreases the cell's sensitivity to AKT1 allosteric kinase inhibitors. This, and other AKT1 mutations, are the subject of much research and development for therapeutics.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 33.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000407796.2", "chromosome": "14", "start": 105246551, "stop": 105246551, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "4"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123660"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13983"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS34409589"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLU17LYS", "RS34409589"], "members": [{"id": "ga4gh:VA.swSBQXaa6uybP38HHxbddf9Cvl8JzGEW", "label": "NC_000014.8:g.105246551C>T", "digest": "swSBQXaa6uybP38HHxbddf9Cvl8JzGEW", "type": "Allele", "location": {"id": "ga4gh:SL.q0g2bHXjBdLjnq8rFLJEU3GpNY9o7FeQ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.eK4D2MosgK_ivBkgi6FVPg5UXs1bYESm"}, "start": 104780213, "end": 104780214}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.u-DUjTNvYupRf-vStLK0YPNPV6jEYG1O", "label": "E17K", "digest": "u-DUjTNvYupRf-vStLK0YPNPV6jEYG1O", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000014.8:g.105246551C>T"}, {"syntax": "hgvs.c", "value": "NM_001014432.1:c.49G>A"}, {"syntax": "hgvs.p", "value": "NP_001014432.1:p.Glu17Lys"}, {"syntax": "hgvs.c", "value": "ENST00000407796.2:c.49G>A"}], "location": {"id": "ga4gh:SL._hc6YN89fA0LVGrpJMVLnhhbELQEYuMw", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.GTSPIWYvuDZU59cW1RECFEU1FMiKdEyc"}, "start": 16, "end": 17}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:7", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C3224"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1909"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4287", "description": "In an in vitro study, CHO and NCI-H3255 cells expressing EGFR L858R mutation were associated with sensitivity to erlotinib treatment. Sensitivity was determined by assessing cell density.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:2070", "label": "Ray et al., 2016, Oncotarget", "type": "Document", "title": "PubMed: Ray et al., 2016, Oncotarget", "pmid": 27612423}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:33", "label": "EGFR L858R", "description": "EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 379.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "T", "variant_bases": "G", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55259515, "stop": 55259515, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "33"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA126713"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16609"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376282"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376280"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434568"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS121434568", "LEU858ARG"], "members": [{"id": "ga4gh:VA.TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "label": "NC_000007.13:g.55259515T>G", "digest": "TAARa2cxRHmOiij9UBwvW-noMDoOq2x9", "type": "Allele", "location": {"id": "ga4gh:SL.ulUNwZvajob7nzyrlpOd6uUWZIYCsoWb", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55191821, "end": 55191822}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "label": "L858R", "digest": "z7c2S8QzZ3yL2UjV_xP7zP913BrYYFGn", "type": "Allele", "expressions": [{"syntax": "hgvs.g", "value": "NC_000007.13:g.55259515T>G"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2573T>G"}, {"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2573T>G"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Leu858Arg"}], "location": {"id": "ga4gh:SL.yVGJnwqxV6oCGqC_8nNb58D_wPXJeNJo", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 857, "end": 858}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:15", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:337525"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C65530"}, "relation": "exactMatch"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:4729", "description": "In an in vitro study, an NCI-H508 cell line expressing BRAF G596R demonstrated insensitivity to vemurafenib treatment compared to HT29 cells expressing BRAF V600E (a known vemurafenib sensitizing mutation; IC50 9.89 uM vs 0.025-0.35uM for BRAF V600E expressing cell lines). Note that NCI-H508 also expresses PIK3CA E545K.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:108", "label": "Yang et al., 2012, Cancer Res.", "type": "Document", "title": "PubMed: Yang et al., 2012, Cancer Res.", "pmid": 22180495}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:5", "label": "BRAF", "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:673"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["B-RAF1", "B-raf", "BRAF", "BRAF-1", "BRAF1", "NS7", "RAFB1"]}}, "direction": "refutes", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1535", "label": "BRAF G596R", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 6.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "G", "representative_transcript": "ENST00000288602.6", "chromosome": "7", "start": 140453149, "stop": 140453149, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1627"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602422"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "375943"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913361"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["G24R", "G204R", "RS121913361", "GLY596ARG"], "members": [{"id": "ga4gh:VA.DNO4gptcvGZgvp72BqGaqssDoBa1QwEb", "label": "NC_000007.13:g.140453149C>G", "digest": "DNO4gptcvGZgvp72BqGaqssDoBa1QwEb", "type": "Allele", "location": {"id": "ga4gh:SL._B1JAcpMBsijHUaAi9aQ0jbmsZG_X4Sg", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 140753348, "end": 140753349}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}], "definingContext": {"id": "ga4gh:VA.lq8WTBtfiMWK1cPiVyabWb29ttWOdPSD", "label": "G596R", "digest": "lq8WTBtfiMWK1cPiVyabWb29ttWOdPSD", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_004333.4:c.1786G>C"}, {"syntax": "hgvs.p", "value": "NP_004324.2:p.Gly596Arg"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.140453149C>G"}, {"syntax": "hgvs.c", "value": "ENST00000288602.6:c.1786G>C"}], "location": {"id": "ga4gh:SL.g7kb4XxsPZQufg5Lp1ks1AXGS1sgby6b", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 595, "end": 596}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "civic.tid:4", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1147220"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C64768"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"]}, "tumorType": {"id": "civic.did:11", "label": "Colorectal Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4978"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:9256"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:8007", "description": "As part of a preclinical study, the efficacy of PI-103 was evaluated for several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. KPL1 is a luminal-like breast cancer cell line harboring PIK3CA E542K, and it had an IC50 of 7.62uM.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1435", "label": "O'Brien et al., 2010, Clin. Cancer Res.", "type": "Document", "title": "PubMed: O'Brien et al., 2010, Clin. Cancer Res.", "pmid": 20453058}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:103", "label": "PIK3CA E542K", "description": "PIK3CA E545K/E542K variants are the second most recurrent PIK3CA mutations in breast cancer and are highly recurrent mutations in many other cancer types. Colorectal cancer patients with the PIK3CA E545K variant, and possibly other variants in the E545 region, may indicate poor prognosis relative to patients with other PIK3CA variants or wild-type PIK3CA. The literature also suggests that E545/E542 variants may confer resistance to EGFR inhibitors (e.g., cetuximab). An FDA approved treatment regimen including a targeted PIK3CA inhibitor is available for specific subtypes of breast cancer. While PIK3CA variants are highly prevalent in many other cancer types, targeted therapies for PIK3CA variants are still in early clinical trial phases in other cancer types.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 75.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000263967.3", "chromosome": "3", "start": 178936082, "stop": 178936082, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "103"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA333572"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "31944"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913273"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLU542LYS", "RS121913273"], "members": [{"id": "ga4gh:VA.52-4tAq0Ya9SeMU4eZSgO0bfqvkd_VE4", "label": "NC_000003.11:g.178936082G>A", "digest": "52-4tAq0Ya9SeMU4eZSgO0bfqvkd_VE4", "type": "Allele", "location": {"id": "ga4gh:SL.65wPuIVC66WPYQqTnuNP-taUZ03NOwmJ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 179218293, "end": 179218294}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.D6daDiDNn1u-e4YtntaYQnxlZ_0T6gtD", "label": "E542K", "digest": "D6daDiDNn1u-e4YtntaYQnxlZ_0T6gtD", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006218.3:c.1624G>A"}, {"syntax": "hgvs.p", "value": "NP_006209.2:p.Glu542Lys"}, {"syntax": "hgvs.c", "value": "ENST00000263967.3:c.1624G>A"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.178936082G>A"}], "location": {"id": "ga4gh:SL.DdVC73cqPrOnzCRvVc8N9tA3ecV5Qunt", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 541, "end": 542}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:19830", "label": "PI-103", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "iuphar.ligand:5701"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:22", "label": "Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9335"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1612"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:8008", "description": "As part of a preclinical study, the efficacy of PI-103 was evaluated for several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. MCF7 is a luminal-like breast cancer cell line harboring PIK3CA E545K, and it had an IC50 of 1.53uM.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1435", "label": "O'Brien et al., 2010, Clin. Cancer Res.", "type": "Document", "title": "PubMed: O'Brien et al., 2010, Clin. Cancer Res.", "pmid": 20453058}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:104", "label": "PIK3CA E545K", "description": "PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 77.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000263967.3", "chromosome": "3", "start": 178936091, "stop": 178936091, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "104"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123334"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13655"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS104886003"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["GLU545LYS", "RS104886003"], "members": [{"id": "ga4gh:VA.uqD1zF6cMOYhBp8ur5oLTMqV0jxiC2a7", "label": "NC_000003.11:g.178936091G>A", "digest": "uqD1zF6cMOYhBp8ur5oLTMqV0jxiC2a7", "type": "Allele", "location": {"id": "ga4gh:SL.5l5tuxgJGb8y7CQzkKLPUvS-Cx4kr2ju", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 179218302, "end": 179218303}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.uw7DyLM7r98pn66LOXU3tAknmkV7jiJ0", "label": "E545K", "digest": "uw7DyLM7r98pn66LOXU3tAknmkV7jiJ0", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006218.3:c.1633G>A"}, {"syntax": "hgvs.p", "value": "NP_006209.2:p.Glu545Lys"}, {"syntax": "hgvs.c", "value": "ENST00000263967.3:c.1633G>A"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.178936091G>A"}], "location": {"id": "ga4gh:SL.SrEa0lPyesLrOX0M_aW51d-JdJhU-D3p", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 544, "end": 545}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:19830", "label": "PI-103", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "iuphar.ligand:5701"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:22", "label": "Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9335"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1612"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:8009", "description": "As part of a preclinical study, the efficacy of PI-103 was evaluated for several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. EFM-19 is a luminal-like breast cancer cell line harboring PIK3CA H1047L, and it had an IC50 of 0.16uM.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1435", "label": "O'Brien et al., 2010, Clin. Cancer Res.", "type": "Document", "title": "PubMed: O'Brien et al., 2010, Clin. Cancer Res.", "pmid": 20453058}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1125", "label": "PIK3CA H1047L", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 12.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "A", "variant_bases": "T", "representative_transcript": "ENST00000263967.3", "chromosome": "3", "start": 178952085, "stop": 178952085, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1151"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA123328"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "13653"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121913279"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["HIS1047LEU", "RS121913279"], "members": [{"id": "ga4gh:VA.Ol69g1SmOdYaopX-zIp42cHsWZCWrCj7", "label": "NC_000003.11:g.178952085A>T", "digest": "Ol69g1SmOdYaopX-zIp42cHsWZCWrCj7", "type": "Allele", "location": {"id": "ga4gh:SL.p0VJw5IIPnKzEpQMcdBaU3xesud6QODJ", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 179234296, "end": 179234297}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.UF5ba9AU6uHA2aqXR1FLbadsmNFgWhUY", "label": "H1047L", "digest": "UF5ba9AU6uHA2aqXR1FLbadsmNFgWhUY", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006218.3:c.3140A>T"}, {"syntax": "hgvs.p", "value": "NP_006209.2:p.His1047Leu"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.178952085A>T"}, {"syntax": "hgvs.c", "value": "ENST00000263967.3:c.3140A>T"}], "location": {"id": "ga4gh:SL.DBBb47ourtRut09MJ_TAvlocEwpTjF9z", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 1046, "end": 1047}, "state": {"type": "LiteralSequenceExpression", "sequence": "L"}}}, "therapeutic": {"id": "civic.tid:19830", "label": "PI-103", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "iuphar.ligand:5701"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:22", "label": "Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9335"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:1612"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:8011", "description": "As part of a preclinical study, the efficacy of PI-103 was evaluated for several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. BT-474 is a HER2 receptor amplified breast cancer cell line harboring PIK3CA K111N, and it had an IC50 of 0.60uM.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:1435", "label": "O'Brien et al., 2010, Clin. Cancer Res.", "type": "Document", "title": "PubMed: O'Brien et al., 2010, Clin. Cancer Res.", "pmid": 20453058}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:37", "label": "PIK3CA", "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:5290"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["CCM4", "CLAPO", "CLOVE", "CWS5", "MCAP", "MCM", "MCMTC", "PI3K", "PI3K-alpha", "PIK3CA", "p110-alpha"]}}, "direction": "supports", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00009"}, "variant": {"id": "civic.mpid:1208", "label": "PIK3CA K111N", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 13.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "C", "representative_transcript": "ENST00000263967.3", "chromosome": "3", "start": 178916946, "stop": 178916946, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "1234"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA16602917"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "376483"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS1057519934"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["LYS111ASN", "RS1057519934"], "members": [{"id": "ga4gh:VA.6gJ0sZTUPrjLKyzA7MbI4GufROt86Qef", "label": "NC_000003.11:g.178916946G>C", "digest": "6gJ0sZTUPrjLKyzA7MbI4GufROt86Qef", "type": "Allele", "location": {"id": "ga4gh:SL.OrbI2eAivw_NYF0pKrtb6EtIvymAX9fl", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.Zu7h9AggXxhTaGVsy7h_EZSChSZGcmgX"}, "start": 179199157, "end": 179199158}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}], "definingContext": {"id": "ga4gh:VA.CNXNKSAtu44QlqQ-CS7tVeV5X3xvh0fP", "label": "K111N", "digest": "CNXNKSAtu44QlqQ-CS7tVeV5X3xvh0fP", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_006218.3:c.333G>C"}, {"syntax": "hgvs.p", "value": "NP_006209.2:p.Lys111Asn"}, {"syntax": "hgvs.g", "value": "NC_000003.11:g.178916946G>C"}, {"syntax": "hgvs.c", "value": "ENST00000263967.3:c.333G>C"}], "location": {"id": "ga4gh:SL.S2OWTTUCKH1qcBAiJeW3zkx8rPaf2dFh", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 110, "end": 111}, "state": {"type": "LiteralSequenceExpression", "sequence": "N"}}}, "therapeutic": {"id": "civic.tid:19830", "label": "PI-103", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "iuphar.ligand:5701"}], "type": "TherapeuticAgent"}, "tumorType": {"id": "civic.did:368", "label": "Her2-receptor Positive Breast Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C53556"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:0060079"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1209", "description": "The P47S (rs1800371) variant of TP53 is observed in 1.5% in African Americans and between 6% and 8% in certain African populations but has not been detected in Caucasian Americans. This paper reports functional studies of this variant. Mouse models with this variant show an increase in spontaneous tumor formation. 16 out of 20 (80%) of S47 homozygous mice developed cancer between 12 and 18 months of age. Cancers predominantly included hepatocellular carcinoma, B-cell lymphoma, and histiocytic sarcoma, as well as other\ntumor types. In S47/wild-type heterozygote mice an increased cancer incidence, with a predisposition for hepatocellular carcinoma, was also found. Mouse embryonic fibroblasts and human lymphoblastoid cell lines with S47 mutations were significantly less sensitive to cisplatinum treatment compared to TP53 wild-type cells (apoptosis and viability).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:834", "label": "Jennis et al., 2016, Genes Dev.", "type": "Document", "title": "PubMed: Jennis et al., 2016, Genes Dev.", "pmid": 27034505}], "predicate": "predictsResistanceTo", "qualifiers": {"alleleOrigin": "germline", "geneContext": {"id": "civic.gid:45", "label": "TP53", "description": "TP53 mutations are universal across cancer types. The loss of a tumor suppressor is most often through large deleterious events, such as frameshift mutations, or premature stop codons. In TP53 however, many of the observed mutations in cancer are found to be single nucleotide missense variants. These variants are broadly distributed throughout the gene, but with the majority localizing in the DNA binding domain. There is no single hotspot in the DNA binding domain, but a majority of mutations occur in amino acid positions 175, 245, 248, 273, and 282 (NM_000546) (Olivier et al., 2010). To fulfill its proper biological function four TP53 polypeptides must form a tetramer which functions as a transcription factor, therefore even if one out of four polypeptides has inactivating mutation it may lead to dominant negative phenotype of variable degree. While a large proportion of cancer genomics research is focused on somatic variants, TP53 is also of note in the germline. Germline TP53 mutations are the hallmark of Li-Fraumeni syndrome, and many (both germline and somatic) variants have been found to have a prognostic impact on patient outcomes. The significance of many polymorphisms for susceptibility and prognosis of disease is still very much up for debate.", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:11998"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:7157"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["BCC7", "BMFS5", "LFS1", "P53", "TP53", "TRP53"]}}, "direction": "supports", "strength": {"label": "inferential evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00010"}, "variant": {"id": "civic.mpid:500", "label": "TP53 P47S", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 0.5}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "A", "representative_transcript": "ENST00000269305.4", "chromosome": "17", "start": 7579548, "stop": 7579548, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "504"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA000053"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "43588"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS1800371"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["RS1800371", "PRO47SER"], "members": [{"id": "ga4gh:VA.6XQdsJHLJS3Kq0Vi4CFQe10KeFCzvthe", "label": "NC_000017.10:g.7579548G>A", "digest": "6XQdsJHLJS3Kq0Vi4CFQe10KeFCzvthe", "type": "Allele", "location": {"id": "ga4gh:SL.F4dR9zWciNNY6RzRc83rkBW1x-QPegvF", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dLZ15tNO1Ur0IcGjwc3Sdi_0A6Yf4zm7"}, "start": 7676229, "end": 7676230}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}], "definingContext": {"id": "ga4gh:VA.3LKIMP_H0GCCMJhoyNqvI2qeWdZJXx3Z", "label": "P47S", "digest": "3LKIMP_H0GCCMJhoyNqvI2qeWdZJXx3Z", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_000546.5:c.139C>T"}, {"syntax": "hgvs.p", "value": "NP_000537.3:p.Pro47Ser"}, {"syntax": "hgvs.g", "value": "NC_000017.10:g.7579548G>A"}, {"syntax": "hgvs.c", "value": "ENST00000269305.4:c.139C>T"}], "location": {"id": "ga4gh:SL.TgIP4pZrTdXJLdwdvaup973pMsPvQ6eT", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.KAxM06sYzBF6zFftFaYq9E_18wsnn7al"}, "start": 46, "end": 47}, "state": {"type": "LiteralSequenceExpression", "sequence": "S"}}}, "therapeutic": {"id": "civic.tid:326", "label": "Cisplatin", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:2555"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:671", "type": "Disease", "label": "Testicular cancer", "mappings": [{"coding": {"system": "ncit", "code": "C5053"}, "relation": "relatedMatch"}]}, {"id": "hemonc:645", "type": "Disease", "label": "Ovarian cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7431"}, "relation": "relatedMatch"}]}, {"id": "hemonc:569", "type": "Disease", "label": "Bladder cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9334"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C376"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(SP-4-2)-Diamminedichloroplatinum", "Abiplatin", "Blastolem", "Briplatin", "CDDP", "Cis-diammine-dichloroplatinum", "Cis-diamminedichloridoplatinum", "Cis-diamminedichloro Platinum (II)", "Cis-diamminedichloroplatinum", "Cis-dichloroammine Platinum (II)", "Cis-platinous Diamine Dichloride", "Cis-platinum", "Cis-platinum II", "Cis-platinum II Diamine Dichloride", "Cismaplat", "Cisplatina", "Cisplatinum", "Cisplatyl", "Citoplatino", "Citosin", "Cysplatyna", "DDP", "Lederplatin", "Metaplatin", "Neoplatin", "Peyrone's Chloride", "Peyrone's Salt", "Placis", "Plastistil", "Platamine", "Platiblastin", "Platiblastin-S", "Platinex", "Platinol", "Platinol- AQ", "Platinol-AQ", "Platinol-AQ VHA Plus", "Platinoxan", "Platinum", "Platinum Diamminodichloride", "Platinum, Diaminedichloro-, Cis- (8CI)", "Platiran", "Platistin", "Platosin"]}, "tumorType": {"id": "civic.did:216", "label": "Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C9305"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:162"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:1246", "description": "116 Ewing's sarcoma tumor samples were analyzed in this study. 2 patient's samples underwent whole genome sequencing, tumor samples from 51 patients underwent exome sequencing and expression analysis, 63 samples underwent FGFR1 copy number analysis, mRNA analysis and IHC. A FGFR1 N546K mutation was detected in one patient. Gain of the FGFR1 locus (qPCR) was observed in 13 of 41 patients (31.7%) and Ewing sarcoma cell lines (A673, CADO, SK-NMC, SK-ES, and VH-64). FGFR1 was also highly expressed in Ewing sarcoma (mRNA and IHC) and correlated with copy number. Retroviral transduction of FGFR1 wild-type or the FGFR1 N546K mutant into NIH3T3 cells led to enhanced proliferation especially for cells harboring the FGFR1 mutation. ShRNA mediated knockdown of FGFR1 inhibited growth of Ewing sarcoma and other cancer cells (A549 lung carcinoma cell line or leukemia cell lines HL60 and Kasumi) with almost complete growth suppression only in the Ewing sarcoma cell lines and knockdown of FGFR1 abrogated growth of cell lines in xenograft. Ponatinib treatment inhibited growth of Ewing sarcoma cell lines.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:446", "label": "Agelopoulos et al., 2015, Clin. Cancer Res.", "type": "Document", "title": "PubMed: Agelopoulos et al., 2015, Clin. Cancer Res.", "pmid": 26179511}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:1885", "label": "FGFR1", "description": "FGFR1 is a member of the Fibroblast Growth Factor family, comprising of 4 receptors and 18 Ligands. \nFGFR1 signalling downstream functions mainly via PI3K and MAPK pathways (Turner et. al.).\nSeveral ways of involvement of FGFR1 in cancer have been proposed: auto- and paracrine activation, amplification and overexpression (Marshall et. al,  Weiss et. al.,  Cheng et. al.).\nEspecially amplification of FGFR1 in lung cancer is an emerging treatment target with clinical studies currently ongoing (e.g. NCT01004224). However, FGFR1 amplification does not always correlate with protein expression and predictive biomarkers still remain to be defined in clinic (von M\u00e4ssenhausen et. al.).\nMutation of FGFR1 seems to be less common, but has been described in glioblastoma, pilocytic astrocytomas and Ewing's sarcoma (Rand et. al., Jones et. al., Agelopoulos et. al.).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3688"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:2260"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["BFGFR", "CD331", "CEK", "ECCL", "FGFBR", "FGFR-1", "FGFR1", "FLG", "FLT-2", "FLT2", "HBGFR", "HH2", "HRTFDS", "KAL2", "N-SAM", "OGD", "bFGF-R-1"]}}, "direction": "supports", "strength": {"label": "inferential evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00010"}, "variant": {"id": "civic.mpid:511", "label": "FGFR1 N546K", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 8.0}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "G", "variant_bases": "T", "representative_transcript": "ENST00000341462.5", "chromosome": "8", "start": 38274849, "stop": 38274849, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "515"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA357830"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "224896"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS779707422"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["ASN546LYS", "RS779707422"], "members": [{"id": "ga4gh:VA.u2sHe5gOQvbCZRZZMFEQ2Sl0hYbNwygf", "label": "NC_000008.10:g.38274849G>T", "digest": "u2sHe5gOQvbCZRZZMFEQ2Sl0hYbNwygf", "type": "Allele", "location": {"id": "ga4gh:SL.dtmGDyMMVpjnu5xGAzt9ruAc-BpIOZEj", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.209Z7zJ-mFypBEWLk4rNC6S_OxY5p7bs"}, "start": 38417330, "end": 38417331}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.wbJ2omrem_S6nPCgzoFBWVeH4GF1jF5e", "label": "N546K", "digest": "wbJ2omrem_S6nPCgzoFBWVeH4GF1jF5e", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "NM_023110.2:c.1638C>A"}, {"syntax": "hgvs.p", "value": "NP_075598.2:p.Asn546Lys"}, {"syntax": "hgvs.c", "value": "ENST00000341462.5:c.1638C>A"}, {"syntax": "hgvs.g", "value": "NC_000008.10:g.38274849G>T"}], "location": {"id": "ga4gh:SL.Iya4HK_WAy421mVW8A9mDcO9HsIJjQkm", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fgaUDXKfU18Tt8FUC5-BeWqLIEhEdMZ-"}, "start": 545, "end": 546}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "civic.tid:55", "label": "Ponatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "rxcui:1364347"}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}]}}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C95777"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["AP-24534", "AP24534", "Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)"]}, "tumorType": {"id": "civic.did:135", "label": "Ewing Sarcoma Of Bone", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C4835"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3368"}, "relation": "exactMatch"}], "type": "Disease"}}
{"id": "civic.eid:278", "description": "In NSCLC containing a T790M mutation, staurosporine may be inhibitive of EGFR, especially when an L858R mutation is also present.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "civic.methods:2019", "label": "CIViC Curation SOP (2019)", "type": "Method", "isReportedIn": {"label": "Danos et al., 2019, Genome Med.", "type": "Document", "title": "Standard operating procedure for curation and clinical interpretation of variants in cancer", "doi": "10.1186/s13073-019-0687-x", "pmid": 31779674}}, "isReportedIn": [{"id": "civic.source:184", "label": "Ai et al., 2014, Amino Acids", "type": "Document", "title": "PubMed: Ai et al., 2014, Amino Acids", "pmid": 24658966}], "predicate": "predictsSensitivityTo", "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "civic.gid:19", "label": "EGFR", "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "mappings": [{"coding": {"system": "https://www.ncbi.nlm.nih.gov/gene/", "code": "ncbigene:1956"}, "relation": "exactMatch"}], "type": "Gene", "aliases": ["EGFR", "ERBB", "ERBB1", "ERRP", "HER1", "NISBD2", "PIG61", "mENA"]}}, "direction": "supports", "strength": {"label": "inferential evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e00010"}, "variant": {"id": "civic.mpid:34", "label": "EGFR T790M", "description": "EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.", "extensions": [{"type": "Extension", "name": "CIViC Molecular Profile Score", "value": 406.25}, {"type": "Extension", "name": "CIViC representative coordinate", "value": {"ensembl_version": 75, "reference_build": "GRCh37", "reference_bases": "C", "variant_bases": "T", "representative_transcript": "ENST00000275493.2", "chromosome": "7", "start": 55249071, "stop": 55249071, "type": "coordinates"}}, {"type": "Extension", "name": "Variant types", "value": [{"label": "missense_variant", "system": "http://www.sequenceontology.org/browser/current_svn/term/", "code": "SO:0001583"}]}], "mappings": [{"coding": {"system": "https://civicdb.org/variants/", "code": "34"}, "relation": "exactMatch"}, {"coding": {"system": "https://reg.clinicalgenome.org/", "code": "CA090928"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/clinvar/variation/", "code": "16613"}, "relation": "relatedMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "RS121434569"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "aliases": ["THR790MET", "RS121434569"], "members": [{"id": "ga4gh:VA.OvEfBRaS34JkfM0_ZHJVDQEjqtwzyjyp", "label": "NC_000007.13:g.55249071C>T", "digest": "OvEfBRaS34JkfM0_ZHJVDQEjqtwzyjyp", "type": "Allele", "location": {"id": "ga4gh:SL.ZCgOjF-_T0EOBXGc-6yICYui-jgFzJfY", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.F-LrLMe1SRpfUZHkQmvkVKFEGaoDeHul"}, "start": 55181377, "end": 55181378}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}], "definingContext": {"id": "ga4gh:VA.faKID4aj8rP8NKZpWL4mWDToEztTUmbr", "label": "T790M", "digest": "faKID4aj8rP8NKZpWL4mWDToEztTUmbr", "type": "Allele", "expressions": [{"syntax": "hgvs.c", "value": "ENST00000275493.2:c.2369C>T"}, {"syntax": "hgvs.c", "value": "NM_005228.4:c.2369C>T"}, {"syntax": "hgvs.p", "value": "NP_005219.2:p.Thr790Met"}, {"syntax": "hgvs.g", "value": "NC_000007.13:g.55249071C>T"}], "location": {"id": "ga4gh:SL.C1y_lDZe8e9pKy3jcj3oJKw_7252Hrxa", "type": "SequenceLocation", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 789, "end": 790}, "state": {"type": "LiteralSequenceExpression", "sequence": "M"}}}, "therapeutic": {"id": "civic.tid:51", "label": "Staurosporine", "extensions": [{"type": "Extension", "name": "therapy_normalizer_id", "value": "ncit:C1237"}], "mappings": [{"coding": {"system": "https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=", "code": "ncit:C1237"}, "relation": "exactMatch"}], "type": "TherapeuticAgent", "aliases": ["(9alpha,10beta,11beta,13alpha)-(+)-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H-9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one", "8,12-Epoxy-1H,8H-2,7b,12a-triazadibenzo(a,g)cyclonona(cde)trinden-1-one, 2,3,9,10,11,12-hexahydro-9-methoxy-8-methyl-10-(methylamino)-, (8alpha,9beta,10beta,12alpha)-(+)-", "AM-2282", "Antibiotic 230", "Antibiotic AM 2282", "CGP-39360"]}, "tumorType": {"id": "civic.did:8", "label": "Lung Non-small Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_id", "value": "ncit:C2926"}], "mappings": [{"coding": {"system": "https://www.disease-ontology.org/", "code": "DOID:3908"}, "relation": "exactMatch"}], "type": "Disease"}}